Clustering O 0 2.5143367943236683e-10
of O 0 6.971285799062948e-14
missense O 0 3.102154622069975e-08
mutations O 0 1.7791730755334356e-08
in O 0 5.920102190588861e-13
the O 0 3.015537597406137e-09
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
telangiectasia I-Disease 1 1.0
gene O 0 3.0742332455702126e-05
in O 0 1.2219874634747385e-13
a O 0 1.170226296507565e-13
sporadic B-Disease 0 1.444036286102346e-07
T I-Disease 0 0.057467833161354065
- I-Disease 0 4.490845458349213e-05
cell I-Disease 0 1.1722059980456834e-06
leukaemia I-Disease 0 0.023936843499541283
. O 0 8.189785655199344e-12

Ataxia B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999990463256836
telangiectasia I-Disease 1 1.0
( O 0 1.9556859115255065e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 5.770694015141357e-15
is O 0 5.149363094903883e-17
a O 0 6.719446725514952e-16
recessive B-Disease 0 3.2991438274621032e-06
multi I-Disease 1 0.8735256195068359
- I-Disease 1 0.999996542930603
system I-Disease 0 0.0036993182729929686
disorder I-Disease 0 0.016414931043982506
caused O 0 2.3722585785405752e-14
by O 0 1.6717852884011173e-17
mutations O 0 2.521190721471722e-13
in O 0 3.030828807319206e-17
the O 0 1.3357042539754354e-16
ATM O 0 1.670893201577428e-09
gene O 0 3.550051919098962e-11
at O 0 9.707337364495139e-12
11q22 O 0 1.5307555223387226e-09
- O 0 1.41119427254921e-08
q23 O 0 1.3478500537900118e-09
( O 0 3.3161529620386043e-14
ref O 0 5.604848141160801e-09
. O 0 4.901745784442746e-16
3 O 0 1.1308473451545568e-14
) O 0 1.356961816336203e-15
. O 0 2.1404446344150917e-14

The O 0 1.0196392341565996e-12
risk O 0 1.2955867489949924e-09
of O 0 1.0842114898479242e-14
cancer B-Disease 0 8.546862773073371e-09
, O 0 1.0912488089803024e-14
especially O 0 2.7585947103545873e-14
lymphoid B-Disease 0 4.325395153159661e-09
neoplasias I-Disease 0 6.129503304919126e-08
, O 0 4.786991348935509e-16
is O 0 2.0194775298771e-15
substantially O 0 8.124625971994703e-12
elevated O 0 3.6024562888314904e-08
in O 0 1.7225301046641661e-12
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 5.6319649957004e-06
and O 0 3.613886967457347e-12
has O 0 1.1642957648341778e-12
long O 0 4.120860011731786e-14
been O 0 1.3585222627832821e-13
associated O 0 5.445751000750926e-15
with O 0 1.3540842926096364e-11
chromosomal O 1 1.0
instability O 1 0.9999995231628418
. O 0 1.860452486512898e-10

By O 0 1.0906646272972401e-13
analysing O 0 6.680122011104572e-10
tumour B-Disease 1 0.9999642372131348
DNA O 0 1.4779623080940496e-09
from O 0 9.637365538039348e-15
patients O 0 1.0300646545848089e-14
with O 0 1.8736048508931943e-16
sporadic B-Disease 0 7.029545834313922e-09
T I-Disease 0 0.00785091519355774
- I-Disease 0 3.149031908833422e-05
cell I-Disease 0 6.566836873389548e-06
prolymphocytic I-Disease 0 0.023262055590748787
leukaemia I-Disease 0 0.00212221872061491
( O 0 9.34225570167757e-13
T B-Disease 0 5.430998157862632e-07
- I-Disease 0 3.2552915918415692e-09
PLL I-Disease 0 5.751262133202317e-09
) O 0 2.6882426525028395e-15
, O 0 1.3455526787562009e-18
a O 0 7.989523296871043e-18
rare O 0 3.561125562999683e-15
clonal B-Disease 0 5.691298543553103e-09
malignancy I-Disease 0 4.992841695639072e-08
with O 0 1.0765735158298464e-16
similarities O 0 1.08357843859897e-15
to O 0 9.943274272884541e-18
a O 0 2.643014269493012e-15
mature B-Disease 0 2.679610089373341e-09
T I-Disease 0 2.614664822431223e-07
- I-Disease 0 4.3210821587535975e-09
cell I-Disease 0 3.130821824015584e-09
leukaemia I-Disease 0 2.0109086108277552e-05
seen O 0 5.699804628278571e-09
in O 0 1.2196775707462582e-13
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
, O 0 3.9214416897069906e-14
we O 0 1.8925119497648904e-15
demonstrate O 0 3.1491113335751036e-17
a O 0 1.1784839085115688e-18
high O 0 1.8377313644506394e-15
frequency O 0 4.181231567716309e-17
of O 0 8.533048291820244e-17
ATM O 0 2.918671704321696e-08
mutations O 0 1.7364890081417172e-10
in O 0 1.1627113117793075e-12
T B-Disease 0 0.00020470863091759384
- I-Disease 0 4.860374247073196e-06
PLL I-Disease 0 2.8996894343435997e-06
. O 0 7.111827186184749e-12

In O 0 5.137431685576718e-14
marked O 0 5.763865404927182e-14
contrast O 0 1.0948341300394404e-15
to O 0 1.752269962002527e-17
the O 0 1.467790307072475e-16
ATM O 0 6.427978860301664e-08
mutation O 0 2.5701692510371466e-11
pattern O 0 8.668342432738285e-11
in O 0 6.516137998104077e-13
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 1.1781530552917017e-15
the O 0 1.6431423295543635e-19
most O 0 1.486081539992828e-19
frequent O 0 4.8178946180971435e-17
nucleotide O 0 7.813126773163759e-15
changes O 0 8.977938318382376e-16
in O 0 2.0256941826096852e-17
this O 0 5.705639767209858e-15
leukaemia B-Disease 0 1.8753254948933318e-07
were O 0 1.477584195405321e-13
missense O 0 1.6638996847007093e-09
mutations O 0 3.1237714637200042e-09
. O 0 2.0377989226605386e-11

These O 0 4.6605060576802165e-14
clustered O 0 1.3574674717631297e-10
in O 0 6.235369513741488e-16
the O 0 1.0436937482253536e-16
region O 0 1.434768992321562e-15
corresponding O 0 1.3966057905341215e-16
to O 0 7.387442186359213e-17
the O 0 2.492769524072735e-16
kinase O 0 1.6297494603856322e-11
domain O 0 2.2331209797998852e-11
, O 0 5.064048139158395e-14
which O 0 4.232312352821623e-16
is O 0 1.3297255248568e-16
highly O 0 4.701676734650178e-17
conserved O 0 3.1515769273705526e-16
in O 0 2.0554134585297354e-17
ATM O 0 1.5201667702413602e-10
- O 0 2.7308840952477986e-11
related O 0 3.75678546431224e-13
proteins O 0 1.445025333115038e-13
in O 0 6.674612212825598e-16
mouse O 0 8.496090941889634e-08
, O 0 2.5544006471665825e-13
yeast O 0 6.350949627309532e-11
and O 0 5.5232883967425844e-14
Drosophila O 0 2.0766665297100584e-12
. O 0 2.7369824614174865e-13

The O 0 5.871822125746995e-14
resulting O 0 1.1494495947509537e-13
amino O 0 1.0389449717207455e-12
- O 0 5.6056370656421e-10
acid O 0 1.8114043251471479e-12
substitutions O 0 1.7736525681315285e-13
are O 0 7.213095938987983e-16
predicted O 0 3.523561854074618e-14
to O 0 2.0665392362919206e-16
interfere O 0 2.0956064574612077e-12
with O 0 1.5164951271736532e-13
ATP O 0 1.3165654877411725e-07
binding O 0 1.1457695903160925e-10
or O 0 9.681409320061451e-13
substrate O 0 1.8423170766723729e-09
recognition O 0 1.9591118657902307e-11
. O 0 7.1722415333208556e-12

Two O 0 1.6033214252780814e-13
of O 0 4.876307267454331e-16
seventeen O 0 1.0769172012481398e-11
mutated O 0 1.598707610739325e-09
T B-Disease 0 1.5686323422414716e-06
- I-Disease 0 2.436174872944008e-10
PLL I-Disease 0 9.536929024278606e-10
samples O 0 3.788341515487126e-11
had O 0 3.621820454224184e-13
a O 0 8.069778841442775e-17
previously O 0 2.1220818505196526e-11
reported O 0 2.2955717327022285e-08
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999992847442627
T I-Disease 1 0.9999997615814209
allele O 0 4.2499806340856594e-08
. O 0 1.526907766891128e-11

In O 0 1.1479340698491991e-12
contrast O 0 5.696913210270771e-13
, O 0 2.0752131183696007e-16
no O 0 1.8513315901495504e-16
mutations O 0 1.4799140103487207e-13
were O 0 1.926764649250786e-14
detected O 0 1.1135596611477894e-10
in O 0 5.803268807871446e-18
the O 0 1.424187983303095e-18
p53 O 0 5.104283736753213e-17
gene O 0 3.0358421041664285e-15
, O 0 2.19646313852942e-18
suggesting O 0 1.0998489886036595e-15
that O 0 1.5058111014456583e-16
this O 0 8.998716036578524e-16
tumour B-Disease 1 1.0
suppressor O 0 4.855333557429731e-08
is O 0 5.381888268374269e-10
not O 0 1.6023011910337726e-12
frequently O 0 3.083137044279649e-12
altered O 0 6.865572693692812e-11
in O 0 6.711278786804579e-15
this O 0 4.986947270066433e-13
leukaemia B-Disease 0 5.711904577765381e-06
. O 0 2.1800087776635557e-12

Occasional O 0 2.4647345497896822e-08
missense O 0 1.3817676745020435e-06
mutations O 0 2.8035310961627147e-08
in O 0 4.009584615824631e-14
ATM O 0 5.89070168643957e-07
were O 0 1.2636298951651526e-10
also O 0 2.474290032843801e-13
found O 0 6.364217963392149e-14
in O 0 1.2330040502196932e-15
tumour B-Disease 1 1.0
DNA O 0 5.520353507648679e-09
from O 0 1.850422755560882e-14
patients O 0 2.004592577543353e-14
with O 0 4.789493801899054e-16
B B-Disease 0 4.341680082120547e-08
- I-Disease 0 9.236025988457186e-08
cell I-Disease 0 9.201435204886366e-06
non I-Disease 1 0.9992613196372986
- I-Disease 1 0.9979085922241211
Hodgkins I-Disease 1 0.9999613761901855
lymphomas I-Disease 0 0.0005703705828636885
( O 0 1.0131950617039975e-12
B B-Disease 0 3.0463517930456874e-08
- I-Disease 0 3.2604554611737058e-09
NHL I-Disease 0 8.589106315071149e-09
) O 0 1.532497747951632e-15
and O 0 5.739253846205172e-16
a O 0 3.45998517041631e-15
B B-Disease 0 1.6935622682012763e-08
- I-Disease 0 1.2882633848576575e-09
NHL I-Disease 0 5.817111237149675e-10
cell O 0 1.725253447049102e-11
line O 0 1.754642475759738e-08
. O 0 1.2259779779907887e-12

The O 0 1.100184625409009e-15
evidence O 0 5.269773129695267e-15
of O 0 3.651735638674069e-18
a O 0 1.541560921077914e-17
significant O 0 3.56556904490142e-16
proportion O 0 1.28107661740047e-13
of O 0 2.535670419362185e-15
loss O 0 3.023862757411955e-11
- O 0 1.7057270873532815e-10
of O 0 3.681298701204566e-13
- O 0 2.146690292192943e-08
function O 0 1.9553990046085323e-13
mutations O 0 2.6928362317768517e-11
and O 0 2.57443019810108e-13
a O 0 4.1681928057474196e-15
complete O 0 7.625977106739956e-12
absence O 0 1.8420295670729114e-12
of O 0 3.71702045492951e-17
the O 0 2.813749813933445e-17
normal O 0 2.8065890768066957e-17
copy O 0 1.0301712960328682e-13
of O 0 3.8526089230889974e-16
ATM O 0 6.020879905754839e-10
in O 0 9.060856491171468e-16
the O 0 5.337609880858496e-15
majority O 0 3.6837693269051175e-14
of O 0 6.25555219129219e-15
mutated O 0 1.1745250048988964e-05
tumours B-Disease 1 1.0
establishes O 0 2.9202960050156435e-09
somatic O 0 2.7187878615109184e-09
inactivation O 0 1.9420645003265236e-07
of O 0 1.2662455174362759e-17
this O 0 2.128128920945802e-19
gene O 0 1.6598595277249198e-15
in O 0 5.282623545947401e-19
the O 0 1.9601138560804092e-18
pathogenesis O 0 4.641202854438649e-14
of O 0 3.6745168048574325e-16
sporadic B-Disease 0 4.845358336780237e-09
T I-Disease 0 4.629251270671375e-05
- I-Disease 0 1.0112629666991779e-07
PLL I-Disease 0 3.789380897956107e-08
and O 0 8.24271410133047e-14
suggests O 0 8.344263864937251e-15
that O 0 9.572906304283516e-17
ATM O 0 1.7355230585991421e-09
acts O 0 7.907473287271927e-11
as O 0 1.4698461089750203e-13
a O 0 1.5095699213221736e-12
tumour B-Disease 1 0.9999994039535522
suppressor O 0 2.9104506893418147e-07
. O 0 2.424150116753232e-11

As O 0 2.0008194862204676e-13
constitutional O 0 2.1577178384952697e-14
DNA O 0 1.7668474322496408e-11
was O 0 1.1274915029391153e-11
not O 0 4.668791011345275e-17
available O 0 1.330973972011714e-16
, O 0 5.480232031202644e-18
a O 0 2.225809620691005e-16
putative O 0 3.3381614139571525e-10
hereditary O 0 9.425213534086652e-07
predisposition O 0 1.6493567045472446e-06
to O 0 3.02805419627461e-10
T B-Disease 0 0.004699931479990482
- I-Disease 0 2.3850060415497865e-07
PLL I-Disease 0 5.6540923054626546e-08
will O 0 1.7684065203946858e-13
require O 0 1.5715523725067188e-16
further O 0 3.4225166944642957e-17
investigation O 0 7.013831247563995e-14
. O 0 1.799095438869292e-15
. O 0 2.552723860744198e-14

Myotonic B-Disease 1 0.9999921321868896
dystrophy I-Disease 1 0.9999936819076538
protein O 0 3.746219476852275e-07
kinase O 0 8.412738594643088e-08
is O 0 8.243185729275501e-14
involved O 0 3.4439332607911306e-15
in O 0 3.014268382622195e-19
the O 0 8.028254426391402e-20
modulation O 0 8.768622051085956e-17
of O 0 5.147985425593676e-18
the O 0 3.2961425286377266e-15
Ca2 O 0 1.3503015372506866e-10
+ O 0 1.0041022180384829e-10
homeostasis O 0 4.2983558046216785e-08
in O 0 4.907551009450048e-14
skeletal O 0 3.4291956581000704e-06
muscle O 0 9.557182600872238e-09
cells O 0 1.3403064248740382e-11
. O 0 1.3218033438622268e-12

Myotonic B-Disease 1 0.9999603033065796
dystrophy I-Disease 1 0.9999947547912598
( O 0 3.014705498571857e-07
DM B-Disease 1 0.9999998807907104
) O 0 6.645405254725179e-13
, O 0 1.2964714414815148e-17
the O 0 1.6082178852129738e-18
most O 0 1.362262442641002e-15
prevalent O 0 8.41734504319902e-08
muscular B-Disease 0 9.598793258192018e-05
disorder I-Disease 0 0.00014365780225489289
in O 0 1.3771831609409469e-14
adults O 0 1.0584497167620555e-10
, O 0 6.48573710047769e-16
is O 0 1.114831942649404e-15
caused O 0 5.84174695040531e-15
by O 0 6.933561566806467e-17
( O 0 1.4885469023845008e-15
CTG O 0 2.6305872410925524e-11
) O 0 1.592037996684962e-16
n O 0 9.788975185998083e-13
- O 0 9.028516823050836e-11
repeat O 0 1.4088934185974011e-10
expansion O 0 1.294302393126806e-13
in O 0 1.0993732853051864e-18
a O 0 5.207632902576992e-19
gene O 0 2.465711850666084e-16
encoding O 0 1.0686514251236913e-17
a O 0 9.102737505852865e-17
protein O 0 1.0525480226980521e-12
kinase O 0 2.9253371280901774e-08
( O 0 6.754261039354503e-11
DM B-Disease 1 0.9999998807907104
protein O 0 5.756464194206501e-09
kinase O 0 8.219002012310739e-08
; O 0 2.046322909298598e-13
DMPK O 0 5.729575036639289e-07
) O 0 7.487797194112025e-16
and O 0 6.3735465609098984e-18
involves O 0 3.0653285916097716e-16
changes O 0 1.685856980579404e-15
in O 0 1.297278471974346e-16
cytoarchitecture O 0 9.364574005132908e-09
and O 0 3.9213242570591833e-13
ion O 0 1.4043880641745332e-11
homeostasis O 0 1.5706929090697486e-08
. O 0 2.5123353918077296e-12

To O 0 1.4484732442543078e-15
obtain O 0 1.5632959717929167e-15
clues O 0 1.2440608710296425e-13
to O 0 1.4365207623356024e-16
the O 0 1.8649614090620562e-17
normal O 0 8.363252861307035e-16
biological O 0 2.0464741216203418e-14
role O 0 7.912707354574763e-15
of O 0 9.442659603083774e-18
DMPK O 0 1.0366819624962886e-09
in O 0 1.3389998738847446e-16
cellular O 0 2.07339059116185e-11
ion O 0 2.170776579324407e-12
homeostasis O 0 1.1331798832614481e-09
, O 0 1.5535937387777107e-15
we O 0 5.299389467289424e-14
have O 0 1.8174785949235522e-15
compared O 0 4.293211057113892e-15
the O 0 1.9594131265680972e-16
resting O 0 4.921769242161034e-11
[ O 0 1.0962980062602032e-13
Ca2 O 0 8.911840449626895e-13
+ O 0 1.2575455000246594e-12
] O 0 3.7880870315532e-12
i O 0 1.17933474097498e-09
, O 0 4.9649915674010196e-18
the O 0 4.257175172266228e-20
amplitude O 0 3.687600122082837e-18
and O 0 4.244859557748419e-16
shape O 0 4.6128711270122975e-15
of O 0 3.6775576531380754e-17
depolarization O 0 1.6308859102608098e-13
- O 0 1.49921941527964e-09
induced O 0 1.889704170920936e-09
Ca2 O 0 1.4853054550179046e-11
+ O 0 1.2047742361034897e-12
transients O 0 1.5502765737807067e-10
, O 0 2.127069004796101e-16
and O 0 2.9866284526464655e-18
the O 0 3.3430123177767015e-20
content O 0 9.792260044353798e-17
of O 0 1.0124269869512422e-18
ATP O 0 2.309695837365844e-12
- O 0 1.142374768999671e-13
driven O 0 3.088467795311217e-13
ion O 0 3.711247075714047e-13
pumps O 0 1.4764899372576856e-11
in O 0 6.64103635619203e-16
cultured O 0 5.1254108596188175e-11
skeletal O 0 1.1504219799007842e-08
muscle O 0 3.3777130398204847e-12
cells O 0 4.945415838587862e-15
of O 0 2.420095883908439e-17
wild O 0 7.402843338333298e-10
- O 0 4.123202415939886e-06
type O 0 9.475648425905092e-07
and O 0 7.745984409446294e-11
DMPK O 0 1.47088121593697e-06
[ O 0 2.538579069177871e-11
- O 0 4.0578512994216e-08
/ O 0 5.381097594181483e-07
- O 0 3.281068572391632e-08
] O 0 2.9934698383277114e-12
knockout O 0 2.275474475510464e-09
mice O 0 3.9749357938489993e-07
. O 0 4.1438475914534756e-12

In O 0 1.522408176087009e-12
vitro O 0 3.6691860660909015e-09
- O 0 3.6625598909267865e-07
differentiated O 0 4.501254480260286e-08
DMPK O 0 2.896068963309517e-06
[ O 0 1.8062371043292558e-11
- O 0 2.1749451128982855e-09
/ O 0 2.5352815402612805e-09
- O 0 2.0272554468458992e-10
] O 0 4.138787972280192e-14
myotubes O 0 3.99721835492306e-12
exhibit O 0 1.2446963659686495e-14
a O 0 8.86258513646055e-16
higher O 0 1.3438786216658782e-13
resting O 0 4.718058929653601e-11
[ O 0 2.487145689053505e-13
Ca2 O 0 2.8984169665041692e-12
+ O 0 1.628658037426678e-12
] O 0 5.294138608405441e-13
i O 0 1.4089269030972962e-12
than O 0 1.7610963761851618e-16
do O 0 1.3886007203776376e-15
wild O 0 2.9025095044446503e-13
- O 0 9.47126932437925e-10
type O 0 8.073006152464757e-11
myotubes O 0 1.1975547220544058e-09
because O 0 2.2161068688681188e-14
of O 0 6.65642165088772e-19
an O 0 9.435386203957595e-18
altered O 0 1.932552642219809e-12
open O 0 1.256073587155293e-12
probability O 0 7.850403263804322e-17
of O 0 1.0243622726121933e-16
voltage O 0 4.354046637122799e-11
- O 0 3.464684539267182e-09
dependent O 0 5.64176316775189e-10
l O 0 1.319367171070951e-09
- O 0 6.146376463345149e-11
type O 0 3.509147139535429e-11
Ca2 O 0 6.858763990785777e-12
+ O 0 2.2089773586697614e-12
and O 0 4.322318327906749e-13
Na O 0 6.383138018151158e-09
+ O 0 8.66035628627193e-12
channels O 0 1.3049433755796258e-10
. O 0 7.53845423584476e-12

The O 0 8.240372224637901e-14
mutant O 0 1.3395150266770628e-10
myotubes O 0 1.6812372327645875e-10
exhibit O 0 5.79719581258846e-14
smaller O 0 2.7503988195569547e-14
and O 0 6.137153396529392e-16
slower O 0 2.433905941373604e-12
Ca2 O 0 4.210468779186627e-12
+ O 0 4.1863233257548316e-13
responses O 0 2.6032803774537865e-14
upon O 0 4.731526043362522e-17
triggering O 0 3.8341396978993844e-14
by O 0 4.150542918836408e-18
acetylcholine O 0 4.168596891285237e-12
or O 0 1.47919805744412e-12
high O 0 5.758789556331578e-10
external O 0 6.733580359963298e-10
K O 0 7.79287523400285e-10
+ O 0 4.790116220343421e-12
. O 0 3.7000730170738683e-13

In O 0 1.3133637515212737e-13
addition O 0 9.507160141607185e-14
, O 0 1.5042495167980562e-16
we O 0 3.361790387846573e-17
observed O 0 7.071847470943489e-18
that O 0 4.601508553910518e-19
these O 0 1.3258096352933618e-17
Ca2 O 0 2.9017801616432193e-12
+ O 0 2.5995369051790007e-12
transients O 0 2.64612953770893e-09
partially O 0 2.854975700294915e-10
result O 0 3.0064065975185983e-16
from O 0 1.5764505307757576e-18
an O 0 6.249528922633472e-19
influx O 0 1.7423392286149093e-16
of O 0 1.4808364135780235e-18
extracellular O 0 1.1718925797214036e-13
Ca2 O 0 2.446475910310858e-13
+ O 0 4.508988888778662e-15
through O 0 5.954940198311639e-16
the O 0 3.6579316879919565e-15
l O 0 3.1936178701563733e-10
- O 0 1.5921140274210988e-12
type O 0 4.3656175679682163e-13
Ca2 O 0 1.6959412390063489e-12
+ O 0 1.449166307787575e-12
channel O 0 7.286734410305584e-11
. O 0 4.043287406274576e-12

Neither O 0 1.0372669390079636e-10
the O 0 7.764720851931425e-16
content O 0 8.009802402505345e-14
nor O 0 2.151315285853564e-14
the O 0 3.988417586727546e-18
activity O 0 1.0566745334359817e-14
of O 0 4.5374373770498143e-17
Na O 0 1.356779577577072e-09
+ O 0 2.7405621175202732e-12
/ O 0 2.9008630567095572e-11
K O 0 8.795025471797224e-12
+ O 0 3.317793088875032e-13
ATPase O 0 4.175872495015831e-11
and O 0 1.6230720652037067e-13
sarcoplasmic O 0 4.243870588283016e-09
reticulum O 0 5.983809558962605e-10
Ca2 O 0 1.1483957118585408e-09
+ O 0 6.190712387166286e-10
- O 0 8.356525427188899e-08
ATPase O 0 2.0513299503477356e-08
are O 0 1.6598040216558863e-13
affected O 0 4.9413269564415815e-14
by O 0 1.0427390626844592e-15
DMPK O 0 2.310671334271319e-06
absence O 0 9.986753611579413e-12
. O 0 5.117412570088131e-14

In O 0 1.4398367480933372e-13
conclusion O 0 2.4815954548446442e-14
, O 0 6.470535638401334e-17
our O 0 1.808989736605288e-17
data O 0 4.718424561250866e-16
suggest O 0 9.322766490000786e-16
that O 0 3.104255049492027e-16
DMPK O 0 3.844415896736564e-09
is O 0 4.668650787687835e-16
involved O 0 8.348653719065515e-16
in O 0 1.6059250439525534e-18
modulating O 0 6.318121244556444e-15
the O 0 8.026145374323333e-19
initial O 0 7.861011689724192e-17
events O 0 5.462764954515729e-17
of O 0 1.0897293271641348e-16
excitation O 0 8.682800138604119e-12
- O 0 8.839270435601065e-07
contraction O 0 8.370147952518892e-08
coupling O 0 5.706804820371225e-11
in O 0 1.4523802896026367e-14
skeletal O 0 4.595342488755705e-07
muscle O 0 2.1799029248370516e-10
. O 0 5.6965705854436065e-15
. O 0 4.199078151162494e-13

Constitutional O 0 7.476606000977881e-09
RB1 O 0 0.00012729538138955832
- O 0 3.408013071748428e-07
gene O 0 9.062686601168934e-09
mutations O 0 8.784992733268382e-10
in O 0 1.1788325239461654e-14
patients O 0 6.149184351815495e-13
with O 0 1.7909889947508896e-14
isolated O 0 4.0087537733768386e-09
unilateral B-Disease 0 9.969864186132327e-05
retinoblastoma I-Disease 0 0.0007679082918912172
. O 0 3.4583907959628846e-10

In O 0 3.0239276116754074e-14
most O 0 5.325343255595477e-16
patients O 0 9.593131783467834e-15
with O 0 6.696877532635362e-16
isolated O 0 1.5984698009674503e-09
unilateral B-Disease 0 3.990446657553548e-06
retinoblastoma I-Disease 0 1.7488026060163975e-05
, O 0 1.505061131062621e-13
tumor B-Disease 0 6.208497049797757e-10
development O 0 3.821433610767507e-15
is O 0 3.366424981557034e-16
initiated O 0 2.0958909131477523e-15
by O 0 3.7490042204944856e-17
somatic O 0 3.0131526614074478e-12
inactivation O 0 3.8365506327409094e-08
of O 0 5.70112995204044e-17
both O 0 7.34224146426907e-16
alleles O 0 9.707841220349747e-15
of O 0 1.3198256949368674e-16
the O 0 3.3958879003086195e-14
RB1 O 0 3.551107568000589e-07
gene O 0 1.502775126560607e-09
. O 0 1.7425432624618153e-11

However O 0 6.853646881792297e-13
, O 0 2.0906505254438818e-17
some O 0 1.6290312745390624e-19
of O 0 5.11203408822059e-19
these O 0 4.488393176787055e-16
patients O 0 3.636366652671336e-15
can O 0 4.3372758815519877e-16
transmit O 0 9.656927341117338e-11
retinoblastoma B-Disease 0 3.169240301303944e-07
predisposition O 0 8.085129366008914e-08
to O 0 6.343412665803239e-13
their O 0 1.5443016873964432e-12
offspring O 0 1.6172987948870343e-10
. O 0 3.285374901816629e-13

To O 0 2.8080486866283822e-15
determine O 0 2.249815646146935e-15
the O 0 4.6603746140486704e-17
frequency O 0 5.249568429287936e-15
and O 0 1.3822272209660226e-15
nature O 0 1.30797768923825e-15
of O 0 9.366894656621469e-17
constitutional O 0 1.311081885418952e-12
RB1 O 0 4.960861588187981e-07
- O 0 2.836943180373197e-10
gene O 0 1.8241713695132944e-11
mutations O 0 1.039706688799047e-11
in O 0 2.2916950197019966e-16
patients O 0 6.202232314295479e-15
with O 0 4.243466982643574e-16
isolated O 0 1.321814879773342e-10
unilateral B-Disease 0 6.372982284119644e-07
retinoblastoma I-Disease 0 3.7434054434015707e-07
, O 0 3.674658471117861e-15
we O 0 8.103773979385235e-17
analyzed O 0 2.94901275674339e-15
DNA O 0 2.5613702131499494e-11
from O 0 8.109039427352943e-15
peripheral O 0 2.4770303141963268e-08
blood O 0 3.715121987823977e-09
and O 0 5.75306425762423e-12
from O 0 3.707834888189328e-14
tumor B-Disease 0 8.174753318712646e-09
tissue O 0 3.449020269385983e-08
. O 0 8.365503602336677e-12

The O 0 3.1610060451998283e-15
analysis O 0 8.472115695622173e-14
of O 0 1.2958807204394018e-13
tumors B-Disease 1 1.0
from O 0 2.281107160800877e-12
54 O 0 1.0634013114518837e-10
( O 0 2.5263257401298388e-14
71 O 0 1.7629155080189918e-11
% O 0 1.3769795077506474e-16
) O 0 1.7604909792384465e-17
of O 0 2.4954037303642467e-17
76 O 0 1.1247378028933497e-11
informative O 0 6.487290704626503e-10
patients O 0 1.1796946752795634e-09
showed O 0 6.509505823260042e-09
loss O 0 1.7787157163828837e-11
of O 0 8.902029978506525e-15
constitutional O 0 2.7838884530950736e-09
heterozygosity O 0 2.608831437100889e-06
( O 0 1.262415727509847e-10
LOH O 1 0.999975323677063
) O 0 3.42279779822971e-13
at O 0 3.997279503925588e-12
intragenic O 0 1.717867981199106e-08
loci O 0 6.58467669278906e-10
. O 0 4.082062812771348e-12

Three O 0 1.922244481644686e-12
of O 0 1.440066632835222e-14
13 O 0 5.1259170519291075e-12
uninformative O 0 8.422293831245042e-06
patients O 0 1.5213277304582107e-09
had O 0 1.0689529122975827e-10
constitutional O 0 5.97557212045352e-11
deletions O 0 9.337402389064664e-07
. O 0 7.227932835585094e-11

For O 0 6.077100899327254e-14
39 O 0 2.4408235849149307e-12
randomly O 0 3.205112911186525e-11
selected O 0 1.2943570482093492e-06
tumors B-Disease 1 1.0
, O 0 5.433392017556438e-12
SSCP O 0 5.437718937173486e-05
, O 0 3.904134773715512e-14
hetero O 0 3.6809830739059635e-09
- O 0 5.414232864126012e-12
duplex O 0 3.274680526743623e-11
analysis O 0 1.4203433859551109e-15
, O 0 6.640798277068125e-19
sequencing O 0 4.613610163258777e-15
, O 0 1.2553004984902682e-15
and O 0 5.3176525140717634e-15
Southern O 0 7.955651607363201e-16
blot O 0 1.98778793425447e-09
analysis O 0 3.0129541304371385e-14
were O 0 2.1532845951042828e-15
used O 0 8.84916892866943e-17
to O 0 3.3263784549509326e-17
identify O 0 2.3714455963178005e-13
mutations O 0 3.878290397163475e-11
. O 0 1.2825146760570005e-12

Mutations O 0 2.966545942229004e-08
were O 0 3.276576601186909e-13
detected O 0 1.4408937931698063e-10
in O 0 1.4715976672308238e-15
21 O 0 7.261988319712254e-13
( O 0 5.063250615286907e-16
91 O 0 9.618786886780861e-14
% O 0 1.148571117823115e-16
) O 0 1.3970054842061072e-16
of O 0 2.7137761642362888e-14
23 O 0 9.3465519057645e-07
tumors B-Disease 1 1.0
with O 0 1.238208369613858e-06
LOH O 1 0.999996542930603
. O 0 7.955660019653976e-10

In O 0 2.5921250822874553e-12
6 O 0 2.9195899170497697e-12
( O 0 7.767802463672655e-16
38 O 0 1.9572786723624433e-14
% O 0 1.0031969541246152e-17
) O 0 7.083295650621223e-18
of O 0 4.954820021884753e-15
16 O 0 1.695963078418572e-06
tumors B-Disease 1 1.0
without O 0 9.050613698491361e-06
LOH O 1 0.9999997615814209
, O 0 1.6714435079599223e-14
one O 0 5.993291467883149e-17
mutation O 0 8.817306016177182e-14
was O 0 1.638541299170404e-12
detected O 0 2.321030034835303e-10
, O 0 1.1770165488347232e-15
and O 0 1.252259269044799e-14
in O 0 1.8368755170667777e-16
9 O 0 4.687737611280829e-12
( O 0 7.482029429136815e-16
56 O 0 3.350018355709368e-14
% O 0 4.480639682033351e-18
) O 0 1.1590901420623802e-17
of O 0 5.835220985063189e-15
the O 0 4.6241634521493324e-08
tumors B-Disease 1 1.0
without O 0 1.0105250112246722e-05
LOH O 1 0.9999995231628418
, O 0 1.6509822751541864e-13
both O 0 1.430444338554413e-14
mutations O 0 7.617309560892238e-13
were O 0 5.097714649493143e-14
found O 0 1.3943542501171358e-12
. O 0 2.2147611435791026e-12

Thus O 0 4.1756472411724754e-12
, O 0 2.097929747921573e-16
a O 0 6.49387867528758e-17
total O 0 7.982254688774972e-15
of O 0 4.707242667555925e-16
45 O 0 1.7667142163287075e-13
mutations O 0 1.974867968809746e-12
were O 0 6.299452604517641e-13
identified O 0 3.0326668953861713e-10
in O 0 5.845032791107485e-12
tumors B-Disease 1 1.0
of O 0 6.564602377315265e-13
36 O 0 5.178397710636773e-10
patients O 0 6.78382350294271e-12
. O 0 2.4465133152858087e-13

Thirty O 0 5.378707479408718e-10
- O 0 7.930757384144727e-09
nine O 0 3.5222755701697084e-12
of O 0 2.0479468300124643e-17
the O 0 4.302043612285394e-17
mutations O 0 1.869984852728712e-12
- O 0 1.6826455506713245e-10
including O 0 6.083598251896416e-13
34 O 0 4.700449014391483e-13
small O 0 8.015361818551354e-15
mutations O 0 1.1910977412710189e-11
, O 0 1.992876248410342e-15
2 O 0 2.1123038970364785e-16
large O 0 3.3551977927752386e-14
structural O 0 3.1422284791915445e-06
alterations O 0 8.320624189650516e-09
, O 0 2.842680247010926e-13
and O 0 1.200709345318407e-12
hypermethylation O 0 5.501310340605414e-08
in O 0 9.750829700963526e-13
3 O 0 5.5244854024749657e-08
tumors O 1 1.0
- O 0 3.3111055017798208e-06
were O 0 2.1945362194131235e-11
not O 0 3.5821349447069054e-15
detected O 0 6.29202289229025e-12
in O 0 3.69832079641183e-18
the O 0 2.214781053194407e-17
corresponding O 0 3.864946116784434e-15
peripheral O 0 1.7201212676454247e-11
blood O 0 4.862849706244177e-12
DNA O 0 1.8108683441653284e-09
. O 0 2.9291165846989653e-12

In O 0 3.782426628851088e-12
6 O 0 2.4532773382213158e-11
( O 0 3.9899910496887445e-15
17 O 0 3.093312484956333e-14
% O 0 4.316342587226231e-18
) O 0 5.073393379880941e-19
of O 0 4.88890935581477e-19
the O 0 1.0346052594018603e-14
36 O 0 3.75861147761114e-10
patients O 0 4.0305728047675127e-13
, O 0 2.7368085339220285e-18
a O 0 7.385465555567457e-18
mutation O 0 3.9080389179759964e-14
was O 0 7.501478604954315e-12
detected O 0 1.4158733907532195e-10
in O 0 2.902292881062346e-17
constitutional O 0 3.0594774997683757e-15
DNA O 0 1.957532747010049e-10
, O 0 3.124991178370465e-14
and O 0 7.617592605421893e-15
1 O 0 1.1633965766802293e-16
of O 0 1.6926148542780602e-17
these O 0 7.169454578083954e-15
mutations O 0 4.499560446458162e-13
is O 0 4.5987100066836265e-15
known O 0 5.4517710333136515e-14
to O 0 3.296120700598676e-13
be O 0 8.615333446648776e-11
associated O 0 1.0145637314214889e-13
with O 0 1.6998403552792585e-12
reduced O 0 5.69547686790628e-10
expressivity O 0 1.722187676023168e-06
. O 0 2.3945921634460632e-11

The O 0 1.3945582969659975e-13
presence O 0 2.332035931550125e-13
of O 0 1.0807412488025826e-17
a O 0 2.039770321710945e-15
constitutional O 0 8.53498532699809e-13
mutation O 0 9.542412866825334e-12
was O 0 5.06027331148573e-10
not O 0 2.3837157155917263e-14
associated O 0 9.455213855589389e-16
with O 0 6.994129716491069e-17
an O 0 5.628804985047947e-16
early O 0 3.518607117908995e-13
age O 0 1.1489910411999205e-10
at O 0 1.455688347640205e-11
treatment O 0 2.9385287605987465e-12
. O 0 1.502834484732197e-14

In O 0 2.0642899282302674e-12
1 O 0 1.022147210621993e-12
patient O 0 9.448129778544256e-12
, O 0 4.718227096695037e-16
somatic O 0 7.967303206068976e-11
mosaicism O 0 1.292149363507633e-06
was O 0 6.797128138114061e-11
demonstrated O 0 2.876820879802735e-16
by O 0 2.2449489569820238e-20
molecular O 0 1.5693119703612311e-16
analysis O 0 2.974284196482959e-16
of O 0 1.0474703074864134e-17
DNA O 0 3.67710618898176e-11
and O 0 4.8789727954360457e-14
RNA O 0 3.8766372382169345e-13
from O 0 9.552779133860639e-15
peripheral O 0 9.165108671993494e-09
blood O 0 9.70855573712015e-09
. O 0 9.801815609167264e-12

In O 0 1.8565619961524726e-12
2 O 0 8.431303615344388e-13
patients O 0 1.7764489965849117e-13
without O 0 3.0006094510880306e-16
a O 0 2.4763175501986553e-15
detectable O 0 3.3536149857127384e-08
mutation O 0 3.753360122704663e-10
in O 0 3.134747507144847e-13
peripheral O 0 2.646660323080141e-05
blood O 0 2.47438219957985e-06
, O 0 1.6062231568674673e-13
mosaicism O 0 2.3829989093115955e-09
was O 0 1.568202859236756e-11
suggested O 0 5.117844624653867e-13
because O 0 4.363615588656722e-15
1 O 0 4.12524202815831e-17
of O 0 1.1293712797326363e-17
the O 0 3.5408491189017205e-14
patients O 0 1.5547707218899198e-11
showed O 0 1.2027746798537464e-08
multifocal O 1 0.981787919998169
tumors B-Disease 1 1.0
and O 0 1.5797837482622867e-09
the O 0 1.2244453116832805e-15
other O 0 4.401934935674033e-15
later O 0 2.0495504165357614e-12
developed O 0 1.1085583145886702e-10
bilateral B-Disease 0 1.842676589092207e-08
retinoblastoma I-Disease 0 2.0984549564673216e-07
. O 0 1.4066881340313309e-11

In O 0 2.0103253642930058e-13
conclusion O 0 4.834047184353214e-14
, O 0 2.0565527972531313e-15
our O 0 3.2771855077617018e-15
results O 0 8.873574727206684e-17
emphasize O 0 1.0270586828857692e-15
that O 0 6.518548509876361e-17
the O 0 1.753011943011987e-17
manifestation O 0 2.521915747793254e-14
and O 0 5.382693209476106e-16
transmissibility O 0 4.0998511551849914e-13
of O 0 4.470242021733559e-18
retinoblastoma B-Disease 0 3.016684818613058e-11
depend O 0 1.1235676051926744e-14
on O 0 2.353160018459064e-14
the O 0 3.7692519475285586e-17
nature O 0 8.397879356432554e-15
of O 0 1.998507899161395e-17
the O 0 3.3804261714773514e-16
first O 0 1.9139533436862005e-13
mutation O 0 1.7923549624332792e-15
, O 0 7.459963095895207e-18
its O 0 9.169012746814747e-19
time O 0 3.8152997687404056e-16
in O 0 1.859959778770193e-17
development O 0 5.60641102210932e-16
, O 0 3.0486526304607025e-16
and O 0 3.12801898234372e-15
the O 0 7.636787510207198e-17
number O 0 1.2765063528777376e-12
and O 0 3.3486863455778337e-12
types O 0 1.9678854899785048e-12
of O 0 4.6999016050556394e-17
cells O 0 1.1146750297959251e-14
that O 0 1.848916392167485e-14
are O 0 1.6686031354372355e-13
affected O 0 2.4322074302501884e-12
. O 0 1.9609170600357268e-15
. O 0 6.605976616419484e-13

Hereditary B-Disease 1 0.9999750852584839
deficiency I-Disease 1 0.9999959468841553
of I-Disease 0 1.2295513999310836e-12
the I-Disease 0 3.2164866608933376e-14
fifth I-Disease 0 2.177888314136567e-09
component I-Disease 0 3.064144077358222e-11
of I-Disease 0 5.175813882438715e-16
complement I-Disease 0 3.407919020766148e-13
in O 0 1.8322434379853788e-15
man O 0 8.673975315787175e-09
. O 0 3.212921248496592e-12

I O 0 0.0007338105351664126
. O 0 1.7845173949648796e-10

Clinical O 0 6.347062480926979e-06
, O 0 4.549859187324978e-12
immunochemical O 0 2.3406034870276926e-06
, O 0 8.42175613101348e-13
and O 0 1.0902569672803855e-13
family O 0 6.453758832685938e-14
studies O 0 3.131725130958718e-12
. O 0 1.7962455524725418e-12

The O 0 1.0584641615875995e-13
first O 0 6.115032525483288e-13
recognized O 0 2.1886411953608853e-12
human O 0 1.8283268995999968e-11
kindred O 0 1.9849869659083197e-06
with O 0 7.17154113871743e-09
hereditary B-Disease 1 0.9998099207878113
deficiency I-Disease 1 0.9999428987503052
of I-Disease 0 6.908332277543935e-14
the I-Disease 0 7.942983700241421e-14
fifth I-Disease 0 7.924361611344466e-09
component I-Disease 0 3.666684664227482e-11
of I-Disease 0 6.706058099234177e-15
complement I-Disease 0 1.5365986261173248e-11
( O 0 5.655841429691357e-15
C5 O 0 7.286348191470893e-10
) O 0 6.216491690446031e-15
is O 0 1.4426948066639626e-14
described O 0 1.1522297005406301e-11
. O 0 3.3022009605920832e-12

The O 0 1.8353070799226323e-12
proband O 0 1.3214380700787842e-08
, O 0 7.432984633304015e-16
a O 0 6.935995463040843e-17
20 O 0 6.877324667158089e-16
- O 0 5.199390722653019e-13
year O 0 8.71290276797769e-14
- O 0 1.653297915238383e-10
old O 0 6.900313098689992e-10
black O 0 9.429243844061297e-12
female O 0 5.720372439621535e-11
with O 0 1.2401767980618761e-11
systemic B-Disease 1 0.9999996423721313
lupus I-Disease 1 0.9978476762771606
erythematosus I-Disease 1 0.9999949932098389
since O 0 3.2648269504553795e-11
age O 0 5.359492710743652e-11
11 O 0 1.54322409885721e-12
, O 0 4.5416326915328955e-15
lacked O 0 1.674857474931457e-11
serum O 0 3.0571709608295805e-09
hemolytic O 0 8.423799044976477e-07
complement O 0 2.6130933354628905e-12
activity O 0 1.9337786927309253e-10
, O 0 1.6136219049584389e-15
even O 0 2.7398066725515396e-14
during O 0 2.4531719429281285e-13
remission O 0 2.1418222750924087e-09
. O 0 2.9327825975047905e-13

C5 O 0 8.324489317601547e-05
was O 0 8.194642298064991e-09
undetectable O 0 1.1603893881328986e-06
in O 0 9.562769040440556e-15
her O 0 1.212954297549404e-13
serum O 0 1.2289207195273488e-12
by O 0 6.389786928748397e-17
both O 0 6.908911648079857e-14
immunodiffusion O 0 5.157396117283497e-06
and O 0 1.597559758093059e-11
hemolytic O 0 3.2465059121022932e-06
assays O 0 4.924499918956826e-08
. O 0 4.86552161407805e-12

Other O 0 1.3162371075069266e-14
complement O 0 2.5179360481938744e-14
components O 0 3.2349737472125994e-11
were O 0 1.443977722765874e-14
normal O 0 4.882601145768904e-15
during O 0 4.543088317652752e-15
remission O 0 8.871025442003244e-12
of O 0 4.2954988931044255e-14
lupus O 0 7.40993755243835e-06
, O 0 1.1107227740640366e-15
but O 0 6.653414154529375e-15
C1 O 0 2.3692090067584104e-08
, O 0 1.3109754235418776e-14
C4 O 0 2.2647979491807746e-08
, O 0 6.223615915158798e-13
C2 O 0 5.75778983602504e-07
, O 0 2.0670233103273206e-13
and O 0 4.30247287450114e-12
C3 O 0 0.041668206453323364
levels O 0 6.587603795793484e-10
fell O 0 1.0463288617756916e-06
during O 0 7.387882840215187e-12
exacerbations O 0 2.839571834556409e-06
. O 0 1.2021208681267659e-12

A O 0 3.401006906655901e-11
younger O 0 9.790385169239357e-11
half O 0 2.52635716166405e-12
- O 0 2.4646498175684428e-08
sister O 0 3.4275731763955264e-07
, O 0 5.39521837037045e-14
who O 0 1.7185315670520396e-10
had O 0 4.569538525345251e-09
no O 0 5.197108299270781e-10
underlying O 0 3.689251570904162e-07
disease O 0 5.7111092246486805e-06
, O 0 2.8978485785974414e-15
was O 0 1.04089577235289e-10
also O 0 4.656307891343081e-12
found O 0 2.3079695706668124e-12
to O 0 2.3350726734150395e-12
lack O 0 2.0692671187649836e-10
immunochemically O 0 2.7436331038188655e-06
detectable O 0 2.645253402988601e-07
C5 O 0 3.321702592984366e-07
. O 0 3.0531296241198547e-11

By O 0 1.908938632166901e-11
hemolytic O 0 0.00022270217596087605
assay O 0 7.036107518842982e-08
, O 0 1.2262257181872016e-12
she O 0 2.973624124713581e-10
exhibited O 0 2.655294317754908e-10
1 O 0 4.636761013663247e-14
- O 0 1.3479013460937495e-09
2 O 0 2.7607527808976018e-14
% O 0 4.0990587839208014e-18
of O 0 6.933792887864767e-19
the O 0 1.0852531550845898e-16
normal O 0 6.211184859624894e-14
serum O 0 1.1678103796486372e-11
C5 O 0 2.532351550676992e-10
level O 0 5.012133937054575e-12
and O 0 2.6785797006405624e-15
normal O 0 1.1455082996254026e-16
concentrations O 0 3.1131253373343516e-16
of O 0 4.0266032940315026e-19
other O 0 2.84260948376093e-17
complement O 0 1.928183768250616e-14
components O 0 1.867316370973704e-11
. O 0 3.203630665870455e-13

C5 O 0 1.6449771464976948e-06
levels O 0 5.600453434340125e-10
of O 0 1.18964612771564e-16
other O 0 4.033648980674803e-17
family O 0 2.2741138450301087e-15
members O 0 9.656566689692639e-17
were O 0 3.850583402614316e-15
either O 0 4.428223397285458e-16
normal O 0 4.109474840717416e-16
or O 0 5.255777498428666e-16
approximately O 0 7.401214650913993e-15
half O 0 6.537394930949958e-11
- O 0 2.6654815883375704e-06
normal O 0 5.306234618362993e-11
, O 0 3.3918092672610006e-14
consistent O 0 2.3642838988674475e-12
with O 0 1.9306567656434195e-14
autosomal O 0 1.3047125602128062e-09
codominant O 0 6.1361218328670475e-09
inheritance O 0 1.9204048073984126e-12
of O 0 8.863295055949467e-16
the O 0 1.2165589479003983e-14
gene O 0 3.895122446806454e-09
determining O 0 3.348966401972575e-06
C5 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999998807907104
. O 0 1.195151339006273e-10

Normal O 0 2.0581178432621527e-06
hemolytic O 0 0.42448896169662476
titers O 0 0.00021792807092424482
were O 0 1.8571145055795713e-12
restored O 0 1.9737759603816185e-12
to O 0 3.1396148633916314e-15
both O 0 1.543978660201173e-11
homozygous O 1 0.9344618320465088
C5 B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
deficient I-Disease 1 1.0
( O 0 5.954484016967854e-09
C5D B-Disease 1 1.0
) O 0 2.1546375184792847e-14
sera O 0 5.574186403255188e-13
by O 0 3.1304850873367876e-18
addition O 0 5.949260313004706e-17
of O 0 1.849460209818935e-17
highly O 0 2.2332805635176534e-13
purified O 0 6.523544204828369e-11
human O 0 1.776322144930731e-11
C5 O 0 4.371061379515595e-08
. O 0 1.8420436617011537e-12

In O 0 1.525989079022294e-13
specific O 0 1.313985270416651e-13
C5 O 0 5.31809725146104e-08
titrations O 0 2.0910316322897415e-07
, O 0 1.7464467507799855e-14
however O 0 7.042672380604825e-16
, O 0 2.1436933167877222e-17
it O 0 7.277215803699541e-16
was O 0 2.89969159794623e-10
noted O 0 8.542285802326521e-12
that O 0 4.142669797222516e-16
when O 0 1.3832934025125553e-14
limited O 0 2.737176645838227e-16
amounts O 0 2.726942370253027e-16
of O 0 6.334819122683023e-16
C5 O 0 9.208208084920955e-10
were O 0 5.6886660739798294e-15
assayed O 0 1.3229441847562029e-11
in O 0 8.60033000479245e-18
the O 0 8.996647952698244e-18
presence O 0 2.2911544538629708e-15
of O 0 7.685501334533303e-18
low O 0 3.9964160995255293e-13
dilutions O 0 2.010043693989605e-11
of O 0 1.4163701238061304e-14
either O 0 7.876742813550663e-09
C5D B-Disease 1 1.0
serum O 0 4.032404831377789e-06
, O 0 1.914125715949758e-16
curving O 0 1.2372363604549325e-13
rather O 0 8.013121601694323e-17
than O 0 1.8885211672687915e-18
linear O 0 9.332048515264815e-17
dose O 0 1.166974096565923e-13
- O 0 2.1890046199291024e-12
response O 0 5.621465973955581e-16
plots O 0 8.713488372676104e-13
were O 0 9.8853585907277e-13
consistently O 0 1.1074124256493789e-11
obtained O 0 4.0464886766661983e-16
, O 0 4.4012398558053044e-18
suggesting O 0 8.299309285327624e-16
some O 0 9.550213762230981e-18
inhibitory O 0 1.720099621549051e-13
effect O 0 6.987196736994716e-13
. O 0 2.8771164053628673e-13

Further O 0 1.0293625760798841e-12
studies O 0 9.295752237620594e-14
suggested O 0 5.070255196595874e-13
that O 0 1.2060829079362282e-15
low O 0 1.1392315910074835e-11
dilutions O 0 6.262760621211783e-08
of O 0 7.333439411283393e-12
C5D B-Disease 1 1.0
serum O 0 3.022667627305964e-08
contain O 0 1.9455432002848244e-14
a O 0 3.101118645307022e-16
factor O 0 3.2134573322607773e-14
( O 0 5.124534772509736e-17
or O 0 2.384668002970589e-16
factors O 0 1.0441322201244557e-15
) O 0 2.3849944746147512e-17
interfering O 0 1.6894953047252165e-14
at O 0 3.0480497547604943e-15
some O 0 7.023776696825582e-18
step O 0 1.2817053191352401e-12
in O 0 1.0669330897500104e-16
the O 0 2.9323543715279766e-15
hemolytic O 0 6.697064014460352e-10
assay O 0 2.9431269704324747e-13
of O 0 4.955516494725633e-16
C5 O 0 1.560870366290601e-08
, O 0 8.368422409263246e-16
rather O 0 2.1156657906564655e-17
than O 0 2.1952663736191784e-17
a O 0 3.120449525350141e-16
true O 0 1.2133847258118807e-13
C5 O 0 1.210156685971242e-08
inhibitor O 0 5.472169384290737e-10
or O 0 5.465509121671541e-12
inactivator O 0 4.56547377325478e-06
. O 0 6.459712972861631e-12

Of O 0 2.0552147223656947e-12
clinical O 0 3.30745848486913e-08
interest O 0 6.478416469946069e-09
are O 0 3.8214231583809377e-13
( O 0 6.211933170882145e-17
a O 0 3.487371624955393e-17
) O 0 1.712978552034013e-17
the O 0 7.688492419628295e-18
documentation O 0 1.1109925479590999e-10
of O 0 3.180024993332253e-11
membranous O 1 0.9943918585777283
glomerulonephritis B-Disease 1 1.0
, O 0 3.8366536614375946e-07
vasculitis B-Disease 1 1.0
, O 0 8.490311231845737e-11
and O 0 2.93279924790113e-07
arthritis B-Disease 1 1.0
in O 0 4.58121581170751e-16
an O 0 5.305006523927494e-16
individual O 0 2.1051812636868616e-12
lacking O 0 1.9392959460518e-11
C5 O 0 1.5852076318267905e-09
( O 0 5.3277436410888775e-15
and O 0 3.210746149203206e-16
its O 0 5.6805251311359275e-18
biologic O 0 6.34263556389611e-14
functions O 0 2.3404097373831635e-16
) O 0 1.8001175958783913e-16
, O 0 1.0456224687160312e-16
and O 0 2.5848253930055992e-14
( O 0 7.121643803376185e-15
b O 0 6.285194803848371e-13
) O 0 1.1899853379412358e-18
a O 0 3.2184439581580733e-18
remarkable O 0 1.4249462476937855e-14
propensity O 0 1.9905117554230856e-09
to O 0 7.327909390397735e-10
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 4.040151493792197e-15
the O 0 1.4738899501443308e-15
proband O 0 8.283267405317929e-10
, O 0 2.982952255209127e-17
even O 0 1.1034498712462253e-16
during O 0 4.2140434403361237e-16
periods O 0 1.1599058268496523e-14
of O 0 7.151941218987406e-16
low O 0 5.317239981650346e-10
- O 0 8.894380787438649e-10
dose O 0 1.1274328909696707e-12
or O 0 3.677056421391538e-15
alternate O 0 5.2774099787477116e-14
- O 0 4.615682003272781e-10
day O 0 1.2122986642326694e-11
corticosteroid O 0 4.9217740993867665e-09
therapy O 0 3.395439485132101e-11
. O 0 7.887366161671988e-14

Other O 0 2.5082235872558303e-15
observations O 0 8.943526122592513e-14
indicate O 0 1.0162874773504693e-13
that O 0 2.189371586789105e-16
the O 0 1.794510957745573e-14
C5D B-Disease 1 1.0
state O 0 1.2452574236522518e-13
is O 0 6.774499631921746e-16
compatible O 0 1.450962695262112e-14
with O 0 7.88483573544536e-15
normal O 0 1.8568141697193315e-15
coagulation O 0 2.2512932951234202e-14
function O 0 9.859325439669653e-15
and O 0 1.5266871019334674e-14
the O 0 2.1153035848098408e-16
capacity O 0 1.4205446409833785e-14
to O 0 6.049220788692555e-17
mount O 0 2.2416839495775776e-09
a O 0 3.3901992324558705e-10
neutrophilic O 0 0.01996798627078533
leukocytosis O 0 0.01291273906826973
during O 0 5.08929176579187e-10
pyogenic B-Disease 0 0.0029108880553394556
infection I-Disease 0 0.0012114846613258123
. O 0 6.371481440321444e-14
. O 0 5.263309861731902e-13

Susceptibility O 0 7.964942483340565e-07
to O 0 9.99221372310899e-10
ankylosing B-Disease 1 0.9999997615814209
spondylitis I-Disease 1 1.0
in O 0 2.88165988848732e-08
twins O 0 2.6337927465647226e-06
: O 0 9.746309830454232e-17
the O 0 6.137237603515749e-19
role O 0 5.222705541695419e-14
of O 0 1.5258745367751576e-18
genes O 0 3.0404664805419633e-15
, O 0 4.7629999347979194e-17
HLA O 0 6.875896119834524e-12
, O 0 1.1697474179605052e-15
and O 0 7.631670293005259e-15
the O 0 3.300396793966959e-14
environment O 0 6.10299311087914e-10
. O 0 4.795553060557567e-13

OBJECTIVE O 0 2.876674766449927e-11
To O 0 4.313071385688604e-16
determine O 0 1.3017406680102613e-15
the O 0 7.201901604496629e-17
relative O 0 1.4633407900609889e-15
effects O 0 5.652648962513156e-15
of O 0 1.2253078112536284e-18
genetic O 0 1.568099491401631e-13
and O 0 8.573805134961957e-16
environmental O 0 2.1202963146383128e-16
factors O 0 6.425816930997737e-17
in O 0 1.5372739748352968e-17
susceptibility O 0 9.344344742423516e-12
to O 0 1.7479290584376805e-11
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 4.074759019090379e-08
AS B-Disease 1 0.999998927116394
) O 0 5.842285070436701e-14
. O 0 4.1499654190521595e-14

METHODS O 0 4.068422043701503e-08
Twins O 0 3.415260653127916e-05
with O 0 5.9257087084430005e-12
AS B-Disease 1 0.999998927116394
were O 0 9.997868689621409e-15
identified O 0 7.020010861133984e-15
from O 0 1.7677809484466559e-15
the O 0 6.253485576590556e-12
Royal O 0 2.073580276373832e-07
National O 0 8.568254088459071e-07
Hospital O 0 3.312298879620812e-09
for O 0 2.9892834735312235e-11
Rheumatic B-Disease 0 0.0014374000020325184
Diseases I-Disease 0 6.568385835237223e-09
database O 0 9.286267588226593e-11
. O 0 2.7581292284806214e-12

Clinical O 0 1.9003520037585986e-06
and O 0 1.0101391077765864e-11
radiographic O 0 9.282363748752687e-07
examinations O 0 6.710150302069451e-08
were O 0 2.0705440400420327e-12
performed O 0 2.4205439627493497e-13
to O 0 1.4460709264669966e-16
establish O 0 1.745283171455947e-12
diagnoses O 0 1.3765722997050034e-06
, O 0 1.0895008853428756e-12
and O 0 1.4207264531496122e-10
disease O 0 1.604384749498422e-07
severity O 0 1.62509477988175e-13
was O 0 1.6191954461258762e-12
assessed O 0 2.669055840058554e-13
using O 0 5.342175473147491e-14
a O 0 8.914981789896401e-14
combination O 0 1.1398782579722516e-13
of O 0 3.442211136930244e-16
validated O 0 6.077110342728176e-11
scoring O 0 4.576633863551116e-11
systems O 0 1.7050473533064547e-10
. O 0 3.826224493491681e-12

HLA O 0 1.75519062395324e-07
typing O 0 1.950169803421886e-09
for O 0 5.554834953016945e-14
HLA O 0 2.6040218870093668e-09
- O 0 1.9908261150725082e-10
B27 O 0 2.1446447048822925e-11
, O 0 1.133956490760528e-16
HLA O 0 1.6279684848449771e-12
- O 0 6.05589417588398e-13
B60 O 0 3.532392477481605e-13
, O 0 4.098480584672627e-18
and O 0 3.130212241811737e-17
HLA O 0 2.093354309340434e-11
- O 0 1.2231139434604188e-09
DR1 O 0 2.2459191768575693e-06
was O 0 6.689814717811271e-13
performed O 0 1.5418212513602968e-15
by O 0 1.082324989482892e-18
polymerase O 0 7.761704249968897e-15
chain O 0 4.793596075636231e-13
reaction O 0 1.7007709543795065e-16
with O 0 8.031409344946467e-20
sequence O 0 4.2517123189895025e-17
- O 0 1.1365045596246556e-13
specific O 0 6.598813881353771e-16
primers O 0 2.6580151968325083e-10
, O 0 1.1323490075150966e-15
and O 0 2.9255596849833395e-16
zygosity O 0 4.673545231370646e-11
was O 0 5.285032851756527e-15
assessed O 0 1.2910003537665478e-14
using O 0 5.007016733193405e-14
microsatellite O 0 1.1154147472325349e-07
markers O 0 1.242209691554308e-06
. O 0 1.038737984515592e-10

Genetic O 0 5.73579406193403e-09
and O 0 4.778200523371549e-15
environmental O 0 5.660673540897206e-16
variance O 0 2.709067328088001e-16
components O 0 7.354225735334285e-12
were O 0 2.4878799310935028e-14
assessed O 0 9.050887209843816e-13
with O 0 7.81407968522942e-15
the O 0 3.604807899122535e-15
program O 0 2.008333603586987e-12
Mx O 0 2.2505229017172335e-12
, O 0 1.7022732387074886e-20
using O 0 4.471158718798027e-20
data O 0 4.854850864109196e-16
from O 0 1.6062987227942742e-18
this O 0 4.379166541159327e-18
and O 0 3.5882073239057715e-15
previous O 0 7.889589284345352e-15
studies O 0 3.133751701330737e-15
of O 0 3.3120597600242926e-16
twins O 0 1.9959113473078105e-08
with O 0 3.201846882246173e-13
AS B-Disease 1 0.9999998807907104
. O 0 2.2419809064810892e-11

RESULTS O 0 1.0624050084118153e-08
Six O 0 3.331900380598718e-11
of O 0 2.986680184852847e-14
8 O 0 6.03974259494322e-10
monozygotic O 0 3.4497841738811985e-07
( O 0 1.462656601738943e-12
MZ O 1 0.9989748001098633
) O 0 2.664785579697959e-11
twin O 0 2.2477326638181694e-05
pairs O 0 3.681926443732664e-07
were O 0 4.988381929749153e-10
disease O 0 3.909862655859797e-08
concordant O 0 5.702691444064989e-11
, O 0 1.464614092338949e-15
compared O 0 4.4658541594562104e-14
with O 0 5.230658842256958e-15
4 O 0 1.1379144967873372e-13
of O 0 1.6652629626536918e-15
15 O 0 1.919628518642913e-12
B27 O 0 4.834380118445836e-10
- O 0 5.164255689749098e-09
positive O 0 2.8672816898556164e-10
dizygotic O 0 9.065884931658275e-09
( O 0 5.1178909742967404e-14
DZ O 0 1.0423587809782475e-05
) O 0 1.3803370881200483e-13
twin O 0 8.74847749798846e-09
pairs O 0 1.245891306789204e-10
( O 0 3.84338177603083e-13
27 O 0 7.53819576204684e-12
% O 0 1.1123419304822724e-16
) O 0 9.219105936171315e-17
and O 0 2.6308590925900287e-14
4 O 0 6.261642951106011e-14
of O 0 1.5617857755754333e-14
32 O 0 2.6395674979085015e-08
DZ O 1 0.9995718598365784
twin O 0 0.0007726523908786476
pairs O 0 1.45891485558991e-08
overall O 0 2.3965055717667383e-08
( O 0 9.657280807288601e-14
12 O 0 1.5484950832440197e-13
. O 0 4.609227720668802e-16
5 O 0 1.5570959235530757e-13
% O 0 5.175458657996461e-16
) O 0 9.389190813724468e-15
. O 0 1.89724849871363e-13

Nonsignificant O 0 2.2560666366189253e-06
increases O 0 1.0711694031773078e-10
in O 0 7.705790916906371e-17
similarity O 0 1.2016879716102808e-15
with O 0 6.845676604572913e-17
regard O 0 8.450518218939673e-15
to O 0 9.488640952061596e-15
age O 0 6.766904370181237e-09
at O 0 3.455260744189559e-09
disease O 0 2.2980395897320705e-06
onset O 0 1.0359061698717031e-11
and O 0 2.1390487241180166e-14
all O 0 2.1959460182976765e-16
of O 0 1.0925675327383145e-17
the O 0 4.023657898836672e-14
disease O 0 1.0862142296730326e-08
severity O 0 4.2192835461368414e-14
scores O 0 3.2470421886194104e-14
assessed O 0 1.4476310775113355e-11
were O 0 4.932405178736943e-12
noted O 0 3.491148689582779e-11
in O 0 3.6925364567223784e-13
disease O 0 0.00015113990230020136
- O 0 2.518412657082081e-05
concordant O 0 0.00010821101750480011
MZ O 1 0.9996321201324463
twins O 0 1.1507725503179245e-05
compared O 0 7.319912037617726e-12
with O 0 3.5118354621901937e-13
concordant O 0 2.5173228550556814e-06
DZ O 1 0.9958971738815308
twins O 0 6.280655361479148e-05
. O 0 4.878996512358569e-12

HLA O 0 1.5554693163721822e-05
- O 0 2.1929827198619023e-06
B27 O 0 7.912611010851833e-09
and O 0 5.399850962965573e-14
B60 O 0 8.085082950359812e-12
were O 0 5.2714190205909e-16
associated O 0 1.68622276646372e-16
with O 0 6.531919454344363e-16
the O 0 5.399644625739622e-14
disease O 0 2.4474255155837454e-07
in O 0 4.110731361155109e-15
probands O 0 1.0710462561291934e-07
, O 0 2.3691915992935094e-15
and O 0 1.5891747341556669e-15
the O 0 6.291421919026041e-16
rate O 0 5.474490638590623e-09
of O 0 8.663762998575679e-15
disease O 0 1.3498927531330196e-09
concordance O 0 2.524082559716284e-13
was O 0 3.1378206782027573e-14
significantly O 0 7.68474029528253e-14
increased O 0 1.1967949417948653e-12
among O 0 1.2125576584476327e-11
DZ O 1 0.9991838335990906
twin O 0 5.66983871976845e-05
pairs O 0 4.3206846433996304e-10
in O 0 2.7114363204227936e-15
which O 0 1.6945104173993197e-14
the O 0 3.412574788182708e-14
co O 0 0.001841857098042965
- O 0 2.5371991796419024e-07
twin O 0 3.536554800120939e-07
was O 0 1.3795829062468457e-11
positive O 0 8.703816476145904e-14
for O 0 3.918026667268876e-17
both O 0 3.5786112876463275e-15
B27 O 0 5.1169520010052594e-11
and O 0 2.541109954835169e-13
DR1 O 0 1.2901670061182813e-06
. O 0 3.963419870078866e-12

Additive O 0 3.5454078908814246e-12
genetic O 0 1.3748100748112169e-11
effects O 0 1.9441392939967272e-12
were O 0 2.504751334507239e-16
estimated O 0 3.671994499559187e-16
to O 0 2.0351990172435115e-16
contribute O 0 1.635992366967945e-13
97 O 0 8.422082475867398e-12
% O 0 1.77298686588004e-16
of O 0 1.9832947655665953e-18
the O 0 6.170390175286262e-17
population O 0 5.617968521976808e-17
variance O 0 3.268186163861951e-14
. O 0 2.868683209814732e-13

CONCLUSION O 0 1.6175764894210687e-10
Susceptibility O 0 6.048827549953728e-10
to O 0 1.7620834533247504e-13
AS B-Disease 1 0.9999986886978149
is O 0 9.098754227539283e-15
largely O 0 5.267679899524365e-16
genetically O 0 2.1772153849762554e-13
determined O 0 7.324051982298199e-14
, O 0 3.2022085864904745e-16
and O 0 6.529627700826448e-16
the O 0 1.437293679899972e-16
environmental O 0 1.0349892600944322e-12
trigger O 0 1.0578462411592326e-10
for O 0 5.460208159094662e-15
the O 0 4.367131114201006e-14
disease O 0 1.3474875659724717e-09
is O 0 1.1229334316250651e-14
probably O 0 1.51240483895268e-13
ubiquitous O 0 2.596417525424499e-10
. O 0 4.858084420855668e-12

HLA O 0 2.286793687744648e-06
- O 0 3.3551696532185815e-08
B27 O 0 1.401667115707994e-10
accounts O 0 6.285020044010693e-15
for O 0 1.8463162617467434e-17
a O 0 3.18477406763247e-17
minority O 0 4.418388127157974e-15
of O 0 1.737147735557047e-18
the O 0 8.002242853150271e-18
overall O 0 1.5224422471402793e-13
genetic O 0 5.430412928142045e-14
susceptibility O 0 3.355308110346289e-13
to O 0 1.1218257225942274e-12
AS B-Disease 1 0.9999998807907104
. O 0 1.1345008266161472e-10

Cell O 0 9.08595154669456e-08
cycle O 0 1.9509340631884697e-07
- O 0 6.651127364420972e-07
dependent O 0 1.8352282193934144e-10
colocalization O 0 7.526401191171317e-08
of O 0 3.0677649548276065e-14
BARD1 O 0 3.127230593236163e-05
and O 0 1.0051679676320938e-13
BRCA1 O 0 1.1704155700176244e-10
proteins O 0 2.984708207448344e-15
in O 0 3.147500812922463e-18
discrete O 0 1.344227328189604e-13
nuclear O 0 2.4849814508343115e-06
domains O 0 4.9281272396228815e-08
. O 0 1.2092687962095283e-11

Germ O 0 0.0005167648778297007
- O 0 3.713283877004869e-05
line O 0 1.1437134572744867e-09
mutations O 0 4.576125069155612e-12
of O 0 2.85992535183187e-17
the O 0 1.8139591730277106e-16
BRCA1 O 0 4.9331090323789795e-09
gene O 0 8.705220572169381e-12
predispose O 0 2.968545201320616e-11
women O 0 1.4739139000009144e-13
to O 0 4.59101280653369e-16
early O 0 3.91327161647359e-12
- O 0 0.09414282441139221
onset O 1 0.6446308493614197
breast B-Disease 1 0.9999988079071045
and I-Disease 1 0.9997636675834656
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999982118606567
by O 0 9.534752366918936e-16
compromising O 0 2.8168692378649496e-10
the O 0 2.816081735341905e-16
genes O 0 2.1367510625452946e-12
presumptive O 0 2.217141137350609e-08
function O 0 3.905291346383011e-13
as O 0 8.38165359329495e-15
a O 0 3.05993430463683e-14
tumor B-Disease 0 1.0147211071398488e-08
suppressor O 0 2.1369388036873715e-08
. O 0 9.330156092168806e-11

Although O 0 4.824802124665795e-13
the O 0 1.7523242912251594e-16
biochemical O 0 3.3629647460883816e-13
properties O 0 8.120930414679678e-14
of O 0 5.680382515272156e-15
BRCA1 O 0 4.572392754198518e-06
polypeptides O 0 7.0728778389650415e-09
are O 0 1.2647371485600273e-13
not O 0 3.332783479870053e-15
understood O 0 7.212277514578522e-14
, O 0 2.0341347335801763e-17
their O 0 1.2161818170685452e-16
expression O 0 2.0148605650398537e-15
pattern O 0 3.445605617231201e-13
and O 0 1.3213986721776101e-14
subcellular O 0 7.594619919927548e-13
localization O 0 8.160964308848162e-13
suggest O 0 2.679098533731744e-13
a O 0 3.723696088346433e-14
role O 0 1.3755767358514248e-10
in O 0 2.271824738490154e-15
cell O 0 1.139384350756778e-10
- O 0 1.7066376756247337e-07
cycle O 0 7.49811732703165e-08
regulation O 0 4.3438710961574145e-10
. O 0 2.4358379896449733e-12

When O 0 1.4212847565531206e-10
resting O 0 1.907390023703215e-09
cells O 0 1.7341645480728474e-11
are O 0 1.5686244443058567e-15
induced O 0 1.1251985671326126e-12
to O 0 8.080468661934921e-17
proliferate O 0 1.8545111279966164e-10
, O 0 8.259568815548167e-18
the O 0 1.3319987040340601e-18
steady O 0 3.162934757855451e-12
- O 0 3.787535606328274e-13
state O 0 1.5779321187863197e-16
levels O 0 7.238840976024185e-16
of O 0 2.8084192139119692e-18
BRCA1 O 0 1.8764708537011288e-11
increase O 0 2.1103710737299626e-16
in O 0 1.845766269357457e-18
late O 0 8.80556552542935e-16
G1 O 0 4.9042832295231875e-11
and O 0 2.5700428046035277e-14
reach O 0 1.2312080492039385e-16
a O 0 4.036050120556922e-17
maximum O 0 3.3355816532113077e-15
during O 0 4.5102986558250013e-14
S O 0 2.2240278951812797e-08
phase O 0 1.1540046696012496e-11
. O 0 7.375433814030274e-13

Moreover O 0 3.190141484310516e-10
, O 0 1.0356003537082947e-14
in O 0 9.866431410822407e-16
S O 0 5.775138145480696e-09
phase O 0 9.028368872822379e-13
cells O 0 2.617671433346319e-13
, O 0 2.6327200663267937e-15
BRCA1 O 0 7.711703275958826e-09
polypeptides O 0 9.78874648005501e-10
are O 0 6.575074957149846e-14
hyperphosphorylated O 0 3.822291372301834e-09
and O 0 7.350035226174993e-15
accumulate O 0 5.581260822430656e-13
into O 0 2.544284109161051e-15
discrete O 0 1.2800812493329872e-11
subnuclear O 0 3.2149320759344846e-05
foci O 0 2.1164906272019834e-08
termed O 0 8.235691018043667e-10
" O 0 2.1117413373517024e-11
BRCA1 O 0 1.2707059227068385e-07
nuclear O 0 2.753194294768946e-08
dots O 0 1.044151876072874e-08
. O 0 3.574470927580897e-11

" O 0 5.3564708224485e-10
BRCA1 O 0 1.3788138630843605e-06
associates O 0 2.2263028753854996e-08
in O 0 5.983043650358705e-14
vivo O 0 1.1968429802777791e-08
with O 0 2.103050882650893e-15
a O 0 4.462920249085158e-16
structurally O 0 4.888197051994281e-13
related O 0 3.022764059456423e-13
protein O 0 5.845596229292482e-10
termed O 0 9.929696176413927e-08
BARD1 O 0 0.0213681198656559
. O 0 3.672627132966788e-11

Here O 0 1.9924383323766115e-12
we O 0 1.102504352190007e-14
show O 0 1.3993643280274005e-14
that O 0 1.1481057005155589e-18
the O 0 1.3934539842461107e-18
steady O 0 4.548346833714578e-13
- O 0 9.473966749995455e-13
state O 0 2.5245697878906214e-16
levels O 0 3.7669418636882696e-15
of O 0 1.3486512973308245e-18
BARD1 O 0 9.2395542605761e-11
, O 0 4.464973605014632e-19
unlike O 0 5.400622514689315e-18
those O 0 3.256928536157103e-18
of O 0 6.310380154203205e-18
BRCA1 O 0 3.554215144419004e-09
, O 0 4.365330406858438e-15
remain O 0 2.8883795972800856e-15
relatively O 0 9.524896741530938e-17
constant O 0 3.747544470382967e-14
during O 0 2.1390324610854293e-14
cell O 0 1.7101477178815827e-10
cycle O 0 9.257154687247748e-08
progression O 0 2.8102913329774992e-09
. O 0 1.81118672577113e-12

However O 0 2.831060559593812e-11
, O 0 1.430463481499021e-14
immunostaining O 0 2.6707671629822016e-09
revealed O 0 4.872017789203653e-10
that O 0 1.9186501074974077e-13
BARD1 O 0 4.554760380415246e-05
resides O 0 3.368953171989375e-10
within O 0 1.712203749821336e-14
BRCA1 O 0 3.4456915098957097e-09
nuclear O 0 1.679929390041579e-10
dots O 0 7.138310125290315e-13
during O 0 1.0095520577011515e-14
S O 0 7.89409537738095e-10
phase O 0 1.7103236754916103e-14
of O 0 4.0583436306819613e-17
the O 0 4.3423416679721604e-16
cell O 0 2.914393552877481e-12
cycle O 0 1.885059747186446e-10
, O 0 9.315585768190438e-16
but O 0 4.920139766636863e-17
not O 0 1.3438297649378295e-17
during O 0 9.225609891891697e-18
the O 0 4.2680276293914984e-17
G1 O 0 3.389409239384911e-11
phase O 0 7.514362396210394e-13
. O 0 2.2104639353735106e-13

Nevertheless O 0 1.4672195902676322e-08
, O 0 5.407253421060854e-13
BARD1 O 0 2.2949988931486587e-07
polypeptides O 0 1.4046003249390537e-10
are O 0 2.473296607192273e-15
found O 0 1.0239369429586634e-15
exclusively O 0 1.3517134731400732e-14
in O 0 3.297032072051021e-17
the O 0 4.884962091290698e-17
nuclear O 0 4.0713790845636755e-12
fractions O 0 8.77290419968102e-17
of O 0 8.4352988905892655e-19
both O 0 1.229405854259757e-16
G1 O 0 4.193109835043396e-12
- O 0 1.9222390346129714e-10
and O 0 1.8130566492580158e-12
S O 0 1.630342616465441e-08
- O 0 1.8290802900056136e-11
phase O 0 7.215542724946233e-13
cells O 0 5.24172990169075e-13
. O 0 5.916430946507553e-14

Therefore O 0 8.401541181507488e-13
, O 0 2.975237637944212e-16
progression O 0 7.933626357866513e-14
to O 0 4.8288844338364046e-15
S O 0 2.255628999137116e-07
phase O 0 1.4385636779024047e-12
is O 0 1.392877495607443e-14
accompanied O 0 9.421656527801542e-16
by O 0 5.746824898002971e-19
the O 0 1.6797752120534049e-18
aggregation O 0 4.19894797913916e-14
of O 0 1.5136154777332022e-15
nuclear O 0 1.6696825033690743e-09
BARD1 O 0 7.341157681750587e-10
polypeptides O 0 2.4461366092409786e-12
into O 0 3.848896028280091e-14
BRCA1 O 0 1.6192265306358422e-08
nuclear O 0 1.0566690855640104e-09
dots O 0 7.849113581315237e-10
. O 0 3.4240403481294868e-12

This O 0 1.2175432001851078e-14
cell O 0 2.310256673465627e-11
cycle O 0 7.361029563668353e-09
- O 0 2.6146148002226255e-07
dependent O 0 2.758904216193514e-11
colocalization O 0 1.5834377364853935e-08
of O 0 2.153662583556995e-15
BARD1 O 0 1.5465706383110955e-05
and O 0 1.8819241141571769e-13
BRCA1 O 0 4.4068521054541065e-10
indicates O 0 1.5838587765545226e-14
a O 0 4.243902079645777e-17
role O 0 1.5882671425878486e-13
for O 0 7.805466313067909e-16
BARD1 O 0 8.580972377103535e-08
in O 0 4.5880564497895356e-15
BRCA1 O 0 3.3403864563297248e-06
- O 0 2.03932040676591e-06
mediated O 0 1.4736765763245785e-07
tumor B-Disease 0 4.356287774953671e-08
suppression O 0 1.9089760328050431e-10
. O 0 1.157047764890895e-12

Ethnic O 0 8.038342214078398e-11
differences O 0 3.045766069909028e-11
in O 0 5.761807792491712e-15
the O 0 2.54218507681446e-14
HFE O 0 3.036471753148362e-05
codon O 0 6.830212839759042e-08
282 O 0 1.4835578987515419e-08
( O 0 2.185847336466651e-11
Cys O 0 0.0002831883612088859
/ O 0 1.0662157365004532e-05
Tyr O 0 4.763258232287626e-08
) O 0 1.0194520602040472e-13
polymorphism O 0 1.3917676733310458e-10
. O 0 7.780184482775176e-12

Recent O 0 3.47896928279412e-12
studies O 0 3.287092549108389e-13
have O 0 2.574001667192405e-14
shown O 0 7.181563937280755e-12
that O 0 1.2295650053673057e-09
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 9.891433592201793e-07
HH B-Disease 0 0.16072218120098114
) O 0 3.938442318584742e-14
is O 0 5.961420847391081e-15
likely O 0 2.334442453797228e-14
to O 0 1.687986050831887e-16
be O 0 1.1280775304763763e-13
caused O 0 3.03066969747402e-15
by O 0 3.0627672433866134e-17
homozygosity O 0 5.968877059281397e-10
for O 0 5.741268196432861e-16
a O 0 1.854765493481455e-14
Cys282Tyr O 0 9.426579516969014e-09
mutation O 0 2.0863616823768583e-12
in O 0 3.560947421382964e-16
the O 0 1.3331953423856681e-15
HFE O 0 3.824612093694668e-08
gene O 0 1.569879642948635e-10
located O 0 7.160094045444154e-11
4 O 0 2.0702933811733715e-10
. O 0 2.9473977512101124e-12

5 O 0 3.264492010046638e-10
Mb O 0 5.7839926626002125e-08
telomeric O 0 6.013792841486065e-08
to O 0 8.60126965311625e-13
HLA O 0 9.98064138002519e-08
- O 0 1.8822591485445628e-08
A O 0 1.2976777638562531e-11
. O 0 5.665034955894266e-13

Population O 0 6.451288071460115e-13
studies O 0 3.871411180457647e-14
of O 0 1.1014938041644967e-17
this O 0 2.800181942577013e-18
polymorphism O 0 3.95247148812089e-13
are O 0 1.581463319734084e-16
facilitated O 0 3.339222836093317e-15
by O 0 9.261652136414102e-17
the O 0 9.821964431022822e-17
fact O 0 5.987039612990672e-14
that O 0 1.5786975718728416e-15
the O 0 9.60481236781047e-15
Cys282Tyr O 0 1.1783150455357827e-07
mutation O 0 5.164326865453317e-12
creates O 0 6.212348886182328e-13
a O 0 3.750161124563625e-14
Rsal O 0 6.203078939392981e-09
restriction O 0 1.979974777882587e-12
site O 0 1.5206270270740063e-11
. O 0 3.325378384114175e-12

We O 0 1.4976189177673405e-09
have O 0 7.69786998359133e-14
studied O 0 2.2681987852605362e-13
the O 0 4.8951524799813184e-15
codon O 0 5.612976194946384e-10
282 O 0 7.529908641057403e-11
( O 0 1.702324804557509e-13
Cys O 0 1.6420242445747135e-06
/ O 0 1.8984232497132325e-07
Tyr O 0 1.584536613030707e-09
) O 0 7.804275702381425e-16
polymorphism O 0 6.327615975675396e-14
in O 0 1.60896125174996e-17
different O 0 2.8925665605477024e-17
ethnic O 0 3.99664830513769e-15
groups O 0 7.50980224187292e-14
. O 0 1.4755368151278536e-13

In O 0 2.347154859794892e-13
agreement O 0 6.429848109024486e-14
with O 0 2.601023279494815e-17
previous O 0 1.1357579974904399e-15
observations O 0 1.0885074715498086e-13
the O 0 1.057230949379033e-14
Tyr O 0 1.8609751517573159e-09
allele O 0 4.407923678839687e-12
appeared O 0 9.131592183797554e-12
to O 0 1.7862042856263514e-16
be O 0 5.54359177648827e-15
rare O 0 3.745733852754916e-15
or O 0 3.195564472757706e-12
absent O 0 1.5273103615154326e-10
in O 0 8.42753313288298e-15
Asiatic O 0 2.993825326536026e-11
( O 0 9.69777423377163e-15
Indian O 0 8.456879402492234e-13
, O 0 2.7121486751314344e-16
Chinese O 0 5.87818101384027e-16
) O 0 5.518039015931094e-16
populations O 0 2.787559679612306e-13
. O 0 4.739321456982692e-13

The O 0 6.81081222236174e-13
highest O 0 1.5491939328593496e-11
allele O 0 4.8788755153961194e-12
frequency O 0 6.62034337940709e-13
( O 0 3.9128270258202355e-14
7 O 0 2.0445633846979255e-13
. O 0 3.760807095218882e-17
5 O 0 1.2572180540279098e-14
% O 0 8.359575778786441e-18
) O 0 6.045504100764231e-18
was O 0 2.796536873600486e-14
found O 0 9.574093904826664e-13
in O 0 2.250955227333512e-13
Swedes O 0 2.644426103870501e-06
. O 0 6.0709549366821935e-12

Saamis O 0 1.7699279851512983e-05
( O 0 1.0548395490417306e-11
2 O 0 5.265438150596491e-13
% O 0 7.113091311707759e-15
) O 0 1.1286919427653261e-15
and O 0 1.1300652796343569e-13
Mordvinians O 0 1.800186488765121e-08
( O 0 7.476152079274054e-16
1 O 0 2.564032523507607e-16
. O 0 1.9393861574959023e-17
8 O 0 5.1097855466178746e-14
% O 0 1.4687857362216212e-18
) O 0 2.2539267552980195e-18
had O 0 4.199458062379997e-15
significantly O 0 5.505258453427329e-15
lower O 0 2.2651970021394206e-14
frequencies O 0 4.7232352848747966e-15
of O 0 9.133872848807157e-16
the O 0 4.965664923521629e-14
Tyr O 0 2.2834569790575188e-09
allele O 0 5.6503864087620315e-11
. O 0 2.899323793201236e-12

Comparisons O 0 6.282369156146439e-12
with O 0 7.815719541015304e-15
allele O 0 3.7191536200568975e-14
frequencies O 0 1.150944662959999e-15
based O 0 7.544797217506319e-16
on O 0 7.370310823240009e-14
prevalence O 0 4.699341957237202e-11
estimates O 0 1.3004459569745594e-14
of O 0 3.7507508289015036e-16
HH B-Disease 0 0.06910835951566696
showed O 0 1.2698943407940533e-07
some O 0 9.782594207285544e-16
disagreements O 0 4.832967012702305e-11
with O 0 4.376497146604557e-17
the O 0 6.535053161920571e-18
RFLP O 0 2.782419043431683e-12
data O 0 6.100260812984259e-13
, O 0 9.698282400600423e-17
particularly O 0 7.988098792594553e-16
in O 0 1.1253472214148557e-15
Finns O 0 4.876773473938556e-08
. O 0 2.26417127234535e-12

The O 0 1.6641541660325498e-12
newly O 0 1.8634900289526968e-09
described O 0 1.923601469083769e-12
HFE O 0 1.1973435221079853e-07
marker O 0 2.459416004185755e-10
provides O 0 1.238921210630975e-15
a O 0 2.728137447714819e-17
new O 0 4.0310205315603547e-16
approach O 0 3.3709740778793814e-16
to O 0 3.0656396590829767e-19
the O 0 2.4159515849624564e-19
screening O 0 1.1877066340246645e-14
of O 0 3.072490007024623e-18
HH B-Disease 0 1.5688215171394404e-08
as O 0 2.911146191188034e-14
well O 0 1.1198442601147813e-15
as O 0 2.2281289027797056e-16
studies O 0 3.007759070907347e-17
of O 0 7.285453732643084e-19
the O 0 3.101708590519895e-17
relationship O 0 9.70094230640095e-14
between O 0 9.196174239660079e-16
the O 0 8.917426496388766e-15
HFE O 0 1.9219608020648593e-06
Tyr O 0 1.2859416642641008e-08
allele O 0 1.5034137823555227e-10
and O 0 1.8434014731338877e-11
different O 0 3.224233759754197e-13
disorders O 0 1.1739332421711879e-06
including O 0 2.495373352395802e-11
cancer B-Disease 0 2.3660584247409133e-06

Autosomal B-Disease 1 0.9999401569366455
dominant I-Disease 1 0.9997829794883728
neurohypophyseal I-Disease 1 0.9999620914459229
diabetes I-Disease 1 0.9999963045120239
insipidus I-Disease 1 0.9998862743377686
associated O 0 2.006794552755764e-08
with O 0 5.787816108543745e-14
a O 0 2.875172701918144e-14
missense O 0 1.1772901764572907e-08
mutation O 0 1.2876878729972674e-10
encoding O 0 5.972814604016108e-11
Gly23 O 0 0.0002962439029943198
- O 0 0.000272978883003816
- O 0 1.0338299034629017e-05
> O 0 7.298449622439307e-10
Val O 0 3.0466846510535106e-05
in O 0 5.569574207213435e-13
neurophysin O 0 1.1750399835364078e-06
II O 0 2.385056063758384e-07
. O 0 2.303475118980991e-12

Autosomal B-Disease 1 0.9998123049736023
dominant I-Disease 1 0.9995548129081726
neurohypophyseal I-Disease 1 0.999829888343811
diabetes I-Disease 1 0.9999797344207764
insipidus I-Disease 1 0.9992364645004272
( O 0 3.8786049927352906e-09
ADNDI B-Disease 0 0.0004952917224727571
) O 0 1.3231680291367343e-12
is O 0 1.2957850938077886e-12
an O 0 6.47386699803576e-10
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 3.3322155559289968e-06
by O 0 5.205503454501492e-13
progressive O 0 1.0178215215095321e-10
degeneration O 0 1.122024784194764e-08
of O 0 1.6662024810108745e-16
the O 0 7.032843092647531e-17
magnocellular O 0 7.280173859591788e-12
neurons O 0 6.754019137586789e-14
of O 0 2.525001907042619e-17
the O 0 3.855564009283731e-16
hypothalamus O 0 1.0730666355485141e-11
leading O 0 9.508439174910066e-12
to O 0 7.792885226823223e-15
decreased O 0 3.685957317145494e-09
ability O 0 1.2024917465849189e-13
to O 0 6.284965278036697e-17
produce O 0 1.270719234046716e-13
the O 0 2.4589889925153742e-14
hormone O 0 1.328355758722921e-10
arginine O 0 1.0701887293018686e-11
vasopressin O 0 8.537236022287953e-12
( O 0 2.248405251586462e-14
AVP O 0 1.080869793668171e-08
) O 0 1.282122736971647e-13
. O 0 1.0586095802039841e-13

Affected O 0 1.0526578497760397e-09
individuals O 0 3.266904162555623e-13
are O 0 1.8944271336102797e-14
not O 0 1.0475159049904998e-14
symptomatic O 0 3.561078862346356e-11
at O 0 5.445509494717005e-12
birth O 0 3.732400499778521e-10
, O 0 5.0502930017213427e-14
but O 0 1.2171544154504499e-12
usually O 0 7.219090880639101e-10
develop O 0 5.28571717950399e-07
diabetes B-Disease 0 2.750007843133062e-05
insipidus I-Disease 0 2.732373786784592e-06
at O 0 7.543155433609172e-09
1 O 0 3.9813274899103135e-10
- O 0 0.00016609196609351784
6 O 0 8.29253465894908e-09
yr O 0 3.2858821214176714e-05
of O 0 4.152089642158602e-13
age O 0 1.2421571549126043e-09
. O 0 1.0500635734198016e-12

The O 0 4.809437150290509e-14
genetic O 0 5.34547319602785e-12
locus O 0 3.112564928020589e-10
of O 0 1.5065315802590545e-13
the O 0 2.532927481039421e-13
disease O 0 8.856993360950582e-08
is O 0 1.0232971154461312e-14
the O 0 1.063464095431288e-14
AVP O 0 0.0001116374260163866
- O 0 4.474035506518703e-07
neurophysin O 0 4.2076996464857075e-07
II O 0 5.40926841097189e-08
( O 0 5.587305029313696e-15
NPII O 0 1.079253700297933e-10
) O 0 7.413636018508562e-18
gene O 0 5.6913795440263586e-15
, O 0 7.600459061192849e-17
and O 0 1.1299844091637178e-15
mutations O 0 1.5810674980614586e-13
that O 0 1.842800814288309e-14
cause O 0 8.137246302122869e-13
ADNDI B-Disease 0 0.0005731804994866252
have O 0 3.6068942277367455e-10
been O 0 2.2659857931012217e-12
found O 0 8.979990145582817e-13
in O 0 1.2087353386709958e-16
both O 0 2.456361136323989e-16
the O 0 2.0014682131375997e-17
signal O 0 2.1538349547617613e-15
peptide O 0 3.574175429041116e-16
of O 0 3.4265514333381456e-18
the O 0 6.29262152943759e-16
prepro O 0 1.4536262860076476e-08
- O 0 3.17077364364593e-09
AVP O 0 3.5598050089902245e-06
- O 0 6.935388707773882e-09
NPII O 0 4.161947231295926e-08
precursor O 0 1.25808532428634e-12
and O 0 9.662495142111899e-14
within O 0 4.682243972425372e-15
NPII O 0 2.1791635163026513e-07
itself O 0 2.1407977387338795e-12
. O 0 1.850848250703474e-12

An O 0 9.684734568124465e-13
affected O 0 3.8774400357155514e-11
girl O 0 5.30532861375832e-06
who O 0 2.4737451670420185e-11
presented O 0 2.527848705369002e-14
at O 0 1.833245198441108e-13
9 O 0 6.54384790170319e-14
months O 0 1.3783368198151073e-14
of O 0 5.682933963797743e-17
age O 0 2.7109453570872688e-11
and O 0 2.653102008378337e-14
her O 0 1.8586017056995696e-13
similarly O 0 3.312532268883589e-13
affected O 0 5.425953740131884e-13
younger O 0 9.026836895152657e-13
brother O 0 8.200356366172556e-11
and O 0 3.9201278399618456e-13
father O 0 8.119761807368064e-12
were O 0 3.5999659199828504e-14
all O 0 1.1306607385023207e-16
found O 0 6.461983014384009e-15
to O 0 1.8099234845505175e-15
have O 0 1.0260532928938609e-13
a O 0 7.278017440974778e-17
novel O 0 1.763351942761504e-12
missense O 0 1.3819044797358515e-09
mutation O 0 2.200983492683939e-11
( O 0 1.9315261602604814e-14
G1758 O 0 3.877521220774227e-11
- O 0 1.733280075022492e-09
- O 0 8.610676616171986e-09
> O 0 7.79251056043373e-12
T O 0 7.265476553719452e-10
) O 0 5.014958653073204e-18
encoding O 0 3.510714992713885e-18
the O 0 8.691451393890679e-19
amino O 0 8.1434441057254e-16
acid O 0 2.9318957031870384e-15
substitution O 0 9.266149960773361e-15
Gly23 O 0 1.2178139385810027e-08
- O 0 9.104181231123221e-07
- O 0 1.1324987099214923e-06
> O 0 2.4822396915702427e-10
Val O 0 9.009895620692987e-06
within O 0 3.1299053626643314e-11
NPII O 0 5.224708729656413e-05
. O 0 5.600779388881261e-12

The O 0 9.936474386351701e-13
mutation O 0 1.4621114041712957e-10
was O 0 7.959203608687293e-12
confirmed O 0 1.7618641056727294e-14
by O 0 9.91237080519956e-18
restriction O 0 4.681603276704069e-14
endonuclease O 0 2.8921645078838765e-09
analysis O 0 1.3632502245120026e-11
. O 0 1.3124378970760797e-12

A O 0 1.678352010321682e-12
T1 O 0 1.403262173127473e-09
- O 0 7.049442952121454e-13
weighted O 0 4.471044438543806e-14
magnetic O 0 6.95929522183744e-16
resonance O 0 6.334652786588006e-15
imaging O 0 9.168076298138317e-10
of O 0 1.6596520978264667e-13
the O 0 1.664942489432164e-11
fathers O 0 1.2659104413614841e-06
pituitary O 0 2.316695372428512e-06
gland O 0 1.914234548650029e-09
demonstrates O 0 2.6263245050950346e-12
an O 0 5.804472842044911e-15
attenuated O 0 7.094525358297687e-07
posterior O 0 3.485137995085097e-06
pituitary O 0 4.058691411046311e-05
bright O 0 5.061492114322164e-09
spot O 0 3.64606194125372e-07
. O 0 1.2559839279724372e-10

This O 0 1.2809935404090034e-13
mutation O 0 1.4996698327607305e-11
may O 0 2.378175273083736e-14
be O 0 8.449404904972709e-19
valuable O 0 6.128026616522726e-17
for O 0 9.424055483926843e-18
developing O 0 3.765207004687021e-13
models O 0 4.2065717575923145e-10
of O 0 2.856353662709227e-14
dominantly B-Disease 0 2.32747224799823e-05
inherited I-Disease 0 0.03844327852129936
neurodegeneration I-Disease 1 1.0
, O 0 1.0769392105522413e-12
as O 0 5.63013588556632e-16
the O 0 8.455051446629149e-18
early O 0 2.77471963421982e-15
age O 0 5.73874021220222e-12
of O 0 2.3824053132706765e-15
onset O 0 9.291157426760677e-11
of O 0 2.1591597596220397e-13
symptoms O 0 4.67756056110602e-10
suggests O 0 7.652830975972684e-16
that O 0 2.2051367889965287e-17
this O 0 2.1169088776810102e-17
mutation O 0 1.2981078885421216e-12
may O 0 1.4103310533308822e-11
be O 0 4.7956874338643193e-14
particularly O 0 1.6005088820228767e-15
deleterious O 0 3.6621638881129126e-14
to O 0 6.110569267479815e-16
the O 0 8.93305340723266e-15
magnocellular O 0 4.286561938737776e-10
neuron O 0 1.595958643019202e-10
. O 0 8.005632289899423e-14
. O 0 5.171539195145125e-13

Frequent O 0 4.759350691330155e-09
inactivation O 0 1.0493952373735738e-07
of O 0 1.8876184794923423e-13
PTEN O 0 2.081551792798564e-05
/ O 0 1.0348863725084811e-05
MMAC1 O 0 0.00021965829364489764
in O 0 2.1179765840456666e-12
primary O 0 1.0996191122103482e-05
prostate B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999996423721313
. O 0 6.129287632994362e-10

Sporadic B-Disease 0 0.002101088408380747
prostate I-Disease 1 0.9999041557312012
carcinoma I-Disease 1 1.0
is O 0 4.986985935317989e-09
the O 0 2.7468954489354635e-15
most O 0 2.002623268292634e-15
common O 0 3.950981035394374e-12
male B-Disease 0 1.8463862383466534e-10
cancer I-Disease 0 3.038547885525489e-11
in O 0 1.6976983423633415e-16
the O 0 1.5705809591239073e-13
Western O 0 2.0497822189602388e-11
world O 0 1.6166395999661631e-09
, O 0 2.5149766103673744e-16
yet O 0 1.0461371074059372e-16
many O 0 2.0802827263642034e-19
of O 0 3.848152518558141e-19
the O 0 1.0213455449182124e-17
major O 0 5.334047683798818e-15
genetic O 0 4.831187516419989e-15
events O 0 3.5532672148315316e-16
involved O 0 1.5275797120295476e-12
in O 0 5.7555216433527825e-16
the O 0 3.8711562976559064e-16
progression O 0 2.4817341649600866e-13
of O 0 1.2258841824326492e-16
this O 0 4.014219156595533e-15
often O 0 3.522276914580402e-11
fatal O 0 6.138957360235509e-07
cancer B-Disease 0 1.3422562687992468e-06
remain O 0 5.220709281550384e-12
to O 0 8.264340377133177e-15
be O 0 3.320278427199064e-11
elucidated O 0 2.508753915719808e-08
. O 0 4.225255562095853e-12

Numerous O 0 8.52718382016171e-11
cytogenetic O 0 9.236304322257638e-06
and O 0 2.3624099204644367e-11
allelotype O 0 5.182177460483217e-07
studies O 0 1.1654805592842266e-11
have O 0 1.015558893490559e-13
reported O 0 2.2877429117773573e-12
frequent O 0 1.0769618703776462e-12
loss O 0 4.156584364894966e-12
of O 0 4.636049018943609e-16
heterozygosity O 0 1.7631561766151549e-09
on O 0 1.2012510430814416e-10
chromosomal O 0 0.09654778987169266
arm O 0 0.012770989909768105
10q O 0 2.23145519839818e-08
in O 0 2.3158219591111473e-13
sporadic B-Disease 0 6.4161854425037745e-06
prostate I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999978542327881
. O 0 8.591670430657672e-11

Deletion O 0 2.2802944954491977e-07
mapping O 0 3.930364655957419e-08
studies O 0 1.1426434909367345e-08
have O 0 4.325124459969576e-12
unambiguously O 0 3.003752357955136e-09
identified O 0 3.580038349104697e-11
a O 0 7.147598078726183e-14
region O 0 4.686912750268002e-13
of O 0 1.7576207882443406e-15
chromosome O 0 1.661606603420296e-07
10q23 O 0 9.445323689849516e-11
to O 0 3.4391395837052633e-16
be O 0 5.957532966163184e-15
the O 0 2.8181434664750814e-17
minimal O 0 5.7827256946406305e-15
area O 0 1.812525823874367e-14
of O 0 1.3603416895539844e-14
loss O 0 9.087053332024198e-10
. O 0 1.3029599101044287e-12

A O 0 1.5261470472788252e-12
new O 0 1.90444075711272e-14
tumor B-Disease 0 9.243669198133464e-13
suppressor O 0 2.924249167465809e-12
gene O 0 5.494590546439859e-11
, O 0 7.495749626464793e-14
PTEN O 0 8.237603651650716e-06
/ O 0 5.92019350733608e-05
MMAC1 O 0 0.010026620700955391
, O 0 1.250121696699108e-13
was O 0 6.88789303371351e-12
isolated O 0 2.4183911817576842e-11
recently O 0 7.757642528360975e-09
at O 0 4.322878589379381e-13
this O 0 1.323188018690773e-16
region O 0 2.8181800900621383e-14
of O 0 8.949353073994912e-16
chromosome O 0 1.7888231340634775e-08
10q23 O 0 1.872794974655534e-11
and O 0 3.9845440984423073e-16
found O 0 7.366255907114913e-16
to O 0 4.975839792980469e-17
be O 0 1.3653013215700425e-14
inactivated O 0 2.746951971444034e-12
by O 0 2.6343032784386917e-18
mutation O 0 1.463241691441325e-13
in O 0 1.0108854569667192e-14
three O 0 3.8302918170529665e-08
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999974966049194
cell O 0 6.811550212759698e-10
lines O 0 5.765804722557277e-09
. O 0 3.1525693514056208e-12

We O 0 9.270380019188451e-10
screened O 0 6.721787144670088e-07
80 O 0 4.216693660907822e-10
prostate B-Disease 0 0.021989936009049416
tumors I-Disease 1 1.0
by O 0 4.84092797179694e-15
microsatellite O 0 5.032229299928304e-09
analysis O 0 9.925454555470559e-12
and O 0 7.771014734481163e-13
found O 0 7.878319307694226e-13
chromosome O 0 3.246042368232338e-08
10q23 O 0 1.0150995322089074e-10
to O 0 5.3220122985304e-16
be O 0 3.4003064053263242e-15
deleted O 0 6.02124123130765e-12
in O 0 3.3751834081107617e-15
23 O 0 1.756034011778096e-13
cases O 0 1.3703738122559928e-13
. O 0 4.237552962606944e-13

We O 0 2.427780199099061e-09
then O 0 4.57872509438545e-13
proceeded O 0 8.133854951608652e-15
with O 0 6.233338930094277e-19
sequence O 0 2.419715877135032e-18
analysis O 0 8.813689663271928e-18
of O 0 1.04495948345507e-18
the O 0 1.0238069862669865e-17
entire O 0 6.189097086391204e-13
PTEN O 0 1.6733775964894448e-07
/ O 0 2.4111626029110766e-09
MMAC1 O 0 7.80043691861465e-08
coding O 0 2.273460308899189e-10
region O 0 3.7952662388686387e-13
and O 0 3.688689148372655e-15
tested O 0 9.8206599102868e-12
for O 0 3.3779477481106016e-18
homozygous O 0 2.0796979047742192e-13
deletion O 0 5.67614260715138e-13
with O 0 1.2940968521118253e-14
new O 0 9.729056752935672e-13
intragenic O 0 2.828181466796309e-09
markers O 0 4.66784610964055e-10
in O 0 3.097406258717884e-16
these O 0 3.72788543918817e-16
23 O 0 7.562338613393421e-14
cases O 0 7.579244882800849e-15
with O 0 1.3190468004962638e-14
10q23 O 0 2.2856953829641924e-10
loss O 0 9.366985269029793e-13
of O 0 9.455722710632452e-15
heterozygosity O 0 6.868503277246418e-08
. O 0 3.002529128104392e-11

The O 0 1.4398571192357186e-15
identification O 0 4.187093498932452e-15
of O 0 9.763949291580803e-17
the O 0 7.822874428320761e-16
second O 0 2.2878837713236067e-11
mutational O 0 3.0733715572495157e-09
event O 0 6.545898263536631e-13
in O 0 1.1387165776960808e-15
10 O 0 5.262643822784817e-14
( O 0 7.714353625909724e-16
43 O 0 1.4350722216463496e-12
% O 0 1.2121719948599789e-14
) O 0 1.846033222119292e-11
tumors B-Disease 1 1.0
establishes O 0 8.450553536931693e-07
PTEN O 0 0.0005449242889881134
/ O 0 8.04575302026933e-06
MMAC1 O 0 5.988672910461901e-06
as O 0 2.587685018587177e-15
a O 0 1.3004396254032787e-16
main O 0 1.248624565964836e-14
inactivation O 0 1.8697265957712261e-10
target O 0 6.076058032362594e-14
of O 0 1.187429018976202e-16
10q O 0 8.120911582087942e-11
loss O 0 6.459651823859103e-12
in O 0 1.8836073041486427e-14
sporadic B-Disease 0 0.0001888275146484375
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 9.094738308811079e-13
. O 0 7.189042655446343e-13

Risk O 0 8.205405777061969e-08
reversals O 0 9.17496426056097e-11
in O 0 9.206459337222114e-16
predictive O 0 5.3206865996413555e-11
testing O 0 5.248340095853621e-10
for O 0 1.5880318978214736e-12
Huntington B-Disease 1 0.9999951124191284
disease I-Disease 1 0.9999998807907104
. O 0 7.146941372049298e-11

The O 0 1.9854399344081597e-15
first O 0 4.468200970115697e-16
predictive O 0 2.1658013923953057e-12
testing O 0 3.3341000099662566e-11
for O 0 5.396144346788388e-14
Huntington B-Disease 1 0.9999979734420776
disease I-Disease 1 1.0
( O 0 5.1154122170798955e-14
HD B-Disease 0 2.0705529379938525e-07
) O 0 1.2808364666192645e-14
was O 0 1.4099531546636623e-13
based O 0 4.962191974617834e-17
on O 0 5.038840608054696e-15
analysis O 0 7.828273866312813e-17
of O 0 4.962035223891755e-19
linked O 0 1.149423302848271e-13
polymorphic O 0 1.2002775346981603e-14
DNA O 0 3.58378555781122e-13
markers O 0 1.481694107685616e-12
to O 0 3.50239479652252e-18
estimate O 0 1.9488066064723584e-15
the O 0 1.2408503281683466e-16
likelihood O 0 1.1185305204839194e-13
of O 0 1.1041825547456003e-16
inheriting O 0 2.4320137917421825e-11
the O 0 9.560939449274487e-16
mutation O 0 6.626719572383477e-14
for O 0 1.136985369406835e-14
HD B-Disease 0 7.889629500823503e-07
. O 0 1.4799212202931677e-11

Limits O 0 2.817247737180173e-12
to O 0 9.459356905492647e-17
accuracy O 0 8.541393842751745e-15
included O 0 7.293135655594288e-17
recombination O 0 1.584144179012144e-16
between O 0 2.6779027691144735e-17
the O 0 2.0734543504075782e-18
DNA O 0 2.4404523540910716e-11
markers O 0 5.946882808416376e-08
and O 0 7.422884355789972e-12
the O 0 5.4170962996617864e-15
mutation O 0 2.284309408295826e-10
, O 0 2.0536462883979228e-13
pedigree O 0 3.742676568663228e-08
structure O 0 1.0220040091990512e-10
, O 0 1.3355477646384301e-14
and O 0 4.755230061868086e-17
whether O 0 9.084521003530977e-18
DNA O 0 7.600470681426094e-14
samples O 0 1.9161960158799868e-13
were O 0 9.805492287176686e-17
available O 0 5.096637279170773e-17
from O 0 9.651299865296391e-17
family O 0 1.81243231143699e-14
members O 0 1.0124489273214202e-13
. O 0 2.2488739657381546e-13

With O 0 4.3053004195568734e-14
direct O 0 2.532423699723712e-14
tests O 0 2.818969363493906e-11
for O 0 1.2117540846856713e-17
the O 0 2.5824952609542398e-17
HD B-Disease 0 7.858016601858253e-07
mutation O 0 1.1095302194369383e-12
, O 0 2.305338338202099e-16
we O 0 5.703289674297701e-15
have O 0 3.6600078583899054e-17
assessed O 0 1.5391415567525394e-15
the O 0 5.7095496580594944e-18
accuracy O 0 7.928487510619475e-13
of O 0 1.7572509789535253e-16
results O 0 1.6574298137157209e-15
obtained O 0 1.7178470062472552e-17
by O 0 8.412776727063401e-18
linkage O 0 2.069801795234749e-12
approaches O 0 6.176405686810632e-14
when O 0 5.044959065845893e-14
requested O 0 2.380571359884929e-14
to O 0 1.810068327184498e-15
do O 0 3.8061475629222463e-13
so O 0 4.0108786836446885e-17
by O 0 3.001785710190887e-18
the O 0 2.9272008113186447e-16
test O 0 6.4553284592760996e-12
individuals O 0 1.8730911783502438e-15
. O 0 1.9142480433892092e-14

For O 0 1.865132397485536e-13
six O 0 6.398972064031172e-13
such O 0 2.699432328312983e-16
individuals O 0 5.3904016328125935e-15
, O 0 6.81992759706977e-16
there O 0 1.9041918723630371e-16
was O 0 1.8442513141647687e-12
significant O 0 7.587315412722288e-15
disparity O 0 4.471176900944229e-12
between O 0 2.3617755293787665e-14
the O 0 3.1509625637859973e-13
tests O 0 3.7704537270144556e-09
. O 0 1.1189743657482806e-13

Three O 0 4.3444360522254533e-13
went O 0 1.95315616978442e-12
from O 0 7.075521641788327e-17
a O 0 4.1963976264624485e-16
decreased O 0 1.7566389315382125e-11
risk O 0 2.4667223016798523e-13
to O 0 3.0068282032050104e-18
an O 0 1.9180957329037593e-15
increased O 0 3.4173366914025394e-10
risk O 0 1.4869113718063431e-09
, O 0 1.6715438178367009e-16
while O 0 4.303851167359945e-16
in O 0 2.626976474464215e-19
another O 0 8.474559343323355e-17
three O 0 7.613060979154082e-15
the O 0 3.573190530893784e-14
risk O 0 4.1159822772307564e-10
was O 0 1.2549397632177772e-10
decreased O 0 9.725328986576187e-09
. O 0 1.5967304518513248e-12

Knowledge O 0 4.656598999626393e-13
of O 0 5.089953328949099e-17
the O 0 2.0184654512365843e-18
potential O 0 2.3845510594843085e-15
reasons O 0 1.2263324812374284e-17
for O 0 3.820230778487472e-19
these O 0 5.604373643173377e-18
changes O 0 1.949966618093623e-15
in O 0 3.385961267089862e-17
results O 0 2.7294702956148775e-13
and O 0 1.799480838860293e-14
impact O 0 3.894575752795863e-15
of O 0 1.766200800211747e-18
these O 0 2.369606168981631e-16
risk O 0 7.531562857101062e-14
reversals O 0 1.4392345076678394e-14
on O 0 7.955507590586344e-14
both O 0 1.4433230001789643e-13
patients O 0 8.018144321783084e-15
and O 0 1.241759432748767e-16
the O 0 1.9047296059356456e-16
counseling O 0 1.5048552681751204e-12
team O 0 1.5162919747915837e-14
can O 0 1.4962032331947324e-16
assist O 0 5.147381633377349e-16
in O 0 6.185706251508294e-18
the O 0 1.2314798607532234e-17
development O 0 2.01839729155411e-17
of O 0 2.0525984129787314e-19
strategies O 0 5.180119986184319e-16
for O 0 6.731652486828499e-18
the O 0 1.1329145078865072e-16
prevention O 0 1.543978660201173e-11
and O 0 8.079986874888478e-14
, O 0 2.2908636370119318e-17
where O 0 2.1325041769906154e-16
necessary O 0 1.9113173517433567e-15
, O 0 6.038500527953867e-17
management O 0 4.518405142295051e-16
of O 0 1.2960109707140218e-18
a O 0 4.9641280669421306e-15
risk O 0 1.4193065125955862e-11
reversal O 0 9.370370588669425e-15
in O 0 1.2076371654179643e-18
any O 0 1.4630992003825642e-17
predictive O 0 3.4410869336268246e-13
testing O 0 1.473439642865615e-12
program O 0 1.9494952866101235e-14
. O 0 5.360028460692153e-17
. O 0 9.828720445219461e-15

A O 0 8.494324167662715e-12
novel O 0 1.2884046260430715e-11
common O 0 2.7090625749626174e-12
missense O 0 8.406943585725912e-09
mutation O 0 6.933423973842778e-11
G301C O 0 2.550391668687535e-11
in O 0 4.012977670992654e-16
the O 0 7.789761263434631e-16
N O 0 3.1306390724239463e-07
- O 0 1.6749774545132823e-07
acetylgalactosamine O 0 8.410696318605915e-05
- O 0 1.6794160728750285e-07
6 O 0 1.9354169655816378e-10
- O 0 1.850067543607281e-09
sulfate O 0 1.3988493696714954e-10
sulfatase O 0 7.600200468971252e-09
gene O 0 3.8833092991241713e-11
in O 0 3.586457438540039e-14
mucopolysaccharidosis B-Disease 0 6.868555146866129e-07
IVA I-Disease 0 0.0003854968526866287
. O 0 3.3934972887283976e-11

Mucopolysaccharidosis B-Disease 0 0.1313926875591278
IVA I-Disease 1 0.9993556141853333
( O 0 5.705190415028483e-05
MPS B-Disease 1 0.9999996423721313
IVA I-Disease 1 0.9999997615814209
) O 0 6.065368346463984e-11
is O 0 4.571554072796413e-12
an O 0 6.627080828547349e-12
autosomal B-Disease 1 0.9999970197677612
recessive I-Disease 1 0.9999985694885254
lysosomal I-Disease 1 0.999997615814209
storage I-Disease 1 0.9999969005584717
disorder I-Disease 1 0.9999967813491821
caused O 0 5.29561845763471e-11
by O 0 9.69222108576943e-16
a O 0 8.568068129988227e-12
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 4.823421393199134e-13
N O 0 1.292016236220661e-06
- O 0 6.185389338497771e-07
acetylgalactosamine O 0 0.00044133723713457584
- O 0 1.0826400966834626e-06
6 O 0 1.4005808957051613e-08
- O 0 2.234143948953715e-06
sulfate O 0 2.646120655924733e-08
sulfatase O 0 1.011664039651805e-06
( O 0 1.0776640268096022e-13
GALNS O 0 7.4159616225699665e-09
) O 0 1.2397633307871352e-14
. O 0 1.424375686300515e-14

In O 0 8.368658955919261e-13
previous O 0 3.1166551544420384e-12
studies O 0 5.157197368807487e-13
, O 0 5.018851477532442e-15
we O 0 1.214380429982037e-13
have O 0 7.089952700929376e-16
found O 0 2.3797257245420375e-15
two O 0 2.0256344006124548e-15
common O 0 2.240950175804498e-15
mutations O 0 3.473754283896992e-14
in O 0 9.989509533223193e-17
Caucasians O 0 3.5581048524191417e-11
and O 0 3.4246412129734782e-12
Japanese O 0 4.616441451332776e-09
, O 0 1.1819033571931412e-14
respectively O 0 5.0478328114667015e-12
. O 0 3.886715602141599e-12

To O 0 9.201618755686793e-15
characterize O 0 1.7781720106774257e-12
the O 0 3.2708782886782094e-15
mutational O 0 1.2299819496242037e-10
spectrum O 0 4.1831921498806934e-14
in O 0 8.9056837279164e-18
various O 0 1.41752204493926e-17
ethnic O 0 2.5239149255432754e-16
groups O 0 4.2798496947061063e-16
, O 0 1.1809821387180862e-17
mutations O 0 1.4953310010172973e-15
in O 0 1.3074718682936737e-18
the O 0 2.949763452927784e-17
GALNS O 0 2.0256600841150885e-09
gene O 0 9.121874262885132e-13
in O 0 5.066596183670325e-15
Colombian O 0 1.9761161240694491e-07
MPS B-Disease 1 0.9999997615814209
IVA I-Disease 1 1.0
patients O 0 2.3581995023391755e-08
were O 0 1.3378779522763267e-14
investigated O 0 6.506122723903829e-11
, O 0 3.583446998742202e-15
and O 0 1.8458508105247823e-14
genetic O 0 1.7893449309053233e-12
backgrounds O 0 4.25243472162648e-13
were O 0 1.4171233902061237e-15
extensively O 0 7.310890445550583e-14
analyzed O 0 1.5602918805070198e-13
to O 0 2.1435391634087668e-16
identify O 0 5.5948159245668844e-14
racial O 0 1.5062788256275939e-13
origin O 0 6.651155541175522e-15
, O 0 1.3543643236289986e-17
based O 0 7.772625786911676e-18
on O 0 8.824194426917432e-16
mitochondrial O 0 3.496874895225245e-14
DNA O 0 4.5849865570879444e-11
( O 0 1.6344560567246977e-15
mtDNA O 0 5.797297863117945e-13
) O 0 1.4911478017523398e-14
lineages O 0 1.2836533919147186e-11
. O 0 8.45362668755456e-12

Three O 0 1.2445338813324436e-12
novel O 0 6.666753260553548e-11
missense O 0 5.197905011300463e-06
mutations O 0 2.7395910251470923e-07
never O 0 9.777177956138416e-10
identified O 0 2.1302208261242406e-11
previously O 0 2.8716586400467925e-11
in O 0 1.6141197485731876e-16
other O 0 1.457319508124666e-14
populations O 0 2.0841741960736515e-12
and O 0 1.7196536078803448e-13
found O 0 5.740404245696551e-12
in O 0 1.3288186172680867e-15
16 O 0 1.8958956854529113e-13
out O 0 2.5429101099122553e-12
of O 0 5.087163837695554e-15
19 O 0 1.2425545314886932e-10
Colombian O 0 3.513090263140839e-08
MPS B-Disease 1 0.9999959468841553
IVA I-Disease 1 0.9999960660934448
unrelated O 0 3.8039741495632384e-11
alleles O 0 2.8618312147149494e-12
account O 0 4.933212041993706e-13
for O 0 1.6326008470471387e-13
84 O 0 2.0962802327328944e-10
. O 0 2.26218566448666e-12

2 O 0 7.400975665650122e-11
% O 0 3.3212168638104694e-14
of O 0 3.7070092534119035e-17
the O 0 1.6809435012710594e-16
alleles O 0 4.889686406966097e-14
in O 0 1.5527397707482008e-16
this O 0 3.3657171796504844e-17
study O 0 1.0355731978320057e-13
. O 0 4.0935221250031073e-13

The O 0 1.6554482394279257e-12
G301C O 0 2.27058394308699e-09
and O 0 1.3594916750507557e-13
S162F O 0 1.36051508600743e-11
mutations O 0 4.112586193903006e-13
account O 0 1.6876338651203304e-14
for O 0 1.599362359401297e-14
68 O 0 1.3572810930728707e-10
. O 0 1.5224952375214595e-12

4 O 0 7.841276961073618e-09
% O 0 1.64750407326969e-12
and O 0 7.830559117794067e-13
10 O 0 3.223059297750852e-13
. O 0 1.3531743000422258e-13

5 O 0 4.919760779320548e-11
% O 0 6.356247722171665e-14
of O 0 2.1579953688404376e-16
mutations O 0 4.427812283491761e-11
, O 0 1.9559249781874594e-13
respectively O 0 1.4552664628908474e-11
, O 0 8.055942425900478e-16
whereas O 0 4.739261995269795e-15
the O 0 4.246918588964076e-15
remaining O 0 2.748588683043618e-11
F69V O 0 1.482938569097314e-05
is O 0 2.203511028156524e-12
limited O 0 3.775272602131105e-14
to O 0 3.810470886847668e-16
a O 0 6.1872025616793985e-15
single O 0 6.487980291902673e-11
allele O 0 2.6068419992086866e-11
. O 0 1.964851241778587e-12

The O 0 2.093543844143217e-13
skewed O 0 2.568494583687908e-10
prevalence O 0 1.4311635432306957e-08
of O 0 9.53970115691327e-16
G301C O 0 6.307246391834553e-12
in O 0 2.723427150434697e-17
only O 0 2.0452544894675022e-16
Colombian O 0 2.236333731045481e-12
patients O 0 1.090537216601314e-14
and O 0 2.044496825113628e-17
haplotype O 0 9.886065422781525e-15
analysis O 0 2.6343563751622114e-16
by O 0 6.609340515654672e-17
restriction O 0 1.6747335533336474e-14
fragment O 0 1.1278709899625178e-13
length O 0 3.8423043501219223e-13
polymorphisms O 0 5.349198167747815e-11
in O 0 2.1555107829781243e-16
the O 0 1.5958990110865635e-16
GALNS O 0 1.4054030827992392e-08
gene O 0 1.0883855665680398e-12
suggest O 0 6.897588511640962e-14
that O 0 8.181618292471375e-16
G301C O 0 3.312165808549289e-13
originated O 0 6.813976025945006e-15
from O 0 2.446971511405879e-16
a O 0 1.8553979306315223e-15
common O 0 4.411106693130197e-14
ancestor O 0 8.763929686128602e-12
. O 0 2.076216108759521e-11

Investigation O 0 3.9114527589090287e-11
of O 0 1.0238197347745871e-15
the O 0 1.7846650679425127e-16
genetic O 0 5.917471374017325e-13
background O 0 2.4623212201298726e-14
by O 0 2.6193640243447083e-17
means O 0 2.7704136892928936e-16
of O 0 3.666839543068981e-18
mtDNA O 0 2.734670671335204e-13
lineages O 0 1.3243067666784958e-12
indicate O 0 7.262615422248819e-12
that O 0 1.5729583434376249e-13
all O 0 6.439710310141011e-12
our O 0 4.707218642652222e-11
patients O 0 4.768292567229279e-16
are O 0 9.83428929807277e-19
probably O 0 8.681259734650637e-16
of O 0 3.809989269207815e-17
native O 0 4.6735605836734084e-12
American O 0 1.6459180685046704e-08
descent O 0 9.62912235991098e-06

Low O 0 4.560254673879882e-10
frequency O 0 7.668564134394318e-13
of O 0 1.2716399758010404e-14
BRCA1 O 0 1.06201787275495e-06
germline O 0 9.014209823021702e-09
mutations O 0 3.1312878956413215e-09
in O 0 3.1100027609622105e-13
45 O 0 5.564350313846944e-09
German O 1 0.9999853372573853
breast B-Disease 1 0.9999997615814209
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.003347005479327e-08
. O 0 1.0400478221705978e-11

In O 0 1.830435149697933e-14
this O 0 4.5778573922460955e-18
study O 0 2.3320503162871516e-16
we O 0 8.54794479556581e-15
investigated O 0 1.0913967646297706e-10
45 O 0 2.0085577645545527e-10
German O 1 0.9988595247268677
breast B-Disease 1 0.999998927116394
/ I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0750115939572522e-13
for O 0 6.554533645849276e-16
germline O 0 3.333364140267747e-10
mutations O 0 9.458196031930655e-11
in O 0 4.496945033180772e-16
the O 0 3.5784749153418196e-15
BRCA1 O 0 4.3759499135376245e-07
gene O 0 2.5674329329206103e-09
. O 0 1.275372862874491e-11

We O 0 1.0614675804987428e-11
identified O 0 5.483173593986979e-13
four O 0 5.984821826624876e-15
germline O 0 1.1373302993833434e-10
mutations O 0 1.4331807962619791e-10
in O 0 4.661623802357413e-15
three O 0 2.3332219836746937e-11
breast B-Disease 0 0.00019729541963897645
cancer I-Disease 0 4.448694710390555e-07
families O 0 2.5844026896836014e-13
and O 0 5.749956175256365e-13
in O 0 1.5428699713226218e-13
one O 0 0.002056556288152933
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 3.86507015628923e-12
. O 0 2.7619390253939408e-17
among O 0 6.777340236319702e-17
these O 0 1.8135510090262525e-16
were O 0 1.157628355154261e-12
one O 0 1.393308753962208e-13
frameshift O 0 1.7981919286924608e-09
mutation O 0 7.467420432005767e-11
, O 0 8.823328081618981e-14
one O 0 2.914044699986462e-11
nonsense O 0 0.0003173628938384354
mutation O 0 1.1348265438471117e-08
, O 0 7.064379463350701e-14
one O 0 6.821879478617599e-16
novel O 0 1.456643833330773e-11
splice O 0 2.89940749098605e-06
site O 0 3.759016919957503e-08
mutation O 0 1.4625541666646313e-07
, O 0 3.144450195016746e-12
and O 0 1.339702003846921e-13
one O 0 9.347240998791931e-14
missense O 0 1.6835532790082652e-07
mutation O 0 1.1234424057704473e-08
. O 0 2.712010650773866e-11

The O 0 4.797165269188053e-12
missense O 0 3.440420641709352e-07
mutation O 0 8.47666683512216e-08
was O 0 1.983547015527165e-08
also O 0 2.801039998903687e-12
found O 0 2.347942803723746e-13
in O 0 5.417839994589476e-15
2 O 0 2.9278656322323515e-12
. O 0 5.599110042796285e-13

8 O 0 4.256644758893202e-10
% O 0 1.1289078091119339e-14
of O 0 1.121916893488431e-17
the O 0 3.448651234307337e-16
general O 0 4.379593679360548e-14
population O 0 6.142185963376164e-17
, O 0 2.5316569059428532e-17
suggesting O 0 2.3057508051309294e-13
that O 0 1.7626833982909611e-15
it O 0 1.1950743129471308e-13
is O 0 1.4726360322153687e-12
not O 0 2.475556435191373e-12
disease O 0 5.391433410828483e-10
associated O 0 1.61511310646208e-14
. O 0 1.8599066785394275e-13

The O 0 7.332802171456515e-14
average O 0 3.792934577528939e-10
age O 0 5.995164920058471e-10
of O 0 1.0551041512924311e-13
disease O 0 2.379885472691967e-06
onset O 0 2.393442666281942e-10
in O 0 1.3010556301141694e-15
those O 0 5.4083439929211025e-14
families O 0 1.5021981935822194e-14
harbouring O 0 4.972153533344681e-07
causative O 0 4.166220435308787e-08
mutations O 0 9.665108990919435e-11
was O 0 3.303034235013769e-11
between O 0 2.341931715828943e-13
32 O 0 1.9285004149161011e-10
. O 0 3.0516724130319473e-12

3 O 0 9.218682484046781e-10
and O 0 4.955073244078401e-12
37 O 0 8.174869808863505e-11
. O 0 1.1061410034457486e-12

4 O 0 2.8057001166814644e-10
years O 0 1.505992270993406e-12
, O 0 1.779586708377029e-16
whereas O 0 2.300840063856587e-16
the O 0 1.0319116191907198e-17
family O 0 4.468493090603381e-15
harbouring O 0 1.4414359839065582e-07
the O 0 1.1781666078188578e-15
missense O 0 8.828884845435425e-10
mutation O 0 5.427056026796606e-11
had O 0 7.200258184819619e-12
an O 0 9.204593879504685e-17
average O 0 1.4970478190434733e-09
age O 0 5.48172840453276e-10
of O 0 2.7776016214712054e-14
onset O 0 1.8953816294242642e-10
of O 0 1.791163144724845e-14
51 O 0 1.1167314850624166e-09
. O 0 2.0546895348333427e-12

2 O 0 3.1057570404335877e-10
years O 0 6.408920616429725e-11
. O 0 2.873876484010829e-12

These O 0 2.140117849104041e-14
findings O 0 1.1611909350728311e-12
show O 0 1.325139303842704e-10
that O 0 2.1829440043238078e-14
BRCA1 O 0 1.3431061063329253e-07
is O 0 5.583944222807558e-13
implicated O 0 2.591890313485834e-10
in O 0 3.135050503932621e-18
a O 0 1.2439960960378858e-18
small O 0 6.12276905654934e-17
fraction O 0 2.480675387328546e-12
of O 0 8.288347430607246e-08
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.093488007731334e-13
suggesting O 0 9.486201835986682e-14
the O 0 5.719885776121712e-17
involvement O 0 3.934847781807138e-13
of O 0 6.787296926634941e-18
another O 0 2.6702957184164154e-15
susceptibility O 0 5.323381167300634e-13
gene O 0 4.875306061635776e-11
( O 0 3.773476756757654e-12
s O 0 4.7163521799120645e-07
) O 0 1.1977026315168615e-10

Paternal O 0 0.00019227774464525282
transmission O 0 0.002074762247502804
of O 0 4.306167866729993e-08
congenital B-Disease 1 0.9999916553497314
myotonic I-Disease 1 0.9999990463256836
dystrophy I-Disease 1 0.9999992847442627
. O 0 4.002582443263236e-08

We O 0 7.72430064355234e-10
report O 0 2.6596999884616335e-13
a O 0 5.1893539687983715e-17
rare O 0 1.3494915680765712e-16
case O 0 9.80449784402683e-14
of O 0 1.6426710523504556e-13
paternally O 0 0.10366137325763702
transmitted O 1 0.9999257326126099
congenital B-Disease 1 0.999997615814209
myotonic I-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999997615814209
( O 0 4.831923661186011e-07
DM B-Disease 1 0.9999998807907104
) O 0 1.1240886693686392e-10
. O 0 2.725543749027004e-12

The O 0 1.1047746918679824e-12
proband O 0 2.3482801481122806e-08
is O 0 1.5528893885304214e-14
a O 0 4.3295392943700037e-16
23 O 0 3.106308003246287e-14
year O 0 9.059449018874663e-14
old O 0 1.8538750623520173e-07
, O 0 2.0894759446971056e-12
mentally B-Disease 1 0.9999998807907104
retarded I-Disease 1 1.0
male O 0 7.919278687040787e-06
who O 0 2.483502612449229e-07
suffers O 0 0.0006435071118175983
severe O 0 4.438905307324603e-05
muscular B-Disease 0 0.00031286897137761116
weakness I-Disease 0 0.002272713230922818
. O 0 4.963532015955785e-11

He O 0 5.124379587329031e-09
presented O 0 1.0711122266915396e-10
with O 0 2.7485074216571093e-09
respiratory O 0 0.0005769822746515274
and O 0 2.2322534098950797e-10
feeding O 0 3.788462345255539e-05
difficulties O 0 2.7559000415067203e-08
at O 0 6.120881579363413e-12
birth O 0 1.0286237139833787e-10
. O 0 1.3824559986358453e-12

His O 0 8.08410394181891e-10
two O 0 3.5398164954791866e-10
sibs O 0 0.25749149918556213
suffer O 0 6.543779136336525e-07
from O 0 3.5834388841665676e-12
childhood O 0 5.7524562180333305e-06
onset O 0 0.007795470301061869
DM B-Disease 1 0.9999996423721313
. O 0 7.810911362149398e-10

Their O 0 7.198043701882317e-13
late O 0 9.324626574352957e-14
father O 0 5.040213472279342e-12
had O 0 1.069167540959648e-13
the O 0 9.69793891385106e-19
adult O 0 2.2212063460237685e-14
type O 0 8.621887925830407e-12
of O 0 3.3937395537038395e-13
DM B-Disease 1 1.0
, O 0 2.0873956046735948e-13
with O 0 1.0317163688319548e-14
onset O 0 7.0311035639536446e-12
around O 0 1.1300766095470594e-12
30 O 0 4.12307686636134e-14
years O 0 5.975015810897807e-14
. O 0 6.329245667065914e-14

Only O 0 4.760155418166538e-14
six O 0 7.531775462370823e-15
other O 0 4.313396169884317e-18
cases O 0 2.9120107577172965e-15
of O 0 1.342811389798491e-15
paternal O 0 9.896683650367777e-08
transmission O 0 0.0016273853834718466
of O 0 1.755354639421114e-09
congenital B-Disease 1 0.9999977350234985
DM I-Disease 1 1.0
have O 0 1.9965739284089068e-08
been O 0 7.037856408764753e-11
reported O 0 7.25573767734744e-11
recently O 0 9.334935491267515e-09
. O 0 1.3460700653070146e-12

We O 0 5.444824278943994e-12
review O 0 3.6655530363414665e-14
the O 0 4.015913897469421e-18
sex O 0 7.73364594477792e-14
related O 0 6.1336692323799794e-15
effects O 0 6.670927915966574e-14
on O 0 7.590242589181409e-14
transmission O 0 4.8392809759434385e-09
of O 0 3.466768105225837e-12
congenital B-Disease 1 0.9990096092224121
DM I-Disease 1 0.9999996423721313
. O 0 1.7644335992272886e-10

Decreased O 0 3.094711757967161e-07
fertility O 0 6.450944223246324e-09
of O 0 7.194440355962062e-15
males O 0 5.13588910983076e-12
with O 0 2.120695925724586e-13
adult O 0 2.4083928451545944e-07
onset O 0 0.0002832040481735021
DM B-Disease 1 1.0
and O 0 5.67671153139937e-11
contraction O 0 6.939192276345096e-11
of O 0 4.2199586750709394e-18
the O 0 4.5613869027611847e-17
repeat O 0 4.845311977162703e-13
upon O 0 1.8731199774704504e-15
male O 0 1.782641092032411e-12
transmission O 0 1.1578248125879154e-12
contribute O 0 5.240902011688104e-16
to O 0 8.766581892823155e-17
the O 0 3.1576797468159607e-15
almost O 0 7.277462595219053e-13
absent O 0 2.549759535452889e-11
occurrence O 0 7.85877873193952e-13
of O 0 1.5717399373649764e-14
paternal O 0 8.445825727676493e-08
transmission O 0 9.050552762346342e-06
of O 0 9.768771347395955e-10
congenital B-Disease 1 0.9999499320983887
DM I-Disease 1 0.9999998807907104
. O 0 4.429244082615469e-09

Also O 0 2.491826467387881e-10
the O 0 4.546240762524196e-16
fathers O 0 4.4539299006753075e-13
of O 0 7.855102311428113e-18
the O 0 3.5329124837134187e-16
reported O 0 1.6499010491166644e-11
congenitally O 0 3.38805676847187e-08
affected O 0 1.26612928474934e-10
children O 0 1.7069295196042722e-12
showed O 0 4.255992780421991e-11
, O 0 5.252825605151097e-18
on O 0 3.006878659568015e-15
average O 0 2.2951991869579746e-12
, O 0 3.9164427818319595e-17
shorter O 0 4.995258221819621e-13
CTG O 0 1.8684645497479835e-10
repeat O 0 1.8342053570430394e-11
lengths O 0 2.7572206670600785e-11
and O 0 1.2393036900523735e-12
hence O 0 1.0218152143642509e-13
less O 0 4.956989679838486e-13
severe O 0 1.519583321396567e-07
clinical O 0 1.5778724105075526e-08
symptoms O 0 3.501059997468303e-10
than O 0 2.0872718235138477e-17
the O 0 2.345800572696845e-15
mothers O 0 8.674197471414402e-11
of O 0 3.49883290717403e-16
children O 0 2.3616799488257456e-11
with O 0 1.550785194703863e-10
congenital B-Disease 1 0.9995575547218323
DM I-Disease 1 0.9999998807907104
. O 0 5.773659328411895e-10

We O 0 2.7873977431758235e-11
conclude O 0 2.0392288118536994e-12
that O 0 1.0031826240476834e-15
paternal O 0 3.9119321670888496e-10
transmission O 0 2.488856807758566e-06
of O 0 3.612069671143914e-11
congenital B-Disease 1 0.9999960660934448
DM I-Disease 1 1.0
is O 0 3.83343079501941e-10
rare O 0 6.907545824393069e-13
and O 0 8.152389218340703e-14
preferentially O 0 6.2285589012833764e-12
occurs O 0 5.126380616120481e-14
with O 0 2.247369520874383e-16
onset O 0 3.2648623388142894e-12
of O 0 6.576555570741646e-14
DM B-Disease 1 1.0
past O 0 1.5215286808256678e-08
30 O 0 7.172196864191349e-13
years O 0 4.835522715747331e-14
in O 0 1.4597542474215223e-17
the O 0 1.9619113443669053e-16
father O 0 5.712421421305569e-12
. O 0 1.6810661622297337e-15
. O 0 2.9890738999617875e-14

The O 0 3.907886601123289e-12
RB1 O 0 1.1541823141669738e-06
gene O 0 5.875377517838842e-09
mutation O 0 3.8627157028514603e-10
in O 0 2.0316485039445498e-14
a O 0 2.337514730388346e-12
child O 0 0.0002919751568697393
with O 0 2.1116242976404465e-07
ectopic B-Disease 1 0.9999698400497437
intracranial I-Disease 1 0.9999703168869019
retinoblastoma I-Disease 1 0.9980393052101135
. O 0 4.5270155624166364e-08

The O 0 2.0809489114509416e-12
RB1 O 0 5.96377333295095e-07
gene O 0 7.896911458082911e-10
mutation O 0 6.41121947198009e-11
was O 0 1.1793374436741555e-12
investigated O 0 8.011296487309139e-11
in O 0 4.50611744708747e-15
a O 0 6.202169854085948e-12
child O 0 0.23116672039031982
with O 0 2.6549374254614122e-08
ectopic B-Disease 1 0.9997468590736389
intracranial I-Disease 0 0.09887764602899551
retinoblastoma I-Disease 0 2.2903354768288864e-09
using O 0 8.979689347242588e-15
DNA O 0 4.3005633776349583e-11
obtained O 0 8.946801768406135e-14
from O 0 2.1050425535714193e-14
both O 0 2.1802228262774587e-14
the O 0 1.9646470119706085e-14
pineal B-Disease 0 1.074587885341316e-08
and I-Disease 0 3.196591880083588e-10
retinal I-Disease 0 2.8142888908178065e-08
tumours I-Disease 1 1.0
of O 0 1.3293682561005271e-12
the O 0 5.1737915167382464e-12
patient O 0 2.2521149389831407e-09
. O 0 1.4936001654225484e-12

A O 0 2.3536139703850267e-10
nonsense O 0 8.768523684921092e-09
mutation O 0 2.020741733665954e-11
in O 0 1.5347852663048106e-15
exon O 0 9.628313701881552e-10
17 O 0 6.893798032425735e-11
( O 0 1.572116972905623e-15
codon O 0 9.100776772810737e-13
556 O 0 5.359648068783453e-14
) O 0 5.242839136333805e-17
of O 0 1.546112544437033e-18
the O 0 3.5797698169599346e-16
RB1 O 0 1.0346384016202137e-07
gene O 0 9.089215491364655e-11
was O 0 5.698143779736542e-12
found O 0 3.776641068560689e-14
to O 0 1.9538151652290323e-16
be O 0 1.3275026965273856e-13
present O 0 1.5474167086582113e-14
homozygously O 0 6.5863883236261245e-09
in O 0 1.5423438971585323e-16
both O 0 2.3869627740433783e-15
the O 0 6.532990951022639e-16
retinal B-Disease 0 6.741074712324213e-13
and I-Disease 0 2.516614694414443e-11
the I-Disease 0 2.341629060792494e-12
pineal I-Disease 0 6.58456192468293e-05
tumours I-Disease 1 0.9999998807907104
. O 0 4.124406649541612e-10

The O 0 2.9721325633903437e-14
same O 0 8.568904625845617e-15
mutation O 0 1.5677773749361856e-12
was O 0 3.7350955661707985e-12
present O 0 2.3447451696445663e-15
heterozygously O 0 6.208402125729151e-10
in O 0 1.2263739436656326e-18
the O 0 1.6161196314119632e-19
DNA O 0 2.407706466926035e-13
from O 0 1.453892084594808e-16
the O 0 3.189880749862127e-17
constitutional O 0 4.09350457448044e-14
cells O 0 9.481693587828216e-15
of O 0 1.5977021324730311e-16
the O 0 1.7289733081110766e-14
patient O 0 5.202667290038487e-12
, O 0 6.6633356400377445e-18
proving O 0 9.256928313076604e-15
it O 0 1.868872186649309e-16
to O 0 7.806832021346459e-17
be O 0 4.8466401925866334e-14
of O 0 5.214180239784599e-16
germline O 0 4.048034824011282e-11
origin O 0 2.2030907913944686e-12
. O 0 3.1072412438187813e-12

The O 0 2.0100713560527832e-14
initial O 0 6.51745299981403e-14
mutation O 0 2.8688637294764507e-13
was O 0 3.4653451440845584e-13
shown O 0 6.071841163537983e-14
to O 0 4.888823238041197e-16
have O 0 2.496056204608077e-13
occurred O 0 3.162008551044551e-14
in O 0 1.153955468040794e-16
the O 0 3.5165371133815066e-15
paternally O 0 6.004594599318125e-10
derived O 0 9.997917207668627e-13
RB1 O 0 6.973652943997877e-07
allele O 0 1.9020716113260505e-09
. O 0 3.4801526244132575e-11

The O 0 1.2757900476074308e-13
mutation O 0 5.002156328037799e-11
is O 0 9.205169856614862e-14
in O 0 2.479320857714378e-17
an O 0 5.559681405549382e-17
area O 0 1.8830525246732455e-12
of O 0 6.452176596316291e-16
the O 0 2.0094866703851172e-16
gene O 0 4.806355644428398e-14
that O 0 1.744074091057229e-17
encodes O 0 1.1866909091720086e-16
the O 0 1.704485226940441e-17
protein O 0 5.295754611743531e-13
- O 0 3.3729672388460585e-09
binding O 0 3.093743317084119e-10
region O 0 4.1109704616154596e-13
known O 0 1.9203964861467387e-13
as O 0 2.5279802665263695e-13
the O 0 5.717669583236648e-14
pocket O 0 1.6798670912976377e-05
region O 0 1.2195939813608447e-09
and O 0 1.0280255119399229e-10
has O 0 1.1068632989330585e-11
been O 0 3.222080466477005e-14
detected O 0 7.000736795825802e-13
in O 0 2.0591155622298836e-19
other O 0 1.4872336216403554e-18
cases O 0 3.4057956023410057e-16
of O 0 4.2476270393802256e-17
retinoblastoma B-Disease 0 4.5571244000619515e-10
. O 0 4.310772930022494e-14
. O 0 1.9614511837656723e-12

Low O 0 9.504466902399145e-08
levels O 0 9.44070776415229e-12
of O 0 7.422298915627708e-17
beta O 0 1.4406380412614397e-14
hexosaminidase O 0 1.1919603082333197e-09
A O 0 1.5294566286204458e-13
in O 0 1.0075624196596985e-15
healthy O 0 5.727217311513044e-11
individuals O 0 2.3279550284542073e-14
with O 0 1.7851307454810894e-13
apparent O 0 7.866585854943153e-11
deficiency O 0 1.0350731827202253e-06
of O 0 2.1455094745406437e-17
this O 0 2.754513451504832e-15
enzyme O 0 1.819405737180091e-09
. O 0 1.4946260375181541e-12

Appreciable O 0 4.995375775251887e-07
beta O 0 1.4944145920736673e-09
hexosaminidase O 0 5.165145466889953e-07
A O 0 5.301376091587651e-12
( O 0 1.681797363421451e-15
hex O 0 5.498081503962915e-11
A O 0 2.0844582977004242e-14
) O 0 3.530121973373359e-17
activity O 0 7.780885311059471e-15
has O 0 1.2923940829537837e-15
been O 0 1.59462793227009e-15
detected O 0 1.910252555095693e-12
in O 0 2.4526254563288013e-16
cultured O 0 1.5280425813557486e-09
skin O 0 2.050513074891569e-07
fibroblasts O 0 7.569110671568069e-09
and O 0 1.1271893418651757e-09
melanoma B-Disease 0 0.020580297335982323
tissue O 0 2.1732259369855456e-07
from O 0 3.78399534742193e-14
healthy O 0 4.5903267298363915e-10
individuals O 0 4.648625234748849e-15
previously O 0 3.4712910323975166e-10
reported O 0 9.543447809789996e-09
as O 0 1.7470176416622962e-09
having O 0 0.0001738880091579631
deficiency B-Disease 0 5.550220521399751e-05
of I-Disease 0 4.9163688156603563e-17
hex I-Disease 0 1.6324243290455343e-08
A I-Disease 0 9.906966468974793e-14
activity O 0 8.894566262988499e-14
indistinguishable O 0 1.7837878594465124e-15
from O 0 1.87168953072844e-17
that O 0 1.632691078290636e-17
of O 0 4.810129112680945e-16
patients O 0 2.3991945583001772e-12
with O 0 2.667010390311475e-09
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.996161699295044
( O 0 1.7662466541418231e-12
TSD B-Disease 0 9.484927687708478e-08
) O 0 1.304229754793898e-13
. O 0 1.1561735455741656e-13

Identification O 0 2.2746214634050688e-11
and O 0 3.369848074630949e-13
quantitation O 0 3.4804881199335114e-09
of O 0 4.280259923350373e-15
hex O 0 1.8833938852935717e-08
A O 0 3.4078282188342024e-13
, O 0 3.340110976608293e-17
amounting O 0 3.273651220437636e-14
to O 0 1.3340398342340807e-15
3 O 0 3.744918437853517e-12
. O 0 2.1102063239158975e-12

5 O 0 2.6149666876307265e-09
% O 0 1.6356820412011253e-11
- O 0 4.467162852961337e-07
6 O 0 3.943080306711977e-10
. O 0 8.69869280772928e-13

9 O 0 2.011939503887561e-10
% O 0 1.3188806973353073e-14
of O 0 6.159830718458655e-17
total O 0 2.5848646953343518e-14
beta O 0 2.9422512061276496e-13
hexosaminidase O 0 6.598511959055031e-08
activity O 0 4.774914907912375e-10
, O 0 1.223044848584114e-15
has O 0 1.4182272435429855e-14
been O 0 5.38856897115209e-16
obtained O 0 4.516095918722599e-16
by O 0 7.465151768267181e-16
cellulose O 0 2.551164435260489e-08
acetate O 0 4.968140565608792e-09
gel O 0 3.635609857610689e-08
electrophoresis O 0 5.5877642790580495e-11
, O 0 2.796940908316326e-15
DEAE O 0 5.360804022913612e-10
- O 0 9.673472960158858e-13
cellulose O 0 6.47939826792232e-11
ion O 0 4.899977450699422e-13
- O 0 9.55531348489913e-11
exchange O 0 6.917539457917954e-13
chromatography O 0 2.8640375661359574e-12
, O 0 8.864478255097663e-16
radial O 0 6.5675902216622e-11
immunodiffusion O 0 1.8440829308019602e-08
, O 0 8.881067607127875e-15
and O 0 2.742243078121022e-14
radioimmunoassay O 0 5.814554882022094e-08
. O 0 1.2587358455898312e-12

Previous O 0 2.487457739785981e-10
family O 0 2.1243892062150493e-12
studies O 0 6.130128549957162e-14
suggested O 0 4.455603637779082e-13
that O 0 2.3498745364753423e-16
these O 0 1.5727339834681385e-16
individuals O 0 2.0971715846123534e-14
may O 0 2.8319111378821704e-13
be O 0 1.0710726324074707e-15
compound O 0 3.536175148747124e-16
heterozygotes O 0 3.223635618968164e-14
for O 0 4.412805908720327e-18
the O 0 6.614158015542181e-17
common O 0 2.30138665421745e-14
mutant O 0 5.737057356958175e-11
TSD B-Disease 0 4.252703078577724e-09
gene O 0 1.0755834417564003e-10
and O 0 7.149356519124683e-14
a O 0 2.085506924489125e-15
rare O 0 5.845765494935651e-13
( O 0 1.2854601823091005e-13
allelic O 0 2.3403799731536168e-11
) O 0 8.592439436285078e-15
mutant O 0 5.808649047867043e-11
gene O 0 3.2489768653221063e-09
. O 0 2.6754091997371887e-11

Thus O 0 2.681855605646266e-12
, O 0 7.767861755978963e-16
the O 0 1.399426310986805e-17
postulated O 0 1.9814104783993924e-12
rate O 0 9.69376176551684e-11
mutant O 0 2.26724940904921e-11
gene O 0 1.068222767186544e-11
appears O 0 9.346528135863522e-14
to O 0 2.509033185317283e-18
code O 0 4.5959696698108016e-17
for O 0 2.504472938600278e-17
the O 0 3.464749558691048e-17
expression O 0 1.9421717973965155e-15
of O 0 4.5141476105950163e-17
low O 0 4.610677074509684e-13
amounts O 0 5.440121513904355e-16
of O 0 1.92555872844378e-15
hex O 0 6.747445269184027e-08
A O 0 2.1029067376332478e-11
. O 0 1.856547684683796e-12

Heterozygotes O 0 1.6284252168929925e-08
for O 0 2.681607208152286e-14
the O 0 3.107406541451405e-16
rare O 0 2.6846163774007017e-14
mutant O 0 1.4008774584794992e-08
may O 0 9.591169872202876e-12
be O 0 2.7944331613968614e-16
indistinguishable O 0 2.3040471423531285e-15
from O 0 3.496723067216428e-17
heterozygotes O 0 1.2853056834995213e-13
for O 0 8.168953164676453e-17
the O 0 7.370978115795856e-16
common O 0 1.073254441048832e-12
TSD B-Disease 0 2.2755578754640737e-08
mutant O 0 1.4199631470646068e-09
. O 0 9.937274961235865e-12

However O 0 3.984230751308965e-13
, O 0 7.956648988658593e-17
direct O 0 1.9657394038929027e-16
visualization O 0 9.813717893880636e-11
and O 0 6.979860699835028e-12
quantitation O 0 5.794192681207733e-09
of O 0 2.2906038824472555e-15
hex O 0 2.4158626210635248e-09
A O 0 9.675449833413795e-16
by O 0 1.4194746047751913e-18
the O 0 1.1728822414033597e-18
methods O 0 7.068757183731995e-15
described O 0 1.5094741049551802e-13
may O 0 8.154951154192968e-15
prevent O 0 2.4943688810958285e-15
false O 0 1.761341831933716e-12
- O 0 1.946568906063817e-09
positive O 0 2.060058894304273e-11
prenatal O 0 3.5243891138847516e-10
diagnosis O 0 6.892230276084321e-12
of O 0 3.2007429547939285e-16
TSD B-Disease 0 2.5733468689281835e-08
in O 0 1.2112059537836353e-14
fetuses O 0 2.6928505647560996e-08
having O 0 8.061533753912775e-13
the O 0 1.068627552691213e-16
incomplete O 0 5.63947916143448e-11
hex B-Disease 0 3.194437886122614e-05
A I-Disease 0 9.020625135747196e-09
deficiency I-Disease 0 0.00023899339430499822
of O 0 2.940103770083288e-16
the O 0 2.3202685432710535e-14
type O 0 2.2360445939284546e-07
described O 0 8.250434363477055e-11
in O 0 1.524207307101262e-15
the O 0 4.31956309913592e-14
four O 0 1.2168631380315986e-10
healthy O 0 1.909960412049827e-09
individuals O 0 6.42147186119546e-12

The O 0 4.859972558939052e-13
tumor B-Disease 0 1.1007799116669048e-09
suppressor O 0 1.0146586904014043e-09
gene O 0 7.083627906467882e-08
Smad4 O 0 8.247938239946961e-05
/ O 0 8.460660865239333e-06
Dpc4 O 0 1.31519641399791e-07
is O 0 8.186462473896722e-15
required O 0 4.365061738595481e-16
for O 0 2.7330851458307436e-17
gastrulation O 0 5.0586593941526203e-11
and O 0 4.860658316813149e-13
later O 0 1.0286692694481611e-13
for O 0 3.2525401100734486e-14
anterior O 0 5.4371351865256656e-08
development O 0 2.23012827111214e-15
of O 0 2.946873283867524e-17
the O 0 1.6724823303422586e-15
mouse O 0 4.8228607774092325e-09
embryo O 0 1.485630729547438e-08
. O 0 8.346350693910765e-11

Mutations O 0 8.202617252095479e-09
in O 0 3.326802199064664e-14
the O 0 6.021372907661499e-14
SMAD4 O 0 8.029063610592857e-05
/ O 0 1.0968157226898256e-07
DPC4 O 0 2.4806565690482785e-08
tumor B-Disease 0 2.1319890297633037e-11
suppressor O 0 2.5534179805275503e-12
gene O 0 4.717489419936438e-12
, O 0 4.0807913272731804e-17
a O 0 2.356345404971222e-17
key O 0 2.8831440273408004e-12
signal O 0 1.5631246297331813e-13
transducer O 0 2.0274244089124593e-11
in O 0 1.3037278337742995e-16
most O 0 2.8627333454613567e-15
TGFbeta O 0 4.206800952033518e-08
- O 0 4.728908375994934e-10
related O 0 1.6690759885307216e-11
pathways O 0 5.912423328702232e-11
, O 0 9.98337648528948e-17
are O 0 1.0184077095751538e-18
involved O 0 1.3545045472864386e-16
in O 0 3.5487275814553916e-17
50 O 0 7.949831114587025e-15
% O 0 1.664792965247084e-15
of O 0 8.925938330475724e-14
pancreatic B-Disease 0 0.002026224974542856
cancers I-Disease 0 0.0023235382977873087
. O 0 1.7503522242723335e-10

Homozygous O 0 0.0013285763561725616
Smad4 O 0 0.00022258351964410394
mutant O 0 1.423570211045444e-05
mice O 0 9.125342330662534e-05
die O 0 5.240263476480322e-07
before O 0 2.8159707204933326e-11
day O 0 4.605724482353857e-11
7 O 0 6.829066392238792e-12
. O 0 5.839834095900526e-14

5 O 0 5.032867178567102e-11
of O 0 3.1893382384943006e-14
embryogenesis O 0 2.601847404193336e-09
. O 0 2.841788783458643e-11

Mutant O 0 5.262356328472606e-09
embryos O 0 2.1186221665914218e-09
have O 0 1.5663964266290908e-12
reduced O 0 2.5720693478704926e-13
size O 0 2.5628849736891723e-11
, O 0 1.0110523529505144e-12
fail O 0 7.785610489641215e-10
to O 0 1.7365351100443946e-14
gastrulate O 0 2.4559178655181313e-06
or O 0 1.2276837532687601e-12
express O 0 3.833993330606099e-14
a O 0 5.666482334030798e-17
mesodermal O 0 5.931487072341479e-12
marker O 0 2.5981876650149616e-09
, O 0 3.708497860877144e-15
and O 0 1.6656069427335718e-14
show O 0 2.529985942967272e-10
abnormal O 0 5.34763011650341e-10
visceral O 0 3.585671204398011e-10
endoderm O 0 5.8233673883023584e-08
development O 0 5.23697786525279e-11
. O 0 3.305635496234083e-12

Growth B-Disease 1 0.9999998807907104
retardation I-Disease 1 0.9999997615814209
of O 0 3.660348527100357e-14
the O 0 1.9613071610595847e-14
Smad4 O 0 3.3100002383434912e-06
- O 0 9.603452610917884e-08
deficient O 0 7.591594020084358e-09
embryos O 0 3.7462402971422115e-12
results O 0 1.002407182325131e-13
from O 0 9.700284839427292e-16
reduced O 0 5.688560787784486e-14
cell O 0 3.2710704804539414e-12
proliferation O 0 3.364761802515659e-09
rather O 0 1.6002761861903981e-16
than O 0 6.72926780784057e-17
increased O 0 7.279968660778117e-15
apoptosis O 0 6.678901680844118e-13
. O 0 1.165399916326637e-12

Aggregation O 0 3.8632166909913224e-10
of O 0 1.7691555685706017e-13
mutant O 0 3.372569779003243e-08
Smad4 O 0 9.463880132898339e-07
ES O 0 9.353127161659813e-10
cells O 0 1.1722597718921701e-12
with O 0 2.5727046056402744e-15
wild O 0 7.452583550282554e-10
- O 0 3.7242446069285506e-06
type O 0 2.1193102384131635e-08
tetraploid O 0 6.183542922144625e-08
morulae O 0 3.120599672001845e-07
rescues O 0 1.8231505194421516e-09
the O 0 4.4015172637277417e-14
gastrulation B-Disease 0 4.8839222444030383e-08
defect I-Disease 0 6.666596732429753e-07
. O 0 2.2053359572532516e-12

These O 0 1.7116233289645594e-13
results O 0 1.4047381964241157e-12
indicate O 0 5.872743697593608e-13
that O 0 2.0479111977186534e-14
Smad4 O 0 7.291568948630811e-08
is O 0 7.194691077714449e-14
initially O 0 1.2182453396764048e-13
required O 0 5.886188783914273e-17
for O 0 1.562226539757449e-18
the O 0 2.1667617710696317e-18
differentiation O 0 1.1370758748772492e-15
of O 0 1.6617203201436946e-17
the O 0 2.960666288971274e-16
visceral O 0 5.4842640845320645e-12
endoderm O 0 1.8454357486596962e-10
and O 0 3.506559531130972e-14
that O 0 1.0408747166977729e-16
the O 0 1.88283327485353e-16
gastrulation B-Disease 0 3.6015662674415694e-10
defect I-Disease 0 3.9877514623753996e-09
in O 0 1.1740518541099944e-16
the O 0 2.875790993617992e-15
epiblast O 0 6.207007796632524e-09
is O 0 1.193166919433164e-11
secondary O 0 1.101449931262266e-09
and O 0 1.620899664489528e-10
non O 0 2.902772280322097e-07
- O 0 7.29966842527574e-08
cell O 0 2.6009741027621658e-09
autonomous O 0 4.314203716493381e-10
. O 0 7.993956885332665e-11

Rescued O 0 3.6724504326457463e-08
embryos O 0 1.4168614370646537e-07
show O 0 0.00018929711950477213
severe O 0 0.02113807387650013
anterior O 0 0.4029650390148163
truncations O 0 1.2818168215744663e-05
, O 0 1.0619185652344099e-12
indicating O 0 3.0390215084025174e-12
a O 0 4.004094995293476e-15
second O 0 5.677788426049213e-13
important O 0 1.2501925086534985e-14
role O 0 3.0305258302831817e-11
for O 0 7.022505542570237e-14
Smad4 O 0 1.9634846637472947e-07
in O 0 3.940921753427945e-14
anterior O 0 1.1477850421215408e-06
patterning O 0 2.815092825514398e-09
during O 0 4.256412930447873e-12
embryogenesis O 0 1.3914471796994121e-09
. O 0 1.444957955371029e-11

Prevalence O 0 3.878525149048073e-06
of O 0 1.2708550303688199e-13
p16 O 0 1.1892011819725212e-09
and O 0 7.75889985940581e-13
CDK4 O 0 1.4015087401730852e-07
germline O 0 1.2958914830107915e-08
mutations O 0 3.3255991294112164e-09
in O 0 6.992925796799401e-14
48 O 0 1.3397660758585062e-09
melanoma B-Disease 1 0.9998748302459717
- O 1 0.995120108127594
prone O 1 0.9324846863746643
families O 0 4.227403704870625e-10
in O 0 3.9809436129523146e-12
France O 0 8.188698075173306e-07
. O 0 8.725500356965288e-12

The O 0 1.9124110295365426e-08
French O 0 0.0008715611766092479
Familial B-Disease 0 0.04814017564058304
Melanoma I-Disease 1 0.9995606541633606
Study O 0 1.0265041261448005e-08
Group O 0 3.088460598377196e-10
. O 0 4.648330765438802e-12

Germline O 0 3.0616536150773754e-06
mutations O 0 4.4638067464575215e-08
in O 0 1.51268988248009e-14
the O 0 3.002235224951167e-16
p16 O 0 1.619613297643152e-11
and O 0 2.987911093131797e-14
CDK4 O 0 5.830169058640422e-08
genes O 0 4.368370595808635e-11
have O 0 2.6885430188562653e-13
been O 0 5.906488948111133e-13
reported O 0 2.4330599926285223e-13
in O 0 2.8177643902798636e-19
a O 0 1.0296860070345846e-17
subset O 0 2.170934855900931e-15
of O 0 7.667094904925328e-15
melanoma B-Disease 0 1.309677190874936e-05
pedigrees O 0 8.527675787739497e-10
, O 0 9.895163573074572e-14
but O 0 1.2843231252807064e-13
their O 0 1.5369429090961867e-13
prevalence O 0 1.064745891454777e-08
is O 0 1.351879220547192e-13
not O 0 8.032165258158985e-15
well O 0 4.52270362274413e-14
known O 0 1.3395212673447676e-12
. O 0 6.430983350014241e-12

We O 0 6.833815062229007e-14
searched O 0 4.46311180558618e-14
for O 0 4.444278890257051e-18
such O 0 1.8224825413211305e-17
germline O 0 2.567082657556341e-11
mutations O 0 3.903426193385684e-11
in O 0 1.4964929184626934e-14
48 O 0 2.7573128225100163e-09
French O 0 1.4616948647017125e-05
melanoma B-Disease 1 0.9999895095825195
- O 1 0.9305034875869751
prone O 0 0.0012940708547830582
families O 0 6.313847963337546e-14
selected O 0 1.368226295743501e-14
according O 0 6.99265506025404e-19
to O 0 9.794309797911704e-18
two O 0 3.1873540638153574e-15
major O 0 2.250336167408662e-10
criteria O 0 6.881816644321859e-11
families O 0 7.8832939501929e-17
with O 0 1.4756324755878452e-17
at O 0 1.1445048196927904e-14
least O 0 5.154000931162345e-17
three O 0 5.839143594641924e-14
affected O 0 4.140529499124801e-12
members O 0 1.577920075036601e-16
( O 0 3.2133192764782867e-16
n O 0 4.4725268627532344e-11
= O 0 1.2836068145893886e-11
20 O 0 1.025707513716001e-12
) O 0 1.0174739333403474e-14
or O 0 3.591785072490361e-13
families O 0 9.696035275130917e-15
with O 0 5.344805002228947e-14
two O 0 7.974076043568146e-13
affected O 0 1.4749446455852855e-11
members O 0 7.837925409700082e-17
, O 0 1.4783642809198322e-18
one O 0 2.66035802016804e-18
of O 0 3.331759688765654e-19
them O 0 1.7421863656377095e-16
affected O 0 1.176576621097743e-15
before O 0 1.0195049357063839e-16
the O 0 3.442878903295146e-17
age O 0 2.89956962249132e-14
of O 0 1.0963375738161474e-17
50 O 0 1.2882495507428684e-15
( O 0 5.782237591904775e-16
n O 0 1.1876954975065246e-10
= O 0 4.593707636502131e-10
28 O 0 3.4879826804612435e-10
) O 0 5.872863637458939e-14
, O 0 1.4751329709944264e-15
and O 0 4.455095782234897e-16
one O 0 6.438920133645067e-17
additional O 0 1.9181247437822027e-15
minor O 0 4.000345627669377e-12
criterion O 0 2.1629799340505684e-10
. O 0 4.026310534976929e-12

Sixteen O 0 3.221292677046961e-11
different O 0 2.5687783538198665e-14
p16 O 0 1.1731064730735596e-10
germline O 0 6.978643218857883e-10
mutations O 0 9.126900346601019e-10
were O 0 1.9358718458557106e-13
found O 0 8.214498959518979e-13
in O 0 8.439211176126775e-15
21 O 0 3.049300048574288e-11
families O 0 1.0630619241879316e-15
, O 0 3.669178313532913e-17
while O 0 3.502493518874267e-15
one O 0 1.234214163839788e-14
germline O 0 4.991047020119765e-10
mutation O 0 3.994265473927783e-10
, O 0 1.723120750902682e-13
Arg24His O 0 1.6916091638563557e-08
, O 0 1.544729433105576e-15
was O 0 7.948125664569705e-13
detected O 0 1.9564427855556232e-10
in O 0 3.021675689881837e-16
the O 0 2.213601853629909e-14
CDK4 O 0 7.483228046112345e-07
gene O 0 7.060201728803506e-11
. O 0 1.2857477669353523e-12

The O 0 3.2535933108400646e-15
frequency O 0 6.140950751111051e-15
of O 0 2.005763596622465e-17
p16 O 0 1.5882529666444434e-12
gene O 0 1.3044320398142295e-12
mutation O 0 5.844093113084592e-13
in O 0 2.1345959513236395e-16
our O 0 2.955454442307259e-15
sample O 0 2.3091253166301548e-14
( O 0 5.610283021469456e-16
44 O 0 1.679073919561968e-14
% O 0 8.35023773685133e-18
) O 0 3.526082354133895e-18
is O 0 3.64453051503565e-16
among O 0 6.881107198663172e-15
the O 0 5.353375281589266e-14
highest O 0 4.060623268742347e-07
rates O 0 1.5470870948774973e-06
yet O 0 6.768920927241462e-12
reported O 0 3.102954698741556e-11
and O 0 7.518687956302797e-14
the O 0 2.0986431349516183e-15
CDK4 O 0 1.562361688911551e-07
mutation O 0 5.756320984109942e-13
is O 0 9.983373584201635e-14
the O 0 9.727037316275135e-16
second O 0 8.963242474624433e-12
mutation O 0 1.5936453545695173e-12
detected O 0 1.6814713510449053e-10
in O 0 8.56163780445967e-18
this O 0 5.519022666028318e-18
gene O 0 3.1495520167595936e-12
worldwide O 0 2.1551392614949094e-10
. O 0 2.5284396971969603e-12

In O 0 5.405202110550511e-13
summary O 0 2.9959090763753693e-12
, O 0 3.4630620175972113e-15
our O 0 3.300521053700321e-15
results O 0 5.150210194025586e-16
show O 0 1.1276687862573492e-13
frequent O 0 1.3427710922060253e-14
involvement O 0 1.3476905409790657e-13
of O 0 5.933392176441857e-18
the O 0 9.444100551710841e-18
p16 O 0 4.940726105150117e-13
gene O 0 3.4169794272710663e-13
in O 0 4.804041063372554e-16
familial B-Disease 0 2.062565451765863e-09
melanoma I-Disease 0 0.00027759448857977986
and O 0 2.1357477689599308e-13
confirm O 0 5.523333526658014e-13
the O 0 4.2111828512545683e-16
role O 0 7.224156689522587e-11
of O 0 3.0027619735652406e-16
the O 0 1.3863354366393243e-15
CDK4 O 0 1.746112410216938e-08
gene O 0 4.0954747731157537e-13
as O 0 3.0038291291996626e-15
a O 0 1.0310828728907033e-14
melanoma B-Disease 0 7.737334271951113e-06
- O 0 5.2681810025489995e-09
predisposing O 0 2.565889445360625e-10
gene O 0 6.706404181988646e-11
. O 0 9.136495813383272e-14
. O 0 4.112695698322427e-13

Progression O 0 1.3591469061324801e-09
of O 0 5.845427901484193e-14
somatic O 0 1.0983806086883874e-09
CTG O 0 3.4336093790443556e-07
repeat O 0 4.372943340769098e-09
length O 0 1.0459582852617721e-11
heterogeneity O 0 1.3272254822949137e-11
in O 0 2.981544751148586e-15
the O 0 4.042523503681864e-16
blood O 0 3.7992026191702166e-11
cells O 0 1.930600818100814e-11
of O 0 2.8552790340419243e-11
myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999992847442627
patients O 0 1.3311893098943983e-07
. O 0 3.789127431957917e-12

The O 0 6.340551947549159e-15
genetic O 0 2.645862912445396e-12
basis O 0 3.911078058638218e-12
of O 0 3.5270366488537874e-11
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999997615814209
( O 0 6.410641617549118e-08
DM B-Disease 1 1.0
) O 0 2.2811800733969767e-13
is O 0 4.4016808257898565e-16
the O 0 7.535326694324301e-18
expansion O 0 3.9838412516784993e-14
of O 0 9.872186867350102e-17
an O 0 9.745576538149926e-15
unstable O 0 3.0410440832184804e-09
CTG O 0 2.145731148317509e-09
repeat O 0 9.65000440666941e-11
in O 0 1.7108374115620318e-16
the O 0 9.987642752016783e-17
34 O 0 4.298760986390891e-14
UTR O 0 7.27245358118217e-13
of O 0 7.874817665019947e-17
the O 0 4.275532293658568e-13
DM B-Disease 1 1.0
protein O 0 1.2133265225866552e-10
kinase O 0 2.2525434295594948e-10
gene O 0 5.843274475392235e-11
on O 0 7.395609298577188e-12
chromosome O 0 2.179955060910288e-08
19 O 0 2.453493797016648e-10
. O 0 5.372936795998429e-13

One O 0 1.4335292935346855e-12
of O 0 6.641365640250275e-16
the O 0 1.7977980490918946e-16
principal O 0 2.4520866565534705e-13
features O 0 5.187837938641464e-14
of O 0 2.5761699762461693e-16
the O 0 8.055466883816198e-12
DM B-Disease 1 1.0
mutation O 0 1.1682922684830288e-10
is O 0 6.074571320133573e-15
an O 0 6.690668251736395e-17
extraordinarily O 0 6.400149854535186e-11
high O 0 1.62337965292636e-08
level O 0 2.3521495515210766e-11
of O 0 1.0926644551450485e-15
somatic O 0 4.0631421838188686e-11
mosaicism O 0 3.7127132479497504e-09
, O 0 6.465875766051353e-16
due O 0 7.893860553861e-16
to O 0 3.355229439381986e-18
an O 0 7.654199331229194e-17
extremely O 0 6.29935611052429e-13
high O 0 1.9767455033958825e-11
degree O 0 2.337332784323144e-15
of O 0 2.0480036937164936e-15
somatic O 0 2.100139173677462e-09
instability O 0 2.960507394789147e-09
both O 0 2.186371526533004e-12
within O 0 2.020079558544361e-14
and O 0 1.5960878452236926e-12
between O 0 1.942475670466343e-15
different O 0 3.504150950593807e-15
tissues O 0 1.360183632392875e-10
. O 0 1.544286210410431e-13

This O 0 3.8467259976318613e-13
instability O 0 3.5252144953146214e-11
appears O 0 9.71465814150925e-15
to O 0 1.0052842823618468e-18
be O 0 8.119891924493076e-18
biased O 0 5.275749794171093e-14
towards O 0 2.432963439342865e-16
further O 0 5.464831053162539e-16
expansion O 0 2.1539922487800664e-14
and O 0 7.343473897207325e-16
continuous O 0 3.6266401203984553e-16
throughout O 0 1.8575771677337953e-17
the O 0 4.285203786656978e-18
life O 0 7.302242980312945e-16
of O 0 3.224071888250731e-18
an O 0 3.386348718488782e-17
individual O 0 5.78016447876637e-16
, O 0 2.214875087086442e-16
features O 0 3.0896812885927716e-13
that O 0 1.3005714127184431e-12
could O 0 3.5791120067685256e-10
be O 0 4.5376562750332194e-12
associated O 0 1.3929040924419867e-14
with O 0 1.5624091918246125e-13
the O 0 9.833939354020674e-14
progressive O 0 5.693852507537844e-12
nature O 0 4.4500795409740945e-11
of O 0 1.9709384677709524e-13
the O 0 2.5519196131251753e-11
disease O 0 1.8646979924596963e-06
. O 0 2.462680450190935e-12

Although O 0 2.9789005463742857e-12
increasing O 0 4.299337307608203e-13
measured O 0 7.767369104676181e-13
allele O 0 2.3591755719115648e-12
size O 0 2.3339340876615822e-11
between O 0 3.876114273299036e-12
patients O 0 8.049799542220182e-12
clearly O 0 6.791347540759107e-15
correlates O 0 2.2939090050074417e-15
with O 0 9.307091483567355e-17
an O 0 9.960476155467072e-17
increased O 0 5.912356021431364e-11
severity O 0 2.8112817629377673e-10
of O 0 3.811025800493084e-11
symptoms O 0 1.7714256728140754e-08
and O 0 1.6089180729219846e-17
an O 0 8.222723709523218e-18
earlier O 0 3.740942017965709e-12
age O 0 4.6060344427445443e-10
of O 0 3.7676906408136424e-14
onset O 0 9.714264982696452e-12
, O 0 3.0022092266645143e-18
this O 0 3.634610285807836e-20
correlation O 0 2.7151416660505575e-15
is O 0 6.833945844116063e-14
not O 0 3.050294603828955e-15
precise O 0 3.3138845400432215e-13
and O 0 1.2367358526166328e-10
measured O 0 2.058156090001262e-09
allele O 0 1.0653822442308059e-11
length O 0 7.469308727081625e-09
cannot O 0 9.819699720026165e-09
be O 0 3.6692274652666557e-13
used O 0 3.258177961370373e-14
as O 0 2.000431994058087e-15
an O 0 5.198683325337051e-18
accurate O 0 4.3898867180258705e-11
predictor O 0 6.005562624977756e-08
of O 0 4.169580533706224e-13
age O 0 5.100178057659832e-09
of O 0 1.1884964583666613e-12
onset O 0 2.467288595653372e-08
. O 0 7.830713508183429e-12

In O 0 5.5019861957454966e-14
order O 0 2.2660330977737435e-16
to O 0 3.775104715651466e-19
further O 0 2.0580408736684182e-18
characterize O 0 2.462301060745728e-15
the O 0 1.0144615162499746e-16
dynamics O 0 7.911055165989167e-13
of O 0 3.861926783140651e-14
DM B-Disease 1 0.9999988079071045
CTG O 0 9.924485233625546e-09
repeat O 0 1.5994256266638196e-11
somatic O 0 4.336189185494277e-10
instability O 0 1.157342416346907e-10
, O 0 6.544889116953602e-16
we O 0 3.045441909722488e-14
have O 0 2.340848394570723e-15
studied O 0 3.881474270684207e-14
repeat O 0 1.6741636289091533e-12
length O 0 1.5609079783915347e-13
changes O 0 3.0338392947626457e-15
over O 0 4.498695215008036e-16
time O 0 1.0801158737897129e-15
in O 0 9.378125387059775e-16
111 O 0 2.907311891231501e-10
myotonic B-Disease 1 0.9999971389770508
dystrophy I-Disease 1 0.9999996423721313
patients O 0 1.8915570498823087e-10
with O 0 7.981668886082607e-17
varying O 0 1.4327235136330613e-15
clinical O 0 2.1757075308048712e-10
severity O 0 7.680894115180692e-12
and O 0 7.845011803803842e-14
CTG O 0 1.4687539184876641e-08
repeat O 0 6.439520583434444e-10
size O 0 2.803537436923964e-11
over O 0 1.2342779576179908e-10
time O 0 6.386388271516219e-13
intervals O 0 2.2546647708565626e-12
of O 0 8.915648441883581e-17
1 O 0 2.6809103117949326e-15
- O 0 3.641969018031155e-11
7 O 0 2.2629095049620657e-13
years O 0 5.1911044364992553e-14
. O 0 7.361319399098315e-14

We O 0 5.594101293304732e-10
have O 0 6.050219546416486e-15
found O 0 2.0949387951754792e-16
a O 0 8.223602175333749e-18
direct O 0 5.665771620448493e-16
progression O 0 1.2670846359988386e-12
of O 0 3.145173953859351e-17
the O 0 4.1466832113801745e-17
size O 0 7.798684014380126e-15
heterogeneity O 0 4.982343341066245e-14
over O 0 2.4846822123110283e-15
time O 0 3.235815743638422e-17
related O 0 5.479317963538548e-16
to O 0 3.707247315992196e-18
initial O 0 9.28649230403462e-16
CTG O 0 9.112748750039756e-12
repeat O 0 1.8871440868317713e-12
size O 0 5.432643267536119e-13
and O 0 6.118999079131326e-13
the O 0 5.475640252360688e-16
time O 0 1.427662106373226e-13
interval O 0 2.777211240926475e-13
and O 0 7.201276758879351e-15
always O 0 3.1472413362904723e-15
biased O 0 3.3916412159242654e-14
towards O 0 3.306858183634763e-16
further O 0 1.465268742928058e-14
expansion O 0 4.009986353387118e-12
. O 0 5.900509573129875e-13

Attempts O 0 1.0165361391187289e-12
to O 0 2.123185755779634e-16
mathematically O 0 2.1315130955027687e-15
model O 0 1.9750639925625313e-12
the O 0 5.926590005567037e-16
dynamics O 0 4.973674805341943e-10
have O 0 3.663595121716767e-11
proved O 0 8.01775919961889e-12
only O 0 3.052205298399724e-14
partially O 0 2.901273665756321e-10
successful O 0 5.593132836219372e-13
suggesting O 0 1.1667194120545954e-11
that O 0 9.500401607487528e-17
individual O 0 2.7068538423996457e-18
specific O 0 8.541645014490385e-17
genetic O 0 5.909192948329312e-13
and O 0 6.176971504819398e-14
/ O 0 1.006166417544252e-11
or O 0 1.2067969778865872e-14
environmental O 0 6.90146128180108e-13
factors O 0 1.1456193795261055e-13
also O 0 1.1451005074714082e-11
play O 0 3.6915963341765945e-11
a O 0 3.795995432592271e-14
role O 0 7.142335334275884e-11
in O 0 2.471804929232599e-16
somatic O 0 3.721243365534255e-12
mosaicism O 0 1.1626908325013119e-09
. O 0 7.151754130585181e-15
. O 0 7.555062261563328e-13

Aspartylglucosaminuria B-Disease 1 0.9999781847000122
among O 0 2.241907282041211e-08
Palestinian O 0 1.7653544404083732e-08
Arabs O 0 1.0804328987035206e-08
. O 0 2.7800015761636487e-11

Aspartylglucosaminuria B-Disease 1 0.9999990463256836
( O 0 1.705503223092819e-06
AGU B-Disease 1 0.9999977350234985
) O 0 1.0321184553720164e-13
is O 0 3.4935648916377003e-16
a O 0 1.0244135048706124e-15
rare O 0 1.0598456140487045e-10
disorder B-Disease 0 0.0014133567456156015
of I-Disease 0 1.4278689179376275e-13
glycoprotein I-Disease 0 1.2999340469832532e-05
metabolism I-Disease 0 7.497266051359475e-05
caused O 0 2.586773850676849e-10
by O 0 1.4476951809647837e-14
the O 0 2.1867646582407474e-11
deficiency B-Disease 0 6.883340392960235e-05
of I-Disease 0 6.663621960334974e-16
the I-Disease 0 1.542858180623996e-13
lysosomal I-Disease 0 2.4686123651918024e-06
enzyme I-Disease 0 1.1888217841260484e-06
aspartylglucosaminidase I-Disease 0 4.060146238771267e-06
( O 0 2.0723406443570042e-13
AGA O 0 1.3327638992421953e-10
) O 0 9.655223669191582e-13
. O 0 5.57466507851434e-13

AGU B-Disease 1 0.9999866485595703
is O 0 9.535514600145234e-09
inherited O 0 4.175817593932152e-06
as O 0 9.370903358840721e-12
an O 0 1.2954168987500125e-12
autosomal O 1 0.9225752949714661
recessive O 1 0.9890092015266418
trait O 0 0.0068302880972623825
and O 0 4.031617262256759e-10
occurs O 0 5.890723835371564e-14
with O 0 5.819121641592964e-17
a O 0 3.870641142805298e-15
high O 0 2.2151859513375172e-10
frequency O 0 2.150283857221824e-12
in O 0 7.772767672553638e-12
Finland O 0 3.4766458156809676e-07
because O 0 5.629994083780621e-13
of O 0 2.7015012393738764e-17
a O 0 8.617316688066818e-16
founder O 0 1.284968745990378e-11
effect O 0 2.7122745022145622e-11
. O 0 9.564712303428147e-13

While O 0 6.439206806652109e-12
very O 0 4.026258035874858e-15
few O 0 5.305292609305429e-15
patients O 0 1.8196441193565026e-14
with O 0 4.794178359965491e-14
AGU B-Disease 1 1.0
have O 0 1.4539643360816923e-12
been O 0 8.036149701142869e-15
reported O 0 5.866135485352308e-14
from O 0 1.0327716024776442e-14
non O 0 1.845448593940091e-07
- O 0 6.071001479313054e-08
Finnish O 0 6.719111933506383e-09
origin O 0 5.114780669314423e-13
, O 0 5.108794247019044e-13
we O 0 1.7831300880288836e-09
diagnosed O 0 3.563269501682953e-06
the O 0 1.0814156373769451e-13
disorder O 0 9.900893616077155e-08
in O 0 6.412108232142018e-16
8 O 0 8.538242270324237e-13
patients O 0 9.77673697445528e-16
originating O 0 2.1202317283760847e-16
from O 0 4.064246060660895e-17
3 O 0 1.0334962391640203e-15
unrelated O 0 1.8333149939559618e-13
families O 0 1.4448455927236308e-14
, O 0 9.44713739643732e-16
all O 0 1.0151909423782718e-13
Palestinian O 0 6.598738482715971e-12
Arabs O 0 2.4374168590586553e-13
from O 0 4.641041748772081e-15
the O 0 7.381058654901129e-14
region O 0 1.358937593530507e-12
of O 0 2.587528444546877e-14
Jerusalem O 0 8.485010027925455e-09
. O 0 5.971968145696005e-12

The O 0 4.5472889234447755e-13
clinical O 0 1.1967236090981714e-09
diagnosis O 0 1.2340741477601114e-06
of O 0 1.4018543270655215e-10
AGU B-Disease 1 1.0
is O 0 4.789620700051955e-09
often O 0 5.314676650158834e-13
difficult O 0 4.418122768676258e-13
, O 0 6.684371091169152e-16
in O 0 1.1012921375311563e-17
particular O 0 6.788546614560774e-16
early O 0 3.0221498165740627e-15
in O 0 3.8964910531082825e-16
the O 0 4.035699912137902e-15
course O 0 1.5772621056453495e-11
of O 0 3.612323622463522e-15
the O 0 3.2303584178265676e-13
disease O 0 3.517697848565149e-07
, O 0 7.286354230409231e-16
and O 0 6.701707208621487e-16
most O 0 1.6908916716259897e-17
of O 0 4.579259165599352e-16
the O 0 1.583754611830801e-12
patients O 0 3.0950858195821773e-12
are O 0 2.8633247438651296e-14
diagnosed O 0 6.97457147591507e-10
after O 0 2.4059698122149385e-14
the O 0 7.419394688467501e-14
age O 0 2.1698900454225623e-09
of O 0 2.1163794119440603e-14
5 O 0 9.11078070625626e-13
years O 0 5.128867708141527e-13
. O 0 8.016072614719372e-13

However O 0 1.0232668662055189e-12
, O 0 6.065792458909993e-16
since O 0 6.198136592358149e-16
these O 0 7.225511986156852e-17
patients O 0 5.159413206997504e-16
excrete O 0 2.780780578473898e-15
early O 0 3.133328727487592e-18
large O 0 1.6873607684632458e-17
amounts O 0 6.139381199059789e-15
of O 0 2.7298072792026132e-14
aspartylglucosamine O 0 2.9208109708633856e-07
in O 0 5.742560451073016e-16
urine O 0 3.8406283361935856e-12
, O 0 1.1257581548170047e-17
biochemical O 0 3.4638281588980028e-15
screening O 0 4.296146026276128e-14
is O 0 3.375194684236872e-16
easy O 0 3.439128042881357e-15
by O 0 5.559048116072411e-16
urine O 0 1.1173461461622125e-11
chromatography O 0 9.977177070630283e-12
. O 0 2.007204445987859e-15
. O 0 8.227133438485495e-14

Detection O 0 6.572674696170289e-12
of O 0 2.090860172715772e-15
heterozygous O 0 1.3197189174807278e-10
carriers O 0 6.507264865840412e-11
of O 0 1.285383508886715e-14
the O 0 1.2062483456531936e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 2.2099826135768552e-10
ATM O 0 3.76120745659847e-10
) O 0 2.0253388258185324e-17
gene O 0 3.9324182202638697e-16
by O 0 6.542086678669109e-18
G2 O 0 1.8132572266599256e-12
phase O 0 1.2894850118239098e-13
chromosomal O 0 4.5352432920253705e-08
radiosensitivity O 0 4.679760579051617e-08
of O 0 1.3368787413897687e-13
peripheral O 0 1.3584384532805416e-06
blood O 0 1.819446993067686e-06
lymphocytes O 0 5.6154622143367305e-06
. O 0 1.1584570976108655e-11

In O 0 1.5381762352717487e-07
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999994039535522
telangiectasia I-Disease 1 1.0
( O 0 1.172044449049281e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.996384737552482e-11
patients O 0 1.6405521689397129e-12
, O 0 1.0359385825668117e-17
mutations O 0 5.1201439125298474e-15
in O 0 7.694946909948046e-18
a O 0 1.329847285842968e-16
single O 0 2.8300373654775723e-13
gene O 0 9.428466037422756e-13
, O 0 4.134933210040532e-16
ATM O 0 5.7023000904488086e-11
, O 0 8.61748535350244e-15
result O 0 7.661985195611676e-13
in O 0 6.101710109396308e-11
an O 1 0.9672041535377502
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.6596936047719169e-09
embraces O 0 9.272851236863389e-11
a O 0 9.129035655403624e-15
variety O 0 2.707222467035475e-13
of O 0 4.783632863299646e-16
clinical O 0 3.0201837124960162e-12
features O 0 3.2874217237299774e-11
and O 0 2.902047178954259e-11
manifests O 0 9.718346960507773e-11
extreme O 0 6.284382736421179e-12
radiosensitivity O 0 2.333757862515995e-07
and O 0 1.0778659865692819e-12
a O 0 8.012369251148704e-14
strong O 0 4.833425326644658e-12
pre O 0 7.65417151882275e-09
- O 0 3.2733613153368424e-08
disposition O 0 1.4536032377776564e-09
to O 0 5.832367466589161e-13
malignancy B-Disease 0 1.0563370551608386e-06
. O 0 5.633410404826122e-13

Heterozygotes O 0 4.008937182220507e-09
for O 0 5.194072948166203e-15
the O 0 1.3795031365378732e-16
ATM O 0 3.088680200491467e-09
gene O 0 2.739296567355609e-09
have O 0 1.0710096004507008e-11
no O 0 8.243685478714381e-15
clinical O 0 2.382244249955756e-13
expression O 0 8.669449130750597e-15
of O 0 5.07871231235444e-14
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 3.768562795158914e-09
may O 0 3.839429121854643e-11
be O 0 5.539224894740569e-12
cancer B-Disease 0 3.8060058576983025e-11
prone O 0 1.3551695356162075e-11
with O 0 8.243613825021e-17
a O 0 1.4645972575591222e-15
moderate O 0 5.285421080837571e-13
increase O 0 5.281592220865439e-13
in O 0 3.6080821049801464e-15
in O 0 2.543722611020316e-14
vitro O 0 4.723862634392617e-09
radiosensitivity O 0 4.585697581660497e-07
. O 0 1.4602649601666573e-12

We O 0 1.1148990619602728e-09
performed O 0 1.175878513483275e-12
a O 0 1.6032649154750053e-15
blind O 0 4.5544869958780154e-12
chromosomal O 0 2.800428500204788e-10
analysis O 0 3.512075070870313e-14
on O 0 2.005797227800938e-14
G2 O 0 1.706598404260795e-11
- O 0 1.4522938407424135e-11
phase O 0 4.0213812097997237e-13
lymphocytes O 0 9.221279989590769e-11
from O 0 2.786193119006853e-17
7 O 0 1.1556741773001119e-15
unrelated O 0 3.701041643294767e-12
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.2865200016420886e-09
, O 0 8.713669465143853e-17
13 O 0 2.3638383510668623e-15
obligate O 0 2.678475663486779e-09
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 2.2962970547268924e-07
( O 0 1.3593242971052136e-15
parents O 0 6.974310998409891e-16
of O 0 6.8035982783641e-19
the O 0 5.995098030340965e-17
patients O 0 7.857927298656104e-16
) O 0 1.8224608691890816e-18
, O 0 9.705604603382743e-18
and O 0 7.98468008291614e-14
14 O 0 4.611785129129964e-13
normal O 0 3.0300706334220745e-14
controls O 0 9.806191449135415e-12
following O 0 1.2045938451907788e-14
X O 0 6.516661432698356e-09
- O 0 1.0412342646079487e-12
irradiation O 0 6.264773584879063e-14
with O 0 9.300956450400172e-16
1 O 0 4.466258617688524e-16
Gy O 0 2.6229967850510683e-11
in O 0 9.624382084674936e-18
order O 0 1.2199309304768805e-17
to O 0 5.581843311238964e-18
evaluate O 0 2.6428931437815547e-15
this O 0 2.0257694560454275e-19
cytogenetic O 0 2.0758179517747083e-13
method O 0 5.805729256603485e-17
as O 0 1.464093140606608e-17
a O 0 2.920259047511602e-19
tool O 0 1.2078562772904235e-14
for O 0 1.3423278117405863e-18
detection O 0 1.1883224269773184e-15
of O 0 5.202517654892091e-16
ATM O 0 5.836483069288079e-06
carriers O 0 3.4667881010364e-08
. O 0 2.0199816212068678e-12

Both O 0 3.1771665298663265e-09
A B-Disease 1 0.9999947547912598
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
homozygotes O 0 2.4721633963054046e-05
and O 0 7.0214571698914204e-15
heterozygotes O 0 6.1592120292885966e-12
showed O 0 1.508250989379345e-13
significantly O 0 4.193663086471356e-15
increased O 0 3.2909912977689996e-15
levels O 0 9.613793458150208e-15
of O 0 8.294811010982112e-17
radiation O 0 6.867174051627956e-10
- O 0 1.059145347426238e-06
induced O 0 2.1927452564796113e-07
chromatid O 0 8.602043521932501e-07
damage O 0 1.2627986156754645e-10
relative O 0 1.9484497938433275e-15
to O 0 1.688088191093925e-17
that O 0 1.6762946138796134e-16
of O 0 5.075433596046384e-16
normal O 0 1.361968372283473e-12
controls O 0 1.0295408969795972e-09
. O 0 1.3199089174062428e-12

These O 0 3.2673885976388164e-14
results O 0 8.592279855277815e-14
show O 0 9.058240133452342e-14
that O 0 4.800152669292677e-18
the O 0 8.845688318087929e-18
G2 O 0 7.426541326349678e-11
- O 0 9.762265995583164e-11
phase O 0 3.147120368127143e-12
chromosomal O 0 1.9221278080294724e-07
radiosensitivity O 0 1.6043106398910822e-08
assay O 0 6.900569525514211e-12
can O 0 9.727408951980742e-16
be O 0 6.036286827198553e-18
used O 0 1.7064230422819538e-18
for O 0 5.34322176364727e-19
the O 0 2.809285789001195e-19
detection O 0 1.7175287071475448e-14
of O 0 3.5277060135910365e-13
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 0.9999998807907104
heterozygotes O 0 1.8653703591553494e-05
. O 0 1.077233614810158e-11

In O 0 3.376655237970899e-13
combination O 0 6.722251878407692e-13
with O 0 1.9357433202526678e-16
molecular O 0 8.538872733887537e-14
genetic O 0 6.163187321606145e-11
analyses O 0 4.113690499352174e-10
, O 0 5.9034643120411e-15
this O 0 7.923512795064209e-17
test O 0 9.475791706847758e-09
may O 0 3.315767053827835e-14
be O 0 2.2159472124219842e-17
of O 0 8.216757901999726e-20
value O 0 1.1469436816578197e-14
in O 0 5.712058000549e-17
studies O 0 6.100324933378367e-15
of O 0 5.986485822849757e-16
familial B-Disease 0 5.904267630363336e-10
and I-Disease 0 5.086453393893242e-12
sporadic I-Disease 0 3.2787335069173196e-09
cancers I-Disease 0 9.58156306296587e-06
aimed O 0 1.0913868697670637e-09
at O 0 1.1736093000203063e-11
determination O 0 2.561748827390603e-13
of O 0 4.945934670256293e-19
the O 0 1.178330983495823e-18
potential O 0 1.1290321323727671e-15
involvement O 0 9.364974141762468e-15
of O 0 1.1662669595802373e-16
ATM O 0 1.45376020554977e-06
mutations O 0 4.923389251842991e-09
in O 0 2.4367648808584948e-14
tumor B-Disease 0 3.510041096888017e-06
risk O 0 7.654463729522831e-09
or O 0 6.834624148100224e-14
development O 0 2.0452176329463848e-14
. O 0 5.183898811920258e-15
. O 0 5.793197410501605e-13

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
telangiectasia I-Disease 1 0.9999998807907104
: O 0 5.51131839818253e-12
identification O 0 6.219408871916375e-15
and O 0 3.9648464134283575e-17
detection O 0 9.879386779750661e-16
of O 0 2.573683471324835e-17
founder O 0 5.875998992932452e-11
- O 0 1.0518816679905285e-06
effect O 0 1.4369464819419253e-11
mutations O 0 1.0308288944660404e-11
in O 0 3.282599755595441e-17
the O 0 1.1589089067901699e-17
ATM O 0 9.74114972712714e-12
gene O 0 8.999876175254731e-14
in O 0 1.0809479116068228e-16
ethnic O 0 1.522017578701844e-14
populations O 0 3.5297539630746444e-12
. O 0 2.776601919305538e-13

To O 0 9.38575355402451e-15
facilitate O 0 2.7126156020436084e-15
the O 0 2.5758247110584897e-17
evaluation O 0 3.856889986423098e-15
of O 0 9.388384147191107e-19
ATM O 0 1.1153871229407919e-11
heterozygotes O 0 6.077173269822267e-13
for O 0 1.0569388785221854e-17
susceptibility O 0 1.0137121753182963e-14
to O 0 1.796399518286639e-16
other O 0 7.171317711754735e-14
diseases O 0 2.140728838639916e-08
, O 0 3.266348965281224e-17
such O 0 2.637644451184334e-16
as O 0 2.1729289201299906e-10
breast B-Disease 0 5.649312697642017e-06
cancer I-Disease 0 3.448374030767809e-09
, O 0 3.210613165030487e-15
we O 0 5.38678910505519e-13
have O 0 2.096970456639028e-15
attempted O 0 4.433450405839229e-14
to O 0 2.6864795534231297e-15
define O 0 1.4133456232613695e-13
the O 0 2.457954617056011e-16
most O 0 1.316075059516205e-16
common O 0 4.693078159095465e-16
mutations O 0 1.3399867466776347e-15
and O 0 8.558381194388048e-16
their O 0 1.860238300408607e-15
frequencies O 0 9.627221762842364e-12
in O 0 1.3704132273417713e-09
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 6.635726458625868e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.9314292421429855e-13
homozygotes O 0 1.0747549378242738e-10
from O 0 5.402503192530016e-16
10 O 0 1.3018698405347176e-15
ethnic O 0 2.9867014877314703e-15
populations O 0 6.724303731019121e-13
. O 0 7.628777844896975e-14

Both O 0 6.749411142828454e-13
genomic O 0 1.415020184358795e-10
mutations O 0 1.3928704856169816e-09
and O 0 1.9544966773504813e-13
their O 0 1.9274905723684507e-16
effects O 0 2.8680034150525835e-14
on O 0 1.0550184993208048e-15
cDNA O 0 2.0944704304248773e-13
were O 0 1.4734135406983123e-13
characterized O 0 1.2541010981428902e-12
. O 0 3.906244902193712e-13

Protein O 0 1.0451476351036604e-09
- O 0 1.4684506943751785e-09
truncation O 0 1.0617921125666285e-10
testing O 0 1.1928769083624502e-09
of O 0 1.0173831016298996e-17
the O 0 3.0342630957864036e-18
entire O 0 2.767679519878716e-15
ATM O 0 7.379518003614027e-12
cDNA O 0 4.753906686708054e-13
detected O 0 1.3093014172849138e-10
92 O 0 2.109280848941464e-12
( O 0 2.6614175425797694e-15
66 O 0 5.87198150346635e-13
% O 0 4.947055164978155e-16
) O 0 4.4417216613933433e-17
truncating O 0 9.532371419984642e-12
mutations O 0 8.149054347983409e-12
in O 0 2.8320581002161014e-16
140 O 0 1.9918171184130952e-14
mutant O 0 1.4310774787418268e-10
alleles O 0 1.65424410281112e-10
screened O 0 3.5915252283302834e-06
. O 0 2.5765008182521143e-11

The O 0 2.645250826108919e-13
haplotyping O 0 1.8440798044139228e-07
of O 0 1.8194047478456085e-14
patients O 0 1.219338540726922e-12
with O 0 2.8763616820662048e-15
identical O 0 6.232983573717377e-11
mutations O 0 2.648199659560646e-09
indicates O 0 4.277544984887527e-10
that O 0 2.183278379050066e-13
almost O 0 7.018166701001222e-14
all O 0 1.2670695384835867e-13
of O 0 1.0478945684225919e-16
these O 0 3.7429041274363766e-16
represent O 0 4.3208632947099555e-15
common O 0 1.0995926391643707e-12
ancestry O 0 6.071899649739976e-10
and O 0 9.022473740349923e-11
that O 0 3.621675713234157e-13
very O 0 6.157373872925365e-14
few O 0 1.8563697400022366e-13
spontaneously O 0 1.0249961469865898e-11
recurring O 0 1.2177443053928982e-08
ATM O 0 4.080654889548896e-07
mutations O 0 3.29057598946747e-08
exist O 0 3.7264891172839043e-10
. O 0 2.8851037878196983e-11

Assays O 0 2.3501025570027423e-09
requiring O 0 2.099351074924538e-12
minimal O 0 1.4885873905593795e-14
amounts O 0 2.3079164947353045e-16
of O 0 6.168901560376397e-19
genomic O 0 1.745588401472556e-13
DNA O 0 3.4066522935916055e-09
were O 0 1.9848741248697233e-13
designed O 0 4.271210053935319e-14
to O 0 5.645874121685775e-18
allow O 0 5.676805283377664e-16
rapid O 0 1.5104315867635917e-15
screening O 0 3.5779440797937753e-14
for O 0 4.183688294135592e-17
common O 0 5.952555271169526e-16
ethnic O 0 4.517924662855721e-15
mutations O 0 1.3207053506381072e-11
. O 0 7.520700100009658e-13

These O 0 2.1295473861420756e-14
rapid O 0 2.720265961271562e-13
assays O 0 2.414832743491413e-11
detected O 0 2.1220818505196526e-11
mutations O 0 9.074534201326812e-13
in O 0 3.545738680117217e-16
76 O 0 6.77989088482267e-12
% O 0 1.4390993423852813e-15
of O 0 2.725363024383312e-15
Costa O 0 3.077890298186503e-08
Rican O 0 1.3966207357274385e-10
patients O 0 1.3331973329130942e-12
( O 0 1.2675890241871845e-17
3 O 0 2.640805736962165e-16
) O 0 2.620483365149615e-17
, O 0 4.3746923212260276e-18
50 O 0 3.7083687412922466e-16
% O 0 2.35080706681071e-16
of O 0 1.4832769344372276e-13
Norwegian O 0 0.24270683526992798
patients O 0 3.247700552932997e-09
( O 0 9.691149589091154e-16
1 O 0 8.14151816456158e-16
) O 0 2.5484500289538843e-16
, O 0 9.997744281657281e-17
25 O 0 3.786477408067269e-15
% O 0 1.9238691094722446e-16
of O 0 1.3293263076408473e-14
Polish O 0 1.652568425924983e-05
patients O 0 8.096904223486856e-12
( O 0 1.7075448356773768e-16
4 O 0 4.929387857643443e-15
) O 0 3.14982198098296e-16
, O 0 4.086354547026518e-16
and O 0 2.7276434149542395e-13
14 O 0 1.0557428412397152e-12
% O 0 2.417448707424922e-16
of O 0 6.111411747624978e-15
Italian O 0 3.34113366307065e-07
patients O 0 9.089956218288897e-12
( O 0 1.9490807804494728e-16
1 O 0 2.1361690238555888e-15
) O 0 1.4242118913043397e-15
, O 0 2.2858626684645587e-16
as O 0 7.868039919134255e-15
well O 0 3.020756997947245e-14
as O 0 2.9512762405366905e-14
in O 0 9.479192299534974e-16
patients O 0 9.237985268244209e-15
of O 0 1.0489268501223887e-15
Amish O 0 1.1238923889322905e-06
/ O 0 9.23163679544814e-06
Mennonite O 0 8.771494321990758e-07
and O 0 2.7312069050822174e-07
Irish O 0 1.4309323887573555e-05
English O 0 3.4802092319097255e-09
backgrounds O 0 3.385755231732901e-09
. O 0 2.2064225446705166e-11

Additional O 0 1.5327427911951408e-12
mutations O 0 1.67968597364343e-10
were O 0 1.8465315539638316e-13
observed O 0 2.527511247442816e-14
in O 0 1.0091197823774542e-16
Japanese O 0 1.1549476652827906e-10
, O 0 5.92355493100707e-18
Utah O 0 5.834350235193412e-16
Mormon O 0 1.7977920669217046e-15
, O 0 2.2337467958628105e-15
and O 0 2.7582159172205752e-14
African O 0 2.4301659859796154e-13
American O 0 1.5596983773957795e-11
patients O 0 2.850912052005522e-13
. O 0 1.724731028298048e-14

These O 0 6.529730403571302e-15
assays O 0 5.936942777673426e-12
should O 0 2.1297645548018398e-16
facilitate O 0 4.354298927686084e-17
screening O 0 7.598992100713367e-14
for O 0 6.231069127468278e-15
A B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
heterozygotes O 0 1.1156463308736875e-08
in O 0 1.6131472488706213e-16
the O 0 1.1040477573929787e-16
populations O 0 8.251613707100681e-15
studied O 0 1.1354645386906989e-13
. O 0 8.288551437501902e-16
. O 0 6.392137524586367e-14

The O 0 1.0654173376867249e-10
von B-Disease 1 0.9946229457855225
Hippel I-Disease 1 0.9982500672340393
- I-Disease 1 0.9984614849090576
Lindau I-Disease 0 0.03334025293588638
tumor I-Disease 0 2.5841193291853415e-06
suppressor O 0 8.465703693616433e-10
gene O 0 3.893815492261865e-09
is O 0 4.2545277739204634e-13
required O 0 1.9235910709073083e-15
for O 0 4.779417153851382e-17
cell O 0 7.0186161570118255e-12
cycle O 0 2.371703500259059e-09
exit O 0 9.212262203073251e-11
upon O 0 1.1680837503844077e-12
serum O 0 1.1500340946213328e-07
withdrawal O 0 2.24694907124956e-09
. O 0 9.909976485256156e-13

The O 0 4.4446797587902043e-13
inactivation O 0 1.6764101218313954e-08
of O 0 4.447762382735806e-15
the O 0 8.714153530708924e-13
von B-Disease 1 0.9998683929443359
Hippel I-Disease 1 0.9999285936355591
- I-Disease 1 0.9999896287918091
Lindau I-Disease 1 0.9997712969779968
( I-Disease 0 1.8937453827305717e-09
VHL I-Disease 0 3.1028409921418643e-06
) I-Disease 0 1.0427078918720002e-14
tumor I-Disease 0 4.486057358921158e-12
suppressor O 0 4.8765984306253785e-11
gene O 0 9.376258658377878e-10
predisposes O 0 4.255764096683379e-08
affected O 0 2.7070043429056057e-10
individuals O 0 4.525240317014567e-14
to O 0 2.341312992142292e-15
the O 0 4.594771611798887e-12
human O 0 0.0004474179295357317
VHL B-Disease 1 0.9999955892562866
cancer I-Disease 1 0.9999858140945435
syndrome I-Disease 1 0.9999943971633911
and O 0 3.0846411037434296e-13
is O 0 7.829017788880607e-14
associated O 0 1.3375069281285068e-12
with O 0 3.2011798767328514e-10
sporadic B-Disease 0 0.12820971012115479
renal I-Disease 1 0.9997574687004089
cell I-Disease 1 0.9999303817749023
carcinomas I-Disease 1 1.0
( O 0 7.880155408201972e-07
RCC B-Disease 0 0.01672520488500595
) O 0 1.8946116897566867e-10
and O 0 2.244575081356004e-10
brain B-Disease 0 4.934979187964927e-06
hemangioblastomas I-Disease 0 0.0034197093918919563
. O 0 7.036567856166798e-11

VHL O 0 0.015245627611875534
- O 0 6.171469976834487e-06
negative O 0 1.785714154323159e-08
786 O 0 4.1209510470707755e-08
- O 0 2.2820008780399803e-06
0 O 0 2.2989583327304164e-12
RCC B-Disease 0 3.0765152647660443e-09
cells O 0 4.2210686335142356e-11
are O 0 6.798625247841916e-13
tumorigenic O 0 1.923328682096326e-06
in O 0 1.7970465339325198e-13
nude O 1 0.9996501207351685
mice O 1 0.7282946109771729
which O 0 4.590365847850775e-12
is O 0 2.751131884221156e-15
suppressed O 0 2.104631869646943e-15
by O 0 1.0699971032237079e-18
the O 0 8.999840869862699e-18
reintroduction O 0 4.713790122123918e-13
of O 0 4.2893833152252495e-14
VHL B-Disease 0 1.017861222862848e-06
. O 0 2.1693901015862327e-12

Remarkably O 0 1.1044982706209794e-09
, O 0 9.116607140968562e-16
this O 0 3.4351616597317866e-19
occurs O 0 7.300763584331007e-17
without O 0 3.9801820111128456e-17
affecting O 0 3.736103426957814e-14
the O 0 5.499252883952178e-16
growth O 0 6.205802804970517e-08
rate O 0 1.090735501918516e-09
and O 0 4.257299401249151e-15
cell O 0 5.246377740878924e-14
cycle O 0 1.1409494876657433e-11
profile O 0 4.1329883959662084e-11
of O 0 5.806418794362109e-16
these O 0 3.3366107453026625e-16
cells O 0 5.750587147039434e-15
in O 0 3.447215645810639e-17
culture O 0 2.6746871861424437e-13
. O 0 5.245830896408177e-13

The O 0 2.0441734784916454e-13
786 O 0 2.4957649835677387e-10
- O 0 3.150219285430467e-08
0 O 0 3.598634045376588e-14
cell O 0 9.69793689797882e-12
line O 0 1.2694444107008707e-10
, O 0 3.4213159590871137e-17
like O 0 2.342500955850816e-15
many O 0 4.381023809788692e-17
cancer B-Disease 0 4.869009384046719e-13
cells O 0 1.830413211544599e-15
, O 0 5.858232726187941e-17
fails O 0 5.944709649671406e-14
to O 0 2.0643802287187082e-16
exit O 0 1.1890555207116904e-10
the O 0 2.4244607108600894e-14
cell O 0 8.981639217087167e-12
cycle O 0 4.3818060291300753e-11
upon O 0 2.1863705236459946e-13
serum O 0 1.1019274381851574e-08
withdrawal O 0 2.338819415914628e-10
. O 0 2.2445714449419174e-13

Here O 0 3.7557018606193537e-10
, O 0 1.2907583564535172e-15
it O 0 5.946285440649721e-18
is O 0 8.671949783769129e-18
shown O 0 6.3880536544928534e-18
that O 0 3.974395401929306e-20
reintroduction O 0 6.853388045464275e-16
of O 0 8.322698412717602e-18
the O 0 5.073979478703965e-17
wild O 0 3.9252284755875166e-10
- O 0 6.791008644313479e-08
type O 0 3.174657203786069e-10
VHL B-Disease 0 2.8148137154460073e-09
gene O 0 1.101500726567728e-12
restores O 0 6.942789659153403e-12
the O 0 7.98258513750352e-16
ability O 0 1.3268805542157591e-12
of O 0 5.0880977762231966e-14
VHL O 0 0.002289822092279792
- O 0 9.085601959668566e-06
negative O 0 3.448797656346869e-07
RCC B-Disease 0 5.6863486861402635e-06
cancer I-Disease 0 2.5021056337948266e-09
cells O 0 4.3731660545436035e-14
to O 0 3.504777225579183e-16
exit O 0 3.516490917898629e-11
the O 0 2.100132642389365e-15
cell O 0 4.161846214878473e-11
cycle O 0 1.1322536686009244e-08
and O 0 2.2556281929070332e-12
enter O 0 5.005761864046443e-12
G0 O 0 1.616813172233833e-08
/ O 0 1.4144810878136127e-09
quiescence O 0 1.1508779484969978e-09
in O 0 1.1549524628774038e-13
low O 0 5.225865296054621e-10
serum O 0 2.8268656304675233e-09
. O 0 1.4451805637610837e-12

Both O 0 5.211739928512316e-10
VHL O 0 3.115000436082482e-05
- O 0 3.694553925015498e-07
positive O 0 1.296486584756451e-09
and O 0 1.7230623395106393e-12
VHL O 0 9.22637354960898e-06
- O 0 2.7974737193403598e-08
negative O 0 5.974024608335071e-10
RCC B-Disease 0 5.997229379772762e-08
cells O 0 3.331766806891068e-11
exit O 0 5.214322723601228e-11
the O 0 2.6050076893914748e-15
cell O 0 5.970350949735526e-12
cycle O 0 1.628820342491899e-11
by O 0 1.4692754205268077e-15
contact O 0 3.489679378798627e-10
inhibition O 0 2.8415585440200175e-09
. O 0 1.7169440782310863e-12

The O 0 3.2482345806161828e-12
cyclin O 0 5.455053155856149e-07
- O 0 6.072368705645204e-07
dependent O 0 3.878765642006954e-10
kinase O 0 6.494458859584995e-10
inhibitor O 0 1.330790200260168e-10
, O 0 4.85348025892142e-16
p27 O 0 2.875936793399203e-13
, O 0 1.785126279036654e-18
accumulates O 0 2.393126421042311e-15
upon O 0 9.858944698359863e-16
serum O 0 4.27750634912627e-09
withdrawal O 0 3.5513314511348426e-11
, O 0 2.3100820204917438e-17
only O 0 8.27900011531765e-18
in O 0 1.3576121449066115e-18
the O 0 1.2692880035345316e-16
presence O 0 9.855124528945769e-13
of O 0 1.261194789011974e-15
VHL B-Disease 0 2.722998004855981e-08
, O 0 2.3436708142300926e-16
as O 0 8.409059211954466e-17
a O 0 9.01702769775808e-17
result O 0 2.2746517109516152e-15
of O 0 1.06633500507991e-16
the O 0 5.283157944327779e-15
stabilization O 0 2.4843258960433046e-12
of O 0 2.711897576184688e-18
the O 0 4.997013168207213e-16
protein O 0 6.186700999590011e-13
. O 0 1.7573677159755247e-13

We O 0 5.848032561678318e-12
propose O 0 7.639585036627039e-13
that O 0 3.452505962136283e-17
the O 0 7.246791207414779e-18
loss O 0 1.6751009962261663e-14
of O 0 8.063620481782318e-18
wild O 0 1.4848659191102342e-08
- O 0 1.1740223271772265e-05
type O 0 4.991109037177921e-08
VHL B-Disease 0 2.683432569483557e-07
gene O 0 2.0884053167358196e-11
results O 0 3.806421391733435e-14
in O 0 9.55932102077519e-19
a O 0 3.1106412312367937e-18
specific O 0 1.7804837956775102e-15
cellular O 0 1.0102250147525638e-09
defect O 0 8.153011599176807e-10
in O 0 3.8548286788063957e-16
serum O 0 3.470970000307716e-08
- O 0 1.0605837132970919e-06
dependent O 0 2.050105685214021e-08
growth O 0 2.822463613938453e-07
control O 0 3.475882082160098e-10
, O 0 2.784835960467115e-15
which O 0 2.676802413758986e-15
may O 0 1.433085692215813e-13
initiate O 0 1.196557501519091e-12
tumor B-Disease 0 9.922814792062695e-10
formation O 0 3.3523355532499854e-12
. O 0 1.110788110797456e-12

This O 0 1.6049246892406444e-13
is O 0 1.2987652742006174e-14
corrected O 0 4.2927020445227004e-12
by O 0 4.1911600201533877e-19
the O 0 3.1447506958796654e-19
reintroduction O 0 6.7225782063209515e-15
of O 0 1.3581367304433834e-16
wild O 0 4.33926095055881e-09
- O 0 3.476884012343362e-05
type O 0 2.304209800740864e-07
VHL B-Disease 0 2.617935933812987e-06
, O 0 3.663237925890031e-15
implicating O 0 6.302626420762181e-09
VHL B-Disease 0 7.810067472746596e-07
as O 0 1.2324968892425247e-14
the O 0 4.406951537934983e-18
first O 0 8.866980708061207e-16
tumor B-Disease 0 2.0795114220005517e-13
suppressor O 0 7.79901588188886e-14
involved O 0 3.7371459551092945e-13
in O 0 4.2992896302411845e-16
the O 0 4.586707232183678e-16
regulation O 0 1.361132127147835e-12
of O 0 1.308790576169818e-16
cell O 0 2.7921161476623935e-12
cycle O 0 3.3868792215230314e-09
exit O 0 2.5794537616974367e-09
, O 0 3.482205639831516e-14
which O 0 2.800688393833216e-15
is O 0 1.8981679021558978e-13
consistent O 0 1.5607272418893814e-12
with O 0 3.969950250156708e-15
its O 0 1.2276449998173573e-14
gatekeeper O 0 5.947424330798867e-09
function O 0 1.4684525703701976e-14
in O 0 5.629749426784136e-16
the O 0 3.609806952051958e-13
kidney O 0 3.478034216186643e-08
. O 0 8.535242011862426e-14
. O 0 9.1995226540742e-13

Piebaldism B-Disease 1 0.9999998807907104
with O 0 0.00020066944125574082
deafness B-Disease 1 1.0
: O 0 4.2914615952646326e-14
molecular O 0 3.799008837005423e-14
evidence O 0 1.0577194502203735e-13
for O 0 8.114381155931508e-14
an O 0 2.3748064278961145e-11
expanded O 1 0.9815518260002136
syndrome O 1 0.9999940395355225
. O 0 9.089088856550909e-12

In O 0 1.2658954830560565e-13
a O 0 5.505243071309007e-13
South O 0 3.2820479667350355e-10
African O 0 7.718397860949355e-13
girl O 0 4.496813477139483e-10
of O 0 1.1775593646050152e-16
Xhosa O 0 6.097545385275183e-11
stock O 0 3.9821836800291166e-11
with O 0 7.437700764523561e-14
severe O 0 6.006862784957434e-10
piebaldism B-Disease 0 5.180784228286939e-07
and O 0 2.2270300187310355e-11
profound O 0 1.778351244041687e-09
congenital O 1 0.9999552965164185
sensorineural B-Disease 1 0.9999634027481079
deafness I-Disease 1 1.0
we O 0 2.785897912360724e-08
identified O 0 2.5535786592895127e-12
a O 0 6.964683410173162e-17
novel O 0 1.90697162379648e-13
missense O 0 2.9829630432409715e-10
substitution O 0 5.476658894183056e-14
at O 0 4.35056992601629e-14
a O 0 7.757581687675052e-17
highly O 0 8.129849226921968e-16
conserved O 0 9.273009233580227e-15
residue O 0 8.802027856580352e-11
in O 0 3.31317175546536e-16
the O 0 1.4700491851241245e-15
intracellular O 0 9.055744001895683e-12
kinase O 0 4.977238239611825e-12
domain O 0 1.27587578089422e-12
of O 0 9.620359657557323e-15
the O 0 8.054399025991463e-14
KIT O 0 5.627103973893099e-07
proto O 0 1.1672624822267608e-07
- O 0 6.885726122618507e-08
oncogene O 0 2.44333309140643e-09
, O 0 1.7979035957498696e-13
R796G O 0 3.9251163430620295e-10
. O 0 4.4738873521653344e-13

Though O 0 2.605758317453244e-11
auditory B-Disease 0 1.4778219536992765e-08
anomalies I-Disease 0 4.816929504158907e-07
have O 0 9.244340319278233e-13
been O 0 1.0996780742955625e-13
observed O 0 4.465700338272989e-14
in O 0 2.663427075307571e-16
mice O 0 1.1952818734783932e-09
with O 0 1.6790361418925204e-13
dominant O 0 1.801607751872325e-09
white O 0 2.6454419210786284e-10
spotting O 0 6.120438200696299e-08
( O 0 1.144209184865408e-12
W O 0 3.7785732274642214e-05
) O 0 1.3728479616136047e-14
due O 0 2.6859787451930656e-14
to O 0 2.0222462688234376e-14
KIT O 0 0.00013597305223811418
mutations O 0 1.2600038417076576e-06
, O 0 7.442796379208971e-10
deafness B-Disease 1 1.0
is O 0 4.0395917166868855e-10
not O 0 1.309801469758301e-13
typical O 0 7.577181341134748e-14
in O 0 2.5490833978401937e-15
human O 0 2.3273195870476826e-11
piebaldism B-Disease 0 4.51524044819962e-07
. O 0 1.3464989756864498e-12

Thus O 0 6.08355553433082e-12
, O 0 1.3352210216790268e-15
the O 0 3.813202369579216e-17
occurrence O 0 6.702257672464018e-12
of O 0 5.9283992645542405e-12
sensorineural B-Disease 1 0.9999734163284302
deafness I-Disease 1 1.0
in O 0 1.5585466944800785e-12
this O 0 6.67670014904058e-16
patient O 0 3.081759565419506e-13
extends O 0 2.5573915205033375e-15
considerably O 0 4.843752085522204e-16
the O 0 5.618716127814434e-18
phenotypic O 0 1.060793553692152e-11
range O 0 1.0487510165857472e-11
of O 0 1.573380640183808e-14
piebaldism B-Disease 0 6.934359220167607e-08
due O 0 1.615354036513597e-13
to O 0 1.625935725838487e-16
KIT O 0 7.759596520884315e-09
gene O 0 4.230004801292209e-12
mutation O 0 2.706592274522718e-13
in O 0 2.3251117267857098e-17
humans O 0 1.78066911801604e-13
and O 0 8.218699700836274e-13
tightens O 0 6.980459943406458e-08
the O 0 1.3305779841088727e-16
clinical O 0 9.869308061766224e-13
similarity O 0 1.4264038219894207e-14
between O 0 1.8868326362051976e-14
piebaldism B-Disease 0 2.6179277412552437e-08
and O 0 1.9035910136600345e-14
the O 0 7.551354145873129e-18
various O 0 1.5141352383254611e-15
forms O 0 1.6130043134499061e-10
of O 0 8.07356848042673e-09
Waardenburg B-Disease 1 0.9994977712631226
syndrome I-Disease 1 0.9998223185539246
. O 0 4.7578135414739695e-14
. O 0 1.0545132475558994e-12

Cycloheximide O 0 1.5610250869713127e-08
facilitates O 0 1.565034668700449e-12
the O 0 1.2744212878926887e-16
identification O 0 8.064309311474338e-15
of O 0 9.855179372211521e-17
aberrant O 0 2.2443255587312194e-11
transcripts O 0 5.7503134198721995e-11
resulting O 0 2.589825868950374e-13
from O 0 2.061508998785753e-15
a O 0 1.0217401630099594e-15
novel O 0 8.225851098365988e-13
splice O 0 3.7064683056087233e-07
- O 0 4.223875915698727e-09
site O 0 7.061787352796722e-12
mutation O 0 4.822359178646707e-11
in O 0 2.444183449520432e-15
COL17A1 O 0 1.6918230016926827e-07
in O 0 1.0975516102575792e-16
a O 0 1.5735868927064644e-15
patient O 0 4.146188167103437e-12
with O 0 2.1652386101526228e-13
generalized O 0 7.484799624535299e-08
atrophic B-Disease 1 0.9974890947341919
benign I-Disease 1 0.9578042030334473
epidermolysis I-Disease 1 0.9172530770301819
bullosa I-Disease 0 0.06544870883226395
. O 0 9.262749678384807e-09

Patients O 0 3.6145696213907286e-08
with O 0 5.5528494129208905e-12
generalized O 0 1.8440745179759688e-06
atrophic B-Disease 1 0.9997844099998474
benign I-Disease 1 0.99904865026474
epidermolysis I-Disease 1 0.991958737373352
bullosa I-Disease 0 0.008301069028675556
often O 0 8.270952811528787e-10
show O 0 1.1668808141962472e-09
decreased O 0 3.5084148919395375e-09
expression O 0 7.302170478527825e-13
of O 0 3.4971147749559076e-14
type O 0 1.2321888789301738e-05
XVII O 0 2.557365587563254e-05
collagen O 0 2.2284741135081276e-05
, O 0 1.2423868628753248e-13
a O 0 7.453091183768582e-15
transmembrane O 0 5.1050393079510314e-11
hemidesmosomal O 0 2.8646301997170553e-10
protein O 0 2.3298962585627248e-14
encoded O 0 2.2181748151055454e-14
by O 0 5.971438621354963e-14
COL17A1 O 0 3.702584217535332e-05
. O 0 3.1800417334137965e-12

This O 0 5.187382912542199e-14
report O 0 3.507134497095568e-14
documents O 0 1.133049630817418e-14
a O 0 4.482182837096905e-16
novel O 0 2.286507300771484e-13
splice O 0 6.794635396545345e-07
- O 0 1.02780299826577e-08
site O 0 8.899904251069568e-12
mutation O 0 3.018998939730011e-11
in O 0 6.387283602282126e-15
COL17A1 O 0 1.486439060727207e-07
in O 0 4.3450401296536554e-17
a O 0 4.3138448326485656e-16
patient O 0 4.683463361056239e-13
with O 0 1.9155301124581733e-14
generalized O 0 4.5395682768401e-09
atrophic B-Disease 1 0.9959375858306885
benign I-Disease 0 0.021914908662438393
epidermolysis I-Disease 0 0.0024290054570883512
bullosa I-Disease 0 4.0887403883971274e-05
, O 0 4.187451600745629e-12
and O 0 1.9079372667673384e-15
applies O 0 1.944966185559287e-16
a O 0 1.0419904840824334e-17
new O 0 1.1813568515355727e-16
methodology O 0 5.662530660634061e-16
to O 0 3.3599444515915994e-17
define O 0 7.610958982192176e-14
and O 0 5.607378778427381e-14
characterize O 0 1.565532507233e-13
the O 0 4.10447708163082e-16
resulting O 0 1.8515030613818102e-14
mRNA O 0 1.0896436476639376e-13
splice O 0 4.995394675688658e-08
variants O 0 1.6439164696180342e-08
. O 0 2.315205839542589e-11

Mutational O 0 3.1871471151134756e-07
analysis O 0 3.609948451277489e-11
of O 0 5.870075204996578e-14
COL17A1 O 0 2.1463929442688823e-06
identified O 0 5.703529662448581e-11
a O 0 1.1597913926984782e-13
maternally O 0 9.297425549448235e-07
inherited O 0 2.792101270188141e-07
G O 0 2.199259597546188e-06
- O 0 4.923013552371458e-09
to O 0 1.6723507344565403e-12
- O 0 7.76468550611753e-06
T O 0 2.8285666076044436e-07
transversion O 0 4.150338128727782e-10
at O 0 4.062330373889693e-14
the O 0 8.885226724187351e-17
- O 0 1.326671238144339e-11
1 O 0 2.501495286918434e-16
position O 0 9.359398547387167e-16
of O 0 1.084226326159391e-17
exon O 0 1.7764305651479795e-11
32 O 0 3.5743207005278776e-11
. O 0 1.6134264605761894e-13

This O 0 4.745858857269601e-14
acceptor O 0 1.6173474018388312e-11
splice O 0 5.101150613029404e-09
- O 0 5.027334104568126e-10
site O 0 1.7447173263421267e-12
mutation O 0 1.3652773356298553e-11
led O 0 8.769706152673279e-14
to O 0 5.3569215703114036e-17
the O 0 4.415216147589184e-17
formation O 0 1.2384965930145164e-14
of O 0 3.422477320667138e-17
aberrant O 0 1.0213481536208713e-12
transcripts O 0 8.361415401204886e-13
present O 0 1.2512374932005261e-14
at O 0 1.2157204496571206e-12
extremely O 0 1.0496775323942664e-11
low O 0 3.997979280967456e-09
levels O 0 7.607647151131047e-11
. O 0 7.940776942244598e-13

Based O 0 5.710087350868642e-13
on O 0 6.350260893300472e-14
our O 0 5.742889205735669e-16
recent O 0 2.5805062224532948e-17
finding O 0 2.895449516593021e-16
that O 0 8.991647546633687e-16
cycloheximide O 0 9.619949281614026e-09
stabilized O 0 1.9032981857236564e-09
mutant O 0 7.278289082535139e-11
COL17A1 O 0 2.060498260902932e-08
transcripts O 0 1.719845620085092e-11
in O 0 2.2036085165665553e-15
keratinocytes O 0 2.2100868010688224e-11
homozygous O 0 1.862045587164296e-11
for O 0 4.757064616117831e-16
a O 0 3.132843258494807e-15
frameshift O 0 3.1219011820127207e-09
mutation O 0 6.721771750317629e-11
, O 0 9.088481411954983e-16
the O 0 3.8152997687404056e-16
effects O 0 1.5801235320189733e-10
of O 0 1.601186720138917e-15
the O 0 2.542597243046594e-14
splice O 0 2.4564005798310973e-06
- O 0 1.0621410417854804e-09
site O 0 7.042092061392002e-13
mutation O 0 1.323190146861053e-13
on O 0 1.266159884390542e-15
splicing O 0 1.836429771272241e-13
of O 0 7.210730070087183e-16
COL17A1 O 0 5.33078636788531e-10
transcripts O 0 2.1895420860510578e-13
were O 0 1.5253173437786388e-16
determined O 0 2.3274366006153514e-17
using O 0 2.9252362242766067e-16
reverse O 0 3.784201684647881e-12
transcriptase O 0 1.1857403947601597e-09
polymerase O 0 3.146381809607246e-12
chain O 0 1.696427373576448e-11
reaction O 0 1.1254421738082429e-14
of O 0 2.585145382200737e-18
total O 0 7.308791603786405e-16
RNA O 0 5.6017134832629656e-14
from O 0 1.0269215694274324e-15
keratinocytes O 0 8.233699095791525e-13
incubated O 0 8.358576959917319e-13
for O 0 2.7181780674082274e-15
2 O 0 7.184927159524859e-14
. O 0 1.0555671056200824e-13

5 O 0 1.1347300876707322e-10
h O 0 2.5099013978291396e-09
in O 0 2.1987719584377332e-15
the O 0 1.7307674085966559e-15
presence O 0 9.662261225493185e-13
or O 0 4.3283386992826536e-14
absence O 0 5.108499072977585e-14
of O 0 3.9470997496944e-17
10 O 0 1.9230199165909748e-14
microg O 0 1.5544394937894168e-10
cycloheximide O 0 2.2978911828896997e-10
per O 0 6.511649807685801e-14
ml O 0 2.5639632639240517e-09
. O 0 6.953918777613532e-13

Using O 0 2.1456859726487476e-13
this O 0 1.0123397913613312e-15
approach O 0 9.450431973437312e-13
, O 0 2.5902233645718614e-15
an O 0 1.2680643320933248e-15
abnormally O 0 1.0710152764659142e-08
spliced O 0 0.00012038199201924726
transcript O 0 1.8020249399341992e-06
was O 0 9.031142944593284e-09
identified O 0 2.0004885335073164e-12
that O 0 5.128482574701207e-18
contains O 0 1.8751330422594676e-18
an O 0 1.922099323464463e-18
extra O 0 5.385427855346316e-15
264 O 0 4.14874670804765e-14
bases O 0 5.641431874599256e-13
upstream O 0 1.1227711739936891e-13
from O 0 8.433027200337108e-16
exon O 0 2.2608238198218444e-11
32 O 0 1.601758135849618e-11
, O 0 3.3312564382848313e-16
resulting O 0 1.1140575692471564e-16
in O 0 1.3170443828452191e-16
a O 0 3.400815328132023e-13
premature O 0 9.240669340826457e-10
termination O 0 9.876091264238163e-12
codon O 0 6.131646579365935e-11
27 O 0 1.3896362359433478e-12
bp O 0 1.0332362569698272e-11
downstream O 0 1.1328821995088e-12
from O 0 1.3667492820417263e-15
the O 0 3.617382844378354e-16
cryptic O 0 2.683462176425455e-12
splice O 0 1.7854613343359915e-09
site O 0 4.3586356746061483e-10
. O 0 9.692037103437023e-12

Three O 0 6.000967409623692e-13
other O 0 5.932719877127198e-16
splice O 0 1.9820152630245502e-08
variants O 0 7.685855285544108e-10
, O 0 9.508745279064677e-16
including O 0 6.419446978536588e-17
one O 0 5.439243991079722e-18
derived O 0 1.3113036170452031e-17
from O 0 1.7622914205597294e-17
the O 0 9.005918993003738e-18
skipping O 0 5.8120153655083495e-12
of O 0 8.063163381775821e-17
exon O 0 1.5163233516024555e-11
32 O 0 8.678797958072693e-11
, O 0 4.3740480699515794e-15
were O 0 7.598412052551087e-14
also O 0 3.190100364858922e-13
identified O 0 9.054275558473268e-12
. O 0 2.078976964539625e-12

These O 0 1.2685543533588056e-13
results O 0 2.641938317421433e-13
indicate O 0 1.8943910500067267e-14
the O 0 8.49280727850852e-18
usefulness O 0 5.758206547213165e-14
of O 0 2.508240084545967e-17
cycloheximide O 0 3.326212638654624e-10
treatment O 0 6.335538105424476e-14
in O 0 1.7325085964891198e-18
evaluating O 0 1.6417055364345394e-14
the O 0 1.3121192171291804e-17
abnormal O 0 1.709247435428829e-14
processing O 0 9.26078265179979e-14
of O 0 3.0346464112822606e-17
mRNA O 0 1.37921519298141e-14
due O 0 1.2542337028448487e-14
to O 0 1.2259643593950627e-15
splice O 0 4.44621900896891e-06
- O 0 3.418631067120259e-08
site O 0 8.92568033372676e-11
mutations O 0 1.8623057262967535e-10
, O 0 3.3644366775924727e-15
because O 0 9.792718156829364e-15
( O 0 1.0273799201310154e-15
i O 0 1.1434118929454229e-10
) O 0 1.4017565449468157e-16
aberrant O 0 6.914844944468784e-14
splicing O 0 8.447980271060473e-13
often O 0 1.5032278807142196e-13
generates O 0 3.4600349928942675e-13
a O 0 5.14894116926401e-13
premature O 0 1.3652370345340614e-09
termination O 0 1.1691549117731626e-10
codon O 0 2.1695248375586118e-10
, O 0 1.0375457342782536e-14
( O 0 4.1614223125813383e-16
ii O 0 6.937425352064597e-13
) O 0 1.3508666731268794e-16
transcripts O 0 2.563821279843309e-13
with O 0 4.1922899613605624e-14
premature O 0 1.086631219032741e-11
termination O 0 2.1652634112773184e-13
codons O 0 1.3803218550795249e-12
can O 0 4.5513126687574124e-14
occur O 0 4.402875565761959e-15
at O 0 1.9744752707828717e-13
low O 0 1.293325224693831e-09
or O 0 2.020041356409763e-10
undetectable O 0 8.475461072521284e-05
levels O 0 1.4650815283179242e-10
due O 0 5.443344749554366e-14
to O 0 1.2085982781522182e-14
nonsense O 0 1.0962217089627302e-07
- O 0 2.7235861135843642e-11
mediated O 0 1.2442134995904741e-12
mRNA O 0 5.012400580485272e-16
decay O 0 2.931897143143049e-14
, O 0 2.9768949108450744e-16
and O 0 5.705766928031065e-16
( O 0 1.833892008946197e-17
iii O 0 2.7779634061836367e-13
) O 0 1.1403336694715076e-15
the O 0 7.479061637447873e-16
levels O 0 4.8737138456933504e-12
of O 0 2.3057856443901434e-17
these O 0 2.0085047077363433e-17
transcripts O 0 3.3957323850595036e-14
can O 0 1.8166789958213442e-14
be O 0 1.4882517114023826e-15
increased O 0 3.682824080487629e-16
by O 0 7.455646470412212e-16
cycloheximide O 0 9.640745446404253e-08
. O 0 1.187395342640285e-12

A O 0 2.455543060553289e-11
deletion O 0 5.276366454864956e-09
mutation O 0 4.2307435332844534e-10
in O 0 6.238206565895021e-14
COL17A1 O 0 6.744152415194549e-06
in O 0 9.301954890486748e-15
five O 0 2.533063819462611e-12
Austrian O 0 1.6473055097776523e-07
families O 0 1.5129473466147375e-13
with O 0 2.526164390517782e-12
generalized O 0 7.609398267049983e-07
atrophic B-Disease 1 0.9996416568756104
benign I-Disease 1 0.9842846393585205
epidermolysis I-Disease 1 0.5563685297966003
bullosa I-Disease 0 0.0005312769208103418
represents O 0 6.221342885304182e-11
propagation O 0 5.623747995064932e-13
of O 0 3.3796669652588155e-15
an O 0 4.7582469682330795e-15
ancestral O 0 5.159074834004684e-10
allele O 0 4.891147042940247e-08
. O 0 1.6467895103122743e-10

Patients O 0 1.748963001091397e-07
with O 0 6.464202784162154e-11
generalized O 0 5.319250703905709e-06
atrophic B-Disease 1 0.9996629953384399
benign I-Disease 1 0.9983610510826111
epidermolysis I-Disease 1 0.990798830986023
bullosa I-Disease 0 0.024311959743499756
, O 0 2.3003886122363593e-12
a O 0 7.115018311662762e-15
usually O 0 7.368030441139411e-15
nonlethal O 0 3.579014515309176e-11
form O 0 4.5471521513407165e-12
of O 0 3.978507193830305e-12
junctional B-Disease 0 0.000784245494287461
epidermolysis I-Disease 0 0.012078072875738144
bullosa I-Disease 0 0.0005648292135447264
, O 0 6.634078009160049e-11
have O 0 2.1332529926559873e-12
generalized O 0 1.3088538065864075e-11
blistering B-Disease 0 1.3631073159103835e-07
, O 0 1.5602599507530401e-12
nail B-Disease 1 0.9989593029022217
dystrophy I-Disease 0 0.066227987408638
, O 0 9.126825684102613e-11
patchy B-Disease 0 0.00010328770440537483
alopecia I-Disease 1 0.9998378753662109
, O 0 1.1788581222305083e-09
and O 0 1.091202577185868e-07
dental B-Disease 0 0.3165900409221649
abnormalities I-Disease 1 0.9826086759567261
. O 0 3.226507255815747e-11

Skin B-Disease 1 0.9963647723197937
fragility I-Disease 0 4.9927834879781585e-06
in O 0 7.892325306644102e-16
most O 0 9.573959636075541e-18
cases O 0 7.509827991674517e-15
is O 0 8.49823683646278e-14
due O 0 2.869303991791445e-15
to O 0 9.861272053731342e-17
mutations O 0 3.3353558088165813e-13
in O 0 1.9385429295794658e-17
the O 0 4.8733478137459634e-17
gene O 0 5.866944300172983e-13
encoding O 0 7.929651943752725e-13
type O 0 2.05227352125803e-05
XVII O 0 1.2739065823552664e-05
collagen O 0 7.830481081327889e-06
( O 0 4.881111834165175e-11
COL17A1 O 0 3.3198512028320692e-06
) O 0 5.548325470935977e-13
. O 0 1.8969880191416905e-13

Recently O 0 5.2083896662225015e-06
, O 0 4.9086179321504095e-14
we O 0 4.9664035362516346e-14
reported O 0 7.185492435432539e-13
five O 0 2.4025730406898593e-13
Austrian O 0 2.47811556164379e-07
families O 0 1.888569053747069e-13
with O 0 6.906834045666832e-13
generalized O 0 2.470858646574925e-07
atrophic B-Disease 1 0.9990341663360596
benign I-Disease 0 0.10574422031641006
epidermolysis I-Disease 0 0.006622917950153351
bullosa I-Disease 0 0.0008611016091890633
who O 0 9.143303714154172e-08
share O 0 1.5256355206938466e-11
the O 0 3.004562447973748e-15
same O 0 2.4790987405293174e-13
COL17A1 O 0 8.265326869150158e-06
mutation O 0 6.821548881319472e-10
. O 0 2.323743194393435e-12

Affected O 0 3.62271923570745e-09
individuals O 0 4.385380134117739e-13
in O 0 4.885448870537573e-16
three O 0 4.3419982914032554e-14
families O 0 1.2120557607637919e-15
are O 0 4.6518132947087466e-17
homozygous O 0 2.6543448428811844e-12
for O 0 1.62409536147212e-15
4003delTC O 0 4.620244464792478e-10
, O 0 7.221709602317069e-17
whereas O 0 2.0768920964897363e-16
those O 0 5.033957568992894e-16
in O 0 5.301784357656579e-18
two O 0 4.756305145201499e-15
others O 0 1.3110161827672995e-13
are O 0 7.994748424746973e-15
compound O 0 6.729176000057e-14
heterozygotes O 0 9.212248741619078e-10
. O 0 1.2807693273997334e-12

To O 0 9.173020382288646e-15
determine O 0 2.6921232915990377e-14
if O 0 8.242238746440471e-15
the O 0 1.6719957231489508e-17
occurrence O 0 3.1946366667486015e-13
of O 0 3.0451094916423378e-15
4003delTC O 0 1.7318920741971056e-09
in O 0 1.6524471291686076e-17
these O 0 5.001471059595221e-18
unrelated O 0 1.0768867724365427e-14
families O 0 3.7262911643627596e-17
signifies O 0 9.737910969386614e-17
propagation O 0 6.987089416861508e-17
of O 0 4.358071202151571e-17
an O 0 4.92814462503511e-16
ancestral O 0 1.9461075806415096e-10
allele O 0 1.7042125488586635e-09
or O 0 2.018577804907551e-10
a O 0 2.535337044473618e-11
mutational O 0 2.061160557786934e-06
hot O 0 2.9255110689518915e-07
spot O 0 1.753129481585347e-07
, O 0 4.560097755673155e-14
haplotypes O 0 6.100705877976065e-12
were O 0 1.5560954759984147e-13
determined O 0 1.5676862070860068e-14
for O 0 2.407730327844159e-16
polymorphisms O 0 1.5012818765924862e-10
both O 0 2.355344868795739e-12
within O 0 3.3568571642002276e-13
and O 0 6.00457183974612e-10
flanking O 0 1.2302807590458542e-05
COL17A1 O 0 0.03567514568567276
. O 0 5.332695743320848e-11

Five O 0 3.326155739724612e-10
intragenic O 0 1.5861634494740429e-07
polymorphisms O 0 1.516966996462088e-09
were O 0 8.202533568818157e-14
chosen O 0 1.8808815521243784e-15
based O 0 3.2552814475039424e-15
on O 0 6.806478557858098e-12
their O 0 9.715667940307648e-13
informativeness O 0 2.50113401989438e-07
. O 0 1.9490690257497473e-13

One O 0 1.401531343238338e-13
of O 0 1.0256486377263868e-16
these O 0 5.5259357452796685e-17
, O 0 4.059272389073736e-17
not O 0 1.386847970981752e-16
previously O 0 1.324959864046349e-10
reported O 0 1.4327736219676979e-10
, O 0 1.2109281481527596e-15
was O 0 6.2410458745443265e-12
2988 O 0 1.7482359310205808e-11
A O 0 9.218206032486284e-14
or O 0 1.72329912926511e-12
C O 0 5.181388304520418e-11
that O 0 2.504187792899519e-16
introduces O 0 9.610643850839137e-14
a O 0 8.681453758135118e-17
new O 0 2.2568112912583083e-16
restriction O 0 3.064473551554188e-17
site O 0 3.859671642621881e-15
for O 0 7.602787316536835e-15
Eco0109 O 0 1.1608775746241307e-10
I O 0 5.795576996092677e-08
. O 0 3.9009735112310873e-13

All O 0 1.1309773647119603e-13
the O 0 8.475339143030421e-16
4003delTC O 0 2.8287411302230225e-10
alleles O 0 2.877726919606194e-12
showed O 0 7.586375277979229e-11
the O 0 9.94122617368786e-18
same O 0 1.8469713887918854e-17
haplotype O 0 1.0322202687322764e-14
for O 0 1.7086189793336136e-17
these O 0 1.6840040695375056e-17
five O 0 3.1286396457358206e-15
polymorphic O 0 7.840666484126846e-12
markers O 0 1.4463961139909998e-09
. O 0 5.148040414099109e-12

Fourteen O 0 1.7800334817241747e-10
microsatellite O 0 1.2545677385844556e-08
polymorphisms O 0 7.761013498530644e-10
were O 0 3.1782861525985265e-14
selected O 0 4.85835482765375e-15
based O 0 1.802329940057501e-16
on O 0 5.291745774210765e-13
their O 0 3.116182374532199e-14
high O 0 2.5577051587788446e-10
heterozygosity O 0 3.5120802099886106e-11
and O 0 1.198977932047188e-14
their O 0 3.520748362671908e-17
location O 0 2.5930903593400804e-15
within O 0 1.9574877200938257e-14
10q23 O 0 6.500742721904373e-10
- O 0 1.069306865275621e-08
q25 O 0 2.3917279268204084e-09
near O 0 1.2948894734243765e-10
COL17A1 O 0 1.36836524688988e-05
. O 0 5.8449213351241536e-12

Three O 0 2.0280470011679874e-11
families O 0 3.882149593112394e-13
shared O 0 4.090251900200348e-13
microsatellite O 0 2.343537097715398e-08
polymorphisms O 0 1.5004080466951564e-07
covering O 0 1.8172656268689025e-07
at O 0 1.0480860623829358e-09
most O 0 7.982775952850713e-14
19 O 0 1.5015816715036046e-11
cM O 0 1.437165664253115e-11
, O 0 3.3550005585064924e-17
whereas O 0 2.6177569116761913e-16
the O 0 1.2796337168918549e-16
others O 0 4.3416503302685233e-14
shared O 0 1.9244371721183207e-13
smaller O 0 2.2190023256374314e-12
regions O 0 7.226316333514005e-12
consistent O 0 2.8574787935137236e-12
with O 0 3.0447609375845426e-15
cross O 0 6.405941888054656e-10
- O 0 6.734446742484579e-07
over O 0 9.00016894345157e-10
events O 0 1.5828486524954721e-12
during O 0 2.067788214960009e-13
passage O 0 2.2302133979233392e-15
of O 0 8.241754653876225e-18
this O 0 1.7903774283602936e-18
mutation O 0 9.228324698662096e-17
through O 0 1.7399606873071253e-17
several O 0 4.736656945440515e-16
generations O 0 1.5818105289153173e-12
. O 0 4.3061734733562673e-13

These O 0 1.4452982810119613e-13
results O 0 2.1292407940964875e-12
indicate O 0 6.9640096640732896e-12
that O 0 1.6833427284469044e-13
4003delTC O 0 2.3361518231013179e-07
occurs O 0 6.427288714271062e-13
on O 0 9.104348541342719e-14
a O 0 7.104599488774179e-16
single O 0 4.519791387946198e-13
ancestral O 0 2.146550732301522e-12
allele O 0 5.921573561357141e-12
. O 0 1.5169485947322953e-14
. O 0 1.9460599581452853e-13

The O 0 5.85607734179816e-13
haptoglobin O 0 8.76340777722362e-09
- O 0 1.1340297589867987e-09
gene O 0 3.405219509144963e-11
deletion O 0 9.58042395415859e-11
responsible O 0 8.098417769719646e-12
for O 0 6.335151858400528e-14
anhaptoglobinemia B-Disease 0 1.6362325823138235e-06
. O 0 7.649923446442775e-13

We O 0 6.788567485926933e-10
have O 0 1.4861250657817113e-14
found O 0 2.569241246737629e-16
an O 0 1.2391043153313697e-17
allelic O 0 5.082118753607645e-12
deletion O 0 3.44204414970406e-10
of O 0 4.6048919072425726e-14
the O 0 4.0938481310438465e-14
haptoglobin O 0 9.433048786533504e-10
( O 0 1.2335121641089274e-15
Hp O 0 8.300425505345516e-14
) O 0 4.263485332493786e-18
gene O 0 2.0393423583143448e-15
from O 0 2.863966096036967e-16
an O 0 1.6188431483942124e-16
individual O 0 2.9203234882396734e-13
with O 0 2.343003013827172e-10
anhaptoglobinemia B-Disease 0 8.137679833453149e-05
. O 0 7.575599869635852e-12

The O 0 5.78126210641107e-14
Hp O 0 5.155629048680943e-11
gene O 0 1.251363422605234e-11
cluster O 0 7.978795575624975e-12
consists O 0 2.340598308093046e-15
of O 0 3.9320113135769426e-17
coding O 0 4.9257323914142503e-11
regions O 0 3.797824468104727e-12
of O 0 8.659533763070038e-15
the O 0 6.078607940347008e-14
alpha O 0 1.2259515776678886e-13
chain O 0 1.842851427014125e-09
and O 0 1.8922396202020186e-13
beta O 0 3.3743450043116575e-16
chain O 0 4.5407192003805996e-13
of O 0 1.778812037189761e-17
the O 0 1.3569041651562304e-16
haptoglobin O 0 2.456553840554654e-12
gene O 0 1.144418219044263e-13
( O 0 6.245960072560127e-17
Hp O 0 8.050144210090815e-14
) O 0 5.1529001192031595e-17
and O 0 2.623805521012975e-16
of O 0 1.5813961195811203e-17
the O 0 5.142262483881499e-15
alpha O 0 1.3678036263028211e-14
chain O 0 6.356793980089037e-10
and O 0 1.6489250286369495e-12
beta O 0 1.394844200231849e-15
chain O 0 8.785246835563143e-13
of O 0 2.1317885664990836e-16
the O 0 2.760256546645453e-15
haptoglobin O 0 2.6454366475192614e-10
- O 0 1.0010134214588629e-11
related O 0 2.95097540153888e-12
gene O 0 1.27831550900126e-10
( O 0 4.147939316242327e-14
Hpr O 0 5.882065667872638e-11
) O 0 1.625862166320974e-15
, O 0 1.0831184831649987e-17
in O 0 6.7082734675856066e-18
tandem O 0 2.115327468743544e-09
from O 0 5.660800604309624e-13
the O 0 9.811836673007113e-13
5 O 0 1.2007837779659525e-10
side O 0 5.875488984230515e-09
. O 0 3.4362747022842477e-12

Southern O 0 8.927251160528726e-10
blot O 0 9.570718475515605e-07
and O 0 5.1936895810542755e-14
PCR O 0 2.534766493922369e-11
analyses O 0 6.785631626905764e-13
have O 0 4.599377045129589e-15
indicated O 0 5.806620917599148e-15
that O 0 1.0266658879000922e-17
the O 0 2.818562681609523e-17
individual O 0 6.659584789550123e-15
with O 0 3.7843296205042343e-13
anhaptoglobinemia B-Disease 0 1.4518390045736851e-08
was O 0 3.3816051629893817e-13
homozygous O 0 9.329790629300505e-13
for O 0 8.16110421328006e-17
the O 0 2.5277580728436458e-17
gene O 0 8.798611795743372e-13
deletion O 0 5.98686586417152e-11
and O 0 3.014708708365399e-13
that O 0 2.3233129067384275e-16
the O 0 7.733471688924846e-17
gene O 0 3.0098211249718343e-12
deletion O 0 2.77241507529169e-10
was O 0 4.5948467253253966e-10
included O 0 2.4638997507303757e-14
at O 0 1.1720355588829e-13
least O 0 6.03589788687453e-17
from O 0 8.591349304881962e-17
the O 0 6.951676822221378e-17
promoter O 0 2.9013388913590177e-11
region O 0 7.476441341025541e-15
of O 0 3.1719464815652425e-17
Hp O 0 1.6648527174922823e-12
to O 0 9.096766585319212e-17
Hpr O 0 4.3496122502373336e-12
alpha O 0 1.9522952704843029e-16
but O 0 6.299058450441131e-16
not O 0 2.799919287917109e-15
to O 0 6.123663232174064e-15
Hpr O 0 3.6238041456471137e-09
beta O 0 4.3438644066300103e-13
( O 0 5.404219281281153e-14
Hpdel O 0 1.5657835028548561e-09
) O 0 6.336395980393456e-14
. O 0 2.0155776461923403e-13

In O 0 6.68190817346842e-13
addition O 0 1.9237252578668124e-13
, O 0 3.516830504418612e-16
we O 0 6.177270465098131e-16
found O 0 1.2408841036071184e-15
seven O 0 1.633322620762153e-14
individuals O 0 4.3673598448605003e-16
with O 0 7.052408177300566e-15
hypohaptoglobinemia B-Disease 0 8.998731537701588e-09
in O 0 2.1805947372687744e-16
three O 0 9.339186054276721e-14
families O 0 7.561109060367187e-15
, O 0 2.430097291607593e-16
and O 0 3.0008283032257775e-15
the O 0 2.0845594651980619e-16
genotypes O 0 5.09795059899093e-13
of O 0 4.330181318874243e-17
six O 0 8.769191969792978e-13
of O 0 2.704111391253175e-16
the O 0 6.931453142982073e-15
seven O 0 9.922218428826124e-12
individuals O 0 1.2415997829200772e-14
were O 0 1.3430912706600875e-14
found O 0 1.9335829256630042e-14
to O 0 1.6462813100595608e-13
be O 0 1.668607119142962e-08
Hp2 O 0 2.179457624151837e-05
/ O 0 2.0554979585085675e-07
Hpdel O 0 7.749614496788126e-07
. O 0 4.155435110592132e-12

The O 0 2.456591353949822e-12
phenotypes O 0 1.9949133456265145e-09
and O 0 1.7497853480822473e-13
genotypes O 0 1.607214708543303e-11
in O 0 5.079556992138288e-17
one O 0 2.9683674066485917e-16
of O 0 1.825146311047735e-18
these O 0 5.0805648289966224e-17
three O 0 4.1326903514994975e-14
families O 0 5.364636584623012e-15
showed O 0 9.715066251470006e-11
the O 0 1.975398888214052e-16
father O 0 3.10093756228369e-11
to O 0 2.0876812580647268e-14
be O 0 2.056941422745595e-11
hypohaptoglobinemic B-Disease 0 5.71657166048567e-09
( O 0 2.141219034287119e-15
Hp2 O 0 8.875192941681931e-11
) O 0 7.922976782027275e-15
and O 0 1.3777276845414188e-13
Hp2 O 0 5.719224560607472e-08
/ O 0 1.0958868479349348e-08
Hpdel O 0 2.6376552497708872e-08
, O 0 1.4379689769171704e-15
the O 0 3.125082067652683e-17
mother O 0 5.327203088378862e-12
to O 0 1.1096719238138492e-16
be O 0 1.6958691937719872e-13
Hp2 O 0 6.50361986487269e-10
- O 0 1.6876878367044768e-11
1 O 0 1.4971752882050014e-14
and O 0 1.5933039393054016e-13
Hp1 O 0 1.9193384659388357e-09
/ O 0 2.975109048009017e-11
Hp2 O 0 2.8201632001900734e-11
, O 0 6.927662445549983e-18
one O 0 2.8518182787253295e-18
of O 0 8.510802385939457e-19
the O 0 4.746204859640643e-17
two O 0 3.1672586306582227e-15
children O 0 2.5215598245488177e-14
to O 0 5.87568954583526e-17
be O 0 2.0745909059659978e-13
hypohaptoglobinemic B-Disease 0 1.1102919694749858e-09
( O 0 3.581247254178183e-15
Hp2 O 0 2.1855023346617486e-10
) O 0 7.932987017397926e-15
and O 0 7.159973568898748e-14
Hp2 O 0 3.0059375433211244e-08
/ O 0 1.4435085127217917e-08
Hpdel O 0 3.244160851068045e-08
, O 0 4.1677315963076396e-15
and O 0 1.9023260175989135e-16
the O 0 1.7093548805655714e-18
other O 0 6.782693749244145e-17
child O 0 2.205711308045366e-11
to O 0 3.8778789599302473e-17
be O 0 2.8207145820469126e-13
Hp1 O 0 1.8648125266196303e-09
and O 0 2.6124043791923846e-13
Hp1 O 0 3.2664619897815328e-09
/ O 0 6.892487136589409e-10
Hpdel O 0 4.007123244331723e-10
, O 0 4.4188554114121725e-17
showing O 0 2.7597841140191218e-14
an O 0 4.662914720273698e-18
anomalous O 0 2.1626291049300396e-14
inheritance O 0 1.5488976204056093e-12
of O 0 1.3296667640636667e-13
Hp O 0 3.5143706611506786e-08
phenotypes O 0 5.547347650680656e-11
in O 0 8.473496846370142e-16
the O 0 2.7144854696263196e-14
child O 0 1.7744948763720458e-06
with O 0 5.53232980260443e-12
Hp1 O 0 5.523731374523777e-07
. O 0 2.0637703785492123e-12

The O 0 1.7769591353911096e-11
Hp2 O 0 7.415737854898907e-07
/ O 0 9.70700170910277e-07
Hpdel O 0 1.833806493323209e-07
individuals O 0 6.341879712351561e-12
had O 0 4.0096443526538295e-11
an O 0 5.437216720290865e-16
extremely O 0 1.2913027418182121e-11
low O 0 1.887474621042884e-09
level O 0 5.98373184768769e-13
of O 0 1.2031139515769835e-16
Hp O 0 5.045763286359861e-12
( O 0 6.537076032108569e-17
mean O 0 2.7063070277074004e-14
+ O 0 1.1576408776893532e-13
/ O 0 1.1189589532722977e-10
- O 0 7.074061891820804e-10
SD O 0 3.820398717380158e-07
= O 0 1.688692415069415e-11
0 O 0 5.8717738448690014e-15
. O 0 8.039329992222454e-17
049 O 0 2.5112157145401603e-11
+ O 0 4.187496974606547e-13
/ O 0 5.665959021405875e-11
- O 0 5.242934905669294e-11
0 O 0 1.7679629546511972e-15
. O 0 5.627446605589625e-18
043 O 0 2.140046820309216e-12
mg O 0 1.5730491995796791e-12
/ O 0 3.965408296863204e-12
ml O 0 3.2940481939358612e-12
; O 0 1.0309127489702252e-16
n O 0 7.299274574525116e-13
= O 0 3.4953162868396614e-13
6 O 0 9.928241734324158e-15
) O 0 6.201867706316355e-18
, O 0 7.211956667266216e-19
compared O 0 7.050091330431589e-16
with O 0 3.1371487269657005e-15
the O 0 5.549426478242137e-13
level O 0 2.6006763409469613e-09
( O 0 2.827373213924397e-16
1 O 0 6.475177775998981e-17
. O 0 5.695627381169614e-18
64 O 0 1.0356240706308178e-14
+ O 0 8.6068085032023e-15
/ O 0 1.9021847898897937e-12
- O 0 1.5198260401930175e-12
1 O 0 1.651478242590957e-15
. O 0 1.8965284410344273e-17
07 O 0 5.320518873565272e-13
mg O 0 3.066906808808084e-13
/ O 0 6.826077246849249e-14
ml O 0 6.360222593683245e-15
) O 0 5.157119890625219e-20
obtained O 0 2.503373201975889e-18
from O 0 7.72059017068168e-17
52 O 0 3.5693030562417016e-13
healthy O 0 2.300042968583771e-11
volunteers O 0 5.407663317244689e-14
having O 0 7.794023130884564e-13
phenotype O 0 7.80128479177522e-12
Hp2 O 0 1.0535939898304036e-09
, O 0 2.055500676453523e-16
whereas O 0 5.2541935468173e-16
the O 0 5.054506654467732e-17
serum O 0 2.4394564493435134e-11
Hp O 0 1.4261537784054923e-10
level O 0 3.5609683604609366e-12
of O 0 4.148534772463313e-17
an O 0 2.2510690431506346e-15
individual O 0 9.470316241280696e-13
with O 0 2.5745372500551866e-10
Hp1 O 0 1.989474185393192e-05
/ O 0 2.4218019234467647e-07
Hpdel O 0 1.5637360206710582e-07
was O 0 4.3551287576271136e-10
0 O 0 3.5863908956317025e-13
. O 0 1.598079307774114e-13

50 O 0 5.565533797713407e-11
mg O 0 6.894843807003781e-09
/ O 0 5.645729928005494e-08
ml O 0 2.077898919594645e-08
, O 0 1.7552487783546733e-15
which O 0 1.546933128284201e-17
was O 0 9.822460871739252e-15
approximately O 0 3.4758731791661958e-15
half O 0 1.7293700922248884e-13
the O 0 8.170545983663985e-16
level O 0 6.86831302010478e-14
of O 0 9.161500912877e-18
Hp O 0 1.3476937664805289e-12
in O 0 5.80922988495581e-17
control O 0 4.2731188596226155e-13
sera O 0 8.222470621044309e-11
from O 0 3.822467255660953e-16
the O 0 4.1254663463055445e-15
Hp1 O 0 9.740458217777359e-09
phenotype O 0 9.056602581596074e-13
( O 0 9.691439962573385e-17
1 O 0 9.863002515572803e-17
. O 0 1.9479425137521508e-17
26 O 0 4.963950867649565e-14
+ O 0 1.513919604912914e-14
/ O 0 1.608155969501368e-11
- O 0 7.183701116603158e-12
0 O 0 3.342827967135509e-16
. O 0 1.221825897862663e-18
33 O 0 1.9675258228484416e-15
mg O 0 1.8376142621456815e-13
/ O 0 8.794199092901356e-13
ml O 0 1.0628040331486788e-12
; O 0 8.406589581517627e-17
n O 0 1.2829649452192338e-12
= O 0 2.530967839822762e-12
9 O 0 2.477378382732126e-13
) O 0 5.558790697465785e-17
, O 0 7.837199744828205e-19
showing O 0 1.6487850378076908e-14
a O 0 3.692572900314934e-16
gene O 0 1.0464511202012972e-11
- O 0 1.253495640618496e-09
dosage O 0 1.1640260283440895e-10
effect O 0 2.9475215670982102e-12
. O 0 1.2369037814385225e-13

The O 0 1.297528030115222e-13
other O 0 2.644224256058165e-15
allele O 0 2.6474178752011746e-12
( O 0 8.585363323043715e-15
Hp2 O 0 2.962243991766478e-11
) O 0 1.943711484918942e-17
of O 0 4.065249689237863e-19
individuals O 0 1.2744997707892078e-15
with O 0 3.549763835739711e-13
Hp2 O 0 5.705164767277893e-06
/ O 0 6.0651686339952e-08
Hpdel O 0 3.0329692091157767e-09
was O 0 3.8486781036434214e-13
found O 0 3.832031687003553e-15
to O 0 4.745666411383985e-15
have O 0 2.2157922198451363e-12
, O 0 6.122956330240021e-17
in O 0 2.4668571070395823e-18
all O 0 1.4523145598459297e-13
exons O 0 2.247523278597896e-09
, O 0 9.254033154462889e-15
no O 0 3.3223999147278995e-15
mutation O 0 4.470280965396798e-16
, O 0 8.755973678868317e-20
by O 0 5.2098752728953493e-20
DNA O 0 8.641685593025264e-14
sequencing O 0 2.7472796260141763e-10
. O 0 1.30341293314018e-11

On O 0 2.9577826732990475e-12
the O 0 2.5011707674205174e-16
basis O 0 2.564190442212711e-15
of O 0 1.170683740091801e-17
the O 0 5.294352437637811e-16
present O 0 1.1742271634602964e-15
study O 0 2.811616283523099e-16
, O 0 8.933380216366513e-18
the O 0 1.5208886022354176e-18
mechanism O 0 2.957576471598368e-14
of O 0 4.6273583550256615e-15
anhaptoglobinemia B-Disease 0 7.025419535011679e-08
and O 0 7.561372318207193e-14
the O 0 1.2956210998118103e-17
mechanism O 0 1.959280550029984e-14
of O 0 4.038835485833572e-18
anomalous O 0 1.0886750993700702e-14
inheritance O 0 6.418431866724028e-13
of O 0 1.330298447354411e-13
Hp O 0 9.453573568407592e-08
phenotypes O 0 8.973549125990132e-10
were O 0 1.1482143361107866e-12
well O 0 3.9759563913790985e-13
explained O 0 1.7717753653112567e-10
. O 0 1.460654839267883e-12

However O 0 3.222816805092954e-11
, O 0 1.3532915166966316e-15
the O 0 3.259279218021856e-17
mechanism O 0 4.075339512469439e-13
of O 0 5.935529591292359e-15
hypohaptoglobinemia B-Disease 0 1.0420883882034104e-05
remains O 0 2.501130691445752e-10
unknown O 0 7.353391784370444e-10

ATM O 0 6.559513622050872e-06
mutations O 0 2.1176836071390426e-06
and O 0 5.747089609764444e-11
phenotypes O 0 7.728742161816626e-07
in O 0 3.3257371856443285e-10
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 1.870936102932319e-06
in O 0 4.669370901218273e-13
the O 0 5.306727713511039e-12
British O 0 0.00010704238957259804
Isles O 0 7.535277859460621e-07
: O 0 1.9977715906257035e-14
expression O 0 2.1261928550912848e-16
of O 0 2.229206255896719e-18
mutant O 0 2.5801864984853484e-13
ATM O 0 4.08573383459121e-11
and O 0 5.857034963367008e-14
the O 0 2.1679969221233795e-15
risk O 0 2.4156736611047336e-09
of O 0 1.4464214331474934e-12
leukemia B-Disease 0 0.0033563454635441303
, O 0 5.083046872300656e-09
lymphoma B-Disease 1 1.0
, O 0 1.9772519732619287e-10
and O 0 1.2777780611372691e-08
breast B-Disease 0 0.0036942686419934034
cancer I-Disease 0 8.142154115375888e-07
. O 0 1.5273679890293046e-11

We O 0 1.4555440186470037e-11
report O 0 8.641421996372078e-14
the O 0 1.1219255788848628e-17
spectrum O 0 1.8894679251106952e-15
of O 0 8.967870008315279e-17
59 O 0 2.668495849636465e-13
ATM O 0 6.371654759362855e-09
mutations O 0 4.865018610189509e-09
observed O 0 8.302473375465524e-09
in O 0 1.7558769993542e-09
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 3.2091429602587596e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.6572995146374447e-12
patients O 0 4.2154945983571834e-14
in O 0 1.9969380757948918e-17
the O 0 6.235161313043053e-14
British O 0 3.1183524242806016e-06
Isles O 0 3.856848707073368e-06
. O 0 3.7592977342182365e-11

Of O 0 2.2658647961387723e-12
51 O 0 6.346229652898217e-10
ATM O 0 6.538982120218861e-07
mutations O 0 1.4075645093925004e-09
identified O 0 1.1424963058948023e-10
in O 0 1.5164639965952592e-16
families O 0 5.976009348781201e-17
native O 0 2.4483534985988834e-16
to O 0 2.7060525790100452e-15
the O 0 1.4007711657271216e-11
British O 0 0.006648867856711149
Isles O 0 2.92047593575262e-06
, O 0 7.036721465930595e-13
11 O 0 3.549897124844291e-14
were O 0 1.4160424702863088e-15
founder O 0 2.84144317233212e-14
mutations O 0 8.999828876934957e-13
, O 0 2.12808451789052e-15
and O 0 1.3860929311065254e-14
2 O 0 1.3090359510267257e-15
of O 0 1.2583868880267158e-17
these O 0 3.1206536073508703e-15
11 O 0 1.551309401033249e-13
conferred O 0 1.8902969586078204e-15
a O 0 3.85891878915045e-16
milder O 0 2.0308456305517808e-11
clinical O 0 1.5114838200491754e-11
phenotype O 0 2.7123287882173386e-13
with O 0 2.619636583665267e-15
respect O 0 2.2882686549633227e-14
to O 0 7.193809316416357e-15
both O 0 1.7193699589079792e-11
cerebellar B-Disease 0 2.57489176647141e-07
degeneration I-Disease 0 1.1444476655242397e-07
and O 0 4.4208588179106556e-11
cellular O 0 6.209826430847443e-09
features O 0 3.006912407954587e-08
. O 0 1.0272180328563252e-10

We O 0 5.503211775170769e-11
report O 0 2.3369251412469483e-13
, O 0 1.1773746386306199e-17
in O 0 2.4066441487100097e-18
two O 0 3.310688040988191e-13
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 1.3884341593106697e-11
, O 0 1.7488042406720523e-17
an O 0 7.53032721470203e-18
ATM O 0 9.323921190684814e-09
mutation O 0 3.5738623432174377e-12
( O 0 2.8587499612686565e-15
7271T O 0 6.423333653166052e-12
- O 0 2.2722452391876757e-11
- O 0 5.130398883501641e-11
> O 0 6.565212783138374e-14
G O 0 3.2453828513467897e-10
) O 0 2.4859037926396467e-16
that O 0 8.159240211400509e-16
may O 0 2.2367207370109499e-13
be O 0 3.1631892726213763e-15
associated O 0 9.12185530417019e-17
with O 0 2.7570229255774157e-17
an O 0 8.423189442050341e-16
increased O 0 5.234784272722948e-10
risk O 0 1.6916542833200765e-08
of O 0 2.3854724619243317e-13
breast B-Disease 0 2.0678587588918163e-06
cancer I-Disease 0 1.7866662316290416e-10
in O 0 1.2211887082291042e-16
both O 0 6.045585852678531e-14
homozygotes O 0 4.762310990003016e-09
and O 0 1.5390366728978457e-14
heterozygotes O 0 6.3221212119601855e-12
( O 0 2.120726130919485e-15
relative O 0 9.873670620257763e-14
risk O 0 4.232391770386812e-09
12 O 0 1.7534980628966523e-12
. O 0 1.5808247892407524e-15
7 O 0 2.5394786100363387e-12
; O 0 3.1663301131414426e-14
P O 0 3.953857230953872e-06
= O 0 2.811226772203579e-11
. O 0 1.4827662201568454e-15
0025 O 0 8.445218135921806e-11
) O 0 2.2677725328704894e-15
, O 0 1.1018887829069908e-17
although O 0 1.589330766888974e-17
there O 0 5.021927236143657e-18
is O 0 1.1964905344325366e-17
a O 0 1.9994772555776335e-16
less O 0 5.515943062549267e-13
severe O 0 2.752373120529228e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 6.41820019353645e-09
in O 0 6.296704228243356e-16
terms O 0 2.111515494651042e-15
of O 0 3.3249686910329584e-18
the O 0 2.4350339055033096e-16
degree O 0 6.947524830826571e-14
of O 0 2.203442777629766e-13
cerebellar B-Disease 0 1.6784822491899831e-06
degeneration I-Disease 0 1.8430320778861642e-05
. O 0 8.593342010199123e-11

This O 0 2.3931562027207365e-13
mutation O 0 2.1402518646240765e-11
( O 0 2.5604869177057836e-14
7271T O 0 8.369657050755208e-11
- O 0 5.291360127834821e-10
- O 0 1.3580017110825793e-09
> O 0 1.5794830721116426e-12
G O 0 7.114303035571368e-10
) O 0 7.220993594778843e-17
also O 0 9.392078335806769e-18
allows O 0 1.654080480006155e-17
expression O 0 1.173080413198612e-16
of O 0 1.7026201000952566e-17
full O 0 2.7066918584922606e-12
- O 0 3.8509895272653694e-10
length O 0 1.006039218945376e-12
ATM O 0 2.9288402259020074e-10
protein O 0 2.5294030108272136e-13
at O 0 1.5063304607560585e-13
a O 0 8.29266325306523e-16
level O 0 1.1433054210394783e-13
comparable O 0 5.17538519906411e-14
with O 0 2.6864181435344537e-15
that O 0 9.351265760544104e-15
in O 0 5.1266910536956495e-15
unaffected O 0 3.879875865031579e-10
individuals O 0 1.4213531339315327e-13
. O 0 6.021421425708717e-13

In O 0 4.690111892065828e-14
addition O 0 8.343659083412912e-15
, O 0 3.471220427186928e-16
we O 0 1.0481754895465267e-14
have O 0 2.5151796335769194e-15
studied O 0 5.6688534075255426e-12
18 O 0 1.3054842762372232e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 3.3781115682529617e-09
, O 0 1.1875870104731996e-17
in O 0 4.3315979690708165e-19
15 O 0 4.300044283657629e-16
families O 0 7.76723521629579e-17
, O 0 7.133740069137687e-16
who O 0 5.795195434643574e-10
developed O 0 1.2300181424507173e-06
leukemia B-Disease 0 0.01410999707877636
, O 0 3.002704085375285e-09
lymphoma B-Disease 1 1.0
, O 0 1.0218626075517157e-12
preleukemic O 0 1.7248273707082262e-06
T O 0 6.186673545016674e-06
- O 0 1.7142154362659312e-08
cell O 0 1.260076771814056e-07
proliferation O 0 0.1676989644765854
, O 0 2.2828709408950765e-11
or O 0 1.4188386558089405e-05
Hodgkin B-Disease 1 0.9999998807907104
lymphoma I-Disease 1 1.0
, O 0 3.377017415706618e-12
mostly O 0 5.072961636268941e-14
in O 0 9.7603462516512e-15
childhood O 0 8.851737121062797e-09
. O 0 3.5706531047868806e-12

A O 0 9.486483647236366e-12
wide O 0 5.010824654511081e-12
variety O 0 1.9630297550237569e-13
of O 0 4.20134721055017e-16
ATM O 0 2.995738270783477e-07
mutation O 0 3.6167985273394265e-11
types O 0 3.591160424587514e-10
, O 0 9.044971447036898e-16
including O 0 4.9489073083964445e-15
missense O 0 2.0615594564787898e-08
mutations O 0 8.746841473339373e-09
and O 0 3.9313613128810765e-12
in O 0 4.303771016867311e-15
- O 0 3.852948395888234e-07
frame O 0 3.0477983727905666e-06
deletions O 0 1.9674696716265316e-07
, O 0 3.8266457602458004e-13
were O 0 6.41830609927202e-14
seen O 0 3.017064723054297e-11
in O 0 1.3772107212754682e-16
these O 0 1.6173325021904758e-14
patients O 0 6.320752298297205e-14
. O 0 6.2203342554112504e-15

We O 0 3.0846694643038575e-10
also O 0 3.0560264334313775e-14
show O 0 1.3974445786744255e-13
that O 0 5.393069693952216e-17
25 O 0 4.473010529069325e-16
% O 0 5.223429984325223e-19
of O 0 5.302328022114179e-19
all O 0 1.1281260647866276e-11
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 3.4667585468994844e-10
carried O 0 8.99460763032281e-14
in O 0 1.2712457084338731e-16
- O 0 3.492547570593807e-11
frame O 0 1.13922404842981e-09
deletions O 0 2.4946333887498895e-09
or O 0 2.1778891624163466e-12
missense O 0 2.968591761298711e-10
mutations O 0 1.7416584667528934e-12
, O 0 9.137279410180222e-18
many O 0 6.9602673203574095e-19
of O 0 4.5530075631560225e-17
which O 0 7.255844362841213e-12
were O 0 4.606781345284361e-10
also O 0 3.2943534011842246e-10
associated O 0 3.383390437391651e-14
with O 0 5.125911359867702e-14
expression O 0 2.801871961440744e-13
of O 0 8.770567182839987e-16
mutant O 0 2.340595495198272e-10
ATM O 0 4.75705697056128e-08
protein O 0 6.773461236342371e-10
. O 0 1.560671383793455e-11

The O 0 1.7639127734402765e-13
DMPK O 0 1.1505360220098737e-08
gene O 0 1.546991840184475e-10
of O 0 4.4577373476545334e-13
severely O 0 0.0005328119732439518
affected O 0 2.844255675427121e-07
myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 1.0
patients O 0 6.560662768606562e-07
is O 0 5.897390323479634e-14
hypermethylated O 0 4.543125597944453e-10
proximal O 0 1.951325039051266e-11
to O 0 1.2295618353769938e-14
the O 0 3.356834980407339e-15
largely O 0 1.0150790798191256e-12
expanded O 0 1.172860281117849e-10
CTG O 0 1.423750290996395e-07
repeat O 0 5.388701040942578e-09
. O 0 2.975322896045518e-12

Using O 0 9.047034226373346e-14
methylation O 0 3.1658998339567646e-11
- O 0 5.785766532540038e-09
sensitive O 0 5.807394742873839e-08
restriction O 0 1.8161923787812784e-12
enzymes O 0 3.4122136539915804e-12
, O 0 4.909097236331525e-17
we O 0 1.8473106982791547e-16
characterized O 0 1.776113443159368e-17
the O 0 5.576668159134102e-19
methylation O 0 6.577383630150882e-14
pattern O 0 4.271526188315278e-11
on O 0 3.1115960502647866e-11
the O 0 2.0647644428635828e-14
5 O 0 2.4301104206182755e-13
side O 0 1.0087133087361214e-13
of O 0 2.4025713181689517e-18
the O 0 1.1234377973935077e-16
CTG O 0 2.2253325571153226e-10
repeat O 0 1.3714937388900617e-12
in O 0 1.7549791439447606e-17
the O 0 1.2909194879281201e-17
DMPK O 0 9.005848150556162e-11
gene O 0 6.988562221868326e-15
of O 0 8.75327735441473e-18
normal O 0 1.1616631237536734e-15
individuals O 0 2.1382634716363526e-16
and O 0 3.819743356521261e-15
of O 0 5.252510068834632e-16
patients O 0 5.62407000311016e-13
affected O 0 1.7140679067079168e-12
with O 0 2.6958388299469505e-10
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 2.551516669387771e-14
showing O 0 3.799983765151449e-12
expansions O 0 1.348697282327338e-11
of O 0 4.7139273456965375e-16
the O 0 2.967474686861745e-15
repetitive O 0 2.853033809202543e-09
sequence O 0 4.8118575096678384e-11
. O 0 1.578222101616955e-11

The O 0 2.550772296833724e-14
gene O 0 3.0702970547913377e-12
segment O 0 4.984914824673892e-12
analyzed O 0 1.1722949542526673e-13
corresponds O 0 6.903873326702999e-16
to O 0 4.1822523085921997e-17
the O 0 4.956140122733049e-16
genomic O 0 3.7820047094072606e-10
SacI O 0 2.3043372721076594e-07
- O 0 2.5632212796722342e-08
HindIII O 0 4.683097465374431e-09
fragment O 0 5.4915915564945905e-12
carrying O 0 5.4461123111249066e-12
exons O 0 1.4618610766348183e-09
11 O 0 1.76613983854379e-11
- O 0 9.62420143579834e-10
15 O 0 2.195632130969072e-12
. O 0 2.1319381535763599e-13

There O 0 7.673143804370897e-13
is O 0 3.888281450964816e-15
constitutive O 0 2.9405007617201717e-13
methylation O 0 6.665284643658786e-13
in O 0 1.9000060737657228e-15
intron O 0 6.356263515527871e-09
12 O 0 7.201201982810768e-13
at O 0 1.3756362458452e-15
restriction O 0 7.287629279692645e-17
sites O 0 1.0394552853545437e-14
of O 0 1.3437438671942996e-15
SacII O 0 2.995286934037722e-07
and O 0 3.7505012116800795e-12
HhaI O 0 5.155339266593728e-09
, O 0 1.070921092919251e-16
localized O 0 1.3456708247976557e-14
1 O 0 4.42925598338772e-15
, O 0 1.4339202388386336e-16
159 O 0 1.2263351141864054e-13
- O 0 1.6198048111149e-11
1 O 0 9.874489870524347e-16
, O 0 1.6753276686948604e-18
232 O 0 1.4724112688464412e-16
bp O 0 4.6342680262928884e-14
upstream O 0 4.334218463189314e-15
of O 0 5.5358909466698055e-18
the O 0 1.477711709862783e-16
CTG O 0 3.3704702917525253e-10
repeat O 0 1.0667160731114844e-11
, O 0 4.842178986520475e-17
whereas O 0 2.4907817759735454e-17
most O 0 4.5832390293113655e-18
, O 0 2.251393059722739e-17
if O 0 1.5025585213979814e-15
not O 0 2.938120971832884e-15
all O 0 1.085842282381273e-14
, O 0 5.651088254677003e-18
of O 0 2.637961045258007e-20
the O 0 7.456512356873578e-20
other O 0 1.5284029177150025e-18
sites O 0 5.4620648553150436e-14
of O 0 1.5250214116426918e-15
SacII O 0 2.1289841001248533e-09
, O 0 5.743264547210421e-15
HhaI O 0 5.149518589320223e-10
, O 0 3.897711892283072e-15
and O 0 1.188799763924414e-13
HpaII O 0 1.0603354860805325e-09
in O 0 1.0046259417200251e-16
this O 0 1.3433794312687434e-16
region O 0 7.221940466440799e-14
are O 0 4.13997009146138e-15
unmethylated O 0 1.4681195148469328e-10
, O 0 4.8420176796835825e-15
in O 0 4.4903605431559514e-17
normal O 0 5.484736962697726e-15
individuals O 0 1.7024789433780856e-15
and O 0 8.332082684122787e-15
most O 0 7.299227013625128e-18
of O 0 2.3971986973723586e-17
the O 0 1.0964611109245265e-13
patients O 0 4.869492396114561e-13
. O 0 2.542296715756908e-14

In O 0 5.268808359168344e-15
a O 0 1.4718384628158604e-16
number O 0 1.8218023010725914e-16
of O 0 2.5936429424590454e-16
young O 0 5.2183777299319445e-09
and O 0 1.2866978316150579e-11
severely O 0 3.0002322546351934e-06
affected O 0 3.974199441758586e-12
patients O 0 1.3875372069848887e-14
, O 0 1.421952093427849e-17
however O 0 5.95539137570495e-17
, O 0 6.986659448379103e-18
complete O 0 1.868935515597006e-17
methylation O 0 4.2453760233825133e-13
of O 0 3.72534280509919e-15
these O 0 2.9890151582268954e-15
restriction O 0 1.742935968620206e-14
sites O 0 4.701688691155503e-12
was O 0 3.5542066512128656e-10
found O 0 6.030340614880669e-13
in O 0 9.488486236199824e-17
the O 0 2.2103257260662983e-16
mutated O 0 3.5094285116832324e-11
allele O 0 4.451250826265074e-11
. O 0 5.8658728915861325e-12

In O 0 4.802800138929003e-14
most O 0 6.126110204479564e-17
of O 0 4.036709631659311e-18
these O 0 2.6569327148822947e-16
patients O 0 2.5355253649699677e-15
, O 0 6.552998224924449e-19
the O 0 7.332549984601827e-18
onset O 0 6.2850302219585874e-12
of O 0 8.359780661498003e-15
the O 0 7.617244335289541e-11
disease O 0 0.003531933296471834
was O 0 2.0187549125694204e-06
congenital O 1 0.9898059964179993
. O 0 4.2091701651925106e-11

Preliminary O 0 4.2697195778984565e-10
in O 0 2.67810215193523e-13
vivo O 0 7.707350313523875e-09
footprinting O 0 7.614785602072516e-08
data O 0 9.904798335680365e-13
gave O 0 4.249462652421154e-15
evidence O 0 7.325791025642207e-16
for O 0 2.7667144217882707e-18
protein O 0 2.383687085878109e-15
- O 0 5.499924734392314e-12
DNA O 0 7.008603697400417e-10
contact O 0 9.512553411639146e-09
in O 0 1.389893927929858e-15
normal O 0 1.557196042847441e-14
genes O 0 7.083323185809454e-14
at O 0 1.8187220392901216e-13
an O 0 2.4825409130203695e-15
Sp1 O 0 4.604095771298944e-09
consensus O 0 2.4061796222759734e-15
binding O 0 1.5055314376362545e-14
site O 0 2.5831940075491874e-14
upstream O 0 2.2565349382889371e-13
of O 0 1.4162308821775136e-16
the O 0 5.042741300655921e-16
CTG O 0 1.8843694660208854e-10
repeat O 0 1.649956863844504e-12
and O 0 1.9855744339757608e-17
for O 0 2.3288273329168882e-20
a O 0 2.640882414536997e-19
significant O 0 1.8042895309286392e-17
reduction O 0 1.2315194132213932e-14
of O 0 1.8807853741801956e-18
this O 0 3.97591557894942e-18
interaction O 0 1.340972931256255e-16
in O 0 2.502227556827503e-18
cells O 0 5.166167765356265e-16
with O 0 2.318248973202827e-16
a O 0 2.0440944672583256e-14
hypermethylated O 0 5.444233153184541e-08
DMPK O 0 3.133022019596865e-08
gene O 0 2.3217993500024292e-11
. O 0 4.5734246332520753e-14
. O 0 2.278179543884623e-13

The O 0 9.165181634462893e-12
hemochromatosis B-Disease 1 0.9999947547912598
gene O 0 2.472560112209976e-08
product O 0 9.071567108609457e-11
complexes O 0 2.4019726637368455e-13
with O 0 1.8972746572086237e-16
the O 0 2.053721642566493e-16
transferrin O 0 2.2284672718253518e-10
receptor O 0 1.0343898480813518e-11
and O 0 1.007237869499189e-11
lowers O 0 6.259294860200271e-09
its O 0 2.1381397915911637e-17
affinity O 0 2.61779688104339e-16
for O 0 2.318875777583795e-17
ligand O 0 9.427808739855686e-15
binding O 0 7.680689417810527e-12
. O 0 1.2197060852633945e-12

We O 0 7.301495519307366e-11
recently O 0 5.376242853682989e-11
reported O 0 1.6873512949291264e-13
the O 0 8.309881249126093e-18
positional O 0 1.8009170001630215e-13
cloning O 0 8.355321371843888e-14
of O 0 5.38798815801318e-18
a O 0 9.86014311763133e-17
candidate O 0 3.246503136851778e-14
gene O 0 2.321586846376622e-11
for O 0 1.218136258529512e-09
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.6146544814109802
HFE O 1 0.767068088054657
. O 0 4.220861715698021e-10

The O 0 8.127465782087513e-15
gene O 0 3.735116816533379e-12
product O 0 2.421849942813026e-10
, O 0 1.5160821700245048e-16
a O 0 2.3135489991367496e-16
member O 0 1.2490103894723104e-14
of O 0 1.1921350976351999e-17
the O 0 2.967892009406945e-16
major O 0 1.1439167755394886e-12
histocompatibility O 0 2.4514424778326882e-12
complex O 0 1.8688313226035598e-14
class O 0 9.666080436065982e-12
I O 0 1.6805904579086928e-07
- O 0 5.551118453794857e-10
like O 0 7.429797228841739e-12
family O 0 1.1324797978724821e-13
, O 0 6.196620403382564e-17
was O 0 2.1237548666289824e-14
found O 0 1.1579871278175318e-14
to O 0 1.7858722381231158e-14
have O 0 2.656644002008157e-12
a O 0 2.84060715081318e-15
mutation O 0 5.043740490366655e-13
, O 0 5.82301354622736e-15
Cys O 0 2.01414547262857e-08
- O 0 1.934215010379603e-09
282 O 0 2.762689277346908e-08
- O 0 1.9721072021638975e-05
- O 0 1.15686452772934e-06
> O 0 1.6945065142714988e-11
Tyr O 0 2.7156574766706854e-09
( O 0 1.6691751537271753e-14
C282Y O 0 6.701819546366117e-13
) O 0 4.2390157583313036e-17
, O 0 8.935931861761086e-19
in O 0 7.13846528875606e-19
85 O 0 4.2715985879482245e-15
% O 0 1.3128908773790189e-16
of O 0 6.666342524282436e-16
patient O 0 7.551093084146032e-11
chromosomes O 0 2.2720904324646796e-10
. O 0 2.136506466535182e-12

This O 0 2.4484491921460995e-14
mutation O 0 2.342334876406782e-12
eliminates O 0 3.454991718068734e-12
the O 0 5.951238664332137e-16
ability O 0 8.402354062086309e-14
of O 0 1.32772851233475e-16
HFE O 0 1.3718470803780747e-08
to O 0 6.422466386295754e-15
associate O 0 3.022713589845294e-12
with O 0 3.0167394190344643e-13
beta2 O 0 3.891860615112819e-06
- O 0 3.2103804414873593e-07
microglobulin O 0 1.1158141433043056e-06
( O 0 5.024639084254441e-14
beta2m O 0 7.333110785268104e-10
) O 0 3.3869835299780797e-16
and O 0 6.11450651484667e-17
prevents O 0 3.52006902901332e-14
cell O 0 8.316788230322558e-12
- O 0 3.8350589193214546e-07
surface O 0 4.6395712161029223e-08
expression O 0 9.721744520518882e-10
. O 0 6.6704510838511144e-12

A O 0 5.969762184587779e-11
second O 0 5.272935408619228e-13
mutation O 0 1.835821642273694e-12
that O 0 6.171338481610273e-15
has O 0 6.438147541129591e-13
no O 0 1.7939393799127658e-14
effect O 0 4.1375353121951564e-13
on O 0 4.189213143046544e-10
beta2m O 0 4.2053867218783125e-05
association O 0 1.0758901365301443e-12
, O 0 1.2460354403549638e-15
H63D O 0 2.684440403299959e-08
, O 0 2.3214703453803534e-16
was O 0 3.14604435168106e-13
found O 0 3.9601682393433646e-13
in O 0 5.156598940030252e-16
eight O 0 1.3343396483220249e-12
out O 0 1.517335909695383e-11
of O 0 1.3473266048029484e-15
nine O 0 1.1879915454149348e-11
patients O 0 5.078280685540343e-16
heterozygous O 0 1.3493685894805417e-15
for O 0 8.458148410842548e-18
the O 0 2.9379975167808216e-15
C282Y O 0 4.297843470002505e-10
mutant O 0 1.3001590914996086e-09
. O 0 4.933590428551904e-12

In O 0 1.7857631402795095e-14
this O 0 8.974544363241847e-17
report O 0 5.023671433815498e-14
, O 0 9.547699960349432e-18
we O 0 3.71568803239881e-17
demonstrate O 0 3.358688460549499e-17
in O 0 4.772233979450517e-19
cultured O 0 2.2686129166091078e-14
293 O 0 4.749034637898742e-15
cells O 0 6.278044092415344e-16
overexpressing O 0 1.0615774231892416e-10
wild O 0 1.2620214873138025e-09
- O 0 2.5524991542624775e-06
type O 0 7.233527981043153e-07
or O 0 4.9514264216510284e-12
mutant O 0 1.0633288693995269e-09
HFE O 0 2.9931548350958792e-09
proteins O 0 2.1620598987894847e-14
that O 0 3.8845417343282395e-17
both O 0 5.08754623336657e-17
the O 0 9.94984324500107e-17
wild O 0 3.596708042508112e-09
- O 0 2.806950305966893e-06
type O 0 1.5295063349185511e-06
and O 0 2.741868065925246e-09
H63D O 0 8.338638872373849e-05
HFE O 0 7.853769602661487e-06
proteins O 0 3.740904919169452e-09
form O 0 5.3333060190396964e-11
stable O 0 2.4914939555920057e-10
complexes O 0 3.8628445060695515e-12
with O 0 7.8093008947476e-14
the O 0 2.7979680204681667e-13
transferrin O 0 1.8923822153738001e-07
receptor O 0 9.891975016884658e-10
( O 0 9.430143298183591e-12
TfR O 0 7.632859251316404e-07
) O 0 8.68164928510308e-14
. O 0 1.9318808976587915e-13

The O 0 1.2139780283457191e-12
C282Y O 0 1.3730976355930125e-09
mutation O 0 1.803359371554958e-11
nearly O 0 1.1918806599228032e-13
completely O 0 1.955623813928997e-12
prevents O 0 3.630996198156211e-11
the O 0 7.934715981049861e-14
association O 0 9.086173111648443e-13
of O 0 8.621652570314474e-17
the O 0 1.2899708275708075e-15
mutant O 0 1.0430605268396675e-09
HFE O 0 1.2483306832677954e-08
protein O 0 7.586313521823485e-12
with O 0 4.4459831053268034e-14
the O 0 1.1377566640560777e-12
TfR O 0 2.3712407710263506e-05
. O 0 1.0008983659243187e-12

Studies O 0 1.2646274652472478e-11
on O 0 1.8249838489373116e-13
cell O 0 5.923620621794967e-11
- O 0 7.851602923381051e-09
associated O 0 5.442620638028417e-13
transferrin O 0 4.8479512071430975e-11
at O 0 8.587385902196487e-13
37 O 0 2.342705673549772e-12
degrees O 0 4.3555708085368794e-13
C O 0 1.2622568268394474e-10
suggest O 0 3.307852377968691e-14
that O 0 1.2706736964966805e-16
the O 0 1.3664826519517985e-16
overexpressed O 0 3.0479658796878084e-09
wild O 0 4.754614479907104e-09
- O 0 1.475556814511947e-07
type O 0 2.49976678246e-10
HFE O 0 1.0325424071311318e-08
protein O 0 5.314942930212396e-12
decreases O 0 3.906207768269304e-13
the O 0 1.3620998685634107e-17
affinity O 0 1.7367338239738205e-14
of O 0 1.0162010969305083e-15
the O 0 7.757120277064947e-14
TfR O 0 6.023905996244139e-08
for O 0 1.075179154014878e-14
transferrin O 0 1.1799647925414547e-09
. O 0 1.7233779507630498e-12

The O 0 1.6449293099504714e-12
overexpressed O 0 8.287067032597406e-08
H63D O 0 8.130749762358391e-08
protein O 0 9.713746300377135e-12
does O 0 4.1402882370363686e-14
not O 0 9.704092517222996e-17
have O 0 2.610824873445201e-17
this O 0 1.8764201869913884e-19
effect O 0 1.4620741581674885e-15
, O 0 1.3617459800178452e-18
providing O 0 1.4682366950900392e-18
the O 0 3.192044230414502e-19
first O 0 3.076163995889726e-16
direct O 0 1.4405376837390579e-16
evidence O 0 3.3455120726673393e-13
for O 0 1.849328092531498e-15
a O 0 4.55704360897524e-15
functional O 0 1.476772805604487e-13
consequence O 0 5.406938680558313e-15
of O 0 2.76152937246738e-16
the O 0 8.16822195819078e-13
H63D O 0 0.0001327438949374482
mutation O 0 7.2646311188862e-10
. O 0 1.1560468728133433e-11

Addition O 0 4.727965848688731e-12
of O 0 1.1329674686215343e-14
soluble O 0 5.5818630967374716e-11
wild O 0 8.380332539026369e-10
- O 0 1.2658001651288942e-05
type O 0 4.694512426794972e-06
HFE O 0 0.042751848697662354
/ O 0 0.00024094522814266384
beta2m O 0 3.5790653782896698e-06
heterodimers O 0 6.591163614899642e-09
to O 0 2.7987874401413405e-15
cultured O 0 3.138304199845621e-11
cells O 0 1.3444696744802087e-11
also O 0 2.968617105608695e-12
decreased O 0 8.549882156427824e-12
the O 0 1.2694569634464517e-17
apparent O 0 3.002878122958133e-15
affinity O 0 1.7338410370523576e-14
of O 0 1.3748859864121696e-15
the O 0 1.9398035356276398e-14
TfR O 0 4.045420665121924e-10
for O 0 4.934043431962961e-19
its O 0 2.1507928942479306e-19
ligand O 0 1.793625353035483e-17
under O 0 8.396910244861777e-17
steady O 0 8.01106316700162e-12
- O 0 1.3440498713990223e-10
state O 0 4.791904720247153e-13
conditions O 0 1.401973155623626e-12
, O 0 2.5284802015184046e-18
both O 0 7.90457929258736e-18
in O 0 6.77842210584286e-18
293 O 0 1.6557371454255752e-14
cells O 0 1.6273698849670866e-15
and O 0 1.4697078731980284e-14
in O 0 8.948054996003245e-16
HeLa O 0 1.4855052743456554e-09
cells O 0 7.064265838963024e-12
. O 0 8.22823580104437e-13

Furthermore O 0 5.742947783993202e-11
, O 0 1.5450131679670825e-14
at O 0 6.83818670091374e-13
4 O 0 1.0481284893823495e-12
degrees O 0 3.2365275823981188e-12
C O 0 2.733035309177012e-08
, O 0 1.7696134407005695e-14
the O 0 1.4095644681848263e-15
added O 0 2.3216444391960245e-11
soluble O 0 6.590871105176602e-14
complex O 0 4.923334007290298e-16
of O 0 2.0727379028092664e-15
HFE O 0 1.309015146944148e-06
/ O 0 1.8806227686241073e-08
beta2m O 0 2.128955900460028e-09
inhibited O 0 1.3369413215391646e-11
binding O 0 1.2554933763626874e-13
of O 0 1.1506059821299954e-16
transferrin O 0 1.729147554307975e-11
to O 0 6.6264636837301116e-15
HeLa O 0 2.7208939545886324e-09
cell O 0 3.0354343483196544e-09
TfR O 0 3.271919979397353e-07
in O 0 1.4689666240779743e-16
a O 0 4.518700545035406e-15
concentration O 0 1.159479623424886e-09
- O 0 6.988746292790893e-08
dependent O 0 3.945058724141859e-10
manner O 0 2.7001717528563063e-10
. O 0 2.1182957731652463e-12

Scatchard O 0 1.270199057046284e-08
plots O 0 3.3258559101190244e-11
of O 0 8.873004171107369e-16
these O 0 1.174638159728172e-17
data O 0 3.2954541873131404e-13
indicate O 0 2.1025317446278502e-13
that O 0 1.228966371215074e-14
the O 0 6.729949171731253e-13
added O 0 9.613074070102812e-08
heterodimer O 0 5.216043916234092e-11
substantially O 0 2.619402091064149e-11
reduced O 0 9.005559427517629e-14
the O 0 2.523067892596021e-16
affinity O 0 1.094709921128055e-13
of O 0 5.322320089127608e-15
TfR O 0 4.933993213995791e-09
for O 0 3.865771973908007e-15
transferrin O 0 7.130306345359827e-10
. O 0 5.308172521326093e-13

These O 0 2.5078815977033764e-13
results O 0 1.228330154603996e-12
establish O 0 8.496839062693221e-15
a O 0 3.275096830392891e-16
molecular O 0 3.647025986330127e-13
link O 0 2.233218054925601e-08
between O 0 3.098419090741267e-11
HFE O 0 2.6822892323252745e-05
and O 0 5.435451893263943e-13
a O 0 1.145062680885808e-16
key O 0 1.6734092681425922e-13
protein O 0 2.3541374944801956e-15
involved O 0 1.985683414028848e-14
in O 0 1.83112556625324e-15
iron O 0 1.4241581993701402e-05
transport O 0 2.8876943058975257e-09
, O 0 8.358472842627442e-15
the O 0 4.1191158014868e-14
TfR O 0 5.960565658824635e-07
, O 0 1.5289642176632626e-16
and O 0 4.907000498914826e-17
raise O 0 1.6913192842980102e-15
the O 0 3.689584114782045e-18
possibility O 0 7.530682789868865e-15
that O 0 1.77897591821272e-16
alterations O 0 8.86996639332116e-14
in O 0 7.974238653512288e-18
this O 0 3.6952765236034513e-17
regulatory O 0 2.4218625369054614e-11
mechanism O 0 9.879040918647775e-10
may O 0 1.3635552409407836e-10
play O 0 8.003942018712518e-13
a O 0 3.1031896408630587e-16
role O 0 6.694764100728667e-14
in O 0 7.904123826262573e-19
the O 0 4.882838222349907e-17
pathogenesis O 0 6.392704941793337e-12
of O 0 1.458612224058964e-11
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 3.189639841139069e-08
. O 0 1.3805121976129264e-11

Genomic O 0 3.701421613655498e-09
organization O 0 1.8219312777206786e-12
of O 0 1.228253360055899e-15
the O 0 9.61250935620217e-15
UBE3A O 0 1.018785837914038e-06
/ O 0 2.091010919968994e-08
E6 O 0 3.2481231926340115e-08
- O 0 7.953601333099414e-09
AP O 0 2.9381297395048023e-09
gene O 0 1.4410298041639402e-12
and O 0 1.4208366767677681e-15
related O 0 1.6612982555374786e-14
pseudogenes O 0 8.555502417628702e-10
. O 0 8.536971585378084e-13

The O 0 1.0808718286722807e-12
UBE3A O 0 3.579074459025833e-08
gene O 0 2.0649211507350884e-11
encodes O 0 5.206658021394972e-12
the O 0 2.5662172650005484e-14
E6 O 0 9.36611055379899e-09
- O 0 7.568952575809362e-09
AP O 0 1.5781785878132837e-09
ubiquitin O 0 7.646335279352934e-13
- O 0 2.9423930739819193e-12
protein O 0 3.217577046406338e-15
ligase O 0 1.3499613854886777e-14
and O 0 3.3052582972160774e-15
has O 0 3.999225402879711e-15
recently O 0 5.605627724156181e-13
been O 0 1.4146071094297153e-14
shown O 0 1.4758253145496884e-15
to O 0 1.718758062973921e-17
be O 0 6.228362687795211e-14
mutated O 0 3.0533321648817946e-08
in O 0 3.747276977605907e-08
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 1.9857189226257788e-09
who O 0 1.7465019231180379e-12
lack O 0 3.584898220290733e-14
15q11 O 0 1.806754051925097e-11
- O 0 3.786617130963066e-10
q13 O 0 4.583590174078722e-10
deletions O 0 4.893785376935966e-09
or O 0 3.1746813511368543e-10
chromosome O 0 0.0002563458983786404
15 O 0 2.2701954094372923e-08
paternal O 0 1.0323944479750935e-05
uniparental B-Disease 0 0.146963968873024
disomy I-Disease 0 0.00803492683917284
. O 0 8.540828599912231e-10

Previous O 0 1.1604918415120125e-11
UBE3A O 0 6.745821679032815e-09
cDNA O 0 2.3643829949460127e-12
analysis O 0 4.3158925326809705e-13
has O 0 1.586202550600893e-13
shown O 0 1.8473678465333147e-15
a O 0 9.073615454335078e-17
coding O 0 2.1295291918743686e-12
region O 0 1.730533881613098e-14
of O 0 5.3818484926345666e-17
approximately O 0 2.0234973364865322e-13
2 O 0 3.933281218088114e-12
. O 0 5.65002471891729e-13

6 O 0 6.5112319980187294e-09
kb O 0 8.59984902490396e-06
and O 0 3.7122830850999655e-12
a O 0 5.575098013994341e-14
3 O 0 8.02360677898406e-11
- O 0 4.0761922718957067e-05
untranslated O 0 0.0032987860031425953
region O 0 1.0462127830734858e-09
( O 0 1.8969219844531225e-14
UTR O 0 4.166386853576842e-12
) O 0 3.344854030240672e-17
of O 0 9.32926348086041e-19
< O 0 2.0741705743362523e-14
50 O 0 5.227962524627611e-16
bp O 0 1.3276508364912232e-11
, O 0 5.821941334865034e-17
whereas O 0 5.445540407184415e-16
Northern O 0 6.978990987792369e-17
analysis O 0 2.1089489001175667e-14
has O 0 3.0592253990463503e-12
indicated O 0 1.0434041529546433e-14
mRNA O 0 2.5941276041235525e-16
sizes O 0 1.0061461890422188e-13
of O 0 2.2113472213309074e-15
5 O 0 7.734642787360357e-12
- O 0 3.2540143024561985e-08
8 O 0 2.2127272236716067e-11
kb O 0 2.386855726399517e-07
. O 0 7.317776593018799e-12

We O 0 1.3255501297299022e-12
have O 0 1.0771481416577747e-17
analyzed O 0 1.065070676057235e-16
additional O 0 1.0553192588828066e-17
cDNA O 0 3.6348275938061746e-15
clones O 0 5.052459145504784e-11
and O 0 2.6822403652803587e-15
provide O 0 2.821089346149597e-18
evidence O 0 8.428552881142135e-17
for O 0 7.105486424914183e-18
an O 0 1.6087893636186714e-17
additional O 0 9.381284269381618e-14
0 O 0 1.797465713597457e-12
. O 0 9.93283580386084e-13

5 O 0 7.798819229298815e-11
kb O 0 7.615671648864009e-08
of O 0 1.586311512919228e-13
5 O 0 2.270365145884412e-11
- O 0 5.872287260899611e-07
UTR O 0 1.8616008290450736e-08
and O 0 4.614274999419077e-13
> O 0 2.5765508975504614e-14
2 O 0 3.093735535561839e-15
kb O 0 5.344989451039339e-10
of O 0 4.506839542675004e-15
3 O 0 5.553770984767503e-12
- O 0 5.026437221999913e-08
UTR O 0 1.709474339861572e-08
. O 0 1.4039534508916707e-12

We O 0 2.213527361405454e-09
have O 0 1.0736954911044674e-14
established O 0 4.269623095356991e-17
the O 0 3.422593167311926e-18
genomic O 0 5.856602095649643e-13
organization O 0 2.0117896470895832e-14
of O 0 2.0175594237680427e-16
UBE3A O 0 2.6038545541950953e-08
and O 0 3.7567812799694806e-15
the O 0 8.310765298405759e-19
sequence O 0 4.994688062767e-16
of O 0 1.9333229236058886e-16
intron O 0 2.485192274193082e-09
- O 0 2.5078161769442886e-08
exon O 0 2.0577362036533486e-09
borders O 0 2.452662295482355e-09
. O 0 3.4726449146815774e-12

We O 0 8.909772475362843e-08
have O 0 5.890965666666137e-12
also O 0 1.6838461031867986e-14
mapped O 0 1.0103675673889256e-09
two O 0 5.492878961024089e-16
highly O 0 3.1238678326879043e-16
homologous O 0 1.8111114482590417e-15
processed O 0 1.968827878506829e-12
pseudogenes O 0 4.2384384196791913e-11
, O 0 2.6619657846548798e-15
UBE3AP1 O 0 8.572838439135921e-09
and O 0 1.9295018870418151e-13
UBE3AP2 O 0 8.478118651567002e-09
, O 0 2.406581241624425e-17
to O 0 2.229027791679561e-18
chromosomes O 0 2.554439678444792e-13
2 O 0 3.7350651000897517e-13
and O 0 1.2966486391541299e-11
21 O 0 1.2689669627585776e-11
, O 0 1.1212592286531696e-15
respectively O 0 6.528192699958857e-13
, O 0 6.210660715637133e-15
and O 0 1.2018955709153234e-13
determined O 0 1.2598785675745766e-13
their O 0 3.3082351945092027e-15
genomic O 0 7.869193144327546e-12
organization O 0 1.2489456517605912e-11
. O 0 1.3233422604258527e-12

These O 0 2.915071829756588e-12
results O 0 1.3722147029771037e-10
will O 0 7.845973220080293e-13
form O 0 6.724626861383004e-16
the O 0 2.588067480432642e-17
basis O 0 9.496462454296542e-15
for O 0 9.974473639618245e-16
studies O 0 8.678974333879827e-16
of O 0 1.0998982554809432e-17
mutation O 0 5.395197363953358e-14
and O 0 2.1568577612406277e-14
imprinting O 0 3.199263354236592e-10
of O 0 8.830235262609343e-13
UBE3A O 0 0.00011378596536815166
. O 0 7.108440225334078e-11

Mutation O 0 3.707703255528827e-09
spectrum O 0 5.165915265004095e-11
and O 0 8.638970615260089e-13
genotype O 0 9.856417904074988e-10
- O 0 4.444826728899898e-08
phenotype O 0 2.5716515028584297e-10
analyses O 0 1.1443587744075501e-10
in O 0 1.2125797056988102e-13
Cowden B-Disease 0 0.00018469155475031585
disease I-Disease 0 0.015049858950078487
and O 0 3.076175092431299e-09
Bannayan B-Disease 1 0.9982130527496338
- I-Disease 1 0.9999878406524658
Zonana I-Disease 1 0.9999643564224243
syndrome I-Disease 1 0.9999992847442627
, O 0 3.458352582173113e-13
two O 0 1.484573965496172e-12
hamartoma B-Disease 0 0.000564193818718195
syndromes I-Disease 0 1.607816193427425e-05
with O 0 1.8870137657306385e-13
germline O 0 4.102353443613538e-07
PTEN O 0 0.0007667398313060403
mutation O 0 1.2517541563283885e-06
. O 0 1.7678999930659245e-10

The O 0 5.425731045005655e-11
tumour B-Disease 1 0.9999943971633911
suppressor O 0 1.679323133885191e-07
gene O 0 2.2356371687237697e-07
PTEN O 0 6.709160516038537e-05
, O 0 7.425960718468027e-15
which O 0 3.946256356341841e-17
maps O 0 2.6712980785714713e-12
to O 0 7.045934473891291e-13
10q23 O 0 7.151751191258882e-08
. O 0 2.763658442719863e-12

3 O 0 7.775856347702614e-11
and O 0 4.623846979942819e-15
encodes O 0 3.5425363661810037e-15
a O 0 2.0244053028664296e-16
403 O 0 2.3677696427333063e-14
amino O 0 1.2827000746284956e-13
acid O 0 6.426299162948235e-12
dual O 0 6.603810387417752e-09
specificity O 0 1.1277146327870469e-08
phosphatase O 1 0.5702019333839417
( O 0 6.078602465126037e-12
protein O 0 1.5913937945200018e-09
tyrosine O 0 1.4304125670605572e-06
phosphatase O 0 0.12781226634979248
; O 0 3.045299689502512e-12
PTPase O 0 5.723120466427645e-08
) O 0 9.382997308814145e-15
, O 0 1.1516285593468457e-17
was O 0 6.375614283477687e-14
shown O 0 7.966854714998306e-13
recently O 0 2.07171257926575e-09
to O 0 1.38301181487957e-13
play O 0 5.386406876084493e-10
a O 0 2.0996852395866253e-14
broad O 0 9.522704673414761e-12
role O 0 3.4712543169751475e-12
in O 0 8.054186817768396e-17
human O 0 8.288406853212971e-13
malignancy B-Disease 0 8.338084889203401e-09
. O 0 1.7621203161986149e-13

Somatic O 0 5.089695491733437e-07
PTEN O 0 2.7594023777055554e-05
deletions O 0 2.921846409265072e-08
and O 0 2.2488922616498153e-12
mutations O 0 2.4793248010190894e-10
were O 0 1.460910385719938e-13
observed O 0 3.525829259630464e-13
in O 0 1.200007415891281e-14
sporadic B-Disease 0 2.432965402476839e-06
breast I-Disease 1 0.9947108030319214
, I-Disease 0 6.852650669131322e-10
brain I-Disease 0 3.947186269215308e-05
, I-Disease 0 1.0366597164024327e-10
prostate I-Disease 0 0.007905971258878708
and I-Disease 0 1.1092620866293146e-07
kidney I-Disease 0 1.8553515701569268e-06
cancer I-Disease 0 1.2438102103828896e-08
cell O 0 9.609679274547034e-09
lines O 0 2.4351467686756223e-07
and O 0 6.836585984826282e-12
in O 0 1.8856005579619893e-16
several O 0 7.207405889285683e-15
primary O 0 1.659448258806151e-07
tumours B-Disease 1 1.0
such O 0 4.464087086097912e-12
as O 0 3.6482994403286284e-09
endometrial B-Disease 1 0.9807619452476501
carcinomas I-Disease 1 1.0
, O 0 0.0023214868269860744
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9999382495880127
thyroid B-Disease 1 0.9999929666519165
tumours I-Disease 1 0.9999998807907104
. O 0 2.2483594985800437e-09

In O 0 9.131448852270352e-13
addition O 0 6.239827990243973e-13
, O 0 7.1526274215538e-15
PTEN O 0 1.547464734130699e-07
was O 0 3.5592436116449466e-12
identified O 0 2.9442274356375475e-13
as O 0 9.223609107426054e-17
the O 0 2.9918967659678157e-18
susceptibility O 0 8.115786044777824e-15
gene O 0 5.749898848066495e-14
for O 0 3.0667586796862684e-14
two O 0 3.221380384665906e-10
hamartoma B-Disease 1 0.9373580813407898
syndromes I-Disease 1 0.9983382225036621
Cowden B-Disease 1 0.769263505935669
disease I-Disease 1 0.9996155500411987
( O 0 1.4862293687412098e-11
CD B-Disease 0 8.017145205485576e-07
; O 0 1.8979743124369897e-11
MIM O 0 0.00013054691953584552
158350 O 0 4.009061171927897e-08
) O 0 2.7539594411353507e-13
and O 0 4.784993148237993e-12
Bannayan B-Disease 0 7.1824157203082e-05
- I-Disease 0 1.8649132471182384e-05
Zonana I-Disease 0 4.733727473649196e-05
( I-Disease 0 2.561407900017465e-12
BZS I-Disease 0 2.4247272634170258e-08
) I-Disease 0 1.2670006704698102e-15
or I-Disease 0 7.309464889100354e-15
Ruvalcaba I-Disease 0 1.0274721518044316e-07
- I-Disease 0 1.1465311217762064e-05
Riley I-Disease 0 0.0008110115304589272
- I-Disease 1 0.9999545812606812
Smith I-Disease 1 0.9953136444091797
syndrome I-Disease 1 0.9999403953552246
( O 0 4.387521704458941e-13
MIM O 0 6.56185193292913e-07
153480 O 0 3.45373196708465e-09
) O 0 1.1519934040981478e-13
. O 0 1.7843478159872833e-13

Constitutive O 0 2.564715106956328e-10
DNA O 0 3.05898334440613e-10
from O 0 5.632214800880414e-14
37 O 0 2.270519926586556e-12
CD B-Disease 0 1.4102464751530874e-09
families O 0 3.856432534421472e-12
and O 0 2.373347178508123e-12
seven O 0 2.8669670804060132e-12
BZS B-Disease 0 1.6494620922458125e-06
families O 0 3.448981788915003e-15
was O 0 3.1366002731323533e-14
screened O 0 4.8189296303347007e-11
for O 0 5.546384020598894e-15
germline O 0 1.8516279620683918e-09
PTEN O 0 3.742605656498199e-07
mutations O 0 1.5695450494845886e-09
. O 0 1.1768433449965698e-12

PTEN O 0 0.00018741516396403313
mutations O 0 1.0133889105645721e-07
were O 0 2.2031149419978607e-13
identified O 0 1.1011598398521713e-13
in O 0 5.822318529224359e-17
30 O 0 4.266257198182839e-15
of O 0 4.797521556656656e-16
37 O 0 1.0380309112267838e-10
( O 0 3.5249465835367894e-14
81 O 0 3.770138715109006e-12
% O 0 2.113779190202579e-16
) O 0 2.897491924787088e-17
CD B-Disease 0 7.464259765832537e-11
families O 0 1.261003562853802e-13
, O 0 3.295901812462029e-16
including O 0 1.1913640375876139e-14
missense O 0 5.1292592395668635e-09
and O 0 5.325882096451906e-12
nonsense O 0 3.925882285926718e-09
point O 0 6.872955438282091e-13
mutations O 0 6.970544475827511e-13
, O 0 2.0137607456974032e-16
deletions O 0 3.019607784301992e-12
, O 0 3.026395357463938e-15
insertions O 0 6.027633253635756e-11
, O 0 2.837110598806914e-14
a O 0 6.56820653638715e-14
deletion O 0 9.89177351584658e-07
/ O 0 3.328865204821341e-05
insertion O 0 3.7362607452351426e-10
and O 0 4.357899457962944e-12
splice O 0 1.0419201856848304e-07
site O 0 9.670977352271848e-10
mutations O 0 3.408994331266513e-08
. O 0 1.4229847335178736e-11

These O 0 9.508446954060654e-14
mutations O 0 5.622456319964719e-11
were O 0 7.433077319884268e-14
scattered O 0 1.339287974142303e-13
over O 0 2.6915443615202483e-13
the O 0 6.206251697388437e-16
entire O 0 6.875446934874463e-13
length O 0 2.5751864291163884e-13
of O 0 1.6232459991842607e-16
PTEN O 0 3.3003231258987853e-09
, O 0 5.009741624949832e-17
with O 0 6.211172247436658e-18
the O 0 2.7698945176532308e-17
exception O 0 2.698899555177072e-14
of O 0 4.868166222040033e-16
the O 0 3.20040597755894e-13
first O 0 7.278726954496051e-09
, O 0 6.149243440833896e-13
fourth O 0 8.928578987266178e-10
and O 0 2.1484317797026975e-11
last O 0 4.842572523533484e-11
exons O 0 3.956448679787172e-08
. O 0 2.6826741782864927e-12

A O 0 2.115535004121316e-11
hot O 0 9.692819463724689e-11
spot O 0 8.746266211279163e-11
for O 0 6.591248543057898e-14
PTEN O 0 1.0148652336283703e-06
mutation O 0 2.553355964163284e-11
in O 0 3.083801056700408e-16
CD B-Disease 0 8.812518714762518e-09
was O 0 4.2253966991978587e-10
identified O 0 3.696963742083614e-12
in O 0 3.9968424212663987e-17
exon O 0 7.830175743905876e-12
5 O 0 5.767286062781374e-14
that O 0 8.19010847427862e-17
contains O 0 2.65424952626363e-15
the O 0 1.9892467122313573e-14
PTPase O 0 2.738733684282124e-08
core O 0 3.452898730826881e-11
motif O 0 6.222855889435885e-13
, O 0 7.488450865319289e-17
with O 0 9.58233219279968e-17
13 O 0 3.2887572483706164e-15
of O 0 2.8649589112953776e-17
30 O 0 1.385017995474483e-13
( O 0 2.9442020331194594e-15
43 O 0 2.8561601868315467e-12
% O 0 1.3147051160729192e-16
) O 0 2.0206710787091202e-16
CD B-Disease 0 7.00056068669852e-10
mutations O 0 4.717104831741814e-11
identified O 0 4.9840999383210516e-11
in O 0 1.2949447638557624e-16
this O 0 3.9251943527127706e-16
exon O 0 1.0770662139947262e-09
. O 0 7.290400921844409e-12

Seven O 0 1.9313668719878052e-11
of O 0 3.6389340095344634e-15
30 O 0 1.0631522517814268e-13
( O 0 7.58369402923542e-16
23 O 0 1.8327897318847104e-14
% O 0 3.015962386478158e-17
) O 0 2.1948478202292266e-17
were O 0 1.9708735511658748e-14
within O 0 5.400522260399074e-17
the O 0 6.20944871736873e-16
core O 0 5.130714741952147e-10
motif O 0 8.683392546671165e-13
, O 0 6.923306512444279e-17
the O 0 5.442066331329753e-18
majority O 0 7.592349117769583e-16
( O 0 3.023230657084539e-17
five O 0 4.4360199649880194e-15
of O 0 9.340881480717901e-17
seven O 0 2.922942649637855e-13
) O 0 6.654930078807164e-17
of O 0 9.480847223242897e-18
which O 0 1.0592821921267398e-13
were O 0 2.701780043180141e-13
missense O 0 4.887253379770584e-10
mutations O 0 3.4234018397860666e-11
, O 0 2.7256645681125345e-15
possibly O 0 2.5759968702403213e-13
pointing O 0 1.4418304772334523e-07
to O 0 4.5269002305406425e-13
the O 0 5.430319754517847e-14
functional O 0 1.9212977292026173e-13
significance O 0 1.9621143411066707e-15
of O 0 2.5555177248053334e-16
this O 0 3.150796968844809e-15
region O 0 1.7095948138048933e-12
. O 0 1.7473415292804106e-12

Germline O 0 5.692022750736214e-05
PTEN O 0 0.0006460721488110721
mutations O 0 1.0219503110420192e-06
were O 0 8.769710760532512e-13
identified O 0 1.089915050572765e-11
in O 0 2.346954125691887e-16
four O 0 1.7921457503775051e-12
of O 0 1.388749819352178e-14
seven O 0 1.3146597144242378e-09
( O 0 2.5594045112431463e-13
57 O 0 3.8927718687409296e-11
% O 0 8.556460017784557e-15
) O 0 2.7206589845590878e-14
BZS B-Disease 0 1.3513098338080454e-06
families O 0 3.311679543874929e-13
studied O 0 3.3528249621106454e-10
. O 0 1.163142065302436e-11

Interestingly O 0 1.0727873034355184e-09
, O 0 1.217502119087166e-13
none O 0 7.919142772094823e-14
of O 0 9.189501803792532e-18
these O 0 2.8831932145440475e-16
mutations O 0 1.6641295980113213e-11
was O 0 4.5861087150100843e-10
observed O 0 4.244042183659813e-12
in O 0 3.706970660473244e-15
the O 0 2.2376039552057109e-13
PTPase O 0 5.19118941610941e-07
core O 0 1.202127286603627e-09
motif O 0 5.834479011035398e-10
. O 0 1.3301392322653816e-12

It O 0 1.7652295640838145e-12
is O 0 4.9605153020155016e-14
also O 0 3.3498376412300713e-15
worthy O 0 5.904860645854649e-15
of O 0 2.1453715339016943e-16
note O 0 1.5566097672989332e-12
that O 0 2.1266388708775734e-16
a O 0 6.989305069763068e-16
single O 0 6.765671356490088e-11
nonsense O 0 6.8798287067295405e-09
point O 0 8.146299390263123e-13
mutation O 0 3.6814111871799615e-13
, O 0 2.1816775630127206e-15
R233X O 0 1.975726873770789e-12
, O 0 2.083112759393931e-16
was O 0 3.2917982575875193e-13
observed O 0 4.725616802709297e-14
in O 0 1.3753986994256095e-17
the O 0 3.4198264549580894e-18
germline O 0 4.3644165430116455e-14
DNA O 0 6.1920520794123135e-12
from O 0 2.170793110231164e-16
two O 0 1.7752599582033357e-17
unrelated O 0 3.045761749363371e-14
CD B-Disease 0 4.9621291964285774e-08
families O 0 4.637491345799161e-12
and O 0 1.1376421506226198e-11
one O 0 8.2934865572315e-12
BZS B-Disease 0 2.9384977096924558e-05
family O 0 1.5385869661654894e-11
. O 0 4.465645735141077e-12

Genotype O 0 8.993370670395961e-07
- O 0 7.1439440034737345e-06
phenotype O 0 1.925477377540119e-08
studies O 0 6.613332798055538e-11
were O 0 1.6394636299585374e-12
not O 0 2.9313813424298183e-15
performed O 0 4.605678251973222e-12
on O 0 6.497485383928636e-13
this O 0 5.979794527264244e-17
small O 0 6.788472710936126e-15
group O 0 5.867343693148272e-14
of O 0 5.91717226974299e-15
BZS B-Disease 0 1.962130909305415e-06
families O 0 2.1806063627959754e-13
. O 0 1.0018547813182496e-13

However O 0 2.6100599546247105e-12
, O 0 8.357006628595745e-15
genotype O 0 1.1690762073690575e-11
- O 0 1.6302703631509985e-09
phenotype O 0 2.2469723998108648e-11
analysis O 0 7.883245515790185e-14
inthe O 0 1.2032697060959663e-09
group O 0 1.6742562197746835e-12
of O 0 2.769420278464442e-16
CD B-Disease 0 1.167535934598618e-08
families O 0 8.537354342626289e-15
revealed O 0 6.0796576106803e-12
two O 0 9.644164671506958e-16
possible O 0 8.51611414444094e-15
associations O 0 1.79031869522808e-15
worthy O 0 2.320196460767242e-15
of O 0 6.859871023884322e-17
follow O 0 5.595480133922803e-13
- O 0 8.307380339189763e-10
up O 0 4.369339889898072e-10
in O 0 1.8286954287275673e-16
independent O 0 2.691722814421576e-14
analyses O 0 1.610200167645459e-11
. O 0 5.63674215810217e-13

The O 0 5.395941397694226e-13
first O 0 1.3138762647302293e-11
was O 0 2.610176796924435e-10
an O 0 1.4741859669835725e-14
association O 0 6.239141148167704e-12
noted O 0 1.1169460495397132e-10
in O 0 9.676334982843676e-16
the O 0 2.8251320706250806e-15
group O 0 2.737210855381384e-14
of O 0 6.10639485088773e-17
CD B-Disease 0 1.8626167275215266e-08
families O 0 9.062598761711005e-13
with O 0 1.474646446619765e-11
breast B-Disease 0 5.3056253818795085e-05
disease I-Disease 0 3.0476064694084926e-06
. O 0 1.3627270969637784e-12

A O 0 4.95027456526298e-12
correlation O 0 3.2806867032025844e-12
was O 0 1.5400600716572455e-12
observed O 0 1.3873969383288234e-14
between O 0 4.258645813058371e-16
the O 0 8.919904914792432e-16
presence O 0 5.243112367880887e-12
/ O 0 4.16653433976677e-10
absence O 0 2.624370176469021e-13
of O 0 1.9289974307467263e-17
a O 0 1.6737331862471164e-15
PTEN O 0 7.767551579718202e-08
mutation O 0 9.185850864679157e-12
and O 0 2.0723594484884332e-14
the O 0 4.643161647245932e-17
type O 0 1.1599087246239037e-09
of O 0 2.134240998990719e-13
breast O 0 2.69081283477135e-06
involvement O 0 1.752231071350252e-08
( O 0 6.638032679952277e-13
unaffected O 0 5.237463351903671e-09
versus O 0 1.4641835299755712e-08
benign O 0 0.0021025952883064747
versus O 0 1.9680674085975625e-06
malignant O 0 0.2659975588321686
) O 0 4.517813553817085e-11
. O 0 3.34739007346041e-12

Specifically O 0 2.319803030226275e-11
and O 0 1.1054854634720448e-15
more O 0 1.0362541312909853e-18
directly O 0 3.998142471256646e-15
, O 0 1.630838611941035e-14
an O 0 5.127280503923644e-14
association O 0 6.552353659650123e-10
was O 0 1.7639904115185345e-07
also O 0 3.923207869682699e-10
observed O 0 8.313513180820131e-14
between O 0 2.1910510943048327e-16
the O 0 1.0906774746694675e-16
presence O 0 1.8272946479910455e-15
of O 0 1.6137548254382507e-18
a O 0 1.9796403421699568e-14
PTEN O 0 3.278667281847447e-05
mutation O 0 1.1224977924939594e-06
and O 0 1.6129206414916553e-07
malignant B-Disease 1 0.9999808073043823
breast I-Disease 1 0.9997555613517761
disease I-Disease 1 0.9953692555427551
. O 0 2.182761194013949e-10

Secondly O 0 1.3075306924292818e-05
, O 0 2.333891543568334e-13
there O 0 7.58531895606561e-15
appeared O 0 1.1731437002393541e-11
to O 0 1.140559933147543e-15
be O 0 8.662091009747908e-12
an O 0 3.9654138805043926e-13
interdependent O 0 0.002866411814466119
association O 0 1.0630027674068954e-12
between O 0 1.3338158998986503e-15
mutations O 0 7.063696415982035e-13
upstream O 0 3.1201718292406255e-11
and O 0 1.7129763319606583e-12
within O 0 5.647042663193516e-16
the O 0 5.09945547160634e-14
PTPase O 0 6.856304679558889e-08
core O 0 8.260295225603898e-10
motif O 0 3.247213956059092e-11
, O 0 5.954553739529454e-16
the O 0 5.1462211320651614e-17
core O 0 8.561403322393524e-12
motif O 0 7.73976965417339e-14
containing O 0 2.7931678847560766e-14
the O 0 7.503809822584275e-16
majority O 0 8.896393821275494e-15
of O 0 4.531437273584151e-16
missense O 0 1.7726348167101946e-09
mutations O 0 2.5055904573356713e-10
, O 0 8.30561629265288e-15
and O 0 2.4318326503582803e-15
the O 0 2.5366945351349747e-16
involvement O 0 3.8403665664210607e-11
of O 0 5.6084245253040614e-15
all O 0 2.509844762577096e-12
major O 0 1.3550402987172472e-11
organ O 0 1.61160820799644e-10
systems O 0 1.628454593394224e-10
( O 0 9.273226582234492e-14
central O 0 2.2109879031784185e-12
nervous O 0 2.3890029510198474e-08
system O 0 3.2018363654851e-12
, O 0 3.36762342729828e-14
thyroid O 0 2.1574358015641337e-06
, O 0 1.3280826091643938e-13
breast O 0 0.010611381381750107
, O 0 1.2917970479975338e-06
skin O 1 0.9999988079071045
and O 1 0.9485039710998535
gastrointestinal O 1 0.9405279159545898
tract O 0 0.0015317868674173951
) O 0 1.265955396068108e-10
. O 0 1.766827135984972e-11

However O 0 5.509129936097368e-13
, O 0 2.795690145055697e-17
these O 0 2.8475881287715216e-19
observations O 0 7.328450285580112e-15
would O 0 5.782464215569813e-14
need O 0 5.337487908114091e-15
to O 0 4.79958745678012e-17
be O 0 6.629753983213721e-14
confirmed O 0 1.1494051594025407e-14
by O 0 1.2711668078111448e-18
studying O 0 2.0177218423356787e-15
a O 0 1.5621259545949625e-17
larger O 0 3.38103232943023e-16
number O 0 5.153433683785481e-16
of O 0 1.023217917865563e-16
CD B-Disease 0 1.9370217430036973e-08
families O 0 6.6093324389837615e-12
. O 0 7.75588144055761e-13

Molecular O 0 2.919045698490663e-07
defects O 1 0.9213552474975586
leading O 0 6.135975061383192e-11
to O 0 1.0446182052779428e-15
human O 0 1.9404948134460476e-11
complement B-Disease 0 4.2365334707028524e-07
component I-Disease 0 0.13800404965877533
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.0374982157299126e-14
an O 0 3.2247059298003145e-14
African O 0 4.203954892534334e-11
- O 0 5.166383765242699e-09
American O 0 2.3162395612619235e-11
family O 0 1.0394602930133279e-12
. O 0 4.880408685688231e-13

Complement B-Disease 0 0.00013506384857464582
component I-Disease 0 0.258115291595459
C6 I-Disease 1 0.9999990463256836
deficiency I-Disease 1 1.0
( O 0 8.885656099799633e-12
C6D B-Disease 0 2.692501993806218e-06
) O 0 5.662647000609367e-13
was O 0 1.5763484961794916e-10
diagnosed O 0 1.1405571740397136e-06
in O 0 1.684351882441472e-16
a O 0 2.8268030548717765e-15
16 O 0 5.811233520216716e-14
- O 0 1.034103250079077e-12
year O 0 1.8048166043269087e-13
- O 0 2.951472052870052e-11
old O 0 4.9547597136267996e-09
African O 0 6.185073070028024e-13
- O 0 7.494984667621996e-12
American O 0 5.593036342226021e-13
male O 0 4.1883219982497e-12
with O 0 6.468331079090284e-12
meningococcal B-Disease 1 0.9999977350234985
meningitis I-Disease 1 0.9999978542327881
. O 0 1.4411761714572258e-11

The O 0 5.570565276419304e-12
patients O 0 5.892224208547958e-12
father O 0 8.626185876714487e-11
and O 0 3.525212457014537e-12
two O 0 7.510207191384344e-13
brothers O 0 6.14158039979884e-08
also O 0 1.8943886459510395e-09
had O 0 5.727974206060082e-10
C6D B-Disease 0 6.454627055063611e-07
, O 0 1.5158856319109622e-16
but O 0 5.837174031281321e-17
gave O 0 6.507018909156573e-14
no O 0 2.396728377828533e-13
history O 0 1.2361803204338773e-12
of O 0 1.6034829020128427e-10
meningitis B-Disease 1 1.0
or O 0 1.9931454490335065e-12
other O 0 9.6890204193123e-13
neisserial B-Disease 0 0.00038279700675047934
infection I-Disease 0 0.00011778973566833884
. O 0 3.1274152104826536e-12

By O 0 5.490323568501342e-16
using O 0 1.5400929865105428e-15
exon O 0 9.335420457501353e-12
- O 0 4.176476005313123e-12
specific O 0 2.6076622906481698e-15
polymerase O 0 1.0964239498950645e-12
chain O 0 1.0352859194928676e-11
reaction O 0 2.396854890669535e-14
( O 0 1.0791510767930106e-17
PCR O 0 2.926233745332435e-13
) O 0 1.0943820361300108e-17
/ O 0 8.466683842738021e-15
single O 0 1.824224195908896e-14
- O 0 1.1400923607962632e-11
strand O 0 1.0836755971743717e-11
conformation O 0 1.5498964958671202e-12
polymorphism O 0 5.15007090792774e-13
as O 0 4.949055750920451e-16
a O 0 1.0887024486080992e-17
screening O 0 1.4186167939954277e-14
step O 0 2.282282842531666e-15
and O 0 3.9818484284953797e-19
nucleotide O 0 6.87306893871179e-18
sequencing O 0 5.350919415437821e-16
of O 0 2.0779686886005864e-17
target O 0 2.300818606817967e-12
exons O 0 4.5782078128553394e-10
, O 0 2.9113221199311787e-15
we O 0 3.2121091946219274e-14
determined O 0 6.8447432272045975e-15
that O 0 4.22133395879226e-15
the O 0 4.1065170334293397e-14
proband O 0 1.0792875855258899e-06
was O 0 8.136939906588925e-12
a O 0 2.5332132297217595e-16
compound O 0 3.227424016176406e-15
heterozygote O 0 1.170910048607643e-12
for O 0 5.223457368139402e-16
two O 0 8.668192980889819e-15
C6 O 0 2.9967438308631245e-08
gene O 0 2.662724207791456e-10
mutations O 0 5.335875297163284e-09
. O 0 8.681310011138255e-12

The O 0 5.453489764807584e-13
first O 0 2.990810507239039e-12
, O 0 3.33252915822764e-15
1195delC O 0 1.8821342054331502e-11
located O 0 1.068335212504358e-14
in O 0 8.816148540360803e-17
exon O 0 9.875249229462923e-11
7 O 0 5.73432239192595e-11
, O 0 6.708506897954469e-17
is O 0 1.65946509492163e-17
a O 0 2.2747609533863926e-18
novel O 0 3.8918599110570815e-14
mutation O 0 3.037351186535586e-13
, O 0 2.533823464020697e-15
while O 0 2.731578086282143e-14
the O 0 3.2703277702020533e-16
second O 0 5.611892547885411e-11
, O 0 1.0996313858395099e-14
1936delG O 0 2.1602742164561484e-11
in O 0 9.016477126342365e-17
exon O 0 3.589918987079166e-11
12 O 0 1.2905443207145151e-11
, O 0 7.175990072546732e-16
has O 0 2.918885700633686e-14
been O 0 1.3462946645633085e-14
described O 0 3.4927003356963497e-15
before O 0 2.812441306319219e-13
to O 0 7.046814371716899e-15
cause O 0 9.895087678922498e-14
C6D B-Disease 0 1.8110281274630324e-08
in O 0 9.802538259773137e-17
an O 0 6.366238751070237e-16
unrelated O 0 2.2298107804630263e-10
African O 0 6.344313963069226e-11
- O 0 2.544204624754798e-09
American O 0 3.1710550851826724e-11
individual O 0 8.433828722204106e-13
. O 0 2.0488782111888204e-12

Both O 0 1.4367820301564027e-11
mutations O 0 2.776062268949886e-09
result O 0 1.1894580372734387e-12
in O 0 4.965295617156626e-14
premature O 0 1.4367368406098535e-09
termination O 0 4.813888732080329e-10
codons O 0 4.430824152024115e-09
and O 0 1.4347308931184077e-11
C6 O 0 7.302981543944043e-07
null O 0 5.643896905382917e-09
alleles O 0 2.3484669764428645e-09
. O 0 2.3849108451989842e-11

Allele O 0 4.942741216318325e-10
- O 0 7.912964727907479e-11
specific O 0 1.6567479945448285e-14
PCR O 0 6.701037502665486e-10
indicated O 0 3.1881962347934945e-13
that O 0 1.0093233018953667e-17
the O 0 8.975091625935112e-17
probands O 0 1.554447663920655e-07
two O 0 3.021030691233162e-12
brothers O 0 9.850411686329608e-08
also O 0 1.861988688234284e-11
inherited O 0 3.999846009961061e-10
the O 0 1.5014419625669108e-14
1195delC O 0 2.6161990351880604e-09
mutation O 0 1.3046857431225911e-12
from O 0 1.6373400980309802e-14
their O 0 1.9862289032468797e-14
heterozygous O 0 2.1458977650379296e-10
mother O 0 2.1755582058080591e-10
and O 0 2.5704777560219428e-15
the O 0 1.575442106619188e-16
1936delG O 0 7.086243258846991e-10
mutation O 0 1.1257696164168607e-12
from O 0 3.5632473805325554e-14
their O 0 2.430801057402149e-13
homozygous O 0 4.6273967990728693e-10
father O 0 6.157147708352184e-11
. O 0 6.223633448740806e-15
. O 0 1.391062287060818e-13

PAX6 O 0 0.00014296661538537592
mutations O 0 7.595318152198161e-07
reviewed O 0 1.3202216564422997e-07
. O 0 2.394227871516108e-10

Mutations O 0 2.866732984330156e-07
in O 0 7.750095324613598e-14
PAX6 O 0 3.0106079407232755e-08
are O 0 6.142728461509101e-16
responsible O 0 3.573754824243245e-15
for O 0 2.3061926768085236e-15
human O 0 1.1120108167617104e-09
aniridia B-Disease 1 1.0
and O 0 1.439046926066112e-08
have O 0 5.7455303535680624e-12
also O 0 4.3787412254024313e-14
been O 0 5.2486101809147076e-14
found O 0 9.560658742555767e-14
in O 0 4.0354072622546255e-15
patients O 0 2.467139821160213e-14
with O 0 2.7675539472442855e-14
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999998807907104
, O 0 1.9710841292486236e-10
with O 0 1.3523468567200325e-08
congenital B-Disease 1 0.9999988079071045
cataracts I-Disease 1 0.9999978542327881
, O 0 1.4168842765727163e-09
with O 0 6.78512468432757e-10
autosomal B-Disease 1 0.6486511826515198
dominant I-Disease 0 0.03738511726260185
keratitis I-Disease 1 0.9890027046203613
, O 0 4.173645040683738e-10
and O 0 1.0855939064358111e-10
with O 0 1.1280238965127865e-09
isolated B-Disease 0 0.0007528379210270941
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 0.9999997615814209
. O 0 3.0957045815682704e-09

No O 0 4.444696834974421e-13
locus O 0 2.820753613325122e-12
other O 0 9.527263536874024e-16
than O 0 8.281882641229051e-16
chromosome O 0 6.736949664798431e-09
11p13 O 0 2.1196032429227074e-10
has O 0 3.0169219715752565e-14
been O 0 9.41551744475808e-15
implicated O 0 6.539359720392213e-09
in O 0 4.9495572571056634e-12
aniridia B-Disease 1 1.0
, O 0 7.42970734848164e-13
and O 0 5.973553747327552e-15
PAX6 O 0 7.241242272471027e-09
is O 0 1.384701137389574e-13
clearly O 0 9.748059564412825e-13
the O 0 3.0724113752355936e-16
major O 0 7.223825704283371e-11
, O 0 1.5286508631183818e-14
if O 0 7.613388001634358e-13
not O 0 1.9102763058995338e-14
only O 0 7.125580494877668e-16
, O 0 4.583608613609054e-17
gene O 0 2.276666675278191e-14
responsible O 0 1.3923378942848341e-11
. O 0 1.3342531289886606e-12

Twenty O 0 9.124320049513912e-11
- O 0 1.1406815048076169e-08
eight O 0 1.782910624692491e-11
percent O 0 1.1604918415120125e-11
of O 0 9.184876209807135e-18
identified O 0 1.957646501501986e-12
PAX6 O 0 2.8504578608590236e-07
mutations O 0 4.1650882742771955e-10
are O 0 6.388654254056714e-13
C O 0 1.0501881320124085e-07
- O 0 5.072930071037263e-05
T O 0 6.032511009834707e-06
changes O 0 1.4361065505189008e-13
at O 0 4.1723630030566367e-14
CpG O 0 2.6452688997591345e-11
dinucleotides O 0 4.760873362208429e-10
, O 0 2.133480647160122e-16
20 O 0 2.0404540625878364e-16
% O 0 1.5094904669847432e-18
are O 0 3.83824186084399e-19
splicing O 0 2.1393436609902505e-13
errors O 0 5.564777794120346e-08
, O 0 1.038942819833543e-16
and O 0 1.2280224112288742e-17
more O 0 1.1396268924417372e-19
than O 0 4.830650603410548e-16
30 O 0 3.1042940977108954e-14
% O 0 2.0564328759166458e-17
are O 0 1.028771674672693e-16
deletion O 0 1.832811788622657e-13
or O 0 3.84455278213975e-14
insertion O 0 4.2506506669516553e-13
events O 0 1.621777018234738e-11
. O 0 1.3146139732356232e-10

There O 0 6.656809977377554e-13
is O 0 4.758700554376334e-15
a O 0 4.055499730796445e-15
noticeably O 0 2.458412362571494e-10
elevated O 0 6.106096606117717e-08
level O 0 9.320782340394018e-11
of O 0 1.6095574173610391e-16
mutation O 0 1.619340620796772e-12
in O 0 5.750649615719294e-16
the O 0 7.689145396003844e-16
paired O 0 6.03614658256646e-11
domain O 0 1.7564840640998947e-12
compared O 0 6.248192067903613e-12
with O 0 9.814670709723354e-15
the O 0 1.681688307929492e-15
rest O 0 1.0908914288391969e-13
of O 0 8.408605255234296e-18
the O 0 2.1606561110860002e-16
gene O 0 2.5163254726429107e-12
. O 0 5.549395036379134e-13

Increased O 0 1.4608437792773543e-09
mutation O 0 4.69656702417609e-10
in O 0 4.995663103568408e-15
the O 0 1.386318972436412e-16
homeodomain O 0 7.009481883812896e-11
is O 0 1.4133118478225977e-15
accounted O 0 1.4252520604690622e-12
for O 0 3.4612076126671266e-18
by O 0 1.05488457547091e-17
the O 0 2.492162360268231e-15
hypermutable O 0 6.48086597720976e-08
CpG O 0 1.058884313565045e-09
dinucleotide O 0 1.4518015956088703e-10
in O 0 2.4063632166672908e-15
codon O 0 4.2012296419535744e-11
240 O 0 1.5563425114634155e-12
. O 0 2.457724236799852e-13

Very O 0 7.566190919237534e-14
nearly O 0 5.264227604989593e-15
all O 0 4.445554485479669e-16
mutations O 0 1.536843162496318e-13
appear O 0 6.649370588645773e-14
to O 0 1.87774138923067e-15
cause O 0 7.01803632568998e-13
loss O 0 7.55492109844047e-12
of O 0 1.0417724392729644e-16
function O 0 3.7836906696708025e-15
of O 0 7.572188674833747e-16
the O 0 3.67116954240812e-15
mutant O 0 3.2903843538711897e-10
allele O 0 1.1133710056329682e-13
, O 0 1.5407209026222543e-16
and O 0 2.077206855256425e-18
more O 0 1.1624004833309005e-20
than O 0 3.680797802315507e-18
80 O 0 1.3823952246571546e-16
% O 0 5.132710294811965e-18
of O 0 2.0029736487652217e-16
exonic O 0 1.3084685406283825e-06
substitutions O 0 6.70501015820335e-11
result O 0 1.866995056817866e-12
in O 0 6.002704301504014e-14
nonsense O 0 1.2072879940205894e-07
codons O 0 4.043679613374707e-09
. O 0 1.0833196319171012e-12

In O 0 7.635080447650905e-14
a O 0 4.4135848150723316e-16
gene O 0 8.182220363490283e-14
with O 0 2.8233529837984913e-16
such O 0 2.298847418848171e-17
extraordinarily O 0 2.9942235756780233e-12
high O 0 8.660401497502523e-13
sequence O 0 2.21778467173004e-15
conservation O 0 1.144783768818145e-15
throughout O 0 1.1042914944322735e-17
evolution O 0 5.857632523935472e-16
, O 0 1.2205878442321456e-16
there O 0 2.5210557592123736e-17
are O 0 5.697999238858049e-17
presumed O 0 3.4775744024891087e-13
undiscovered O 0 6.24148626116039e-08
missense O 0 2.6192459756657627e-08
mutations O 0 6.852598488649164e-10
, O 0 6.171288294908148e-16
these O 0 7.734238650788805e-17
are O 0 3.331345376744293e-16
hypothesized O 0 3.892021101426944e-15
to O 0 2.1962486472878627e-15
exist O 0 5.359099123670996e-13
in O 0 1.551887920301059e-15
as O 0 1.4120322099075988e-11
- O 0 1.267545854943819e-07
yet O 0 2.974324345844659e-12
unidentified O 0 1.1119889731237009e-10
phenotypes O 0 1.8127877671192394e-11
. O 0 3.4905425192632194e-15
. O 0 1.1232831207070096e-13

Genetic O 0 3.810384541225176e-08
heterogeneity O 0 5.054545670901689e-09
and O 0 4.032395348619461e-13
penetrance O 0 1.014107242625073e-09
analysis O 0 1.555629540114789e-13
of O 0 1.8848751007124456e-15
the O 0 1.84973916609113e-13
BRCA1 O 0 0.0015429616905748844
and O 0 1.1299554625310293e-09
BRCA2 O 0 2.800677793857176e-05
genes O 0 1.966338869507922e-09
in O 0 8.743354889921562e-13
breast B-Disease 0 0.05488969758152962
cancer I-Disease 0 3.547384767443873e-05
families O 0 4.796527411365936e-11
. O 0 2.2841153881486553e-12

The O 0 1.0469236713106511e-06
Breast B-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.9999997615814209
Linkage O 0 8.272742707049474e-05
Consortium O 0 8.945308849206413e-08
. O 0 9.471983093700675e-12

The O 0 3.3112021391651977e-15
contribution O 0 2.5911932172964676e-14
of O 0 8.114233645143743e-16
BRCA1 O 0 9.968376616598107e-06
and O 0 2.2823856138387555e-09
BRCA2 O 1 0.9956985712051392
to O 0 9.087439138966147e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 5.393613378146256e-07
assessed O 0 6.375538291747418e-11
by O 0 1.4415828429866309e-15
linkage O 0 3.0997355793260795e-08
and O 0 5.802309045559173e-13
mutation O 0 7.382970408263082e-15
analysis O 0 9.50385451082723e-15
in O 0 5.276368339980826e-16
237 O 0 1.530598456138399e-12
families O 0 1.5264948254544407e-14
, O 0 2.39061576244709e-16
each O 0 2.1009820046772243e-15
with O 0 2.902662986814693e-14
at O 0 1.3057562843477033e-12
least O 0 8.66993609528593e-17
four O 0 9.691787574307026e-14
cases O 0 9.080429463903528e-11
of O 0 4.100074446622415e-11
breast B-Disease 0 0.007077027577906847
cancer I-Disease 0 3.2837088603798747e-09
, O 0 1.0225852405022456e-17
collected O 0 4.1161467816000843e-14
by O 0 1.1934423067849753e-11
the O 0 3.812876821029931e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Linkage O 0 1.9927592802559957e-05
Consortium O 0 8.486789937478534e-09
. O 0 1.5464955704924677e-11

Families O 0 1.6204104030803634e-11
were O 0 8.595705256516512e-14
included O 0 8.874159206410069e-15
without O 0 1.2446862227491061e-15
regard O 0 4.483396741189439e-16
to O 0 9.85573871174173e-18
the O 0 1.909851640637472e-16
occurrence O 0 7.008145452847003e-11
of O 0 1.5524593763305283e-11
ovarian B-Disease 0 3.0500599677907303e-05
or I-Disease 0 3.0613734203904786e-12
other I-Disease 0 7.405091080256443e-13
cancers I-Disease 0 2.0990995608372032e-07
. O 0 1.3767459394742332e-12

Overall O 0 0.00010494370508240536
, O 0 7.429772075351337e-11
disease O 0 6.486393999693973e-07
was O 0 2.001971505238842e-10
linked O 0 3.180381824563483e-08
to O 0 5.21120581582768e-13
BRCA1 O 0 1.0954980780297774e-06
in O 0 6.138437842584564e-17
an O 0 1.355309480876417e-18
estimated O 0 2.921379153872166e-15
52 O 0 6.614439898577906e-12
% O 0 2.841548574994494e-16
of O 0 2.902416362584188e-16
families O 0 5.1605797407724627e-14
, O 0 7.964700036822245e-16
to O 0 5.937700430857053e-16
BRCA2 O 0 1.866756527135749e-08
in O 0 2.884129821225474e-15
32 O 0 9.551349511652263e-13
% O 0 4.8300770032865795e-17
of O 0 2.072198111211294e-17
families O 0 9.411351736723483e-15
, O 0 9.421009606388076e-16
and O 0 1.7090835769051826e-15
to O 0 3.756046836229762e-17
neither O 0 1.4398687659387434e-14
gene O 0 1.4068370220946674e-13
in O 0 9.685641757351633e-16
16 O 0 1.3886022323314484e-13
% O 0 2.2117414953155196e-17
( O 0 6.656301213390532e-17
95 O 0 6.402145523790037e-13
% O 0 4.060645483056069e-12
confidence O 0 0.0005184803740121424
interval O 0 6.821692100089649e-10
[ O 0 1.747216676895036e-10
CI O 0 1.1488033123896457e-05
] O 0 5.933648104111677e-12
6 O 0 2.1056630831323142e-12
% O 0 2.7323061534519555e-15
- O 0 6.221539283757238e-09
28 O 0 1.7482233716226148e-10
% O 0 4.9771305256082965e-17
) O 0 3.005876325115115e-18
, O 0 5.240494203374309e-19
suggesting O 0 4.462667197992166e-15
other O 0 4.05328638076571e-16
predisposition O 0 7.275152702490573e-11
genes O 0 1.3076560667624193e-11
. O 0 1.7821820408325806e-12

The O 0 5.201930466242066e-13
majority O 0 4.860083689661732e-13
( O 0 2.938043891834684e-14
81 O 0 9.32668926898611e-14
% O 0 2.6064065709213102e-17
) O 0 4.730350619712084e-18
of O 0 1.1891698040317075e-16
the O 0 5.652881718276603e-09
breast B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.844458581653726e-12
were O 0 1.2595781080475266e-13
due O 0 3.3180427772472234e-15
to O 0 5.195477222913632e-16
BRCA1 O 0 3.179890484261705e-08
, O 0 2.7922488751841294e-16
with O 0 2.6659164257302126e-17
most O 0 2.0470028184101942e-16
others O 0 7.428768971501354e-14
( O 0 3.848644967714525e-15
14 O 0 2.5840676712123034e-13
% O 0 9.233042936876098e-17
) O 0 3.9129650498389906e-16
due O 0 2.844123049051961e-13
to O 0 8.843994113438836e-12
BRCA2 O 0 0.0009314624476246536
. O 0 1.619505779482111e-10

Conversely O 0 2.36143771203956e-10
, O 0 2.223943660047763e-15
the O 0 6.28345253013246e-18
majority O 0 2.459455453559427e-16
of O 0 1.781862447678285e-16
families O 0 6.212725104336181e-14
with O 0 4.2579256093189244e-11
male B-Disease 0 1.25593453503825e-06
and I-Disease 0 1.2681026895222658e-08
female I-Disease 0 1.7157025240521762e-06
breast I-Disease 0 1.1909812656085705e-06
cancer I-Disease 0 2.727005288249984e-08
were O 0 7.738917471265816e-13
due O 0 2.1604780139385105e-13
to O 0 2.930160183500091e-13
BRCA2 O 0 3.4943757782457396e-05
( O 0 3.870529331068129e-12
76 O 0 8.887157121328926e-10
% O 0 8.441388050801218e-14
) O 0 1.887978570138879e-13
. O 0 8.891551232272088e-13

The O 0 1.0811763675100047e-13
largest O 0 8.310889303142499e-12
proportion O 0 8.506435139610247e-12
( O 0 5.5830255647542834e-14
67 O 0 5.952067397979599e-12
% O 0 5.129505532421139e-16
) O 0 2.3717121046467422e-17
of O 0 4.1922195041012186e-17
families O 0 2.7690097851223788e-15
due O 0 3.732711144707355e-15
to O 0 7.326430006121792e-17
other O 0 1.4144552364222726e-15
genes O 0 1.887207973444785e-13
was O 0 1.513549355292021e-11
found O 0 9.571830090690514e-13
in O 0 1.1208615466844337e-15
families O 0 6.700173549591365e-16
with O 0 1.570264829487333e-15
four O 0 2.1258948106669256e-14
or O 0 6.149201699050255e-15
five O 0 1.4785054962013905e-14
cases O 0 3.846595784950946e-12
of O 0 2.373909749331382e-11
female O 0 0.0005330708809196949
breast B-Disease 0 1.1090459338447545e-05
cancer I-Disease 0 2.4156243227935192e-08
only O 0 2.9650236259282092e-12
. O 0 1.183312735991704e-11

These O 0 2.08556401450977e-14
estimates O 0 1.470768629498534e-13
were O 0 5.464555132179971e-14
not O 0 1.8434106409526407e-16
substantially O 0 3.448496777849405e-14
affected O 0 1.1258882637099144e-15
either O 0 1.9046402290704592e-18
by O 0 1.1638442799149675e-17
changing O 0 9.474557504654188e-14
the O 0 1.253648863652461e-16
assumed O 0 6.48978158539204e-13
penetrance O 0 2.3680307714712967e-11
model O 0 1.323695710334083e-12
for O 0 4.1158931799356764e-15
BRCA1 O 0 1.2322273201803569e-09
or O 0 6.581270240829358e-15
by O 0 1.3926902483865405e-16
including O 0 1.1235681303531017e-13
or O 0 1.4190736259689363e-11
excluding O 0 9.49462872767981e-08
BRCA1 O 0 3.8972726201791374e-07
mutation O 0 5.010071871258681e-11
data O 0 5.266814540050291e-09
. O 0 3.04814888607563e-11

Among O 0 1.579959145285581e-12
those O 0 6.546731201855643e-14
families O 0 7.476130988153668e-14
with O 0 3.8323302864462505e-12
disease O 0 2.330438292119652e-06
due O 0 4.589925987029397e-13
to O 0 1.9915359034746068e-14
BRCA1 O 0 2.487229039616068e-06
that O 0 1.2169060247327335e-12
were O 0 5.492821976882563e-14
tested O 0 1.1030818185958635e-12
by O 0 3.9775199474462545e-20
one O 0 2.9914403690648396e-18
of O 0 7.594216603113489e-20
the O 0 4.850678101878335e-19
standard O 0 1.5855225927849023e-16
screening O 0 4.555459657363875e-16
methods O 0 2.5626621168431784e-17
, O 0 1.1311082763009364e-18
mutations O 0 4.514114920417208e-16
were O 0 1.6895837667286453e-16
detected O 0 3.016804254324379e-12
in O 0 3.206790968560671e-17
the O 0 2.8476252422976554e-16
coding O 0 2.735167778031289e-12
sequence O 0 3.7172264506953046e-13
or O 0 1.6358300076926152e-13
splice O 0 5.45833656051542e-10
sites O 0 1.2402034954561714e-10
in O 0 2.3991670894452143e-16
an O 0 2.2550372866294026e-17
estimated O 0 3.205445891357739e-13
63 O 0 7.127586298949495e-10
% O 0 5.203989162879709e-15
( O 0 7.469025355814093e-16
95 O 0 1.0562538121710804e-13
% O 0 4.476684661532983e-14
CI O 0 7.277586701093242e-05
51 O 0 6.946691000209171e-10
% O 0 1.7842320774053705e-13
- O 0 1.7417524134089035e-07
77 O 0 3.131202797046484e-10
% O 0 6.827323571127839e-15
) O 0 2.462404398765293e-15
. O 0 3.079924959818389e-14

The O 0 4.9066152074499214e-14
estimated O 0 1.7348707919469936e-13
sensitivity O 0 1.4384477495851117e-13
was O 0 2.507221589630876e-13
identical O 0 1.1694932021972105e-15
for O 0 6.780875626937269e-19
direct O 0 1.523559671830928e-18
sequencing O 0 3.0829925743401654e-14
and O 0 3.793141863296266e-15
other O 0 1.1703354143358549e-17
techniques O 0 1.272330222949758e-12
. O 0 5.608686800585849e-13

The O 0 2.2256786257751626e-12
penetrance O 0 4.644192586056306e-07
of O 0 2.8132820373413456e-14
BRCA2 O 0 7.234197028083145e-07
was O 0 2.5280333924328213e-13
estimated O 0 1.2144062242528634e-16
by O 0 3.970005373472728e-18
maximizing O 0 4.555466247280204e-13
the O 0 1.855437698828396e-14
LOD O 0 6.683275159957702e-07
score O 0 6.875151836727156e-11
in O 0 7.057874927942145e-14
BRCA2 O 0 4.178857125225477e-05
- O 0 3.2934525506789214e-07
mutation O 0 3.109099921960734e-10
families O 0 1.3682053740297039e-14
, O 0 1.3761963496902944e-17
over O 0 1.7022061987690697e-15
all O 0 3.520968916816483e-14
possible O 0 7.980903671224102e-14
penetrance O 0 3.1235274366991916e-09
functions O 0 2.3309078191896537e-12
. O 0 2.1364414144048327e-12

The O 0 2.854946571577248e-15
estimated O 0 1.1363701863179032e-13
cumulative O 0 7.98007840363546e-11
risk O 0 1.1550763474588166e-06
of O 0 9.394974381793375e-12
breast B-Disease 1 0.5638262629508972
cancer I-Disease 0 0.0012735618511214852
reached O 0 3.558128014446993e-07
28 O 0 1.4034194639744868e-10
% O 0 1.702569893540797e-15
( O 0 1.9272553883766896e-16
95 O 0 4.542197916618598e-14
% O 0 1.6341079897108472e-14
CI O 0 7.68776226323098e-06
9 O 0 1.0931586365281465e-11
% O 0 2.712181074141667e-15
- O 0 7.186312100948555e-10
44 O 0 2.414357125682387e-12
% O 0 5.466076489380024e-18
) O 0 7.311370593704078e-20
by O 0 2.6242819336188234e-19
age O 0 2.8161275598243517e-14
50 O 0 1.1924859380202081e-16
years O 0 2.4424868425270817e-15
and O 0 7.853769446852094e-14
84 O 0 1.0783296930621904e-14
% O 0 5.053057764906784e-18
( O 0 2.7392003266632256e-18
95 O 0 1.4687712241649546e-15
% O 0 1.3360056918255395e-15
CI O 0 4.809231768376776e-07
43 O 0 1.8140805697897111e-12
% O 0 1.2175518399211698e-15
- O 0 4.7523700252849466e-11
95 O 0 2.245342177161283e-13
% O 0 1.0507846051339541e-16
) O 0 1.1271798921743455e-18
by O 0 5.5546968978961986e-18
age O 0 3.06654956419225e-13
70 O 0 8.214741515873755e-15
years O 0 3.675810266519537e-14
. O 0 4.9764740803681304e-14

The O 0 2.0187973515106705e-10
corresponding O 0 0.0005268081440590322
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 1 0.9417911171913147
were O 0 3.5249924507096964e-11
0 O 0 6.237007980393339e-13
. O 0 2.859592716699527e-13

4 O 0 3.3299707435929804e-10
% O 0 2.1799493362794492e-13
( O 0 3.402797740982436e-15
95 O 0 2.0400525615592996e-13
% O 0 6.588231750512957e-14
CI O 0 1.1443179573689122e-05
0 O 0 1.094271564637192e-13
% O 0 4.639943570555966e-15
- O 0 2.156101269745747e-10
1 O 0 1.6801503290313387e-14
% O 0 3.814509893973479e-18
) O 0 2.64187852094027e-20
by O 0 1.993495711976964e-19
age O 0 8.9265473471648e-15
50 O 0 1.5509932946900808e-16
years O 0 8.15252006375523e-16
and O 0 1.4372539752305694e-14
27 O 0 3.979335798728759e-15
% O 0 2.965341424871508e-19
( O 0 2.2711528432532246e-19
95 O 0 5.749114368502396e-16
% O 0 2.8391755592532017e-16
CI O 0 4.3733464849537995e-08
0 O 0 9.97238655043621e-15
% O 0 1.1603433405427328e-15
- O 0 3.8188443518549775e-09
47 O 0 1.5837803291063324e-10
% O 0 1.9960631834046067e-16
) O 0 1.2134881240832816e-18
by O 0 9.531979392807862e-18
age O 0 6.396884974849137e-13
70 O 0 1.511755435732679e-14
years O 0 4.380762923640938e-14
. O 0 5.947658679580567e-14

The O 0 1.9316303114316757e-13
lifetime O 0 1.931777848795946e-09
risk O 0 2.927540094788128e-07
of O 0 1.0879537288427388e-12
breast B-Disease 0 0.032457027584314346
cancer I-Disease 0 7.675979531995836e-07
appears O 0 3.492839047505858e-12
similar O 0 1.5049793415612342e-15
to O 0 3.0185552205041523e-15
the O 0 4.3788944367219307e-13
risk O 0 5.0845208043881485e-09
in O 0 2.7547025516103064e-15
BRCA1 O 0 4.8128285357051936e-08
carriers O 0 5.138311998109657e-11
, O 0 7.184779627561271e-17
but O 0 4.456147360404023e-17
there O 0 5.975234445983362e-17
was O 0 2.0677251957087334e-13
some O 0 6.4132268284843734e-18
suggestion O 0 3.5371774004819626e-14
of O 0 3.367284190602905e-17
a O 0 4.770064551684605e-13
lower O 0 1.993377729547774e-08
risk O 0 3.036906903730596e-08
in O 0 2.9050113009576606e-14
BRCA2 O 0 5.105514446768211e-07
carriers O 0 2.2891584461337544e-11
< O 0 3.2676766566035187e-13
50 O 0 8.452001373630315e-15
years O 0 6.321150064969236e-14
of O 0 1.4962047578540374e-14
age O 0 2.4688124877769724e-09
. O 0 1.6064445780561432e-12

Eye B-Disease 1 0.9452621340751648
movement I-Disease 0 5.100897926268999e-09
abnormalities I-Disease 0 9.040996519615874e-05
correlate O 0 9.541580719973908e-11
with O 0 1.842006061569812e-11
genotype O 0 2.9795097589158104e-07
in O 0 1.908567401343042e-11
autosomal O 1 0.9999512434005737
dominant O 1 0.9902259707450867
cerebellar B-Disease 1 0.9866833090782166
ataxia I-Disease 1 0.9998290538787842
type I-Disease 1 0.9999551773071289
I I-Disease 1 0.9997085928916931
. O 0 5.89780377313609e-11

We O 0 7.737301771504335e-11
compared O 0 2.9005697149697696e-11
horizontal O 0 7.832213668734767e-06
eye O 1 0.984853982925415
movements O 0 1.2224643342051422e-07
( O 0 4.0652932951391885e-13
visually O 0 6.860415707743428e-11
guided O 0 1.1945297728743753e-07
saccades O 0 1.7200210322698695e-06
, O 0 2.610989495357291e-13
antisaccades O 0 1.3992298875109555e-08
, O 0 1.3616390263918227e-15
and O 0 4.94860258829367e-16
smooth O 0 1.0742531945375985e-13
pursuit O 0 3.829422022538775e-12
) O 0 2.0200016315132137e-15
in O 0 7.632535140114185e-17
control O 0 3.193887211996871e-13
subjects O 0 3.5456800689948054e-11
( O 0 6.004694066600409e-15
n O 0 3.4123325692858586e-11
= O 0 4.078609325275373e-11
14 O 0 5.335582670129568e-12
) O 0 2.2717911536337954e-14
and O 0 1.4918064613483883e-12
patients O 0 2.0453414691632733e-15
with O 0 1.8365661184304584e-17
three O 0 5.3347600385074585e-15
forms O 0 2.9198128290164327e-12
of O 0 3.489617622642882e-11
autosomal O 0 0.41429227590560913
dominant O 0 0.0004406638036016375
cerebellar B-Disease 0 0.0004069986753165722
ataxias I-Disease 0 0.04939667880535126
type I-Disease 1 0.9233843684196472
I I-Disease 1 0.5889829397201538
spinocerebellar B-Disease 1 0.974640965461731
ataxias I-Disease 0 0.0012346126604825258
1 I-Disease 0 2.8594756770750074e-11
and I-Disease 0 5.258462935919805e-13
2 I-Disease 0 9.918859489180601e-14
( O 0 1.800537088945519e-15
SCA1 B-Disease 0 1.4317286911591509e-08
, O 0 6.631622537895364e-15
n O 0 3.529257788792428e-11
= O 0 1.2036264346315662e-11
11 O 0 3.496556614124985e-13
; O 0 4.846912577206647e-16
SCA2 B-Disease 0 8.46683878563681e-09
, O 0 6.396866086014414e-15
n O 0 3.8480434116916484e-11
= O 0 7.419402765773686e-12
10 O 0 2.2047164441318934e-13
) O 0 9.107609957002827e-15
and O 0 1.1190800022764513e-11
SCA3 B-Disease 1 1.0
/ O 0 2.8497240123215306e-07
Machado B-Disease 0 9.280823221047285e-09
- I-Disease 0 3.193724751326954e-08
Joseph I-Disease 0 1.5642738659948918e-08
disease I-Disease 0 1.0904076589213219e-05
( O 0 2.145857683167815e-13
MJD B-Disease 1 0.9999991655349731
) O 0 5.4565665950478265e-14
( O 0 5.277357039188508e-15
n O 0 5.909304157114548e-10
= O 0 2.760490169784191e-10
16 O 0 6.840368983046519e-12
) O 0 1.228875670927082e-13
. O 0 1.7534637750029475e-13

In O 0 3.5709117954252356e-12
SCA1 B-Disease 0 2.2510253216978526e-08
, O 0 5.268664575325548e-16
saccade O 0 3.452961115819886e-13
amplitude O 0 1.7419614783902135e-15
was O 0 7.787781921078651e-13
significantly O 0 2.049991171823931e-13
increased O 0 3.229717925393172e-13
, O 0 9.602310920698551e-17
resulting O 0 2.5417231050450274e-15
in O 0 1.194098514051235e-14
hypermetria B-Disease 0 4.376936431071954e-06
. O 0 1.965173683504684e-12

The O 0 6.475682078239953e-14
smooth O 0 1.7023061562801423e-12
pursuit O 0 3.497547390596267e-11
gain O 0 3.528141945263741e-10
was O 0 1.455936815553116e-09
decreased O 0 1.0998424393449113e-08
. O 0 6.653547613040545e-13

In O 0 2.674234531735431e-12
SCA2 B-Disease 0 7.93746437466325e-08
, O 0 8.087935389713865e-16
saccade O 0 3.862446387031815e-12
velocity O 0 1.8582483642115566e-12
was O 0 1.8559750958324628e-11
markedly O 0 3.291112660175344e-10
decreased O 0 2.9481670438258334e-09
. O 0 5.538302563952435e-13

The O 0 1.0495958790957775e-14
percentage O 0 5.238913903388154e-12
of O 0 1.439290692422022e-16
errors O 0 5.4431059659521e-10
in O 0 1.6900543994099635e-16
antisaccades O 0 1.542746597138489e-09
was O 0 1.259110437440425e-12
greatly O 0 1.5212572819283884e-14
increased O 0 1.6585224946880084e-13
and O 0 1.4181569398083634e-14
was O 0 5.830198520143104e-13
significantly O 0 1.600637991019862e-14
correlated O 0 7.849161858669573e-13
with O 0 5.731101899476843e-13
age O 0 1.1292423662823126e-09
at O 0 1.6993179086099985e-09
disease O 0 2.787599555631459e-07
onset O 0 4.104035444818521e-10
. O 0 7.122546909904548e-13

In O 0 6.341534421064679e-14
addition O 0 7.212411854003956e-15
, O 0 1.0781142058951754e-17
a O 0 2.1068377055689933e-18
correlation O 0 1.9725694805328674e-14
between O 0 3.804154985676466e-15
smooth O 0 2.432035909466501e-12
pursuit O 0 4.275936202335906e-11
gain O 0 1.4783738677692781e-09
and O 0 7.884543170265379e-13
the O 0 1.6562974894839195e-16
number O 0 4.3753937511948823e-14
of O 0 3.7802284224989005e-15
trinucleotide O 0 3.112342739086671e-08
repeats O 0 1.703374219452769e-09
was O 0 1.7636108502402936e-12
found O 0 2.7924448235509824e-13
. O 0 3.070646764202073e-13

In O 0 5.998822272257343e-11
SCA3 B-Disease 1 0.9999988079071045
, O 0 2.909068992640318e-11
gaze B-Disease 0 0.006778332404792309
- I-Disease 0 0.0001736937992973253
evoked I-Disease 0 1.4779720913793426e-07
nystagmus I-Disease 0 6.748353825969389e-06
was O 0 3.1161510871680065e-11
often O 0 7.462194246852724e-15
present O 0 3.720980532481271e-16
as O 0 1.5138926692651912e-15
was O 0 3.6133200381413544e-13
saccade O 0 3.927968020289718e-11
hypometria O 0 2.45324365266697e-08
and O 0 9.99775434017353e-15
smooth O 0 1.0909204990099466e-13
pursuit O 0 1.4966007599870323e-11
gain O 0 9.537760164990416e-11
was O 0 5.547371451086747e-10
markedly O 0 1.3704680723591878e-09
decreased O 0 3.186038544100711e-09
. O 0 1.6551135462172795e-12

Three O 0 1.3560744541174508e-11
major O 0 1.4331856014460076e-11
criteria O 0 5.339468559135974e-13
, O 0 9.568044467515174e-18
saccade O 0 1.1362250387520617e-13
amplitude O 0 8.631298555048027e-16
, O 0 4.486764954469306e-17
saccade O 0 1.0454485177948183e-13
velocity O 0 8.940097333222027e-14
, O 0 5.196586836074535e-16
and O 0 5.714196494043021e-16
presence O 0 5.433925404367719e-14
of O 0 4.059431234221126e-15
gaze B-Disease 1 0.9444777965545654
- I-Disease 0 4.164997153566219e-05
evoked I-Disease 0 1.9309609911033476e-08
nystagmus I-Disease 0 4.295249667052303e-08
, O 0 2.3464797872414247e-16
permitted O 0 9.40951642808502e-16
the O 0 1.782065338538932e-17
correct O 0 2.1663209149713064e-13
assignment O 0 4.190135651643834e-12
of O 0 1.5082652470614296e-17
90 O 0 5.187238239314808e-16
% O 0 4.93671936124457e-18
of O 0 2.073066816290597e-18
the O 0 3.57599141474047e-15
SCA1 B-Disease 0 2.111677758875885e-06
, O 0 8.119647906212372e-17
90 O 0 9.729402589605893e-18
% O 0 1.0790146126714547e-18
of O 0 1.5387575646229413e-18
the O 0 2.4204779619420996e-14
SCA2 B-Disease 0 4.415532657731092e-06
, O 0 1.8561484018227896e-15
and O 0 1.296017795781256e-15
93 O 0 4.791397296689771e-15
% O 0 7.463147120868077e-19
of O 0 6.051476551582017e-19
the O 0 5.990485935943165e-15
patients O 0 2.5228200401677427e-14
with O 0 4.2735732758581585e-14
SCA3 B-Disease 1 1.0
to O 0 2.3499307900509518e-14
their O 0 8.354360497668523e-15
genetically O 0 3.3204109600726284e-11
confirmed O 0 3.250509019933623e-12
patient O 0 1.0363251055911515e-11
group O 0 5.573981285756681e-14
and O 0 2.1604390151863662e-11
, O 0 4.918887613712805e-15
therefore O 0 9.514260522342486e-16
, O 0 1.1994713922664347e-15
may O 0 6.261523688867038e-14
help O 0 1.8165509244397193e-14
orient O 0 5.506928940635092e-11
diagnoses O 0 2.168732571306009e-08
of O 0 8.734649830678676e-14
SCA1 B-Disease 0 3.649467771538184e-06
, O 0 1.4745542569090386e-14
SCA2 B-Disease 0 2.9634353637675304e-08
, O 0 5.973508431064874e-15
and O 0 1.6571921786223687e-12
SCA3 B-Disease 1 1.0
at O 0 6.5602537291376e-11
early O 0 3.2754625156920444e-14
clinical O 0 5.8725220866695516e-12
stages O 0 8.098784230053946e-13
of O 0 9.725256429503532e-16
the O 0 8.47701737364398e-13
diseases O 0 8.937209372561483e-08
. O 0 5.760664721529392e-15
. O 0 9.000378567436407e-13

Genetic O 0 2.796767928359145e-09
basis O 0 6.2797098250577665e-12
and O 0 1.3253623459136277e-13
molecular O 0 1.241502733950739e-10
mechanism O 0 5.013999384573253e-07
for O 0 3.467843896487466e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999867677688599
fibrillation I-Disease 1 0.9999992847442627
. O 0 1.2705024232673168e-07

Ventricular B-Disease 0 0.005822851322591305
fibrillation I-Disease 0 1.733207000143011e-06
causes O 0 2.3554751898968718e-12
more O 0 1.9855441591653413e-17
than O 0 2.2997508655132015e-17
300 O 0 1.4118939411386736e-16
, O 0 2.0861323408610253e-18
000 O 0 2.196607895136617e-16
sudden O 0 2.7405526544681865e-15
deaths O 0 9.69237846449103e-14
each O 0 4.6727893906681195e-14
year O 0 2.8882366984173125e-11
in O 0 5.287772579824421e-16
the O 0 4.4286080878863654e-14
USA O 0 2.4871103505574865e-06
alone O 0 5.295924254689055e-10
. O 0 3.8148688851977197e-13

In O 0 1.1756088181928692e-13
approximately O 0 1.4463986106917626e-13
5 O 0 4.5338648742461463e-13
- O 0 3.717815388881718e-09
12 O 0 2.550525437551576e-13
% O 0 9.66388905791108e-19
of O 0 6.744879586268188e-21
these O 0 2.750341001948243e-18
cases O 0 2.74150408422619e-15
, O 0 1.8402619614073453e-17
there O 0 7.11034462208783e-17
are O 0 4.4252849870518736e-16
no O 0 3.711981622685906e-14
demonstrable O 0 6.64843895492595e-08
cardiac O 0 1.2003360971846178e-08
or O 0 1.4763471001266737e-10
non O 0 0.020254209637641907
- O 0 0.22687050700187683
cardiac O 0 6.561913892255689e-07
causes O 0 7.516770409235485e-13
to O 0 3.9102344273752795e-16
account O 0 6.987420082642248e-14
for O 0 7.795056172267036e-15
the O 0 9.31011499414236e-16
episode O 0 2.3498023526968836e-09
, O 0 5.140771282377858e-15
which O 0 7.926112789165586e-17
is O 0 6.743687749674186e-16
therefore O 0 2.003020738503133e-15
classified O 0 9.367471420773654e-08
as O 0 3.103981362073682e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9998855590820312
fibrillation I-Disease 1 0.9999986886978149
( O 0 1.767445780842536e-07
IVF B-Disease 1 0.9999990463256836
) O 0 1.0609843559272747e-10
. O 0 1.8775653774782963e-12

A O 0 2.2308977581930733e-12
distinct O 0 5.4407701082078916e-14
group O 0 2.1363820949934706e-14
of O 0 1.2852119000116013e-14
IVF B-Disease 1 1.0
patients O 0 3.67705377257721e-09
has O 0 3.3455998930433106e-14
been O 0 2.084361735944437e-15
found O 0 1.1597287969636761e-14
to O 0 7.41831539908611e-15
present O 0 2.398822785375232e-13
with O 0 3.701991038479631e-14
a O 0 1.3409622533471638e-13
characteristic O 0 7.989273305419875e-12
electrocardiographic O 0 8.427801390098466e-07
pattern O 0 8.880688184831342e-09
. O 0 2.0524424174106493e-11

Because O 0 2.253572762428435e-12
of O 0 4.3914644834803365e-17
the O 0 3.84695067682689e-18
small O 0 1.1180681379035075e-16
size O 0 1.2836587803995159e-14
of O 0 2.9174670130912637e-17
most O 0 3.4886105429896507e-16
pedigrees O 0 5.0307817807404565e-12
and O 0 4.160932462840029e-15
the O 0 5.120411773464527e-17
high O 0 7.34783622835522e-11
incidence O 0 4.799274866407188e-10
of O 0 6.984941325425403e-14
sudden B-Disease 0 7.496533255269e-11
death I-Disease 0 6.20493031955327e-11
, O 0 2.1826360231441862e-14
however O 0 6.37454629139823e-17
, O 0 2.4926992116527163e-19
molecular O 0 1.1786290083987198e-16
genetic O 0 6.020534683856896e-14
studies O 0 3.466235680643984e-14
of O 0 4.3950913329766916e-14
IVF B-Disease 1 1.0
have O 0 5.570432448642748e-10
not O 0 4.036454194977432e-15
yet O 0 1.7159962551393723e-14
been O 0 7.776026459023477e-13
done O 0 9.65304156053115e-11
. O 0 1.220660291595399e-12

Because O 0 1.4372604217882667e-09
IVF B-Disease 1 0.9999984502792358
causes O 0 4.558873570204014e-06
cardiac O 0 0.0001032258733175695
rhythm O 0 1.2799997648471617e-06
disturbance O 0 4.725520419412987e-09
, O 0 1.5091694547326236e-16
we O 0 8.833553082193408e-17
investigated O 0 2.434488395109454e-14
whether O 0 2.2472938173047222e-15
malfunction O 0 5.345881289725574e-12
of O 0 4.7209224150902044e-18
ion O 0 4.3985465497751314e-14
channels O 0 7.744984098501106e-10
could O 0 7.949338964863273e-09
cause O 0 4.437244842392385e-12
the O 0 8.292924859190989e-14
disorder O 0 4.0893902847338737e-11
by O 0 3.689680739817349e-19
studying O 0 1.4826935659057947e-14
mutations O 0 8.128171529939165e-13
in O 0 9.892166256993462e-17
the O 0 8.618861464404373e-16
cardiac O 0 5.2271858716479436e-12
sodium O 0 9.193606162818946e-14
channel O 0 1.785324249548026e-10
gene O 0 1.6589410734013654e-08
SCN5A O 0 0.0005799112841486931
. O 0 1.024364794377508e-11

We O 0 5.139581649160618e-09
have O 0 2.432076350207535e-13
now O 0 1.26658081741368e-14
identified O 0 2.843958860185465e-14
a O 0 1.7328880614592254e-15
missense O 0 2.502172247176304e-09
mutation O 0 3.0005425227797033e-11
, O 0 4.661994696909192e-16
a O 0 9.45312168420967e-16
splice O 0 0.000370177993318066
- O 0 0.0020550955086946487
donor O 0 8.054296785076076e-09
mutation O 0 1.3573361323793165e-09
, O 0 1.030293201014637e-13
and O 0 2.1002459753977076e-14
a O 0 2.6175687644827824e-15
frameshift O 0 1.3641282547993683e-09
mutation O 0 1.6978669989051176e-12
in O 0 5.1118246460894913e-17
the O 0 2.617157900563805e-16
coding O 0 6.276739978466894e-12
region O 0 1.5324818237322235e-13
of O 0 1.2600020607431216e-15
SCN5A O 0 1.991212172924861e-07
in O 0 9.408080707239423e-16
three O 0 9.057691662678335e-13
IVF B-Disease 1 0.9999966621398926
families O 0 1.8601845324511812e-12
. O 0 5.478842883934257e-14

We O 0 9.847050258526835e-12
show O 0 4.3268299641970043e-13
that O 0 1.0317934977992472e-17
sodium O 0 3.604641351269281e-16
channels O 0 4.8458263633309115e-14
with O 0 4.2180477885942684e-16
the O 0 2.0205554057722608e-16
missense O 0 7.809064506147934e-10
mutation O 0 3.0131927768878297e-12
recover O 0 7.435874832539824e-13
from O 0 2.1138515850497897e-16
inactivation O 0 6.127087032181677e-11
more O 0 6.351989200171001e-19
rapidly O 0 9.276648722396342e-16
than O 0 1.8229135024202707e-17
normal O 0 6.573388069859565e-16
and O 0 2.0907166006312126e-15
that O 0 1.5119412377036153e-16
the O 0 1.804153707872058e-15
frameshift O 0 3.03020519787367e-09
mutation O 0 2.314807416928244e-12
causes O 0 1.438232975911006e-14
the O 0 7.52309517460648e-17
sodium O 0 4.5708869225421014e-14
channel O 0 3.812557908267067e-12
to O 0 7.282030881072821e-13
be O 0 1.945733796304694e-09
non O 0 1.1719897941020463e-07
- O 0 1.2039979679911994e-08
functional O 0 3.5805164388946764e-11
. O 0 5.772703278936198e-13

Our O 0 7.041830313303521e-11
results O 0 3.1506682028961674e-13
indicate O 0 4.257236720811054e-14
that O 0 5.115218733578919e-17
mutations O 0 2.4680024733950146e-13
in O 0 3.493298340957111e-16
cardiac O 0 1.1163278634818141e-11
ion O 0 7.599923836955347e-13
- O 0 3.0789575333756147e-09
channel O 0 2.637998153254273e-11
genes O 0 4.0980687268134253e-13
contribute O 0 1.2326842952821047e-15
to O 0 1.9699721532617856e-17
the O 0 3.282851946420596e-16
risk O 0 4.846716561077158e-13
of O 0 6.16067708966142e-17
developing O 0 7.732282696071291e-12
IVF B-Disease 1 0.9912108182907104
. O 0 2.1803132046929307e-15
. O 0 9.577518425151095e-15

Molecular O 0 6.101131266866844e-10
heterogeneity O 0 2.6730453406287324e-09
in O 0 7.941322295937359e-13
mucopolysaccharidosis B-Disease 0 3.447913513809908e-06
IVA I-Disease 0 0.02469979040324688
in O 0 3.070802293003716e-11
Australia O 0 1.4685768974231905e-06
and O 0 5.502015509861735e-11
Northern O 0 1.2193205646549021e-11
Ireland O 0 2.964905299052134e-08
: O 0 5.385362951446733e-16
nine O 0 5.008081771245459e-16
novel O 0 6.206728788695978e-15
mutations O 0 1.5830228566795362e-13
including O 0 1.5006224158387949e-15
T312S O 0 1.3002687034718852e-12
, O 0 1.0423959680187069e-17
a O 0 7.89545218170845e-17
common O 0 7.918897471353298e-15
allele O 0 2.0604417965645189e-13
that O 0 2.775786599271829e-13
confers O 0 7.711974808755073e-11
a O 0 6.671192764873268e-11
mild O 0 8.08067170510185e-07
phenotype O 0 1.5419171495167916e-09
. O 0 3.3488014878485517e-12

Mucopolysaccharidosis B-Disease 0 0.04476490244269371
IVA I-Disease 1 0.9988570213317871
( O 0 6.759959069313481e-05
MPS B-Disease 1 0.9999996423721313
IVA I-Disease 1 0.9999998807907104
) O 0 1.3216938654636579e-10
is O 0 5.9876392038971105e-12
an O 0 1.5158607008514124e-11
autosomal B-Disease 1 0.999998927116394
recessive I-Disease 1 0.9999990463256836
lysosomal I-Disease 1 0.9999992847442627
storage I-Disease 1 0.999997615814209
disorder I-Disease 1 0.9999990463256836
caused O 0 2.2877484628924805e-11
by O 0 6.067458466838124e-16
a O 0 3.194991797170199e-12
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 2.2996898439361924e-13
N O 0 3.130740537926613e-07
- O 0 1.3262412323911121e-07
acetylgalactosamine O 0 8.799257921054959e-05
- O 0 4.7186330220938544e-07
6 O 0 5.5949151978040845e-09
- O 0 1.0343972007831326e-06
sulfate O 0 3.004641868642466e-08
sulfatase O 0 1.0892972568399273e-06
( O 0 1.3473692105601953e-13
GALNS O 0 1.5521125718009898e-08
) O 0 5.449473541147519e-14
. O 0 8.211706596823742e-14

Previous O 0 1.3454855285477407e-11
studies O 0 2.5990941712218663e-13
of O 0 1.1757684193171644e-16
patients O 0 4.864511910147341e-15
from O 0 2.2691374073509815e-17
a O 0 7.085957797088593e-14
British O 0 9.220299398293719e-05
- O 0 0.09467287361621857
Irish O 0 1.397383584844647e-06
population O 0 2.721729363153874e-13
showed O 0 1.992109949222609e-10
that O 0 1.4597781694848373e-15
the O 0 3.54534639798352e-16
I113F O 0 7.321486082331741e-13
mutation O 0 1.197688282033346e-15
is O 0 2.840820788404345e-17
the O 0 9.407025696270755e-19
most O 0 6.464389603732003e-18
common O 0 4.748090302041672e-16
single O 0 2.1712115612360083e-12
mutation O 0 3.176851670616543e-09
among O 0 3.701854609516886e-07
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 0.00011623102182056755
and O 0 1.4547993885949406e-12
produces O 0 4.237961370723298e-11
a O 0 7.693683190534983e-11
severe O 0 4.7514349716948345e-06
clinical O 0 3.4331371523421694e-08
phenotype O 0 7.762882781037206e-09
. O 0 1.5536799277682256e-11

We O 0 2.9365762599375955e-10
studied O 0 8.502785281416791e-12
mutations O 0 5.559695499118833e-12
in O 0 6.993222464795221e-17
the O 0 7.754057236521086e-18
GALNS O 0 2.801657239537292e-10
gene O 0 5.592809811734607e-14
from O 0 4.724152092161081e-16
23 O 0 4.0416200117535106e-13
additional O 0 2.5981355955551066e-11
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
patients O 0 4.942303277744031e-08
( O 0 3.6235839196456434e-16
15 O 0 1.1606045443278423e-15
from O 0 8.134382653134792e-15
Australia O 0 9.249909727060412e-10
, O 0 1.5322338971885622e-16
8 O 0 1.3473831442521777e-15
from O 0 8.00252535187307e-16
Northern O 0 2.753792636631114e-12
Ireland O 0 4.5416288507738045e-09
) O 0 6.079970202260254e-16
, O 0 1.486303353643963e-18
with O 0 2.70610028086161e-18
various O 0 1.221021710389597e-15
clinical O 0 6.89991896951625e-10
phenotypes O 0 7.002800422872824e-11
( O 0 1.5950287965416088e-12
severe O 0 1.0391095095485525e-08
, O 0 1.20637812009417e-14
16 O 0 2.152235773498004e-13
cases O 0 1.9926199362405028e-13
; O 0 3.6517255305269834e-16
intermediate O 0 3.503365674818737e-13
, O 0 1.3486231581353106e-14
4 O 0 9.79777240242563e-13
cases O 0 1.693881368503014e-09
; O 0 5.5348760297224686e-11
mild O 0 2.6850701217995265e-08
, O 0 1.2498492061999763e-14
3 O 0 1.209853614861367e-13
cases O 0 4.706947071692058e-12
) O 0 1.1029008652532757e-12
. O 0 1.7620540443408217e-12

We O 0 1.646858482917679e-10
found O 0 8.500154248004821e-13
two O 0 1.956598250795914e-15
common O 0 3.3884970719757048e-15
mutations O 0 6.271085674402002e-14
that O 0 3.689222090915155e-16
together O 0 2.3772045733261825e-14
accounted O 0 8.56458015618955e-10
for O 0 1.8035044147663402e-14
32 O 0 3.795652160631935e-12
% O 0 6.402328310323681e-17
of O 0 7.930494033998034e-18
the O 0 1.453416719116897e-14
44 O 0 7.022857230649937e-13
unrelated O 0 3.2513366456619897e-14
alleles O 0 5.27810454576446e-14
in O 0 3.833682501278192e-16
these O 0 3.126016765863e-14
patients O 0 4.110515638804102e-13
. O 0 4.6821213220546096e-14

One O 0 2.4622578281841e-12
is O 0 4.1658344119123794e-14
the O 0 1.752880156596795e-15
T312S O 0 2.2575381564138297e-09
mutation O 0 6.038887445658503e-11
, O 0 3.252710278992552e-16
a O 0 2.3044226161767785e-17
novel O 0 1.7772963005827092e-13
mutation O 0 1.6288071152253947e-12
found O 0 4.580399441352946e-14
exclusively O 0 4.4642721051986467e-13
in O 0 6.6334949042252695e-15
milder O 0 2.8445396038634385e-10
patients O 0 3.37730104299494e-12
. O 0 1.8395709760164747e-13

The O 0 2.9895014821935614e-14
other O 0 3.408265232777844e-16
is O 0 9.778005406293794e-16
the O 0 3.145173953859351e-17
previously O 0 2.8857864015074952e-11
described O 0 8.705049485066563e-13
I113F O 0 9.303282103023669e-12
that O 0 1.0882005650432388e-16
produces O 0 1.9069643054318158e-13
a O 0 3.7413683804700393e-13
severe O 0 8.113674176968289e-09
phenotype O 0 9.590608168741355e-11
. O 0 1.561784447427772e-12

The O 0 3.6863928251119893e-13
I113F O 0 6.474904501452272e-10
and O 0 7.421004728693642e-15
T312S O 0 1.7341338868354095e-12
mutations O 0 1.0787087233654277e-13
accounted O 0 8.948449620183041e-12
for O 0 4.089678357251103e-15
8 O 0 3.664557372828892e-12
( O 0 1.3283523256306233e-15
18 O 0 6.78573462611215e-13
% O 0 3.212043234578138e-17
) O 0 1.4838688452959337e-16
and O 0 4.3739523721691986e-13
6 O 0 2.835122761557507e-12
( O 0 2.8974381911344967e-16
14 O 0 1.9375109562526013e-14
% O 0 1.438729404881471e-18
) O 0 7.432859902739448e-19
of O 0 1.843472083928541e-18
44 O 0 8.107493592224204e-15
unrelated O 0 1.691094333523043e-14
alleles O 0 1.7666568891388373e-13
, O 0 5.455609447817429e-14
respectively O 0 1.0960315120767117e-11
. O 0 2.5103714679924893e-12

The O 0 5.2601555787989626e-14
relatively O 0 1.561723264543926e-14
high O 0 5.470025040560378e-12
residual O 0 1.4511924995019854e-10
GALNS O 0 1.431505438631575e-07
activity O 0 6.701119693863777e-12
seen O 0 4.415764086850016e-13
when O 0 2.989926248040786e-16
the O 0 5.558681840497173e-18
T312S O 0 1.6196293167302506e-14
mutant O 0 2.8999053863516117e-15
cDNA O 0 2.3783465431456707e-15
is O 0 1.9444913177132326e-16
overexpressed O 0 9.427536008799198e-12
in O 0 2.6528296012590112e-17
mutant O 0 4.9067698688898265e-12
cells O 0 3.338687934787126e-15
provides O 0 2.132803111792186e-18
an O 0 1.1098141399425897e-19
explanation O 0 4.620544874937507e-17
for O 0 5.131151952712364e-15
the O 0 3.572506223140093e-12
mild O 0 5.7247113716130116e-09
phenotype O 0 6.7611658459421076e-12
in O 0 8.349800389917861e-16
patients O 0 2.7746349309250946e-15
with O 0 4.43839970405333e-18
this O 0 3.9924084023108694e-17
mutation O 0 2.570100555987498e-11
. O 0 6.024181587599431e-12

The O 0 1.5734427912263128e-15
distribution O 0 4.540073727393474e-15
and O 0 8.935532540320376e-17
relative O 0 2.2204391753794228e-18
frequencies O 0 3.279483269919586e-17
of O 0 5.0479714313201954e-18
the O 0 7.306422558512053e-16
I113F O 0 9.652097697487871e-12
and O 0 1.1485061609839723e-15
T312S O 0 1.7533968255187965e-13
mutations O 0 2.6529549634586938e-14
in O 0 5.0373750822372686e-17
Australia O 0 1.0859319492890693e-13
corresponded O 0 4.9670213859061635e-17
to O 0 7.525474146048182e-18
those O 0 4.1896158042306977e-16
observed O 0 4.8529485551646045e-14
in O 0 1.1033079323470672e-14
Northern O 0 3.264415820991573e-11
Ireland O 0 1.0297853236806986e-07
and O 0 1.519501321642358e-12
are O 0 1.2703343539221867e-16
unique O 0 8.759285373998855e-19
to O 0 7.803284409135341e-18
these O 0 1.2066070360421214e-16
two O 0 1.5834781199480265e-14
populations O 0 5.5158743173552675e-15
, O 0 4.665299481979689e-18
suggesting O 0 2.519712318635914e-15
that O 0 8.688746976508773e-16
both O 0 7.488429398328032e-15
mutations O 0 1.1066853813565536e-12
were O 0 1.1322033263184983e-13
probably O 0 3.3973905367570487e-14
introduced O 0 2.1298368342408114e-13
to O 0 4.1169969993912203e-13
Australia O 0 1.2188899667364694e-08
by O 0 5.9350768521820516e-15
Irish O 0 4.758915039815292e-09
migrants O 0 1.3525659542032442e-12
during O 0 1.2302234528120942e-14
the O 0 2.117573262531568e-15
19th O 0 2.368951172379563e-12
century O 0 6.742573860352152e-11
. O 0 7.211270469653641e-11

Haplotype O 0 8.494466463560002e-09
analysis O 0 7.574396296804176e-13
using O 0 4.790598256629308e-13
6 O 0 6.511085507560077e-12
RFLPs O 0 2.6935245700521193e-11
provides O 0 2.7607289263322247e-16
additional O 0 1.8169708714635672e-17
data O 0 7.93725843514434e-14
that O 0 1.5949503341856387e-15
the O 0 1.1927640559944832e-15
I113F O 0 4.794469335434037e-11
mutation O 0 1.060618539066964e-13
originated O 0 9.402596804180662e-15
from O 0 4.0709668700506635e-16
a O 0 5.578825805995207e-16
common O 0 4.941795196254824e-15
ancestor O 0 1.152321402360379e-12
. O 0 2.9111099381778915e-12

The O 0 1.0282514450359395e-13
other O 0 2.3713165931999337e-15
9 O 0 1.9302959296078892e-14
novel O 0 4.6372542409484335e-15
mutations O 0 1.0324340124143183e-12
identified O 0 2.770678434946272e-12
in O 0 3.360380210338292e-17
these O 0 2.6642311742723114e-15
23 O 0 7.195796042358538e-12
patients O 0 7.239507590953674e-15
were O 0 1.1214474817256969e-15
each O 0 3.3258742321193e-15
limited O 0 2.888261190544389e-13
to O 0 9.417529148007808e-15
a O 0 4.1145006238890725e-13
single O 0 1.8590389672112906e-08
family O 0 4.545093190699845e-10
. O 0 7.768203615088343e-12

These O 0 1.2688966478431206e-15
data O 0 2.6480413253316716e-14
provide O 0 9.032554208727946e-17
further O 0 1.7405845469251128e-17
evidence O 0 1.410371267067086e-15
for O 0 6.352213738348278e-17
extensive O 0 2.558062268953609e-13
allelic O 0 4.4311518343498335e-10
heterogeneity O 0 6.656807882698956e-10
in O 0 1.3214618288515112e-10
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 0.9999998807907104
in O 0 1.765514123786005e-10
British O 0 8.562480797991157e-05
- O 0 0.2559581995010376
Irish O 0 2.8714277959807077e-06
patients O 0 1.1076405417864699e-11
and O 0 1.7245178870152503e-17
provide O 0 1.664376831360424e-19
evidence O 0 6.661454631324799e-18
for O 0 1.5926862250437953e-18
their O 0 3.479398596467117e-17
transmission O 0 9.938217783445058e-13
to O 0 7.905764013747883e-16
Australia O 0 4.328540997855512e-12
by O 0 1.7941472841496693e-15
British O 0 1.1077862893671409e-07
- O 0 5.919958994127228e-07
Irish O 0 4.811669729321011e-09
migrants O 0 3.454991718068734e-12
. O 0 1.4958329739176639e-15
. O 0 1.307497675667041e-13

Identification O 0 3.354510245967557e-12
of O 0 4.750151620246286e-14
constitutional O 0 1.4040451960795064e-11
WT1 O 0 7.108938007149845e-07
mutations O 0 1.675610206142153e-09
, O 0 1.0484747462867917e-15
in O 0 4.0210513508178656e-17
patients O 0 7.880354931154385e-15
with O 0 2.0062858387565616e-15
isolated O 0 3.1725160276607767e-09
diffuse B-Disease 0 9.317435615230352e-05
mesangial I-Disease 1 0.9999998807907104
sclerosis I-Disease 1 1.0
, O 0 8.42345466924195e-14
and O 0 2.3460845603447468e-17
analysis O 0 3.3084736342838547e-16
of O 0 2.606727378032638e-15
genotype O 0 1.0503354852531288e-09
/ O 0 4.351015263637237e-07
phenotype O 0 5.2886032358978596e-11
correlations O 0 3.291647553485544e-13
by O 0 9.728257440765875e-17
use O 0 1.6806759976784047e-14
of O 0 1.407237509860041e-16
a O 0 1.2823463663752164e-15
computerized O 0 1.404742988597718e-09
mutation O 0 2.164438767104926e-12
database O 0 7.483622610493512e-10
. O 0 7.372821103635019e-12

Constitutional O 0 1.34124322759277e-10
mutations O 0 2.0821053214881147e-11
of O 0 1.775186372216043e-16
the O 0 6.387618392054528e-17
WT1 O 0 4.173819900810116e-10
gene O 0 5.605649408199631e-13
, O 0 9.680164663643674e-18
encoding O 0 1.4853470501377904e-16
a O 0 3.044855424109809e-14
zinc O 0 8.808132406556979e-05
- O 0 1.8195424900113721e-07
finger O 0 2.1782898329547606e-05
transcription O 0 3.7780031880707554e-10
factor O 0 1.4015614840587332e-12
involved O 0 1.2838118155361622e-12
in O 0 8.937216065948647e-14
renal O 0 2.651752311066957e-06
and O 0 7.985651029329688e-11
gonadal O 0 0.0011210553348064423
development O 0 1.4894409490484595e-12
, O 0 3.983495101076692e-16
are O 0 4.560323231211503e-18
found O 0 2.832706345118547e-16
in O 0 1.7285618075938996e-17
most O 0 7.5229595434558e-15
patients O 0 4.2070150531661743e-13
with O 0 2.6180035569978166e-11
Denys B-Disease 1 0.999992847442627
- I-Disease 1 0.9999998807907104
Drash I-Disease 1 0.9999985694885254
syndrome I-Disease 1 0.9999997615814209
( O 0 5.083325982369047e-10
DDS B-Disease 1 0.9999998807907104
) O 0 2.0510637459281167e-12
, O 0 1.598525872014236e-15
or O 0 5.147196037447177e-12
diffuse B-Disease 0 0.00013537611812353134
mesangial I-Disease 1 0.9999997615814209
sclerosis I-Disease 1 1.0
( O 0 7.367125576251965e-09
DMS B-Disease 0 0.04346850514411926
) O 0 9.977071659074063e-14
associated O 0 1.346706356456992e-13
with O 0 7.071333102404154e-11
pseudohermaphroditism B-Disease 1 1.0
and O 0 2.0444515484996373e-06
/ O 0 3.851372457575053e-05
or O 0 1.307047181597909e-08
Wilms B-Disease 0 0.45476746559143066
tumor I-Disease 0 0.0013143615797162056
( O 0 1.1737223415408948e-09
WT B-Disease 1 0.9999991655349731
) O 0 3.3672604635159864e-12
. O 0 1.8156373485841287e-13

Most O 0 3.5122507116222557e-13
mutations O 0 1.450693076776588e-08
in O 0 1.3456190155192171e-11
DDS B-Disease 1 1.0
patients O 0 2.954923729703296e-06
lie O 0 3.5796443587088334e-10
in O 0 2.80853064837537e-15
exon O 0 1.7542224617361768e-10
8 O 0 1.6036587205739417e-12
or O 0 2.647312749942091e-15
exon O 0 2.981255173284403e-11
9 O 0 2.6796568436404655e-12
, O 0 6.307590983895738e-17
encoding O 0 4.367472976698518e-14
zinc O 0 0.003863356076180935
finger O 1 0.9540289044380188
2 O 0 1.272094429793924e-09
or O 0 2.2629215168379346e-10
zinc O 0 0.00841475185006857
finger O 1 0.7206132411956787
3 O 0 1.6283188131183124e-09
, O 0 1.1010506742459292e-13
respectively O 0 7.0628919379700505e-12
, O 0 2.7817991355929715e-15
with O 0 7.22477514690208e-15
a O 0 1.4830569498164303e-12
hot O 0 2.784256594168255e-06
spot O 0 8.48830552513391e-07
( O 0 6.355159454241033e-13
R394W O 0 4.859242782456752e-12
) O 0 1.1934279974762325e-16
in O 0 2.720924598209479e-17
exon O 0 3.274811671838407e-11
9 O 0 1.5479599546619482e-10
. O 0 9.350848003894519e-13

We O 0 4.639809370043935e-12
analyzed O 0 4.2959190892088994e-13
a O 0 1.7474589339761307e-15
series O 0 1.222225879532468e-12
of O 0 2.9654602307549374e-15
24 O 0 3.085784449144424e-12
patients O 0 1.2865848133641585e-15
, O 0 3.945260679038511e-18
10 O 0 2.3971908557001516e-16
with O 0 7.523594648759652e-14
isolated B-Disease 0 8.911709414860525e-08
DMS I-Disease 1 0.9473845362663269
( O 0 1.5367971652191503e-12
IDMS B-Disease 0 5.899308916923474e-07
) O 0 7.819388040709863e-15
, O 0 6.300520905764125e-17
10 O 0 4.649902136916835e-15
with O 0 3.0364374209446154e-12
DDS B-Disease 1 1.0
, O 0 4.7832619809451415e-11
and O 0 6.329010666245027e-12
4 O 0 4.0461726850959945e-12
with O 0 7.552922870468493e-11
urogenital B-Disease 1 0.9756577610969543
abnormalities I-Disease 1 0.9997226595878601
and O 0 5.219987775362256e-10
/ O 0 3.648841811809689e-05
or O 0 4.064304164330679e-07
WT B-Disease 1 0.9999997615814209
. O 0 1.169752628094045e-10

We O 0 5.972862759939801e-10
report O 0 4.679467924262326e-11
WT1 O 0 4.2716672510323406e-07
heterozygous O 0 1.6484504428149194e-08
mutations O 0 7.030172555211323e-10
in O 0 1.823431034257087e-14
16 O 0 3.802985704126627e-12
patients O 0 2.9188741809856034e-14
, O 0 2.0605634850234906e-17
4 O 0 5.65512949849919e-15
of O 0 9.03014625287758e-16
whom O 0 1.1602051541714786e-09
presented O 0 8.602263346091377e-11
with O 0 1.8623518005522754e-10
IDMS B-Disease 0 0.03137799724936485
. O 0 2.0078022577862953e-11

One O 0 8.670492102069716e-11
male O 0 6.880170655421125e-09
and O 0 7.594818599975656e-14
two O 0 2.6593042546686763e-13
female O 0 1.5563992761258305e-08
IDMS B-Disease 0 0.004697517957538366
patients O 0 1.383396452947494e-10
with O 0 5.075886542679764e-13
WT1 O 0 0.10518088936805725
mutations O 0 0.004032686352729797
underwent O 0 4.029971478303196e-06
normal O 0 4.583140267300223e-08
puberty O 0 6.81266319588758e-05
. O 0 2.296439600979472e-11

Two O 0 1.3830561695904464e-10
mutations O 0 3.6364632194363367e-08
associated O 0 8.015954219842136e-12
with O 0 6.84414981286241e-13
IDMS B-Disease 0 0.0031652539037168026
are O 0 1.810946615647506e-14
different O 0 4.149624334766168e-18
from O 0 3.5522642748824233e-16
those O 0 3.808743363151743e-15
described O 0 1.664278090340865e-12
in O 0 1.83805683347249e-12
DDS B-Disease 1 1.0
patients O 0 1.0270584382965353e-08
. O 0 4.490112979777666e-13

No O 0 1.4421695782029786e-10
WT1 O 0 1.1961169548158068e-06
mutations O 0 5.348122833481739e-09
were O 0 1.1060327865164074e-13
detected O 0 2.7755828885256406e-11
in O 0 3.26550193233397e-17
the O 0 2.241316941070659e-16
six O 0 1.4333605483085599e-11
other O 0 3.6157191064985217e-13
IDMS B-Disease 0 0.007154668681323528
patients O 0 2.7231741167588197e-12
, O 0 3.1221607552423603e-18
suggesting O 0 5.558647787125715e-15
genetic O 0 1.0971790967082007e-12
heterogeneity O 0 4.497778018086596e-12
of O 0 9.56988496423044e-15
this O 0 9.52179090782379e-13
disease O 0 3.3578151487745345e-05
. O 0 7.23819311779228e-12

We O 0 1.331406512816713e-11
analyzed O 0 1.8490083075750618e-10
genotype O 0 8.181366695225734e-09
/ O 0 2.7444448846836167e-07
phenotype O 0 7.469671409188194e-11
correlations O 0 2.244779362392535e-11
, O 0 4.518663487343964e-16
on O 0 3.20831156475456e-15
the O 0 1.7985720585346727e-17
basis O 0 6.259013167914671e-15
of O 0 2.1552230564738539e-16
the O 0 9.078199617821442e-14
constitution O 0 1.0783971805816694e-11
of O 0 4.959029249545737e-18
a O 0 7.802515462037912e-17
WT1 O 0 3.1251511795060694e-11
mutation O 0 2.346677675313727e-15
database O 0 6.099908447278202e-14
of O 0 5.900151989700862e-16
84 O 0 1.6100835942278735e-11
germ O 0 6.486458460130962e-06
- O 0 1.0396256584499497e-05
line O 0 4.2120515075794174e-08
mutations O 0 8.934942195837348e-12
, O 0 3.8239070793223874e-18
to O 0 8.810621236789662e-20
compare O 0 3.431710787120488e-15
the O 0 9.88171383733712e-18
distribution O 0 8.683785841009234e-14
and O 0 7.337475082819928e-14
type O 0 1.3402502198334165e-11
of O 0 1.9801369787627557e-16
mutations O 0 3.3560045069542035e-14
, O 0 6.485631188272059e-18
according O 0 1.2039389442968163e-18
to O 0 2.3189477753843117e-16
the O 0 2.9843925182689024e-13
different O 0 1.4145290494482765e-10
symptoms O 0 4.575460454958602e-09
. O 0 1.631856067917277e-14

This O 0 2.9974051127430734e-13
demonstrated O 0 9.520864999168488e-13
( O 0 9.523193543562467e-16
1 O 0 5.839025857062256e-16
) O 0 1.4662680300475813e-16
the O 0 5.756487790308244e-16
association O 0 9.521477708921214e-14
between O 0 5.468587432525375e-15
mutations O 0 4.9541096051874955e-12
in O 0 3.4329154797297203e-15
exons O 0 5.573102868083879e-09
8 O 0 3.985739863154869e-11
and O 0 1.0216365513987524e-12
9 O 0 4.2014521202393684e-12
and O 0 1.7809757574954732e-12
DMS B-Disease 0 4.237392204231583e-06
; O 0 4.02969836606925e-16
( O 0 4.391967078420524e-17
2 O 0 4.821556116534997e-16
) O 0 2.0292762717087339e-16
among O 0 2.1989492000819462e-14
patients O 0 1.1977207657468732e-14
with O 0 9.449700306377474e-15
DMS B-Disease 0 9.233239325112663e-06
, O 0 1.2846266287000617e-17
a O 0 3.4651842834619753e-18
higher O 0 4.786005614343142e-16
frequency O 0 4.3582541745030675e-17
of O 0 4.855682213712036e-17
exon O 0 4.464512960711264e-12
8 O 0 8.641932249019504e-14
mutations O 0 1.3244804829715823e-13
among O 0 2.1823697159855694e-14
46 O 0 4.3687683679016764e-12
, O 0 2.7672532505480102e-14
XY O 0 4.3629563151625916e-05
patients O 0 4.444953519838757e-12
with O 0 5.58613315923117e-15
female O 0 1.6252452508802584e-11
phenotype O 0 2.853859658899331e-14
than O 0 3.03616498253801e-16
among O 0 3.6146551653541345e-14
46 O 0 3.77669007178838e-11
, O 0 2.2951370079633826e-13
XY O 0 8.337994950124994e-05
patients O 0 1.2981531648248446e-11
with O 0 1.7720623823576712e-14
sexual O 0 2.714745983567468e-09
ambiguity O 0 1.1947799694045358e-10
or O 0 2.1694739754662962e-11
male O 0 7.009566260762767e-10
phenotype O 0 1.0454536542026105e-11
; O 0 5.287916575425454e-15
and O 0 1.101500726567728e-12
( O 0 1.1180606204861006e-14
3 O 0 1.307534352193657e-14
) O 0 3.291489961946916e-17
statistically O 0 1.5050251872195043e-15
significant O 0 5.135614228157618e-16
evidence O 0 4.722756040409504e-12
that O 0 4.1840185829866705e-12
mutations O 0 3.024797426420811e-11
in O 0 3.213088195302364e-15
exons O 0 1.0175256193178939e-08
8 O 0 1.1991901395502769e-11
and O 0 5.164242650049569e-14
9 O 0 1.682620378749486e-13
preferentially O 0 1.1129385173863637e-12
affect O 0 2.429785973118159e-13
amino O 0 2.1056527561066213e-14
acids O 0 6.059716395117806e-14
with O 0 3.2588315478743424e-17
different O 0 5.6505493465079246e-18
functions O 0 1.5752444303051226e-15
. O 0 5.367133637751518e-15
. O 0 9.599181258895806e-13

The O 0 5.828926230577736e-11
185delAG O 0 4.299120519135613e-06
BRCA1 O 0 3.4163410873588873e-06
mutation O 0 1.1245254727398901e-11
originated O 0 5.276735740521697e-14
before O 0 6.611285912106499e-16
the O 0 9.878694421306148e-19
dispersion O 0 9.24514184961556e-15
of O 0 1.5334436322908087e-17
Jews O 0 3.2729626250031655e-15
in O 0 8.385134898708166e-16
the O 0 4.090047324802927e-14
diaspora O 0 6.4894378933033625e-12
and O 0 1.0900974133781771e-12
is O 0 1.43644556698571e-14
not O 0 2.738337239794643e-15
limited O 0 2.2594839343167798e-14
to O 0 6.440023346413262e-14
Ashkenazim O 0 2.3834326157157193e-07
. O 0 1.2722962874217592e-12

The O 0 9.7683146293992e-12
185delAG O 0 2.079434011648118e-07
mutation O 0 3.8577971372966147e-10
in O 0 9.224392083506672e-15
BRCA1 O 0 7.299194493270988e-08
is O 0 2.6278014052943943e-13
detected O 0 1.3521552766349032e-09
in O 0 1.7007004918262068e-15
Ashkenazi O 0 1.1050955289748643e-11
Jews O 0 2.86719233865394e-15
both O 0 2.6286120835875525e-14
in O 0 3.7276350626017085e-13
familial B-Disease 1 0.9895073771476746
breast I-Disease 1 0.9999997615814209
and I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.4244253271632488e-09
in O 0 2.249616805162567e-16
the O 0 9.631738698170737e-16
general O 0 4.1218680487016546e-13
population O 0 2.6415527141425248e-15
. O 0 7.030573361986245e-14

All O 0 4.642928055909046e-11
tested O 0 5.611851747744367e-07
Ashkenazi O 0 1.6791412704719733e-10
mutation O 0 7.705292025088351e-13
carriers O 0 2.8425840240681177e-12
share O 0 3.475941661779981e-14
the O 0 1.189768682795196e-16
same O 0 1.1335986775738282e-14
allelic O 0 6.821298387249541e-11
pattern O 0 2.32119851117929e-10
at O 0 2.2399111645338143e-12
the O 0 1.5780059482955848e-14
BRCA1 O 0 4.3446789277368225e-08
locus O 0 5.7922591167880455e-09
. O 0 3.048300153962735e-11

Our O 0 3.0062694954952063e-12
previous O 0 9.837572786551216e-15
study O 0 1.2629279243011747e-15
showed O 0 1.0617004671253927e-11
that O 0 8.568045972665118e-17
this O 0 1.6481741788219547e-15
Ashkenazi O 0 1.5075781734097404e-09
mutation O 0 2.4271702269568207e-12
also O 0 3.6200129265723247e-12
occurs O 0 1.934010846707957e-14
in O 0 3.403769605410292e-16
Iraqi O 0 3.2309658420937026e-11
Jews O 0 5.242324180006544e-15
with O 0 4.088693416752124e-16
a O 0 6.973911304737905e-16
similar O 0 2.104865862498622e-14
allelic O 0 7.358330611495489e-10
pattern O 0 1.2060643150846317e-08
. O 0 2.773386728605054e-11

We O 0 1.165050000917489e-10
extended O 0 6.919699459696088e-14
our O 0 8.816552204499729e-17
analysis O 0 1.0082458164294551e-17
to O 0 2.6718605869710493e-18
other O 0 3.728824057572846e-16
non O 0 4.917146134708617e-10
- O 0 1.4915413348859374e-09
Ashkenazi O 0 1.5692972095415758e-12
subsets O 0 2.5104311668746118e-14
354 O 0 1.9489351267814453e-13
of O 0 1.012084940323326e-15
Moroccan O 0 2.016341087152096e-11
origin O 0 1.4288790216678872e-14
, O 0 4.803051623011043e-16
200 O 0 2.0382135280934508e-16
Yemenites O 0 4.639732348321601e-11
and O 0 8.894460045056913e-15
150 O 0 3.791955593653636e-15
Iranian O 0 6.05981139833317e-13
Jews O 0 9.33367098887583e-13
. O 0 7.303521936535828e-13

Heteroduplex O 0 1.4529976510857523e-07
analysis O 0 3.7388858285455906e-13
complemented O 0 3.1082043406086e-14
by O 0 6.723103265005034e-19
direct O 0 2.427611729672157e-18
DNA O 0 7.515272719459468e-15
sequencing O 0 1.2471066659826974e-13
of O 0 1.4290881541025643e-15
abnormally O 0 3.245053184497415e-11
migrating O 0 5.72428497831734e-13
bands O 0 2.1542862979617716e-12
were O 0 8.105734643605936e-14
employed O 0 8.023204496609981e-12
. O 0 6.647037521095855e-14

Four O 0 1.8425165559943224e-10
of O 0 3.873494203881535e-14
Moroccan O 0 7.584151084927271e-10
origin O 0 2.9129248926146323e-13
( O 0 9.563389915590893e-15
1 O 0 1.7928816051682346e-15
. O 0 5.471691225941911e-17
1 O 0 3.390747003241849e-15
% O 0 2.5418659690629827e-17
) O 0 1.7509401864497867e-17
and O 0 2.275901508065289e-15
none O 0 5.090774739149699e-15
of O 0 8.344378816572617e-18
the O 0 2.048550665242183e-15
Yemenites O 0 6.510765537814933e-11
or O 0 4.045996868161199e-15
Iranians O 0 3.915865841221805e-14
was O 0 5.5854965292680137e-14
a O 0 1.4492850194551326e-16
carrier O 0 1.576836399083334e-13
of O 0 3.103673309910831e-17
the O 0 8.863400193914045e-15
185delAG O 0 3.0197275791010725e-09
mutation O 0 1.3663611041214718e-11
. O 0 4.56351915891634e-13

BRCA1 O 0 0.0017072114860638976
allelic O 0 2.481816174793039e-08
patterns O 0 1.0087808366421314e-09
were O 0 7.821808522059936e-14
determined O 0 5.148425495605721e-15
for O 0 3.532575523419089e-16
four O 0 1.3672140913715321e-14
of O 0 2.1295116360577456e-17
these O 0 1.9274832931790603e-16
individuals O 0 5.636453692561653e-16
and O 0 1.4772954461087667e-15
for O 0 7.687939035798497e-17
12 O 0 3.863707754615548e-15
additional O 0 7.363481704806066e-14
non O 0 4.258492651842971e-07
- O 0 1.1240435924264602e-05
Ashkenazi O 0 4.959553212557921e-09
185delAG O 0 4.2624778706645827e-10
mutation O 0 8.111376154085193e-11
carriers O 0 1.305857755262707e-09
who O 0 3.8461195117633906e-08
had O 0 6.567901891685324e-06
breast B-Disease 1 0.9999616146087646
/ I-Disease 1 0.9999986886978149
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
. O 0 9.078715557109263e-11

Six O 0 1.6802964353246352e-08
non O 0 1.126597680922714e-06
- O 0 5.44880676898174e-05
Ashkenazi O 0 5.4468920041017554e-08
individuals O 0 1.552300903919987e-13
shared O 0 6.020548642959866e-13
the O 0 1.4852807433398882e-14
common O 0 6.562756588168739e-11
Ashkenazi O 0 7.41042893714905e-10
haplotype O 0 5.140602787195858e-12
, O 0 5.494516805106724e-15
four O 0 1.3410006069990155e-13
had O 0 2.096366049503251e-12
a O 0 2.313892014393163e-17
closely O 0 1.30866034697176e-13
related O 0 2.40158001992008e-12
pattern O 0 1.671303512251754e-10
, O 0 2.004921395733477e-14
and O 0 4.294589518532253e-14
the O 0 2.7201385251646474e-15
rest O 0 6.5931782602945965e-12
( O 0 2.0209352312276774e-14
n O 0 4.4726595760380405e-09
= O 0 2.4445403479234074e-09
6 O 0 2.556929390440388e-10
) O 0 2.1431815672742598e-14
displayed O 0 7.32258281788134e-11
a O 0 5.349131510998251e-13
distinct O 0 2.5120875865591863e-11
BRCA1 O 0 7.76299748395104e-06
allelic O 0 6.59297683114346e-08
pattern O 0 1.7102057370266266e-07
. O 0 5.972369820916867e-11

We O 0 1.5170869768765805e-11
conclude O 0 7.180012877652797e-13
that O 0 6.445976844537981e-16
the O 0 2.5579279041171863e-15
185delAG O 0 4.066269525537791e-07
BRCA1 O 0 1.5176036072261923e-07
mutation O 0 3.445936027843266e-12
occurs O 0 2.2542924693830582e-14
in O 0 3.47747267184691e-18
some O 0 1.730667511648439e-16
non O 0 1.491519263652208e-08
- O 0 2.043322865574737e-06
Ashkenazi O 0 3.4507181112530816e-08
populations O 0 3.85740354588715e-12
at O 0 3.986277887640943e-12
rates O 0 1.870497090550316e-10
comparable O 0 1.457078544191831e-13
with O 0 1.77893605472464e-15
that O 0 7.180128887285253e-15
of O 0 4.1763759063475486e-14
Ashkenazim O 0 2.242489500758893e-07
. O 0 1.092441133214439e-12

The O 0 3.968228740394708e-13
majority O 0 3.701039854361182e-13
of O 0 4.525342130374827e-15
Jewish O 0 2.2620056869260274e-11
185delAG O 0 9.068257611488661e-08
mutation O 0 1.01853669942642e-09
carriers O 0 3.091548961275947e-10
have O 0 1.5790710075234624e-15
a O 0 1.4219684716039775e-17
common O 0 7.644660813800825e-16
allelic O 0 1.4549492253351781e-12
pattern O 0 1.1748837146219326e-11
, O 0 3.639362555266215e-16
supporting O 0 8.96730267623512e-14
the O 0 4.8351651566705156e-17
founder O 0 9.571464714558386e-13
effect O 0 6.327533982886102e-13
notion O 0 9.337155208082384e-14
, O 0 4.303621409673002e-16
but O 0 6.596142683545266e-17
dating O 0 5.804911130773138e-13
the O 0 1.6618297263602333e-15
mutations O 0 1.5254011703942638e-13
origin O 0 3.4539176616568907e-16
to O 0 1.5612033504269453e-16
an O 0 8.954748673868922e-16
earlier O 0 5.023233348375178e-13
date O 0 3.566948169123063e-13
than O 0 7.788368000115516e-15
currently O 0 2.100249314740399e-11
estimated O 0 1.047772762649557e-12
. O 0 7.131686300537732e-12

However O 0 1.4171525281395092e-12
, O 0 1.221920332937295e-16
the O 0 3.561595699372634e-18
different O 0 8.381165358210197e-17
allelic O 0 1.4975489598390013e-11
pattern O 0 3.456008743074612e-11
at O 0 2.6323211731009433e-13
the O 0 3.5596435200397844e-16
BRCA1 O 0 6.684417463986847e-10
locus O 0 1.5322671950701583e-11
even O 0 3.5236663847165728e-12
in O 0 1.5494145046857376e-16
some O 0 2.1440297807736843e-16
Jewish O 0 6.129745691065003e-13
mutation O 0 4.993593646224204e-12
carriers O 0 1.8959193590073475e-11
, O 0 1.9626523658468548e-16
might O 0 2.707649405522209e-14
suggest O 0 5.660325181656989e-13
that O 0 4.841182251087706e-13
the O 0 2.0343241116183367e-14
mutation O 0 9.550985219722308e-13
arose O 0 4.835999934109814e-15
independently O 0 7.702010958263866e-14
. O 0 2.861610349179887e-14
. O 0 1.1374485337986573e-12

Crystal O 0 9.78521484285011e-07
structure O 0 3.840441853419918e-10
of O 0 1.0359440796782905e-14
the O 0 4.956185743927588e-13
hemochromatosis B-Disease 1 1.0
protein O 0 1.98379339622079e-07
HFE O 0 1.4054239727556705e-06
and O 0 2.7670999375845572e-14
characterization O 0 6.326472006858153e-13
of O 0 4.7157053869668325e-17
its O 0 7.213009647506481e-17
interaction O 0 7.747087743551959e-16
with O 0 3.574054673906573e-15
transferrin O 0 2.660394127218524e-10
receptor O 0 5.040242095216696e-12
. O 0 2.62068388908257e-13

HFE O 0 6.579238834092394e-05
is O 0 4.6309702600444425e-11
an O 0 2.3852984813569657e-14
MHC O 0 1.1272430766595676e-09
- O 0 8.795281863926974e-11
related O 0 5.420099048400462e-13
protein O 0 4.719854064874629e-13
that O 0 1.628462133952571e-16
is O 0 5.925840513757615e-17
mutated O 0 3.814679691918621e-13
in O 0 4.392689835752548e-16
the O 0 1.1237937663777231e-12
iron B-Disease 1 0.9999783039093018
- I-Disease 1 0.9999948740005493
overload I-Disease 1 0.9995515942573547
disease I-Disease 1 0.999968409538269
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 7.260288157340256e-07

HFE O 0 8.094307872852369e-07
binds O 0 1.3026034417773502e-10
to O 0 4.4205063871524675e-14
transferrin O 0 1.1691487777909515e-09
receptor O 0 4.004049869443804e-11
( O 0 1.2984836188049964e-13
TfR O 0 3.7056192780937636e-08
) O 0 3.6501519021296626e-16
and O 0 1.0012667281652227e-16
reduces O 0 6.442022682981961e-15
its O 0 1.0028372959942772e-17
affinity O 0 5.566223226289484e-15
for O 0 5.899772518940492e-15
iron O 0 1.2113885077269515e-06
- O 0 8.980435950434185e-09
loaded O 0 3.5257625707885154e-09
transferrin O 0 1.8409497537508202e-10
, O 0 3.781958910810141e-15
implicating O 0 2.9749147145707866e-08
HFE O 0 4.512632585829124e-05
in O 0 2.8104584631760687e-12
iron O 0 2.0339175534900278e-05
metabolism O 0 2.460653604430263e-06
. O 0 1.6191437079982052e-11

The O 0 1.4652485821886607e-11
2 O 0 5.45466033452513e-11
. O 0 2.6656994753931906e-12

6 O 0 2.4365816031490795e-08
A O 0 8.340017565444668e-11
crystal O 0 7.739157013020304e-07
structure O 0 1.0333964239883642e-10
of O 0 6.61519941608105e-15
HFE O 0 2.4799192033242434e-07
reveals O 0 5.053114524034008e-11
the O 0 2.019592038143657e-16
locations O 0 3.6661635099272116e-13
of O 0 1.976476030366922e-13
hemochromatosis B-Disease 1 1.0
mutations O 0 1.3030817171966191e-05
and O 0 3.2667685830739535e-12
a O 0 9.391161859392729e-15
patch O 0 1.1139366506540682e-05
of O 0 2.574728421461149e-14
histidines O 0 8.527049999429437e-08
that O 0 5.228025416823944e-15
could O 0 1.1183043965683204e-13
be O 0 1.9440110870898308e-14
involved O 0 5.175239577159818e-13
in O 0 1.4570090197275204e-13
pH O 0 2.362466222649573e-09
- O 0 9.362064595785924e-11
dependent O 0 1.179517421234788e-12
interactions O 0 1.0903261800365716e-12
. O 0 3.3606304588110203e-13

We O 0 1.7791169926173467e-10
also O 0 9.979317990450182e-14
demonstrate O 0 5.78963756819352e-14
that O 0 4.28270429102956e-14
soluble O 0 6.519423578765782e-08
TfR O 0 2.3759670511935838e-05
and O 0 3.775735420933485e-13
HFE O 0 4.3860356413460977e-07
bind O 0 2.901639206687179e-10
tightly O 0 5.539850869706875e-11
at O 0 3.4177892720838043e-12
the O 0 8.183054542712563e-16
basic O 0 2.6425026446522115e-13
pH O 0 1.2322437449759083e-13
of O 0 3.5994963395579895e-19
the O 0 1.477750388828226e-17
cell O 0 2.9478925810816348e-12
surface O 0 5.386427415210449e-10
, O 0 5.465188289308044e-15
but O 0 2.0057807953617612e-15
not O 0 4.1045103276739995e-15
at O 0 9.614316721223704e-13
the O 0 3.0435330362725554e-13
acidic O 0 2.308708335618803e-09
pH O 0 9.988239402236587e-12
of O 0 9.195227680341522e-16
intracellular O 0 2.7598318075305883e-10
vesicles O 0 1.98687044594692e-09
. O 0 2.6947373152341747e-11

TfR O 1 0.8763610124588013
HFE O 0 9.334875358035788e-05
stoichiometry O 0 1.1306851632753023e-07
( O 0 7.803190385513581e-12
2 O 0 2.7915606566793205e-13
1 O 0 6.237513777647462e-15
) O 0 9.963440770782462e-17
differs O 0 5.504901429040062e-15
from O 0 2.438128366734349e-13
TfR O 0 3.0570581657229923e-06
transferrin O 0 1.5991032109585746e-10
stoichiometry O 0 2.3387824663045897e-11
( O 0 2.976091934198989e-14
2 O 0 2.3388636269687166e-14
2 O 0 8.48831875827679e-15
) O 0 4.536885813017364e-16
, O 0 1.640582381334392e-17
implying O 0 1.3521821152939653e-15
a O 0 1.7471762665084866e-18
different O 0 3.673655924906724e-19
mode O 0 1.5387423924761458e-15
of O 0 4.527009772811848e-18
binding O 0 2.909181074750404e-14
for O 0 2.396241172947602e-15
HFE O 0 6.897227677882256e-08
and O 0 1.0401703370160886e-12
transferrin O 0 1.3410998700447152e-10
to O 0 3.1118358757853404e-13
TfR O 0 1.85682420124067e-05
, O 0 1.2222705545912051e-15
consistent O 0 7.671077315030139e-14
with O 0 3.3417567351550284e-16
our O 0 1.9693892106291064e-14
demonstration O 0 6.117079245075057e-15
that O 0 1.2775899852088079e-16
HFE O 0 4.7657180424209855e-09
, O 0 7.1202046943988e-15
transferrin O 0 6.938401519995807e-10
, O 0 1.0487050464136338e-11
and O 0 1.4755997312931868e-08
TfR O 0 0.0002766849647741765
form O 0 4.7455061527503645e-14
a O 0 9.013322484479214e-15
ternary O 0 3.1693678931299374e-11
complex O 0 6.233170663644261e-12
. O 0 4.887957226473727e-12

Identification O 0 9.877481861944593e-13
of O 0 8.727979425043224e-16
three O 0 9.120433612307783e-16
novel O 0 8.281512276072864e-14
mutations O 0 1.4640027037882142e-11
and O 0 5.80055531466386e-15
a O 0 8.516592691586359e-17
high O 0 6.080999419288968e-13
frequency O 0 1.5584788954218815e-15
of O 0 1.5853480510582088e-15
the O 0 1.8088623047335384e-13
Arg778Leu O 0 9.100190823119192e-08
mutation O 0 2.0704108566471646e-11
in O 0 1.8287985126372482e-14
Korean O 0 3.665837056132659e-08
patients O 0 6.385195107025399e-13
with O 0 1.1510110491672401e-14
Wilson B-Disease 0 1.2177007135960594e-07
disease I-Disease 0 7.821479357517092e-07
. O 0 1.6621239974645707e-12

Four O 0 7.287957043411453e-11
mutations O 0 4.398826192186789e-09
- O 0 1.164231321126863e-06
- O 0 3.7664526075786853e-07
R778L O 0 2.328804926676753e-09
, O 0 1.550254946657871e-15
A874V O 0 2.598697895327823e-13
, O 0 8.3710322302703e-18
L1083F O 0 1.9438183023910358e-14
, O 0 2.7026029612317357e-18
and O 0 9.62838481165908e-18
2304delC O 0 8.710435150938167e-12
- O 0 2.57579201023983e-12
- O 0 1.7933288317881213e-12
in O 0 1.0945323348473117e-17
the O 0 4.746184510997574e-18
copper O 0 1.0307817099874939e-11
- O 0 7.372922903442752e-15
transporting O 0 6.650981984124629e-14
enzyme O 0 8.539773163791786e-13
, O 0 6.431632870971822e-16
P O 0 1.4188829311478912e-07
- O 0 7.859589423730995e-09
type O 0 7.3357169227961094e-09
ATPase O 0 1.846888331158425e-08
( O 0 2.982144696114797e-13
ATP7B O 0 3.132293002749975e-08
) O 0 6.177176232682749e-16
, O 0 3.53099580697246e-18
were O 0 1.4215352936607957e-16
identified O 0 6.805669851457641e-13
in O 0 4.1710741577240945e-14
Korean O 0 7.203128689070581e-07
Patients O 0 3.848046826928492e-13
with O 0 1.1417228246808284e-14
Wilson B-Disease 0 1.2307087615681667e-07
disease I-Disease 0 1.2205165944578766e-07
. O 0 3.1235983851546356e-13

Arg778Leu O 0 2.290207021360402e-06
, O 0 1.4606171767949164e-14
the O 0 1.8879386666814317e-17
most O 0 6.524868169756267e-17
frequently O 0 2.887517698904607e-13
reported O 0 6.987000387981279e-12
mutation O 0 4.915910343725183e-13
of O 0 1.819440932034324e-16
this O 0 8.611265828798768e-17
enzyme O 0 1.6076306952328423e-12
, O 0 1.7349376164937848e-16
was O 0 3.6453706806632846e-13
found O 0 1.4548520808205234e-12
in O 0 3.767818119272204e-15
six O 0 1.2806373799953419e-12
of O 0 1.7229539531747086e-16
eight O 0 6.327244500906049e-13
unrelated O 0 1.4982688700815316e-11
patients O 0 2.4913854616490094e-13
studied O 0 3.018799945263273e-13
, O 0 2.0237402165667125e-17
an O 0 1.1354616244672264e-18
allele O 0 6.272087121455541e-15
frequency O 0 3.230585016080617e-14
of O 0 8.732022266713657e-13
37 O 0 1.345518363393694e-08
. O 0 2.4059598063841392e-11

5 O 0 1.8089394870912656e-08
% O 0 1.7788030163418123e-12
, O 0 1.112567505944038e-15
which O 0 3.6059873395620273e-17
is O 0 2.5643930749930068e-17
considerably O 0 8.770232075430229e-16
higher O 0 3.7809329950923385e-16
than O 0 1.836671335804375e-17
those O 0 7.796623950843064e-17
in O 0 3.978160960722195e-18
other O 0 4.723035067461889e-16
Asian O 0 1.8244304992535293e-13
populations O 0 5.214006852140296e-14
. O 0 3.5029094967546637e-14

The O 0 4.5946074026036e-15
novel O 0 6.358963648613741e-14
single O 0 1.0005357002976223e-12
nucleotide O 0 2.18195669865473e-11
deletion O 0 5.578991713051096e-10
, O 0 5.1102920723203327e-14
2304delC O 0 5.080584841721247e-09
, O 0 7.174325017530667e-15
was O 0 8.379792085927429e-13
found O 0 6.965972937367226e-13
in O 0 1.0065597444083862e-15
one O 0 3.330602503862079e-12
patient O 0 1.700266871740297e-10
. O 0 1.7147505746058223e-13

Since O 0 9.44618341880421e-12
a O 0 9.622928708486345e-15
mutation O 0 3.415109449574072e-13
at O 0 5.643398007476423e-14
cDNA O 0 1.3339967151748677e-11
nucleotide O 0 2.9807506463086497e-10
2302 O 0 1.4744828469304139e-08
( O 0 3.178770994257535e-14
2302insC O 0 4.858494509485389e-11
) O 0 4.165029561205898e-15
had O 0 4.1066444949472425e-13
been O 0 2.3948865893880233e-13
previously O 0 1.5885173385021822e-11
described O 0 2.7798995744232613e-12
, O 0 1.5462909383438393e-16
this O 0 3.2637817275321047e-18
region O 0 2.3109216617530444e-15
of O 0 1.2686919868159627e-17
the O 0 8.725649025647091e-16
ATP7B O 0 9.007505852309805e-09
gene O 0 1.8581668322081857e-12
may O 0 2.0988683610122932e-14
be O 0 7.011172284087622e-17
susceptible O 0 1.1681204370754192e-14
to O 0 2.2330460283001903e-17
gene O 0 3.1727547672444345e-11
rearrangements O 0 1.8497797782401904e-07
causing O 0 5.004778813599842e-08
Wilson B-Disease 0 0.0001496562035754323
disease I-Disease 0 0.006590882781893015
. O 0 1.5254174659529163e-11

Disruption O 0 1.4209608600879164e-08
of O 0 1.5480919421479388e-15
splicing O 0 4.6054788455096585e-11
regulated O 0 1.3372014433243873e-11
by O 0 2.280045405001494e-16
a O 0 5.8705198125905914e-15
CUG O 0 5.369015525502618e-07
- O 0 2.2357048157228832e-10
binding O 0 2.983392395974893e-12
protein O 0 3.046294813624506e-11
in O 0 4.949988986410747e-13
myotonic B-Disease 1 0.999992847442627
dystrophy I-Disease 1 0.9999873638153076
. O 0 4.650319365695488e-11

Myotonic B-Disease 1 0.9999614953994751
dystrophy I-Disease 1 0.9999978542327881
( O 0 7.857455784687772e-06
DM B-Disease 1 1.0
) O 0 2.6009877585053687e-10
is O 0 4.6315995336958585e-14
caused O 0 6.154294061129148e-15
by O 0 7.38360688073105e-18
a O 0 2.691187574302206e-15
CTG O 0 7.516814726216126e-09
expansion O 0 1.5991412838020636e-12
in O 0 1.8300422111137016e-16
the O 0 5.746483272409987e-16
3 O 0 9.12098223554772e-14
untranslated O 0 2.21914431275394e-10
region O 0 7.093581178317177e-15
of O 0 2.9374806149247597e-16
the O 0 1.3596271461122078e-12
DM B-Disease 1 0.9999996423721313
gene O 0 9.636379472155454e-10
. O 0 1.2299854060607296e-12

One O 0 4.5779538878276335e-14
model O 0 1.1304523289679125e-11
of O 0 2.2211850007934977e-14
DM B-Disease 1 0.9999997615814209
pathogenesis O 0 8.444319687939128e-10
suggests O 0 4.4880234511407435e-13
that O 0 3.986290574500427e-17
RNAs O 0 1.343335436377463e-13
from O 0 2.1283677445322583e-16
the O 0 4.8067700314750403e-17
expanded O 0 3.2072990639210597e-13
allele O 0 3.952135453210055e-15
create O 0 2.257343962485568e-17
a O 0 1.5469753144954412e-16
gain O 0 1.272063292374892e-12
- O 0 2.4287805100442483e-09
of O 0 1.1704500216258573e-12
- O 0 1.15920162357952e-08
function O 0 3.0752507355539084e-15
mutation O 0 9.292870462127446e-16
by O 0 4.458083293909642e-18
the O 0 3.4157735181107634e-17
inappropriate O 0 3.2564524536128625e-13
binding O 0 3.4189725974399093e-14
of O 0 7.974264606304007e-19
proteins O 0 1.687677016155037e-16
to O 0 1.3301262773199698e-16
the O 0 2.4765313836661897e-14
CUG O 0 1.9082601284026168e-05
repeats O 0 8.215127245136955e-09
. O 0 7.877177642806599e-13

Data O 0 1.0043191833730702e-09
presented O 0 1.650502304273438e-11
here O 0 3.75934973797544e-14
indicate O 0 4.9592569498690606e-14
that O 0 3.223667769162468e-17
the O 0 2.99143052561555e-17
conserved O 0 3.429221425051143e-13
heterogeneous O 0 1.6478443609635463e-11
nuclear O 0 5.155366133990924e-10
ribonucleoprotein O 0 3.544050816706168e-11
, O 0 8.091792565997425e-16
CUG O 0 4.411345067012462e-09
- O 0 1.0735579092369107e-11
binding O 0 3.7093789953708545e-13
protein O 0 2.2747016943658327e-13
( O 0 5.588623859612571e-16
CUG O 0 4.179651624802716e-10
- O 0 3.313951196792786e-11
BP O 0 8.123891004352402e-10
) O 0 4.3128410986060693e-16
, O 0 1.7910000472073623e-17
may O 0 6.092766434873543e-15
mediate O 0 6.197011220149262e-13
the O 0 1.6624956001358936e-15
trans O 0 2.4307733603734505e-09
- O 0 4.6760220584474155e-08
dominant O 0 9.185609911588344e-11
effect O 0 7.123522014233427e-14
of O 0 9.561769475388347e-18
the O 0 2.322621516095231e-16
RNA O 0 3.331313957327664e-12
. O 0 6.31229484372546e-14

CUG O 0 0.00011219087173230946
- O 0 5.103989224153338e-06
BP O 0 4.0885004182200646e-07
was O 0 7.027345827644027e-13
found O 0 6.873023327972814e-16
to O 0 1.120740084310467e-18
bind O 0 4.057511434046174e-15
to O 0 1.5311639225226126e-17
the O 0 3.400498999442706e-16
human O 0 5.965365354465568e-12
cardiac O 0 2.360973916371023e-10
troponin O 0 2.7355959275610076e-08
T O 0 1.1692474544133802e-08
( O 0 2.306034281647387e-15
cTNT O 0 1.5552031234003505e-12
) O 0 2.03926358425025e-16
pre O 0 2.630139378859142e-12
- O 0 9.064297923355724e-12
messenger O 0 2.3549135731715243e-12
RNA O 0 9.518772624500862e-14
and O 0 9.524751157743129e-17
regulate O 0 7.181302557312792e-16
its O 0 4.1604661910549005e-18
alternative O 0 8.716666241241459e-16
splicing O 0 3.2599589260690065e-12
. O 0 1.4537057267585002e-13

Splicing O 0 1.1488711093576853e-09
of O 0 6.247974143266943e-13
cTNT O 0 3.518533908675181e-09
was O 0 2.9611368912441094e-11
disrupted O 0 9.415114909927524e-09
in O 0 3.3309709157602896e-12
DM B-Disease 1 1.0
striated O 0 0.09459388256072998
muscle O 0 1.567602885188535e-05
and O 0 7.521044334199423e-13
in O 0 2.548333297225841e-16
normal O 0 1.0596171258947431e-14
cells O 0 1.3501932184063412e-14
expressing O 0 4.114792354741601e-16
transcripts O 0 5.072804088140752e-15
that O 0 2.6539950987420984e-16
contain O 0 6.579118218101587e-13
CUG O 0 2.6060311938636005e-05
repeats O 0 1.1321720450041539e-07
. O 0 4.6406411699506656e-12

Altered O 0 1.601308419196812e-08
expression O 0 1.2364160259861756e-12
of O 0 1.9841445033944526e-16
genes O 0 7.906620779103701e-13
regulated O 0 1.4791818811477064e-11
posttranscriptionally O 0 4.664917896413101e-10
by O 0 3.789901962273018e-15
CUG O 0 2.259268057969166e-06
- O 0 4.843078826866076e-08
BP O 0 2.4685453681172476e-08
therefore O 0 4.594416481377289e-14
may O 0 1.4413636096840578e-14
contribute O 0 1.6268112667383724e-15
to O 0 1.988427461964773e-14
DM B-Disease 1 0.9999985694885254
pathogenesis O 0 1.3563081213696648e-10
. O 0 4.289642507307109e-15
. O 0 3.2080681698371666e-14

Identification O 0 2.1347710925379015e-12
of O 0 1.0212297197801203e-15
a O 0 3.640822045973893e-15
novel O 0 2.546041849571523e-11
nonsense O 0 1.58032003128028e-06
mutation O 0 5.1328750277912505e-11
and O 0 2.117848124722952e-15
a O 0 5.525408334921105e-17
missense O 0 6.842975079808522e-13
substitution O 0 1.2635778103299556e-16
in O 0 9.761183075535334e-19
the O 0 1.1634225005206267e-17
vasopressin O 0 2.1505544740840765e-12
- O 0 2.1059554100588684e-09
neurophysin O 0 5.8503761835027035e-08
II O 0 8.801629980403902e-10
gene O 0 2.889838758915464e-12
in O 0 1.1364340356614672e-15
two O 0 1.761502049909755e-13
Spanish O 0 1.7328131984850614e-10
kindreds O 0 3.6572023418557364e-06
with O 0 4.0421041513916123e-10
familial B-Disease 1 0.9283386468887329
neurohypophyseal I-Disease 1 0.9997072815895081
diabetes I-Disease 1 0.9998984336853027
insipidus I-Disease 1 0.9877074360847473
. O 0 3.932882020052375e-09

Familial B-Disease 1 0.9992875456809998
neurohypophyseal I-Disease 1 0.999647855758667
diabetes I-Disease 1 0.9999839067459106
insipidus I-Disease 1 0.9997233748435974
( O 0 7.42755355531699e-06
FNDI B-Disease 1 1.0
) O 0 1.5549636231404484e-11
is O 0 2.6818643334737546e-13
an O 0 1.2552306199661856e-12
autosomal B-Disease 1 0.9999994039535522
dominant I-Disease 1 0.9999994039535522
disease I-Disease 1 0.9999998807907104
caused O 0 1.674408878216127e-07
by O 0 8.834923244382953e-12
deficiency O 0 0.002581927925348282
in O 0 4.1395100996314616e-16
the O 0 7.568990871347978e-14
antidiuretic O 0 3.2227530937234405e-06
hormone O 0 1.636488722311924e-09
arginine O 0 1.1576007513669495e-10
vasopressin O 0 3.143954194206877e-11
( O 0 1.914528241888161e-15
AVP O 0 2.898893972091976e-11
) O 0 9.509927998448117e-19
encoded O 0 1.5518803300917582e-17
by O 0 2.831862091498151e-17
the O 0 6.049319573910028e-15
AVP O 0 0.00011643158359220251
- O 0 1.305164261111713e-07
neurophysin O 0 8.518886716046836e-07
II O 0 5.621146215162298e-08
( O 0 4.654465018700399e-14
AVP O 0 5.324593388422727e-08
- O 0 2.2772372876289637e-09
NPII O 0 7.577027005822856e-09
) O 0 3.0982556077708534e-17
gene O 0 6.094579508897141e-15
on O 0 3.7724509659772115e-14
chromosome O 0 2.659944042804341e-09
20p13 O 0 6.649628403465613e-09
. O 0 2.095614480557284e-12

In O 0 9.187804325943433e-14
this O 0 2.7783180287031033e-17
study O 0 8.19079960022402e-16
, O 0 2.2889940433914395e-17
we O 0 9.092911096484102e-18
analyzed O 0 9.746245694178257e-15
two O 0 8.637029262331794e-16
families O 0 1.398407720780507e-16
with O 0 2.18127818697809e-15
FNDI B-Disease 1 0.9999996423721313
using O 0 2.217336167784469e-15
direct O 0 4.068221318631257e-15
automated O 0 6.833743640410894e-12
fluorescent O 0 1.77346061013689e-12
, O 0 2.5075347377114757e-15
solid O 0 4.918219911193011e-12
phase O 0 5.939598314054495e-14
, O 0 5.559978528825411e-17
single O 0 7.149135951745218e-15
- O 0 2.8354998470730974e-13
stranded O 0 2.367202977691593e-16
DNA O 0 5.146047027089831e-16
sequencing O 0 5.358030574667376e-15
of O 0 3.0961187686380574e-16
PCR O 0 9.08455755066484e-10
- O 0 4.2521309390197715e-11
amplified O 0 2.2428460477730283e-10
AVP O 0 1.0760651036889612e-07
- O 0 2.3982407726386157e-10
NPII O 0 1.6511030764831958e-08
DNA O 0 5.457098106731451e-10
. O 0 1.9754144067046786e-12

In O 0 1.2585472181287412e-14
one O 0 5.376105940124427e-16
of O 0 9.322828429285054e-18
the O 0 7.780877078958015e-17
families O 0 3.784859998654487e-15
, O 0 1.1019901952500898e-16
affected O 0 1.2804212510685205e-14
individuals O 0 9.680355080620684e-17
presented O 0 3.3913827014687634e-14
a O 0 3.190808899448971e-15
novel O 0 1.737803477508404e-11
nonsense O 0 2.4094983785971635e-09
mutation O 0 1.964782909936666e-13
in O 0 1.439602969646873e-17
exon O 0 2.8577173179916704e-13
3 O 0 1.600467059771106e-14
of O 0 1.1797214327464941e-17
the O 0 2.2691644727006242e-16
gene O 0 7.079626056401278e-13
, O 0 3.670593983520461e-16
consisting O 0 3.558732165528098e-17
in O 0 2.082697473367399e-18
a O 0 3.405056777852763e-15
G O 0 5.206367781340759e-09
to O 0 2.392932314972118e-13
T O 0 4.5405704440781847e-07
transition O 0 4.760430331179899e-13
at O 0 1.560902882641324e-12
nucleotide O 0 1.2759999220429696e-12
2101 O 0 6.936304395438464e-12
, O 0 5.4014702093810595e-17
which O 0 1.4308697414961453e-18
produces O 0 4.491202149798387e-16
a O 0 1.0259147251858328e-16
stop O 0 2.3524949349651436e-11
signal O 0 2.0621266846876374e-11
in O 0 2.4110919898535747e-14
codon O 0 2.9750666374894763e-09
82 O 0 9.137276352211288e-11
( O 0 3.8171671905154816e-14
Glu O 0 1.2195056076080846e-09
) O 0 2.8658800728604064e-15
of O 0 7.021751937357065e-15
NPII O 0 7.305372128030285e-05
. O 0 6.666991611559148e-12

The O 0 3.4620763287446232e-12
premature O 0 2.395872389371334e-10
termination O 0 5.865962229845145e-12
eliminates O 0 1.5380815111126767e-12
part O 0 8.437504404738057e-15
of O 0 5.334897059321567e-17
the O 0 1.895503246618119e-15
C O 0 8.829031949986188e-11
- O 0 3.778986672198226e-12
terminal O 0 1.2985003222947163e-14
domain O 0 7.546615479606718e-15
of O 0 6.38640342917081e-16
NPII O 0 5.352123189084068e-09
, O 0 3.817974953559463e-18
including O 0 4.798777171331578e-19
a O 0 2.903286593811721e-19
cysteine O 0 5.350470487975776e-16
residue O 0 1.8209930091606097e-12
in O 0 2.852017108129169e-16
position O 0 5.1992177924065075e-11
85 O 0 1.3697779076369404e-13
, O 0 2.2092383475202606e-16
which O 0 1.5915528850342017e-15
could O 0 1.0868462163235448e-12
be O 0 5.34432849537414e-13
involved O 0 7.585644352242626e-13
in O 0 2.2574925175061376e-15
the O 0 4.6774883906463074e-14
correct O 0 4.1461128974518147e-10
folding O 0 1.8027842330070598e-08
of O 0 1.3423203859747913e-14
the O 0 2.955429412483668e-13
prohormone O 0 8.01121416316164e-07
. O 0 7.61028479817627e-12

In O 0 1.323811719966539e-12
the O 0 4.809562765276587e-15
second O 0 2.2782851993863318e-12
family O 0 1.382512692245071e-14
, O 0 4.7499514915071404e-18
a O 0 1.6811855549978078e-18
G279A O 0 5.113292686535981e-15
substitution O 0 3.7607779784613204e-17
at O 0 1.5719647399091777e-14
position O 0 3.3046186772266173e-13
- O 0 4.383057718854166e-12
1 O 0 1.754344200106565e-16
of O 0 1.5611422093719685e-18
the O 0 2.3145100837468627e-17
signal O 0 6.3834105441308055e-15
peptide O 0 9.923882479261114e-16
was O 0 1.1484846886987594e-14
observed O 0 3.309117114625972e-16
in O 0 5.238058363265494e-18
all O 0 6.722450304345916e-15
affected O 0 1.220119654182089e-13
individuals O 0 3.4751839061053676e-15
. O 0 4.778202979767096e-14

This O 0 9.987924522820643e-14
missense O 0 1.3839336787668799e-08
mutation O 0 2.3952706484919872e-09
, O 0 3.965111659148812e-13
which O 0 5.180622640946209e-13
replaces O 0 2.8353173547657207e-05
Ala O 0 1.8733766538048258e-08
with O 0 1.1045408294593773e-12
Thr O 0 3.0184100978658535e-06
, O 0 2.128035813496053e-15
is O 0 3.309369901021168e-16
frequent O 0 4.333858846881228e-13
among O 0 1.689227924206449e-10
FNDI B-Disease 1 1.0
patients O 0 3.7144008757650226e-08
and O 0 1.745180521227135e-15
is O 0 4.0193950043592894e-17
thought O 0 2.7413681354381556e-15
to O 0 1.0826687781531781e-16
reduce O 0 9.21150972881847e-14
the O 0 2.5467977853111464e-16
efficiency O 0 4.4330614483098496e-14
of O 0 7.09665627187518e-18
cleavage O 0 2.0231134476023094e-11
by O 0 1.101196618022741e-15
signal O 0 1.3368998833321322e-12
peptidases O 0 1.657206316618698e-10
. O 0 6.432690921002061e-15
. O 0 2.9418473408183987e-13

Genetic O 0 5.1935340472653024e-09
heterogeneity O 0 4.719719726153926e-09
of O 0 1.1891734819080568e-10
Saethre B-Disease 1 0.9998794794082642
- I-Disease 1 0.9999982118606567
Chotzen I-Disease 1 0.9999927282333374
syndrome I-Disease 1 0.9999995231628418
, O 0 7.687389814341541e-15
due O 0 2.734078569894085e-15
to O 0 3.5170454390289776e-16
TWIST O 0 4.148885679455816e-08
and O 0 9.236242326515764e-11
FGFR O 0 8.385598562199448e-07
mutations O 0 3.015075689116742e-10
. O 0 8.594776366305235e-13

Thirty O 0 4.5609765964016447e-10
- O 0 1.8003410318101487e-08
two O 0 7.300659134580698e-15
unrelated O 0 4.704126086059468e-13
patients O 0 2.388794863956642e-14
with O 0 3.687684494505317e-18
features O 0 1.8098503381733244e-12
of O 0 6.7450138356572875e-12
Saethre B-Disease 1 0.9999747276306152
- I-Disease 1 0.9999988079071045
Chotzen I-Disease 1 0.9999921321868896
syndrome I-Disease 1 0.9999991655349731
, O 0 6.090415706686675e-16
a O 0 3.8926894104223276e-15
common O 0 1.6729652385638616e-10
autosomal B-Disease 0 0.12066768109798431
dominant I-Disease 0 0.014839710667729378
condition I-Disease 0 3.955060279281497e-08
of O 0 4.6224434870068e-12
craniosynostosis B-Disease 1 0.9208002090454102
and O 0 5.3922075693435545e-09
limb B-Disease 0 0.01347628515213728
anomalies I-Disease 0 9.295178460888565e-05
, O 0 8.993337758528286e-14
were O 0 4.718642672234784e-15
screened O 0 1.0470405792384341e-10
for O 0 2.121211480798262e-15
mutations O 0 2.940624360767835e-13
in O 0 4.992668947978983e-16
TWIST O 0 7.262570989041706e-09
, O 0 6.787728473907351e-13
FGFR2 O 0 5.393968081079947e-07
, O 0 2.3959407727128582e-14
and O 0 6.188813567523099e-13
FGFR3 O 0 3.4687309380387887e-06
. O 0 2.154298657866538e-12

Nine O 0 2.898331297185308e-10
novel O 0 1.647323527587119e-10
and O 0 7.343464725195759e-11
three O 0 2.391204421969828e-12
recurrent O 0 3.9035890608829504e-07
TWIST O 0 7.100387477976255e-08
mutations O 0 2.582556568597738e-08
were O 0 4.966785446466893e-13
found O 0 8.56463229330362e-13
in O 0 2.563613189259157e-15
12 O 0 4.277851076844863e-12
families O 0 5.3542124889543324e-14
. O 0 2.896237936977908e-13

Seven O 0 3.8504460730948153e-10
families O 0 1.9366326847302523e-13
were O 0 5.259728377732015e-16
found O 0 5.530261171964382e-16
to O 0 1.2637994947341198e-16
have O 0 1.6652709755853728e-13
the O 0 4.28584779970341e-15
FGFR3 O 0 5.43615124115604e-06
P250R O 0 6.705096113751585e-12
mutation O 0 1.0173643611582905e-12
, O 0 1.115950873172727e-15
and O 0 9.583689695446553e-16
one O 0 2.0545443233165137e-16
individual O 0 1.4623586553586475e-15
was O 0 5.84227180522312e-11
found O 0 3.302547254765975e-12
to O 0 9.870211202175905e-13
have O 0 2.895462168639451e-11
an O 0 2.2131966330679424e-14
FGFR2 O 0 7.342448952840641e-06
VV269 O 0 2.5495661137853176e-10
- O 0 8.420732861003088e-12
270 O 0 3.7532184391647627e-13
deletion O 0 9.998052163950888e-09
. O 0 1.648032925405385e-11

To O 0 8.165694411876173e-14
date O 0 8.926828460459335e-13
, O 0 2.462091843607756e-17
our O 0 1.1523316628675157e-17
detection O 0 8.997343843203972e-16
rate O 0 4.6331987319002746e-14
for O 0 1.0320966594937479e-17
TWIST O 0 3.037053247778587e-11
or O 0 6.629883816423876e-13
FGFR O 0 3.148033727029542e-07
mutations O 0 7.913927325964298e-12
is O 0 6.816787667110122e-14
68 O 0 1.999042858330524e-12
% O 0 3.8038481479913235e-16
in O 0 2.386352910321355e-15
our O 0 3.1146166747930693e-06
Saethre B-Disease 1 0.999729573726654
- I-Disease 1 0.9999933242797852
Chotzen I-Disease 1 0.9999289512634277
syndrome I-Disease 1 0.9999970197677612
patients O 0 1.0222646514013167e-11
, O 0 7.820240784512066e-18
including O 0 1.995286692419991e-16
our O 0 7.31273548659761e-13
five O 0 2.0675042895160894e-13
patients O 0 3.585375269246627e-15
elsewhere O 0 7.672415436504388e-16
reported O 0 9.568010310911576e-14
with O 0 3.4747599661152668e-15
TWIST O 0 8.294704656464091e-08
mutations O 0 3.8214036379713434e-08
. O 0 1.1000694279117429e-11

More O 0 7.332501114771237e-16
than O 0 1.346447411073478e-16
35 O 0 1.4297861092511018e-15
different O 0 1.5322098096891246e-17
TWIST O 0 2.430308732037645e-10
mutations O 0 1.1399544641577108e-09
are O 0 5.899316950740141e-13
now O 0 9.995743382312794e-13
known O 0 2.1792748270028917e-14
in O 0 1.8106200103309566e-16
the O 0 2.739068652744597e-15
literature O 0 1.206936243655643e-12
. O 0 2.421662696761029e-12

The O 0 8.241830476559894e-15
most O 0 2.2368665770262257e-16
common O 0 8.124579093803271e-16
phenotypic O 0 2.9087845413583446e-12
features O 0 4.2745110229169825e-10
, O 0 1.4219489369066314e-14
present O 0 2.386042049229713e-16
in O 0 1.3671800396544358e-18
more O 0 8.085886426113444e-19
than O 0 8.867141247274492e-18
a O 0 2.5771430053443277e-16
third O 0 1.0009108125652588e-10
of O 0 1.400729575731785e-13
our O 0 8.642724869112328e-10
patients O 0 2.80736301345758e-15
with O 0 1.4080475182030775e-17
TWIST O 0 4.72490310765572e-11
mutations O 0 1.1269502692146105e-10
, O 0 4.170341982444488e-14
are O 0 1.728294157093968e-14
coronal B-Disease 0 2.1044145981363727e-08
synostosis I-Disease 0 3.4667964428081177e-06
, O 0 1.9041222049619166e-13
brachycephaly B-Disease 0 1.600950963620562e-05
, O 0 1.6579494721558063e-10
low B-Disease 0 0.018154090270400047
frontal I-Disease 1 0.9999996423721313
hairline I-Disease 1 1.0
, O 0 2.2178268466177542e-07
facial B-Disease 1 0.5899745225906372
asymmetry I-Disease 0 4.032774086226709e-06
, O 0 3.7754981363491424e-09
ptosis B-Disease 1 0.99983811378479
, O 0 3.637513623644395e-10
hypertelorism B-Disease 0 0.009533766657114029
, O 0 7.716653704914478e-11
broad B-Disease 0 6.721423233102541e-06
great I-Disease 0 4.463067853066605e-06
toes I-Disease 1 0.9999960660934448
, O 0 4.188250007225447e-12
and O 0 8.294368338858382e-13
clinodactyly B-Disease 0 2.2869367910516303e-07
. O 0 1.1026989868087589e-12

Significant O 0 4.329655557688827e-12
intra O 0 2.0483085449995997e-07
- O 0 7.682595423830207e-06
and O 0 1.6409410288908965e-11
interfamilial O 0 2.3724837205918448e-07
phenotypic O 0 1.3482511773688088e-09
variability O 0 9.198759809425638e-11
is O 0 8.212924630201894e-15
present O 0 1.0005947928100337e-16
for O 0 6.60510601266289e-17
either O 0 4.989399464330052e-14
TWIST O 0 3.3970771085023443e-08
mutations O 0 1.8956824998639377e-09
or O 0 1.8137217422387053e-11
FGFR O 0 2.2449370590038598e-05
mutations O 0 2.9287245961739927e-09
. O 0 4.2462448487934346e-12

The O 0 2.4097463933135665e-13
overlap O 0 6.931965852025046e-12
in O 0 7.249452710666505e-16
clinical O 0 1.6337323204343446e-12
features O 0 6.525059138839939e-12
and O 0 1.422704510624373e-12
the O 0 3.3410318867104155e-15
presence O 0 2.0151788224231915e-12
, O 0 6.497050416628353e-17
in O 0 1.5341274211441757e-18
the O 0 1.123064523870287e-17
same O 0 4.286614311581116e-16
genes O 0 1.7707033179938016e-15
, O 0 1.4313283097482294e-18
of O 0 1.0193628608445824e-20
mutations O 0 5.746633488409227e-17
for O 0 4.668252206573773e-19
more O 0 8.074051022511459e-19
than O 0 9.659002571160485e-16
one O 0 1.1728681177311517e-12
craniosynostotic B-Disease 0 1.6674227936164243e-06
condition I-Disease 0 3.688511735627786e-12
- O 0 3.2702098407694224e-12
such O 0 1.7946068418752022e-14
as O 0 4.11166239944194e-12
Saethre B-Disease 0 4.0009149415709544e-07
- I-Disease 0 3.8955260350803655e-08
Chotzen I-Disease 0 4.61431319820349e-08
, I-Disease 0 1.2389786394647988e-14
Crouzon I-Disease 0 6.137945152140389e-10
, I-Disease 0 2.1007577527044387e-15
and I-Disease 0 3.9273099339655684e-14
Pfeiffer I-Disease 0 0.00040211490704678
syndromes I-Disease 0 4.5313694130300064e-08
- O 0 6.520906731255494e-11
support O 0 2.4593547413419986e-14
the O 0 2.4858742788353908e-17
hypothesis O 0 7.195593167803275e-15
that O 0 7.745432852931261e-16
TWIST O 0 9.510475046381472e-11
and O 0 8.38661930700757e-13
FGFRs O 0 1.9889245805870814e-10
are O 0 1.465921275934799e-16
components O 0 3.8980727283186023e-13
of O 0 7.695651667829941e-18
the O 0 2.2983388682075735e-17
same O 0 1.5646784685291786e-17
molecular O 0 7.668787488512179e-16
pathway O 0 1.9862212799503544e-14
involved O 0 1.0517401430017517e-14
in O 0 3.5961358666207045e-18
the O 0 5.27099371740715e-17
modulation O 0 1.9189904114542966e-13
of O 0 8.680543805462959e-13
craniofacial O 0 0.0004992522881366313
and O 0 4.1023134889073276e-10
limb O 0 1.294737330681528e-06
development O 0 6.927733126743663e-13
in O 0 1.5578183950114803e-16
humans O 0 5.920313745537767e-14
. O 0 4.036346198276657e-15
. O 0 2.557101123727701e-13

Mutation O 0 1.6278840497818692e-09
analysis O 0 9.203879845764984e-12
of O 0 5.633756915840449e-12
UBE3A O 1 0.9859717488288879
in O 0 6.625224614253966e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 5.058646365796449e-06
. O 0 1.1073616849877066e-11

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.4055168321647216e-05
AS B-Disease 1 0.9999998807907104
) O 0 3.081606692913186e-13
is O 0 1.0170975118985875e-14
caused O 0 1.0194359157560725e-14
by O 0 2.3609534627276325e-16
chromosome O 0 1.0674502846086398e-06
15q11 O 0 1.593879517258756e-08
- O 0 6.378290673403342e-10
q13 O 0 4.962594918334062e-11
deletions O 0 3.712270768563286e-11
of O 0 1.9255779560916828e-14
maternal O 0 7.769263010715122e-10
origin O 0 3.623090258256072e-14
, O 0 1.2249124503536913e-15
by O 0 2.98550687481431e-14
paternal O 0 1.4447654166360735e-06
uniparental B-Disease 0 0.31698861718177795
disomy I-Disease 0 0.21816889941692352
( O 0 1.084197731593406e-09
UPD B-Disease 1 0.9999977350234985
) O 0 5.98738506690788e-13
15 O 0 3.275725095905693e-14
, O 0 2.8857206897211217e-18
by O 0 1.2134523857449162e-16
imprinting O 0 0.0002515084051992744
defects O 1 0.9999971389770508
, O 0 1.3160111191165991e-14
and O 0 2.1753440594380837e-16
by O 0 5.63311916207633e-17
mutations O 0 3.3359794961163036e-13
in O 0 1.611941418060866e-16
the O 0 6.003113926637306e-15
UBE3A O 0 1.783516125897222e-07
gene O 0 4.5451103991567265e-10
. O 0 4.689606775826194e-12

UBE3A O 0 2.5924127839971334e-06
encodes O 0 5.318718035440817e-11
a O 0 1.1325957905642791e-14
ubiquitin O 0 4.847049411144111e-13
- O 0 2.0433793546104084e-12
protein O 0 9.512269783158202e-15
ligase O 0 6.236446092617448e-14
and O 0 2.6229076555009737e-14
shows O 0 4.434083308857417e-11
brain O 0 8.366955484007121e-08
- O 0 3.2678453276702157e-09
specific O 0 3.74098495237174e-12
imprinting O 0 9.47570242715301e-07
. O 0 2.3494414747027292e-11

Here O 0 9.02913247641246e-12
we O 0 4.282352941763039e-14
describe O 0 1.1879746860711526e-13
UBE3A O 0 7.590222139697289e-08
coding O 0 9.602386441542876e-09
- O 0 2.1267251781864616e-07
region O 0 1.4614630035672538e-12
mutations O 0 2.1748670572807605e-12
detected O 0 2.2717327151366984e-12
by O 0 2.2284763517242024e-17
SSCP O 0 2.537941246050224e-10
analysis O 0 8.2297975265112e-15
in O 0 3.9347888537249976e-16
13 O 0 5.304956994522936e-12
AS B-Disease 1 0.9999997615814209
individuals O 0 1.122078124859982e-12
or O 0 3.8804935827141396e-12
families O 0 1.1675068464084282e-12
. O 0 6.284546993050311e-13

Two O 0 3.03415959024278e-10
identical O 0 3.497404144070515e-09
de O 0 2.0115194843128847e-08
novo O 0 2.6127596086666927e-08
5 O 0 1.0754803297929882e-11
- O 0 9.575240600412371e-10
bp O 0 2.3661267389840646e-10
duplications O 0 7.412036956422341e-11
in O 0 6.543791150495724e-16
exon O 0 2.0920610729890932e-11
16 O 0 1.0185701023943117e-12
were O 0 2.755007483471318e-15
found O 0 6.563435369201856e-14
. O 0 3.192029431574317e-13

Among O 0 2.665948625052428e-12
the O 0 1.2243052336096284e-15
other O 0 4.070066103450818e-16
11 O 0 4.497222330591879e-15
unique O 0 1.5369758258553082e-16
mutations O 0 1.2510454911601743e-12
, O 0 1.1708417845283578e-14
8 O 0 2.1270639871846797e-13
were O 0 1.5260108520042033e-15
small O 0 2.867551957079609e-16
deletions O 0 1.4246230584102904e-10
or O 0 1.0042064835930065e-12
insertions O 0 3.023271855084886e-09
predicted O 0 1.8825094816321553e-09
to O 0 8.136439113605454e-13
cause O 0 3.345324017800522e-11
frameshifts O 0 1.0718326848291326e-06
, O 0 9.806499552287781e-14
1 O 0 4.035899811913454e-15
was O 0 2.5179864703711585e-12
a O 0 4.88099718300416e-16
mutation O 0 1.5702686411355957e-14
to O 0 3.001891647211937e-16
a O 0 2.6930156831606175e-15
stop O 0 4.2909113762146234e-11
codon O 0 1.0516414995775936e-11
, O 0 1.1954692145302174e-16
1 O 0 2.1471716112635077e-17
was O 0 7.875487032806515e-15
a O 0 7.561739464638181e-16
missense O 0 6.856468171001495e-10
mutation O 0 2.139775301390756e-10
, O 0 2.6292553204076974e-13
and O 0 1.1517802228459828e-13
1 O 0 1.9112883408649133e-15
was O 0 3.7157416032940205e-11
predicted O 0 2.926113865098223e-11
to O 0 4.5097630768924524e-15
cause O 0 2.001646766359392e-14
insertion O 0 8.096741186585169e-14
of O 0 3.4230035001809505e-15
an O 0 4.5552730560055946e-14
isoleucine O 0 1.230582000744107e-07
in O 0 1.8907729911241773e-15
the O 0 8.84403908538262e-17
hect O 0 7.642828731002638e-11
domain O 0 2.26321054047152e-14
of O 0 8.617020755930871e-16
the O 0 5.874530090079367e-15
UBE3A O 0 4.256573760130777e-09
protein O 0 2.838791268028329e-12
, O 0 4.336829336370107e-16
which O 0 4.840627526563571e-17
functions O 0 3.58344514585763e-16
in O 0 1.4937054124426183e-16
E2 O 0 5.0520157501843244e-11
binding O 0 1.342808243071092e-12
and O 0 7.751758600860474e-16
ubiquitin O 0 3.938547350670202e-14
transfer O 0 1.3253023895334892e-12
. O 0 3.822300115308153e-12

Eight O 0 6.188096909887086e-12
of O 0 1.586266790638404e-16
the O 0 1.1647286683386847e-16
cases O 0 5.899891035790472e-13
were O 0 1.5342900561154948e-12
familial O 0 7.992756456687289e-10
, O 0 2.4394586827999887e-13
and O 0 3.773554006162444e-13
five O 0 9.86251445095343e-13
were O 0 2.6729139734893437e-12
sporadic O 0 1.0889976698180703e-09
. O 0 1.650917033288457e-12

In O 0 6.417550410357797e-13
two O 0 1.5256362728591037e-14
familial O 0 2.0109278686675225e-09
cases O 0 2.9500499265644464e-10
and O 0 4.610307903669952e-13
one O 0 1.821740652955899e-15
sporadic O 0 4.9738598656423605e-12
case O 0 3.749885818526977e-12
, O 0 1.1423974652474927e-15
mosaicism O 0 3.7634034777411784e-10
for O 0 1.8860735252778683e-14
UBE3A O 0 2.5337561737615033e-07
mutations O 0 8.398201578607711e-11
was O 0 1.2495025630485102e-12
detected O 0 1.6116513679165223e-10
in O 0 2.6040622418036614e-16
the O 0 4.932056329064649e-16
mother O 0 1.0673928407811673e-09
of O 0 6.854224490499689e-16
three O 0 6.710524497188786e-11
AS B-Disease 1 1.0
sons O 0 1.1493517249050456e-08
, O 0 5.127825654328497e-15
in O 0 5.054583416828577e-17
the O 0 8.040292200474711e-14
maternal O 0 1.015983408514387e-09
grandfather O 0 1.4652108415447174e-09
of O 0 3.0584972708901656e-15
two O 0 4.1768605935077474e-11
AS B-Disease 1 1.0
first O 0 1.1694297752384841e-09
cousins O 0 3.617808488343144e-07
, O 0 1.194564412665411e-12
and O 0 1.4135189329786413e-12
in O 0 1.1330057756865739e-15
the O 0 2.517380292936522e-13
mother O 0 3.109031965209397e-08
of O 0 2.0808660309711187e-15
an O 0 2.7711076489023156e-11
AS B-Disease 1 1.0
daughter O 1 0.9300651550292969
. O 0 1.3351403316264054e-10

The O 0 2.0819549765281088e-14
frequencies O 0 8.513275398221512e-14
with O 0 4.648075510366081e-15
which O 0 5.01951883361576e-16
we O 0 1.6834341487129015e-15
detected O 0 2.1628281576726444e-13
mutations O 0 5.236780518773354e-14
were O 0 1.472589648691177e-14
5 O 0 4.223460435006342e-15
( O 0 1.2491329869035136e-16
14 O 0 8.487250649730303e-15
% O 0 3.2425482080030216e-18
) O 0 1.6403249006892196e-18
of O 0 3.1640775123980255e-18
35 O 0 4.667889813288022e-14
in O 0 9.098015958916412e-17
sporadic O 0 5.480440060101621e-11
cases O 0 1.2050881126324242e-10
and O 0 9.670875211753582e-12
8 O 0 4.575913758152195e-13
( O 0 6.499702688544443e-17
80 O 0 3.5147383330388937e-16
% O 0 1.6137186983249974e-17
) O 0 8.503023620818039e-17
of O 0 3.958455483666875e-16
10 O 0 5.621538933138492e-13
in O 0 1.7376266814035212e-16
familial O 0 2.5908128420404353e-10
cases O 0 4.91850345174516e-11
. O 0 2.0598277654403953e-14
. O 0 6.407399025416816e-13

The O 0 1.0008840978237288e-10
hemochromatosis B-Disease 1 0.999921441078186
845 O 0 8.04237245688455e-08
G O 0 8.365406074517523e-07
- O 0 3.779403456860564e-09
- O 0 1.783928699206072e-10
> O 0 2.981074181994739e-14
A O 0 2.3199487036301703e-15
and O 0 2.7375106944568003e-16
187 O 0 4.486546750841159e-15
C O 0 1.6140922149202042e-12
- O 0 1.58374945102846e-11
- O 0 9.059981237458103e-11
> O 0 1.718558428160863e-13
G O 0 8.751477320600998e-10
mutations O 0 6.686348089784966e-12
: O 0 7.44215260028774e-15
prevalence O 0 4.629577554648989e-10
in O 0 6.614770393893266e-15
non O 0 4.773926889356517e-07
- O 0 7.141118203435326e-07
Caucasian O 0 4.16229681832192e-08
populations O 0 4.431870148646766e-10
. O 0 3.8062126150525954e-13

Hemochromatosis B-Disease 0 0.035301823168992996
, O 0 2.1321365506477008e-10
the O 0 7.018622905086147e-10
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 5.180414763827912e-09
iron I-Disease 1 0.9024237394332886
metabolism I-Disease 0 4.08014384447597e-05
, O 0 1.3099115162788083e-13
leads O 0 9.985229657005767e-12
, O 0 4.27820332735444e-15
if O 0 2.2205930941699564e-13
untreated O 0 5.080287479586332e-08
, O 0 4.1756704655453397e-16
to O 0 6.344084074939209e-15
progressive O 0 4.6867971725816915e-09
iron B-Disease 1 0.9789150357246399
overload I-Disease 0 0.0003377503890078515
and O 0 3.6852246254603926e-10
premature B-Disease 0 9.765729197530604e-11
death I-Disease 0 1.1994458161065924e-12
. O 0 1.3704999591787614e-12

The O 0 2.2597030149840158e-11
hemochromatosis B-Disease 1 0.9999963045120239
gene O 0 3.5158194577888935e-07
, O 0 3.703214763919188e-13
HFE O 0 5.965069931335165e-07
, O 0 1.2366584806969977e-13
recently O 0 6.502903993066411e-09
has O 0 5.8863608431991565e-12
been O 0 1.6426302592437159e-13
identified O 0 3.4443851850557428e-12
, O 0 5.35224661018705e-16
and O 0 5.083882220299654e-16
characterization O 0 9.982357822291288e-15
of O 0 9.487390428683344e-19
this O 0 1.952948817614475e-18
gene O 0 6.2447013705890786e-12
has O 0 2.553439959473991e-10
shown O 0 3.089475019129456e-13
that O 0 4.938702361327043e-16
it O 0 1.8951335167366424e-16
contains O 0 1.088197097502111e-15
two O 0 1.0991406996531655e-14
mutations O 0 2.698756745422165e-13
that O 0 3.1848398159180225e-14
result O 0 6.326755898420754e-15
in O 0 2.737260025643972e-16
amino O 0 8.693596515417512e-14
acid O 0 1.8378446551073346e-14
substitutions O 0 4.491153339524802e-15
- O 0 1.772861100545614e-13
cDNA O 0 4.959297404162621e-13
nucleotides O 0 7.263276351893166e-13
845 O 0 3.892494833401816e-12
G O 0 1.4333182418724277e-09
- O 0 8.99004648502455e-10
- O 0 8.117911898253283e-10
> O 0 1.4651967790088594e-13
A O 0 7.617145710838921e-14
( O 0 2.2037250894759212e-16
C282Y O 0 5.0736775485159605e-14
) O 0 2.521006417888835e-18
and O 0 5.685121360209578e-18
187 O 0 1.3052593911039214e-14
C O 0 2.526030773442045e-11
- O 0 2.7594646567763448e-09
- O 0 4.025433764098807e-09
> O 0 4.210886413863468e-12
G O 0 7.809246582723972e-09
( O 0 2.107573488017815e-14
H63D O 0 4.044280910164844e-09
) O 0 1.520514603440236e-14
. O 0 3.3311071593157895e-14

Although O 0 1.915827274601156e-09
hemochromatosis B-Disease 1 0.9999996423721313
is O 0 1.5121708052401317e-10
common O 0 6.862341776639816e-14
in O 0 8.381101830739153e-17
Caucasians O 0 1.0844489368999621e-11
, O 0 2.8705724236299584e-16
affecting O 0 9.492120902222095e-14
> O 0 2.8412803725996576e-14
= O 0 6.619169188454288e-13
1 O 0 1.888192717008604e-15
/ O 0 8.182661362723942e-13
300 O 0 1.5460550926075882e-16
individuals O 0 2.851289930343951e-15
of O 0 3.727304109888557e-15
northern O 0 2.643051055795098e-10
European O 0 4.727630287248985e-09
origin O 0 1.2128796908874098e-14
, O 0 2.0551488401430573e-15
it O 0 1.0419205747475273e-14
has O 0 6.7742547682492216e-12
not O 0 2.167451221147111e-15
been O 0 4.170312641223195e-13
recognized O 0 5.5426405584885034e-15
in O 0 2.2035558814098173e-17
other O 0 4.616092816827179e-15
populations O 0 1.979324364999313e-13
. O 0 1.290178765689029e-13

The O 0 2.2365703378408354e-14
present O 0 4.661034373305243e-16
study O 0 4.891563323451116e-17
used O 0 7.868666088240513e-16
PCR O 0 5.896120258697124e-10
and O 0 7.867409726621498e-15
restriction O 0 1.608435776332285e-14
- O 0 1.703871012380745e-13
enzyme O 0 7.993197168607372e-14
digestion O 0 9.922486992480512e-15
to O 0 2.83384762482125e-19
analyze O 0 1.6770502731476827e-15
the O 0 6.8670677433677176e-18
frequency O 0 2.0880682330076138e-17
of O 0 1.910359769415957e-18
the O 0 2.4481467365329697e-17
845 O 0 2.655953798905153e-13
G O 0 2.3172679053384826e-12
- O 0 2.667345782182001e-13
- O 0 3.065613897717395e-13
> O 0 3.949345644319155e-16
A O 0 7.2451672533489905e-16
and O 0 3.168912515427296e-16
187 O 0 1.0772565023180192e-14
C O 0 3.1083835050176034e-13
- O 0 6.008369149435033e-12
- O 0 1.2597211468401426e-11
> O 0 8.854771299873776e-14
G O 0 3.062519682295317e-11
mutations O 0 5.699703675612205e-14
in O 0 1.3771627447999401e-17
HLA O 0 8.002231689785422e-13
- O 0 8.561618448433336e-15
typed O 0 9.91367700279612e-14
samples O 0 7.641315965395412e-14
from O 0 2.5739118393483485e-15
non O 0 3.108245882899041e-10
- O 0 1.3272123844387806e-08
Caucasian O 0 2.398754306298656e-09
populations O 0 6.488856327258041e-12
, O 0 3.0880740732215097e-16
comprising O 0 2.6844730594260263e-14
Australian O 0 3.4796252545987727e-09
Aboriginal O 0 1.1825043982199857e-12
, O 0 1.162305915881521e-15
Chinese O 0 1.3611404416232452e-15
, O 0 1.0996937698160751e-15
and O 0 8.522682884946897e-14
Pacific O 0 5.42002172310152e-11
Islanders O 0 2.563521894760612e-10
. O 0 2.0339952595468946e-13

Results O 0 3.5073155491005537e-10
showed O 0 1.0249086301872268e-10
that O 0 1.7049932812726712e-16
the O 0 4.082909240513561e-17
845 O 0 9.472272792521164e-12
G O 0 3.5255136587863944e-09
- O 0 6.35192176634547e-10
- O 0 4.2828843249687054e-10
> O 0 2.0785427890033896e-14
A O 0 3.879036933378483e-15
mutation O 0 1.370399968633404e-13
was O 0 5.977685794272825e-13
present O 0 1.4395543314268548e-16
in O 0 4.1682499606190245e-18
these O 0 7.570712322876462e-17
populations O 0 1.466660418060397e-15
( O 0 1.4407835011375933e-18
allele O 0 1.1740428543849298e-16
frequency O 0 4.990231610673258e-16
0 O 0 6.133341854145866e-15
. O 0 1.158198044315354e-16
32 O 0 5.605713918228894e-13
% O 0 1.5042954418656652e-16
) O 0 4.965849237890951e-16
, O 0 1.3987979382713953e-15
and O 0 1.8195835463363785e-12
, O 0 1.3602164345569091e-15
furthermore O 0 3.6300329638082416e-15
, O 0 3.0270289381084843e-16
it O 0 1.419055980578579e-13
was O 0 5.3356036033846976e-08
always O 0 1.1539067479304776e-09
seen O 0 2.5309403878237546e-11
in O 0 9.877719382159101e-18
conjunction O 0 5.847697356859772e-16
with O 0 3.3248213701658627e-15
HLA O 0 3.172108964388798e-10
haplotypes O 0 1.4933387859628056e-11
common O 0 2.1222577189540515e-13
in O 0 1.563289301408457e-16
Caucasians O 0 8.954727150761732e-13
, O 0 2.4247794632547754e-18
suggesting O 0 5.85151271089156e-16
that O 0 1.3256478387655464e-17
845 O 0 4.639161233985223e-13
G O 0 1.5242264117532045e-09
- O 0 6.390203033390662e-09
- O 0 1.1125353083230038e-08
> O 0 3.6065378114513713e-13
A O 0 6.168362348679679e-11
may O 0 3.015535876560449e-10
have O 0 8.675933167961829e-15
been O 0 1.022352250193469e-15
introduced O 0 7.438630107897465e-16
into O 0 5.234925003105143e-17
these O 0 5.575057700520008e-17
populations O 0 1.4332810730705915e-15
by O 0 2.2696234586789177e-16
Caucasian O 0 7.451627509480474e-11
admixture O 0 2.477306693116077e-10
. O 0 4.549945923498777e-12

187 O 0 1.2180713104825713e-09
C O 0 3.869857678751032e-08
- O 0 1.1011458411758213e-08
- O 0 6.686639242303727e-09
> O 0 2.3361419135975448e-12
G O 0 2.624735984113613e-09
was O 0 1.056784434266822e-12
present O 0 2.2052639101130658e-16
at O 0 1.5541095818425886e-15
an O 0 6.099777178512637e-19
allele O 0 1.8522084280686362e-15
frequency O 0 1.0700028297950886e-15
of O 0 4.1749241765792495e-15
2 O 0 2.0275703858929628e-12
. O 0 2.435269867706591e-13

68 O 0 1.2992024949198822e-06
% O 0 2.3301610207332457e-12
in O 0 1.1925540977026825e-16
the O 0 1.0868517974236343e-17
two O 0 3.113814345697384e-16
populations O 0 2.2590000243940134e-15
analyzed O 0 2.3655333334510198e-12
( O 0 2.6475866380455855e-14
Australian O 0 3.6400855663032416e-08
Aboriginal O 0 7.706754678871164e-11
and O 0 7.695353035352959e-12
Chinese O 0 3.645125312159124e-14
) O 0 3.5188586189316938e-15
. O 0 1.1584156417855478e-14

In O 0 5.5983595716050175e-14
the O 0 6.307088852176694e-16
Australian O 0 9.811728686470733e-12
Aboriginal O 0 1.244078688367688e-15
samples O 0 2.287626138121183e-15
, O 0 6.043244656921043e-18
187 O 0 2.0072887257661107e-15
C O 0 1.2670724929345067e-12
- O 0 1.930578787112669e-11
- O 0 1.5035542255681378e-10
> O 0 6.83667057970079e-14
G O 0 1.5074709536211373e-10
was O 0 6.742228438961009e-14
found O 0 1.7717167929151914e-15
to O 0 3.89414133077304e-17
be O 0 6.413114719041593e-15
associated O 0 1.7438820197189942e-16
with O 0 7.284020125243953e-16
HLA O 0 9.775047438154161e-11
haplotypes O 0 3.8179719802355905e-12
common O 0 8.958293633808123e-14
in O 0 2.0648055980769075e-16
Caucasians O 0 1.9377865197872657e-12
, O 0 1.9252043113298032e-17
suggesting O 0 2.3894147226674427e-14
that O 0 9.027597742497528e-16
it O 0 1.1378922028801655e-14
was O 0 1.508798403056233e-12
introduced O 0 3.1032267514940603e-15
by O 0 5.2403195441879687e-17
recent O 0 2.083254901051601e-13
admixture O 0 4.34768991641743e-11
. O 0 3.938326227637123e-12

In O 0 3.858746005017122e-14
the O 0 4.5091736081356125e-17
Chinese O 0 5.197513691950901e-18
samples O 0 7.541081389845833e-17
analyzed O 0 9.866468468513849e-16
, O 0 6.694082667189377e-19
187 O 0 4.859260729390838e-16
C O 0 1.1064230992985022e-13
- O 0 1.5675770143747103e-12
- O 0 7.311176837554445e-12
> O 0 1.938775237629673e-14
G O 0 4.803973330247402e-10
was O 0 1.965497035960606e-11
present O 0 1.0241879908187354e-13
in O 0 1.5054567293303067e-14
association O 0 1.2816135346450756e-14
with O 0 1.222106680185691e-16
a O 0 1.3777467343124026e-16
wide O 0 1.141959248517066e-12
variety O 0 1.819207761863395e-13
of O 0 4.2795725561136765e-16
HLA O 0 2.1552297446714164e-10
haplotypes O 0 1.0251226950641623e-12
, O 0 5.964963509753413e-17
showing O 0 1.1302183554285847e-13
this O 0 1.4951062097227523e-18
mutation O 0 1.6725460695715395e-15
to O 0 1.0738173500288197e-16
be O 0 5.487107079468756e-13
widespread O 0 2.3600384342105374e-13
and O 0 2.9430594788472375e-13
likely O 0 2.600332533390752e-14
to O 0 1.1789020483112144e-18
predate O 0 3.61064310909617e-15
the O 0 9.787656991040093e-19
more O 0 1.6115463566003106e-18
genetically O 0 2.8749809336588855e-14
restricted O 0 3.097821410741157e-15
845 O 0 4.5162753203008277e-13
G O 0 2.9529110268100567e-09
- O 0 1.8680351487887492e-08
- O 0 8.223608460866672e-09
> O 0 3.998528125357531e-13
A O 0 1.1096360375689729e-12
mutation O 0 1.9269083550987887e-10
. O 0 1.4257360483188597e-12

Genotype O 0 0.0001037454348988831
- O 0 0.00022647000150755048
phenotype O 0 4.954256951350544e-07
correlations O 0 3.092168867624423e-07
in O 0 5.732542773806415e-10
attenuated B-Disease 1 0.9885711073875427
adenomatous I-Disease 1 0.9999921321868896
polyposis I-Disease 1 0.9998629093170166
coli I-Disease 1 0.9999982118606567
. O 0 1.7042783184706423e-08

Germ O 0 0.0003694819752126932
- O 0 0.0002242138289147988
line O 0 1.2011789785049132e-08
mutations O 0 1.601972027254206e-11
of O 0 2.7194303791509632e-17
the O 0 3.389191572818004e-17
tumor B-Disease 0 8.384944648331949e-12
suppressor O 0 9.477223693321601e-12
APC O 0 8.996771105884704e-10
are O 0 3.745421805817148e-14
implicated O 0 1.0336798084153997e-07
in O 0 4.490186000793983e-11
attenuated B-Disease 1 0.9997596144676208
adenomatous I-Disease 1 0.9999996423721313
polyposis I-Disease 1 0.9999884366989136
coli I-Disease 1 1.0
( O 0 2.91819310405117e-06
AAPC B-Disease 1 0.9999985694885254
) O 0 3.000197746488853e-12
, O 0 2.0783026710447108e-16
a O 0 6.737083222026208e-15
variant O 0 1.145884016295895e-05
of O 0 3.8280609260255005e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999960660934448
polyposis I-Disease 1 0.9999998807907104
( O 0 1.3187237080103387e-08
FAP B-Disease 0 8.09043569915957e-08
) O 0 1.933551842941972e-12
. O 0 1.1508454779429744e-12

AAPC B-Disease 1 0.9999946355819702
is O 0 7.891234887758003e-10
recognized O 0 4.676231054939403e-14
by O 0 1.741149014975119e-17
the O 0 1.9394601074426645e-17
occurrence O 0 1.8140138913561032e-13
of O 0 1.6008875057502993e-15
< O 0 5.1697892494706466e-11
100 O 0 2.9252614870342586e-14
colonic B-Disease 0 6.751176506725187e-09
adenomas I-Disease 0 6.625540208915481e-06
and O 0 4.2604696761641345e-14
a O 0 1.071015457683531e-15
later O 0 1.0098920397855204e-12
onset O 0 2.9666930245753065e-08
of O 0 8.33942479516736e-08
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.7300043776008467e-12
age O 0 1.0889648557887988e-12
> O 0 8.611163946617081e-14
40 O 0 3.297371869905724e-13
years O 0 3.3007778368204788e-12
) O 0 1.4560755216570104e-13
. O 0 2.687548534413553e-13

The O 0 2.1337566316701612e-13
aim O 0 1.3847995016316728e-12
of O 0 9.424882664539396e-18
this O 0 5.325314854349145e-19
study O 0 8.688572805358994e-18
was O 0 5.505069565080092e-15
to O 0 1.0148021823134484e-16
assess O 0 9.1813310426625e-12
genotype O 0 7.048284178523545e-10
- O 0 2.1344622069818797e-08
phenotype O 0 1.7301579613437923e-10
correlations O 0 1.2069749644183503e-09
in O 0 4.463576210034237e-12
AAPC B-Disease 1 0.9999946355819702
families O 0 1.6978071726292399e-10
. O 0 5.485997940646303e-13

By O 0 1.4242127171614632e-14
protein O 0 1.5304415720840403e-11
- O 0 2.270974874818421e-08
truncation O 0 2.2308303471163526e-07
test O 0 1.6171189827218768e-06
( O 0 2.731201622488736e-15
PTT O 0 9.246407459140293e-12
) O 0 4.745987476575664e-17
assay O 0 3.588946360152251e-15
, O 0 1.0203519976049597e-18
the O 0 3.794899923191684e-19
entire O 0 1.245503842477267e-14
coding O 0 3.639078621775482e-12
region O 0 1.607466770640626e-14
of O 0 9.87734301498039e-18
the O 0 6.1321420055063e-17
APC B-Disease 0 1.111292373227879e-12
gene O 0 4.7315060533849665e-14
was O 0 1.3013448283381857e-13
screened O 0 2.538385474037952e-11
in O 0 8.079728831595053e-17
affected O 0 1.0023492283308798e-14
individuals O 0 3.4326386058350865e-16
from O 0 3.021736845660629e-14
11 O 0 5.806129799168502e-09
AAPC B-Disease 1 0.9999994039535522
kindreds O 0 1.482283209952584e-06
, O 0 7.069622936107384e-14
and O 0 5.257123539660971e-15
their O 0 1.2253331080911214e-15
phenotypic O 0 2.4901777861963126e-10
differences O 0 5.404650685325585e-11
were O 0 7.895257798234967e-13
examined O 0 2.643123053758245e-09
. O 0 4.03535191373372e-12

Five O 0 4.4227711770705724e-12
novel O 0 4.357045627068068e-11
germ O 0 1.7028578440658748e-05
- O 0 2.2478054233943112e-05
line O 0 7.971996751621191e-08
APC B-Disease 0 2.3133366333638605e-09
mutations O 0 3.3896399142391287e-12
were O 0 2.4687906036711168e-15
identified O 0 1.0790997137738803e-13
in O 0 7.086762033696188e-16
seven O 0 1.0994322813262514e-10
kindreds O 0 1.2424665328580886e-05
. O 0 2.1712706285703653e-11

Mutations O 0 1.3527023838832974e-06
were O 0 6.158601406625053e-12
located O 0 7.9708781892604e-14
in O 0 3.753468679696557e-17
three O 0 1.5851303635907644e-15
different O 0 1.5137822108749133e-16
regions O 0 7.140876533476542e-15
of O 0 5.12629178684886e-18
the O 0 3.2160909271003804e-16
APC B-Disease 0 6.666864109383663e-12
gene O 0 2.3969750338227735e-13
( O 0 2.4756644877963222e-16
1 O 0 1.2823311197821658e-16
) O 0 7.867852142517761e-17
at O 0 7.526669717171364e-13
the O 0 4.5840528638610434e-14
5 O 0 1.2875490604247197e-12
end O 0 5.479224279153483e-12
spanning O 0 2.753247976827744e-11
exons O 0 8.840334686510687e-08
4 O 0 3.864246422846662e-11
and O 0 9.230086313316566e-13
5 O 0 1.9573308495919942e-14
, O 0 5.011062797824202e-16
( O 0 2.930562274804713e-17
2 O 0 9.780089901437428e-17
) O 0 3.791862929572696e-18
within O 0 1.699536970477603e-18
exon O 0 6.445818271499926e-12
9 O 0 2.6237334527223766e-10
, O 0 1.1643656247235356e-14
and O 0 5.926934832679864e-14
( O 0 2.0798731230684794e-16
3 O 0 1.3854684984178096e-15
) O 0 4.948204019587317e-17
at O 0 2.867576849260346e-14
the O 0 7.440587812796806e-16
3 O 0 1.4833498470333273e-14
distal O 0 1.1701107747660866e-12
end O 0 9.821877686166935e-12
of O 0 5.688768564966447e-17
the O 0 1.1286015219982067e-15
gene O 0 3.596414182086005e-12
. O 0 2.8709600343769515e-13

Variability O 0 1.5107157746996336e-09
in O 0 1.4103820667371635e-15
the O 0 3.7029530905601885e-17
number O 0 1.6727965583898663e-13
of O 0 5.994273410969697e-10
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 1.3673426835225655e-09
most O 0 3.6411677942350506e-16
apparent O 0 1.3972414093516971e-14
in O 0 1.9026089795428557e-16
individuals O 0 3.656634033516763e-15
with O 0 3.299188586170995e-14
mutations O 0 1.2133303910200066e-11
in O 0 4.335078201630777e-15
region O 0 6.361647862142272e-13
1 O 0 4.559430090422811e-13
, O 0 9.594586410088812e-13
and O 0 2.2196630311555055e-08
upper O 0 0.004648035857826471
- O 1 0.9999933242797852
gastrointestinal O 0 0.02313876710832119
manifestations O 0 2.667697174274508e-09
were O 0 1.1080620064074856e-13
more O 0 4.4146626644977127e-16
severe O 0 3.222030281468946e-11
in O 0 3.594752572482332e-17
them O 0 2.28056207815866e-13
. O 0 4.1926141378101356e-12

In O 0 3.785961344773825e-13
individuals O 0 1.624195501942309e-14
with O 0 9.189341860149289e-15
mutations O 0 2.8641483282298985e-11
in O 0 4.208085939980729e-15
either O 0 2.892784969898976e-11
region O 0 5.3617419532026034e-11
2 O 0 6.524013534264794e-12
or O 0 1.904480878556214e-10
region O 0 8.925267643011825e-12
3 O 0 6.962820890601268e-14
, O 0 7.441261369425996e-18
the O 0 2.3063209956825877e-18
average O 0 7.300972977228315e-13
number O 0 3.807493989554543e-15
of O 0 1.8338098136630888e-15
adenomas B-Disease 0 1.620122986878414e-07
tended O 0 1.811557327757729e-11
to O 0 3.247466086257864e-16
be O 0 4.8675585182520256e-14
lower O 0 1.0715636785828177e-14
than O 0 6.613959889241862e-16
those O 0 1.1890115941590282e-15
in O 0 1.0572776089830259e-17
individuals O 0 8.391082261137973e-17
with O 0 1.6688878401514666e-15
mutations O 0 7.231041395001914e-13
in O 0 8.103534560228737e-15
region O 0 1.1134055916822705e-12
1 O 0 2.362661065055671e-12
, O 0 6.14442524637937e-13
although O 0 2.683514868651038e-11
age O 0 5.075567965917571e-09
at O 0 5.789185242299766e-10
diagnosis O 0 2.2094737150979427e-09
was O 0 2.1029990249221697e-11
similar O 0 1.1533454042072372e-13
. O 0 6.90106999323703e-12

In O 0 6.990896750380671e-11
all O 0 1.4481406074295933e-09
AAPC B-Disease 1 0.9999979734420776
kindreds O 0 7.55031067001255e-07
, O 0 1.210046175096431e-15
a O 0 1.7498194559814508e-16
predominance O 0 5.723742226709794e-12
of O 0 7.618613449529923e-14
right O 0 0.06304684281349182
- O 1 0.9999899864196777
sided O 1 0.9999983310699463
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 4.2439296521479264e-05
rectal B-Disease 1 0.9993950128555298
polyp I-Disease 0 0.010466566309332848
sparing O 0 1.316284858887684e-10
was O 0 7.446059047122588e-11
observed O 0 9.041747385529764e-12
. O 0 8.46142925690907e-13

No O 0 2.137331875928794e-06
desmoid B-Disease 1 0.9983052015304565
tumors I-Disease 1 1.0
were O 0 1.8859874773013985e-10
found O 0 1.7140418858557771e-12
in O 0 1.6323313804556287e-15
these O 0 8.013133613680307e-14
kindreds O 0 3.487112962829997e-06
. O 0 3.3603697081885375e-12

Our O 0 3.5034880812440106e-12
data O 0 1.8814036971143838e-13
suggest O 0 8.33108538753069e-14
that O 0 7.73666595604806e-15
, O 0 5.78930290547606e-15
in O 0 1.6367601176313362e-13
AAPC B-Disease 1 1.0
families O 0 2.5582441980781523e-12
, O 0 2.1935661452291063e-18
the O 0 1.0054256268490168e-19
location O 0 1.0206533138595137e-15
of O 0 2.567536328233484e-16
the O 0 1.2944825062127102e-13
APC B-Disease 0 8.23233818891822e-08
mutation O 0 2.1671177352633464e-10
may O 0 2.090329992432416e-11
partially O 0 3.2286371492995514e-11
predict O 0 1.0906375900055637e-13
specific O 0 6.23342523431436e-14
phenotypic O 0 1.2222982626042267e-08
expression O 0 3.6855005713931632e-09
. O 0 4.8627497861719604e-11

This O 0 3.200282242986005e-14
should O 0 6.179135843406222e-15
help O 0 3.8164062055277565e-16
in O 0 5.566551223254696e-19
the O 0 2.312646652621934e-18
design O 0 1.0318886587215581e-12
of O 0 4.149059072622774e-16
tailored O 0 1.819661643587267e-10
clinical O 0 3.83367920742117e-10
- O 0 2.3220718681216113e-09
management O 0 5.018397264584806e-13
protocols O 0 1.697402187881246e-14
in O 0 9.767845627628536e-20
this O 0 2.303803826917452e-20
subset O 0 1.1317999978163778e-16
of O 0 3.5149662378412643e-16
FAP B-Disease 0 3.1811672740467145e-10
patients O 0 1.7002512679026305e-13
. O 0 1.4997803592101057e-16
. O 0 9.68085000726572e-14

Wilms B-Disease 1 0.9895248413085938
' I-Disease 0 3.359480615472421e-05
tumor I-Disease 0 9.939869869413087e-07
1 O 0 4.550865760621914e-12
and O 0 1.6311379872659126e-13
Dax O 0 0.00016843981575220823
- O 0 2.625206718676054e-09
1 O 0 2.7850695298023203e-15
modulate O 0 2.3057288500369366e-13
the O 0 1.6802326818096355e-15
orphan O 0 7.102318178020539e-10
nuclear O 0 1.6615099920902487e-11
receptor O 0 2.1428300486011492e-14
SF O 0 6.905135574442056e-09
- O 0 7.080280806093242e-11
1 O 0 6.713759428669732e-16
in O 0 1.7739051604370658e-18
sex O 0 7.614269186950046e-14
- O 0 2.334294265383106e-15
specific O 0 1.607611458426396e-17
gene O 0 5.1660553005566934e-14
expression O 0 1.3459410452484888e-13
. O 0 2.1755868455505464e-14

Products O 0 4.779233675478167e-10
of O 0 1.4894849066702902e-14
steroidogenic O 0 1.3440666357666942e-08
factor O 0 2.7830879961721067e-12
1 O 0 7.851418083390516e-14
( O 0 7.587836337984849e-15
SF O 0 1.2005593816866167e-05
- O 0 9.531426314879354e-08
1 O 0 9.657415925984347e-13
) O 0 1.1566317056953355e-14
and O 0 6.990888987493116e-13
Wilms B-Disease 0 1.2541101568785962e-05
tumor I-Disease 0 4.771214179299932e-08
1 O 0 1.1135493568903421e-13
( O 0 4.1354697524730586e-16
WT1 O 0 8.983853244659556e-11
) O 0 2.8836313555709046e-17
genes O 0 4.725017124558464e-16
are O 0 6.883407455597784e-18
essential O 0 1.6543201969476727e-17
for O 0 6.20470741735925e-18
mammalian O 0 6.79294470608445e-14
gonadogenesis O 0 2.0541586487343722e-10
prior O 0 4.055896650435528e-14
to O 0 2.09641992757496e-14
sexual O 0 1.8352983022218439e-10
differentiation O 0 1.1255190356107558e-11
. O 0 2.0319558752604494e-13

In O 0 8.829326159087714e-13
males O 0 4.549564284334062e-12
, O 0 9.198915873552104e-15
SF O 0 2.0350214981590398e-05
- O 0 8.24682757638584e-08
1 O 0 8.014753818301815e-14
participates O 0 2.049451645717848e-13
in O 0 2.6930744196015536e-17
sexual O 0 1.1368899087936795e-14
development O 0 8.469993947407037e-19
by O 0 2.610961482323364e-19
regulating O 0 4.736348032524651e-13
expression O 0 7.227284058491847e-15
of O 0 6.254257024976279e-17
the O 0 6.4715794741599265e-15
polypeptide O 0 2.6096424221577763e-07
hormone O 0 6.024880594424076e-09
Mullerian O 0 2.95134583438994e-09
inhibiting O 0 4.795770447429959e-10
substance O 0 1.0885745638233857e-08
( O 0 5.677030568730645e-13
MIS O 0 0.0010446362430229783
) O 0 3.573092125994104e-12
. O 0 9.965893128099923e-13

Here O 0 4.1014823481955176e-11
, O 0 1.4827096807076162e-15
we O 0 8.991030271373376e-16
show O 0 2.3858897103541492e-14
that O 0 1.3031965058883546e-15
WT1 O 0 3.305762064087503e-08
- O 0 1.3957506261874641e-09
KTS O 0 1.4061216191407766e-08
isoforms O 0 1.5310042730115603e-12
associate O 0 1.9292978672980077e-11
and O 0 1.444798667098353e-14
synergize O 0 2.2185104864291816e-09
with O 0 1.3737601822164797e-13
SF O 0 0.00011568457557586953
- O 0 6.035303101725731e-08
1 O 0 3.517518443402548e-14
to O 0 1.0151550112406493e-15
promote O 0 7.615555755458026e-12
MIS O 0 0.011134999804198742
expression O 0 1.530124082993467e-10
. O 0 3.4875382204542504e-13

In O 0 8.267123422465994e-13
contrast O 0 1.3251152562385182e-12
, O 0 1.4141863034615194e-14
WT1 O 0 3.252711735513003e-07
missense O 0 1.0618766310699357e-07
mutations O 0 5.302254191263955e-09
, O 0 3.220819065011954e-15
associated O 0 2.2721811276027112e-14
with O 0 1.979491440554093e-12
male B-Disease 0 5.663283445755951e-06
pseudohermaphroditism I-Disease 1 1.0
in O 0 4.76508210667248e-09
Denys B-Disease 1 0.9999943971633911
- I-Disease 1 0.9999992847442627
Drash I-Disease 1 0.9999945163726807
syndrome I-Disease 1 0.9999988079071045
, O 0 5.237069865228136e-14
fail O 0 2.8550818393507926e-12
to O 0 4.892218781368503e-16
synergize O 0 1.4467740072632296e-07
with O 0 1.6621818504924946e-11
SF O 0 0.36357200145721436
- O 0 4.398804776428733e-06
1 O 0 9.68921037153292e-12
. O 0 4.3441129599780526e-13

Additionally O 0 2.6980712108937155e-10
, O 0 2.232818235994383e-15
the O 0 4.952698588163685e-17
X O 0 1.8902084093497251e-06
- O 0 1.7219457859596332e-08
linked O 0 3.736257525588371e-08
, O 0 3.628648911972428e-15
candidate O 0 5.31471203919537e-15
dosage O 0 1.955623813928997e-12
- O 0 2.454360770610259e-13
sensitive O 0 5.096867025655705e-11
sex O 0 2.640218252358828e-11
- O 0 1.8266136758531004e-13
reversal O 0 2.7701101232725095e-14
gene O 0 3.182920778072723e-14
, O 0 8.164125076877104e-17
Dax O 0 1.0615910639444337e-07
- O 0 2.648369856750321e-10
1 O 0 3.895496901126002e-15
, O 0 8.806602876091941e-17
antagonizes O 0 7.472047286460892e-12
synergy O 0 1.0380812962701436e-12
between O 0 6.618257374427228e-14
SF O 0 1.0597480468277354e-05
- O 0 3.089441591441755e-08
1 O 0 6.208460801666524e-14
and O 0 2.6194568009222123e-15
WT1 O 0 6.580655464993868e-11
, O 0 2.6960039624589714e-17
most O 0 1.1415592897502376e-18
likely O 0 7.26087958217166e-17
through O 0 3.0525481300220414e-18
a O 0 1.3288679701721541e-17
direct O 0 7.177523202181262e-16
interaction O 0 9.222743418578136e-14
with O 0 8.924887738570586e-13
SF O 0 0.008091953583061695
- O 0 1.347856709799089e-06
1 O 0 7.121192958231548e-12
. O 0 4.578305508144698e-13

We O 0 2.2574456193247272e-11
propose O 0 6.889627323508618e-12
that O 0 3.976725666701795e-15
WT1 O 0 2.031019263881717e-08
and O 0 1.645651063336695e-12
Dax O 0 0.00025525575620122254
- O 0 3.2641822578227675e-09
1 O 0 1.9847053450846534e-15
functionally O 0 2.560164706372648e-14
oppose O 0 4.7496868532681275e-15
each O 0 3.5197415184303084e-17
other O 0 7.910345403201345e-17
in O 0 4.069210467825193e-17
testis O 0 3.6648652862458775e-12
development O 0 2.1220116887054008e-16
by O 0 1.8684444350109455e-16
modulating O 0 5.4408717115039806e-11
SF O 0 0.0002821693487931043
- O 0 1.7272984109695244e-07
1 O 0 1.3796960969536531e-11
- O 0 1.5343662340683295e-08
mediated O 0 2.0762340735558382e-09
transactivation O 0 5.381647483204688e-08
. O 0 6.5043510941859e-14
. O 0 1.0085402429643384e-13

A O 0 4.900316263878324e-12
mouse O 0 1.174624952859915e-09
model O 0 6.398938268148413e-08
for O 0 1.1973955160726746e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.8082485198974609
- O 1 0.8415073156356812
centre O 0 1.5861104429859552e-07
mutations O 0 8.403673312784576e-09
. O 0 2.7717036565205744e-12

Imprinting O 0 9.116136290288068e-09
in O 0 5.251443675529863e-14
the O 0 3.441464371508121e-15
15q11 O 0 1.661374510186775e-10
- O 0 5.30497257233975e-10
q13 O 0 2.9612329949246785e-11
region O 0 2.322153530391873e-15
involves O 0 1.226998268986305e-15
an O 0 8.519127172983222e-17
imprinting O 0 4.351045745920601e-09
centre O 0 5.923262436091647e-10
( O 0 1.0591719253776662e-15
IC O 0 6.355890206505288e-12
) O 0 1.1470561199876118e-16
, O 0 2.2963394072309103e-18
mapping O 0 6.643044946595678e-14
in O 0 4.1881297908038584e-16
part O 0 1.7198561842800102e-14
to O 0 7.306812723063382e-16
the O 0 2.0339960981095124e-16
promoter O 0 2.5702672629135392e-11
and O 0 5.5641213140308725e-15
first O 0 1.0616192153205207e-15
exon O 0 1.246921836617343e-12
of O 0 8.549628697064951e-14
SNRPN O 0 6.525565368065145e-06
. O 0 4.332869566608943e-12

Deletion O 0 3.2929476923015955e-09
of O 0 3.068069547875439e-14
this O 0 2.8667876686633894e-15
IC O 0 6.053634393765606e-08
abolishes O 0 1.8679230384677226e-10
local O 0 3.642442928221759e-14
paternally O 0 8.03328514820123e-11
derived O 0 7.812470322629637e-15
gene O 0 5.368841222291865e-12
expression O 0 2.103816469992137e-12
and O 0 1.2604559323364795e-12
results O 0 1.7420331843709391e-09
in O 0 2.7631222110358067e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.9027280018235615e-07
PWS B-Disease 1 0.9999967813491821
) O 0 2.7737093871715857e-11
. O 0 1.0115305945287978e-12

We O 0 2.6902720051680262e-09
have O 0 2.859896970934181e-14
created O 0 1.9861215841724626e-15
two O 0 5.239662696607153e-16
deletion O 0 8.738462037305439e-11
mutations O 0 1.9231550379972262e-11
in O 0 3.9932478913709372e-16
mice O 0 6.387884110559128e-10
to O 0 8.229188679228713e-14
understand O 0 1.994331144672401e-09
PWS B-Disease 1 1.0
and O 0 5.281554273789402e-12
the O 0 1.631103387822902e-17
mechanism O 0 2.299070188513299e-14
of O 0 1.6738719342143436e-17
this O 0 5.402730303238998e-16
IC O 0 1.0769028335744224e-07
. O 0 6.23244132084283e-13

Mice O 0 5.294170023262268e-06
harbouring O 0 6.342012852655898e-07
an O 0 3.471859979413752e-14
intragenic O 0 6.536494367992418e-08
deletion O 0 1.765064894243551e-08
in O 0 6.330986624704382e-13
Snrpn O 0 1.285321377508808e-05
are O 0 2.1479790602435544e-13
phenotypically O 0 7.733746282267973e-11
normal O 0 8.359593806029839e-14
, O 0 2.1305193074799577e-17
suggesting O 0 3.5211951593166948e-15
that O 0 2.2431118237382256e-17
mutations O 0 1.0093657951560503e-13
of O 0 2.1101788766602746e-15
SNRPN O 0 6.712109097861685e-06
are O 0 6.283749918106285e-15
not O 0 2.1869175735222317e-16
sufficient O 0 8.402778594999473e-16
to O 0 1.669168716276776e-14
induce O 0 2.554892963857469e-09
PWS B-Disease 1 0.9999892711639404
. O 0 8.777852056329749e-11

Mice O 0 1.725521906337235e-05
with O 0 1.873135097008559e-14
a O 0 1.7759991267987131e-16
larger O 0 7.225267802440027e-16
deletion O 0 2.9460041177375995e-12
involving O 0 2.8045482602934158e-11
both O 0 2.157135798111498e-12
Snrpn O 0 3.7810636399626674e-08
and O 0 1.7018045569213054e-14
the O 0 7.141036199187099e-16
putative O 0 4.115798191151043e-08
PWS O 1 0.9999991655349731
- O 0 1.75622171809664e-05
IC O 0 7.913866284070536e-06
lack O 0 1.073749921441658e-12
expression O 0 6.014459932965777e-15
of O 0 3.081400644737228e-17
the O 0 1.0959163205086762e-15
imprinted O 0 7.874729313073203e-09
genes O 0 9.465775385741892e-11
Zfp127 O 0 3.814076610098027e-09
( O 0 1.2867859836891314e-15
mouse O 0 1.2096886860268885e-11
homologue O 0 8.9556591309492e-11
of O 0 3.1269840774887647e-13
ZNF127 O 0 2.3839471396058798e-05
) O 0 9.519316758466179e-14
, O 0 1.856049298967961e-15
Ndn O 0 4.4141204580405713e-10
and O 0 7.125536597395177e-13
Ipw O 0 2.9032031889641985e-08
, O 0 1.1803444777570143e-14
and O 0 1.6834149845924699e-15
manifest O 0 4.5180649315117866e-14
several O 0 1.4756951097038277e-16
phenotypes O 0 1.163972130485691e-11
common O 0 1.5241224081419258e-12
to O 0 3.784701718689831e-11
PWS B-Disease 1 0.9999998807907104
infants O 0 0.003387229284271598
. O 0 1.060847698748646e-12

These O 0 5.954258866184691e-16
data O 0 3.267824989013242e-14
demonstrate O 0 4.475743269115404e-15
that O 0 4.6915718962872304e-17
both O 0 9.893605286561509e-16
the O 0 7.301240305061633e-16
position O 0 8.319581135118881e-12
of O 0 8.48662244906846e-18
the O 0 1.4165550046287364e-16
IC O 0 2.2382733166903535e-10
and O 0 2.863847405545233e-15
its O 0 1.6748556173987917e-17
role O 0 3.840084446173758e-13
in O 0 6.290983596019449e-18
the O 0 4.591799025162309e-17
coordinate O 0 7.418135658694702e-14
expression O 0 2.3788363399474205e-15
of O 0 4.971530430143251e-18
genes O 0 1.2231941381410675e-15
is O 0 5.2603248245845024e-18
conserved O 0 8.707394406842577e-16
between O 0 6.045236451587789e-15
mouse O 0 4.082593534349144e-07
and O 0 6.972070698552102e-10
human O 0 1.0229595642785583e-10
, O 0 1.1078880936027553e-14
and O 0 2.0043745512627296e-14
indicate O 0 9.962196744080741e-15
that O 0 2.0024782139004167e-15
the O 0 9.672160698600489e-17
mouse O 0 2.0123704924657204e-09
is O 0 5.206670022157769e-15
a O 0 9.72120440255488e-18
suitable O 0 4.8237844484609865e-15
model O 0 1.1117408382776972e-10
system O 0 1.7741465577463672e-13
in O 0 4.912600842534055e-17
which O 0 3.625699649129207e-16
to O 0 1.8410414964166153e-17
investigate O 0 1.478847426461538e-13
the O 0 1.3086407572172724e-16
molecular O 0 4.926533017798017e-14
mechanisms O 0 8.700231155086766e-14
of O 0 2.286271626559405e-17
imprinting O 0 1.0571927361313627e-10
in O 0 5.237666769346066e-15
this O 0 1.7797157485525874e-16
region O 0 3.379357586474831e-15
of O 0 2.768572476239218e-18
the O 0 1.5634553992754577e-17
genome O 0 8.050835388975774e-14
. O 0 3.3370069979033e-15
. O 0 1.0287340505279671e-13

Mutations O 0 7.070042329360149e-10
of O 0 1.9235910709073083e-15
the O 0 2.9743069604934165e-16
ATM O 0 1.0726584065423594e-09
gene O 0 6.752907955043241e-11
detected O 0 1.9382005334023233e-08
in O 0 6.706640451326074e-13
Japanese O 0 0.08427019417285919
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.0001419873588019982
: O 0 1.7683541779937102e-15
possible O 0 7.414973536471836e-16
preponderance O 0 7.788528502694625e-12
of O 0 2.846604302898418e-16
the O 0 3.529706199310265e-16
two O 0 6.025321859964893e-15
founder O 0 6.490997843389135e-12
mutations O 0 1.9085309721500465e-11
4612del165 O 0 2.502228146905594e-10
and O 0 6.57949443625544e-13
7883del5 O 0 6.573332989034952e-10
. O 0 4.572702893418379e-13

The O 0 5.745483299193777e-13
ATM O 0 2.9368212040026265e-07
( O 0 5.313701700870865e-10
A O 1 0.9999998807907104
- O 1 1.0
T O 1 1.0
, O 0 1.736316575544003e-14
mutated O 0 7.24641904099009e-14
) O 0 1.4995623144006367e-17
gene O 0 6.032014267281149e-15
on O 0 1.1920141353746316e-14
human O 0 1.3069940637579214e-13
chromosome O 0 5.579101181041324e-09
11q22 O 0 1.4708705364796515e-08
. O 0 2.331814862727155e-12

3 O 0 4.438369227699468e-09
has O 0 3.8459228857146144e-11
recently O 0 3.0030805620029355e-10
been O 0 5.828149784612921e-14
identified O 0 4.0182738186107445e-14
as O 0 4.2415389900718353e-17
the O 0 6.648805385397638e-20
gene O 0 4.996193663830745e-16
responsible O 0 3.923130503997226e-15
for O 0 1.327055121141683e-16
the O 0 2.8043248333307208e-14
human O 0 2.1117692483585415e-07
recessive B-Disease 1 0.9997602105140686
disease I-Disease 1 0.9999992847442627
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.02310977131128311
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.7036230892951707e-11
. O 0 2.048357414675267e-13

In O 0 1.3154547709361836e-13
order O 0 1.5524089514427387e-15
to O 0 5.5463969676298415e-18
define O 0 2.7712078356205037e-15
the O 0 1.1356230280842508e-16
types O 0 9.922142968354919e-12
of O 0 1.1578324596013632e-14
disease O 0 4.737941239341126e-08
- O 0 1.6977425021380554e-10
causing O 0 1.7868007420873688e-12
ATM O 0 2.1114856529891313e-09
mutations O 0 4.055012922665746e-11
in O 0 1.0093672351120606e-14
Japanese O 0 3.374312200321583e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 3.5186547009402602e-09
as O 0 5.565094872524623e-16
well O 0 3.5515985599254406e-17
as O 0 1.4916945032862774e-17
to O 0 7.779622804315686e-19
look O 0 1.603981399469264e-14
for O 0 1.3863658735771438e-17
possible O 0 1.4246683361837913e-15
mutational O 0 2.2658316195522943e-11
hotspots O 0 5.388579773363267e-12
, O 0 1.7144642478234971e-15
reverse O 0 4.2577608105887066e-12
- O 0 1.9297036191190386e-10
transcribed O 0 2.370832870302042e-11
RNA O 0 4.080893067047453e-13
derived O 0 1.0682048541337755e-14
from O 0 6.212813555751698e-16
ten O 0 2.1812045374633264e-14
patients O 0 8.511692738335391e-16
belonging O 0 8.773234741053797e-18
to O 0 3.371202297010385e-18
eight O 0 8.12424604044841e-14
unrelated O 0 4.746879972428175e-11
Japanese O 0 0.00010294826643075794
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 2.7140392364066734e-11
was O 0 3.529484647254999e-12
analyzed O 0 1.8235931428106644e-12
for O 0 1.1624382383097499e-16
mutations O 0 7.254321561926441e-16
by O 0 3.8876511682893722e-19
the O 0 1.638011483311062e-18
restriction O 0 1.4949546007513611e-15
endonuclease O 0 3.800645215212839e-11
fingerprinting O 0 9.979270881865787e-12
method O 0 1.1962881856994456e-12
. O 0 2.0655898866350775e-12

As O 0 6.437634713502005e-12
has O 0 6.047950091040907e-14
been O 0 1.999058741892351e-15
reported O 0 9.741078793200006e-15
by O 0 2.3538838809043868e-17
others O 0 1.7674311450152635e-14
, O 0 7.006276036605798e-18
mutations O 0 4.577879560686512e-16
that O 0 1.7405656210326976e-16
lead O 0 3.2591971114125096e-14
to O 0 8.675230051206269e-17
exon O 0 9.382514903899519e-11
skipping O 0 2.3062757037450865e-08
or O 0 3.8795480716835584e-11
premature O 0 4.852988670644987e-13
protein O 0 7.742541823603163e-15
truncation O 0 4.477118675794145e-11
were O 0 3.1797961486113024e-10
also O 0 8.138138773983172e-11
predominant O 0 1.8691905662171493e-11
in O 0 1.5875267256776652e-15
our O 0 4.678671079033636e-12
mutants O 0 1.791340166479305e-11
. O 0 1.3942179930091086e-13

Six O 0 3.336269108200618e-11
different O 0 1.117953470818273e-15
mutations O 0 2.679166350577633e-12
were O 0 6.77597601034881e-15
identified O 0 5.0108002599622004e-14
on O 0 3.1760653135259886e-12
12 O 0 5.411814117499414e-13
of O 0 1.171175647858474e-16
the O 0 5.70918841174238e-15
16 O 0 1.0812650688002412e-13
alleles O 0 5.89683941325074e-14
examined O 0 1.2642572544407926e-09
. O 0 4.045709513927909e-12

Four O 0 2.4354292454259463e-12
were O 0 2.498845026705594e-15
deletions O 0 4.4775923420392605e-13
involving O 0 1.946862809854011e-12
a O 0 4.3939702679303416e-13
loss O 0 2.0196049693721463e-11
of O 0 6.2784207904663e-18
a O 0 4.174364711317588e-16
single O 0 9.09977063319467e-13
exon O 0 3.9528522816079104e-11
exon O 0 2.4361562767083456e-10
7 O 0 7.45386998651787e-12
, O 0 1.9928525314878189e-16
exon O 0 1.3410985646652995e-12
16 O 0 5.179396950390214e-13
, O 0 5.1914923961179435e-17
exon O 0 1.024157213029564e-12
33 O 0 8.527174734547505e-13
or O 0 1.6737787777955024e-14
exon O 0 2.397774478968273e-10
35 O 0 3.1483540774424057e-10
. O 0 6.8310335686605494e-12

The O 0 1.6389405837254761e-13
others O 0 2.5480443425237968e-14
were O 0 5.596944899528161e-16
minute O 0 9.129484159349196e-16
deletions O 0 6.960716725235017e-12
, O 0 2.3829052744677934e-15
4649delA O 0 4.2419865363407805e-12
in O 0 1.9319282970931242e-17
exon O 0 9.44265238916886e-12
33 O 0 3.761088662734835e-12
and O 0 2.6652478255672534e-15
7883del5 O 0 3.731633058112749e-13
in O 0 1.7977217168649682e-17
exon O 0 4.566658509674859e-11
55 O 0 3.434736522978099e-11
. O 0 5.968366534499225e-13

The O 0 1.4695964714248055e-13
mutations O 0 4.0895464098467116e-11
4612del165 O 0 1.319321318860034e-10
and O 0 9.145906010614088e-15
7883del5 O 0 2.7865192792075888e-12
were O 0 2.2421377689361077e-16
found O 0 1.9094654465530832e-16
in O 0 9.647346738129727e-20
more O 0 4.95293681876504e-20
than O 0 3.323648148883806e-19
two O 0 2.2378374719984037e-18
unrelated O 0 1.0048492460747009e-14
families O 0 1.2108034225512764e-15
; O 0 5.0520969119072424e-17
44 O 0 1.9240041688756843e-13
% O 0 1.0887113656151025e-16
( O 0 9.531656461496721e-17
7 O 0 1.2128896519948695e-13
of O 0 8.651407117215844e-16
16 O 0 2.6184002882567725e-13
) O 0 4.240582355693418e-18
of O 0 6.7133647642558705e-19
the O 0 1.1125032637889447e-16
mutant O 0 1.7345556935222106e-10
alleles O 0 1.1112670028970428e-12
had O 0 8.151316843729717e-10
one O 0 6.7571591734255556e-15
of O 0 3.7661761591388415e-17
the O 0 2.141700175470939e-16
two O 0 1.7966421265221827e-13
mutations O 0 1.3862325350111337e-11
. O 0 1.2582173801109486e-12

The O 0 3.809822737236429e-13
4612del165 O 0 1.1654700815544317e-10
mutations O 0 4.404007540592669e-12
in O 0 1.1237930218357625e-17
three O 0 2.2843186531331672e-17
different O 0 3.666727873686286e-18
families O 0 1.3102691780583688e-16
were O 0 1.0416338964465291e-15
all O 0 1.816250231713911e-17
ascribed O 0 4.5889624574057424e-17
to O 0 1.772120476906452e-17
the O 0 3.731370979766121e-16
same O 0 6.303731408391355e-13
T O 0 1.8484888641978614e-07
- O 0 1.815196881693737e-10
- O 0 4.432127841819122e-12
> O 0 1.8562040148297328e-16
A O 0 2.119067322771406e-16
substitution O 0 2.1447006573376893e-16
at O 0 3.2095355273633426e-15
the O 0 3.3271397919867264e-17
splice O 0 2.7092822429963803e-10
donor O 0 6.809251106758632e-14
site O 0 5.204630129651555e-13
in O 0 4.8871852880794445e-15
intron O 0 3.5795935104943055e-08
33 O 0 1.5170508183004472e-09
. O 0 1.326642788679333e-12

Microsatellite O 0 3.3312196023871365e-07
genotyping O 0 6.606496327776767e-08
around O 0 5.426784022155573e-12
the O 0 1.4901092546557113e-15
ATM O 0 6.51733289558365e-09
locus O 0 8.971260179180263e-09
also O 0 1.6708485706118381e-09
indicated O 0 1.2305937518997112e-11
that O 0 1.839954217132251e-16
a O 0 1.3880499372036855e-15
common O 0 1.3392573454309303e-13
haplotype O 0 7.0417998689065175e-12
was O 0 6.013405051685794e-11
shared O 0 7.279579872655328e-15
by O 0 9.726953307812124e-18
the O 0 3.455668439054196e-17
mutant O 0 1.948386937900004e-11
alleles O 0 1.4061851455384605e-13
in O 0 2.3194165551810577e-16
both O 0 1.073180105437381e-13
mutations O 0 2.4158150480069196e-10
. O 0 2.780297259780129e-12

This O 0 7.24163449068423e-15
suggests O 0 2.1468361756284832e-13
that O 0 9.456578902123448e-17
these O 0 1.919447796010924e-17
two O 0 3.5411042452254335e-15
founder O 0 9.652856985953306e-11
mutations O 0 5.085103005342262e-09
may O 0 5.1233385589544156e-11
be O 0 5.94595783742248e-14
predominant O 0 1.5098002058636095e-12
among O 0 1.105836071584737e-14
Japanese O 0 3.226482622742388e-11
ATM O 0 4.338679138182755e-10
mutant O 0 2.1976718223015723e-09
alleles O 0 9.030036718371548e-10
. O 0 1.5757886315248548e-11

W474C O 0 4.983743639996874e-09
amino O 0 5.887326216813538e-12
acid O 0 7.661722818685934e-13
substitution O 0 3.979684776303028e-15
affects O 0 9.402775528132533e-15
early O 0 4.986421335530431e-18
processing O 0 2.788544694226668e-16
of O 0 1.0977928791967214e-19
the O 0 5.207751809790046e-19
alpha O 0 1.994616014379333e-17
- O 0 2.886969499181144e-15
subunit O 0 3.949539601629186e-17
of O 0 4.339921536023177e-17
beta O 0 1.0076129451750022e-14
- O 0 2.291714214230911e-11
hexosaminidase O 0 5.643054912241041e-10
A O 0 3.2665161537031445e-14
and O 0 1.2969179800459505e-15
is O 0 7.113467923731932e-16
associated O 0 8.3378328731643415e-16
with O 0 9.653413593664617e-14
subacute O 0 0.00010305963951395825
G B-Disease 0 1.4146471585263498e-06
( I-Disease 0 1.8475036767367364e-13
M2 I-Disease 0 8.987017281469889e-07
) I-Disease 0 6.797315531617554e-13
gangliosidosis I-Disease 0 3.1875666195446684e-07
. O 0 7.864601331286636e-12

Mutations O 0 5.437249228634755e-08
in O 0 4.2931482072692054e-14
the O 0 1.3305330119533294e-15
HEXA O 0 5.8966548976968625e-08
gene O 0 1.710765860571395e-12
, O 0 6.9343783249433014e-18
encoding O 0 3.407481404701195e-18
the O 0 2.1826889786679754e-19
alpha O 0 5.063709369654629e-18
- O 0 2.636700062387705e-15
subunit O 0 1.0897043793968602e-16
of O 0 1.310099242073326e-16
beta O 0 9.896899651803265e-14
- O 0 2.621872718933105e-10
hexosaminidase O 0 2.7357562881746844e-09
A O 0 1.3743184108100381e-13
( O 0 5.5292249462674244e-17
Hex O 0 9.233767179692154e-13
A O 0 4.1774889923435355e-15
) O 0 1.9801282768227116e-17
, O 0 7.898216205725296e-19
that O 0 4.2679926396515874e-18
abolish O 0 1.0886740727661381e-12
Hex O 0 3.8607858576789056e-10
A O 0 5.1875214871323697e-14
enzyme O 0 5.706002337291238e-10
activity O 0 4.562084043868708e-09
cause O 0 1.0804121757246321e-06
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.8382694125175476
( O 0 7.962338741899361e-14
TSD B-Disease 0 1.9642021342747285e-09
) O 0 1.905144599140241e-15
, O 0 3.1781235355075435e-17
the O 0 2.2330312647806175e-15
fatal O 0 2.197535832237918e-05
infantile B-Disease 0 8.960581908468157e-05
form I-Disease 0 2.452614222825389e-10
of I-Disease 0 3.661658216219665e-12
G I-Disease 0 1.6633791801723419e-06
( I-Disease 0 1.8846601661020798e-14
M2 I-Disease 0 4.102588491150527e-07
) I-Disease 0 2.1108773908505574e-13
gangliosidosis I-Disease 0 1.0406649408878366e-07
, I-Disease 0 2.0227871840635542e-13
Type I-Disease 0 9.113192978027485e-10
1 I-Disease 0 1.0203672975994671e-11
. O 0 4.527161631684429e-12

Less O 0 1.0865411903537847e-09
severe O 0 3.1570499459121493e-07
, O 0 5.980625201887704e-14
subacute O 0 3.8154284993652254e-06
( O 0 1.3657578215066357e-13
juvenile O 0 1.3082640180073213e-05
- O 0 0.00445583974942565
onset O 0 1.529197470517829e-05
) O 0 5.322155910425508e-12
and O 0 3.2809074901329893e-11
chronic O 0 1.962220721907215e-06
( O 0 1.2015779632062562e-15
adult O 0 5.829165594661845e-09
- O 0 8.29458367661573e-05
onset O 0 2.4582741176004674e-08
) O 0 1.4743341130460472e-15
variants O 0 7.636551574473696e-14
are O 0 7.115258869019783e-16
characterized O 0 2.0811022141970597e-17
by O 0 5.345586466223406e-19
a O 0 5.807235387062822e-17
broad O 0 4.4144503048675066e-13
spectrum O 0 2.2420642274180447e-13
of O 0 9.146743726198923e-15
clinical O 0 3.119535185724942e-11
manifestations O 0 3.927067004916296e-12
and O 0 3.36979521977504e-14
are O 0 5.815174997454351e-16
associated O 0 2.312588410835004e-15
with O 0 3.5705151942705404e-13
residual O 0 4.436312337929849e-06
levels O 0 1.766907331557377e-08
of O 0 3.456108554726611e-14
Hex O 0 2.545351946992014e-07
A O 0 2.3072433720516816e-12
enzyme O 0 8.28803969898928e-10
activity O 0 5.107574363449885e-10
. O 0 9.672992658596447e-13

We O 0 3.571595103002423e-11
identified O 0 1.6695271467387363e-12
a O 0 2.6846626253996218e-14
1422 O 0 6.271098085264271e-10
G O 0 2.6668598707146884e-07
- O 0 3.855903329963439e-08
- O 0 7.358856635164557e-08
> O 0 1.6006067998786122e-11
C O 0 2.3869278775734415e-10
( O 0 2.3808675051026016e-17
amino O 0 2.9317824654699024e-16
acid O 0 4.026409760651535e-16
W474C O 0 1.7180716552667348e-15
) O 0 1.7196025109817612e-19
substitution O 0 4.364339328679314e-19
in O 0 3.4266021498494527e-19
the O 0 4.844766076604296e-17
first O 0 1.3619065944436848e-11
position O 0 4.695747263250283e-12
of O 0 2.3632768476321715e-17
exon O 0 1.6061074996007174e-12
13 O 0 2.468718046828855e-13
of O 0 5.201842675512248e-16
HEXA O 0 1.339092676744258e-07
of O 0 1.0421664684121153e-15
a O 0 1.8380839927369108e-13
non O 0 2.3581372943226597e-07
- O 0 5.265009690447187e-07
Jewish O 0 3.0661930772168944e-09
proband O 0 0.00011133137013530359
who O 0 6.295981958004404e-09
manifested O 0 1.3213560801084157e-10
a O 0 1.5408960796236583e-14
subacute O 0 1.7147883113466378e-07
variant O 0 1.6815009384885116e-09
of O 0 8.493391808004486e-14
G B-Disease 0 4.097493615518033e-07
( I-Disease 0 8.648396804472949e-14
M2 I-Disease 0 8.920338245843595e-07
) I-Disease 0 6.710146219050805e-13
gangliosidosis I-Disease 0 6.076574550206715e-07
. O 0 1.015124182629501e-11

On O 0 1.396277121701317e-10
the O 0 1.4547374806508917e-13
second O 0 7.033109650222968e-10
maternally O 0 2.509092155378312e-05
inherited O 0 4.1229449720958655e-07
allele O 0 4.2574566094799593e-10
, O 0 5.952425103381356e-14
we O 0 4.30333022092156e-14
identified O 0 1.5542948872404594e-13
the O 0 6.217229964362858e-14
common O 0 8.138892226838834e-09
infantile O 0 0.008997120894491673
disease O 0 0.013348878361284733
- O 0 1.2807186067220755e-07
causing O 0 1.1368824992530335e-08
4 O 0 8.641496372641111e-12
- O 0 6.569576438408831e-09
bp O 0 5.493964727598666e-10
insertion O 0 8.458399779198711e-12
, O 0 4.34493071946665e-14
+ O 0 1.7553687453250588e-12
TATC O 0 1.2952366290619466e-08
1278 O 0 2.7438848068661592e-11
, O 0 1.6337447078676817e-16
in O 0 1.1746829101993111e-17
exon O 0 5.888272508469683e-11
11 O 0 1.8941338081335246e-11
. O 0 2.5853296825410765e-13

Pulse O 0 2.8750539726729585e-09
- O 0 6.549255027188394e-10
chase O 0 6.188938944662326e-11
analysis O 0 1.2072297270193395e-14
using O 0 1.4455925063765196e-14
proband O 0 6.839162014493638e-10
fibroblasts O 0 7.556824090093617e-12
revealed O 0 6.74850106352487e-12
that O 0 6.960618975515321e-17
the O 0 2.810510243782442e-17
W474C O 0 3.305803981251687e-13
- O 0 1.8353425197811454e-15
containing O 0 3.525521327155237e-16
alpha O 0 1.162456105410981e-16
- O 0 2.6614279187333733e-15
subunit O 0 1.5249508696800533e-16
precursor O 0 1.0018446508042005e-14
was O 0 2.536888451046271e-12
normally O 0 5.869778447003507e-16
synthesized O 0 3.1817416235068504e-15
, O 0 7.941937250592093e-18
but O 0 5.382482443856027e-18
not O 0 5.7996168054670245e-18
phosphorylated O 0 1.2534446069511866e-14
or O 0 1.2874439165309112e-15
secreted O 0 8.455846699922942e-13
, O 0 2.9222374100059713e-15
and O 0 4.712832449733093e-15
the O 0 9.12342575619396e-16
mature O 0 1.4806638554132334e-11
lysosomal O 0 1.5879591478556998e-12
alpha O 0 7.649065385126547e-16
- O 0 8.527012646322718e-13
subunit O 0 1.4872819433810712e-14
was O 0 2.0626036989490615e-10
not O 0 2.7435364635501613e-13
detected O 0 6.107767624996541e-10
. O 0 3.1499108876786863e-13

When O 0 1.7663612543114549e-12
the O 0 1.115223165991917e-15
W474C O 0 1.3401372025989566e-12
- O 0 2.0267873818602573e-14
containing O 0 7.549518896791669e-16
alpha O 0 2.6547441935048264e-16
- O 0 1.3172291524947508e-14
subunit O 0 1.4771658500678368e-15
was O 0 1.5077389749033887e-13
transiently O 0 9.958944259536029e-12
co O 0 2.123209608129173e-09
- O 0 1.1199582233833993e-10
expressed O 0 7.74697265295025e-15
with O 0 2.418460837350636e-18
the O 0 9.128251354179665e-19
beta O 0 6.110868905384907e-17
- O 0 1.1453908796830894e-15
subunit O 0 1.1148860237178527e-17
to O 0 1.4185173086522837e-17
produce O 0 8.363034115048407e-15
Hex O 0 4.473448347863673e-11
A O 0 6.341135299139933e-14
( O 0 3.2959269587526504e-16
alphabeta O 0 9.14497817749993e-12
) O 0 4.402534807054256e-17
in O 0 1.863944307780861e-17
COS O 0 1.1794195415859576e-06
- O 0 5.317564166773536e-10
7 O 0 2.463722314268585e-13
cells O 0 3.3910574408170177e-15
, O 0 2.5922159152816873e-18
the O 0 3.225484816134548e-19
mature O 0 2.569075916494237e-15
alpha O 0 1.7160450139623237e-18
- O 0 9.873886359549429e-16
subunit O 0 4.7224737096109864e-17
was O 0 4.448923000832661e-12
present O 0 1.254520847013968e-14
, O 0 1.8942950864677587e-16
but O 0 1.8770743772544867e-16
its O 0 1.1046628488964731e-16
level O 0 1.1703907394839449e-14
was O 0 3.450417848573778e-14
much O 0 8.334043856563257e-17
lower O 0 4.507974566824325e-15
than O 0 2.6378026660200972e-18
that O 0 9.985618475621743e-18
from O 0 2.8692341529323273e-18
normal O 0 4.666387224485196e-17
alpha O 0 1.8825591802857543e-17
- O 0 2.2532694229893645e-14
subunit O 0 5.24186127650087e-16
transfections O 0 3.4157707912152446e-11
, O 0 4.136995768354321e-18
although O 0 7.954877043709413e-20
higher O 0 2.132396345725963e-18
than O 0 2.2001025264295003e-18
in O 0 1.2328993854024256e-17
those O 0 1.4004637344412893e-15
cells O 0 1.8888121098512836e-15
transfected O 0 5.80671578528924e-13
with O 0 7.63900170727088e-17
an O 0 1.200770366921886e-17
alpha O 0 4.6324981509496006e-15
- O 0 2.4701723999598357e-10
subunit O 0 7.064127386345598e-13
associated O 0 2.9651625599314e-10
with O 0 7.087378461889671e-10
infantile O 0 0.10853111743927002
TSD B-Disease 0 0.00048049481119960546
. O 0 3.816925248090186e-11

Furthermore O 0 5.0550619246081396e-11
, O 0 5.7390791456598e-16
the O 0 9.884160017203592e-19
precursor O 0 1.1723881278768652e-14
level O 0 1.441735592673174e-13
of O 0 4.807446334343864e-18
the O 0 2.8276735797484273e-17
W474C O 0 1.4711615172607884e-13
alpha O 0 2.5636302490321104e-17
- O 0 7.206330263321789e-16
subunit O 0 3.677641694688311e-17
was O 0 3.5593874513919176e-15
found O 0 8.147173168275687e-16
to O 0 1.7302176577441082e-17
accumulate O 0 3.29767849583263e-14
in O 0 3.9133325413697295e-19
comparison O 0 6.886536018110582e-17
to O 0 2.3053106772824155e-17
the O 0 4.7930007829984826e-17
normal O 0 4.297830086593947e-16
alpha O 0 5.861741957218636e-17
- O 0 5.51385456729254e-15
subunit O 0 2.0837414960688102e-15
precursor O 0 4.4117232653531624e-13
levels O 0 1.2463381715566157e-10
. O 0 6.468957314265111e-13

We O 0 6.933261690461601e-12
conclude O 0 3.02027418916731e-13
that O 0 1.6521957324368405e-16
the O 0 2.742485954230735e-16
1422 O 0 1.1112299275195525e-10
G O 0 4.1353128921173266e-08
- O 0 1.5801944641680166e-08
- O 0 1.1141300326755754e-08
> O 0 1.3162484340314973e-12
C O 0 6.86020615314753e-11
mutation O 0 4.810106645132019e-14
is O 0 2.2735152044946368e-15
the O 0 5.514543152139098e-17
cause O 0 9.01414749456984e-15
of O 0 9.691929706435575e-15
Hex B-Disease 0 0.0001782716135494411
A I-Disease 0 7.149513976401067e-07
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 8.885168093625533e-15
the O 0 6.435001457475581e-14
proband O 0 3.626818624979933e-06
. O 0 1.653800794226834e-12

The O 0 4.2374378338887533e-14
resulting O 0 1.2111927400696582e-13
W474C O 0 1.2068263922915268e-11
substitution O 0 2.709183551596276e-14
clearly O 0 1.8930337982933643e-13
interferes O 0 3.6976793019649276e-14
with O 0 6.552426849916328e-18
alpha O 0 1.0874323954955853e-17
- O 0 4.342805683208578e-16
subunit O 0 7.623772154140921e-18
processing O 0 1.9745794897167018e-14
, O 0 7.034096291955064e-19
but O 0 6.870283640643565e-20
because O 0 3.2756540957677135e-19
the O 0 5.313180631750875e-19
base O 0 1.0605916373005592e-14
substitution O 0 1.8249393670020865e-16
falls O 0 5.880489872822636e-09
at O 0 1.9315824710108148e-13
the O 0 5.325221494609309e-16
first O 0 8.226482862971896e-12
position O 0 2.724466431538314e-13
of O 0 3.017364829847711e-18
exon O 0 7.758070986844945e-13
13 O 0 8.308424206873027e-14
, O 0 5.258539355232307e-18
aberrant O 0 1.9633358049682588e-14
splicing O 0 1.168465411233166e-11
may O 0 4.3354528300731943e-10
also O 0 1.0464106794602634e-12
contribute O 0 3.3369577852890644e-14
to O 0 5.81165500381127e-14
Hex B-Disease 0 0.0001294854300795123
A I-Disease 0 3.828494854474229e-08
deficiency I-Disease 0 1.6879434951988515e-06
in O 0 4.499394761652072e-18
this O 0 5.796545566570676e-17
proband O 0 2.4038795398695356e-09
. O 0 2.5957129851030165e-15
. O 0 4.447866228975139e-14

Two O 0 1.9326300542549246e-12
frequent O 0 4.4412884481204173e-10
missense O 0 1.9425273421802558e-05
mutations O 0 0.00021553288388531655
in O 0 1.3667808218542632e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.5179625334482694e-09

Pendred B-Disease 1 0.9999992847442627
syndrome I-Disease 1 1.0
is O 0 3.2354844734072685e-05
an O 0 3.357251262059435e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 8.91851304913871e-05
by O 0 1.6734325513842463e-12
early O 0 4.885538640309051e-10
childhood O 0 0.1927589625120163
deafness B-Disease 1 1.0
and O 0 1.3233217941888142e-05
goiter B-Disease 1 0.9999995231628418
. O 0 1.0222456908737243e-10

A O 0 1.111517648755278e-11
century O 0 3.802648029360006e-14
after O 0 9.500266479262661e-15
its O 0 4.438452643612534e-17
recognition O 0 6.713964304763849e-16
as O 0 7.476041541474437e-15
a O 0 1.3815043943890548e-12
syndrome O 0 0.0003921643947251141
by O 0 8.230362497487018e-15
Vaughan O 0 3.2949793649095227e-07
Pendred O 0 9.002220480169854e-08
, O 0 1.3687736907856641e-15
the O 0 5.667803970126311e-16
disease O 0 1.635059754256929e-09
gene O 0 8.600191739316365e-12
( O 0 3.3271704889901305e-14
PDS O 0 8.542555551827036e-10
) O 0 4.3341664765421764e-16
was O 0 4.652530056635691e-14
mapped O 0 2.336396143221009e-08
to O 0 1.108346314032671e-11
chromosome O 0 9.146283446170855e-06
7q22 O 0 2.1415930007151474e-07
- O 0 7.710971061669625e-08
q31 O 0 1.1077118777791384e-08
. O 0 1.7509847738406137e-12

1 O 0 8.767516157526245e-10
and O 0 3.29315611238834e-12
, O 0 2.1228303725187017e-15
recently O 0 7.387379596934807e-11
, O 0 8.15848486315235e-18
found O 0 3.7402331281512183e-17
to O 0 1.5899908570177913e-18
encode O 0 2.4410896616805858e-15
a O 0 1.5261194204522176e-14
putative O 0 1.0434062641673236e-10
sulfate O 0 8.84219863994673e-10
transporter O 0 1.624200329786163e-08
. O 0 2.866453168576255e-12

We O 0 6.507938077326969e-10
performed O 0 1.573024344244875e-13
mutation O 0 6.435390838521434e-15
analysis O 0 5.581933887516038e-16
of O 0 8.788978469652518e-18
the O 0 6.324046584129623e-17
PDS B-Disease 0 1.0359150204308776e-09
gene O 0 2.0631248445757144e-12
in O 0 1.0728883534090287e-15
patients O 0 1.3814424661162152e-14
from O 0 1.8343476531148157e-16
14 O 0 2.8924787369953575e-13
Pendred B-Disease 0 1.76672690366253e-10
families O 0 7.819499134374851e-17
originating O 0 7.175583708490287e-15
from O 0 3.350593660487143e-14
seven O 0 3.8587685824431617e-10
countries O 0 9.958944259536029e-12
and O 0 4.829365802660329e-14
identified O 0 5.310620785356837e-14
all O 0 1.2782549812465765e-13
mutations O 0 3.947019360656112e-12
. O 0 2.1837781962515818e-13

The O 0 1.6811416625114872e-13
mutations O 0 4.9309591132473685e-11
include O 0 1.5343214437683883e-13
three O 0 8.669123361879083e-14
single O 0 8.927795724922305e-10
base O 0 7.55259521589835e-10
deletions O 0 1.2268498439382824e-09
, O 0 4.682674942788935e-14
one O 0 1.0743837900774062e-14
splice O 0 6.865202522021718e-07
site O 0 1.0122448657057248e-08
mutation O 0 5.430191052369082e-08
and O 0 7.461185141943716e-11
10 O 0 8.241838201500373e-13
missense O 0 1.692926154817087e-08
mutations O 0 4.529500774452799e-09
. O 0 1.7192946719091218e-11

One O 0 4.729356836707943e-11
missense O 0 6.763783630958642e-07
mutation O 0 1.3603951742879872e-08
( O 0 4.0400785473147793e-13
L236P O 0 1.473294229670241e-11
) O 0 5.841654835572296e-16
was O 0 8.85485024334446e-15
found O 0 1.7784756076145124e-14
in O 0 1.3226170490011521e-17
a O 0 4.228116628056958e-16
homozygous O 0 1.2873244137345807e-10
state O 0 1.0346836734769524e-15
in O 0 2.7976637979972485e-17
two O 0 5.814644860708488e-15
consanguineous O 0 9.969450154301285e-09
families O 0 2.0101335960337474e-13
and O 0 2.1916006810447468e-14
in O 0 1.5881065395823955e-17
a O 0 1.2846028886164814e-16
heterozygous O 0 1.3012164045908547e-12
state O 0 4.704334168173291e-16
in O 0 9.28017899690182e-18
five O 0 1.0252350421261543e-14
additional O 0 2.568544606607742e-13
non O 0 1.0738543778643361e-06
- O 0 1.4060003650229191e-06
consanguineous O 0 6.422699698305223e-06
families O 0 1.443898056674442e-10
. O 0 3.293872336343484e-12

Another O 0 7.849124822323361e-11
missense O 0 6.332813882181654e-07
mutation O 0 4.879804116342257e-09
( O 0 2.1123233099728383e-13
T416P O 0 1.3229290059257881e-11
) O 0 8.495019953559874e-16
was O 0 3.996924522581789e-14
found O 0 2.758226420429121e-14
in O 0 1.9087215795718265e-17
a O 0 5.581423020769726e-16
homozygous O 0 1.2892385770069126e-10
state O 0 2.8261669331283885e-15
in O 0 3.9400892285668904e-17
one O 0 9.468753465493012e-15
family O 0 7.069070670625774e-14
and O 0 7.733188546986403e-14
in O 0 1.4908006312368372e-18
a O 0 1.046975471500372e-16
heterozygous O 0 1.1157249169696515e-12
state O 0 4.490296565698654e-15
in O 0 1.302862801376916e-16
four O 0 4.352331754546579e-13
families O 0 2.2617185088755903e-13
. O 0 4.428314540148165e-13

Pendred B-Disease 0 4.99902234878391e-05
patients O 0 9.366325492976557e-09
in O 0 1.7458263838494165e-15
three O 0 3.8706012136721646e-13
non O 0 4.16976604356023e-08
- O 0 9.612759868105059e-07
consanguineous O 0 5.9681588027160615e-06
families O 0 2.159358629405528e-12
were O 0 5.1964339678033794e-14
shown O 0 9.165955280475598e-15
to O 0 3.377163704966993e-17
be O 0 1.1663877676543395e-15
compound O 0 1.1824169132690614e-15
heterozygotes O 0 2.2382186978375102e-13
for O 0 2.018529144143751e-16
L236P O 0 1.2470389304519713e-11
and O 0 3.7468363508390626e-14
T416P O 0 1.0304362224600183e-10
. O 0 9.54291306349761e-14

In O 0 1.417330879396883e-12
total O 0 1.9628950429038255e-13
, O 0 1.295765062325619e-16
one O 0 1.3816940401955056e-16
or O 0 3.9228182876528683e-14
both O 0 1.4087051532598368e-14
of O 0 2.9512831491491665e-17
these O 0 3.2094480712115386e-16
mutations O 0 9.123296329559619e-14
were O 0 8.285584810483262e-15
found O 0 2.1409589528206645e-14
in O 0 8.645629558422181e-17
nine O 0 1.2784093445308842e-12
of O 0 2.4812236709082706e-16
the O 0 3.3310692122397526e-14
14 O 0 3.6540952555452755e-12
families O 0 2.207318732633766e-15
analyzed O 0 8.559235958882638e-11
. O 0 1.694674608976321e-11

The O 0 1.907908255888895e-15
identification O 0 5.157664083961424e-15
of O 0 1.7649096126345822e-16
two O 0 7.127678066092425e-15
frequent O 0 4.425243158023839e-12
PDS B-Disease 0 8.505884352416615e-08
mutations O 0 4.5989916735988956e-11
will O 0 2.4277543984754877e-15
facilitate O 0 2.3914365903125387e-16
the O 0 1.5067305292401233e-16
molecular O 0 5.663862781557505e-11
diagnosis O 0 8.90973569767084e-06
of O 0 3.0433380970862345e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 8.647638716219319e-10

Insertional O 0 1.0932291161225294e-06
mutation O 0 1.5059192781663455e-10
by O 0 6.5653972669142864e-15
transposable O 0 2.239876062404278e-09
element O 0 1.2907960811325836e-10
, O 0 6.491622560680921e-14
L1 O 0 3.419570049345566e-08
, O 0 1.8887113129305603e-15
in O 0 1.588785158556934e-17
the O 0 1.3963062002746336e-14
DMD B-Disease 1 0.9999998807907104
gene O 0 4.895484462252853e-09
results O 0 3.461933170689768e-11
in O 0 4.0037634665979205e-13
X B-Disease 1 0.9999980926513672
- I-Disease 1 0.9999988079071045
linked I-Disease 1 0.9999959468841553
dilated I-Disease 1 0.9999904632568359
cardiomyopathy I-Disease 1 0.9999996423721313
. O 0 2.982422642183735e-10

X B-Disease 1 0.9999804496765137
- I-Disease 1 0.9999969005584717
linked I-Disease 1 0.9999934434890747
dilated I-Disease 1 0.999996542930603
cardiomyopathy I-Disease 1 1.0
( O 0 3.0342403589678213e-10
XLDCM B-Disease 0 3.684142211568542e-05
) O 0 1.202280089992059e-14
is O 0 5.069512835745077e-16
a O 0 3.3521513117254964e-15
clinical O 0 8.593018518965323e-10
phenotype O 0 5.073917674902617e-11
of O 0 2.2049465321616855e-14
dystrophinopathy B-Disease 0 1.1025814274034929e-05
which O 0 2.3683344443025355e-14
is O 0 9.69728846037638e-16
characterized O 0 4.1127388292401014e-15
by O 0 1.9041855460857123e-15
preferential O 0 2.0660161226260243e-07
myocardial B-Disease 0 9.877821867121384e-07
involvement I-Disease 0 4.731116540201974e-11
without O 0 4.849247698811461e-14
any O 0 4.9248206559918475e-15
overt O 0 3.594847475252294e-10
clinical O 0 1.7786156991661528e-09
signs O 0 1.4273497939143454e-08
of O 0 3.722890919155564e-12
skeletal B-Disease 1 0.9999997615814209
myopathy I-Disease 1 1.0
. O 0 2.6681870934908147e-08

To O 0 2.5265378371798312e-14
date O 0 3.23424284316004e-13
, O 0 1.7618614520773243e-17
several O 0 3.4616962696139923e-18
mutations O 0 4.134332578977634e-13
in O 0 1.2410544631086349e-15
the O 0 1.9203829065145284e-12
Duchenne B-Disease 0 0.012154530733823776
muscular I-Disease 0 8.624858310213313e-06
dystrophy I-Disease 0 7.387827167804062e-07
gene O 0 5.6433616890672056e-08
, O 0 6.558627252406524e-11
DMD O 1 1.0
, O 0 1.4264324313742471e-12
have O 0 8.643251587538148e-14
been O 0 4.3897654608548997e-13
identified O 0 2.3556021716553133e-11
in O 0 1.627371468918698e-13
patients O 0 1.019032623041094e-12
with O 0 1.0147379491580802e-13
XLDCM B-Disease 0 0.0001390047837048769
, O 0 1.8566015644495707e-15
but O 0 7.720351280920775e-18
a O 0 9.421858078629596e-19
pathogenic O 0 4.683190531743929e-15
correlation O 0 2.748666806586409e-15
of O 0 2.478376316716516e-16
these O 0 1.019078213742447e-14
cardiospecific O 0 3.386028168961275e-08
mutations O 0 8.532943102101953e-11
in O 0 6.988006229441748e-14
DMD O 1 0.9999997615814209
with O 0 2.076406234452488e-11
the O 0 1.5719575164122035e-12
XLDCM B-Disease 1 0.9717046022415161
phenotype O 0 1.1027095752069727e-06
has O 0 2.952907074416089e-08
remained O 0 3.03283721921066e-12
to O 0 2.1432528927423745e-16
be O 0 1.154768121403027e-12
elucidated O 0 1.2683585293160604e-09
. O 0 1.0149649133303629e-12

We O 0 2.0958004776083783e-10
report O 0 7.756414325925387e-13
here O 0 2.862599130443886e-17
the O 0 7.299833362863524e-20
identification O 0 8.25579257061574e-17
of O 0 7.109933347887268e-18
a O 0 3.071592612012954e-15
unique O 0 1.0163611353355625e-13
de O 0 3.755725508369778e-09
novo O 0 5.913534995016789e-09
L1 O 0 5.551247905799528e-09
insertion O 0 6.62802495179915e-13
in O 0 2.8015953543614885e-16
the O 0 2.2077218938468794e-16
muscle O 0 9.831131134868665e-13
exon O 0 1.925594666357666e-12
1 O 0 5.1314285936729376e-14
in O 0 1.0999292026237645e-14
DMD O 1 0.9999998807907104
in O 0 1.2574826162986552e-13
three O 0 9.50894658152679e-12
XLDCM B-Disease 0 1.3097645933157764e-05
patients O 0 4.372223476279899e-14
from O 0 4.499943595988501e-18
two O 0 9.773190553384245e-17
unrelated O 0 2.997509358781958e-12
Japanese O 0 1.4097039091609531e-08
families O 0 3.7852967288420913e-13
. O 0 2.662263042397389e-13

The O 0 2.954531896372757e-14
insertion O 0 3.4172287395606293e-12
was O 0 2.518889610780839e-12
a O 0 2.183759146480598e-15
5 O 0 3.3197030465271365e-14
- O 0 1.8146084634906856e-10
truncated O 0 5.158164260304909e-12
form O 0 5.835271502108164e-13
of O 0 9.68800709685684e-16
human O 0 5.425702408515774e-14
L1 O 0 2.6739143885179395e-11
inversely O 0 4.233043088145219e-14
integrated O 0 3.1951743768160457e-12
in O 0 5.604953993091144e-17
the O 0 2.4432498603938803e-16
5 O 0 3.243744248898617e-13
- O 0 1.1604448957314162e-08
untranslated O 0 9.489276067142782e-07
region O 0 3.1896698823863368e-12
in O 0 7.340728981062629e-16
the O 0 3.803284235806689e-15
muscle O 0 2.494401169991778e-12
exon O 0 2.661125985368995e-13
1 O 0 6.9408725728720144e-15
, O 0 2.074602559815863e-17
which O 0 1.227798212195648e-16
affected O 0 1.724809061208314e-15
the O 0 1.0394927501842836e-18
transcription O 0 3.9164784154492593e-14
or O 0 3.775856038425174e-14
the O 0 1.5849074033432234e-14
stability O 0 3.273881166165893e-11
of O 0 9.033316273682679e-16
the O 0 3.2648357758610635e-13
muscle O 0 1.4622404398423328e-09
form O 0 3.347129888655936e-15
of O 0 9.895336674845256e-17
dystrophin O 0 1.1696510730449527e-12
transcripts O 0 1.1164884934546787e-13
but O 0 1.0751458020925799e-15
not O 0 6.72208390965667e-17
that O 0 3.866033402686243e-17
of O 0 1.4415435353639223e-16
the O 0 1.322082634341859e-13
brain O 0 5.7058120006558966e-08
or O 0 6.470556035420572e-11
Purkinje O 0 6.324943768731828e-08
cell O 0 3.2358434509660583e-07
form O 0 7.797235745954367e-09
, O 0 2.7446922512552874e-10
probably O 0 3.575703644287387e-08
due O 0 1.255212080109036e-11
to O 0 2.2546094291119208e-15
its O 0 1.771830798255936e-16
unique O 0 2.6416002935713588e-17
site O 0 3.7020142810637036e-13
of O 0 2.5484963193044517e-14
integration O 0 4.920588936307979e-10
. O 0 1.8001761106084535e-12

We O 0 4.720538738546554e-13
speculate O 0 8.826661325673016e-14
that O 0 1.0310420042127428e-17
this O 0 1.2303468921477248e-19
insertion O 0 6.864848401240626e-16
of O 0 1.939474831257568e-17
an O 0 1.2614587721239417e-16
L1 O 0 5.736453800864183e-08
sequence O 0 7.949539464202626e-12
in O 0 1.79067654801357e-12
DMD O 1 1.0
is O 0 5.99515608597917e-13
responsible O 0 6.6967276078036975e-15
for O 0 4.672194032385318e-17
some O 0 4.327454517984962e-18
of O 0 6.022781656132553e-19
the O 0 1.969603892453077e-17
population O 0 7.872741937990807e-18
of O 0 3.4654106414366004e-17
Japanese O 0 2.061929116337069e-08
patients O 0 4.954706519469821e-15
with O 0 3.3098871205145854e-16
XLDCM B-Disease 0 3.020224426109053e-08
. O 0 3.678543387730443e-15
. O 0 1.6954486588543344e-13

Severe O 0 6.21132567175664e-05
early O 0 1.6435989236285309e-09
- O 1 0.9906560778617859
onset O 1 0.9994391798973083
obesity B-Disease 1 1.0
, O 0 8.398469475423553e-08
adrenal B-Disease 1 0.9999997615814209
insufficiency I-Disease 1 0.9999998807907104
and O 0 1.703322149992914e-09
red O 0 2.9775545584698193e-08
hair O 1 0.9998214840888977
pigmentation O 0 3.168019975419156e-05
caused O 0 2.431452608697704e-11
by O 0 2.852442953943401e-15
POMC O 0 7.877344501139305e-07
mutations O 0 7.015019121148214e-11
in O 0 6.136381537756206e-16
humans O 0 6.896092312642932e-13
. O 0 9.467697893034144e-13

Sequential O 0 8.101175841268571e-10
cleavage O 0 1.6973920935470233e-07
of O 0 2.0126864432224887e-15
the O 0 2.6939889504867923e-17
precursor O 0 8.259518218564459e-15
protein O 0 1.5796268644247685e-13
pre O 0 4.34038627261657e-09
- O 0 1.3428978036245098e-06
pro O 0 3.355951037065097e-07
- O 0 1.238188360730419e-06
opiomelanocortin O 0 2.7907594812859315e-07
( O 0 3.255231684318291e-15
POMC O 0 3.9446654276353854e-11
) O 0 4.628519226914763e-17
generates O 0 1.360413687354501e-15
the O 0 1.7978467005468025e-15
melanocortin O 0 2.3967800188984256e-08
peptides O 0 6.768553495462015e-10
adrenocorticotrophin O 0 3.9167442622556337e-08
( O 0 3.290691490457319e-14
ACTH O 0 7.231190646272978e-10
) O 0 3.791360764766427e-16
, O 0 2.9671789135444755e-16
melanocyte O 0 1.496574597581457e-08
- O 0 3.3547396469657542e-06
stimulating O 0 4.585913848131895e-05
hormones O 0 6.6281190811423585e-06
( O 0 1.6387763482721683e-15
MSH O 0 7.178663913309791e-11
) O 0 6.126948303876202e-18
alpha O 0 1.033132537774848e-17
, O 0 5.175115398721766e-19
beta O 0 1.4563718231787317e-18
and O 0 1.1134276009003452e-18
gamma O 0 6.48802887467512e-19
as O 0 5.935885795116459e-17
well O 0 6.791574360300514e-17
as O 0 2.1317468435089864e-17
the O 0 9.858064536829076e-19
opioid O 0 5.774280246760913e-16
- O 0 2.707983814129785e-15
receptor O 0 2.297815097443705e-15
ligand O 0 1.2645531052412479e-14
beta O 0 1.0308519446042275e-12
- O 0 4.593367908256596e-09
endorphin O 0 2.558776941441465e-07
. O 0 4.555798880506723e-12

While O 0 1.0615641395442243e-12
a O 0 3.7128418693471374e-16
few O 0 6.293218555316506e-17
cases O 0 1.010469055569849e-14
of O 0 3.735889974655106e-14
isolated O 0 1.6839956515468657e-05
ACTH B-Disease 1 0.9948835968971252
deficiency I-Disease 0 0.012323737144470215
have O 0 1.240629913254812e-13
been O 0 4.253805695273588e-13
reported O 0 3.393212100188947e-11
( O 0 2.5780748792291613e-14
OMIM O 0 6.956987164130624e-08
201400 O 0 6.14952255784118e-10
) O 0 4.4272120928859956e-15
, O 0 1.4311059718713812e-16
an O 0 7.082252536164124e-15
inherited O 0 0.019567638635635376
POMC O 1 0.9998146891593933
defect O 1 0.9992631077766418
has O 0 1.2553912576152015e-08
not O 0 7.649015156072775e-14
been O 0 1.3837479881546877e-13
described O 0 2.0571265773716013e-14
so O 0 4.37234036682662e-14
far O 0 3.4056576460848864e-13
. O 0 1.5185850623863906e-13

Recent O 0 1.0858501597876824e-11
studies O 0 4.961745193854915e-14
in O 0 3.54365291111544e-18
animal O 0 6.375404388713358e-15
models O 0 4.303827259855009e-12
elucidated O 0 3.4515075259672345e-12
a O 0 3.1712466205925736e-16
central O 0 1.1813844859854769e-15
role O 0 1.259321016607376e-13
of O 0 7.452453950294451e-18
alpha O 0 8.801334066462223e-16
- O 0 5.219387769206385e-11
MSH O 0 4.646192319768261e-09
in O 0 9.591402062780201e-17
the O 0 1.2192609968987738e-17
regulation O 0 1.5851061172726492e-15
of O 0 2.2008414055116633e-18
food O 0 3.317585591213943e-16
intake O 0 6.772813407699444e-18
by O 0 2.297660395282112e-20
activation O 0 9.9765234593506e-17
of O 0 2.639807296875589e-17
the O 0 2.5282634126999777e-14
brain O 0 8.415318220045265e-09
melanocortin O 0 2.1931576554834464e-09
- O 0 1.454465020644946e-10
4 O 0 8.497739187665609e-13
- O 0 9.108461207496532e-11
receptor O 0 3.1204897064755766e-13
( O 0 4.129465612366006e-15
MC4 O 0 3.1473768036249794e-09
- O 0 1.9008783436191834e-09
R O 0 5.557859061866566e-09
; O 0 1.0809979527251598e-15
refs O 0 8.336741019743243e-11
3 O 0 4.1024773638972944e-14
- O 0 1.3356210235015986e-11
5 O 0 4.911893662667326e-15
) O 0 1.6964925322331016e-18
and O 0 7.713547099997067e-19
the O 0 5.059053686974451e-19
linkage O 0 9.281871278521425e-12
of O 0 5.085689153334384e-15
human O 0 6.0411862179421405e-09
obesity B-Disease 1 1.0
to O 0 7.909300249247728e-14
chromosome O 0 3.6378209333776113e-09
2 O 0 1.919417824279481e-14
in O 0 1.181135332567531e-17
close O 0 7.482004653423108e-15
proximity O 0 3.2733372253240887e-15
to O 0 1.1598477203894706e-15
the O 0 2.8327833192376287e-15
POMC O 0 2.388372832839991e-09
locus O 0 2.763062998886734e-12
, O 0 1.1719538329089843e-15
led O 0 1.4086077444709025e-15
to O 0 1.515798050027705e-17
the O 0 5.010429508347231e-17
proposal O 0 2.1715582890907692e-13
of O 0 3.02270026887577e-17
an O 0 5.5877954613901566e-15
association O 0 4.5403034088474514e-13
of O 0 9.392200321786063e-15
POMC O 0 4.6493914851453155e-06
with O 0 2.343533526960595e-11
human O 0 1.7295215002377518e-06
obesity B-Disease 1 1.0
. O 0 2.2634394358789223e-10

The O 0 2.269505655454196e-13
dual O 0 5.787816337310403e-10
role O 0 1.6427471362379098e-12
of O 0 1.3008910674943856e-16
alpha O 0 1.1217774010586525e-14
- O 0 4.19093926229408e-10
MSH O 0 1.1743074956882538e-08
in O 0 3.684129106796442e-17
regulating O 0 3.6617329177493496e-13
food O 0 6.9583697324634465e-15
intake O 0 3.656438792422421e-15
and O 0 2.2351766801220044e-17
influencing O 0 4.798004983770643e-13
hair O 0 1.8070155647365027e-06
pigmentation O 0 1.4136443404755283e-10
predicts O 0 1.573536093091299e-11
that O 0 9.174420527750457e-15
the O 0 4.8572430969104786e-15
phenotype O 0 2.3087236983299064e-11
associated O 0 1.6001556904596953e-14
with O 0 1.2660543017336667e-14
a O 0 1.2456238297764433e-12
defect O 0 1.2812650993510033e-06
in O 0 5.8461163698637214e-15
POMC O 0 5.885861469323572e-07
function O 0 5.522577620903357e-12
would O 0 1.7950066780181295e-11
include O 0 1.62554147919991e-09
obesity B-Disease 1 1.0
, O 0 2.665026944785598e-13
alteration O 0 2.0171037062866048e-10
in O 0 1.7928021263727278e-12
pigmentation O 0 0.0017059996025636792
and O 0 7.622932571393903e-06
ACTH B-Disease 1 0.9945642948150635
deficiency I-Disease 0 0.0052331313490867615
. O 0 1.1257804584385855e-12

The O 0 2.8382756756852034e-13
observation O 0 1.9104903423161623e-11
of O 0 2.6735978763612863e-15
these O 0 3.1980689797761475e-13
symptoms O 0 7.607560414957248e-11
in O 0 8.9700168728771e-19
two O 0 1.496197542192118e-16
probands O 0 9.345935830795682e-11
prompted O 0 2.2953720426655867e-14
us O 0 1.6856254229474484e-15
to O 0 8.418161517754757e-20
search O 0 5.587174903877174e-16
for O 0 1.2248378055752145e-15
mutations O 0 2.1452562220126287e-13
within O 0 3.489051529517815e-15
their O 0 4.12937337047805e-14
POMC O 0 2.6698621979903692e-08
genes O 0 3.066330522827343e-11
. O 0 5.764649283097889e-13

Patient O 0 4.412274847709341e-06
1 O 0 2.7822175986680353e-12
was O 0 1.299792738718164e-12
found O 0 1.5793247785944597e-14
to O 0 5.2385209226640334e-17
be O 0 1.8274549489763134e-15
a O 0 2.0984409124529063e-17
compound O 0 7.208337202011189e-16
heterozygote O 0 1.3355177966127563e-13
for O 0 1.967516419459238e-17
two O 0 1.1421876657743697e-16
mutations O 0 2.18765401573031e-14
in O 0 2.527893234155737e-17
exon O 0 5.144703239812198e-12
3 O 0 5.202029670740849e-13
( O 0 2.3041085522418044e-15
G7013T O 0 4.324579756798119e-12
, O 0 9.988142633804561e-16
C7133delta O 0 4.151951352171501e-11
) O 0 2.089272541805042e-16
which O 0 2.837993815942884e-17
interfere O 0 3.256970854717241e-15
with O 0 1.7889660100810944e-16
appropriate O 0 8.927831819689752e-17
synthesis O 0 1.7286690962280702e-15
of O 0 2.9962530547611834e-15
ACTH O 0 2.1640923719701277e-08
and O 0 3.2513366456619897e-14
alpha O 0 8.053062746813874e-14
- O 0 3.364076661682702e-08
MSH O 0 9.002483238873538e-06
. O 0 2.1108986954232467e-12

Patient O 0 1.6884715705600684e-06
2 O 0 5.669480510062108e-12
was O 0 9.855124528945769e-13
homozygous O 0 2.7713296935072407e-11
for O 0 3.994116100141873e-16
a O 0 9.279551927823056e-16
mutation O 0 5.791252893905252e-13
in O 0 2.862515022719202e-15
exon O 0 7.672701918259861e-10
2 O 0 8.279436164437826e-12
( O 0 9.250045323347215e-15
C3804A O 0 4.407335173900462e-12
) O 0 1.4419238796270191e-15
which O 0 2.6576738687111422e-15
abolishes O 0 4.761257166308042e-09
POMC O 0 9.78988282440696e-07
translation O 0 1.1706348113094123e-09
. O 0 1.2184836473139171e-11

These O 0 1.0250199804608465e-14
findings O 0 8.715744732922318e-14
represent O 0 3.2374965084686807e-16
the O 0 1.2290395125100695e-17
first O 0 2.7882283274208684e-14
examples O 0 9.319002275583188e-15
of O 0 7.119222983212933e-16
a O 0 8.406515067393983e-12
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
within O 0 3.9802768523331585e-15
the O 0 2.762804421750794e-16
POMC O 0 8.205711110598202e-10
gene O 0 5.893783724952861e-13
and O 0 1.414746615756128e-15
define O 0 2.139913883570342e-14
a O 0 7.321328601966187e-14
new O 0 3.3698419610317387e-09
monogenic B-Disease 1 0.8670287728309631
endocrine I-Disease 0 0.26354750990867615
disorder I-Disease 0 1.2682183978540706e-06
resulting O 0 2.6482014992619974e-15
in O 0 6.827711300459445e-16
early O 0 1.4643056767127405e-09
- O 1 0.999993085861206
onset O 1 0.9999481439590454
obesity B-Disease 1 1.0
, O 0 1.075884483725531e-07
adrenal B-Disease 1 0.9999998807907104
insufficiency I-Disease 1 0.9999998807907104
and O 0 9.968831315987359e-11
red O 0 3.043502949662269e-10
hair O 0 0.0015144497156143188
pigmentation O 0 5.615016362980896e-08
. O 0 4.046878460052701e-14
. O 0 1.9271921298386063e-13

A O 0 6.5382494973675875e-09
European O 0 5.67409763618798e-09
multicenter O 0 2.325274408576661e-06
study O 0 6.726128276568488e-08
of O 0 2.2408571567211766e-06
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
: O 0 2.805920372352805e-13
classification O 0 2.1435179748795913e-13
of O 0 5.2026738927661903e-17
105 O 0 1.1304942848814822e-13
mutations O 0 4.314216085071765e-12
and O 0 1.281071738490694e-13
a O 0 4.830797775385134e-16
general O 0 1.9333311027677855e-15
system O 0 1.6231840598999927e-16
for O 0 9.602929155488373e-18
genotype O 0 1.5967165672872534e-14
- O 0 4.298131674792399e-13
based O 0 3.3380255550223732e-15
prediction O 0 4.8621167855755765e-12
of O 0 8.955333761877238e-15
metabolic O 0 1.5669695585529553e-07
phenotype O 0 2.0783844090210835e-10
. O 0 1.6199986230952534e-12

Phenylketonuria B-Disease 0 0.003028684062883258
( O 0 1.3627543538063946e-10
PKU B-Disease 0 1.9978372733930883e-07
) O 0 7.398865049280945e-13
and O 0 4.161621568188334e-12
mild B-Disease 0 7.884033834670845e-07
hyperphenylalaninemia I-Disease 1 1.0
( O 0 7.987033967538082e-08
MHP B-Disease 1 1.0
) O 0 6.3180107846838585e-12
are O 0 5.5617533148422105e-12
allelic B-Disease 0 2.2920054107089527e-05
disorders I-Disease 1 0.8853719830513
caused O 0 7.917244334090801e-13
by O 0 6.67420140184618e-17
mutations O 0 1.2301496626898611e-12
in O 0 1.2830796851493018e-16
the O 0 4.083847805958678e-15
gene O 0 1.3885739669206032e-08
encoding O 0 1.3113321983837523e-08
phenylalanine O 1 0.7137543559074402
hydroxylase O 1 0.7569949626922607
( O 0 3.34819810765552e-10
PAH O 0 5.274294835544424e-06
) O 0 1.0350484575330499e-12
. O 0 1.4698432629443176e-13

Previous O 0 8.300597015287181e-11
studies O 0 1.4237822075838236e-12
have O 0 1.489888433166362e-14
suggested O 0 1.1074360321188057e-14
that O 0 1.646488285471898e-17
the O 0 5.4575159972207124e-17
highly O 0 5.3847169778631354e-12
variable O 0 2.6120194895895565e-10
metabolic O 0 2.1909150746068917e-05
phenotypes O 0 2.3430997941886744e-07
of O 0 1.676689898033601e-10
PAH B-Disease 1 0.9993301630020142
deficiency I-Disease 1 0.7503809332847595
correlate O 0 1.7588132061874262e-09
with O 0 4.872268699607218e-10
PAH O 0 0.0050027379766106606
genotypes O 0 3.2486707368661882e-06
. O 0 3.511169480163723e-11

We O 0 2.048953368083417e-11
identified O 0 3.797121905096956e-12
both O 0 7.516763497446635e-15
causative O 0 6.505385563571053e-09
mutations O 0 6.949576331072294e-11
in O 0 3.086650951991004e-15
686 O 0 3.791141012232657e-10
patients O 0 8.593599790107653e-12
from O 0 9.942415983663511e-15
seven O 0 1.9318109334420797e-09
European O 0 1.8693562253702112e-07
centers O 0 7.15144499174869e-10
. O 0 2.913420806688327e-12

On O 0 2.5242184644586052e-12
the O 0 3.362483234327647e-17
basis O 0 1.1332947462704856e-16
of O 0 2.9373863390823955e-19
the O 0 3.0100184320324743e-18
phenotypic O 0 1.4261820890926202e-12
characteristics O 0 2.4766211691585986e-14
of O 0 4.063734532170092e-17
297 O 0 1.7751425329670667e-12
functionally O 0 2.4069099144319317e-11
hemizygous O 0 1.3866953452179587e-07
patients O 0 5.68542045040199e-12
, O 0 9.658624053312181e-18
105 O 0 1.567218078445839e-16
of O 0 5.562457506403171e-18
the O 0 3.618819941652489e-15
mutations O 0 3.370578122163792e-11
were O 0 1.0612666344680943e-12
assigned O 0 9.676013787950077e-14
to O 0 1.4007354731986803e-16
one O 0 8.101835412136545e-15
of O 0 1.528392735121662e-16
four O 0 6.165338523728397e-15
arbitrary O 0 9.929497545371757e-14
phenotype O 0 5.4109529357138086e-11
categories O 0 7.406348867533552e-09
. O 0 1.2169785144899858e-11

We O 0 4.0461127503998995e-11
proposed O 0 1.337420191954708e-12
and O 0 6.861111207174045e-14
tested O 0 4.74595675259426e-11
a O 0 6.425222601727617e-19
simple O 0 1.9870509927281986e-18
model O 0 2.4231662751100953e-14
for O 0 6.888998989743489e-19
correlation O 0 1.5310485804579982e-15
between O 0 1.200570099878142e-15
genotype O 0 3.87955889202124e-13
and O 0 2.4230277005199245e-14
phenotypic O 0 8.791893602033696e-11
outcome O 0 8.925100936085784e-11
. O 0 1.7540909696966978e-11

The O 0 4.344118923090001e-14
observed O 0 3.06609365717872e-13
phenotype O 0 4.0144632409977454e-12
matched O 0 8.373001185620066e-13
the O 0 4.449015673860387e-16
predicted O 0 7.531470239130478e-12
phenotype O 0 1.381634303493362e-11
in O 0 3.2134680895792075e-15
79 O 0 7.004350571770956e-11
% O 0 1.2071409314966876e-16
of O 0 5.669182003395988e-18
the O 0 4.333507379030094e-15
cases O 0 5.023307880769323e-10
, O 0 1.0148486868574724e-12
and O 0 1.322620507039629e-12
in O 0 7.029436432012793e-17
only O 0 4.2870722387682253e-16
5 O 0 1.7604179557339703e-16
of O 0 2.096359601954631e-18
184 O 0 7.255685581433052e-14
patients O 0 8.88198240271091e-15
was O 0 7.205076379274145e-13
the O 0 7.367492575217904e-16
observed O 0 1.0406148599068077e-12
phenotype O 0 4.083725070884621e-14
more O 0 1.434844034146733e-17
than O 0 1.5865813839689702e-16
one O 0 1.5260223928281096e-15
category O 0 5.231721631436537e-13
away O 0 4.217282447739612e-13
from O 0 3.579089014228579e-15
that O 0 4.0132648045738614e-14
expected O 0 3.5764193256210275e-12
. O 0 2.2128769628336487e-13

Among O 0 1.4924895087170542e-12
the O 0 6.637465053528169e-16
seven O 0 6.453487782142817e-14
contributing O 0 7.927247183334152e-13
centers O 0 2.0682064459480454e-13
, O 0 8.508632897987884e-18
the O 0 3.3367599438697487e-18
proportion O 0 5.2451671613907083e-14
of O 0 1.0569192412544434e-16
patients O 0 6.483535873606013e-16
for O 0 6.284243728388367e-18
whom O 0 2.153285653895467e-14
the O 0 3.5163729081037474e-17
observed O 0 1.3431841901744013e-13
phenotype O 0 6.971873707690979e-13
did O 0 2.4438328964648814e-12
not O 0 7.100410754148911e-13
match O 0 4.4344215799352327e-11
the O 0 1.2469293777516723e-15
predicted O 0 3.5578470725106115e-11
phenotype O 0 1.0659039840002493e-12
was O 0 5.7152359234091676e-11
4 O 0 1.1804357404748833e-12
% O 0 7.557821725498893e-15
- O 0 8.531389816823776e-09
23 O 0 2.205784027653479e-10
% O 0 3.469106105895639e-14
( O 0 1.0884093004312218e-14
P O 0 1.0192721333623922e-07
< O 0 3.1957089426971896e-13
. O 0 2.3089984138892994e-17
0001 O 0 3.870111831916559e-14
) O 0 7.817794811440747e-18
, O 0 4.890326936589533e-19
suggesting O 0 2.1317407356073433e-15
that O 0 2.0199774381346577e-16
differences O 0 7.778892771930174e-16
in O 0 2.4504973615290558e-20
methods O 0 7.615020066272227e-19
used O 0 2.8966616008882074e-18
for O 0 4.432019246398403e-19
mutation O 0 2.0028600140013916e-15
detection O 0 6.691700551965038e-14
or O 0 2.279694662210563e-11
phenotype O 0 2.584792380133649e-09
classification O 0 7.26925097893627e-09
may O 0 6.329158724893702e-11
account O 0 7.954532994477233e-15
for O 0 1.0387213736573952e-15
a O 0 1.0964223168155422e-15
considerable O 0 6.477012767000089e-15
proportion O 0 3.7728652667323725e-12
of O 0 1.0767887368432275e-13
genotype O 0 1.15221165941648e-08
- O 0 7.073439974192297e-06
phenotype O 0 2.384004815780827e-08
inconsistencies O 0 4.761632155236839e-08
. O 0 1.6406844632887996e-11

Our O 0 1.4176986407737902e-12
data O 0 4.267336267335664e-13
indicate O 0 1.965291604043469e-14
that O 0 2.54975287150588e-16
the O 0 8.976539231711749e-15
PAH O 0 4.574788545141928e-05
- O 0 1.2378863267770157e-08
mutation O 0 1.0004026253229714e-11
genotype O 0 3.3571216553202055e-12
is O 0 4.090208599876084e-15
the O 0 2.8729359929686552e-18
main O 0 5.9638547965650164e-15
determinant O 0 2.264077640645734e-11
of O 0 2.9876929397962314e-15
metabolic O 0 3.3167196988870273e-08
phenotype O 0 1.386255693569538e-12
in O 0 4.455178566470601e-17
most O 0 1.2105507568582752e-13
patients O 0 2.182039965381577e-11
with O 0 6.047047584889498e-11
PAH B-Disease 1 0.9309801459312439
deficiency I-Disease 0 0.03325331583619118
. O 0 1.1728188949525209e-12

In O 0 1.1357553352658867e-12
the O 0 5.045358632462936e-16
present O 0 5.711712040529606e-16
study O 0 1.3069203803618397e-15
, O 0 1.5037210476483083e-17
the O 0 7.570473805346832e-19
classification O 0 1.1731441894855844e-14
of O 0 6.071970240771233e-17
105 O 0 2.871956958274552e-13
PAH O 0 2.8274478314216367e-09
mutations O 0 6.916487348129774e-12
may O 0 6.802214634659201e-14
allow O 0 7.5619375909385e-17
the O 0 1.6363945313291586e-17
prediction O 0 5.124193712575942e-13
of O 0 2.517202255610734e-17
the O 0 1.4402966234562252e-15
biochemical O 0 1.5062438796231703e-10
phenotype O 0 7.312508617293018e-14
in O 0 2.8180683584754616e-17
> O 0 7.644490136661953e-15
10 O 0 1.561718012939653e-13
, O 0 8.151556034382136e-16
000 O 0 1.4282823716598413e-14
genotypes O 0 6.387905482352352e-11
, O 0 3.589153713817739e-14
which O 0 3.784293570781999e-13
may O 0 2.511492316198405e-12
be O 0 4.1754475900010934e-16
useful O 0 2.5877330347673746e-16
for O 0 5.385298828405648e-17
the O 0 3.848686895845414e-16
management O 0 8.036954348561443e-13
of O 0 1.1263097896561155e-14
hyperphenylalaninemia B-Disease 1 0.9999998807907104
in O 0 2.3537820997843184e-12
newborns O 0 9.544030454833319e-09
. O 0 4.526069054050161e-14

Somatic O 0 5.413995154412987e-07
instability O 0 1.95928659962874e-08
of O 0 3.71927931974627e-15
the O 0 2.7993318705681882e-15
CTG O 0 1.4543140913758634e-08
repeat O 0 6.242402861983409e-12
in O 0 1.3279153062606768e-17
mice O 0 3.895684773033703e-14
transgenic O 0 6.328837735998516e-13
for O 0 3.786648879299529e-16
the O 0 4.0672245302589283e-13
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
region O 0 1.3196188586306334e-09
is O 0 1.4244756416093018e-11
age O 0 3.9379825789165324e-11
dependent O 0 7.782966979230643e-14
but O 0 6.45736824653847e-17
not O 0 9.83298131872917e-18
correlated O 0 6.019231057799424e-16
to O 0 3.2234709001766805e-17
the O 0 3.693150470905843e-16
relative O 0 3.336060269178154e-14
intertissue O 0 1.448521969038552e-09
transcription O 0 2.523138087351384e-10
levels O 0 1.4142033100128515e-09
and O 0 4.517175869467316e-11
proliferative O 0 2.527509604988154e-05
capacities O 0 1.8362944942396098e-08
. O 0 5.587374638481302e-13

A O 0 1.475862904110059e-10
( O 0 2.1880724500062537e-13
CTG O 0 7.921485689621477e-10
) O 0 7.551222491806835e-15
nexpansion O 0 5.939244929198395e-11
in O 0 3.42168302875574e-16
the O 0 8.578319820570822e-16
3 O 0 3.494799935555015e-11
- O 0 5.835236152051948e-06
untranslated O 0 3.583678699214943e-05
region O 0 4.839479164631122e-11
( O 0 4.893322888815249e-15
UTR O 0 1.1042732483632078e-12
) O 0 1.6270391186011838e-17
of O 0 6.0242323241318176e-18
the O 0 2.0081255180850327e-13
DM O 1 1.0
protein O 0 9.024354596931516e-10
kinase O 0 1.953732953197118e-09
gene O 0 1.2392865622601335e-09
( O 0 1.1023871567114249e-13
DMPK O 0 1.0516932213988639e-08
) O 0 1.9212426125040417e-17
is O 0 1.7794501243142844e-17
responsible O 0 1.3368889057851358e-13
for O 0 4.820924562332074e-11
causing O 0 0.00025297104730270803
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
( O 0 1.3042895830039924e-07
DM B-Disease 1 0.9999998807907104
) O 0 3.3355755657549224e-11
. O 0 9.098624631498353e-13

Major O 0 9.155255611403845e-07
instability O 0 6.048567797733995e-07
, O 0 9.00558992070373e-15
with O 0 3.241152382078369e-17
very O 0 2.973827419076901e-18
large O 0 1.5665657638147796e-17
expansions O 0 1.74760162938159e-12
between O 0 9.324652197099611e-16
generations O 0 2.626092702670557e-13
and O 0 2.873262391900333e-12
high O 0 5.690240292843818e-11
levels O 0 2.563893175999872e-14
of O 0 1.1608912451281532e-17
somatic O 0 1.403086848095203e-11
mosaicism O 0 8.594428502206597e-10
, O 0 5.142396844482757e-16
is O 0 2.1679296094738524e-16
observed O 0 1.175545934466865e-13
in O 0 1.0659008398139491e-14
patients O 0 1.5864637077991905e-12
. O 0 7.377596661839111e-14

There O 0 1.3526329578975038e-12
is O 0 1.912177937217767e-15
a O 0 9.82005331293558e-17
good O 0 1.5069332771639604e-14
correlation O 0 1.1618897474187113e-14
between O 0 7.855203981851563e-15
repeat O 0 1.7283891332042778e-11
size O 0 1.1603761571402083e-12
( O 0 9.356970739202099e-16
at O 0 1.0181612158737495e-14
least O 0 8.250598538113397e-17
in O 0 1.1569571410476265e-16
leucocytes O 0 5.40922195924054e-10
) O 0 5.635379019509825e-16
, O 0 1.836671335804375e-17
clinical O 0 6.908691826089386e-13
severity O 0 1.5055845025563341e-12
and O 0 4.1004010083167675e-12
age O 0 1.2967134310759576e-10
of O 0 1.1536886897201004e-13
onset O 0 7.450669414765798e-09
. O 0 2.879923296367215e-12

The O 0 1.0023814243920182e-11
trinucleotide O 0 1.204614477501309e-06
repeat O 0 1.6747993214494272e-08
instability O 0 2.2591178927555688e-10
mechanisms O 0 4.593420370631318e-13
involved O 0 2.0173160288506492e-13
in O 0 8.012308264776502e-14
DM B-Disease 1 1.0
and O 0 1.1424820508046385e-12
other O 0 2.969343029785151e-15
human O 0 1.23493729131674e-10
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 1.0745360357793457e-13
unknown O 0 3.534899695005478e-13
. O 0 1.2319246100664372e-12

We O 0 3.6395819691392717e-10
studied O 0 1.4019793138919656e-11
somatic O 0 1.061181253980692e-09
instability O 0 5.597770511012179e-11
by O 0 3.7681878623885704e-17
measuring O 0 5.6376969759242e-10
the O 0 4.98779586155431e-16
CTG O 0 5.421495696822376e-09
repeat O 0 1.492997045438038e-11
length O 0 2.920340293373347e-13
at O 0 5.347191263447952e-14
several O 0 1.1072954670012089e-16
ages O 0 2.568642455853809e-13
in O 0 7.765364795494686e-18
various O 0 1.7453252844517767e-17
tissues O 0 6.056711799847306e-14
of O 0 6.119401004569692e-19
transgenic O 0 8.65051693471619e-12
mice O 0 1.566558688326225e-11
carrying O 0 2.9082780021033594e-13
a O 0 1.0693749454471126e-14
( O 0 8.005338877686494e-15
CTG O 0 9.67972479948287e-10
) O 0 5.1274737121389125e-15
55expansion O 0 4.2840994640691576e-11
surrounded O 0 2.4361328248732536e-14
by O 0 5.851554400794433e-17
45 O 0 2.18477579777554e-15
kb O 0 1.4285467253571937e-10
of O 0 6.477084129525895e-16
the O 0 3.9314471816931373e-14
human O 0 2.0121948551832247e-08
DM B-Disease 1 1.0
region O 0 1.5344831525224145e-12
, O 0 2.660205612140177e-18
using O 0 1.6599789064309235e-16
small O 0 1.5019305243946235e-12
- O 0 3.994283815700328e-06
pool O 0 1.0393528260266294e-09
PCR O 0 2.3508064384003546e-09
. O 0 5.331733860837462e-13

These O 0 5.1849393918959596e-14
mice O 0 7.473584417994061e-09
have O 0 2.3104734542690047e-14
been O 0 1.0289180260841108e-14
shown O 0 2.8567988208746562e-15
to O 0 3.071575972447752e-18
reproduce O 0 6.437508403948911e-13
the O 0 4.276585970881217e-16
intergenerational O 0 2.3021102385500924e-11
and O 0 2.8967986812593197e-15
somatic O 0 3.712776613928881e-13
instability O 0 1.7226804292953812e-13
of O 0 3.0470918399064885e-18
the O 0 4.982052978171926e-16
55 O 0 2.1694179384770113e-13
CTG O 0 1.9776329185372532e-10
repeat O 0 2.8569121894583827e-12
suggesting O 0 2.501623311713247e-13
that O 0 1.3737312687468251e-17
surrounding O 0 1.3288534779678222e-16
sequences O 0 1.205150007023946e-14
and O 0 1.447435650069745e-14
the O 0 7.048094152473416e-18
chromatin O 0 1.1107450679712083e-13
environment O 0 7.740065099265392e-14
are O 0 1.724662643622447e-17
involved O 0 2.6004701338930335e-15
in O 0 2.9232072627305775e-15
instability O 0 1.2240053415268903e-09
mechanisms O 0 1.335917210187887e-10
. O 0 4.094648665270428e-12

As O 0 1.389535513561524e-12
observed O 0 3.5450998690442215e-14
in O 0 4.113658521732362e-18
some O 0 1.6931491457453446e-19
of O 0 1.1832679075842693e-18
the O 0 4.0969837517233754e-16
tissues O 0 2.444105751120418e-10
of O 0 3.719907411617318e-13
DM B-Disease 1 1.0
patients O 0 1.0807977623983334e-08
, O 0 9.335324150490525e-17
there O 0 2.4233754896010892e-17
is O 0 1.1756165092520303e-15
a O 0 4.52818890223143e-16
tendency O 0 4.690007063268276e-13
for O 0 6.241985370455136e-16
repeat O 0 7.499589491088976e-12
length O 0 8.639839738826607e-14
and O 0 2.916635557609305e-15
somatic O 0 1.0300397009941828e-13
mosaicism O 0 6.445424489270879e-12
to O 0 2.564816399560732e-15
increase O 0 1.0162447868899277e-13
with O 0 1.3819307297883304e-13
the O 0 1.4489887696818304e-13
age O 0 1.2800037418880805e-10
of O 0 7.385413277752743e-17
the O 0 1.3288997206727863e-15
mouse O 0 1.1295272273059709e-08
. O 0 6.513992036744076e-12

Furthermore O 0 1.686611517115466e-09
, O 0 8.880563791930848e-14
we O 0 8.546999506796674e-15
observed O 0 2.38805587006181e-15
no O 0 2.663436041945411e-17
correlation O 0 1.8253648951789634e-15
between O 0 3.2944438570015673e-16
the O 0 3.2745721993611854e-16
somatic O 0 1.663489485048686e-10
mutation O 0 1.6883011655366431e-09
rate O 0 2.3029444662370224e-07
and O 0 1.353769266826399e-11
tissue O 0 3.524480973737809e-07
proliferation O 0 0.0043774857185781
capacity O 0 3.6355024546352865e-10
. O 0 7.463255274203773e-13

The O 0 3.8705475456646266e-14
somatic O 0 3.4429042949923883e-10
mutation O 0 3.647548041385562e-09
rates O 0 1.763584123182227e-08
in O 0 3.2822508177258417e-16
different O 0 6.893136654700959e-16
tissues O 0 3.0163699316076986e-10
were O 0 3.973800861934926e-14
also O 0 1.2068245911606677e-14
not O 0 1.6400567907731758e-17
correlated O 0 6.807789614935616e-16
to O 0 1.448776402640086e-16
the O 0 9.18575382858472e-14
relative O 0 1.4407337302346779e-11
inter O 0 6.340234648405385e-08
- O 0 1.4836309674137738e-06
tissue O 0 8.843738896757714e-07
difference O 0 2.007322476640927e-12
in O 0 3.069645084743869e-17
transcriptional O 0 8.287943627834776e-14
levels O 0 2.0708353651657796e-13
of O 0 2.5328630179940168e-18
the O 0 6.095689148527823e-17
three O 0 9.911397213618585e-16
genes O 0 1.1900558799038743e-14
( O 0 5.526613106939676e-16
DMAHP O 0 3.064977160960325e-09
, O 0 7.685718618336609e-15
DMPK O 0 4.243962052896677e-07
and O 0 1.394293795003998e-11
59 O 0 2.2723394346724213e-12
) O 0 5.305813719856447e-17
surrounding O 0 8.50805632001371e-16
the O 0 6.180809580509997e-15
repeat O 0 4.779008300204168e-09
. O 0 1.0145946989460405e-13
. O 0 4.087467669021405e-13

A O 0 3.717278221349041e-12
novel O 0 7.710073898770098e-12
missense O 0 5.218639387294388e-08
mutation O 0 7.754473174692578e-10
in O 0 3.235572049612519e-15
patients O 0 8.111854964869616e-15
from O 0 1.1621672539410775e-17
a O 0 7.350088165734197e-16
retinoblastoma B-Disease 0 1.428604576858561e-07
pedigree O 0 1.641085145820398e-05
showing O 0 0.0001185408400488086
only O 0 1.0878765666078039e-09
mild O 0 1.4014353011404523e-09
expression O 0 2.0847684811657087e-14
of O 0 8.284375300374143e-17
the O 0 2.908260180530149e-14
tumor B-Disease 0 3.8378239253233914e-08
phenotype O 0 1.7611688496455002e-10
. O 0 8.255699184174514e-13

We O 0 8.655988703587525e-10
have O 0 3.2684962202722935e-15
used O 0 6.081892437654929e-17
single O 0 4.245446699811632e-14
strand O 0 1.53702068433903e-11
conformation O 0 1.081185163100129e-12
polymorphism O 0 2.7503059508646177e-13
analysis O 0 1.9875060595247497e-14
to O 0 2.645302423120901e-16
study O 0 3.63621418674083e-15
the O 0 2.8151701161324228e-15
27 O 0 5.353010244270318e-13
exons O 0 3.3590814591671903e-12
of O 0 2.3783892719873928e-17
the O 0 3.4273525908486277e-16
RB1 O 0 3.5632021777587397e-09
gene O 0 2.812126182957786e-12
in O 0 7.714584177690055e-17
individuals O 0 3.6348791039972795e-17
from O 0 4.1077799145550705e-17
a O 0 1.2081742534588227e-14
family O 0 3.5310754320505566e-11
showing O 0 0.00020954317005816847
mild O 0 1.9481223745287934e-08
expression O 0 6.511224004223217e-15
of O 0 1.210377920844179e-16
the O 0 3.2664226412657676e-14
retinoblastoma B-Disease 0 1.5004981435140508e-07
phenotype O 0 1.8115972055809948e-09
. O 0 5.319831380967699e-12

In O 0 2.360690141360155e-14
this O 0 3.123329768243051e-17
family O 0 1.3142194750265668e-15
affected O 0 2.6239183352136375e-14
individuals O 0 8.931316142657842e-15
developed O 0 4.662262753640789e-08
unilateral B-Disease 1 0.9999814033508301
tumors I-Disease 1 1.0
and O 0 2.1234779268297643e-08
, O 0 9.013489349969823e-16
as O 0 7.24544042147448e-17
a O 0 2.635098653956692e-17
result O 0 3.523975227328702e-16
of O 0 4.0649127682346124e-17
linkage O 0 7.969906401505966e-10
analysis O 0 3.292542280486366e-11
, O 0 3.1162908625120833e-13
unaffected O 0 1.6375931166656699e-10
mutation O 0 7.08894332124288e-11
carriers O 0 8.766384063108035e-09
were O 0 3.829275872085924e-12
also O 0 2.802659146428077e-12
identified O 0 2.940670710410709e-12
within O 0 2.837509551325071e-15
the O 0 1.0396228149189835e-12
pedigree O 0 1.0401056897535454e-05
. O 0 4.0540387019616375e-11

A O 0 1.3413293913078217e-11
single O 0 1.6410121959214985e-12
band O 0 7.533933871727017e-14
shift O 0 3.292900086515637e-15
using O 0 1.437957965488856e-15
SSCP O 0 6.309951228189448e-09
was O 0 4.344682369406515e-14
identified O 0 5.1254984313059155e-15
in O 0 1.257590230378766e-17
exon O 0 1.2628437358330746e-11
21 O 0 1.2467433769397518e-12
which O 0 1.4094939262221878e-16
resulted O 0 1.7629388846036767e-15
in O 0 2.813363686023505e-17
a O 0 1.1943667482098067e-15
missense O 0 2.3510879354482483e-10
mutation O 0 1.84555970224147e-13
converting O 0 1.9000515679053198e-13
a O 0 2.7609753133935044e-13
cys O 0 3.7042809708509594e-06
- O 0 3.711129750172404e-07
- O 0 2.6317453105662025e-08
> O 0 2.1873850387238436e-12
arg O 0 5.628091881426656e-10
at O 0 2.9986687503751053e-13
nucleotide O 0 2.4542028565638363e-12
position O 0 1.8933283760236286e-11
28 O 0 1.2216372492323668e-14
in O 0 1.825431688359066e-18
the O 0 1.3249862431680143e-16
exon O 0 8.51103687526944e-10
. O 0 2.8794178413144023e-12

The O 0 3.457180288574113e-12
mutation O 0 3.293479933219601e-10
destroyed O 0 2.3321286568567245e-10
an O 0 2.412284781649898e-13
NdeI O 0 1.4623996094087488e-06
restriction O 0 6.7324435956694906e-12
enzyme O 0 7.474716678945725e-11
site O 0 2.3946743893388245e-11
. O 0 1.855528317801225e-12

Analysis O 0 3.06669143204652e-12
of O 0 2.8198025393209565e-15
all O 0 1.3898620583152176e-15
family O 0 1.3440720924613606e-15
members O 0 2.46261793047734e-17
demonstrated O 0 2.459361485841841e-16
that O 0 2.575793898580672e-18
the O 0 6.950563106244636e-17
missense O 0 2.0230768171813907e-09
mutation O 0 2.5716906382200477e-10
co O 0 3.633219023413403e-07
- O 0 6.1862301947712695e-09
segregated O 0 4.769435402174338e-10
with O 0 1.6462414114196133e-12
patients O 0 6.201294686092318e-12
with O 0 2.3652864389323014e-11
tumors B-Disease 1 1.0
or O 0 2.387312925122842e-08
who O 0 1.6310134469676996e-06
, O 0 9.410598724433374e-15
as O 0 1.5030379420461273e-14
a O 0 3.893521196776531e-15
result O 0 8.600014451932373e-15
of O 0 5.1619498059767347e-17
linkage O 0 2.892422412692497e-10
analysis O 0 1.3375712863694655e-11
had O 0 3.5631340100650277e-09
been O 0 1.861632592872753e-12
predicted O 0 6.451740183766042e-14
to O 0 1.5698927173256924e-16
carry O 0 1.4856844053612317e-12
the O 0 5.327116582598025e-14
predisposing O 0 5.911208744713292e-10
mutation O 0 2.4630389741653325e-11
. O 0 1.7936778364674444e-12

These O 0 5.448722392329894e-15
observations O 0 3.947398844969009e-14
point O 0 3.069362797779307e-14
to O 0 8.287215673161527e-18
another O 0 8.462352539762236e-16
region O 0 6.800446792194987e-15
of O 0 9.425817378631581e-18
the O 0 2.902482801730988e-16
RB1 O 0 2.403966803399271e-09
gene O 0 9.96709117150052e-13
where O 0 2.3867262400928575e-15
mutations O 0 2.0640595420448778e-14
only O 0 5.451315451349015e-17
modify O 0 3.75359635138451e-14
the O 0 2.1088097537801565e-16
function O 0 5.234468267058116e-16
of O 0 5.0202441717512954e-17
the O 0 2.1213571704651896e-15
gene O 0 1.8300538168203317e-11
and O 0 2.582053711466803e-12
raise O 0 9.43659348795825e-14
important O 0 7.55458944777217e-16
questions O 0 2.349025650643516e-14
for O 0 2.9615911430705573e-17
genetic O 0 4.627396217398404e-14
counseling O 0 2.3467428629693476e-13
in O 0 1.4091274852108268e-17
families O 0 9.278343317686442e-17
with O 0 5.511559743280191e-16
these O 0 8.288714597223367e-15
distinctive O 0 1.6129113669660633e-11
phenotypes O 0 5.962771509188114e-12
. O 0 3.3293017509403644e-15
. O 0 3.0869363597425814e-13

Maternal B-Disease 0 0.12704016268253326
disomy I-Disease 1 0.995257556438446
and O 0 0.0074820504523813725
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 1.51674210968622e-08
with O 0 3.47670399143251e-14
gamete O 0 6.665876184364095e-11
complementation O 0 1.1555459700218762e-08
in O 0 1.4567901284144998e-16
a O 0 2.0260586053003516e-16
case O 0 3.225617743827375e-13
of O 0 1.8887761109510253e-15
familial O 0 1.131730709147405e-09
translocation O 0 1.1372057073799624e-08
( O 0 2.609426075824567e-13
3 O 0 3.003282030619031e-13
; O 0 1.7885848187850504e-15
15 O 0 1.144475004133047e-13
) O 0 4.349304543496387e-16
( O 0 7.451406408766714e-17
p25 O 0 6.821678096534389e-14
; O 0 1.6590609344743366e-16
q11 O 0 7.074644689519793e-13
. O 0 4.866585777674465e-17
2 O 0 3.3102172516057777e-15
) O 0 2.519423903917374e-15
. O 0 2.5691263149545986e-14

Maternal B-Disease 0 0.15040522813796997
uniparental I-Disease 1 0.9805468916893005
disomy I-Disease 1 0.819179356098175
( I-Disease 0 1.166111562866945e-08
UPD I-Disease 1 0.9999923706054688
) I-Disease 0 1.3602029658860149e-12
for I-Disease 0 4.267592122107712e-15
chromosome I-Disease 0 1.9043636712012812e-07
15 I-Disease 0 4.030661915344069e-11
is O 0 1.9893227757900207e-14
responsible O 0 2.0465054618393902e-14
for O 0 1.5996413085266514e-16
an O 0 2.5901316269332068e-17
estimated O 0 3.927761436407773e-13
30 O 0 6.793449537721014e-14
% O 0 1.7498910732788857e-18
of O 0 1.413903626067708e-17
cases O 0 4.439298373348777e-10
of O 0 3.739106205102871e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 3.837873574497053e-09
PWS B-Disease 1 0.9999948740005493
) O 0 8.927225278454465e-12
. O 0 3.2019566577161374e-13

We O 0 8.990710953504788e-11
report O 0 1.3103662035648944e-13
on O 0 9.430425436387992e-17
an O 0 4.095321581913287e-19
unusual O 0 1.0194111003376959e-17
case O 0 8.94656256630183e-14
of O 0 1.0384367282354704e-14
maternal B-Disease 0 2.7819668790840524e-09
disomy I-Disease 0 4.914047622150974e-07
15 I-Disease 0 1.6450234186990431e-12
in O 0 1.4571028370967583e-14
PWS B-Disease 1 1.0
that O 0 8.09274251344777e-14
is O 0 2.35268313890976e-15
most O 0 1.5430316482070334e-17
consistent O 0 9.27145323405612e-15
with O 0 1.1151375362549056e-16
adjacent O 0 4.765717985175111e-13
- O 0 1.9646378746074333e-08
1 O 0 6.669658857323679e-13
segregation O 0 1.2357842613802683e-12
of O 0 9.033006047865747e-16
a O 0 1.3462595296366564e-13
paternal O 0 8.242829530047402e-09
t O 0 1.2559516093801903e-08
( O 0 1.3145353124367743e-15
3 O 0 7.12612799579895e-15
; O 0 1.1081490512189146e-16
15 O 0 5.1847293277250406e-15
) O 0 6.591665320325639e-17
( O 0 1.7488442762136998e-17
p25 O 0 1.0006721030953163e-14
; O 0 2.7576436419090755e-17
q11 O 0 5.12084949097491e-14
. O 0 3.163811987421396e-18
2 O 0 1.1285794197322393e-16
) O 0 1.087930275506281e-17
with O 0 1.9741860429127022e-16
simultaneous O 0 1.2590869319373255e-11
maternal O 0 1.4463719999469049e-08
meiotic O 0 8.15270428944359e-09
nondisjunction O 0 6.13706063745667e-08
for O 0 1.2431209693900512e-14
chromosome O 0 1.98065008838455e-09
15 O 0 1.151118176473398e-11
. O 0 6.265636338757818e-13

The O 0 2.6378710413915707e-12
patient O 0 2.749067085083823e-10
( O 0 3.776007149102964e-14
J O 0 6.238986998141627e-07
. O 0 1.03318935912723e-14
B O 0 7.094573817312266e-10
. O 0 5.189727440844939e-18
) O 0 2.1660179289037934e-18
, O 0 8.196033796481005e-20
a O 0 5.233105205757526e-18
17 O 0 3.127637182242745e-15
- O 0 1.403053156512693e-13
year O 0 2.3239017047510524e-13
- O 0 2.236917318043652e-09
old O 0 5.0338055501697454e-08
white O 0 2.235066354216997e-09
male O 0 9.216602481210145e-11
with O 0 1.323836466881126e-13
PWS B-Disease 1 0.9999982118606567
, O 0 3.2393369522443866e-16
was O 0 7.208804658318955e-16
found O 0 1.973448912490354e-15
to O 0 1.9559613667228734e-14
have O 0 6.222150572554597e-11
47 O 0 1.4158266573027767e-11
chromosomes O 0 5.30139890320136e-11
with O 0 2.2090235456823093e-12
a O 0 2.3835555057472035e-11
supernumerary O 0 0.07980292290449142
, O 0 2.4634910777976415e-10
paternal O 0 3.3050562819880724e-07
der O 1 0.8694559931755066
( O 0 8.359415243353041e-11
15 O 0 1.838509162618851e-12
) O 0 1.0806222009688239e-16
consisting O 0 4.036406072918116e-16
of O 0 5.600215081979273e-15
the O 0 2.1206900818748764e-11
short O 0 1.322406023973599e-05
arm O 1 0.9012797474861145
and O 0 1.381961125396236e-11
the O 0 1.8902753592676654e-15
proximal O 0 3.15775988690703e-10
long O 0 2.92063173645829e-08
arm O 0 0.0013050310080870986
of O 0 2.35803184703981e-13
chromosome O 0 8.42194367578486e-07
15 O 0 9.852245685948446e-10
, O 0 2.709648742090908e-14
and O 0 4.741563587075392e-13
distal O 0 2.644814458108158e-06
chromosome O 1 0.9621366858482361
arm O 1 0.9995005130767822
3p O 0 0.0017669666558504105
. O 0 4.34189934006568e-10

The O 0 8.510703426722888e-12
t O 0 9.285306390438564e-08
( O 0 4.627499809527853e-15
3 O 0 1.5981356015837885e-15
; O 0 1.1621584031085232e-17
15 O 0 4.133040885496807e-16
) O 0 3.999158526981547e-18
was O 0 1.037407735670487e-13
present O 0 3.683990603674676e-16
in O 0 7.619643695703669e-18
the O 0 8.020828278025357e-17
balanced O 0 1.2562365427418176e-12
state O 0 2.337056439824102e-15
in O 0 9.498843199213478e-17
the O 0 1.8755589664904218e-14
patients O 0 1.914602272567751e-14
father O 0 1.472980808506219e-13
and O 0 4.0330704677597404e-14
a O 0 2.544906593673988e-14
sister O 0 5.468230597216461e-07
. O 0 3.1001431890359532e-12

Fluorescent O 0 3.469428910829464e-11
in O 0 4.57173645423655e-16
situ O 0 7.742707842060825e-14
hybridization O 0 1.5830222468158142e-14
analysis O 0 1.9937783384991678e-14
demonstrated O 0 4.1933853443679517e-14
that O 0 1.792251571474155e-16
the O 0 4.080315255052154e-14
PWS B-Disease 1 0.9999998807907104
critical O 0 3.5783491725283056e-09
region O 0 1.6862863373452025e-13
resided O 0 2.29008305374645e-12
on O 0 4.0929599661766736e-13
the O 0 5.165438787626034e-16
derivative O 0 2.063817432923498e-12
chromosome O 0 1.6223542509408162e-09
3 O 0 7.565329114035679e-13
and O 0 6.181933085011235e-14
that O 0 2.35688717518522e-15
there O 0 1.9548758092976723e-14
was O 0 1.0741565276140008e-10
no O 0 9.69322397277898e-15
deletion O 0 3.808937974053572e-12
of O 0 1.5790838824242606e-14
the O 0 6.523519224810315e-11
PWS B-Disease 1 1.0
region O 0 9.282402103905074e-12
on O 0 2.7274679910427313e-12
the O 0 1.0105417521725471e-15
normal O 0 2.3794458225046174e-14
pair O 0 8.908968398071981e-13
of O 0 1.2475091982738475e-16
15s O 0 4.99765051391321e-13
present O 0 4.0936115547416784e-15
in O 0 6.928254323056767e-15
J O 0 8.820571383694187e-05
. O 0 2.947399269093154e-11

B O 0 0.0011766881216317415
. O 0 2.5607363451918275e-10

Methylation O 0 1.4214954734137475e-11
analysis O 0 5.975143882279432e-13
at O 0 4.006358436735129e-14
exon O 0 4.407282373254662e-13
alpha O 0 1.3932063561492144e-15
of O 0 4.294433467931845e-18
the O 0 2.793536497612854e-17
small O 0 4.7266623801793875e-14
nuclear O 0 8.851876032167638e-08
ribonucleoprotein O 0 1.7345037628402338e-09
- O 0 2.281339978038588e-10
associated O 0 1.9844048008543086e-13
polypeptide O 0 8.872184653618831e-10
N O 0 1.0351886459147863e-08
( O 0 5.50515342134187e-15
SNRPN O 0 2.097904211462165e-10
) O 0 2.647532171180099e-17
gene O 0 4.6356469959310184e-14
showed O 0 4.526090873618882e-12
a O 0 5.058983686815114e-16
pattern O 0 3.586038757608101e-11
characteristic O 0 2.5295585938389653e-12
of O 0 8.687326608135346e-15
only O 0 2.0420856845781987e-12
the O 0 2.7395013341147134e-12
maternal O 0 3.917730495572869e-08
chromosome O 0 1.7091035431349155e-07
15 O 0 2.1859901389031933e-10
in O 0 3.949878889675934e-13
J O 0 0.002621107967570424
. O 0 6.089316550994539e-11

B O 0 0.0009153180872090161
. O 0 1.0095893010486634e-09

Maternal B-Disease 0 0.0016920528141781688
disomy I-Disease 0 0.0001655546948313713
was O 0 5.767338343010131e-11
confirmed O 0 2.034743223520638e-14
by O 0 4.950712362076823e-18
polymerase O 0 7.306931074741937e-14
chain O 0 2.3650324320473315e-12
reaction O 0 8.525861481960587e-16
analysis O 0 4.5071619048858835e-17
of O 0 6.7050499447384875e-18
microsatellite O 0 5.962479121546238e-11
repeats O 0 5.897781568675597e-11
at O 0 3.438524955422912e-15
the O 0 4.548806478260988e-17
gamma O 0 1.4551206105935938e-13
- O 0 7.816921332448601e-09
aminobutyric O 0 2.1100017022490647e-07
acid O 0 2.7298217505911104e-11
receptor O 0 4.984313200888379e-13
beta3 O 0 1.4620779587026789e-10
subunit O 0 1.2595211332233625e-12
( O 0 1.912661516797684e-13
GABRB3 O 0 1.3363875339678088e-08
) O 0 2.8146723572209688e-14
locus O 0 6.890029102812889e-10
. O 0 3.200598466812643e-11

A O 0 5.0678534285752974e-11
niece O 0 4.1245809256906796e-07
( O 0 2.1677026493249762e-12
B O 0 2.1118694348842837e-08
. O 0 3.637974480023902e-16
B O 0 9.568859593578338e-12
. O 0 1.8688704578418287e-18
) O 0 1.5805450748078951e-18
with O 0 1.4550738279051257e-16
45 O 0 1.630165940725973e-15
chromosomes O 0 3.333497147479762e-14
and O 0 1.3522962318077841e-14
the O 0 1.1790285862654197e-17
derivative O 0 2.857586400579343e-13
3 O 0 8.898397054195751e-15
but O 0 6.632656553365725e-16
without O 0 2.5387288435764835e-15
the O 0 2.2945656672998006e-15
der O 0 1.7960655895876698e-05
( O 0 1.6228275776138112e-13
15 O 0 4.511047094137195e-14
) O 0 7.518705161659538e-17
demonstrated O 0 1.3993743441920018e-15
a O 0 2.8441293785056593e-16
phenotype O 0 5.376086294889282e-12
consistent O 0 4.762973327375464e-13
with O 0 2.8626664298585236e-16
that O 0 1.8162241391286686e-15
reported O 0 2.3845901924064716e-13
for O 0 5.258243952491952e-16
haploinsufficiency O 0 2.5485271670788734e-09
of O 0 3.8738450978678467e-16
distal O 0 7.495150056158195e-10
3 O 0 5.07819952755284e-10
p O 0 5.777272690465907e-06
. O 0 5.823514587222078e-11

Uniparental B-Disease 1 0.9999662637710571
disomy I-Disease 1 0.9999953508377075
associated O 0 2.4388739916503255e-08
with O 0 4.3060910739911584e-13
unbalanced O 0 1.5938026365347469e-07
segregation O 0 7.213320912802246e-11
of O 0 2.9845716233855993e-15
non O 0 1.3474747984076885e-09
- O 0 5.442330142102492e-09
Robertsonian O 0 1.1426630308619679e-08
translocations O 0 7.67148051750155e-08
has O 0 1.3175947962892898e-12
been O 0 3.416573461320106e-14
reported O 0 1.7786664610781877e-13
previously O 0 2.3262941920010327e-11
but O 0 1.556905781597076e-13
has O 0 5.303156351554872e-12
not O 0 2.5822320322309907e-15
, O 0 9.445397570911324e-18
to O 0 2.882059050662564e-17
our O 0 1.1554675436126292e-14
knowledge O 0 6.036614820855042e-16
, O 0 1.254366459377463e-16
been O 0 2.1398240980779332e-14
observed O 0 1.018910543570538e-15
in O 0 3.9670512013125717e-19
a O 0 1.234523653796847e-16
case O 0 1.0600789994083537e-12
of O 0 3.0250840894752162e-12
PWS B-Disease 1 0.9999990463256836
. O 0 8.492676006888189e-11

Furthermore O 0 1.2732546128546574e-09
, O 0 4.891468225473941e-14
our O 0 2.5953875550446814e-14
findings O 0 3.7883646821770464e-14
are O 0 2.1257629858705533e-16
best O 0 1.0907665423014537e-13
interpreted O 0 1.676691978210994e-15
as O 0 1.489068701149789e-16
true O 0 7.388914885486913e-15
gamete O 0 9.114591893732982e-12
complementation O 0 1.8780275112817435e-08
resulting O 0 1.1924690401787785e-10
in O 0 2.2165838609033983e-11
maternal B-Disease 0 0.018725955858826637
UPD I-Disease 1 0.9999996423721313
15 I-Disease 0 3.1383083296532277e-06
and O 0 1.227813157811397e-07
PWS B-Disease 1 0.9999889135360718

Schwartz B-Disease 1 0.9816188216209412
- I-Disease 1 0.9999631643295288
Jampel I-Disease 1 0.9997633099555969
syndrome I-Disease 1 0.9999905824661255
type I-Disease 0 1.4039289908396313e-06
2 I-Disease 0 1.6914397660272584e-10
and O 0 1.583341280309014e-08
Stuve B-Disease 1 0.9999864101409912
- I-Disease 1 0.9999997615814209
Wiedemann I-Disease 1 0.999997615814209
syndrome I-Disease 1 0.9999994039535522
: O 0 1.1059915656580293e-15
a O 0 9.057806378467964e-18
case O 0 5.378878173081672e-15
for O 0 4.562241214897829e-16
" O 0 3.330116130767502e-14
lumping O 0 2.685820454928489e-10
" O 0 6.260873330193872e-12
. O 0 1.6648454262326723e-13

Recent O 0 1.6626764201554955e-11
studies O 0 1.3087134457731575e-12
demonstrated O 0 8.595427429709812e-14
the O 0 3.922974778975107e-18
existence O 0 1.1550212737164564e-16
of O 0 2.7353484774228112e-17
a O 0 2.2781249695518315e-15
genetically O 0 2.9050947758513246e-10
distinct O 0 5.157684412752158e-15
, O 0 1.493500271650705e-16
usually O 0 2.4605144101796175e-17
lethal O 0 8.351456868725335e-16
form O 0 3.2413166270607975e-15
of O 0 3.0660685172408456e-14
the O 0 1.090042944795755e-09
Schwartz B-Disease 1 0.9999421834945679
- I-Disease 1 0.9999940395355225
Jampel I-Disease 1 0.9998675584793091
syndrome I-Disease 1 0.999987006187439
( O 0 1.0041509724417752e-12
SJS B-Disease 0 0.07257498800754547
) O 0 1.6421564967756576e-14
of O 0 9.491102429806317e-15
myotonia B-Disease 0 0.09980003535747528
and O 0 3.7219288762102565e-10
skeletal B-Disease 0 0.00038405292434617877
dysplasia I-Disease 0 0.0012411121279001236
, O 0 3.987680343808635e-14
which O 0 4.87503815798946e-14
we O 0 1.9573984100240693e-10
called O 0 2.0630415153988224e-09
SJS B-Disease 1 0.9996782541275024
type I-Disease 0 8.204623469509897e-08
2 I-Disease 0 1.0186599827544107e-11
. O 0 6.371058736999446e-13

This O 0 3.396398093324926e-11
disorder O 0 4.369454472907819e-06
is O 0 5.041994111717324e-15
reminiscent O 0 8.369006036139728e-14
of O 0 6.273516436614473e-17
another O 0 1.5358608075654104e-14
rare O 0 2.6985935187850973e-12
condition O 0 7.0767267913718346e-12
, O 0 8.410864371513962e-15
the O 0 1.8397868298269948e-11
Stuve B-Disease 1 0.9999896287918091
- I-Disease 1 0.9999998807907104
Wiedemann I-Disease 1 0.9999971389770508
syndrome I-Disease 1 0.9999991655349731
( O 0 3.691376197767493e-12
SWS B-Disease 0 1.2157296396253514e-06
) O 0 2.1024101445779424e-14
, O 0 6.167166817875266e-17
which O 0 6.696366136493457e-16
comprises O 0 4.851621274865048e-12
campomelia B-Disease 0 7.687957577218185e-07
at O 0 7.501138599153023e-11
birth O 0 4.826373745103751e-10
with O 0 4.2671286643036765e-11
skeletal B-Disease 0 0.0013658530078828335
dysplasia I-Disease 0 0.0004915765603072941
, O 0 9.575330708454927e-14
contractures B-Disease 0 7.401776542792504e-07
, O 0 9.041065015787456e-14
and O 0 5.892150916481098e-14
early B-Disease 0 9.687536824164525e-14
death I-Disease 0 7.051803585511607e-11
. O 0 1.0412328117770375e-11

To O 0 4.4187865714563623e-14
test O 0 4.3225489919189453e-13
for O 0 4.335236633187861e-18
possible O 0 2.2112618298219123e-16
nosologic O 0 1.3236767237856384e-10
identity O 0 7.199169645838444e-13
between O 0 1.4314138524658404e-13
these O 0 4.222481468207223e-13
disorders O 0 7.731217444018057e-09
, O 0 1.8638660564949135e-17
we O 0 2.3956929308724915e-15
reviewed O 0 7.015708001524568e-13
the O 0 2.0828267534253348e-16
literature O 0 1.9785296278662223e-15
and O 0 6.681719878044246e-16
obtained O 0 4.140092567131597e-17
a O 0 4.353833721309584e-17
follow O 0 3.052810757550421e-14
- O 0 4.6310788537340386e-10
up O 0 6.674839347908801e-09
of O 0 1.505725789346002e-15
the O 0 3.7565503576122354e-16
only O 0 5.309602736457532e-16
two O 0 9.847330817861822e-16
surviving O 0 7.27955944222064e-13
patients O 0 6.0282187126445026e-15
, O 0 1.1855721225781123e-18
one O 0 1.2399086657590162e-16
with O 0 7.451080225907847e-13
SJS B-Disease 1 0.9956888556480408
type I-Disease 0 1.1209129979761201e-07
2 I-Disease 0 1.4085210862241349e-12
at O 0 1.3292833500599954e-10
age O 0 2.511494623380628e-10
10 O 0 9.982210777371645e-14
years O 0 4.8909362887830654e-14
and O 0 1.1296746280390832e-14
another O 0 2.9775778840983574e-15
with O 0 1.1210470485939483e-12
SWS B-Disease 0 1.066839672603237e-06
at O 0 1.546009709141316e-10
age O 0 5.978752215529681e-11
7 O 0 1.2796509728588146e-12
years O 0 1.959139637628879e-13
. O 0 1.2632954307211647e-13

Patients O 0 2.375018581801669e-08
reported O 0 2.9046501315299622e-11
as O 0 4.007932901577485e-14
having O 0 3.0448674137595333e-10
either O 0 1.9376646065438763e-08
neonatal O 1 0.9999299049377441
SJS B-Disease 1 0.9999866485595703
or O 0 2.881592298109581e-09
SWS B-Disease 0 5.587171472143382e-06
presented O 0 6.035758237611308e-14
a O 0 3.691150414359139e-16
combination O 0 6.948713980381221e-15
of O 0 9.429813984479193e-17
a O 0 1.2768075713463084e-13
severe O 0 5.923446622091433e-09
, O 0 3.5221645885248273e-14
prenatal O 0 4.450527558219619e-05
- O 0 0.010345312766730785
onset O 0 7.966753764776513e-05
neuromuscular B-Disease 1 0.8983763456344604
disorder I-Disease 1 0.9625656008720398
( O 0 5.733933293450288e-13
with O 0 1.5117952029131132e-11
congenital B-Disease 1 0.9999802112579346
joint I-Disease 0 0.0005801282241009176
contractures I-Disease 1 0.9999517202377319
, O 0 1.5636594241641433e-08
respiratory O 0 0.0005002407706342638
and O 0 8.201779533312248e-11
feeding O 0 4.308248662709957e-06
difficulties O 0 7.22399473573887e-10
, O 0 5.209426002670338e-17
tendency O 0 5.216971128642507e-14
to O 0 1.5614714892943105e-16
hyperthermia B-Disease 0 2.0897002878106363e-11
, O 0 5.0677002064137763e-14
and O 0 2.0328550854372546e-13
frequent O 0 1.0252014515099717e-11
death O 0 1.0985854587142185e-10
in O 0 1.2967165047891166e-13
infancy O 0 5.464918101383276e-11
) O 0 1.5342167483785253e-16
with O 0 2.236635164978058e-17
a O 0 2.5501434595736824e-15
distinct O 0 3.851749648398073e-12
campomelic B-Disease 0 0.001634211279451847
- I-Disease 0 0.11493728309869766
metaphyseal I-Disease 0 0.09959014505147934
skeletal I-Disease 0 0.2105882614850998
dysplasia I-Disease 0 0.20562589168548584
. O 0 1.9785913185632609e-10

The O 0 8.456516906272128e-15
similarity O 0 9.008068677920575e-14
of O 0 1.4472187884594242e-16
the O 0 9.320277271927043e-16
clinical O 0 5.700995231450179e-11
and O 0 3.3209966352441833e-13
radiographic O 0 9.374153009389374e-09
findings O 0 1.1946647013663658e-12
is O 0 2.1545994019966583e-15
so O 0 7.532657382487592e-17
extensive O 0 7.473735578978832e-14
that O 0 1.2430950713238076e-10
these O 0 1.1451491838121441e-10
disorders O 0 4.4032606894006676e-08
appear O 0 5.943006351117773e-15
to O 0 8.596336211358921e-16
be O 0 1.6471710063623024e-12
a O 0 6.188882143310509e-14
single O 0 6.809735442203646e-09
entity O 0 5.3962327939416355e-08
. O 0 5.035891842419815e-11

The O 0 1.275619082477357e-14
follow O 0 6.744775636439992e-14
- O 0 3.723888697404476e-10
up O 0 4.743959114428264e-10
observation O 0 1.3033053369165826e-12
of O 0 3.3332233331607782e-18
an O 0 9.65354020126743e-18
identical O 0 6.617805804222388e-13
and O 0 1.7911734785268016e-14
unique O 0 6.555683493075174e-16
pattern O 0 4.1923944871236074e-10
of O 0 9.18840416079536e-13
progressive O 0 1.469684374200142e-08
bone B-Disease 1 0.9635627865791321
dysplasia I-Disease 0 0.0313204824924469
in O 0 1.2390730836384176e-14
the O 0 7.877650354953802e-15
two O 0 5.3033280891789936e-12
patients O 0 1.536432215991628e-14
( O 0 6.3360202716505115e-18
one O 0 1.801506094637178e-15
with O 0 2.391324291362018e-11
SJS B-Disease 1 0.9999611377716064
type I-Disease 0 2.3535501441074302e-06
2 I-Disease 0 1.5569727798703248e-11
, O 0 1.588980869489864e-15
one O 0 5.631183453563837e-14
with O 0 1.4063394546126595e-11
SWS B-Disease 0 1.919623900903389e-05
) O 0 1.3370361709333454e-14
surviving O 0 2.663833997135212e-12
beyond O 0 1.5570478240078955e-10
infancy O 0 8.209561919159114e-10
adds O 0 6.642215857194378e-12
to O 0 1.5004434271891282e-17
the O 0 3.8491968857802774e-18
evidence O 0 5.237769514442568e-14
in O 0 7.260214528959167e-17
favor O 0 7.132274066864227e-15
of O 0 9.213621397837843e-17
identity O 0 2.1287372906075852e-12
. O 0 2.650973787276384e-13

The O 0 6.270822755375174e-14
hypothesis O 0 9.242651782814804e-12
that O 0 8.040430436251703e-14
SWS B-Disease 0 2.692571433726698e-05
and O 0 8.314155787447763e-12
SJS B-Disease 1 0.8951351046562195
type I-Disease 0 3.8144133185369355e-08
2 I-Disease 0 9.212599352001818e-14
are O 0 1.1982234798010687e-14
the O 0 5.981629444149969e-14
same O 0 3.2221300627632843e-10
disorder O 0 1.049788124873885e-06
should O 0 1.0526913610015183e-14
be O 0 6.984660980019175e-18
testable O 0 9.34911689089648e-17
by O 0 1.130508130917135e-19
molecular O 0 3.561273264369861e-16
methods O 0 1.1412966654644058e-13
. O 0 1.6706530568135446e-14
. O 0 4.723528426037182e-13

A O 0 1.5784168676952204e-12
mouse O 0 2.16363305050038e-09
model O 0 1.0485789658787326e-07
of O 0 3.002920134775877e-10
severe O 1 0.9997909665107727
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.3485035300254822
defects O 1 0.9999964237213135
in O 0 6.119262041526241e-11
hemostasis O 1 0.9986686706542969
and O 0 7.746245955786435e-07
thrombosis B-Disease 0 0.0033634891733527184
. O 0 4.5886787425342135e-11

von B-Disease 0 0.031216923147439957
Willebrand I-Disease 0 0.0015753440093249083
factor I-Disease 0 3.3609828165026556e-07
( I-Disease 0 2.2940549460059856e-10
vWf I-Disease 0 1.5572129996144213e-05
) I-Disease 0 2.0919610221881157e-07
deficiency I-Disease 1 0.9999821186065674
causes O 1 0.6907581090927124
severe O 1 0.9999994039535522
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 2.6125888119565843e-09
humans O 0 4.4631935480765605e-08
. O 0 1.2109029057238985e-11

We O 0 2.6765601453954124e-13
generated O 0 5.559813727977611e-15
a O 0 3.2524993148491264e-16
mouse O 0 1.8902586440550095e-10
model O 0 1.7715794109474103e-10
for O 0 2.2161257841726221e-16
this O 0 1.2115599453959051e-17
disease O 0 3.3868836012661274e-14
by O 0 2.5500784366117897e-20
using O 0 1.140320090474572e-16
gene O 0 1.2094988639105297e-12
targeting O 0 2.0017194846122521e-10
. O 0 2.701532845084814e-13

vWf B-Disease 0 0.0005130309145897627
- I-Disease 1 0.8433249592781067
deficient I-Disease 0 0.010371781885623932
mice O 0 0.00024292600573971868
appeared O 0 2.584783942438662e-08
normal O 0 7.432400506678094e-13
at O 0 1.4866991101744609e-12
birth O 0 8.677631096326577e-13
; O 0 4.9841986185064397e-17
they O 0 2.667180331236414e-15
were O 0 7.728485142436889e-14
viable O 0 5.315581742132425e-12
and O 0 1.654891637137626e-13
fertile O 0 1.3564237406893387e-11
. O 0 1.9700599658556417e-12

Neither O 0 3.598363562673512e-08
vWf O 0 4.051953510497697e-06
nor O 0 2.077550220747071e-08
vWf O 0 2.053677008007071e-06
propolypeptide O 0 0.0005588332423940301
( O 0 3.720111718674701e-10
von B-Disease 0 0.0017869871808215976
Willebrand I-Disease 0 0.00016417355800513178
antigen O 0 8.057509148784447e-07
II O 0 4.404257651913213e-06
) O 0 7.380326818434702e-14
were O 0 6.6874860548326795e-15
detectable O 0 1.2408581974432398e-11
in O 0 2.6359331137586355e-17
plasma O 0 5.573806607234166e-12
, O 0 4.356164239819726e-15
platelets O 0 1.9426352887430554e-11
, O 0 1.0915391321699518e-16
or O 0 8.56870440843271e-16
endothelial O 0 1.1897523710582142e-13
cells O 0 5.062886602877825e-15
of O 0 2.995188704923399e-16
the O 0 5.4344851237392647e-14
homozygous O 0 3.0426241437453427e-07
mutant O 0 1.738977317700119e-07
mice O 0 4.025432644993998e-07
. O 0 1.2674914069699117e-11

The O 0 3.8940153727386184e-13
mutant O 0 1.8846552762852298e-08
mice O 0 1.4200082659954205e-05
exhibited O 0 5.661160003000987e-07
defects O 1 0.9939263463020325
in O 0 2.4232680884703553e-14
hemostasis O 0 1.1344237691446324e-06
with O 0 9.62476897226755e-14
a O 0 1.832685885645377e-13
highly O 0 4.207087567209555e-09
prolonged O 0 1.2902215530630201e-05
bleeding O 0 0.20722992718219757
time O 0 2.393817088996997e-10
and O 0 1.8952839297980972e-10
spontaneous O 0 2.833621358389049e-11
bleeding O 0 5.00622445542831e-06
events O 0 1.8205953373562692e-14
in O 0 5.331319073038356e-16
approximately O 0 1.4198302364550053e-13
10 O 0 6.136390766180166e-13
% O 0 7.393394313349349e-16
of O 0 2.9501268168272664e-15
neonates O 0 2.673322683222068e-07
. O 0 7.903213131675579e-13

As O 0 3.2662700669150446e-12
in O 0 3.0934860843588726e-16
the O 0 1.2769323435346037e-16
human O 0 1.0587872538350002e-13
disease O 0 4.818350926583115e-11
, O 0 6.5994363513083294e-18
the O 0 2.0755050138641584e-17
factor O 0 4.63920785467864e-12
VIII O 0 7.318750494533788e-09
level O 0 1.8625757880474936e-10
in O 0 2.4509136556819596e-16
these O 0 4.3652279688113796e-16
mice O 0 3.682554261530413e-10
was O 0 4.385735871692553e-11
reduced O 0 1.1950652327539363e-13
strongly O 0 1.744490104671828e-13
as O 0 7.680702595102087e-16
a O 0 1.7945638390712613e-16
result O 0 1.7837878594465124e-15
of O 0 1.7040180022432467e-16
the O 0 5.005393479253287e-14
lack O 0 2.1172069631335277e-14
of O 0 2.5779958533712882e-18
protection O 0 4.95981243407587e-15
provided O 0 1.6063922934651662e-16
by O 0 9.3594694863965e-16
vWf O 0 4.84034234915498e-09
. O 0 9.798843160491177e-12

Defective O 0 0.009316612035036087
thrombosis B-Disease 0 0.00417395681142807
in O 0 9.824865259463328e-14
mutant O 0 5.557180493553915e-09
mice O 0 1.6238058151429868e-06
was O 0 1.318995401788925e-08
also O 0 2.1545709660841794e-11
evident O 0 2.07660223652123e-13
in O 0 2.1871571498430454e-18
an O 0 1.4641824761127637e-17
in O 0 2.0884039359874123e-16
vivo O 0 1.2337647570248578e-10
model O 0 9.213188371937076e-12
of O 0 7.586541529540358e-13
vascular B-Disease 0 0.007109207101166248
injury I-Disease 0 4.7898440243443474e-05
. O 0 9.490537695999723e-12

In O 0 1.0700359699591499e-14
this O 0 6.9267637138144445e-18
model O 0 4.869817656766307e-13
, O 0 6.696924384145257e-17
the O 0 4.2446468730693196e-17
exteriorized O 0 1.0516430393181508e-08
mesentery O 0 1.949921646371422e-08
was O 0 6.356851156574805e-11
superfused O 0 1.2962400930405238e-08
with O 0 4.503473264336026e-14
ferric O 0 5.749523773745935e-11
chloride O 0 1.411360313558277e-13
and O 0 8.499043042421977e-15
the O 0 4.2198945685734665e-18
accumulation O 0 9.788427934951521e-14
of O 0 1.0992365837827946e-15
fluorescently O 0 2.9780003387713805e-06
labeled O 0 4.5168422957431176e-07
platelets O 0 1.1174287273263417e-08
was O 0 3.690102043374388e-12
observed O 0 2.6870448208604798e-14
by O 0 3.99157235432215e-16
intravital O 0 5.16766240910016e-10
microscopy O 0 5.705408367973064e-12
. O 0 4.619374002236276e-13

We O 0 1.2269211688287207e-11
conclude O 0 2.26787433776042e-13
that O 0 2.3630063595718666e-17
these O 0 9.336276938479094e-19
mice O 0 4.878417006297375e-13
very O 0 8.123614402685687e-17
closely O 0 8.500510950519569e-13
mimic O 0 4.760433469641612e-08
severe O 0 3.0037595024623442e-06
human O 0 0.0001419004547642544
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 1 0.5227484703063965
will O 0 9.151343682844981e-09
be O 0 4.8813560073364404e-14
very O 0 1.1307200184009193e-18
useful O 0 4.967397835802936e-18
for O 0 4.507415208268963e-19
investigating O 0 2.3770584177911338e-15
the O 0 2.6305389035480547e-17
role O 0 4.930634351328622e-13
of O 0 7.671123446562029e-17
vWf O 0 1.9283476725140414e-12
in O 0 1.2916844811022214e-15
normal O 0 1.4723685053293079e-13
physiology O 0 3.759757088994675e-11
and O 0 9.705684606703402e-13
in O 0 1.0545155735083725e-15
disease O 0 3.796929992638809e-10
models O 0 6.407722963341911e-11
. O 0 5.130643309427538e-15
. O 0 3.6279049968161725e-13

Oral O 0 5.384532641983242e-08
contraceptives O 0 0.00036854163045063615
and O 0 2.8826710983531623e-12
the O 0 8.525446922860377e-14
risk O 0 4.947207230543427e-07
of O 0 1.0226830493564876e-09
hereditary B-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.0948005169097996e-08

Hereditary B-Disease 1 0.9999988079071045
Ovarian I-Disease 1 0.999998927116394
Cancer I-Disease 1 0.9995929598808289
Clinical O 0 5.875738861504942e-05
Study O 0 3.3473057658994776e-09
Group O 0 2.554054967518482e-09
. O 0 2.399777251915758e-11

BACKGROUND O 0 3.974101127823815e-05
Women O 0 2.266265841655013e-09
with O 0 4.0480290696082513e-14
mutations O 0 1.583326525445017e-11
in O 0 5.192702660615782e-16
either O 0 2.0238369628170633e-13
the O 0 5.764374437847164e-13
BRCA1 O 0 4.037504913867451e-05
or O 0 9.974265337275856e-12
the O 0 7.396360305093278e-15
BRCA2 O 0 2.346158112231933e-08
gene O 0 4.9874472607402964e-11
have O 0 3.7652911658806604e-14
a O 0 7.286938683142836e-16
high O 0 2.7893404253021004e-10
lifetime O 0 1.4664417236076588e-08
risk O 0 3.8436086470028386e-05
of O 0 4.816593559553439e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 1.4389053837327026e-10

Oral O 0 1.555530246832859e-07
contraceptives O 0 0.03116605430841446
protect O 0 0.00018820090917870402
against O 0 0.0045468625612556934
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.414941940338423e-12
general O 0 5.626927309515528e-12
, O 0 1.4762202013096984e-14
but O 0 2.420384364801428e-15
it O 0 4.7670218060501604e-15
is O 0 3.822150454750768e-14
not O 0 5.920056866914644e-17
known O 0 3.0306237459366316e-15
whether O 0 8.855281959097017e-13
they O 0 5.222011516779757e-13
also O 0 6.6652113515919265e-12
protect O 0 2.2282748562973964e-11
against O 0 2.3100098223149956e-11
hereditary B-Disease 0 4.78080664834124e-07
forms I-Disease 0 1.036617689464947e-07
of I-Disease 0 4.876459570368752e-05
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
. O 0 2.1851979947751232e-10

METHODS O 0 2.8045657463060536e-10
We O 0 2.051189079699256e-12
enrolled O 0 2.2225318807578276e-11
207 O 0 8.258959738327576e-09
women O 0 1.2116164072040192e-08
with O 0 1.4986998309041155e-08
hereditary B-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.313388287016437e-10
161 O 0 1.039401377467275e-11
of O 0 2.6554457485433898e-14
their O 0 2.9922956473749096e-11
sisters O 0 1.1535887267655198e-07
as O 0 4.784278984266976e-13
controls O 0 2.4996607214666788e-11
in O 0 1.522956140176494e-17
a O 0 6.376714431045405e-16
case O 0 8.12426948632039e-12
- O 0 2.661984188634392e-09
control O 0 1.2453679580637367e-11
study O 0 3.2042374396162865e-12
. O 0 1.4405927622682113e-12

All O 0 1.9051331692776508e-12
the O 0 1.4441210407405494e-14
patients O 0 2.0358999317134086e-14
carried O 0 2.378455386879393e-15
a O 0 2.0204090278910634e-16
pathogenic O 0 3.305120066521283e-11
mutation O 0 6.279203502643216e-13
in O 0 3.129461691211131e-16
either O 0 2.0157237424350827e-13
BRCA1 O 0 5.813467396365013e-07
( O 0 5.06280510136764e-13
179 O 0 4.03243029245548e-11
women O 0 1.5435899086702065e-11
) O 0 3.207332394667534e-15
or O 0 4.2778836029100376e-12
BRCA2 O 0 0.00020175088138785213
( O 0 1.4000613168807519e-10
28 O 0 1.546173322708455e-08
women O 0 8.623389502471213e-11
) O 0 3.844252254850064e-14
. O 0 2.309941517578129e-13

The O 0 1.151543704142055e-12
control O 0 1.3974181811704511e-09
women O 0 2.1571110783019654e-12
were O 0 1.81050349036115e-15
enrolled O 0 5.406856518362429e-15
regardless O 0 9.52133589443002e-17
of O 0 1.3230807664525494e-18
whether O 0 1.5556472939253635e-13
or O 0 5.51030922280038e-12
not O 0 1.5718675276318872e-12
they O 0 1.7143099006328155e-12
had O 0 4.1230362873845294e-11
either O 0 1.0678244177558457e-13
mutation O 0 4.6352630934942685e-12
. O 0 3.554777457635827e-13

Lifetime O 0 1.1376910524774075e-09
histories O 0 5.859323443102582e-11
of O 0 4.11229964265695e-15
oral O 0 3.543030105412903e-11
- O 0 1.7645455097081708e-09
contraceptive O 0 3.634018641562875e-10
use O 0 3.1534183240583243e-15
were O 0 2.2904803215160747e-16
obtained O 0 8.236824326553164e-17
by O 0 2.2178174677869666e-16
interview O 0 4.687500942957001e-10
or O 0 9.238694743040829e-14
by O 0 1.4999692210875638e-16
written O 0 8.674344981185727e-15
questionnaire O 0 5.757833175090016e-14
and O 0 1.7145343133301028e-17
were O 0 1.1064294254434781e-17
compared O 0 4.22861690689143e-16
between O 0 3.678655619595954e-15
patients O 0 9.185946274470336e-14
and O 0 2.4922316814446344e-13
control O 0 1.425967521839766e-08
women O 0 4.843632439577306e-12
, O 0 3.6709820635766464e-18
after O 0 1.367974356381252e-16
adjustment O 0 4.945345890607078e-13
for O 0 1.3670398738996387e-17
year O 0 7.770447832270225e-14
of O 0 7.104844069537699e-16
birth O 0 2.2905823071628362e-11
and O 0 5.724691987812891e-12
parity O 0 1.3745538041121108e-10
. O 0 9.596764572253336e-13

RESULTS O 0 1.235318930481455e-10
The O 0 2.263951779003662e-15
adjusted O 0 1.0903787028837542e-07
odds O 0 6.422354204005387e-07
ratio O 0 1.2308289569773478e-06
for O 0 5.010575932828942e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 5.350767572076531e-12
with O 0 6.271724697233234e-16
any O 0 4.246334983263418e-15
past O 0 1.2534010288001163e-11
use O 0 3.2819930041901035e-13
of O 0 2.163866958879157e-14
oral O 0 2.2602729410348132e-10
contraceptives O 0 1.3170045498611671e-08
was O 0 2.5594838748421722e-12
0 O 0 1.789569469175245e-13
. O 0 1.5691916895651387e-13

5 O 0 1.1595735656400041e-11
( O 0 1.7704001649019793e-14
95 O 0 3.253399502925469e-12
percent O 0 2.774540064365283e-07
confidence O 0 2.9432801511575235e-06
interval O 0 5.334035730469866e-12
, O 0 5.442799196808863e-16
0 O 0 1.1603561254462804e-16
. O 0 1.0047859060427836e-18
3 O 0 2.8883889675820646e-16
to O 0 2.734650899468633e-16
0 O 0 3.862646845849112e-15
. O 0 6.888112955230353e-17
8 O 0 1.3885863758746758e-13
) O 0 5.518418063174991e-16
. O 0 6.638355179276615e-15

The O 0 2.6377203372895952e-12
risk O 0 1.7515393579969896e-08
decreased O 0 3.259040259884216e-11
with O 0 1.2092288677116695e-16
increasing O 0 5.490284181469294e-15
duration O 0 5.129997023288783e-15
of O 0 2.6009722424510205e-18
use O 0 3.0688520369121126e-15
( O 0 1.0922722127160208e-16
P O 0 1.392560892987671e-11
for O 0 6.536726631017827e-17
trend O 0 6.748874462753074e-12
, O 0 5.540206397556331e-16
< O 0 1.689475992374019e-14
0 O 0 9.784903430857996e-17
. O 0 1.117819619760272e-18
001 O 0 3.714118771515123e-15
) O 0 2.5280448977210485e-19
; O 0 2.0027316924260658e-21
use O 0 2.705809630273874e-19
for O 0 3.8747442762809164e-17
six O 0 4.15243333424728e-15
or O 0 4.0260873587359865e-16
more O 0 1.0840815695521942e-17
years O 0 1.1713271682884524e-13
was O 0 7.461896378568866e-11
associated O 0 2.911731607421617e-16
with O 0 1.0042729506654242e-17
a O 0 1.233869188496195e-16
60 O 0 5.639016390743571e-15
percent O 0 5.950785003649983e-12
reduction O 0 1.7077762815009834e-12
in O 0 1.6791027186821746e-14
risk O 0 1.0155304153158795e-08
. O 0 1.7007807922436724e-12

Oral O 0 5.487100196432948e-08
- O 0 1.344041606898827e-07
contraceptive O 0 3.561241044280905e-07
use O 0 1.732432253209737e-11
protected O 0 0.00015099441225174814
against O 0 0.0007729605422355235
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
both O 0 2.7835947183862085e-14
for O 0 2.308409362031488e-16
carriers O 0 3.5398382359011493e-13
of O 0 8.583646599017868e-18
the O 0 5.0391026800485766e-14
BRCA1 O 0 1.770220251273713e-06
mutation O 0 1.3993112224497395e-10
( O 0 1.964629224278716e-13
odds O 0 3.933077419304709e-09
ratio O 0 3.7552577714095037e-10
, O 0 2.3783475595852074e-14
0 O 0 1.012100292795495e-15
. O 0 4.780417380648081e-18
5 O 0 1.9217786586282006e-16
; O 0 1.1131522531539416e-17
95 O 0 2.615889547075839e-13
percent O 0 1.2230419770276058e-06
confidence O 0 9.0853325673379e-05
interval O 0 2.130995900573307e-12
, O 0 4.744776815031131e-16
0 O 0 8.288325914979696e-17
. O 0 1.380254456416449e-18
3 O 0 5.945520133146987e-16
to O 0 6.535608812225247e-16
0 O 0 1.3097351767246842e-15
. O 0 1.7105559054559678e-17
9 O 0 5.683134948834259e-15
) O 0 3.297707764874143e-19
and O 0 1.802286968024679e-18
for O 0 1.0664396062042704e-18
carriers O 0 1.4414290006275858e-15
of O 0 8.232448871985004e-19
the O 0 8.350250693808445e-15
BRCA2 O 0 2.266284866436763e-07
mutation O 0 1.4476503329419188e-11
( O 0 3.7625918412843504e-14
odds O 0 3.9252512351595215e-10
ratio O 0 7.153869163722959e-11
, O 0 5.225692264570732e-15
0 O 0 1.3656131991012215e-15
. O 0 4.094651979207425e-18
4 O 0 1.4681997945629132e-15
; O 0 4.369324167204742e-17
95 O 0 5.854937845314878e-13
percent O 0 2.283367848576745e-06
confidence O 0 0.0009256264893338084
interval O 0 1.278528823610292e-12
, O 0 1.3707279016740982e-15
0 O 0 2.317099655372521e-16
. O 0 5.890116154744614e-18
2 O 0 1.1277279133922323e-15
to O 0 1.013750207097628e-15
1 O 0 6.3241737184810496e-15
. O 0 4.1982046521414073e-17
1 O 0 1.3235724128301488e-15
) O 0 8.569554088357924e-16
. O 0 9.965427327741569e-15

CONCLUSIONS O 0 9.337036921408526e-09
Oral O 0 2.74200440131267e-09
- O 0 8.290589548209937e-09
contraceptive O 0 2.8250437544841134e-09
use O 0 2.20703362134372e-14
may O 0 7.68290477488583e-15
reduce O 0 3.60838491925879e-15
the O 0 5.257825729974245e-15
risk O 0 4.562451749734464e-07
of O 0 4.272378006930921e-09
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.4069369584299163e-12
women O 0 5.827619745275847e-13
with O 0 1.1533217815171295e-16
pathogenic O 0 2.7115905007479846e-12
mutations O 0 5.993037961509948e-14
in O 0 7.989314020176067e-17
the O 0 1.8425559201225988e-13
BRCA1 O 0 2.4381342882406898e-05
or O 0 3.037577522846391e-09
BRCA2 O 0 0.00014429398288484663
gene O 0 5.20076582688489e-06

A O 0 7.959678055557973e-11
Japanese O 0 5.116515544578704e-10
family O 0 4.2872750163382156e-13
with O 0 1.2682138325614822e-12
adrenoleukodystrophy B-Disease 1 0.9999998807907104
with O 0 5.024641726997237e-13
a O 0 1.4811672125348424e-14
codon O 0 5.2365885933047807e-11
291 O 0 3.8730255981500594e-12
deletion O 0 6.02575905839231e-11
: O 0 1.0238749613227481e-14
a O 0 1.5442816703138337e-15
clinical O 0 3.8611964320312e-11
, O 0 2.9241440811702407e-15
biochemical O 0 8.173232229902183e-11
, O 0 5.9394932819690355e-15
pathological O 0 1.017931250402171e-08
, O 0 8.208574607797975e-14
and O 0 1.4899913984914304e-13
genetic O 0 3.301018833279379e-11
report O 0 1.324015785897359e-09
. O 0 2.527933157941975e-12

We O 0 2.5473970155509562e-11
report O 0 1.0220647841518299e-13
a O 0 8.482260990396264e-16
Japanese O 0 9.594975855509169e-12
family O 0 5.769067542476039e-14
with O 0 1.5630965272128705e-11
adrenoleukodystrophy B-Disease 1 1.0
( O 0 4.1669795391996445e-10
ALD B-Disease 1 0.9999998807907104
) O 0 8.688188040642704e-15
with O 0 5.059908143867703e-17
a O 0 3.6002984545300306e-16
three O 0 1.7670748490763305e-13
base O 0 3.7159136878628374e-10
pair O 0 7.979500393773264e-11
deletion O 0 3.451320063074803e-10
( O 0 7.376273935188679e-14
delGAG O 0 4.228401656591885e-11
291 O 0 1.0935710887186034e-12
) O 0 4.713459889388772e-16
in O 0 5.2728237717943624e-17
the O 0 7.651641635835621e-14
ALD B-Disease 1 0.9999995231628418
gene O 0 4.381361762284541e-08
. O 0 6.5521216924269154e-12

A O 0 8.630855578839469e-12
variety O 0 1.3054524908989729e-12
of O 0 3.0490846172638022e-15
phenotypes O 0 2.4695695488574643e-10
were O 0 2.9951475327694155e-13
observed O 0 5.059182443096187e-14
within O 0 2.300453869772198e-16
this O 0 1.0660019755478513e-15
family O 0 3.9202942107852135e-12
. O 0 1.2348400080242072e-11

While O 0 4.709131348756834e-11
the O 0 7.306151126804106e-14
proband O 0 7.486077038265648e-07
( O 0 1.8474472982237672e-13
patient O 0 9.417849312909343e-12
1 O 0 3.472109600023308e-15
) O 0 1.604206154367862e-16
was O 0 3.0246210267273477e-13
classified O 0 7.800310952710277e-10
as O 0 7.173435456753197e-11
having O 0 2.0621176207574754e-12
a O 0 2.0127537691069057e-17
rare O 0 6.99976116210133e-17
intermediate O 0 4.155919721858178e-15
type O 0 2.0876207013076353e-11
of O 0 1.3334452594567555e-14
adult O 0 2.1610357947565717e-08
cerebral O 0 1.2865800158579077e-07
and O 0 1.905148608316587e-11
cerebello O 0 0.00011573864321690053
- O 0 0.00010022587230196223
brain O 0 3.405874304007739e-05
stem O 0 8.361512371379831e-09
forms O 0 1.1680375416878164e-11
, O 0 7.604762766776421e-14
his O 0 1.6912959747983347e-12
younger O 0 1.6044198192233239e-09
brother O 0 2.101661733533433e-09
( O 0 1.1788241552606465e-13
patient O 0 1.752061343229805e-11
2 O 0 8.555582322244612e-14
) O 0 1.6937518824543946e-13
and O 0 2.470210147542673e-10
nephew O 0 2.5223589545930736e-05
( O 0 3.63729157903947e-10
patient O 0 1.3732816661615743e-08
3 O 0 1.218157736140868e-12
) O 0 1.1201268726576327e-14
had O 0 1.7198530100070997e-10
a O 0 5.582693335393074e-11
childhood O 0 3.943912815884687e-05
ALD B-Disease 1 0.9999992847442627
type O 0 3.0342660465976223e-05
. O 0 2.978936194941717e-11

Another O 0 1.3301887369365772e-10
nephew O 0 3.5582669966061076e-07
( O 0 4.205733417778079e-12
patient O 0 4.970820421945632e-10
4 O 0 4.942762236830045e-13
) O 0 3.1094952188202157e-15
of O 0 3.1831741679788942e-15
patient O 0 4.725716484799136e-10
1 O 0 4.575228135803369e-15
was O 0 4.148228635592055e-12
classified O 0 1.225232360013706e-08
as O 0 2.981201285834345e-09
having O 0 5.428524119110989e-08
an O 0 8.927645406796303e-13
adolescent O 0 4.14596769360287e-07
form O 0 2.965606276175703e-12
. O 0 1.3607634984091899e-12

The O 0 1.882167178731721e-14
tau O 0 2.652521485877607e-13
level O 0 9.357774971574528e-12
in O 0 8.542627440360302e-16
the O 0 6.518758785805517e-14
cerebrospinal O 0 9.381798008689657e-06
fluid O 0 3.15446868626168e-09
( O 0 1.9809352075350617e-11
CSF O 0 0.003639479400590062
) O 0 8.492662682043489e-14
in O 0 2.4506439815673775e-15
patient O 0 4.77094301565284e-11
1 O 0 3.6421002186913e-15
was O 0 6.480424530330708e-11
as O 0 5.497373389840021e-13
high O 0 9.881291965219141e-12
as O 0 1.7845434128354633e-15
that O 0 8.564619592044576e-16
of O 0 3.0918965846817026e-14
patients O 0 5.475818583289271e-12
with O 0 6.698704958785218e-12
Alzheimers B-Disease 0 0.007857270538806915
disease I-Disease 0 0.0014602334704250097
( O 0 9.661610839714965e-14
AD B-Disease 0 1.0466802535802344e-08
) O 0 9.142746455748085e-12
. O 0 7.56879313997677e-13

His O 0 2.9105381299521227e-12
brain O 0 8.166687465172018e-11
magnetic O 0 1.9257075860139306e-13
resonance O 0 5.388806154776882e-12
image O 0 2.5098473299678403e-10
( O 0 1.346328783050424e-13
MRI O 0 6.09632095915913e-08
) O 0 4.962492954540751e-14
showed O 0 4.7846353545821785e-09
abnormalities B-Disease 0 3.600044874474406e-05
in I-Disease 0 1.6047638461542902e-15
the I-Disease 0 3.1428071950445613e-12
bilateral I-Disease 0 6.666698027402163e-05
cerebellar I-Disease 0 4.1635117668192834e-05
hemispheres I-Disease 0 8.996639735414647e-06
and O 0 1.1962945078991538e-09
brain O 0 2.254315401017948e-09
stem O 0 3.2633060750159038e-12
, O 0 1.4447585547943445e-16
but O 0 1.9505386035610363e-16
not O 0 4.938515908199529e-15
in O 0 5.396368132893053e-15
the O 0 4.314711782305025e-11
cerebral O 0 9.955544300055408e-08
white O 0 1.5443937795289742e-11
matter O 0 7.796420001191233e-16
, O 0 3.0207852216806177e-18
where O 0 5.000326241627447e-18
marked O 0 7.437271996445661e-15
reductions O 0 1.1295255529508719e-11
of O 0 1.5245445320933877e-15
the O 0 2.7029721776788973e-12
cerebral O 0 1.771815050233272e-07
blood O 0 7.290342107779679e-09
flow O 0 1.1439578173622067e-09
and O 0 1.8361105691422352e-10
oxygen O 0 1.4927563850818115e-13
metabolism O 0 8.043276981950509e-12
were O 0 4.020229109466186e-14
clearly O 0 2.289329479026464e-14
demonstrated O 0 2.960664700784498e-17
by O 0 2.499621937897961e-19
positron O 0 3.9649276835926686e-14
emission O 0 8.460719104486092e-13
tomography O 0 4.139299666916507e-11
( O 0 2.7565132793526403e-13
PET O 0 5.269430047860624e-08
) O 0 1.1106651622710961e-12
. O 0 2.3670486144072855e-13

In O 0 3.233703235738794e-11
patients O 0 5.921429319100113e-11
2 O 0 1.4376145673206109e-12
and O 0 1.0522709006227648e-12
3 O 0 2.7660130249066404e-14
, O 0 6.378334902680815e-19
the O 0 8.435777879862722e-20
autopsy O 0 4.3114023635937304e-12
findings O 0 1.1904385897182346e-12
showed O 0 1.0344909651127665e-10
massive O 0 1.920376531405754e-11
demyelination B-Disease 1 0.9999997615814209
of I-Disease 0 1.8716085539022265e-12
the I-Disease 0 2.6573333377494235e-12
cerebral I-Disease 0 1.4122013780593079e-08
white I-Disease 0 1.425015595975243e-12
matter I-Disease 0 8.768120448762504e-17
with O 0 2.378887069280027e-18
sparing O 0 7.318888104168778e-17
of O 0 9.736903463400524e-18
the O 0 3.6332749824138574e-15
U O 0 2.059139490029338e-07
- O 0 8.401545414926659e-08
fibers O 0 1.9284470909042284e-08
, O 0 2.7718512630230618e-16
compatible O 0 1.535411858927542e-15
with O 0 3.586549786307113e-16
the O 0 1.276250614360962e-16
findings O 0 1.6529746321714e-12
of O 0 2.0741004400082197e-13
childhood O 0 4.793178618456295e-07
ALD B-Disease 1 0.9999949932098389
. O 0 1.1094932611532826e-10

Oleic O 0 0.0030171331018209457
and O 0 2.505380070072505e-10
erucic O 0 9.655740313974093e-07
acids O 0 1.9868277856271988e-10
( O 0 2.3208882325752647e-14
Lorenzos O 0 1.4066843245785776e-09
Oil O 0 1.880109566296251e-12
) O 0 7.7269590643516445e-16
were O 0 9.688302499597195e-16
administered O 0 1.752647031953887e-14
to O 0 4.779713747731819e-15
patients O 0 1.2569788688642641e-13
1 O 0 7.024963568655698e-16
and O 0 2.878861699810026e-13
4 O 0 4.02449442857538e-14
, O 0 6.742141385149855e-17
but O 0 2.347840598610748e-16
sufficient O 0 1.7163349200875083e-16
effectiveness O 0 1.2241797033268453e-14
was O 0 1.1812572404609756e-13
not O 0 4.0506894306889876e-16
obtained O 0 1.1254169661077326e-13
. O 0 3.5926296659827273e-12

The O 0 2.3801232794558314e-13
findings O 0 8.329166891786477e-13
in O 0 7.999987958800451e-17
this O 0 5.276098124890123e-19
family O 0 1.0828174721400907e-16
suggest O 0 2.170070797591437e-14
that O 0 7.704153443400651e-15
delGAG291 O 0 1.641157765241985e-10
is O 0 5.850132153066654e-15
part O 0 3.2249360686520834e-16
of O 0 2.6369287083439043e-17
the O 0 6.58229620948672e-16
cause O 0 3.84071038658112e-15
of O 0 1.8500406589983757e-15
Japanese O 0 6.546556505782064e-07
ALD B-Disease 1 0.9999990463256836
with O 0 4.553544092353659e-14
phenotypic O 0 2.2612303696156744e-10
variations O 0 7.326036999266705e-10
. O 0 2.1270662314831768e-11

Moreover O 0 2.56388382746664e-10
, O 0 1.2499106160886522e-15
although O 0 1.962928214037529e-17
the O 0 2.5151756217509485e-18
scale O 0 4.468007908098315e-11
of O 0 5.03620538267667e-16
the O 0 2.3919215166748418e-15
study O 0 3.532969679613182e-14
is O 0 7.266103409057922e-13
limited O 0 3.4352749323559445e-14
, O 0 1.4194760771566817e-16
there O 0 4.2491828006763153e-17
is O 0 6.358614792800459e-17
a O 0 9.070392758668571e-18
possibility O 0 2.9026944540886833e-15
that O 0 3.8952721197576244e-16
PET O 0 8.397616824140641e-09
can O 0 3.5548606159424567e-12
detect O 0 6.608428387844256e-11
an O 0 8.448137209324941e-14
insidious B-Disease 0 1.8058424302580534e-06
lesion I-Disease 1 0.5991973876953125
which O 0 7.081847608336744e-11
is O 0 2.779245746303144e-13
undetectable O 0 2.4506537424362485e-11
by O 0 6.026281415945234e-17
computed O 0 1.9607267198740175e-11
tomogram O 0 5.791576427327527e-07
( O 0 5.410511042013358e-14
CT O 0 2.137105958865959e-08
) O 0 8.255954433318005e-16
or O 0 3.244556263386249e-16
MRI O 0 1.2568082685682214e-10
analysis O 0 2.2435688628642293e-14
, O 0 1.940883036767268e-15
and O 0 2.4148693332818553e-15
that O 0 4.206671342019255e-16
the O 0 3.431145974963347e-16
higher O 0 4.342334217893873e-12
level O 0 1.4678429099360818e-13
of O 0 1.3662936122305086e-18
tau O 0 6.673284885727471e-17
reflects O 0 1.7228290158149886e-16
the O 0 1.0609537443818187e-18
process O 0 1.851932057099815e-16
of O 0 1.038193989768611e-16
neuronal B-Disease 0 6.3740276078083635e-12
degeneration I-Disease 0 4.681465952671715e-07
in O 0 7.0335348656414e-11
ALD B-Disease 1 0.9999994039535522
. O 0 3.139826731946016e-10

Lorenzos O 0 6.178925559652271e-06
Oil O 0 9.06444963533204e-09
should O 0 6.804398082309315e-13
be O 0 1.8150943295259294e-16
given O 0 1.0354955032716976e-18
in O 0 1.6815116192555185e-19
the O 0 1.9500169172923113e-17
early O 0 1.4078777714769588e-14
stage O 0 2.632112930389674e-11
. O 0 4.954836221389869e-16
. O 0 1.2841387092674302e-14

Nonsense O 0 2.1891817141295178e-06
mutation O 0 8.442677668085707e-10
in O 0 3.624498450530882e-15
exon O 0 4.6825748140078005e-11
4 O 0 4.345364400335644e-13
of O 0 1.473422546776124e-16
human O 0 9.785777060639794e-14
complement O 0 4.2846263104308335e-13
C9 O 0 1.1371113078917361e-10
gene O 0 4.2590871801584385e-11
is O 0 1.0226497789865216e-13
the O 0 1.4602507873996256e-16
major O 0 4.623801341807621e-12
cause O 0 6.447975291722086e-14
of O 0 6.369038597301563e-14
Japanese O 0 6.2270783018902875e-06
complement B-Disease 0 1.9362460079719312e-08
C9 I-Disease 0 0.0003134807338938117
deficiency I-Disease 0 0.008518919348716736
. O 0 3.9369740106875994e-12

Deficiency B-Disease 1 0.9997484087944031
of I-Disease 0 4.646632674443728e-14
the I-Disease 0 4.566526989852699e-15
ninth I-Disease 0 5.875819275580341e-11
component I-Disease 0 4.871369150075133e-13
of I-Disease 0 2.7924725448217637e-16
human I-Disease 0 5.795764475985399e-12
complement I-Disease 0 6.670539988429258e-12
( O 0 1.4068248459960507e-15
C9 O 0 6.216548109616582e-12
) O 0 1.1161930187165233e-16
is O 0 5.177134525917493e-17
the O 0 6.140238614778092e-18
most O 0 4.2257023618111345e-14
common O 0 1.3013332633704522e-08
complement B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
in O 0 5.078344361242153e-14
Japan O 0 5.532327929103076e-09
but O 0 4.0220673403683176e-15
is O 0 1.8654390562349688e-16
rare O 0 1.1040899105169944e-16
in O 0 8.982764553297154e-17
other O 0 1.8460314657117727e-13
countries O 0 2.5183194071742854e-11
. O 0 7.119478075655328e-13

We O 0 5.135649683296606e-10
studied O 0 3.5333625673754365e-13
the O 0 1.512632595259587e-17
molecular O 0 1.2658134902667623e-13
basis O 0 2.7855254994962886e-12
of O 0 1.558475353977129e-12
C9 B-Disease 0 0.454087495803833
deficiency I-Disease 1 0.9348422884941101
in O 0 2.2121823958169e-15
four O 0 6.376456437515166e-13
Japanese O 0 3.71188502157338e-09
C9 B-Disease 0 5.127511144564778e-07
- I-Disease 0 4.993812126485864e-06
deficient I-Disease 0 2.10180260182824e-05
patients O 0 1.4354104016511826e-10
who O 0 5.992764062767719e-10
had O 0 2.1524792614968646e-08
suffered O 0 1.2460693596949568e-06
from O 0 1.3801949583225337e-09
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 0.9999998807907104
. O 0 1.6056130036634642e-10

Direct O 0 3.026374181640257e-14
sequencing O 0 4.678659803331042e-13
of O 0 2.012801851461552e-15
amplified O 0 1.0121139169816384e-11
C9 O 0 1.8617551944544175e-10
cDNA O 0 5.401728868890954e-13
and O 0 5.215734545242811e-15
DNA O 0 3.137069597147768e-12
revealed O 0 1.3338185590738849e-11
a O 0 1.7751263122861268e-15
nonsense O 0 1.1172651345758844e-11
substitution O 0 2.4392465179873604e-15
( O 0 8.596692891639054e-17
CGA O 0 3.0900542541401066e-12
- O 0 1.4327926345369946e-10
- O 0 7.190915224386529e-11
> O 0 6.886599444996463e-14
TGA O 0 5.091991273076246e-10
) O 0 3.1307033885722465e-16
at O 0 6.625398539798939e-16
codon O 0 1.245323966560588e-13
95 O 0 3.3419496469087656e-15
in O 0 6.700243198198942e-18
exon O 0 8.587631473988555e-13
4 O 0 5.708222116556153e-14
in O 0 2.4511275645883658e-17
the O 0 6.577978459038091e-16
four O 0 3.5840403995318626e-12
C9 B-Disease 0 9.62000399340468e-07
- I-Disease 0 2.765262479442754e-06
deficient I-Disease 0 3.35119210603807e-07
individuals O 0 1.2907456136898587e-12
. O 0 1.2288129498314038e-12

An O 0 8.400378950659902e-15
allele O 0 3.441233192499893e-12
- O 0 7.212119790267479e-12
specific O 0 3.0457369312980164e-15
polymerase O 0 1.8905452290468583e-12
chain O 0 1.0115741577720883e-10
reaction O 0 8.743967870724831e-14
system O 0 2.7572150630900995e-15
designed O 0 4.228758117871649e-14
to O 0 1.3539562754328262e-17
detect O 0 1.9113703675355254e-13
exclusively O 0 1.2801379185476639e-14
only O 0 5.107207919480261e-16
one O 0 1.215523248952055e-16
of O 0 4.043676146778232e-18
the O 0 1.8266387268525155e-16
normal O 0 1.852653755640655e-15
and O 0 2.346220118703532e-16
mutant O 0 2.4487074694323763e-13
alleles O 0 2.0582214521592222e-14
indicated O 0 1.615474382954743e-13
that O 0 2.0635457689167647e-16
all O 0 3.1406689958944894e-15
the O 0 2.6162595162441233e-16
four O 0 3.1439328679501444e-13
patients O 0 5.581167852094365e-16
were O 0 1.1848809718172936e-17
homozygous O 0 8.280371322692912e-15
for O 0 1.0731129891936185e-16
the O 0 5.144672716132911e-16
mutation O 0 3.5888544740181327e-13
in O 0 3.5039084874126554e-16
exon O 0 8.478174412518413e-11
4 O 0 8.26962318067892e-11
and O 0 1.4093945194942892e-12
that O 0 4.2508998979260554e-14
the O 0 3.307410565583403e-14
parents O 0 4.378729583781604e-12
of O 0 7.389503255747899e-16
patient O 0 2.4156607703745836e-12
2 O 0 2.3448133557968202e-14
were O 0 6.870884612132644e-13
heterozygous O 0 9.336746931154494e-10
. O 0 2.3295432423353635e-12

The O 0 3.382688552010238e-13
common O 0 1.3614845741690557e-13
mutation O 0 4.899304161150309e-13
at O 0 9.863168089338167e-14
codon O 0 2.1023083447702096e-12
95 O 0 4.879363785844498e-14
in O 0 5.0498810604823353e-17
exon O 0 4.334638550873571e-12
4 O 0 2.855831890413718e-13
might O 0 4.16359451798666e-14
be O 0 3.7093306530829723e-16
responsible O 0 1.07984452678506e-14
for O 0 1.5047438664018975e-15
most O 0 7.691734754547777e-14
Japanese O 0 7.860687389893428e-08
C9 B-Disease 0 1.4020049547980307e-06
deficiency I-Disease 0 9.30020064515702e-07
. O 0 1.3326461473984921e-15
. O 0 1.5982592853347466e-13

BRCA1 O 0 5.587714895227691e-06
required O 0 6.864871626884039e-13
for O 0 2.528242787447712e-15
transcription O 0 1.1840386449080142e-09
- O 0 2.064666205114918e-06
coupled O 0 1.107711367076547e-09
repair O 0 9.056634331372493e-10
of O 0 3.0534578219006966e-17
oxidative O 0 7.799956969374577e-13
DNA O 0 3.0913853699132687e-09
damage O 0 3.368185730323603e-08
. O 0 1.8925484443488294e-11

The O 0 6.801946561552086e-09
breast B-Disease 1 0.9999759197235107
and I-Disease 1 0.998976469039917
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 2.5170271555907675e-07
gene O 0 1.3979968116473174e-06
BRCA1 O 0 0.0021255635656416416
encodes O 0 8.67144720473334e-08
a O 0 3.4575813323556304e-09
zinc O 0 0.28233960270881653
finger O 0 0.014327903278172016
protein O 0 3.1195919181215004e-09
of O 0 1.5879089492951137e-14
unknown O 0 2.3148956709850843e-12
function O 0 2.3273372812271376e-11
. O 0 4.103642078923109e-11

Association O 0 1.2647903835372176e-09
of O 0 2.7632169267961066e-15
the O 0 1.0995217162486641e-15
BRCA1 O 0 1.175737374126129e-08
protein O 0 9.92116748455528e-14
with O 0 5.663799539150105e-18
the O 0 1.3388248052440008e-18
DNA O 0 4.449434223841031e-11
repair O 0 1.5466209424275235e-09
protein O 0 2.3001439294900727e-11
Rad51 O 0 4.8762153426196164e-08
and O 0 1.4273604000136775e-12
changes O 0 1.7000128069521547e-15
in O 0 4.590200477949035e-19
the O 0 5.886676324167312e-19
phosphorylation O 0 1.0497593776304212e-15
and O 0 1.2946998887482936e-13
cellular O 0 3.3813889188660795e-11
localization O 0 7.636711494294138e-14
of O 0 1.3274999788751139e-17
the O 0 1.7912869134437957e-17
protein O 0 5.3158271580704304e-15
after O 0 3.892004690163591e-16
exposure O 0 1.2158669855099626e-15
to O 0 1.506889914536453e-18
DNA O 0 2.080275188220959e-11
- O 0 1.1934565835591826e-10
damaging O 0 2.2319383841118423e-10
agents O 0 7.117770782494315e-12
are O 0 8.423097221338209e-15
consistent O 0 5.143792648900714e-15
with O 0 5.064752444407059e-18
a O 0 1.1735190174466122e-16
role O 0 1.5002297364466455e-12
for O 0 4.100908690642715e-16
BRCA1 O 0 4.503804447442139e-12
in O 0 5.811756425418792e-17
DNA O 0 6.302743327246674e-10
repair O 0 7.266480679390952e-07
. O 0 1.540977588587733e-11

Here O 0 1.1558225210261952e-10
, O 0 3.888932607543018e-16
it O 0 5.2988730954906986e-18
is O 0 1.7129384337743043e-18
shown O 0 3.7725891249918426e-17
that O 0 5.190321356524752e-18
mouse O 0 2.4518458444089397e-11
embryonic O 0 1.4385184710086207e-10
stem O 0 1.2594598974846605e-10
cells O 0 2.366982044393895e-12
deficient B-Disease 0 6.101631422339437e-10
in I-Disease 0 1.7088155174471562e-16
BRCA1 I-Disease 0 3.140225146580633e-08
are O 0 3.851773060388735e-15
defective O 0 1.4948357829336345e-10
in O 0 5.06469718874214e-17
the O 0 1.575610322068557e-16
ability O 0 6.308298881093494e-14
to O 0 4.286221764749623e-16
carry O 0 8.197944059706863e-12
out O 0 3.7311689848884555e-10
transcription O 0 2.2337791616422464e-09
- O 0 1.0433794273012609e-08
coupled O 0 1.3429984555002328e-11
repair O 0 3.347564239697398e-11
of O 0 3.690020452555167e-18
oxidative O 0 4.468734071476875e-14
DNA O 0 5.698065574932798e-09
damage O 0 7.766173837353563e-08
, O 0 1.9490576416269362e-13
and O 0 3.440916171784658e-13
are O 0 4.367778755592477e-15
hypersensitive O 0 2.6067339953250723e-10
to O 0 2.2986994527801976e-16
ionizing O 0 1.8149528104374757e-12
radiation O 0 1.79303728982394e-13
and O 0 3.346976575692483e-15
hydrogen O 0 1.687396424844556e-13
peroxide O 0 1.855201992029265e-09
. O 0 3.710539362745957e-13

These O 0 7.276557150879756e-14
results O 0 3.2468949404118597e-13
suggest O 0 1.534962613828142e-13
that O 0 3.977956744387334e-14
BRCA1 O 0 6.94323944117059e-07
participates O 0 2.1863862109672283e-10
, O 0 5.648873842546362e-16
directly O 0 6.159649426938163e-15
or O 0 1.3898377891272129e-12
indirectly O 0 3.0191615874031186e-10
, O 0 2.4601429902027135e-14
in O 0 3.362651714474812e-16
transcription O 0 1.63011804055202e-09
- O 0 4.220189850911993e-07
coupled O 0 2.0089141461454574e-10
repair O 0 1.3942014209789022e-10
of O 0 7.892648039431895e-18
oxidative O 0 2.9117679133713187e-14
DNA O 0 1.2875209232099394e-10
damage O 0 2.2178803238404043e-09
. O 0 2.189211031693953e-14
. O 0 1.4206625242527138e-12

Truncation O 0 5.6344347854064836e-08
mutations O 0 8.5610567523986e-09
in O 0 1.9478562778571865e-14
the O 0 1.4625873542544062e-15
transactivation O 0 2.099211542372359e-07
region O 0 1.4788707368082465e-12
of O 0 8.73127597139482e-16
PAX6 O 0 5.977649948363251e-07
result O 0 4.340261602810841e-13
in O 0 2.3644787079749865e-15
dominant O 0 8.82853612438339e-09
- O 0 3.0721196253580274e-07
negative O 0 1.5796240981913456e-09
mutants O 0 9.446589066541833e-10
. O 0 5.40422253388767e-13

PAX6 O 0 2.756204230536241e-05
is O 0 1.435252958148503e-12
a O 0 5.546910133938257e-16
transcription O 0 2.964750840661612e-13
factor O 0 3.309493250194112e-14
with O 0 3.4171011016348804e-18
two O 0 9.876853324057758e-18
DNA O 0 4.581334756004196e-10
- O 0 3.6312411566541414e-07
binding O 0 5.755651955041685e-09
domains O 0 9.399168021673177e-08
( O 0 2.9203679405287453e-13
paired O 0 2.5103610301613344e-09
box O 0 2.0560188218610165e-08
and O 0 1.697437156111814e-11
homeobox O 0 1.6650599302114877e-11
) O 0 3.602965602462257e-15
and O 0 5.981463446868131e-16
a O 0 2.5246096513787016e-15
proline O 0 1.1557576229392907e-08
- O 0 2.278453647974743e-09
serine O 0 1.8676102886416857e-09
- O 0 1.5419722443343886e-10
threonine O 0 3.520317926053451e-10
( O 0 2.672598589241763e-15
PST O 0 9.81109707365313e-11
) O 0 1.3235976120603296e-15
- O 0 4.1527548001914216e-13
rich O 0 6.779367106753142e-14
transactivation O 0 1.898809109945887e-09
domain O 0 6.916464623252239e-11
. O 0 1.3878933809510774e-12

PAX6 O 0 0.0014895969070494175
regulates O 0 1.977776082640048e-05
eye O 0 0.00020276779832784086
development O 0 8.620530775760998e-14
in O 0 2.2904267202123813e-17
animals O 0 4.845805611023704e-15
ranging O 0 8.349550197561065e-15
from O 0 9.44525364148474e-18
jellyfish O 0 1.3419875867298151e-14
to O 0 4.9640638843440414e-18
Drosophila O 0 2.0388756431604076e-15
to O 0 4.9074498234235646e-17
humans O 0 2.560136618760117e-13
. O 0 2.9252346530304896e-13

Heterozygous O 0 7.854727073208778e-07
mutations O 0 6.653536388512293e-09
in O 0 4.164266808036896e-15
the O 0 1.2688040036145146e-16
human O 0 4.789416679549206e-14
PAX6 O 0 1.518693260038617e-08
gene O 0 1.093121704265343e-10
result O 0 3.5134282907068465e-14
in O 0 2.028555400348506e-17
various O 0 2.3680521282212156e-16
phenotypes O 0 2.2780243403436318e-12
, O 0 6.587269881073879e-16
including O 0 9.688687569245347e-13
aniridia B-Disease 1 1.0
, O 0 5.823264093152147e-09
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 8.83759998515643e-09
autosomal B-Disease 0 0.21341070532798767
dominant I-Disease 0 0.0012178464094176888
keratitis I-Disease 1 0.9924915432929993
, O 0 3.91278520694982e-09
and O 0 1.6485376397312734e-09
familial B-Disease 0 0.004381126258522272
foveal I-Disease 1 0.9691360592842102
dysplasia I-Disease 1 0.9502850770950317
. O 0 1.5912594852895978e-10

It O 0 1.7716982937156234e-13
is O 0 1.4728221592351983e-15
believed O 0 1.6790666350786215e-15
that O 0 7.08183650402068e-18
the O 0 6.122836389051201e-18
mutated O 0 5.762673324638534e-12
allele O 0 7.920737850330983e-12
of O 0 2.6280955628963168e-14
PAX6 O 0 8.046995958466141e-07
produces O 0 8.506841064903625e-12
an O 0 3.017183503585633e-16
inactive O 0 4.960749519500318e-11
protein O 0 4.176828327651094e-11
and O 0 7.939233270803925e-09
aniridia B-Disease 1 1.0
is O 0 1.894641554756049e-09
caused O 0 1.3423326686301529e-11
due O 0 2.590926232511493e-14
to O 0 2.173429156172358e-15
genetic O 0 9.18543907602043e-10
haploinsufficiency O 0 6.7558685259427875e-06
. O 0 5.009543994904941e-12

However O 0 7.876516279481383e-13
, O 0 1.1032772882832223e-16
several O 0 3.232977852392875e-17
truncation O 0 5.1625859837090005e-11
mutations O 0 1.4570341599906556e-09
have O 0 1.348593762703909e-12
been O 0 3.038241790857647e-14
found O 0 2.6506334155568592e-14
to O 0 1.4022331862681035e-15
occur O 0 3.783416654512366e-15
in O 0 2.565988210086254e-17
the O 0 8.73081412668033e-15
C O 0 1.4198927589248456e-09
- O 0 4.681737775236172e-10
terminal O 0 3.722178544118132e-13
half O 0 1.664462622397655e-15
of O 0 7.504636473801236e-17
PAX6 O 0 1.5658850882616093e-09
in O 0 3.4824012620906846e-16
patients O 0 2.686911497874582e-14
with O 0 5.536441124347549e-14
Aniridia B-Disease 1 0.9999998807907104
resulting O 0 1.3012115256810786e-12
in O 0 1.3500424041900825e-16
mutant O 0 3.661148207517728e-12
proteins O 0 2.0372829671096854e-14
that O 0 4.659576417844781e-16
retain O 0 2.6047692496168227e-15
the O 0 4.094857037281277e-17
DNA O 0 2.259645981439462e-08
- O 0 1.365569062272698e-07
binding O 0 5.94124194286394e-10
domains O 0 4.868072167596438e-09
but O 0 2.1395079718294907e-12
have O 0 2.7381103027274145e-13
lost O 0 1.4204113579774358e-11
most O 0 1.3751896212539806e-16
of O 0 1.2075463161712876e-16
the O 0 1.2634683101456993e-14
transactivation O 0 1.93841138695916e-08
domain O 0 7.839896509764799e-10
. O 0 1.3994173007902955e-11

It O 0 8.499343806880888e-13
is O 0 1.3403760218443691e-14
not O 0 1.9430738941027862e-17
clear O 0 1.3598415827730797e-17
whether O 0 3.8487436735226596e-17
such O 0 4.0127896362958085e-18
mutants O 0 1.6544412324501212e-12
really O 0 6.497091926960241e-12
behave O 0 2.506616553996652e-15
as O 0 2.4615660876104174e-17
loss O 0 6.8049881593416905e-15
- O 0 4.261969683422295e-12
of O 0 4.63310149251793e-14
- O 0 3.090431732744037e-08
function O 0 4.4624819518866016e-14
mutants O 0 3.6370316480738296e-12
as O 0 1.4168583747727515e-15
predicted O 0 4.702239709804615e-14
by O 0 1.0063951659067347e-14
haploinsufficiency O 0 3.0758252478335635e-07
. O 0 1.8001486802934896e-12

Contrary O 0 2.555932245365544e-12
to O 0 8.870326223505066e-17
this O 0 2.7017047464840797e-19
theory O 0 1.1429281082278904e-17
, O 0 4.381472720707125e-18
our O 0 8.689765599802296e-18
data O 0 2.192222487931326e-15
showed O 0 3.95738773510939e-14
that O 0 1.4470564511622833e-19
these O 0 3.0212213526585863e-19
mutants O 0 1.9646179756811766e-13
are O 0 5.52492952307789e-15
dominant O 0 4.596051837724158e-12
- O 0 1.156806761493101e-09
negative O 0 5.695872593025619e-12
in O 0 9.427255018536199e-18
transient O 0 1.4348347432540927e-15
transfection O 0 8.288342885284794e-13
assays O 0 1.3714107106876927e-11
when O 0 5.853148776205006e-14
they O 0 1.1258071603052148e-14
are O 0 7.749689193491214e-16
coexpressed O 0 1.5319522039813904e-10
with O 0 2.139169849829474e-15
wild O 0 3.029663631082258e-08
- O 0 0.00043882770114578307
type O 0 8.070983312791213e-07
PAX6 O 0 8.52610100992024e-05
. O 0 3.434481171682435e-11

We O 0 7.912292782769059e-13
found O 0 1.178085716172395e-15
that O 0 4.438433618458445e-18
the O 0 4.3990434431247924e-17
dominant O 0 4.3103706715008627e-10
- O 0 6.243581651688146e-08
negative O 0 6.721108114504659e-10
effects O 0 3.0372889533308856e-12
result O 0 2.0156042334977634e-17
from O 0 2.5122785767518464e-19
the O 0 1.3448284304311224e-19
enhanced O 0 1.1828229596881515e-15
DNA O 0 1.4212608412216e-13
binding O 0 5.220119583988769e-13
ability O 0 1.6758296139673945e-14
of O 0 1.0206445093490737e-17
these O 0 6.033874669270675e-16
mutants O 0 3.733345230183538e-11
. O 0 3.9946862549593287e-13

Kinetic O 0 3.144031909818601e-11
studies O 0 1.6495487267786935e-11
of O 0 1.934995946025614e-14
binding O 0 2.175127855608139e-09
and O 0 6.971887802319221e-13
dissociation O 0 1.1226903738267846e-12
revealed O 0 4.410646110494798e-13
that O 0 1.9931404896026608e-17
various O 0 4.095247466530402e-17
truncation O 0 7.707959964742273e-11
mutants O 0 3.3749991690257275e-10
have O 0 6.750802174215753e-13
3 O 0 1.6638446059835145e-14
- O 0 1.1577442476928823e-10
5 O 0 4.662749136449817e-13
- O 0 5.577268091805365e-10
fold O 0 1.7073764277397707e-11
higher O 0 2.1247963783409263e-14
affinity O 0 8.371675280478499e-17
to O 0 1.4553936562549936e-19
various O 0 1.7019560343296202e-19
DNA O 0 1.6063947318612631e-13
- O 0 4.051698077522578e-14
binding O 0 8.933594026011246e-16
sites O 0 1.415632082823364e-15
when O 0 2.5762401211621138e-15
compared O 0 4.2414926017830834e-16
with O 0 1.2968869343032002e-17
the O 0 2.0488153365684204e-16
wild O 0 2.974561486013272e-09
- O 0 1.9733147382794414e-06
type O 0 1.5585676749196864e-08
PAX6 O 0 6.532595307362499e-06
. O 0 3.126063297109738e-11

These O 0 3.5377981062257105e-14
results O 0 5.0423332637094045e-14
provide O 0 4.3328580753364645e-17
a O 0 2.0263124173995073e-17
new O 0 1.1677767958087181e-15
insight O 0 4.432636491880212e-15
into O 0 8.141234673222046e-17
the O 0 1.0043194216722374e-16
role O 0 1.4608380152249245e-13
of O 0 1.1141844918403465e-17
mutant O 0 1.9216626553908434e-11
PAX6 O 0 1.5182992640916382e-08
in O 0 2.2985265627677512e-14
causing O 0 4.4278733457581154e-10
aniridia B-Disease 1 0.9999996423721313
. O 0 6.493743260130302e-13
. O 0 6.894474683001584e-13

Reversal O 0 1.3355369787859672e-07
of O 0 1.1032055269311059e-09
severe O 0 0.2612181305885315
hypertrophic B-Disease 1 0.9997952580451965
cardiomyopathy I-Disease 1 1.0
and O 0 1.0699810482073246e-10
excellent O 0 2.0828806734929373e-10
neuropsychologic O 0 1.9120066951927583e-07
outcome O 0 8.816772182132504e-13
in O 0 4.6194923835609844e-15
very B-Disease 0 2.0892927145299556e-12
- I-Disease 0 3.956958153139567e-06
long I-Disease 0 1.9726289224308857e-07
- I-Disease 0 1.2938115787619608e-06
chain I-Disease 0 1.867779104713918e-07
acyl I-Disease 0 1.2939568305725402e-09
- I-Disease 0 5.964373439582005e-09
coenzyme I-Disease 0 7.526906875554573e-11
A I-Disease 0 1.1435209029686533e-10
dehydrogenase I-Disease 0 1.0367793947807513e-06
deficiency I-Disease 0 0.00040371259092353284
. O 0 1.6549051625597277e-12

Very B-Disease 0 2.0323037697167479e-10
- I-Disease 0 1.2946730976182153e-06
long I-Disease 0 1.672016125553455e-08
- I-Disease 0 6.373578003149305e-07
chain I-Disease 0 5.078531373214901e-09
acyl I-Disease 0 5.117889098626982e-11
- I-Disease 0 3.730355954689735e-11
coenzyme I-Disease 0 4.356775357150511e-13
A I-Disease 0 2.516149994521294e-14
dehydrogenase I-Disease 0 2.4017322852731837e-11
( I-Disease 0 3.8825625386148394e-14
VLCAD I-Disease 0 1.551294758428412e-06
) I-Disease 0 4.911280258347583e-13
deficiency I-Disease 0 2.744486380379385e-07
is O 0 3.885775503990364e-15
a O 0 5.334978877939711e-13
disorder O 0 2.5552863007760607e-05
of O 0 6.242798416205382e-15
fatty O 0 2.4922046648612195e-08
acid O 0 2.6018037550812334e-12
beta O 0 1.3706024349187862e-15
oxidation O 0 2.3113814735884614e-14
that O 0 3.80758123394811e-15
reportedly O 0 7.226258258441476e-09
has O 0 6.041309674742479e-10
high O 0 3.490621480750633e-08
rates O 0 3.613778062572237e-06
of O 0 1.6931398991171243e-11
morbidity O 0 0.00037407688796520233
and O 0 5.339639841395183e-10
mortality O 0 1.0723112175980987e-08
. O 0 7.409018602626272e-13

We O 0 1.0557468527877534e-12
describe O 0 2.0405963905927547e-14
the O 0 8.331373717545935e-17
outcome O 0 2.7730781373076004e-16
of O 0 5.933596490053157e-18
a O 0 2.6884362524708463e-16
5 O 0 3.749923277712036e-15
- O 0 6.987973567851302e-12
year O 0 3.4852724005440816e-12
- O 0 1.8612599461675927e-08
old O 0 1.2239807745118014e-07
girl O 0 1.710992364678532e-05
with O 0 2.934623655193036e-09
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 5.979288592028453e-11
was O 0 5.969755397482179e-13
first O 0 2.5807229075101856e-13
seen O 0 1.2778497704424296e-10
at O 0 3.205794462356193e-13
5 O 0 1.7694473798912603e-15
months O 0 3.387167865523226e-14
of O 0 3.416674417059507e-16
age O 0 4.051909474611648e-09
with O 0 7.917505229215749e-08
severe O 0 0.14406269788742065
hypertrophic B-Disease 1 0.9993488192558289
cardiomyopathy I-Disease 1 1.0
, O 0 4.659343630919466e-06
hepatomegaly B-Disease 1 1.0
, O 0 1.2056506193403038e-07
encephalopathy B-Disease 1 0.9999966621398926
, O 0 7.865295220677027e-11
and O 0 1.095225909963915e-09
hypotonia B-Disease 0 0.001045981072820723
. O 0 5.640423024477759e-12

Biochemical O 0 1.3409677194431424e-05
studies O 0 8.670469355820387e-07
indicated O 0 0.4243129789829254
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 1.425600348881062e-08
by O 0 2.8231390021001912e-15
a O 0 1.0554407825144607e-12
stable O 0 3.40893380190721e-09
yet O 0 2.692192822839612e-12
inactive O 0 1.0215094325971563e-09
enzyme O 0 7.247649702613046e-10
. O 0 2.722186354369577e-13

Molecular O 0 8.40837469096023e-12
genetic O 0 8.671711786145675e-12
analysis O 0 4.334107129178727e-13
of O 0 3.3969500796244764e-14
her O 0 4.9564894410991656e-09
VLCAD O 0 0.0001588379527674988
gene O 0 2.496807760543618e-10
revealed O 0 1.2111466274333793e-09
a O 0 1.2816582918660085e-13
T1372C O 0 1.4371773215948735e-10
( O 0 4.366812714516133e-15
F458L O 0 1.1165855566541705e-11
) O 0 2.1213652172781886e-15
missense O 0 2.390724507250752e-09
mutation O 0 1.2820066785934614e-07
and O 0 1.4736639686319108e-09
a O 0 3.183588948019178e-10
1668 O 0 0.00013877276796847582
ACAG O 0 0.00986058171838522
1669 O 0 5.729430263556878e-09
splice O 0 4.792520371665887e-07
site O 0 2.647785324327856e-09
mutation O 0 1.636574609165109e-07
. O 0 1.1659637144667556e-10

After O 0 1.6005936810323251e-12
initial O 0 4.413338997640709e-13
treatment O 0 2.5576684867245625e-12
with O 0 9.422415681080518e-15
intravenous O 0 1.1873059480027592e-10
glucose O 0 2.803501319981194e-10
and O 0 2.339296291398174e-14
carnitine O 0 1.2617591416130836e-09
, O 0 2.613556422351198e-16
the O 0 5.203467655281996e-17
patient O 0 4.710718794209701e-12
has O 0 6.695785283649877e-14
thrived O 0 1.2777291160878668e-12
on O 0 4.635154564856803e-13
a O 0 2.0643755530968394e-13
low O 0 1.2118336556454778e-08
- O 0 3.996753861201796e-08
fat O 0 2.877676319457123e-09
diet O 0 3.719944925012486e-12
supplemented O 0 1.3552561037386696e-13
with O 0 7.068110050560293e-15
medium O 0 1.1281029582699276e-10
- O 0 1.4623778632483209e-08
chain O 0 1.117325898469801e-09
triglyceride O 0 2.447041014264073e-09
oil O 0 5.77103920207378e-10
and O 0 6.527342956506171e-14
carnitine O 0 2.0654196131175695e-09
and O 0 1.5338817997874454e-14
avoidance O 0 7.649679500953965e-12
of O 0 3.693166564531841e-15
fasting O 0 4.1449901844181625e-10
. O 0 1.8970677080013681e-13

Her O 0 1.268261939912918e-06
ventricular O 0 7.550364443886792e-06
hypertrophy O 0 1.2985088915229426e-06
resolved O 0 2.1101199954021155e-10
significantly O 0 6.5873456862874935e-12
over O 0 3.413227274602637e-13
1 O 0 4.166939281688778e-14
year O 0 9.80962815318176e-13
, O 0 1.606485017103111e-15
and O 0 3.504393159665074e-14
cognitively O 0 2.04615716731249e-11
, O 0 3.1863294980563145e-17
she O 0 1.1484880971593392e-12
is O 0 2.997886504860404e-16
in O 0 1.038791197627262e-18
the O 0 3.958408301284735e-17
superior O 0 4.5638128421798124e-14
range O 0 1.019996600745178e-13
for O 0 4.937953732432436e-14
age O 0 2.6239838080144295e-10
. O 0 1.415669339567549e-12

Clinical O 0 3.2005033290261053e-07
recognition O 0 4.464383529523275e-09
of O 0 3.4853064789786004e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 8.760724784506735e-11
important O 0 3.693633194982483e-14
because O 0 2.110542169091352e-14
it O 0 1.85278102234098e-15
is O 0 2.6461417268925118e-15
one O 0 2.684050474688641e-16
of O 0 1.9373527821141245e-17
the O 0 6.092460761858702e-16
few O 0 1.130239836184127e-13
directly O 0 6.246420047872903e-11
treatable O 0 8.404315963161935e-07
causes O 0 2.3306944482021086e-12
of O 0 7.216059000336728e-11
cardiomyopathy B-Disease 1 1.0
in O 0 1.1050239716314803e-11
children O 0 5.7931948127532e-10
. O 0 1.1405344374558306e-14
. O 0 1.276571350797978e-13

Cloning O 0 3.5782313223542417e-10
of O 0 4.6791548432667356e-15
a O 0 1.3156792304320412e-15
novel O 0 1.5995156046021142e-13
member O 0 2.0455931057112436e-13
of O 0 7.446603467257986e-17
the O 0 2.9714637461751917e-14
low O 0 1.1128986443509348e-07
- O 0 4.529934827246507e-08
density O 0 2.8260471220120653e-12
lipoprotein O 0 1.0684728977139457e-06
receptor O 0 1.4975953810392184e-10
family O 0 1.870945585957795e-11
. O 0 3.978567909151964e-12

A O 0 4.0257402446342017e-13
gene O 0 5.5915996659272604e-12
encoding O 0 3.0750540460332265e-13
a O 0 4.1633482008055986e-14
novel O 0 2.591503400761752e-11
transmembrane O 0 1.5422324750602456e-08
protein O 0 1.825456452664298e-10
was O 0 1.0377764186192406e-12
identified O 0 1.7158055244954743e-15
by O 0 1.4206982116963104e-19
DNA O 0 4.458702236766069e-15
sequence O 0 1.3327115806936675e-16
analysis O 0 2.551729528767416e-15
within O 0 1.2092755868726665e-15
the O 0 2.293868870892335e-12
insulin B-Disease 0 0.00761099299415946
- I-Disease 1 0.9999889135360718
dependent I-Disease 1 0.9998760223388672
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 5.3327724458540615e-09
IDDM B-Disease 0 1.0584230039967224e-05
) O 0 3.8632013983196795e-14
locus O 0 3.2871855237814884e-10
IDDM4 O 0 0.00014353716687764972
on O 0 3.1682453882631023e-10
chromosome O 0 7.85198608355131e-07
11q13 O 0 1.0744469847168148e-07
. O 0 2.790657245219097e-12

Based O 0 3.441060641724142e-13
on O 0 3.43109248695031e-13
its O 0 3.148214153630394e-15
chromosomal O 0 5.667297500622226e-06
position O 0 1.91621563061517e-08
, O 0 1.3938169345552868e-16
this O 0 5.451162241989934e-20
gene O 0 1.1987212387125227e-15
is O 0 3.465542659462364e-17
a O 0 2.0529752195971435e-18
candidate O 0 9.848682894203877e-16
for O 0 9.539186452048914e-17
conferring O 0 7.261946577928613e-13
susceptibility O 0 1.262437376858827e-10
to O 0 6.18431278409659e-11
diabetes B-Disease 0 0.0498468317091465
. O 0 1.7768719828836765e-10

The O 0 1.4720700786813312e-14
gene O 0 6.9216871817490144e-12
, O 0 2.3231104658640337e-15
termed O 0 5.889370154749107e-12
low O 0 2.72821609748064e-09
- O 0 4.3257355031300904e-08
density O 0 2.2695931505695155e-12
lipoprotein O 0 2.601470043828158e-07
receptor O 0 2.7840169405934923e-12
related O 0 6.11598879179942e-13
protein O 0 1.7498304888396987e-11
5 O 0 9.097826658699404e-13
( O 0 5.939357333181001e-15
LRP5 O 0 2.9945724122626416e-08
) O 0 2.735569136123016e-16
, O 0 4.763431226769305e-19
encodes O 0 1.1250074553238883e-16
a O 0 1.426609021014849e-16
protein O 0 1.91751969120732e-13
of O 0 4.621290210991532e-15
1615 O 0 2.8956444880767762e-11
amino O 0 1.8856977611336756e-12
acids O 0 1.63871010944866e-12
that O 0 7.204508216042906e-18
contains O 0 9.131533979081551e-17
conserved O 0 5.656836693404381e-14
modules O 0 2.3527027548375656e-10
which O 0 6.924588940443455e-13
are O 0 7.326102310250323e-15
characteristic O 0 4.066281613182045e-15
of O 0 3.6085347911508946e-16
the O 0 1.6314778304368782e-12
low O 0 2.4890772692742757e-05
- O 0 0.004332472570240498
density O 0 9.07818797912796e-09
lipoprotein O 0 0.493058443069458
( O 0 3.8712419381248253e-10
LDL O 0 5.658182271872647e-05
) O 0 2.261485676459049e-13
receptor O 0 7.377516024302533e-13
family O 0 1.4374281929671606e-12
. O 0 6.2109774788543515e-12

These O 0 5.939312016918323e-15
modules O 0 6.833036740594434e-13
include O 0 1.5261330365068447e-15
a O 0 1.4513146890677662e-17
putative O 0 3.9904498027329774e-14
signal O 0 2.3103134920969158e-15
peptide O 0 3.407875332924311e-16
for O 0 1.6159901259473104e-19
protein O 0 1.129962201018632e-16
export O 0 3.9547662020189556e-12
, O 0 6.844654871080287e-18
four O 0 3.8289761744650104e-16
epidermal O 0 7.937672741320512e-09
growth O 0 1.073240163407263e-08
factor O 0 1.1457859400848536e-12
( O 0 2.38174331467075e-14
EGF O 0 7.909053323373882e-08
) O 0 3.20712626919982e-14
repeats O 0 2.5898347355557405e-10
with O 0 2.3674176158404274e-14
associated O 0 2.435623046564278e-13
spacer O 0 5.1495119279820756e-09
domains O 0 1.0470100875181743e-07
, O 0 5.793658603000726e-14
three O 0 9.495054346725026e-14
LDL O 0 2.28723838517908e-05
- O 0 1.1572183211683296e-07
receptor O 0 2.3512523525393014e-11
( O 0 4.3919068279081944e-14
LDLR O 0 1.2466276189115888e-07
) O 0 3.7666398964425734e-15
repeats O 0 6.683036762877848e-11
, O 0 1.5116817015146207e-16
a O 0 2.0015377955707276e-16
single O 0 1.4377805890308792e-10
transmembrane O 0 2.0407561751589753e-10
spanning O 0 1.2290812811954765e-10
domain O 0 1.0530022365173863e-07
, O 0 2.4527017569719867e-11
and O 0 6.5864726324881e-14
a O 0 1.421633628892016e-15
cytoplasmic O 0 2.330670101358123e-10
domain O 0 2.0914447951270176e-09
. O 0 1.4272558135353108e-10

The O 0 3.827167176787471e-15
encoded O 0 5.732848413651445e-14
protein O 0 2.0464643434719987e-12
has O 0 3.6824906459679424e-14
a O 0 1.1081147232234936e-17
unique O 0 2.3198323954186004e-16
organization O 0 3.73808514524121e-14
of O 0 3.127310693393226e-14
EGF O 0 0.0004231685306876898
and O 0 2.0010564316663704e-09
LDLR O 0 3.8615191442659125e-05
repeats O 0 6.660113349710173e-09
; O 0 3.526691556111428e-16
therefore O 0 2.9334717668040827e-16
, O 0 2.675871842187309e-16
LRP5 O 0 8.764348535805766e-08
likely O 0 4.0394312786178055e-13
represents O 0 6.483284807746491e-17
a O 0 2.3945039083727833e-16
new O 0 6.808734348898171e-13
category O 0 1.2175357944066434e-11
of O 0 6.158494391635464e-16
the O 0 8.194824213745427e-14
LDLR O 0 3.3493404316686792e-06
family O 0 3.2976440588611267e-12
. O 0 9.241625477038329e-13

Both O 0 2.281624975758456e-12
human O 0 5.407790101136234e-13
and O 0 2.113007373781041e-14
mouse O 0 2.0936690603434727e-08
LRP5 O 0 0.00013584863336291164
cDNAs O 0 5.551523685198845e-09
have O 0 2.698386219329718e-13
been O 0 7.625682854270344e-13
isolated O 0 1.9368072683850768e-12
and O 0 3.256236053635498e-16
the O 0 2.6402273908894316e-19
encoded O 0 4.542721870023946e-16
mature O 0 3.6160344738054434e-14
proteins O 0 7.744986043051584e-17
are O 0 4.168077079871001e-17
95 O 0 1.3658841437652245e-15
% O 0 1.8868009624669263e-17
identical O 0 2.6896510734765455e-13
, O 0 1.283543668621984e-14
indicating O 0 5.2753526373627846e-12
a O 0 1.3895487408280283e-12
high O 0 1.8272686475029332e-07
degree O 0 1.1640020273605972e-13
of O 0 3.282676716479633e-16
evolutionary O 0 6.804809943609588e-14
conservation O 0 6.112326898961851e-13
. O 0 7.597423056881873e-15
. O 0 2.889231009387677e-13

The O 0 6.103307421088944e-14
APC B-Disease 0 7.012718183929678e-11
variants O 0 1.285149612596792e-12
I1307K O 0 1.0418546234070014e-11
and O 0 5.513452332521712e-16
E1317Q O 0 2.6976657669861015e-13
are O 0 3.392465950729183e-16
associated O 0 4.0466493545811277e-13
with O 0 0.007512450683861971
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.511434000178724e-08
but O 0 1.828510867024624e-12
not O 0 4.125110409508581e-12
always O 0 4.951400747743584e-11
with O 0 1.8501819017423303e-15
a O 0 3.72332517261883e-15
family O 0 3.587923686453054e-13
history O 0 2.217810310400914e-11
. O 0 1.0076068451825293e-11

Classical O 1 0.8433940410614014
familial B-Disease 1 0.9999991655349731
adenomatous I-Disease 1 0.9999377727508545
polyposis I-Disease 1 0.9999985694885254
( O 0 4.716714130381661e-09
FAP B-Disease 0 9.688077895475544e-09
) O 0 1.6982636203886035e-14
is O 0 9.863609732316866e-16
a O 0 1.4130923265288226e-13
high O 0 0.04468381777405739
- O 1 0.9999995231628418
penetrance O 1 0.9999964237213135
autosomal B-Disease 1 0.9999995231628418
dominant I-Disease 1 0.8942362070083618
disease I-Disease 0 0.004723829682916403
that O 0 4.2123880203198336e-16
predisposes O 0 1.9373863407654013e-13
to O 0 9.505503616146724e-19
hundreds O 0 2.7061635601784702e-17
or O 0 4.2960108186419223e-16
thousands O 0 7.252834129719415e-14
of O 0 2.3571684604206666e-09
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.09655210375785828
carcinoma I-Disease 1 1.0
and O 0 8.062634587746587e-11
that O 0 5.9585104421843154e-15
results O 0 1.3840251373350293e-13
from O 0 1.7627774189481063e-15
truncating O 0 2.5956961025030978e-09
mutations O 0 1.812428332415017e-11
in O 0 6.779149445755478e-17
the O 0 3.655865139358893e-16
APC B-Disease 0 1.2973616625444606e-10
gene O 0 2.502637506951455e-11
. O 0 1.3017178480956293e-12

A O 0 3.39835343025896e-12
variant O 0 1.9887955171604688e-10
of O 0 4.34179940806724e-14
FAP B-Disease 0 2.5019929239533667e-07
is O 0 1.9288351471580256e-10
attenuated B-Disease 0 0.17857366800308228
adenomatous I-Disease 1 0.9999992847442627
polyposis I-Disease 1 0.9999806880950928
coli I-Disease 1 1.0
, O 0 6.652913354769641e-13
which O 0 7.915450364895328e-16
results O 0 2.6878750825553785e-14
from O 0 6.34231758772771e-15
germ O 0 2.917397068813443e-06
- O 0 4.964790036865452e-07
line O 0 3.039872575882896e-09
mutations O 0 6.232611649004127e-12
in O 0 4.4739807126661764e-17
the O 0 2.710628250991113e-16
5 O 0 6.059670316525476e-14
and O 0 2.9165258668426355e-14
3 O 0 1.1275988467468944e-15
regions O 0 2.9315029445973085e-16
of O 0 4.4345409064957705e-18
the O 0 8.976705885444121e-16
APC B-Disease 0 4.9617338016005874e-11
gene O 0 8.263658854423817e-12
. O 0 4.744168924895875e-13

Attenuated B-Disease 1 0.9960864782333374
adenomatous I-Disease 1 0.9999887943267822
polyposis I-Disease 1 0.9999785423278809
coli I-Disease 1 1.0
patients O 0 0.0060218460857868195
have O 0 7.535899682054037e-11
" O 0 3.1547407915166747e-12
multiple O 0 5.091423460612532e-08
" O 0 0.2507951259613037
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 5.057161286958767e-12
typically O 0 4.178397435179466e-15
fewer O 0 8.074279101021758e-16
than O 0 5.385627715417199e-17
100 O 0 5.138984889892098e-16
) O 0 8.640980141635143e-17
without O 0 6.453481027055062e-16
the O 0 1.1549116358893462e-15
florid O 0 3.0508275905560822e-09
phenotype O 0 3.2990342228866876e-12
of O 0 4.9713268940817265e-16
classical O 0 1.23622804701351e-11
FAP B-Disease 0 2.497738904594371e-08
. O 0 1.7881440685790784e-12

Another O 0 7.126651699329578e-13
group O 0 2.857292039689513e-13
of O 0 5.622324124210268e-16
patients O 0 4.1232344144895294e-14
with O 0 3.1162622709149487e-16
multiple O 0 1.0852999055011026e-10
adenomas B-Disease 0 0.4620901346206665
has O 0 1.922450110214413e-08
no O 0 6.241947063390096e-13
mutations O 0 4.2754016472967837e-13
in O 0 3.978755289992314e-17
the O 0 7.049415159911664e-17
APC B-Disease 0 3.502325382834237e-12
gene O 0 5.538799128547434e-13
, O 0 1.74881270438408e-15
and O 0 1.5623786986385113e-14
their O 0 2.5699189260349918e-15
phenotype O 0 4.56291905301387e-13
probably O 0 1.7938650781826326e-13
results O 0 2.6037535300581227e-13
from O 0 1.281848840397823e-13
variation O 0 2.1786048659544477e-11
at O 0 1.8293289105741906e-10
a O 0 6.656315039085814e-13
locus O 0 2.8543565289140815e-09
, O 0 1.2207580866313572e-12
or O 0 1.3314477016572457e-14
loci O 0 2.418042979387969e-13
, O 0 5.843329631467255e-15
elsewhere O 0 1.7599094924436454e-14
in O 0 5.981297514437253e-18
the O 0 4.195405274425181e-16
genome O 0 1.0419227286506683e-10
. O 0 3.854086754601083e-12

Recently O 0 6.87680721966899e-06
, O 0 1.1472725167886028e-13
however O 0 7.317328107707952e-16
, O 0 1.2276384339885271e-17
a O 0 5.590647077216427e-17
missense O 0 1.5033907452277617e-10
variant O 0 7.033041926618466e-10
of O 0 2.4644825093980867e-14
APC B-Disease 0 2.2387995901596014e-09
( O 0 7.976471994844067e-15
I1307K O 0 4.389533007909119e-12
) O 0 3.5675826010357213e-16
was O 0 1.5201491934267904e-14
described O 0 3.881642406724237e-15
that O 0 1.6477019579538604e-16
confers O 0 2.3307363458398116e-14
an O 0 1.2309785826845714e-15
increased O 0 1.0687990936730785e-08
risk O 0 0.004390656016767025
of O 0 0.0213285181671381
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.0346404288874567e-11
including O 0 1.8849468867547254e-15
multiple O 0 1.0274506939689232e-11
adenomas B-Disease 0 3.023797762580216e-05
, O 0 4.989268546917724e-13
in O 0 1.5279987832742675e-13
Ashkenazim O 0 7.5705029303208e-05
. O 0 3.534511919256467e-11

We O 0 1.042834263387249e-08
have O 0 6.052695779475148e-13
studied O 0 2.511337492128174e-13
a O 0 1.8147066796036625e-16
set O 0 4.125120333346591e-15
of O 0 5.134315852380931e-18
164 O 0 2.6906014308908377e-12
patients O 0 4.394854587267934e-15
with O 0 2.0202019548052393e-15
multiple O 0 0.00018255048780702055
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.0005604767356999218
/ I-Disease 0 0.27039840817451477
or I-Disease 0 2.1582404770015273e-06
carcinoma I-Disease 1 1.0
and O 0 2.101715068647536e-08
analyzed O 0 1.740937882743765e-08
codons O 0 2.2111575503913627e-07
1263 O 0 3.0771374337490442e-09
- O 0 2.8919728833898262e-08
1377 O 0 2.637693841123223e-09
( O 0 1.0368064100405722e-13
exon O 0 9.386918325970939e-11
15G O 0 9.849802085071246e-10
) O 0 3.735686347934586e-16
of O 0 1.3857993582551216e-18
the O 0 5.1519736769171e-18
APC B-Disease 0 1.2184591985549276e-13
gene O 0 9.39807788340706e-15
for O 0 4.811890941211234e-16
germ O 0 3.8461045903659397e-08
- O 0 7.166635640487584e-08
line O 0 6.2682312673700835e-09
variants O 0 1.6145895731511928e-10
. O 0 1.1762935460749024e-12

Three O 0 5.701538546842855e-11
patients O 0 2.047007095079545e-12
with O 0 2.735339643133869e-16
the O 0 7.674727836450392e-16
I1307K O 0 7.074166252785119e-11
allele O 0 3.344759094258548e-13
were O 0 9.693372203544749e-15
detected O 0 1.1231316441109862e-12
, O 0 7.415700661317495e-18
each O 0 1.312830790979323e-16
of O 0 1.972262007573014e-13
Ashkenazi O 0 4.0795182343345004e-08
descent O 0 1.2883469846514117e-09
. O 0 2.2188046538973438e-11

Four O 0 4.380805718184888e-10
patients O 0 7.779386856920922e-11
had O 0 6.033147614305234e-13
a O 0 1.0593543762745048e-14
germ O 0 3.532666232786141e-05
- O 0 2.1010930140619166e-05
line O 0 2.0030849867680445e-08
E1317Q O 0 9.159804165159713e-11
missense O 0 6.052332940376104e-11
variant O 0 4.791294964945347e-12
of O 0 6.005810350145772e-17
APC O 0 2.6672863136928404e-12
that O 0 3.430230120589128e-16
was O 0 1.3577716425142161e-12
not O 0 3.3023093520102116e-15
present O 0 1.710244541438513e-15
in O 0 1.4766861382521152e-16
controls O 0 2.1241593553544824e-11
; O 0 4.6611366955470155e-18
one O 0 5.628350631281084e-17
of O 0 3.525102641416387e-17
these O 0 1.0609882181264636e-14
individuals O 0 2.774542748329445e-13
had O 0 1.9219018043692415e-10
an O 0 1.0094975723068194e-15
unusually O 0 7.982775952850713e-14
large O 0 3.0317355613831976e-14
number O 0 1.9194756895046794e-11
of O 0 4.387055389104555e-12
metaplastic B-Disease 0 2.926294291683007e-05
polyps I-Disease 0 7.204131406979286e-07
of I-Disease 0 9.847742687632425e-16
the I-Disease 0 1.873832848869189e-13
colorectum I-Disease 0 3.6380699839355657e-06
. O 0 1.8614905623881572e-12

There O 0 2.457958695519652e-13
is O 0 2.002087572893055e-16
increasing O 0 1.1259518970600769e-16
evidence O 0 1.041837057298928e-14
that O 0 6.629801417058767e-15
there O 0 1.2906310474015449e-14
exist O 0 1.126202877157513e-13
germ O 0 6.664613749762793e-08
- O 0 3.299009421198207e-08
line O 0 3.77084752312129e-10
variants O 0 1.31995868228596e-13
of O 0 5.542843399718314e-18
the O 0 6.443954520289187e-18
APC B-Disease 0 7.40028698043016e-14
gene O 0 1.1981405976271798e-15
that O 0 2.063622481646773e-18
predispose O 0 5.745957053191505e-16
to O 0 1.3671389701370225e-17
the O 0 1.6787190471677818e-17
development O 0 2.7291708609976937e-15
of O 0 5.4549226735037953e-14
multiple O 0 0.21044793725013733
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.07691793143749237
carcinoma I-Disease 1 1.0
, O 0 1.8762632073010543e-11
but O 0 1.3968363581963201e-14
without O 0 7.64816541262009e-15
the O 0 1.4212595579666848e-15
florid O 0 1.509117986131514e-08
phenotype O 0 8.963344823309516e-12
of O 0 1.7853187391497766e-16
classical O 0 3.5869039943098313e-13
FAP B-Disease 0 4.713455736826688e-10
, O 0 7.02571372220961e-16
and O 0 8.254879363219482e-17
possibly O 0 1.878486566466017e-15
with O 0 3.1571257872684564e-15
importance O 0 2.8233818061274008e-11
for O 0 1.0358589861425571e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 4.425000952323899e-06
in O 0 4.0259338340142966e-16
the O 0 5.534017763085455e-16
general O 0 1.986713744905888e-14
population O 0 2.8978899640978487e-17
. O 0 4.1841693823798526e-16
. O 0 1.3102838041997855e-13

Genomic O 0 4.699920452821971e-09
structure O 0 7.865925272243501e-11
of O 0 2.4131670511677583e-14
the O 0 2.9184987759833803e-12
human O 0 2.9382824777712813e-06
congenital B-Disease 1 0.9999986886978149
chloride I-Disease 1 0.999894380569458
diarrhea I-Disease 1 1.0
( O 0 4.0482013297094e-09
CLD B-Disease 0 0.00019366912601981312
) O 0 3.7625439331008537e-13
gene O 0 3.8045783190554516e-10
. O 0 8.665743470026577e-12

Congenital B-Disease 1 0.9999961853027344
chloride I-Disease 1 0.9999483823776245
diarrhea I-Disease 1 1.0
( O 0 7.875424046233093e-08
CLD B-Disease 0 0.05785895138978958
) O 0 9.150771286547954e-12
is O 0 4.696881989244006e-13
caused O 0 1.4475080205647584e-13
by O 0 1.0428504475170231e-15
mutations O 0 5.313063322631706e-10
in O 0 2.7586565014080895e-15
a O 0 2.0932223358474276e-15
gene O 0 3.346623976205332e-12
which O 0 3.484821658737464e-15
encodes O 0 2.4663283568204797e-12
an O 0 2.1038916052026901e-13
intestinal O 0 1.9689102828124305e-06
anion O 0 1.6618538767332325e-09
transporter O 0 8.64368848851882e-06
. O 0 9.317173421674596e-11

We O 0 2.7038307703897146e-10
report O 0 1.5388033729191175e-12
here O 0 5.522018482596413e-16
the O 0 1.4208126728135724e-18
complete O 0 5.620115485800302e-16
genomic O 0 7.24222222990567e-13
organization O 0 8.963916577325176e-14
of O 0 6.053815280686919e-17
the O 0 2.4389489976646373e-15
human O 0 5.704535151543344e-13
CLD B-Disease 0 5.825130600101147e-09
gene O 0 1.2516445128604725e-12
which O 0 3.5168572388960095e-16
spans O 0 8.541173952998637e-13
approximately O 0 3.155131754820073e-12
39kb O 0 2.5092022042372264e-05
, O 0 1.6669624664997218e-12
and O 0 1.53847464282042e-12
comprises O 0 1.7457101736395586e-11
21 O 0 2.8470999863250412e-11
exons O 0 1.8314045391321088e-08
. O 0 4.458012084485041e-12

All O 0 2.1295536948434668e-12
exon O 0 2.412985722344274e-08
/ O 0 5.497082611327642e-07
intron O 0 2.2367996166394732e-07
boundaries O 0 9.045684340458493e-11
conform O 0 2.6598079207879044e-12
to O 0 1.2895518109597127e-16
the O 0 5.014390049120135e-16
GT O 0 4.7123460689135754e-08
/ O 0 6.394131446540996e-07
AG O 1 0.6917446851730347
rule O 0 2.746440054546273e-11
. O 0 5.789463418219565e-13

An O 0 2.315996236140045e-15
analysis O 0 4.5866219994933604e-15
of O 0 2.3320400261603315e-17
the O 0 8.515906297114063e-18
putative O 0 1.3109661739420936e-13
promoter O 0 9.37004553808185e-12
region O 0 5.7035721597856106e-15
sequence O 0 1.411060751886151e-14
shows O 0 1.346470678009748e-12
a O 0 7.874826347107657e-15
putative O 0 5.872951430729856e-11
TATA O 0 1.8620487026055343e-05
box O 0 9.376767451385604e-08
and O 0 1.4709889556430156e-11
predicts O 0 2.255857306510123e-11
multiple O 0 1.5642400027181258e-13
transcription O 0 2.4283798930047062e-11
factor O 0 6.644695644403287e-13
binding O 0 6.556184414807653e-12
sites O 0 2.450426972444575e-09
. O 0 3.4884796440426413e-11

The O 0 2.0889488598109518e-13
genomic O 0 9.762600450269332e-11
structure O 0 9.135896032741453e-12
was O 0 6.715635670175371e-14
determined O 0 1.7858695421760634e-17
using O 0 1.2210762447530215e-17
DNA O 0 3.052730594352293e-13
from O 0 1.5197350988712124e-17
several O 0 1.701035097964513e-18
sources O 0 3.1909989326141764e-18
including O 0 1.5346607458441193e-17
multiple O 0 5.835468826903556e-14
large O 0 7.288176138986469e-12
- O 0 0.00010905017552431673
insert O 0 2.950959867575875e-07
libaries O 0 4.191462821268033e-08
and O 0 1.1364638406332987e-16
genomic O 0 3.449266222578691e-14
DNA O 0 1.2101993018820423e-10
from O 0 1.8134579124820527e-12
Finnish O 0 7.129197001631837e-07
CLD B-Disease 0 0.0011073031928390265
patients O 0 1.4586115426595825e-08
and O 0 2.690442270011917e-12
controls O 0 2.70161688575854e-08
. O 0 8.72862979811595e-12

Exon O 0 3.3056530845954057e-09
- O 0 5.156113314086497e-10
specific O 0 9.72007508661353e-14
primers O 0 4.914232576425093e-09
developed O 0 3.6046228502062405e-11
in O 0 6.408164896725855e-18
this O 0 1.1230463155570532e-19
study O 0 5.1080818192538114e-17
will O 0 7.03329903460117e-17
facilitate O 0 4.359451601157799e-17
mutation O 0 3.691898556209801e-15
screening O 0 5.631669718238197e-13
studies O 0 8.433065105061498e-15
of O 0 5.915837981092828e-16
patients O 0 2.1916550605599605e-14
with O 0 8.041573041345901e-16
the O 0 6.102949092270937e-13
disease O 0 6.845654070275486e-07
. O 0 4.3973427329979664e-12

Genomic O 0 3.024405031970545e-11
sequencing O 0 4.5824490035872856e-12
of O 0 8.841349385198174e-15
a O 0 2.149682714551026e-14
BAC O 0 2.794123377114488e-09
clone O 0 8.291130626503218e-08
H O 1 0.9999998807907104
_ O 0 1.0184807641352989e-12
RG364P16 O 0 9.381001834715685e-13
revealed O 0 1.5608939921835097e-12
the O 0 2.614882823007039e-16
presence O 0 2.382606441244002e-14
of O 0 2.668672426095117e-18
another O 0 8.93628653199233e-16
, O 0 4.612917028918849e-18
highly O 0 1.4203040187753983e-17
homologous O 0 2.3763774033015413e-16
gene O 0 1.8416458679240688e-13
3 O 0 2.8844156948451723e-15
of O 0 2.350312776763873e-17
the O 0 3.9940267381659376e-15
CLD B-Disease 0 2.049293215122816e-07
gene O 0 5.540051403740698e-11
, O 0 9.669398841796848e-16
with O 0 5.003954007639921e-17
a O 0 6.488232671298538e-17
similar O 0 2.8652557036991616e-16
genomic O 0 6.263567442488238e-10
structure O 0 1.422239992443508e-09
, O 0 1.0495998601506296e-14
recently O 0 2.1076100586991942e-10
identified O 0 1.729422161034222e-10
as O 0 4.232277028837217e-10
the O 0 6.474564884229039e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 3.048299035413038e-08
( O 0 5.641496384628519e-13
PDS B-Disease 0 2.7710047589835085e-09
) O 0 5.273935873114548e-15
. O 0 1.665008958648634e-15
. O 0 5.017698496284639e-13

The O 0 8.511433745306274e-12
APCI1307K O 0 9.195934580930043e-06
allele O 0 3.216300115127524e-08
and O 0 1.738475030599318e-09
cancer B-Disease 0 1.426929998160631e-06
risk O 0 2.420443756534496e-08
in O 0 5.559366282823224e-16
a O 0 1.492707189408235e-14
community O 0 5.048345164755837e-15
- O 0 1.1039137486068551e-11
based O 0 1.0752278584093451e-15
study O 0 5.439750619352576e-15
of O 0 5.5357944146923205e-15
Ashkenazi O 0 5.5740540655380144e-11
Jews O 0 1.005371187776799e-13
. O 0 7.63962596525905e-14

Mutations O 0 5.650599277373658e-08
in O 0 4.3693642318631473e-14
APC O 0 1.2304852248234965e-08
are O 0 1.0808986084659411e-12
classically O 0 4.200337116344599e-06
associated O 0 3.5514502449984775e-09
with O 0 1.4646978343080264e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999983310699463
polyposis I-Disease 1 0.9999998807907104
( O 0 5.928755819617493e-10
FAP B-Disease 0 3.5746294813066015e-10
) O 0 8.104272537684033e-16
, O 0 6.801760179645431e-18
a O 0 5.935393642504325e-15
highly O 0 1.2565252518470515e-06
penetrant O 1 0.9999982118606567
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 1.5385598572947856e-08
by O 0 4.8463440698682733e-14
multiple O 0 4.7470230413182435e-08
intestinal O 0 0.10651688277721405
polyps B-Disease 0 0.1512872278690338
and O 0 1.6485075457484122e-11
, O 0 1.8253928472662228e-15
without O 0 1.0441766470025392e-14
surgical O 0 3.2180904607770344e-09
intervention O 0 3.0215074691385124e-13
, O 0 2.9925601234600526e-17
the O 0 1.102368580749496e-16
development O 0 2.8865678944334228e-11
of O 0 4.6387657448576647e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.6730792098962333e-11
CRC B-Disease 0 1.18618260103176e-07
) O 0 2.946109068507896e-13
. O 0 1.728492837142076e-13

APC B-Disease 0 3.5774228024365584e-08
is O 0 1.8434663788969435e-13
a O 0 1.5686859092516742e-13
tumour O 1 0.9999998807907104
- O 0 1.3145902144628963e-08
suppressor O 0 6.621170972609391e-11
gene O 0 2.801069654001509e-10
, O 0 3.4337273608096635e-15
and O 0 1.8920141061501417e-15
somatic O 0 3.533354442364356e-10
loss O 0 1.619175488132285e-10
occurs O 0 4.3995938836527415e-11
in O 0 4.236084573394638e-12
tumours B-Disease 1 1.0
. O 0 1.0087962687421737e-09

The O 0 5.567821594401612e-13
germline O 0 1.2309031127699654e-08
T O 0 4.97901453400118e-07
- O 0 1.7791669179589853e-11
to O 0 2.3844328983881665e-15
- O 0 7.361312948095389e-12
A O 0 3.193427078288934e-15
transversion O 0 2.7823184294700765e-12
responsible O 0 7.36277248411933e-16
for O 0 2.2434958009785727e-18
the O 0 1.5300194354270842e-17
APC O 0 1.2805201777404962e-12
I1307K O 0 3.4326355776923e-14
allele O 0 3.4953775421448245e-16
converts O 0 1.2206996790509628e-16
the O 0 8.631783547584779e-18
wild O 0 2.2202682400940255e-12
- O 0 2.0418685839351802e-11
type O 0 3.998863414879372e-13
sequence O 0 3.650320673444403e-15
to O 0 5.0352280125346566e-15
a O 0 4.949755449262794e-12
homopolymer O 0 0.0012784755090251565
tract O 0 0.00032858585473150015
( O 0 4.692798883862426e-13
A8 O 0 1.0898693147964877e-07
) O 0 1.4812567015657198e-15
that O 0 3.0387935640013565e-17
is O 0 3.016927731399298e-14
genetically O 0 1.278121786185693e-08
unstable O 0 2.562858014698577e-07
and O 0 1.9077885105023284e-11
prone O 0 2.3577408470032424e-08
to O 0 1.0751053774451722e-14
somatic O 0 1.2915651881328927e-09
mutation O 0 1.3289240818892267e-09
. O 0 2.893721503735569e-12

The O 0 3.2670552461283586e-12
I1307K O 0 1.2464029808256782e-09
allele O 0 1.7127943160999415e-11
was O 0 6.399927029304697e-12
found O 0 3.602914407790925e-13
in O 0 3.2971862849869808e-15
6 O 0 2.926638792422054e-11
. O 0 3.666827854808402e-13

1 O 0 9.867887756920268e-11
% O 0 4.061728167345513e-13
of O 0 4.28856254029936e-15
unselected O 0 0.00012621446512639523
Ashkenazi O 0 2.652437615324743e-06
Jews O 0 2.6466806177238844e-12
and O 0 1.2104519860403617e-12
higher O 0 1.5928885814531224e-12
proportions O 0 1.2442081809282968e-09
of O 0 2.6972440123410046e-13
Ashkenazim O 0 9.954392226063646e-06
with O 0 9.340900448961964e-13
family O 0 3.437367578074113e-13
or O 0 1.6262181488577165e-12
personal O 0 1.482483580339533e-11
histories O 0 8.843580867612388e-10
of O 0 7.178054808529288e-13
CRC B-Disease 0 2.155883066734532e-06
( O 0 1.264293303295666e-13
ref O 0 3.82537095333646e-08
. O 0 6.585991602477354e-15
2 O 0 8.35685077453345e-14
) O 0 3.446432050337178e-14
. O 0 1.5135158751289346e-13

To O 0 1.3980144963226561e-14
evaluate O 0 1.7742140493316044e-13
the O 0 6.433101414344124e-17
role O 0 1.0530132674027928e-13
of O 0 4.169572291546252e-17
I1307K O 0 4.8045278693009674e-12
in O 0 1.135670806036432e-16
cancer B-Disease 0 4.109702595594955e-12
, O 0 9.080440951703172e-16
we O 0 5.917155871185131e-13
genotyped O 0 1.8111928623554263e-09
5 O 0 1.8941391424082132e-13
, O 0 1.2340729634474808e-14
081 O 0 1.4872552966949115e-08
Ashkenazi O 0 1.247160846817863e-10
volunteers O 0 4.2343512458289587e-14
in O 0 5.9828720527332474e-18
a O 0 1.0980379262833114e-15
community O 0 6.899220235910553e-14
survey O 0 6.004002184312185e-09
. O 0 9.892489388416137e-13

Risk O 0 1.216481223309529e-06
of O 0 8.392172048433955e-13
developing O 0 8.354645251529291e-05
colorectal B-Disease 1 1.0
, I-Disease 0 6.946814234964904e-09
breast I-Disease 0 0.0011131729697808623
and I-Disease 0 6.067546465260421e-10
other I-Disease 0 4.4970185344647695e-14
cancers I-Disease 0 8.33032753888574e-09
were O 0 5.824680083551083e-15
compared O 0 1.1771338840737416e-14
between O 0 6.290512629157164e-15
genotyped O 0 2.6975593314659818e-08
I1307K O 0 1.2117515324483463e-10
carriers O 0 9.076754105274976e-12
and O 0 9.850152919883837e-15
non O 0 1.1984766477846076e-11
- O 0 5.348140263983225e-10
carriers O 0 5.940956060435099e-11
and O 0 1.4464724042021274e-14
their O 0 8.579100414371276e-17
first O 0 1.6399350681681885e-13
- O 0 5.636546229759176e-10
degree O 0 3.4341680297004726e-14
relatives O 0 2.175987471805807e-12
. O 0 1.5730423691059925e-13

Sperm O 0 1.0156451200893368e-11
DNA O 0 5.2503001946035965e-11
analysis O 0 4.4959402954042327e-13
in O 0 3.079723281273648e-15
a O 0 4.894401398926329e-13
Friedreich B-Disease 0 0.0002949458721559495
ataxia I-Disease 1 0.9425586462020874
premutation O 0 0.0018407562747597694
carrier O 0 5.2370934255918655e-09
suggests O 0 2.8035039567608777e-12
both O 0 2.9575747775324734e-15
meiotic O 0 4.454809784948388e-11
and O 0 8.022060155098241e-15
mitotic O 0 1.0088177038528046e-12
expansion O 0 1.2748833022255268e-12
in O 0 6.872417699415527e-17
the O 0 1.8173053766858387e-15
FRDA B-Disease 0 1.320088358625071e-07
gene O 0 5.6658618768912206e-11
. O 0 1.8228975186967977e-12

Friedreich B-Disease 1 0.982361376285553
ataxia I-Disease 1 0.9998687505722046
is O 0 2.231039843536564e-06
usually O 0 1.190407911133562e-10
caused O 0 3.676693891290113e-14
by O 0 2.9665647732986855e-18
an O 0 2.811068094387548e-17
expansion O 0 2.281785871360853e-12
of O 0 4.698436277761559e-15
a O 0 2.2372722164459846e-12
GAA O 0 9.883402896093685e-08
trinucleotide O 0 7.013851472947863e-07
repeat O 0 5.0525508221710425e-09
in O 0 1.5741631927479525e-15
intron O 0 3.840425200074549e-11
1 O 0 7.397940021539907e-15
of O 0 4.587524652065003e-18
the O 0 2.9958515082046256e-16
FRDA B-Disease 0 9.22494880484237e-09
gene O 0 1.1291034079929929e-11
. O 0 3.677635453114281e-13

Occasionally O 0 8.664470385610912e-08
, O 0 1.4534777054890993e-14
a O 0 4.057201843503952e-15
fully O 0 3.843119832785957e-12
expanded O 0 7.669968718308773e-13
allele O 0 9.958444659174948e-13
has O 0 5.5485688743237e-13
been O 0 3.2487190597450897e-15
found O 0 1.522754433838484e-15
to O 0 1.90058510019451e-16
arise O 0 4.972789825860753e-15
from O 0 6.710804123272136e-19
a O 0 6.400227933312286e-17
premutation O 0 7.188995926332709e-11
of O 0 2.8660957883292704e-17
100 O 0 7.822337091794847e-16
or O 0 1.1667977951282816e-14
less O 0 2.246103524255593e-14
triplet O 0 1.2228937521285843e-05
repeats O 0 8.088213832024849e-08
. O 0 2.87079734984097e-12

We O 0 5.881252373995949e-09
have O 0 2.161128162547505e-14
examined O 0 1.2923683119763635e-13
the O 0 2.5503715364296205e-19
sperm O 0 3.721122410499936e-16
DNA O 0 2.210389206738772e-12
of O 0 9.738026509974575e-16
a O 0 2.327712404336796e-13
premutation O 0 9.150838309324172e-07
carrier O 0 7.3676276191037e-10
. O 0 7.532386173125794e-13

This O 0 5.644547515889142e-15
mans O 0 1.466271722094792e-11
leucocyte O 0 1.121014614469118e-09
DNA O 0 7.855708084036905e-09
showed O 0 1.2756667722158e-08
one O 0 8.312081695139271e-15
normal O 0 4.641663301548776e-14
allele O 0 7.282280789673579e-13
and O 0 5.011433976132018e-13
one O 0 5.717968967031855e-16
allele O 0 2.313117806427038e-15
of O 0 1.9681320072711e-17
approximately O 0 6.162743384184599e-14
100 O 0 1.665982618786338e-13
repeats O 0 3.975630491481752e-09
. O 0 1.9316241314792926e-12

His O 0 2.6183816399794058e-12
sperm O 0 4.899813887959681e-11
showed O 0 8.037943921568313e-11
an O 0 8.227905334316372e-17
expanded O 0 3.3277068166998047e-12
allele O 0 4.5766229347932175e-12
in O 0 2.798735432318379e-14
a O 0 2.5611979984768718e-12
tight O 0 1.4421049243651396e-08
range O 0 8.500636311395762e-14
centering O 0 2.268769888754893e-13
on O 0 1.5852580749833867e-14
a O 0 1.4572728710199857e-17
size O 0 2.192179633358151e-16
of O 0 1.8290781486533833e-17
approximately O 0 7.461144603624487e-14
320 O 0 4.326182467817574e-11
trinucleotide O 0 1.749747298163129e-07
repeats O 0 9.708133319463741e-08
. O 0 1.1895901798342212e-11

His O 0 8.814985963390143e-10
affected O 0 1.983046837850111e-09
son O 0 4.1910876547035514e-08
has O 0 9.518727819846085e-12
repeat O 0 1.0782058405822692e-11
sizes O 0 1.3774183616616087e-12
of O 0 3.746246731204479e-16
1040 O 0 2.9960632499242967e-12
and O 0 8.216344271616549e-14
540 O 0 4.5072075412211365e-12
. O 0 1.637197322157391e-13

These O 0 1.0121853137275757e-15
data O 0 2.430869192732426e-14
suggest O 0 8.783562256437644e-15
that O 0 2.491969772769294e-17
expansion O 0 4.522513887363945e-14
occurs O 0 2.145298980235806e-15
in O 0 9.397669249567014e-18
two O 0 4.952457646994861e-15
stages O 0 2.4816121380055733e-12
, O 0 1.6941079814581674e-16
the O 0 5.258341162757539e-17
first O 0 1.950966731917303e-12
during O 0 4.147842415673161e-15
meiosis O 0 1.3286013321412923e-14
followed O 0 1.7160673635552943e-15
by O 0 5.299519950729715e-18
a O 0 1.182889981170103e-16
second O 0 1.4495906712941493e-14
mitotic O 0 5.4325551002154526e-11
expansion O 0 5.172573480649589e-10
. O 0 5.1265229041030924e-12

We O 0 3.2587998965993847e-10
also O 0 6.501200809248472e-14
show O 0 1.5388797007520605e-12
that O 0 2.1790065504926725e-16
in O 0 7.229064726887768e-18
all O 0 2.1136500176781228e-16
informative O 0 5.805962264779363e-13
carrier O 0 1.0848947066231795e-13
father O 0 9.084500357102888e-15
to O 0 1.9128701219543515e-16
affected O 0 1.4879919941600955e-13
child O 0 2.3312735422664765e-11
transmissions O 0 2.906512010236728e-11
, O 0 6.287336556698703e-18
with O 0 1.262680348316657e-18
the O 0 3.639497915101653e-18
notable O 0 2.8798199058316072e-15
exception O 0 1.4667730734423817e-14
of O 0 2.6857096004740755e-16
the O 0 1.4899743223072137e-13
premutation O 0 5.331742727321398e-07
carrier O 0 8.470088345979843e-12
, O 0 1.536312460091265e-17
the O 0 1.5090874232312767e-18
expansion O 0 3.679064905916067e-14
size O 0 1.4967448938238426e-13
decreases O 0 4.548273563331762e-11
. O 0 1.1678932628389656e-14
. O 0 7.230021160757605e-13

The O 0 2.587579130998441e-13
R496H O 0 8.371828924547131e-11
mutation O 0 3.023405527671774e-12
of O 0 4.80840487123769e-16
arylsulfatase O 0 1.1492902629584023e-08
A O 0 8.790510095009474e-13
does O 0 1.3877246574089952e-11
not O 0 1.2971878779466373e-11
cause O 0 5.400080826944986e-09
metachromatic B-Disease 1 0.9999997615814209
leukodystrophy I-Disease 1 0.9999972581863403
. O 0 2.2436772439959896e-09

Deficiency B-Disease 1 0.9992885589599609
of I-Disease 0 3.815582290227215e-13
arylsulfatase I-Disease 0 3.172008291585371e-06
A I-Disease 0 1.0196480465518576e-10
( O 0 2.2533793407608638e-12
ARSA O 0 2.4107599529088475e-05
) O 0 1.9851618450212466e-13
enzyme O 0 2.0304847581087415e-08
activity O 0 1.3718945979235286e-07
causes O 0 1.1448506484157406e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999998807907104
( O 0 9.056967655851622e-07
MLD B-Disease 1 0.9999920129776001
) O 0 1.5667378852612934e-11
. O 0 7.245123554919242e-13

A O 0 4.5197049228229425e-13
number O 0 5.189616707830698e-15
of O 0 1.5967767489781558e-15
ARSA O 0 2.9977905796840787e-05
gene O 0 4.43816372541761e-10
mutations O 0 1.0735256433802576e-10
responsible O 0 2.9518436306386064e-11
for O 0 7.428719965563158e-12
MLD B-Disease 1 1.0
have O 0 1.7218157455367589e-10
been O 0 1.2852230130838693e-12
identified O 0 1.3080352773142678e-11
. O 0 1.4655580351727315e-12

Recently O 0 2.2767995488948145e-08
, O 0 2.374557129497892e-15
the O 0 8.324829726283906e-17
R496H O 0 5.235917168583404e-12
mutation O 0 1.3655468086588157e-13
of O 0 5.478439696251364e-16
ARSA O 0 1.1929819265787955e-06
was O 0 3.83663803851797e-12
proposed O 0 2.318011327521563e-15
to O 0 8.752681288065324e-17
be O 0 3.114255543983785e-15
a O 0 4.114290223022557e-16
cause O 0 6.513339130195805e-14
of O 0 9.95571030129594e-13
MLD B-Disease 1 0.9999997615814209
( O 0 3.1839077815204453e-12
Draghia O 0 1.3596948456040536e-08
et O 0 2.665386800160263e-10
al O 0 4.708085032945064e-09
. O 0 6.907097506794746e-13
, O 0 5.13457142472043e-14
1997 O 0 1.4862200012344395e-12
) O 0 2.142217135560516e-14
. O 0 5.978960273926581e-14

We O 0 1.1811530920002866e-10
have O 0 3.887569519772649e-15
investigated O 0 9.159725929130946e-13
the O 0 9.79375916032154e-16
R496H O 0 3.9896492359803304e-11
mutation O 0 4.788086160195659e-13
and O 0 2.9063383898277713e-16
found O 0 2.1417083811026155e-16
this O 0 2.169754975814943e-19
mutation O 0 5.34333211781279e-16
at O 0 4.510176005454239e-15
a O 0 1.4768044581669348e-16
relatively O 0 1.3375805643025016e-16
high O 0 1.394580306270099e-12
frequency O 0 2.7922822271064275e-15
in O 0 1.4355841291843963e-16
an O 0 1.9184625405215677e-14
African O 0 2.865587812612286e-13
American O 0 3.653498741062501e-14
population O 0 6.556027153532465e-18
( O 0 2.2801322258785874e-16
f O 0 8.090871722599147e-11
= O 0 9.417556795163207e-13
0 O 0 3.009381684278799e-14
. O 0 3.4324178478732084e-15
09 O 0 6.91725954293787e-10
, O 0 2.090615007499519e-13
n O 0 5.944679859481994e-09
= O 0 1.5677020792637109e-09
61 O 0 1.2922989067742918e-10
subjects O 0 9.418864577170893e-10
) O 0 1.1122593731455188e-12
. O 0 5.223047471955566e-13

The O 0 6.647564443351683e-12
ARSA O 0 6.53744382361765e-06
enzyme O 0 3.862187014647134e-09
activity O 0 2.875160873272442e-11
in O 0 5.442819843236952e-16
subjects O 0 2.892762938910831e-11
with O 0 6.969853296942552e-13
and O 0 5.996413760499253e-13
without O 0 1.0135497991023076e-14
the O 0 3.2327205661351465e-16
R496H O 0 4.630225890200901e-12
mutation O 0 2.0018310468473965e-13
was O 0 3.507855811379912e-11
determined O 0 1.9267411017348524e-12
and O 0 7.319150033225849e-14
found O 0 4.327249076099306e-14
to O 0 6.867392464697704e-15
be O 0 8.127694697823706e-12
normal O 0 2.8987139836893216e-13
. O 0 1.749401676038459e-13

It O 0 4.053139768256386e-12
is O 0 3.463539405366284e-14
therefore O 0 2.7295859071418483e-16
concluded O 0 1.5262793402726592e-14
that O 0 1.4278007566669663e-17
the O 0 1.411463013126758e-16
R496H O 0 4.132119126032396e-12
mutation O 0 3.7754741959725516e-14
of O 0 8.828163173322013e-17
ARSA O 0 7.984566252616787e-08
does O 0 3.435635429578296e-14
not O 0 4.757116695409197e-17
negatively O 0 9.034182364871246e-15
influence O 0 4.460433148593783e-17
the O 0 1.6391060293771074e-17
activity O 0 8.19190581254764e-13
of O 0 2.372474698997067e-15
ARSA O 0 9.060346201295033e-05
and O 0 8.232588222245596e-12
is O 0 1.3166539324202704e-14
not O 0 6.3789527156085245e-16
a O 0 5.105788821656255e-15
cause O 0 1.026825109315399e-12
of O 0 1.7185053380330828e-10
MLD B-Disease 1 0.9999960660934448

Down O 0 7.764868996673613e-07
- O 0 7.283313152584014e-08
regulation O 0 2.0713904549940487e-11
of O 0 5.464041830213935e-15
transmembrane O 0 3.300192830124615e-08
carbonic O 0 1.436120413700337e-07
anhydrases O 0 9.98858013190329e-07
in O 0 6.131734117849341e-13
renal B-Disease 0 0.0002642988401930779
cell I-Disease 0 0.014662746340036392
carcinoma I-Disease 1 1.0
cell O 0 0.0006246828124858439
lines O 0 3.1013189794038e-09
by O 0 1.2430119562497396e-14
wild O 0 4.853305881624692e-07
- O 1 0.8310921788215637
type O 0 0.06358449906110764
von B-Disease 1 0.9999551773071289
Hippel I-Disease 1 0.998853325843811
- I-Disease 1 0.9961503744125366
Lindau I-Disease 1 0.6476854085922241
transgenes O 0 0.0001274808746529743
. O 0 1.0074733269860303e-09

To O 0 1.2664358900764047e-14
discover O 0 2.4538095080156586e-12
genes O 0 5.87115599193222e-12
involved O 0 2.7925968829056735e-11
in O 0 5.438098756027632e-12
von B-Disease 1 0.9999643564224243
Hippel I-Disease 1 0.9999756813049316
- I-Disease 1 0.9999927282333374
Lindau I-Disease 1 0.9998623132705688
( O 0 1.761609857986457e-09
VHL B-Disease 0 1.4617268789152149e-05
) O 0 3.10143105858654e-13
- O 0 2.820951472415345e-09
mediated O 0 1.8341442808988973e-09
carcinogenesis O 0 1.2889428546714043e-07
, O 0 2.607704633825203e-13
we O 0 1.4076833232054553e-12
used O 0 5.3973440300447706e-12
renal B-Disease 0 0.0002636341378092766
cell I-Disease 0 0.1428598165512085
carcinoma I-Disease 1 1.0
cell O 1 0.9087755084037781
lines O 0 2.7272291845292784e-05
stably O 0 3.072556864935905e-05
transfected O 0 4.992432423023274e-07
with O 0 6.675055473637226e-13
wild O 0 1.733752839072622e-07
- O 0 0.019816763699054718
type O 0 0.0006019517895765603
VHL O 0 0.12743638455867767
- O 0 1.5479785133720725e-06
expressing O 0 1.6873248631643634e-10
transgenes O 0 1.286408348732948e-07
. O 0 1.277373953140204e-11

Large O 0 1.2273934039269685e-12
- O 0 1.2329443022096598e-09
scale O 0 4.2693432122931085e-11
RNA O 0 1.3004498736549075e-12
differential O 0 9.551253288709455e-14
display O 0 2.467299910387244e-14
technology O 0 2.246131449237798e-12
applied O 0 1.1788370132207859e-14
to O 0 2.784164210400383e-17
these O 0 8.734497872967938e-18
cell O 0 9.627046474456127e-14
lines O 0 2.505252136384556e-13
identified O 0 5.426423826476951e-15
several O 0 4.740721975668396e-17
differentially O 0 5.6487345183320326e-12
expressed O 0 2.000371007685885e-15
genes O 0 2.0176449740957154e-15
, O 0 1.776276066867796e-17
including O 0 2.558296092134001e-17
an O 0 4.114429454063262e-17
alpha O 0 2.836699449014317e-14
carbonic O 0 1.7305078203744273e-10
anhydrase O 0 1.3779953567105707e-10
gene O 0 5.5973860962899025e-11
, O 0 4.958358417318613e-14
termed O 0 2.680682065214768e-10
CA12 O 0 6.352091440930963e-05
. O 0 2.316111365197049e-11

The O 0 4.5283658685899356e-14
deduced O 0 7.278975599350757e-13
protein O 0 2.5360310097581606e-13
sequence O 0 6.164542482164567e-14
was O 0 1.4566478448788112e-13
classified O 0 2.665292682738074e-12
as O 0 1.5911530854830977e-14
a O 0 2.3267910357780905e-15
one O 0 1.876090428842847e-12
- O 0 1.1791882570832968e-05
pass O 0 6.474440965575923e-07
transmembrane O 0 1.8693326637730934e-05
CA O 0 2.9563332191173686e-06
possessing O 0 1.6106964650930422e-09
an O 0 3.4509030713976126e-15
apparently O 0 5.589019264756745e-12
intact O 0 1.8185695733596158e-13
catalytic O 0 3.3015584623846683e-12
domain O 0 1.1500340610370863e-11
in O 0 2.4685565684677904e-14
the O 0 4.7654971467451027e-14
extracellular O 0 3.2057992371825605e-10
CA O 0 2.3240820610226365e-06
module O 0 1.227905666034701e-09
. O 0 1.5688422783100009e-12

Reintroduced O 0 6.3425544816198e-09
wild O 0 1.1332414828757464e-07
- O 0 0.0007963307434692979
type O 0 1.7361186337438994e-06
VHL B-Disease 0 2.092590329993982e-05
strongly O 0 3.465404504153502e-13
inhibited O 0 7.359722640348787e-13
the O 0 7.607154922815343e-18
overexpression O 0 4.0882766871299867e-14
of O 0 1.3677648977065414e-17
the O 0 1.1653597078843892e-16
CA12 O 0 2.593909309567266e-09
gene O 0 4.2452383297066076e-13
in O 0 8.738640393475604e-16
the O 0 2.1721218031699185e-13
parental O 0 8.631095988675952e-05
renal B-Disease 0 6.579427281394601e-05
cell I-Disease 0 0.00011334715964039788
carcinoma I-Disease 1 1.0
cell O 0 0.0014865664998069406
lines O 0 1.2878685993200634e-05
. O 0 6.258404905423731e-11

Similar O 0 6.076802472679277e-13
results O 0 1.1712762921015085e-12
were O 0 8.21966362433025e-15
obtained O 0 1.0742568198386128e-14
with O 0 1.9473138379577648e-14
CA9 O 0 5.9356413117939155e-08
, O 0 6.805734368898442e-17
encoding O 0 1.5951024824787893e-15
another O 0 3.285748062520355e-11
transmembrane O 0 0.00014485452265944332
CA O 0 0.18824690580368042
with O 0 4.893253228825667e-13
an O 0 2.1373917159149504e-15
intact O 0 5.672660258193574e-12
catalytic O 0 3.3766989204764286e-10
domain O 0 9.375525911181626e-10
. O 0 1.8541139110150873e-11

Although O 0 2.6968954413425505e-12
both O 0 1.035706995156354e-14
domains O 0 7.305758775721927e-11
of O 0 2.135826822544898e-15
the O 0 4.187141356293972e-15
VHL B-Disease 0 8.604306600545897e-09
protein O 0 7.278916645857628e-14
contribute O 0 2.373298226780035e-15
to O 0 1.0828422213840183e-16
regulation O 0 9.53978866388705e-13
of O 0 7.156638969591997e-15
CA12 O 0 9.393788218403643e-07
expression O 0 1.4376303966723292e-13
, O 0 2.7842806774306306e-17
the O 0 1.9966181223339563e-17
elongin O 0 4.2304770797585434e-10
binding O 0 5.393749683002547e-13
domain O 0 3.9356300336745864e-12
alone O 0 1.8698763371016724e-10
could O 0 1.6073250369563752e-11
effectively O 0 1.817517941704594e-10
regulate O 0 4.323440272457901e-09
CA9 O 0 5.204776971368119e-05
expression O 0 1.2567513696382093e-09
. O 0 3.895146358234847e-12

We O 0 2.798143106108597e-10
mapped O 0 1.7151613462829118e-07
CA12 O 0 6.400150596164167e-05
and O 0 1.0040800656196947e-12
CA9 O 0 2.3016220040972257e-08
loci O 0 4.589551828859673e-12
to O 0 2.6886119588678424e-15
chromosome O 0 6.7572827333606256e-09
bands O 0 1.2368821245001271e-10
15q22 O 0 1.0735063504796472e-08
and O 0 2.8439941374136524e-12
17q21 O 0 1.1986196479796263e-09
. O 0 7.09013956486787e-13

2 O 0 2.8264218743245806e-10
respectively O 0 8.682937702175764e-11
, O 0 5.325691703774154e-15
regions O 0 1.2253484902094436e-13
prone O 0 2.106264718193529e-09
to O 0 2.2066776610415924e-16
amplification O 0 1.0195613884406152e-12
in O 0 5.03869832306317e-18
some O 0 8.172132185206617e-17
human O 0 1.3951869173856046e-12
cancers B-Disease 0 7.032227689052206e-09
. O 0 1.8295843898057107e-13

Additional O 0 4.208353094172293e-14
experiments O 0 9.90921971213976e-13
are O 0 8.35942533117663e-16
needed O 0 8.378835620558554e-16
to O 0 6.292828725773325e-19
define O 0 2.705939076595113e-15
the O 0 1.0531602678532064e-16
role O 0 5.547344701650747e-12
of O 0 5.944888458326572e-15
CA O 0 1.1848138683490106e-06
IX O 0 6.818368092353921e-08
and O 0 7.719513916981668e-10
CA O 0 4.66235178464558e-07
XII O 0 1.6426798810087462e-10
enzymes O 0 6.428536224395778e-14
in O 0 4.3927860699450125e-18
the O 0 1.4661387582614516e-17
regulation O 0 9.993241856850327e-14
of O 0 6.858879995336035e-16
pH O 0 6.562649187101532e-13
in O 0 8.72151010337509e-19
the O 0 1.7732024291476713e-17
extracellular O 0 5.979986200232296e-14
microenvironment O 0 2.1750965611966322e-11
and O 0 1.2708392120285299e-15
its O 0 9.524273378221318e-18
potential O 0 6.5719376318165105e-15
impact O 0 1.321142360007771e-13
on O 0 4.534195935379515e-12
cancer B-Disease 0 5.367574787418228e-11
cell O 0 1.6059797589007552e-11
growth O 0 3.2868106014660725e-09
. O 0 5.407996099549006e-13

A O 0 7.900032624602593e-13
gene O 0 8.071970175604903e-12
encoding O 0 1.0581714947636642e-13
a O 0 1.6411890157433037e-14
transmembrane O 0 4.01350827572422e-11
protein O 0 1.45629778310237e-13
is O 0 1.0257230178070675e-16
mutated O 0 9.022487618137731e-12
in O 0 3.4262206244882465e-13
patients O 0 7.469138196825043e-09
with O 0 3.5012311627724557e-07
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.45545247197151184
optic B-Disease 1 0.9999997615814209
atrophy I-Disease 1 0.9999903440475464
( O 0 0.0028357936535030603
Wolfram B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
) O 0 6.180563005830919e-11
. O 0 9.746478797645342e-13

Wolfram B-Disease 1 0.9999823570251465
syndrome I-Disease 1 1.0
( O 0 2.38980106814779e-07
WFS B-Disease 0 0.0018606306985020638
; O 0 1.6699865448832618e-11
OMIM O 0 1.7024520275299437e-05
222300 O 0 2.493921158475132e-08
) O 0 1.1836682350420402e-13
is O 0 1.601377721833358e-13
an O 0 2.23689686565387e-12
autosomal B-Disease 1 0.999998927116394
recessive I-Disease 1 0.9999996423721313
neurodegenerative I-Disease 1 0.999987006187439
disorder I-Disease 1 0.9996832609176636
defined O 0 4.367802126925557e-12
by O 0 2.601885483596248e-14
young O 0 5.0797932971136106e-08
- O 0 6.809777460148325e-06
onset O 0 0.0002707916428335011
non O 0 0.002578567713499069
- O 0 0.00869766715914011
immune O 0 0.0002042329142568633
insulin B-Disease 0 0.00012081264867447317
- I-Disease 1 0.5001001954078674
dependent I-Disease 0 0.26119938492774963
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 1.11920599010773e-07
progressive O 0 8.779941396142021e-08
optic B-Disease 1 0.9999455213546753
atrophy I-Disease 0 0.032031938433647156
. O 0 2.4020085920284373e-10

Linkage O 0 8.557432096267803e-09
to O 0 1.785273724642586e-13
markers O 0 1.6056544538400885e-08
on O 0 1.1467709420953653e-10
chromosome O 0 2.7324278562446125e-05
4p O 0 8.522052667103708e-05
was O 0 1.878295297075283e-09
confirmed O 0 9.791687426152773e-12
in O 0 5.811072181616088e-16
five O 0 1.0138098043357968e-12
families O 0 3.5811276361853717e-13
. O 0 2.372423004576296e-13

On O 0 4.5419579013626643e-13
the O 0 8.021746117633046e-17
basis O 0 1.0573028413004312e-15
of O 0 7.59813964675525e-17
meiotic O 0 1.4360828082260468e-08
recombinants O 0 0.00017847471463028342
and O 0 1.8213501817854194e-09
disease O 0 1.4416642443393357e-05
- O 0 9.052963889644161e-08
associated O 0 1.5284549667593517e-11
haplotypes O 0 3.128434178378825e-09
, O 0 3.376118828946062e-14
the O 0 3.637587650664803e-15
WFS B-Disease 0 2.7435907767880963e-08
gene O 0 7.437056179226964e-12
was O 0 3.07824647933011e-13
localized O 0 1.1987772699419835e-13
to O 0 2.468621197081666e-15
a O 0 2.2531244448301124e-13
BAC O 0 1.5090488858504614e-08
/ O 0 3.382732427503754e-10
P1 O 0 6.384766049194468e-10
contig O 0 2.6729559537974623e-11
of O 0 2.671055533439882e-18
less O 0 4.1507484732186276e-18
than O 0 1.0182178923040882e-17
250 O 0 2.0596696667407903e-15
kb O 0 3.048263863547618e-08
. O 0 2.7839798608791932e-12

Mutations O 0 4.433988465279981e-08
in O 0 9.683541539158916e-15
a O 0 1.5181079022574226e-16
novel O 0 6.054228976872314e-14
gene O 0 4.245793300272638e-11
( O 0 3.1582114717485996e-14
WFS1 O 0 1.672563865184884e-09
) O 0 5.2902514746841196e-17
encoding O 0 7.0282331158321e-16
a O 0 9.658417694910406e-15
putative O 0 1.2248728940844611e-11
transmembrane O 0 4.997693231478806e-11
protein O 0 1.2680355029881518e-11
were O 0 2.292702872442199e-14
found O 0 4.1175836882918065e-14
in O 0 8.670928712020993e-17
all O 0 5.581005492819036e-13
affected O 0 1.5479583760635851e-12
individuals O 0 9.574627501702116e-16
in O 0 1.4778195477448803e-15
six O 0 3.729539732599818e-10
WFS B-Disease 0 1.5861741076150793e-07
families O 0 1.052637794637934e-13
, O 0 4.31572127532453e-16
and O 0 4.610179679822397e-15
these O 0 4.152777878133465e-17
mutations O 0 1.2525950329050906e-12
were O 0 2.0840219740886345e-13
associated O 0 4.4948896018551406e-15
with O 0 7.399693379740724e-14
the O 0 6.140892655492891e-11
disease O 0 8.246915240306407e-05
phenotype O 0 3.448885066426044e-10
. O 0 3.5564340101351677e-12

WFS1 O 0 1.5966163118719123e-05
appears O 0 1.8244367128161798e-10
to O 0 2.290446546077303e-15
function O 0 5.473178774615967e-15
in O 0 3.4090712375667157e-16
survival O 0 5.970848815373131e-13
of O 0 2.681953644627713e-15
islet O 0 1.0080815826540857e-07
beta O 0 7.104804158192257e-12
- O 0 2.6892012172652358e-08
cells O 0 4.454068190662408e-12
and O 0 1.9420173409385837e-14
neurons O 0 2.2356075324303504e-13
. O 0 1.1096809235389138e-15
. O 0 1.1216496346088886e-13

Stable O 0 2.792209519153488e-10
interaction O 0 4.019462036429153e-14
between O 0 1.107841062098359e-15
the O 0 2.207762922005262e-17
products O 0 1.033465465982708e-10
of O 0 8.975296766727025e-17
the O 0 1.5172872385046075e-14
BRCA1 O 0 1.053966229846992e-06
and O 0 2.319346104062703e-12
BRCA2 O 0 8.005439866565212e-09
tumor B-Disease 0 8.749765668947251e-12
suppressor O 0 5.867473173992721e-12
genes O 0 1.5231583355701517e-11
in O 0 3.7908853675247805e-15
mitotic O 0 4.043293699851347e-09
and O 0 1.028876289721481e-11
meiotic O 0 2.58858875668011e-07
cells O 0 8.899743164647589e-10
. O 0 5.873709938569727e-12

BRCA1 O 1 0.9949395656585693
and O 0 1.3365806239562517e-09
BRCA2 O 0 1.3962446701043518e-06
account O 0 2.999308090843693e-14
for O 0 1.7983114966417185e-17
most O 0 6.13843494745242e-18
cases O 0 3.401642599800618e-15
of O 0 7.155597754341585e-16
familial O 0 2.9859361649897664e-09
, O 0 1.2323933818163702e-14
early O 0 1.974735208253725e-13
onset O 0 1.0734039435078557e-08
breast B-Disease 0 0.0003000794386025518
and I-Disease 0 3.6606044773179747e-07
/ I-Disease 1 0.9183164834976196
or I-Disease 1 0.9951724410057068
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.453662002310092e-14
encode O 0 8.754455557392026e-16
products O 0 5.306442396602051e-09
that O 0 2.273947561874651e-16
each O 0 3.090171803254944e-16
interact O 0 6.996354586169887e-14
with O 0 2.233264571535609e-12
hRAD51 O 0 1.128523649640556e-06
. O 0 3.185863682239609e-12

Results O 0 1.753356071443335e-10
presented O 0 1.1974341873957628e-12
here O 0 1.730497459196366e-14
show O 0 9.533717565402e-12
that O 0 3.415643690194564e-13
BRCA1 O 0 1.0327164090995211e-05
and O 0 1.0110108583649691e-10
BRCA2 O 0 1.5824464583147346e-07
coexist O 0 2.4462857954599126e-12
in O 0 8.231448810624427e-18
a O 0 5.300978352867707e-17
biochemical O 0 2.0182100348570264e-12
complex O 0 5.271602720861336e-15
and O 0 2.3311688408626796e-13
colocalize O 0 1.6815819847693092e-08
in O 0 1.7661698917809782e-15
subnuclear O 0 1.8760260900307912e-08
foci O 0 7.010040117827465e-12
in O 0 3.3895538779263025e-17
somatic O 0 1.20392899208982e-12
cells O 0 2.3427180334545383e-13
and O 0 1.0054276848743809e-15
on O 0 1.9707257015649316e-15
the O 0 3.979481968160442e-18
axial O 0 3.755792369003561e-15
elements O 0 2.706434590869257e-15
of O 0 6.797464389187704e-15
developing O 0 1.1363052720980704e-09
synaptonemal O 0 9.146530999259994e-08
complexes O 0 3.95944943498705e-10
. O 0 4.112917471876809e-12

Like O 0 1.0739736211462514e-07
BRCA1 O 0 0.001655939151532948
and O 0 5.81643205821436e-11
RAD51 O 0 3.536447911756113e-05
, O 0 1.9465130191281127e-13
BRCA2 O 0 5.412247983116458e-09
relocates O 0 1.6208246550464267e-11
to O 0 2.8616525314206602e-15
PCNA O 0 1.677820726797563e-08
+ O 0 2.049888511430724e-14
replication O 0 8.638285941588164e-15
sites O 0 3.598839704976181e-14
following O 0 1.1788273993968345e-15
exposure O 0 6.166802637118385e-13
of O 0 1.4769904083686367e-16
S O 0 9.019330282633575e-10
phase O 0 1.8588488699135784e-14
cells O 0 1.4483738237621238e-15
to O 0 7.373702385512462e-17
hydroxyurea O 0 2.30250540855792e-11
or O 0 1.549410285402869e-14
UV O 0 2.7322441184529644e-11
irradiation O 0 9.446290971659721e-12
. O 0 2.5415802275274846e-13

Thus O 0 6.869057406211354e-11
, O 0 4.2317457047205687e-13
BRCA1 O 0 2.590724761830643e-06
and O 0 2.5056560992720023e-11
BRCA2 O 0 4.394393727125134e-06
participate O 0 4.947574901853491e-12
, O 0 1.2082387126661088e-14
together O 0 2.1224359346861538e-13
, O 0 3.3366872429657114e-16
in O 0 1.7171321360823716e-18
a O 0 2.8432402586088383e-16
pathway O 0 1.546463131163467e-11
( O 0 9.451274263000062e-14
s O 0 1.918387004806732e-09
) O 0 1.9314210699415067e-16
associated O 0 8.805426956133135e-17
with O 0 3.455063803113644e-16
the O 0 1.4684679334302784e-16
activation O 0 2.0507252105760217e-14
of O 0 4.887723154000951e-16
double O 0 3.3628178019995403e-09
- O 0 8.508737892043428e-07
strand O 0 1.9186607005394762e-06
break O 0 1.6899907677725423e-06
repair O 0 2.5295956220361404e-05
and O 0 6.224556460543429e-12
/ O 0 9.227010648593659e-12
or O 0 3.69067184074394e-16
homologous O 0 6.386544396629057e-14
recombination O 0 1.1235130664352666e-12
. O 0 2.6243716401419537e-12

Dysfunction O 0 5.277558011584915e-05
of O 0 6.139685707404327e-15
this O 0 1.764889363253187e-16
pathway O 0 4.67718364038916e-11
may O 0 1.2958475438529238e-11
be O 0 4.527804793965674e-14
a O 0 2.6880992921765167e-15
general O 0 2.5766245894168725e-14
phenomenon O 0 9.761450274394651e-14
in O 0 2.3151281531005623e-17
the O 0 4.8930184995847194e-17
majority O 0 3.2201910959606833e-16
of O 0 5.8752604045334675e-18
cases O 0 4.2307691096137023e-13
of O 0 5.983709079442068e-13
hereditary B-Disease 0 0.49582892656326294
breast I-Disease 1 0.9999940395355225
and I-Disease 1 0.6746203899383545
/ I-Disease 1 0.9999740123748779
or I-Disease 1 0.9993740916252136
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 5.179594817286692e-13
. O 0 8.064486578529539e-13

A O 0 9.907562617539334e-12
novel O 0 1.3122784109365071e-11
Arg362Ser O 0 4.7794756596886145e-08
mutation O 0 1.3969716876338634e-11
in O 0 3.527175953078139e-16
the O 0 1.2313260779511824e-15
sterol O 0 2.1936446614745364e-07
27 O 0 9.76636271854403e-11
- O 0 1.3001764109787928e-09
hydroxylase O 0 1.9632445003026078e-08
gene O 0 3.158372868794501e-11
( O 0 4.892389034990901e-15
CYP27 O 0 8.841371523793384e-10
) O 0 4.254048607911597e-17
: O 0 2.04297543317199e-18
its O 0 1.0457809772009117e-18
effects O 0 2.793071831219858e-14
on O 0 2.0000295094125403e-13
pre O 0 1.9951443275267877e-10
- O 0 1.291041058781861e-12
mRNA O 0 2.0733704246626286e-15
splicing O 0 4.786542798403126e-13
and O 0 3.7988204568779535e-14
enzyme O 0 6.290426946692351e-12
activity O 0 4.0813307594644854e-12
. O 0 1.594611216074876e-13

A O 0 4.775073565721488e-12
novel O 0 6.1189087650903584e-12
C O 0 1.0031818709066442e-09
to O 0 2.0094175842603568e-16
A O 0 2.1453235441912764e-15
mutation O 0 2.5939523424188538e-14
in O 0 2.4525680169070656e-17
the O 0 1.4540647204973702e-15
sterol O 0 3.3547672728673206e-07
27 O 0 6.8240309236689e-11
- O 0 1.6523717949468164e-09
hydroxylase O 0 5.8000225067189604e-08
gene O 0 8.702572551477772e-10
( O 0 8.814716128237657e-14
CYP27 O 0 1.2037247643092996e-08
) O 0 5.409656650467374e-17
was O 0 1.0380435090715754e-16
identified O 0 6.52850313224007e-17
by O 0 2.93647876685406e-19
sequencing O 0 4.799780364828088e-13
amplified O 0 9.48978187698124e-11
CYP27 O 0 3.979049867375295e-10
gene O 0 6.321924862946748e-13
products O 0 3.709849788480213e-11
from O 0 1.688939359944242e-16
a O 0 2.3980712299817922e-14
patient O 0 9.585363613950904e-10
with O 0 1.190417653340603e-09
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 0.9999997615814209
( O 0 1.3866926704131366e-11
CTX B-Disease 0 2.2890367290528957e-06
) O 0 8.005697342029772e-13
. O 0 3.3806827779911397e-13

The O 0 8.476495872399015e-14
mutation O 0 6.51319709971121e-12
changed O 0 4.840730138781779e-13
the O 0 6.967955074931931e-16
adrenodoxin O 0 6.295066135031391e-10
cofactor O 0 4.041961210177192e-12
binding O 0 4.778134918975718e-12
residue O 0 2.9577629234722735e-10
362Arg O 0 1.0399020533569114e-09
to O 0 4.03027864716559e-14
362Ser O 0 7.785243560931576e-09
( O 0 4.8466120710927846e-14
CGT O 0 3.079767996183591e-09
362Arg O 0 1.0414915457834795e-10
to O 0 2.4882865492598322e-15
AGT O 0 3.832191808328389e-08
362Ser O 0 8.318399302709167e-10
) O 0 1.3840422008137517e-15
, O 0 3.0520474789562937e-18
and O 0 1.531818222387142e-17
was O 0 1.7777133118433014e-13
responsible O 0 3.343306317557526e-12
for O 0 1.8051891361933747e-12
deficiency O 0 3.1761062668778095e-09
in O 0 2.845233507459101e-18
the O 0 1.8680106747326125e-15
sterol O 0 2.1101708114201756e-07
27 O 0 3.3111017400111464e-11
- O 0 3.0942509665621287e-10
hydroxylase O 0 1.1473190397737199e-08
activity O 0 4.6954627686002226e-11
, O 0 5.0789756496037855e-17
as O 0 2.793259557543771e-17
confirmed O 0 2.850972875323882e-16
by O 0 8.071679599092846e-19
expression O 0 5.2669739505023874e-17
of O 0 1.8894145223303488e-18
mutant O 0 9.589404330280146e-14
cDNA O 0 4.4513119590045697e-14
into O 0 1.1747570418611103e-13
COS O 0 0.000232507853070274
- O 0 1.812544225821e-09
1 O 0 2.750105068530847e-14
cells O 0 1.4366325240978278e-13
. O 0 7.013202410303954e-14

Quantitative O 0 2.944838539686856e-10
analysis O 0 3.852411011723289e-12
showed O 0 2.0189359906108706e-10
that O 0 4.3898233571450313e-17
the O 0 2.0345226812874637e-17
expression O 0 1.39266436094209e-15
of O 0 3.788337320365872e-17
CYP27 O 0 3.882644483699238e-10
gene O 0 3.234845930618485e-14
mRNA O 0 3.554773662928223e-15
in O 0 4.261812856013265e-17
the O 0 2.1958789174063862e-16
patient O 0 4.875852326058361e-12
represented O 0 6.921138738080063e-14
52 O 0 1.0657689314408358e-10
. O 0 4.9761089346289644e-12

5 O 0 1.3425227596286504e-10
% O 0 4.4251460948243476e-14
of O 0 9.679617235514287e-17
the O 0 7.107666912713542e-15
normal O 0 1.0979773513997149e-11
level O 0 1.0754028917370206e-10
. O 0 5.639269433366234e-13

As O 0 3.2473099187933785e-13
the O 0 1.4329851938742037e-16
mutation O 0 7.284652752976434e-14
occurred O 0 6.963228736965371e-15
at O 0 6.333468634527745e-15
the O 0 2.9639517097436305e-18
penultimate O 0 6.81837399041374e-14
nucleotide O 0 2.6341681115017723e-14
of O 0 2.6753295756649436e-17
exon O 0 4.517432435069413e-12
6 O 0 4.014363494397877e-12
( O 0 1.2931535538701156e-15
- O 0 4.2953498397002576e-11
2 O 0 7.090743872053759e-14
position O 0 3.8457282605826315e-13
of O 0 1.8188510529959002e-16
exon O 0 8.569837894878418e-11
6 O 0 5.494213417556182e-11
- O 0 1.1197622828973408e-09
intron O 0 1.890584133690254e-09
6 O 0 1.393974020415245e-12
splice O 0 4.118618987525302e-11
site O 0 5.640248467927989e-13
) O 0 2.551504376822124e-16
of O 0 8.88440367947786e-19
the O 0 1.1275805164245203e-17
gene O 0 4.467559948286709e-13
, O 0 7.128054360479243e-16
we O 0 5.919630041718567e-16
hypothesized O 0 1.269719752109615e-15
that O 0 1.417929024418081e-15
the O 0 1.1018820370836593e-14
mutation O 0 5.294106264486231e-10
may O 0 5.4406229521575256e-11
partially O 0 6.393707785434799e-11
affect O 0 8.562728908627186e-15
the O 0 5.807697946461361e-18
normal O 0 8.71782588228581e-17
splicing O 0 4.403742588686768e-14
efficiency O 0 5.403271620819765e-14
in O 0 1.494645056531254e-17
exon O 0 2.083738043223704e-11
6 O 0 1.5818355306174148e-11
and O 0 4.522132299021207e-15
cause O 0 2.7569703168904573e-17
alternative O 0 2.2025736540632473e-16
splicing O 0 1.1545125749509721e-12
elsewhere O 0 3.146695751188311e-11
, O 0 6.987599357165535e-16
which O 0 3.165577852593074e-16
resulted O 0 5.647328579164862e-14
in O 0 6.5322960663685356e-15
decreased O 0 2.5964125294208884e-10
transcript O 0 3.9103000893693507e-13
in O 0 1.0534340183138472e-15
the O 0 5.850224140844726e-14
patient O 0 1.4085978217170947e-10
. O 0 1.1743581909869072e-13

Transfection O 0 1.8206009144705604e-08
of O 0 1.661558802872054e-13
constructed O 0 2.2259449838912815e-09
minigenes O 0 9.496495295024943e-06
, O 0 2.708734115914463e-14
with O 0 7.47481588479976e-15
or O 0 1.7196609804551177e-12
without O 0 7.31306630378549e-14
the O 0 1.637725762719777e-16
mutation O 0 6.602698395625703e-14
, O 0 6.972285530874769e-17
into O 0 8.62554317792967e-15
COS O 0 0.0011080058757215738
- O 0 4.968592759446722e-10
1 O 0 4.350366511054007e-16
cells O 0 5.09168445253505e-16
confirmed O 0 6.339874321191355e-15
that O 0 1.7866326990092048e-17
the O 0 1.6030438663455516e-16
mutant O 0 2.754846073482753e-10
minigene O 0 6.8356320603868426e-09
was O 0 1.4161527853162603e-12
responsible O 0 1.2079299691568346e-14
for O 0 7.370946219711436e-17
a O 0 1.7307203188587445e-16
mRNA O 0 2.621445846040602e-15
species O 0 4.084733802421506e-16
alternatively O 0 1.5633065046476158e-13
spliced O 0 2.8547671604428615e-07
at O 0 2.3088416511996e-08
an O 0 1.2981302231068748e-12
activated O 0 1.8056996964332939e-07
cryptic O 0 3.78617276419746e-12
5 O 0 2.4560440283643604e-15
splice O 0 6.825618542594114e-11
site O 0 2.295444433489391e-12
88 O 0 1.2247110877522394e-12
bp O 0 2.3079135824666253e-11
upstream O 0 1.538333804958214e-12
from O 0 4.488549983761416e-15
the O 0 6.605790256465594e-16
3 O 0 7.906612105486321e-15
end O 0 1.078621665319109e-14
of O 0 3.667163301560734e-17
exon O 0 2.2497644372454495e-11
6 O 0 2.271434949852047e-11
. O 0 4.586766621898775e-13

Our O 0 4.885829154449572e-13
data O 0 9.68491305490711e-14
suggest O 0 8.55662264811043e-15
that O 0 4.259114592855117e-17
the O 0 2.0626799424259932e-16
C O 0 6.616815428905909e-11
to O 0 2.7581814747433574e-16
A O 0 1.0364762027164146e-13
mutation O 0 1.2496282491853555e-13
at O 0 1.0936455734078532e-13
the O 0 2.297497294652362e-17
penultimate O 0 2.121253070115972e-14
nucleotide O 0 2.9424842503024276e-15
of O 0 2.832757349075117e-18
exon O 0 4.3963346418179894e-13
6 O 0 4.4421009839229475e-14
of O 0 5.215288976134053e-18
the O 0 1.1174925525460686e-16
CYP27 O 0 4.950706955497708e-09
gene O 0 2.308079725607537e-12
not O 0 4.1957617800047683e-14
only O 0 2.593337481202442e-15
causes O 0 2.2878991453104125e-13
the O 0 1.953871526377826e-12
deficiency B-Disease 0 6.36382367247279e-07
in I-Disease 0 6.376176168077204e-17
the I-Disease 0 8.54638032571223e-15
sterol I-Disease 0 1.4840484254818875e-06
27 I-Disease 0 5.893713850291249e-10
- I-Disease 0 2.4278172805480835e-09
hydroxylase I-Disease 0 1.1147810141665104e-07
activity I-Disease 0 2.716641800404318e-09
, O 0 1.463464393343817e-14
but O 0 4.252318847519296e-14
also O 0 6.583464242509995e-12
partially O 0 2.7195139473690233e-09
leads O 0 8.291098710366818e-12
to O 0 6.159481185019015e-16
alternative O 0 3.3351888416820186e-14
pre O 0 2.1190889321065498e-11
- O 0 1.1057691898632219e-13
mRNA O 0 8.134715828250638e-17
splicing O 0 7.356768291072718e-15
of O 0 1.6551281869700145e-17
the O 0 2.19965903354408e-17
gene O 0 1.2847205937971395e-12
. O 0 1.8435367165128835e-13

To O 0 7.424437583822274e-13
our O 0 1.0139254073924381e-13
knowledge O 0 8.032686183421546e-15
, O 0 4.6149589242609365e-18
this O 0 2.0145712400090495e-20
is O 0 2.1092028630944662e-17
the O 0 8.655321695698011e-19
first O 0 1.1319738142711103e-14
report O 0 1.5754804687413693e-13
regarding O 0 9.61290809696209e-16
effects O 0 8.723257745757874e-15
on O 0 7.626140014892636e-15
pre O 0 1.3528599898324223e-12
- O 0 5.815957253556964e-14
mRNA O 0 3.740590139303596e-17
splicing O 0 4.836645796732096e-15
of O 0 6.011285706774444e-18
a O 0 1.9793503961746668e-17
mutation O 0 2.8172866397093745e-15
at O 0 1.7902385574409402e-13
the O 0 4.470379348273622e-14
- O 0 8.141694706864655e-06
2 O 0 3.384397762040692e-10
position O 0 4.142068021906198e-09
of O 0 2.9100896869929237e-15
a O 0 3.267538014250712e-14
5 O 0 1.2851041574207106e-14
splice O 0 2.2972689028843973e-10
site O 0 1.7223544812594582e-10
. O 0 8.196161631335297e-12

ATM O 0 1.7024092358042253e-06
germline O 0 2.4938058231782634e-06
mutations O 0 3.7265185710566584e-06
in O 0 5.5664677728328726e-11
classical O 0 5.584348036791198e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9894291758537292
in O 0 1.2906760079103852e-13
the O 0 9.528544674206746e-14
Dutch O 0 4.5839794893254293e-07
population O 0 1.7159774848892612e-13
. O 0 7.678253107108735e-13

Germline O 0 3.2794846447359305e-06
mutations O 0 2.461225356853447e-08
in O 0 2.476685797772474e-15
the O 0 2.4748229804155598e-17
ATM O 0 5.815167097855678e-11
gene O 0 3.882862781301455e-12
are O 0 4.703472841545051e-16
responsible O 0 2.1814467550049232e-13
for O 0 6.361275221855589e-12
the O 0 0.0005154088721610606
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.005189867690205574
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.632938922968563e-11
. O 0 2.0812374718591486e-13

In O 0 1.5214560297391322e-12
our O 0 4.515738979038626e-14
study O 0 1.812078971643043e-15
, O 0 1.1675134215016812e-16
we O 0 1.970770806069373e-15
have O 0 2.921420605547022e-17
determined O 0 5.43143002942324e-17
the O 0 1.0583833840258868e-17
ATM O 0 1.464696003372623e-10
mutation O 0 4.1520237091139875e-14
spectrum O 0 2.030889223610631e-14
in O 0 2.9578779623880313e-16
19 O 0 1.1187140217016125e-13
classical O 0 7.45108402061545e-12
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 9.511309795318112e-11
, O 0 1.170780840755957e-19
including O 0 8.096840623869119e-20
some O 0 9.754110681298005e-19
immigrant O 0 1.5205044254923417e-12
populations O 0 1.4893883449143032e-14
, O 0 7.543613886009225e-17
as O 0 2.479474441993072e-15
well O 0 1.3600985572168045e-13
as O 0 1.903197434718895e-12
12 O 0 2.2035025713795786e-12
of O 0 9.331702687594319e-15
Dutch O 0 3.736115061769851e-08
ethnic O 0 1.9095933601748216e-12
origin O 0 2.8361408707655578e-11
. O 0 1.8039510857326135e-11

Both O 0 1.4574231849574099e-13
the O 0 3.697844621620408e-16
protein O 0 1.579554493929755e-13
truncation O 0 1.8091282916188334e-09
test O 0 6.152872629172634e-07
( O 0 3.984409102566339e-15
PTT O 0 2.154309092228246e-10
) O 0 3.738009865188023e-16
and O 0 2.970801633755213e-17
the O 0 1.5768955539453112e-18
restriction O 0 7.505073595741579e-15
endonuclease O 0 2.376674690385272e-10
fingerprinting O 0 2.9014288194240123e-10
( O 0 2.3296330430743655e-15
REF O 0 3.2785864301221324e-11
) O 0 5.769977683348331e-19
method O 0 4.21661190231255e-18
were O 0 4.164501343519057e-17
used O 0 2.6345271052406424e-16
and O 0 2.6164407283552765e-15
compared O 0 3.450098601855958e-16
for O 0 1.6376794478433043e-19
their O 0 1.9464986376811968e-20
detection O 0 1.0125550138305501e-17
efficiency O 0 5.12566643830577e-18
, O 0 7.359696682287928e-20
identifying O 0 3.104980872024529e-14
76 O 0 1.518221659502217e-11
% O 0 2.7798475716824976e-15
and O 0 1.3463140107958238e-12
60 O 0 3.1227405101856565e-13
% O 0 3.6176864527503853e-16
of O 0 4.504379335479704e-16
the O 0 7.707540660394085e-13
mutations O 0 1.334455601575968e-10
, O 0 1.3673087727143762e-13
respectively O 0 6.517425488183903e-11
. O 0 8.379332817887164e-12

Most O 0 5.2572616399126915e-12
patients O 0 6.39757170850519e-12
were O 0 2.8430245828446436e-15
found O 0 3.0071539452758726e-15
to O 0 5.164059712108786e-16
be O 0 5.042364637809771e-13
compound O 0 7.284003044824572e-13
heterozygote O 0 2.5817474824663122e-09
. O 0 3.1010658450847384e-12

Seventeen O 0 1.0027004115897853e-08
mutations O 0 2.033190327210832e-07
were O 0 4.5989804846324756e-12
distinct O 0 3.056794311149711e-15
, O 0 2.8684285832404578e-15
of O 0 2.0990344641732498e-16
which O 0 9.29199967837635e-13
10 O 0 7.161124991605927e-13
were O 0 1.2440426293280904e-12
not O 0 3.366340138501872e-13
reported O 0 1.0182021198401614e-10
previously O 0 7.114656086493198e-10
. O 0 2.6804851741002444e-12

Mutations O 0 5.391548711486394e-06
are O 0 4.2499050069075284e-13
small O 0 3.143595410023958e-14
deletions O 0 2.272556542948223e-08
or O 0 9.79591852079409e-10
point O 0 4.838228928605304e-09
mutations O 0 8.275299734350483e-08
frequently O 0 8.301487830486565e-10
affecting O 0 1.6435636185363478e-10
splice O 0 5.916866143707011e-07
sites O 0 1.4697018002607365e-07
. O 0 9.966018288398715e-11

Moreover O 0 8.145954466520777e-10
, O 0 8.520163470148584e-14
a O 0 2.478851745721898e-14
16 O 0 4.394634829651967e-12
. O 0 8.38536800217525e-14

7 O 0 5.722088913806544e-10
- O 0 2.1560777607732007e-09
kb O 0 2.8924583617140343e-08
genomic O 0 9.924778360259623e-11
deletion O 0 4.461929437038492e-10
of O 0 3.830468064182921e-15
the O 0 6.991172248016172e-16
3 O 0 1.067903310404553e-14
end O 0 1.1025085873547433e-14
of O 0 7.734113394964549e-19
the O 0 9.659688014375077e-19
gene O 0 5.263783018571403e-16
, O 0 1.7068591732599224e-18
most O 0 4.956775906159566e-19
likely O 0 1.7054560524294477e-15
a O 0 1.4039551248405327e-17
result O 0 1.0396564450916048e-16
of O 0 1.445970130373454e-18
recombination O 0 4.044468820724352e-15
between O 0 4.968793930991422e-13
two O 0 2.617234554080916e-11
LINE O 0 4.6174131966836285e-06
elements O 0 2.0077284019343056e-12
, O 0 1.672885158036149e-14
was O 0 5.974794010238371e-12
identified O 0 6.15445958085381e-11
. O 0 3.1077154738490265e-12

The O 0 1.7817561662192283e-13
most O 0 8.112103145523162e-15
frequently O 0 5.376955391350746e-13
found O 0 1.0776188291315367e-13
mutation O 0 1.6681511586565806e-13
, O 0 4.70700642477298e-17
identified O 0 1.6861215724963026e-14
in O 0 2.407609592561951e-17
three O 0 1.5240103084135544e-14
unrelated O 0 1.3763010175971147e-10
Turkish O 0 3.963168904164149e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
individuals O 0 1.8660080147725466e-09
, O 0 2.0773062903069878e-14
was O 0 1.2814364369964637e-12
previously O 0 2.72826401227777e-12
described O 0 1.8118481975165635e-14
to O 0 2.80835785365413e-16
be O 0 3.0752302288862554e-13
a O 0 1.9016105151040824e-13
Turkish O 0 1.369462099276575e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
T I-Disease 1 0.9999998807907104
founder O 0 9.258090472030744e-08
mutation O 0 4.0088377062375e-09
. O 0 2.9887689545482488e-12

The O 0 3.6648911986778e-13
presence O 0 1.9552432589664548e-12
of O 0 1.437029776197343e-17
a O 0 3.5503134521257783e-16
founder O 0 1.367319777366427e-12
mutation O 0 2.8862912494070914e-12
among O 0 2.25351760364291e-15
relatively O 0 6.710116425990375e-18
small O 0 1.4274093348011063e-16
ethnic O 0 1.7472189060147025e-15
population O 0 3.0378100793402554e-16
groups O 0 1.4867019058067033e-16
in O 0 1.0246949315673376e-15
Western O 0 2.218160334230279e-12
Europe O 0 1.0061228239433007e-10
could O 0 1.2657217396579157e-13
indicate O 0 1.1507865854362177e-15
a O 0 1.2927337431656327e-16
high O 0 5.894131753850229e-13
carrier O 0 2.205606879047365e-14
frequency O 0 6.880969423460345e-17
in O 0 1.8359288584865475e-17
such O 0 5.806576871885891e-15
communities O 0 2.1097073740761196e-12
. O 0 4.024465764980445e-13

In O 0 8.831279891402533e-13
patients O 0 6.605173873130976e-12
of O 0 2.818598058469961e-15
Dutch O 0 1.7472116198291587e-08
ethnic O 0 4.068541497085319e-14
origin O 0 8.859860002770337e-13
, O 0 2.96543930904114e-14
however O 0 1.911886134367438e-15
, O 0 6.175688763418032e-17
no O 0 2.9833991180283626e-15
significant O 0 2.6262300998849313e-15
founder O 0 1.6451758011459816e-10
effect O 0 1.0281300255599035e-09
could O 0 5.988133600087764e-11
be O 0 2.361511051811316e-13
identified O 0 2.195096101414995e-12
. O 0 1.9159694176259373e-13

The O 0 1.2232694817217258e-14
observed O 0 1.7204894261113775e-14
genetic O 0 1.2114468499538344e-13
heterogeneity O 0 4.269957868188734e-13
including O 0 5.032693266439998e-15
the O 0 3.5700329085334504e-16
relative O 0 1.3517193007267503e-13
high O 0 7.450835504130282e-10
percentage O 0 1.8408664592683976e-09
of O 0 2.772434339328128e-15
splice O 0 9.18796649784781e-06
- O 0 4.630650707326822e-08
site O 0 7.890452735637155e-10
mutations O 0 7.935405932357753e-08
had O 0 6.546835074061619e-09
no O 0 1.1152796080323574e-13
reflection O 0 2.571361804308992e-14
on O 0 2.807526617871342e-13
the O 0 7.63708706870295e-15
phenotype O 0 3.006689688889175e-11
. O 0 3.169745282222136e-13

All O 0 7.123719582974308e-12
patients O 0 1.3400253129347561e-11
manifested O 0 4.149178396695152e-12
classical O 0 1.22978724426126e-10
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
and O 0 2.2480110828393407e-10
increased O 0 2.048500902056532e-14
cellular O 0 1.841817985018951e-13
radioresistant O 0 1.4519385043224031e-12
DNA O 0 6.420158458683711e-13
synthesis O 0 2.250746030524331e-12
. O 0 8.977969192733304e-13

Determination O 0 5.582693335393074e-11
of O 0 5.314486410794045e-16
the O 0 3.482200422637957e-17
genomic O 0 4.3172591695193885e-13
structure O 0 1.41929138797528e-13
of O 0 2.5982661210770533e-17
the O 0 3.5595079947682237e-16
COL4A4 O 0 2.663228304555787e-09
gene O 0 1.1307832247604496e-13
and O 0 6.177129116475058e-16
of O 0 1.368031084427661e-17
novel O 0 1.8700627713030826e-09
mutations O 0 0.0001360918686259538
causing O 0 0.00021409524197224528
autosomal B-Disease 1 0.9999957084655762
recessive I-Disease 1 0.9999967813491821
Alport I-Disease 1 0.9999977350234985
syndrome I-Disease 1 0.9999994039535522
. O 0 8.346772162326488e-09

Autosomal B-Disease 1 0.9999908208847046
recessive I-Disease 1 0.9999942779541016
Alport I-Disease 1 0.9999978542327881
syndrome I-Disease 1 0.9999997615814209
is O 0 1.675299343695258e-10
a O 0 9.800619517330578e-12
progressive O 0 5.177168418413203e-07
hematuric B-Disease 1 0.9997797608375549
glomerulonephritis I-Disease 1 0.9999997615814209
characterized O 0 1.1854859849336208e-07
by O 0 1.0209917763667753e-12
glomerular B-Disease 0 0.01103767566382885
basement I-Disease 1 0.9271860122680664
membrane I-Disease 1 0.9827218651771545
abnormalities I-Disease 1 0.9999992847442627
and O 0 3.675234075406486e-11
associated O 0 8.537146141927854e-14
with O 0 1.1643078570765329e-14
mutations O 0 6.586466181485173e-12
in O 0 1.1762265847322902e-15
either O 0 6.251022513200158e-14
the O 0 1.3417348829203313e-13
COL4A3 O 0 1.0030620614998043e-05
or O 0 2.7041980850753267e-13
the O 0 1.1150450984905805e-14
COL4A4 O 0 7.354071840381948e-08
gene O 0 1.217930053684646e-12
, O 0 1.7081041421203606e-17
which O 0 1.6886597522176838e-19
encode O 0 1.6585737581807674e-16
the O 0 4.539669015051276e-14
alpha3 O 0 6.334538193186745e-05
and O 0 5.963323723712222e-10
alpha4 O 0 1.2190885172458366e-05
type O 0 4.4985431486566085e-06
IV O 0 5.1059727411484346e-05
collagen O 0 0.0009005814790725708
chains O 0 1.8884978999267332e-05
, O 0 7.712629363290646e-13
respectively O 0 1.049329286656464e-11
. O 0 3.156696909076273e-12

To O 0 3.735982470652946e-14
date O 0 4.0231763775468166e-13
, O 0 4.525440611189835e-17
mutation O 0 7.410957541510667e-16
screening O 0 9.072560953372888e-13
in O 0 1.548149414656899e-17
the O 0 1.3726835617829655e-17
two O 0 2.2876697603179666e-15
genes O 0 3.93568072012615e-13
has O 0 4.116268523951527e-12
been O 0 4.683955046741461e-13
hampered O 0 1.6081460165254247e-12
by O 0 1.1073329548265698e-17
the O 0 2.4497747140052577e-15
lack O 0 5.42112732945777e-15
of O 0 2.8562479343031276e-19
genomic O 0 1.0095949006276236e-13
structure O 0 1.9807292199643112e-13
information O 0 8.367529759356618e-12
. O 0 5.621970770863793e-12

We O 0 4.053020419281239e-10
report O 0 2.549359378115068e-12
here O 0 4.533668146608982e-16
the O 0 9.037680246983937e-19
complete O 0 4.5878070515261284e-17
characterization O 0 1.150453616784652e-14
of O 0 5.585676879787841e-18
the O 0 9.359643260499584e-17
48 O 0 1.3863045199367496e-14
exons O 0 8.213058054831746e-13
of O 0 1.4627643576706027e-17
the O 0 4.0095805394785723e-16
COL4A4 O 0 1.5153656107713687e-08
gene O 0 2.704115685710218e-13
, O 0 1.0647654960420397e-17
a O 0 2.430187570099647e-18
comprehensive O 0 1.1445689231462386e-13
gene O 0 5.924039037097373e-11
screen O 0 0.00020220519218128175
, O 0 1.836115677902872e-12
and O 0 6.260063488769266e-15
the O 0 1.8986483395082782e-18
subsequent O 0 8.151054961454276e-17
detection O 0 2.278473904774453e-14
of O 0 1.7968930473273126e-16
10 O 0 5.062748748265659e-16
novel O 0 3.181093897412085e-14
mutations O 0 4.294102400048683e-12
in O 0 2.660270659969187e-15
eight O 0 4.3069543487206374e-09
patients O 0 9.149803137376011e-10
diagnosed O 0 1.913760024763178e-05
with O 0 1.607907051948132e-08
autosomal B-Disease 1 0.9999957084655762
recessive I-Disease 1 0.9999984502792358
Alport I-Disease 1 0.9999991655349731
syndrome I-Disease 1 0.9999996423721313
. O 0 1.1777799180379134e-08

Furthermore O 0 3.0370213011110536e-09
, O 0 4.3059414540913554e-14
we O 0 2.4929706414581485e-15
identified O 0 8.092842357456428e-16
a O 0 2.8495129263581442e-18
glycine O 0 1.053503394547392e-13
to O 0 7.193029430682508e-18
alanine O 0 8.885956206960977e-13
substitution O 0 4.385509272760877e-15
in O 0 6.448604764256838e-17
the O 0 2.7538382802190865e-17
collagenous O 0 1.2623724288118865e-10
domain O 0 1.922159127828657e-13
that O 0 1.4358977060754258e-14
is O 0 2.3122205105446936e-13
apparently O 0 1.536205082412756e-12
silent O 0 7.28184387788211e-11
in O 0 6.482740192031186e-17
the O 0 3.068124594429099e-16
heterozygous O 0 3.12994734297245e-11
carriers O 0 3.222542946466206e-13
, O 0 3.807054432394477e-17
in O 0 7.476405130367046e-17
11 O 0 1.9305999941071628e-12
. O 0 2.0913248888719538e-13

5 O 0 1.4277505393234247e-11
% O 0 1.2519249451405177e-14
of O 0 3.001237248085734e-17
all O 0 9.572075391432039e-15
control O 0 3.0708107497806614e-13
individuals O 0 2.4670127662181247e-14
, O 0 5.8966452732992294e-15
and O 0 3.4100567286371106e-14
in O 0 6.41230013804413e-17
one O 0 7.192495568315166e-14
control O 0 7.048545774823722e-12
individual O 0 6.89997697514563e-16
homozygous O 0 1.2055529914189317e-13
for O 0 4.016281579251701e-18
this O 0 1.615005005536548e-18
glycine O 0 2.164686615721556e-12
substitution O 0 2.721355855505453e-13
. O 0 4.883891685167341e-13

There O 0 9.974875092577662e-12
has O 0 1.3820342439907485e-12
been O 0 1.0540200168825814e-13
no O 0 1.3860498806569812e-15
previous O 0 4.064451598499502e-15
finding O 0 5.8941939599498755e-15
of O 0 6.860728024357958e-19
a O 0 3.351059621914106e-18
glycine O 0 1.1106385789890795e-14
substitution O 0 2.8934274901292476e-17
that O 0 1.7760533898468966e-16
is O 0 1.1045412334940931e-15
not O 0 3.637308500369123e-16
associated O 0 4.262920417766249e-16
with O 0 4.748035774295692e-16
any O 0 3.9316572458640564e-14
obvious O 0 2.1302552007541192e-13
phenotype O 0 6.820770619316019e-13
in O 0 2.633240938649796e-16
homozygous O 0 2.493444117845911e-09
individuals O 0 6.989533084256205e-12
. O 0 3.1023200501578696e-12

Founder O 0 3.3843178925963e-07
BRCA1 O 0 0.02489992417395115
and O 0 1.4528792058321471e-10
BRCA2 O 0 5.9237907407805324e-05
mutations O 0 9.95444295881498e-08
in O 0 3.115622343452529e-11
French O 0 0.0007245633751153946
Canadian O 1 0.9806157946586609
breast B-Disease 1 0.9999997615814209
and I-Disease 1 0.9999986886978149
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.651807438196045e-10
. O 0 4.226996357103996e-12

We O 0 2.520287090135298e-09
have O 0 5.313295715404266e-14
identified O 0 4.1276744934364007e-13
four O 0 1.6055975383326253e-14
mutations O 0 1.3821916159360847e-13
in O 0 1.6131216393588566e-17
each O 0 3.410672818051296e-15
of O 0 2.0610264864673496e-14
the O 0 2.820821076721103e-10
breast B-Disease 0 0.18339554965496063
cancer I-Disease 0 7.093199201335665e-07
- O 0 1.0855784715602113e-08
susceptibility O 0 4.191113081586373e-11
genes O 0 1.507140384715555e-10
, O 0 1.897559800262405e-13
BRCA1 O 0 1.1699521564878523e-06
and O 0 1.2527109904958422e-10
BRCA2 O 0 5.093879735795781e-06
, O 0 4.4079383155690155e-13
in O 0 4.918423524361004e-13
French O 0 0.00010050227137980983
Canadian O 0 0.11865144968032837
breast B-Disease 1 0.9999674558639526
cancer I-Disease 1 0.9998650550842285
and O 0 0.46323102712631226
breast B-Disease 1 0.9999995231628418
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.6680160724868998e-11
from O 0 1.691102444710546e-12
Quebec O 0 3.249976643360242e-08
. O 0 4.9711495336834943e-11

To O 0 5.152062655081231e-14
identify O 0 1.1574936972444383e-12
founder O 0 1.1317473347371987e-10
effects O 0 1.2934572168887826e-07
, O 0 9.358622411097597e-14
we O 0 1.5777628498397228e-13
examined O 0 5.209260973970675e-12
independently O 0 3.5644950532875974e-12
ascertained O 0 9.45281271924614e-07
French O 0 2.92599834210705e-05
Canadian O 0 1.5274816860255669e-06
cancer B-Disease 0 1.3676825005859428e-08
families O 0 4.63081753170313e-16
for O 0 6.5466055663554864e-18
the O 0 2.921653415530425e-18
distribution O 0 8.293359408268754e-16
of O 0 2.0285089127980807e-17
these O 0 4.927580818729594e-16
eight O 0 5.831399816150218e-13
mutations O 0 6.373481169913431e-12
. O 0 1.9719761847752926e-13

Mutations O 0 2.2258851117840095e-07
were O 0 5.223924049412021e-13
found O 0 3.0979887844515344e-14
in O 0 8.947538570603216e-17
41 O 0 2.390332127111955e-13
of O 0 2.4296523346124886e-16
97 O 0 7.656500433661506e-11
families O 0 1.5670718845825493e-12
. O 0 4.204169564564486e-12

Six O 0 2.1766870250683468e-10
of O 0 4.7221904697343584e-15
eight O 0 4.014210405051122e-12
mutations O 0 1.574373791057848e-11
were O 0 1.9942004997200793e-14
observed O 0 5.2018285512378526e-14
at O 0 6.838134117108374e-13
least O 0 2.0935828754214264e-14
twice O 0 1.1613615846783887e-08
. O 0 1.6765738103385885e-11

The O 0 2.035441086511991e-11
BRCA1 O 0 2.4200080588343553e-05
C4446T O 0 3.035243389959419e-09
mutation O 0 7.588285555470975e-11
was O 0 2.3714830012927512e-12
the O 0 1.168007876984641e-16
most O 0 1.2583785103414719e-15
common O 0 3.451997734426997e-14
mutation O 0 8.795390088987831e-13
found O 0 1.0483735407573747e-10
, O 0 2.9704985944834427e-15
followed O 0 4.079083669146846e-15
by O 0 5.535748886671406e-16
the O 0 3.9591810732653165e-12
BRCA2 O 0 0.0003400713612791151
8765delAG O 0 2.061250825136085e-06
mutation O 0 3.3589842018955096e-09
. O 0 5.894933412936565e-12

Together O 0 4.6662770869509984e-11
, O 0 8.445582875593377e-16
these O 0 5.68598865908184e-18
mutations O 0 2.6033114466222917e-13
were O 0 1.657892336056569e-14
found O 0 1.6046063403777483e-13
in O 0 5.221106851710771e-16
28 O 0 3.473464463103759e-13
of O 0 2.0610664108359228e-17
41 O 0 3.895991331197973e-13
families O 0 1.0785630506391589e-16
identified O 0 1.990459446571391e-12
to O 0 7.204564093747645e-14
have O 0 6.781471911798675e-11
a O 0 1.587879540311185e-13
mutation O 0 1.0194204508318094e-10
. O 0 2.1708264526243415e-12

The O 0 6.014646788433942e-14
odds O 0 5.0754244557138506e-12
of O 0 2.276827043761397e-18
detection O 0 3.2792863612291293e-15
of O 0 2.6245237288516303e-18
any O 0 1.2648033611255141e-15
of O 0 1.3295582358497174e-16
the O 0 4.802816147851706e-15
four O 0 1.038537311703891e-11
BRCA1 O 0 5.899793364960715e-08
mutations O 0 1.402343657863625e-10
was O 0 1.4997055819421234e-09
18 O 0 1.1050160092507255e-10
. O 0 8.695126324682889e-13

7x O 0 4.833932962355902e-06
greater O 0 2.1547312545333597e-11
if O 0 2.2433377922762184e-14
one O 0 1.733831775276475e-17
or O 0 6.375686063564267e-18
more O 0 2.778463746907762e-19
cases O 0 4.233335958257062e-13
of O 0 1.6999507579384954e-08
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 1.2766062873481587e-08
also O 0 1.3766739137555106e-10
present O 0 8.956734754371996e-15
in O 0 1.5032457827555599e-16
the O 0 3.440750830953354e-14
family O 0 1.5628102978393343e-11
. O 0 2.649751728797667e-12

The O 0 4.0512962450924006e-14
odds O 0 4.002619850146383e-12
of O 0 2.064638052643835e-18
detection O 0 2.8752099290161757e-15
of O 0 1.8513165685496265e-17
any O 0 4.292719778004484e-15
of O 0 1.0183821008905697e-15
the O 0 8.408654631961165e-14
four O 0 3.1594829530412483e-10
BRCA2 O 0 1.899550966300012e-06
mutations O 0 7.217862418862353e-11
was O 0 8.67449514996288e-11
5 O 0 2.2169167543384383e-12
. O 0 5.05806551157062e-13

3x O 0 9.295758331973047e-07
greater O 0 3.948572024903285e-11
if O 0 1.0928871739881996e-12
there O 0 6.378858589072261e-15
were O 0 4.850040775759975e-15
at O 0 4.949924489086978e-16
least O 0 1.4044687212828669e-18
five O 0 3.233226138925539e-16
cases O 0 8.435545556344237e-14
of O 0 2.857242979541208e-13
breast B-Disease 0 0.0002497151435818523
cancer I-Disease 0 2.4645560259273225e-08
in O 0 2.9207663255348274e-15
the O 0 7.022545522525347e-14
family O 0 2.792980430266212e-11
. O 0 9.626376952509563e-12

Interestingly O 0 2.3679100347173687e-10
, O 0 6.215613740796202e-15
the O 0 7.137601877632677e-17
presence O 0 1.9712531913328342e-14
of O 0 6.01390348525899e-17
a O 0 8.035360571367889e-13
breast B-Disease 0 5.047264494351111e-06
cancer I-Disease 0 6.998931989521395e-10
case O 0 1.297080119092714e-13
< O 0 1.265688508861329e-12
36 O 0 1.1143063468471714e-12
years O 0 1.0826497982624125e-13
of O 0 8.540248865965294e-16
age O 0 1.539728934629725e-11
was O 0 2.125240088080016e-12
strongly O 0 1.2415848116127345e-15
predictive O 0 1.657330278874089e-13
of O 0 1.6610612226316124e-17
the O 0 2.0474714658580423e-16
presence O 0 6.64555072416354e-15
of O 0 1.4487245125662848e-19
any O 0 1.4762356226032943e-16
of O 0 1.0051237886434962e-17
the O 0 2.8277509376793133e-16
eight O 0 4.3259636866611884e-13
mutations O 0 2.1825549180454207e-12
screened O 0 8.692958886058477e-08
. O 0 6.282464999618487e-12

Carriers O 0 8.822863328816766e-09
of O 0 1.0710686090009713e-15
the O 0 6.130528672439577e-17
same O 0 9.871433802120433e-17
mutation O 0 5.94817748726076e-15
, O 0 1.7019707633144024e-17
from O 0 8.311593512994077e-18
different O 0 2.4237093396963156e-16
families O 0 8.233754017407825e-15
, O 0 3.3363926343187445e-17
shared O 0 2.0234875956076388e-15
similar O 0 5.638733799376544e-16
haplotypes O 0 3.404984193905447e-12
, O 0 2.5855130143521803e-16
indicating O 0 9.282424004788958e-15
that O 0 3.772647027634721e-17
the O 0 2.9949586163642114e-17
mutant O 0 1.8502491205829585e-11
alleles O 0 1.9623110645086705e-13
were O 0 3.0884087062928167e-13
likely O 0 2.8681894234878005e-14
to O 0 1.9976475320626662e-16
be O 0 2.140470147047463e-13
identical O 0 5.6808839587769305e-14
by O 0 3.2508139839818864e-15
descent O 0 3.3199994836641267e-11
for O 0 2.569274545720368e-13
a O 0 8.015426023648756e-14
mutation O 0 2.3596526208674584e-12
in O 0 5.596389563552117e-16
the O 0 4.869506016404353e-15
founder O 0 4.4799824960861656e-10
population O 0 5.075664281234404e-13
. O 0 9.993055645127202e-13

The O 0 4.3756836905727275e-15
identification O 0 2.87990931015919e-14
of O 0 2.6147345922412695e-15
common O 0 9.22542771342183e-12
BRCA1 O 0 0.0013266172027215362
and O 0 4.788031304769902e-09
BRCA2 O 0 1.6667689124005847e-05
mutations O 0 2.1616768097754147e-10
will O 0 2.0003872283668248e-14
facilitate O 0 4.371512476823974e-15
carrier O 0 2.49384822688381e-13
detection O 0 4.861900812502817e-13
in O 0 3.500547020220818e-13
French O 0 4.025653652206529e-06
Canadian O 0 0.00047690889914520085
breast B-Disease 1 0.9989050626754761
cancer I-Disease 1 0.9036752581596375
and O 0 0.006065200548619032
breast B-Disease 1 0.9999967813491821
/ I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 1.0775593750622647e-09
. O 0 8.611484789144974e-12

Are O 0 2.3056004327948187e-10
Dp71 O 0 2.9871675906179007e-06
and O 0 4.590934837150895e-12
Dp140 O 0 4.0757186514639443e-10
brain O 0 3.018746919103421e-10
dystrophin O 0 4.320245550193391e-11
isoforms O 0 1.1144268830236975e-13
related O 0 4.541102303218247e-12
to O 0 9.094876544588071e-13
cognitive B-Disease 0 4.227547833579592e-06
impairment I-Disease 0 1.273855559702497e-05
in O 0 1.1331032466477264e-11
Duchenne B-Disease 1 0.9619065523147583
muscular I-Disease 0 0.020489845424890518
dystrophy I-Disease 0 0.00327940727584064
? O 0 6.94448488047783e-07

Molecular O 0 7.482608976872029e-10
study O 0 1.9142911214520275e-11
and O 0 4.680822136143847e-12
neuropsychological O 0 1.6701983440725598e-07
analysis O 0 1.7429536546681446e-13
were O 0 1.1978288640916018e-13
performed O 0 1.6594970569158013e-13
concurrently O 0 1.2173888199601413e-12
on O 0 7.780811411839395e-11
49 O 0 8.992585009970355e-10
patients O 0 8.062595187839638e-13
with O 0 3.965867890164121e-13
Duchenne B-Disease 0 0.0004993744078092277
muscular I-Disease 0 5.448245792649686e-05
dystrophy I-Disease 0 5.2014827815582976e-05
( O 0 1.1948117495386157e-10
DMD B-Disease 1 0.9999998807907104
) O 0 2.2367357965791257e-11
in O 0 1.8241676141080194e-15
order O 0 4.959282614967362e-15
to O 0 1.709753374825669e-17
find O 0 1.3244765146222244e-15
a O 0 1.54460335340943e-18
molecular O 0 2.450222000340967e-16
explanation O 0 2.1321940173481325e-17
for O 0 1.4562899819289257e-16
the O 0 4.762035153683085e-14
cognitive B-Disease 0 7.1163426262899065e-09
impairment I-Disease 0 1.2605191196390919e-11
observed O 0 1.5880666668298925e-14
in O 0 1.2141660374727576e-15
most O 0 1.1690182676049599e-11
DMD B-Disease 1 0.9999998807907104
patients O 0 4.465390190944163e-08
. O 0 2.351861327215543e-12

Complete O 0 1.6506580987046132e-13
analysis O 0 1.0900630475574411e-14
of O 0 8.207967634575884e-17
the O 0 9.140943985729954e-17
dystrophin O 0 6.18413263306361e-12
gene O 0 1.99673350770313e-12
was O 0 3.347046945156862e-11
performed O 0 1.0204947238807993e-13
to O 0 2.4498001051413407e-17
define O 0 2.246077943860586e-14
the O 0 3.616858478044444e-16
localization O 0 3.9350052621726916e-13
of O 0 1.3911875589985522e-16
deletions O 0 9.73563868411631e-11
and O 0 8.427653648730715e-13
duplications O 0 2.44969683427243e-10
in O 0 7.363418876137203e-16
relation O 0 6.121179138649652e-14
to O 0 4.944960876016068e-16
the O 0 4.479586681113571e-15
different O 0 1.2284145055330153e-12
DMD B-Disease 1 0.9999943971633911
promoters O 0 5.446341688752909e-08
. O 0 1.2164401430592164e-11

Qualitative O 0 7.150294939473056e-11
analysis O 0 5.45931789358578e-13
of O 0 8.988115419243637e-16
the O 0 2.7076221310613074e-15
Dp71 O 0 2.3281787608908644e-09
transcript O 0 2.5503078381755584e-12
and O 0 6.046182163873398e-15
testing O 0 2.4817706212581364e-14
for O 0 2.1278771478468561e-19
the O 0 2.0598293286256374e-20
specific O 0 4.454494260629351e-19
first O 0 1.120711277745635e-16
exon O 0 4.2073197139766427e-13
of O 0 3.5438338088979605e-15
Dp140 O 0 5.947123349336891e-11
were O 0 9.400956575700281e-13
also O 0 2.305359408146662e-13
carried O 0 1.0715326195787078e-11
out O 0 9.181695403981394e-09
. O 0 4.339833614003252e-12

Neuropsychological O 0 1.5169496236921987e-06
analysis O 0 7.752247628556308e-12
assessed O 0 5.828984517286528e-10
verbal O 0 9.512479692830311e-09
and O 0 2.4768585077904193e-13
visuospatial O 0 1.1752037565315732e-08
intelligence O 0 1.3201777449012297e-09
, O 0 1.4196725358608855e-14
verbal O 0 6.262369789400424e-11
memory O 0 7.749667574330488e-10
, O 0 5.4757925488846046e-14
and O 0 3.3360814111205173e-13
reading O 0 6.319852641212265e-09
skills O 0 1.2775177538060234e-07
. O 0 1.288703844158634e-12

Comparison O 0 2.985145550887802e-12
of O 0 5.546571850154947e-16
molecular O 0 4.2335319277997385e-12
and O 0 3.4957098522282737e-13
psychometric O 0 1.0403589101315447e-08
findings O 0 1.6211854992134733e-12
demonstrated O 0 1.56072867845726e-14
that O 0 1.4622066725016195e-17
deletions O 0 3.3201750810479824e-12
and O 0 7.6365627553086e-15
duplications O 0 1.9906741532960126e-10
that O 0 2.8044008630080663e-13
were O 0 4.568951621664215e-14
localized O 0 2.9722359014099087e-13
in O 0 2.4182052137259387e-16
the O 0 2.1957783322438997e-16
distal O 0 2.218718698349109e-12
part O 0 2.556348992351857e-14
of O 0 6.425964500019016e-17
the O 0 2.7301690363864737e-16
gene O 0 2.83466869768767e-12
seemed O 0 2.308464800337886e-14
to O 0 4.926936709730211e-18
be O 0 1.2044692042925903e-15
preferentially O 0 6.567031532282719e-13
associated O 0 1.4951783572098726e-13
with O 0 1.5984253851075714e-11
cognitive B-Disease 0 1.4769858580621076e-06
impairment I-Disease 0 1.4740953702130355e-07
. O 0 1.9767937287085147e-12

Two O 0 6.850644617556467e-12
altered O 0 2.7829964999170897e-09
Dp71 O 0 5.950899506501628e-08
transcripts O 0 2.9403482426637595e-10
and O 0 1.2394985482878235e-14
two O 0 6.3534948756810005e-18
deleted O 0 1.3837058397952323e-13
Dp140 O 0 7.828778586776303e-14
DNA O 0 1.0868161161607312e-14
sequences O 0 8.865628631719153e-16
were O 0 7.302688731401438e-16
found O 0 1.3288744155634871e-15
in O 0 2.4169588841533928e-17
four O 0 5.574005883593469e-13
patients O 0 1.3209005829233067e-13
with O 0 1.4077672187695622e-11
severe O 0 5.2663170208688825e-05
cerebral B-Disease 0 0.00024128498625941575
dysfunction I-Disease 0 7.033194833638845e-06
. O 0 2.0660004956818412e-11

These O 0 2.286972863960613e-14
findings O 0 7.726494276197662e-14
suggest O 0 1.847804915534098e-15
that O 0 9.227541979007468e-19
some O 0 1.9819399988195983e-19
sequences O 0 1.8163271595108784e-16
located O 0 1.1538560634304779e-13
in O 0 1.0594946846352395e-16
the O 0 1.5330692503455672e-17
distal O 0 4.850101440259658e-13
part O 0 3.779999045976784e-14
of O 0 1.3258608046860543e-16
the O 0 2.589767237329765e-16
gene O 0 1.4334636993032501e-12
and O 0 2.4268874670302365e-12
, O 0 1.512950067178685e-17
in O 0 1.7475353662919112e-19
particular O 0 2.4931678611685158e-17
, O 0 3.216467823674684e-18
some O 0 3.5842913847114965e-17
DMD B-Disease 1 0.9999986886978149
isoforms O 0 2.885707948638294e-12
expressed O 0 9.016598774037876e-13
in O 0 3.611152599413943e-15
the O 0 3.552662450247851e-13
brain O 0 1.70737834537249e-07
may O 0 1.0663940433822128e-12
be O 0 7.964605142662373e-17
related O 0 9.423274360730797e-16
to O 0 2.978986923406115e-15
the O 0 6.1338659845810994e-12
cognitive B-Disease 0 2.041809466390987e-06
impairment I-Disease 0 1.0989323229182446e-08
associated O 0 5.016234281250698e-13
with O 0 2.978454705093725e-10
DMD B-Disease 1 0.9999998807907104
. O 0 4.784065157914519e-11
. O 0 2.4884436525263176e-11

I1307K O 0 3.1735410743749526e-07
APC O 0 1.5784947038355313e-07
and O 0 1.5113734916361032e-12
hMLH1 O 0 1.1836118751773483e-09
mutations O 0 1.977477383230397e-11
in O 0 3.1815579232364146e-16
a O 0 1.183378634477374e-14
non O 0 5.259829904957769e-08
- O 0 6.290798637564876e-08
Jewish O 0 6.656598015852833e-12
family O 0 3.085972883482002e-12
with O 0 7.686452169197722e-11
hereditary B-Disease 1 0.9999473094940186
non I-Disease 1 0.9999990463256836
- I-Disease 1 0.999997615814209
polyposis I-Disease 1 0.9999836683273315
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 1.3831807921249606e-09

We O 0 6.908022764928745e-12
describe O 0 4.2141463929556977e-13
a O 0 9.042880376800011e-13
French O 0 4.846728529628308e-07
Canadian O 0 2.062243947875686e-05
hereditary B-Disease 1 0.9999765157699585
non I-Disease 1 0.9999990463256836
- I-Disease 1 0.9999996423721313
polyposis I-Disease 1 0.9999986886978149
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 6.239557848175536e-08
HNPCC B-Disease 0 0.010569097474217415
) O 0 2.1395528577994316e-12
kindred O 0 2.439370483386938e-09
which O 0 5.3601390090796813e-14
carries O 0 4.985672790412676e-13
a O 0 1.6792844284251843e-15
novel O 0 4.671555243335179e-12
truncating O 0 3.984522223277054e-08
mutation O 0 1.6595922414097686e-09
in O 0 2.8699308554647196e-13
hMLH1 O 0 3.224027125270368e-07
. O 0 8.512846677577457e-12

Interestingly O 0 1.8241338994862133e-10
, O 0 6.213788808311343e-15
the O 0 3.833901671053294e-16
I1307K O 0 1.411822134894658e-11
APC O 0 1.8455967656927363e-11
polymorphism O 0 1.6873585861887364e-12
, O 0 8.196577688413274e-17
associated O 0 3.4287238577808936e-17
with O 0 5.838485608860585e-18
an O 0 2.672383125235805e-16
increased O 0 1.0754244605948315e-08
risk O 0 0.0009216303587891161
of O 0 8.250455721281469e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.011500766981646e-12
is O 0 2.9196496565894736e-13
also O 0 5.382129204117847e-12
present O 0 4.744870200413566e-15
in O 0 6.129686271703753e-17
this O 0 1.6249011015631956e-15
family O 0 2.332446518912845e-12
. O 0 6.908036642716553e-12

The O 0 5.585850792327873e-13
I1307K O 0 1.0081884216361914e-09
polymorphism O 0 5.18498222135122e-09
has O 0 1.5018059018601093e-10
previously O 0 1.6003656733154514e-11
only O 0 1.79735309209679e-15
been O 0 9.25721630427867e-14
identified O 0 3.0920394283179276e-13
in O 0 8.959903266399658e-17
individuals O 0 2.8996194280286186e-14
of O 0 1.375288636229141e-13
self O 0 8.524368240614422e-06
- O 0 2.7000229238183238e-05
reported O 0 2.3568563847220503e-06
Ashkenazi O 0 1.8951475944106733e-09
Jewish O 0 5.692730900390408e-13
origins O 0 1.09752864348861e-12
. O 0 2.578653002932585e-12

In O 0 8.572440310774046e-14
addition O 0 6.420522615088395e-14
, O 0 2.640664653036888e-16
in O 0 1.0523961473546514e-18
this O 0 2.987152678359671e-18
family O 0 2.153100831306376e-14
, O 0 2.9321978821909714e-15
there O 0 1.870355685447086e-16
appears O 0 3.633699515327021e-14
to O 0 1.5942629669489419e-15
be O 0 2.9935685874615814e-11
no O 0 5.412619679713571e-13
relationship O 0 6.774429243483829e-14
between O 0 5.163013229372233e-17
the O 0 8.808014377089201e-17
I1307K O 0 1.2822211825289087e-12
polymorphism O 0 8.130218503640818e-13
and O 0 3.7377734371166205e-13
the O 0 2.188338587758281e-14
presence O 0 4.3189354870243335e-11
or O 0 2.28237350893834e-12
absence O 0 1.8356674687247665e-12
of O 0 4.493223911564365e-16
cancer B-Disease 0 1.802785004612062e-11
. O 0 3.2013673768947325e-15
. O 0 2.0003120796037444e-13

Identification O 0 3.0784947074175006e-12
of O 0 5.556949062549997e-16
a O 0 1.6324364390108678e-16
novel O 0 2.3487925471764315e-14
mutation O 0 6.488122756068138e-13
of O 0 7.701823096944077e-17
the O 0 4.910111293588066e-16
CPO O 0 1.2614878919237071e-08
gene O 0 3.5412767011334945e-13
in O 0 1.506787968661859e-16
a O 0 6.445614441491498e-14
Japanese O 0 8.225934067240814e-08
hereditary B-Disease 0 2.1785058379464317e-06
coproporphyria I-Disease 0 0.00014505520812235773
family O 0 6.70594746399189e-10
. O 0 3.5564901718077024e-11

Hereditary B-Disease 1 0.9883133172988892
coproporphyria I-Disease 0 0.0701717883348465
( O 0 6.235337246529582e-11
HCP B-Disease 0 1.9889055238309084e-06
) O 0 5.984188296802306e-13
is O 0 5.279094219060032e-13
an O 0 4.6606173781382765e-12
autosomal B-Disease 1 0.9999997615814209
dominant I-Disease 1 0.9999996423721313
disease I-Disease 1 0.9999998807907104
characterized O 0 3.3032894197759788e-09
by O 0 1.7884152004373627e-14
a O 0 1.803073836070812e-11
deficiency B-Disease 0 1.1820685358543415e-05
of I-Disease 0 6.953775213999302e-16
coproporphyrinogen I-Disease 0 2.925805908660095e-08
oxidase I-Disease 0 1.8331290652096044e-10
( O 0 6.931082989584123e-15
CPO O 0 1.364295911798763e-07
) O 0 1.1677722430066266e-15
caused O 0 6.114812902545559e-16
by O 0 3.2490858299743345e-18
a O 0 1.459449626580421e-15
mutation O 0 2.462811042342611e-13
in O 0 1.8939194802952106e-16
the O 0 5.288884734084166e-15
CPO O 0 4.5532630110756145e-07
gene O 0 1.267186876263704e-11
. O 0 3.0467506772699493e-13

Only O 0 1.3059312312102556e-11
11 O 0 4.735653058932088e-13
mutations O 0 2.5933403102924857e-13
of O 0 2.3325204526601023e-17
the O 0 2.0920558391301604e-16
gene O 0 6.746767727827674e-11
have O 0 3.671259910659197e-12
been O 0 4.574098803715454e-13
reported O 0 1.4794971888235087e-12
in O 0 1.0540335694097375e-14
HCP B-Disease 0 0.0003862349840346724
patients O 0 1.374428071354572e-10
. O 0 3.368691230912907e-13

We O 0 3.648144286660937e-10
report O 0 6.814398763148322e-13
another O 0 1.9010210309947703e-15
mutation O 0 2.2383553073112433e-13
in O 0 7.30689266179778e-17
a O 0 6.0069391274271064e-15
Japanese O 0 8.335139245474465e-10
family O 0 1.997871676038751e-13
. O 0 5.141933970623236e-13

Polymerase O 0 2.0605952499863633e-09
chain O 0 1.940718918902462e-09
reaction O 0 1.0962316124296656e-12
- O 0 4.179583762420336e-12
single O 0 1.5362892707114495e-13
strand O 0 5.296163854695557e-11
conformational O 0 4.309312238645613e-13
polymorphism O 0 9.520447581332081e-13
and O 0 1.1690018172086846e-16
direct O 0 3.87737636499006e-17
sequence O 0 8.817301272792677e-15
analyses O 0 1.1212822120451604e-12
demonstrated O 0 7.89985955883081e-15
a O 0 8.263512481836575e-17
C O 0 3.36999579717695e-13
to O 0 3.412115791616503e-16
T O 0 2.0690687010938014e-11
substitution O 0 1.444565060705456e-17
in O 0 9.77288251132413e-19
exon O 0 2.198970206499038e-14
1 O 0 9.225861023925668e-17
of O 0 2.390885685956627e-19
the O 0 7.048174388992834e-18
CPO O 0 6.388149731417769e-11
gene O 0 2.9226609264795984e-15
at O 0 1.2485238113957601e-15
nucleotide O 0 7.571608270917629e-13
position O 0 3.184846275594566e-10
85 O 0 1.5052830943523832e-12
, O 0 8.381429976596876e-15
which O 0 5.0475774140924454e-14
lies O 0 1.7956444664513072e-10
in O 0 1.842174475775462e-15
the O 0 1.0814552049328893e-16
putative O 0 5.016387695858104e-13
presequence O 0 5.820601813033566e-12
for O 0 1.9643066278102874e-17
targeting O 0 2.136301796270071e-13
to O 0 2.0362951572865974e-15
mitochondria O 0 1.3598715903340164e-11
. O 0 1.3880998130447186e-12

This O 0 3.3161447881706633e-15
mutation O 0 8.799048187117797e-13
changes O 0 3.759748859900186e-15
the O 0 7.439501956263096e-18
codon O 0 5.246305234858639e-15
for O 0 9.912327585012554e-19
glutamine O 0 6.36699155160211e-16
to O 0 1.514930999309627e-17
a O 0 5.962304620392423e-16
termination O 0 2.9408615299930663e-12
codon O 0 7.726179071521067e-12
at O 0 3.856612159616399e-14
amino O 0 1.6081697063428935e-13
acid O 0 7.557976813843403e-12
position O 0 4.655502025552316e-11
29 O 0 5.954670784236171e-11
. O 0 7.326207240691829e-13

MaeI O 0 1.3442671331631573e-07
restriction O 0 2.238416049737957e-12
analysis O 0 9.795114751850326e-14
showed O 0 9.624448807366015e-12
two O 0 1.5963060501223886e-17
other O 0 1.403677456852511e-16
carriers O 0 6.530807795598892e-13
in O 0 3.972610578811964e-18
the O 0 1.2052320633407112e-15
family O 0 2.687729162495489e-12
. O 0 2.2691041753897245e-12

The O 0 1.5272835079960245e-11
C O 0 0.00013526798284146935
- O 0 0.24673934280872345
T O 0 0.0008745826780796051
mutation O 0 5.886543336108829e-11
is O 0 6.59052185655179e-13
located O 0 5.865822421975003e-14
within O 0 5.1598236209302284e-17
a O 0 2.479104500353359e-16
recently O 0 9.99818977609479e-12
proposed O 0 6.3337346028731825e-15
putative O 0 1.818125592569983e-13
alternative O 0 1.962503552745934e-15
translation O 0 7.05474852933383e-15
initiation O 0 2.5838557096875825e-13
codon O 0 1.4688476823732088e-10
( O 0 3.6909711398358525e-14
TIC O 0 3.476162246940362e-09
- O 0 1.738799104700206e-10
1 O 0 8.408618887170791e-15
) O 0 2.184690207743198e-17
, O 0 5.58109512637491e-19
supporting O 0 1.0555297895835911e-15
that O 0 3.0428668660353636e-16
TIC O 0 2.8182316924585393e-08
- O 0 7.5503119381648e-12
1 O 0 3.7499355596897713e-16
is O 0 8.699023074345744e-17
the O 0 4.560914251759172e-18
real O 0 1.028330415611678e-12
TIC O 0 1.0560842478302135e-10
rather O 0 2.9738532684710434e-16
than O 0 4.327623941118025e-16
TIC O 0 5.368253064297335e-10
- O 0 3.6354153194750882e-12
2 O 0 7.913492554116868e-15
. O 0 1.9724621985161417e-16
. O 0 1.0477677278857185e-14

Human B-Disease 0 7.474235674820306e-10
complement I-Disease 0 1.589902076659655e-08
factor I-Disease 0 4.6768077481829096e-06
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999897480010986
associated O 0 2.3473582189126319e-07
with O 0 6.808608304709196e-06
hemolytic B-Disease 1 0.9999967813491821
uremic I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999994039535522
. O 0 2.658341102801387e-09

This O 0 2.672659787372202e-15
study O 0 2.3911642692199964e-15
reports O 0 2.7077578257394576e-14
on O 0 8.05087706299678e-15
six O 0 7.719718690245986e-14
cases O 0 1.2747465030164135e-13
of O 0 5.426488793904005e-14
deficiency B-Disease 0 2.2870939631047804e-07
in I-Disease 0 2.7177695245580486e-18
the I-Disease 0 4.4701594691084264e-17
human I-Disease 0 2.3952280791910384e-14
complement I-Disease 0 3.750538223631743e-15
regulatory I-Disease 0 2.5806381703341423e-14
protein I-Disease 0 5.171164603294531e-13
Factor I-Disease 0 4.001179249035758e-11
H I-Disease 1 0.9999998807907104
( O 0 2.0062650271570476e-13
FH O 0 5.762553101362755e-08
) O 0 9.336998364050333e-17
in O 0 8.431788025876861e-20
the O 0 1.996106966074429e-18
context O 0 6.353695781308177e-16
of O 0 1.0395583692642246e-14
an O 0 8.044758192937707e-10
acute B-Disease 1 0.5325132608413696
renal I-Disease 1 0.9999998807907104
disease I-Disease 1 1.0
. O 0 1.5179509871288133e-09

Five O 0 5.47878582779493e-12
of O 0 1.2900931179525674e-16
the O 0 3.5855222294629754e-17
cases O 0 2.6327464514031007e-14
were O 0 5.9759245925469166e-15
observed O 0 3.4094761722550625e-15
in O 0 4.193115175268491e-17
children O 0 1.7274777528580865e-13
presenting O 0 3.017179908693102e-11
with O 0 1.4536393200259567e-09
idiopathic O 1 0.9993743300437927
hemolytic B-Disease 1 0.9999957084655762
uremic I-Disease 1 0.9999997615814209
syndrome I-Disease 1 1.0
( O 0 3.6382016332936473e-06
HUS B-Disease 1 0.999903678894043
) O 0 3.104751788995941e-09
. O 0 5.4889134903923775e-11

Two O 0 6.887531858864801e-14
of O 0 3.2167778178810444e-16
the O 0 3.324732643464638e-15
children O 0 1.7112072175917703e-11
exhibited O 0 2.323529590952944e-09
a O 0 3.0718916993466294e-11
homozygous O 1 0.7283645272254944
deficiency O 0 0.0014012333704158664
characterized O 0 1.075741245078676e-14
by O 0 1.1136581402729668e-16
the O 0 6.874102236189379e-15
absence O 0 1.1697865170013505e-13
of O 0 2.164860393034102e-19
the O 0 3.1721989784472243e-18
150 O 0 8.433666842561183e-17
- O 0 2.854839506612715e-14
kD O 0 9.155196945605931e-14
form O 0 7.381501970769898e-16
of O 0 4.97859496616476e-16
Factor O 0 3.9964580256235394e-11
H O 1 1.0
and O 0 6.52137926993035e-11
the O 0 1.0414589841429211e-15
presence O 0 4.28825405089997e-14
, O 0 3.286969409559556e-19
upon O 0 3.868893296936084e-18
immunoblotting O 0 6.21857556767913e-12
, O 0 1.608046038440716e-18
of O 0 8.448111272042858e-20
the O 0 5.649301461835827e-17
42 O 0 2.487453873521034e-13
- O 0 8.346251641200286e-12
kD O 0 1.5595444380345214e-10
Factor O 0 3.491696654034371e-10
H O 1 0.9999997615814209
- O 0 1.0929845917218017e-09
like O 0 1.9726910805827752e-13
protein O 0 3.985786716951753e-14
1 O 0 2.0310041659815734e-15
( O 0 1.6277540673482257e-16
FHL O 0 8.636985571186528e-11
- O 0 5.172094523497872e-12
1 O 0 7.106415845050448e-16
) O 0 1.467519943089262e-18
and O 0 5.645722747633678e-18
other O 0 1.2758360976123994e-17
FH O 0 3.395638970005166e-08
- O 0 9.949972703399146e-14
related O 0 8.324044341453344e-15
protein O 0 4.479811229547888e-14
( O 0 5.773927669296618e-16
FHR O 0 2.0778018194889114e-10
) O 0 7.115313396765762e-16
bands O 0 6.572119693078193e-13
. O 0 1.2693778320138627e-12

Southern O 0 4.0654701827236295e-10
blot O 0 3.5340050885679375e-08
and O 0 3.215957307652951e-15
PCR O 0 7.477528253703458e-14
analysis O 0 6.694545991729983e-18
of O 0 1.0099804193438577e-20
DNA O 0 1.5655645589597242e-14
of O 0 7.903916720916705e-18
one O 0 2.90023911733283e-14
patient O 0 3.383414728941325e-11
with O 0 3.1893460311974153e-13
homozygous O 0 0.0006006984040141106
deficiency O 0 0.09203770011663437
ruled O 0 1.8765244566565364e-11
out O 0 2.460072978660577e-10
the O 0 3.357534587270124e-14
presence O 0 6.429970759395248e-14
of O 0 4.220391549025246e-19
a O 0 3.686981390984647e-18
large O 0 7.666648068575872e-17
deletion O 0 2.967581042012668e-12
of O 0 1.6903775954189002e-15
the O 0 3.4923022725627875e-14
FH O 0 4.504092885326827e-07
gene O 0 1.0298142547049416e-12
as O 0 8.137419583888054e-16
the O 0 8.21382076459031e-18
underlying O 0 2.317913222471546e-12
defect O 0 1.6135182079324295e-10
for O 0 5.787492372551304e-15
the O 0 5.19985235425402e-11
deficiency O 0 0.00016910361591726542
. O 0 1.591846771585581e-12

The O 0 2.5692328293477158e-15
other O 0 2.4058022690979716e-16
four O 0 8.462034478890542e-15
children O 0 1.0151212146260538e-13
presented O 0 1.201283674314227e-13
with O 0 3.1678793702832886e-12
heterozygous O 0 5.3418691095430404e-05
deficiency O 0 2.432375003991183e-05
and O 0 2.1986764554729303e-14
exhibited O 0 4.340282647175009e-11
a O 0 7.672408173196865e-14
normal O 0 8.737940926373255e-12
immunoblotting O 0 6.97763766766002e-08
pattern O 0 2.750123696479423e-12
of O 0 2.0450740317450676e-17
proteins O 0 6.1570185426039915e-15
of O 0 3.8849438764548383e-16
the O 0 9.759421461079387e-14
FH O 0 0.0001573529589222744
family O 0 4.380886972632503e-11
. O 0 1.7846890415160188e-12

Factor B-Disease 0 0.04025302827358246
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999420642852783
is O 0 6.868027739408145e-13
the O 0 7.275140911791947e-14
only O 0 3.339221521514446e-08
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 1.4893537791937916e-11
with O 0 7.240043200379409e-12
HUS B-Disease 1 0.9977092742919922
. O 0 1.632958351871494e-10

These O 0 3.2890833560553093e-15
observations O 0 3.6760067781633e-14
suggest O 0 2.335168361033025e-14
a O 0 3.193669170893171e-16
role O 0 3.3070399717283205e-13
for O 0 2.0166907914806334e-15
FH O 0 4.5962158765178174e-05
and O 0 2.7619763030492517e-13
/ O 0 8.845483373542962e-11
or O 0 5.233614987242875e-14
FH O 0 2.56365723316776e-07
receptors O 0 2.629118439883421e-14
in O 0 3.438585050094414e-18
the O 0 9.183404655497404e-18
pathogenesis O 0 7.782643886983243e-13
of O 0 5.502970193920322e-15
idiopathic O 0 5.5448278857284095e-08
HUS B-Disease 0 0.03793169558048248
. O 0 2.145032198738739e-12
. O 0 6.2491930033492515e-12

Further O 0 9.676641269957403e-14
evidence O 0 1.491969931930945e-14
for O 0 6.972870513003966e-17
a O 0 1.0451877687605224e-16
major O 0 7.877440290782883e-15
ancient O 0 4.4488162611287796e-14
mutation O 0 7.514791377616348e-06
underlying O 0 4.1943323594750836e-05
myotonic B-Disease 1 0.9999986886978149
dystrophy I-Disease 1 0.9999983310699463
from O 0 2.7638642242922007e-12
linkage O 0 1.4898019706777177e-08
disequilibrium O 0 1.7462788548527897e-08
studies O 0 3.624310270303188e-12
in O 0 2.0498002770673996e-16
the O 0 6.908747471918856e-16
Japanese O 0 5.665875546512211e-10
population O 0 2.0964666837936484e-15
. O 0 3.740881031593507e-14

The O 0 2.8747138003382133e-09
myotonic B-Disease 1 0.999992847442627
dystrophy I-Disease 1 0.9999992847442627
( O 0 4.2511967990321864e-07
DM B-Disease 1 1.0
) O 0 2.757145857110177e-12
mutation O 0 1.1036295141653163e-11
is O 0 1.1018679593960759e-13
an O 0 1.3247323397481189e-14
unstable O 0 5.3047450876420044e-08
( O 0 6.94320631804829e-14
CTG O 0 5.958469273537048e-10
) O 0 8.612687758889192e-15
n O 0 2.1431032296015395e-11
repeat O 0 2.8766775628241703e-09
, O 0 3.713143074263181e-14
present O 0 1.6454226981719175e-15
at O 0 6.30764598809775e-15
a O 0 2.624473684424571e-18
copy O 0 7.80118767436562e-14
number O 0 2.8555201822891285e-14
of O 0 9.92300685895189e-17
5 O 0 3.781080876457017e-14
- O 0 1.4462822606198245e-10
37 O 0 1.0680632810469715e-12
repeats O 0 3.87537710255792e-11
on O 0 4.409754625258472e-13
normal O 0 3.237374747482513e-15
chromosomes O 0 3.984622131352573e-15
but O 0 1.4194421379361486e-18
amplified O 0 2.0220522982785163e-15
to O 0 1.170964526550732e-18
50 O 0 2.4308100235105933e-17
- O 0 1.288171687239192e-14
3000 O 0 6.727140961049574e-16
copies O 0 1.2507472271425235e-12
on O 0 3.6280010817790753e-07
DM B-Disease 1 0.9999995231628418
chromosomes O 0 1.239091051985497e-08
. O 0 4.4125922533944095e-12

Previous O 0 5.047796902690749e-11
findings O 0 1.1129708266111038e-11
in O 0 1.5157715577487907e-14
Caucasian O 0 8.068638535085881e-10
populations O 0 3.2272670863822683e-13
of O 0 2.003913855336674e-16
a O 0 1.2555569431360603e-11
DM B-Disease 1 1.0
founder O 0 4.393090780041575e-09
chromosome O 0 8.78001628734637e-06
raise O 0 6.259228552130125e-11
a O 0 2.8827216289506637e-15
question O 0 3.1405508347983474e-14
about O 0 5.049264314617616e-17
the O 0 9.85535293538355e-20
molecular O 0 8.522182447293748e-17
events O 0 9.921833585971044e-17
involved O 0 6.127498682062527e-14
in O 0 7.215734049571986e-17
the O 0 4.734471071041006e-16
expansion O 0 2.0905135261761743e-11
mutation O 0 1.2456102121971568e-11
. O 0 8.40760078744951e-13

To O 0 3.7537034163490426e-14
investigate O 0 2.704684132909252e-12
whether O 0 9.594014222392283e-14
a O 0 1.825120287945664e-16
founder O 0 3.23130601052532e-14
chromosome O 0 5.931059809949346e-11
for O 0 6.734950816581495e-15
the O 0 9.292176403330465e-13
DM B-Disease 1 1.0
mutation O 0 9.098217318426194e-11
exists O 0 1.3757812367099463e-14
in O 0 1.40172901637603e-17
the O 0 3.122330732586434e-16
Japanese O 0 2.393068243566887e-10
population O 0 1.1782912374673899e-17
, O 0 2.5268905258172002e-17
we O 0 1.4488996618157793e-14
genotyped O 0 5.290598254631407e-12
families O 0 2.2904866908067914e-18
using O 0 7.233454905270832e-17
polymorphic O 0 5.76322279829955e-12
markers O 0 3.104341783632947e-10
near O 0 9.674473028242758e-12
the O 0 1.115415167185236e-14
( O 0 1.10153322891598e-14
CTG O 0 4.134898534680076e-10
) O 0 1.018642923510853e-14
n O 0 1.845893438101598e-10
repeat O 0 1.0521309690147973e-07
region O 0 1.3053566561005425e-10
and O 0 9.089055029443127e-12
constructed O 0 1.1313588260675189e-10
haplotypes O 0 1.3273161236782016e-08
. O 0 7.2199646435067155e-12

Six O 0 4.24218082537009e-12
different O 0 1.1883359795044745e-15
haplotypes O 0 2.2339815761163173e-11
were O 0 3.823039839345385e-14
found O 0 2.1146181593961755e-12
and O 0 4.417382459820374e-09
DM B-Disease 1 1.0
alleles O 0 5.2250332061021254e-08
were O 0 8.718251814920919e-11
always O 0 5.744237550897591e-12
haplotype O 0 2.97268112903204e-11
A O 0 6.542356066618904e-12
. O 0 1.5935996012378384e-12

To O 0 1.1524873428910096e-14
find O 0 1.0021160401605007e-14
an O 0 5.095040903306607e-18
origin O 0 2.346220118703532e-16
of O 0 7.340893093696159e-17
the O 0 1.6563931512674e-15
( O 0 2.2654292162219104e-15
CTG O 0 3.9213583769015514e-11
) O 0 3.546766766356947e-16
n O 0 1.3556316442661642e-12
repeat O 0 2.6397850919068766e-11
mutation O 0 4.7754196430549456e-12
and O 0 6.010262461195659e-15
to O 0 3.0541902903331123e-18
investigate O 0 4.842516582089515e-15
the O 0 7.231192400859377e-17
mechanism O 0 6.994349997996915e-15
of O 0 1.472791668530639e-18
the O 0 2.0415977225027522e-17
expansion O 0 7.97382416985095e-15
mutation O 0 2.4874704330151527e-15
in O 0 7.906358558084962e-18
the O 0 3.377255356578864e-16
Japanese O 0 1.8765861087288727e-10
population O 0 8.980395508022802e-18
we O 0 1.4010362016586911e-14
have O 0 8.776256597267575e-16
studied O 0 1.9373779720798824e-14
90 O 0 1.920168464877338e-14
Japanese O 0 2.6751990844786633e-08
DM B-Disease 1 0.9999998807907104
families O 0 6.449869935018504e-14
comprising O 0 1.4706219911547053e-14
190 O 0 9.195009527005957e-14
affected O 0 9.859298707309838e-13
and O 0 1.6406350561957994e-14
130 O 0 7.611423156247271e-14
unaffected O 0 7.76693293014219e-11
members O 0 1.197502112661869e-13
. O 0 3.1564543188401795e-13

The O 0 1.4165734286541304e-13
results O 0 6.003486011270376e-13
suggest O 0 1.7493947642496094e-13
that O 0 7.51139553202253e-17
a O 0 5.582612837362822e-17
few O 0 7.138911734676267e-16
common O 0 2.146239213277038e-16
ancestral O 0 6.2018532670515825e-15
mutations O 0 4.938467169923744e-12
in O 0 7.152377440955242e-16
both O 0 2.4318828201197462e-12
Caucasian O 0 5.339041653229515e-09
and O 0 2.9452848580163726e-12
Japanese O 0 9.54467546665505e-11
populations O 0 1.0246324628874776e-15
have O 0 1.3020721159729888e-17
originated O 0 1.1015273876973663e-17
by O 0 1.4722748874429465e-18
expansion O 0 3.4471534682983546e-15
of O 0 7.1047824942129e-18
an O 0 7.177930572089332e-17
ancestral O 0 1.0605346462133625e-11
n O 0 1.352197642745523e-07
= O 0 1.2546166883176113e-10
5 O 0 1.6066491127959825e-13
repeat O 0 1.254724379951e-10
to O 0 1.190368116577023e-12
n O 0 2.1115553749950777e-08
= O 0 1.261087345660883e-10
19 O 0 8.373038373754582e-12
- O 0 4.2843530806413455e-11
37 O 0 1.0031148275305851e-13
copies O 0 3.6107451664019186e-12
. O 0 2.6337185470709512e-12

These O 0 4.507266659038657e-16
data O 0 8.257060975984474e-15
support O 0 5.571340152323847e-16
multistep O 0 2.4977185575890404e-13
models O 0 1.1183274445381031e-10
of O 0 2.08937701802513e-15
triplet O 0 1.366282049275469e-06
repeat O 0 2.7924050224892305e-11
expansion O 0 7.220783758248028e-14
that O 0 1.5739403436734858e-16
have O 0 4.961926945949572e-17
been O 0 2.2656083239855853e-17
proposed O 0 1.5573423691125683e-17
for O 0 6.055804881670681e-16
both O 0 3.7312827827484796e-10
DM B-Disease 1 1.0
and O 0 1.61568500800513e-08
Friedreichs B-Disease 0 5.074293198958912e-07
ataxia I-Disease 0 3.932142078610923e-07
. O 0 7.525517752363098e-14
. O 0 9.00041271980484e-13

The O 0 7.074394611512446e-15
molecular O 0 2.4305149906589385e-12
basis O 0 5.6627504768647086e-11
of O 0 6.181300360452724e-09
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.1096927469035154e-14
the O 0 1.482054564250386e-14
western O 0 2.830562607220033e-12
Cape O 0 1.0541718539758271e-11
, O 0 8.973457725849638e-15
South O 0 2.680035230198663e-12
Africa O 0 5.797345676433752e-12
. O 0 4.167638592090031e-14

Deficiency B-Disease 1 0.9996898174285889
of I-Disease 0 9.451256644714759e-14
the I-Disease 0 1.901608448343691e-15
sixth I-Disease 0 1.30743721404869e-10
component I-Disease 0 5.416884931060129e-13
of I-Disease 0 1.530703414531992e-16
human I-Disease 0 1.0989783302134404e-12
complement I-Disease 0 1.1529678036956148e-12
( O 0 1.4708008209856943e-15
C6 O 0 6.517512224357702e-11
) O 0 7.498630745507407e-16
has O 0 2.835661935297884e-13
been O 0 3.4813193994231995e-12
reported O 0 4.1130432393288174e-12
in O 0 2.788945934726399e-18
a O 0 2.9497075355183755e-17
number O 0 3.556564290578719e-15
of O 0 9.969328807818737e-18
families O 0 1.4223319347651333e-17
from O 0 6.827808097134726e-18
the O 0 5.423195360398491e-15
western O 0 4.870684151142557e-12
Cape O 0 1.6747075948231327e-11
, O 0 5.795117532549077e-14
South O 0 7.201975127379967e-12
Africa O 0 9.613551274489929e-12
. O 0 2.1295199761559025e-13

Meningococcal B-Disease 1 0.5829328894615173
disease I-Disease 0 0.48256319761276245
is O 0 1.409055923155822e-12
endemic O 0 1.3319099989583805e-10
in O 0 1.4846056580809265e-15
the O 0 8.892717020658053e-14
Cape O 0 2.7120208856423744e-11
and O 0 1.856651115876985e-15
almost O 0 7.932188099892543e-18
all O 0 7.220387436825964e-17
pedigrees O 0 2.452144173478721e-12
of O 0 6.330452519609162e-14
total O 0 7.250169801409356e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 5.456790835162151e-12
C6Q0 O 0 1.0215663905910333e-06
) O 0 7.477096944526716e-15
have O 0 2.7078597238030123e-15
been O 0 2.278194638011743e-15
ascertained O 0 1.452016133197953e-12
because O 0 8.032632718701915e-13
of O 0 8.234626088649e-13
recurrent O 0 0.04973501339554787
disease O 0 0.0024180812761187553
. O 0 1.1801796519217422e-11

We O 0 2.5654672830555114e-11
have O 0 1.593934529923644e-15
sequenced O 0 8.167660883566519e-13
the O 0 1.286451670372762e-16
expressed O 0 2.507810711633603e-16
exons O 0 5.543597265261768e-13
of O 0 3.634613827174834e-18
the O 0 1.2255048043165079e-17
C6 O 0 4.270741746359441e-12
gene O 0 5.0193495329054275e-15
from O 0 2.6163681416021638e-17
selected O 0 6.62548154902777e-14
cases O 0 2.1441843526398552e-13
and O 0 5.538440257628341e-13
have O 0 1.3300980054777728e-13
found O 0 8.986508809500932e-15
three O 0 2.0302761411634083e-15
molecular O 0 3.5162626282891907e-11
defects O 0 0.014692998491227627
leading O 0 1.0694021224111339e-09
to O 0 5.058177141026299e-11
total O 0 0.0003083756600972265
deficiency O 1 0.9994434714317322
879delG O 0 1.2405498637235723e-06
, O 0 2.189407204524537e-14
which O 0 2.551350058007046e-15
is O 0 1.6806502478768082e-14
the O 0 7.996483359981187e-16
common O 0 1.0803503274273152e-12
defect O 0 1.809444816203154e-10
in O 0 9.8730908103235e-17
the O 0 1.3430169858706133e-14
Cape O 0 1.7634704460589568e-11
and O 0 1.1698997991877163e-14
hitherto O 0 4.4988741464829785e-13
unreported O 0 6.011788289406184e-11
, O 0 4.3529294209941616e-13
and O 0 4.090511349780224e-12
1195delC O 0 9.002322798323803e-08
and O 0 3.628225107507599e-12
1936delG O 0 1.3509540153222588e-09
, O 0 3.1207827798753265e-16
which O 0 1.5178761593370098e-16
have O 0 4.666857110718729e-14
been O 0 3.090229623841506e-13
previously O 0 1.0204943834413172e-10
reported O 0 1.5553708321291992e-10
in O 0 4.5755618667845874e-14
African O 0 1.5823273247228542e-11
- O 0 2.677714494581096e-09
Americans O 0 1.896809098678176e-11
. O 0 1.519549866794631e-13

We O 0 1.6127828239564934e-10
also O 0 8.270964174780706e-15
show O 0 7.797289967555535e-14
that O 0 9.65815024425731e-17
the O 0 4.431467533473442e-16
879delG O 0 6.250373019156541e-08
and O 0 9.561648348088703e-13
1195delC O 0 3.856366603827155e-08
defects O 0 0.00030025746673345566
are O 0 2.117993390873406e-15
associated O 0 2.4959204336969616e-15
with O 0 7.80800527315148e-14
characteristic O 0 1.8475426744046786e-09
C6 O 0 0.0005187811912037432
/ O 0 0.0002585062466096133
C7 O 0 1.1905579412996303e-05
region O 0 1.187364095933674e-11
DNA O 0 4.167569844781838e-09
marker O 0 1.351616276679124e-07
haplotypes O 0 1.5168135636400848e-09
, O 0 1.069293376174292e-14
although O 0 2.4906119723374005e-16
small O 0 1.9061851367642955e-14
variations O 0 1.590561710118621e-10
were O 0 6.918074446637945e-11
observed O 0 1.3599806177044815e-11
. O 0 2.2551550470789605e-12

The O 0 8.143709664953924e-12
1936delG O 0 2.0785894605523936e-07
defect O 0 1.648521788411017e-06
was O 0 9.099908326870576e-13
observed O 0 5.862910915625406e-15
only O 0 2.843077469464288e-16
once O 0 3.922640749547124e-13
in O 0 1.5469280659388522e-16
the O 0 1.3544542176475039e-14
Cape O 0 7.660337641990367e-12
, O 0 1.2890994424263197e-16
but O 0 3.6636117188826764e-17
its O 0 2.2770020751790132e-17
associated O 0 7.494369640387126e-16
haplotype O 0 6.54337640928343e-13
could O 0 1.690708987742151e-12
be O 0 4.343754360109503e-14
deduced O 0 1.8354441230772345e-11
. O 0 9.816966033485142e-13

The O 0 2.3289664281448763e-15
data O 0 6.094954320976301e-14
from O 0 9.024253285844854e-17
the O 0 3.036800389597349e-17
haplotypes O 0 1.2732971794993109e-11
indicate O 0 9.905705812898735e-13
that O 0 1.0878982007508486e-15
these O 0 9.367858818343461e-17
three O 0 5.811917414618329e-15
molecular O 0 1.4399314206270386e-11
defects O 0 2.286566768816556e-06
account O 0 8.315348701216831e-15
for O 0 7.280138406180747e-14
the O 0 3.721392551753189e-12
defects O 1 0.8315376043319702
in O 0 9.693700217053573e-16
all O 0 1.7101801881103454e-14
the O 0 4.4309267558761793e-16
38 O 0 2.323706548360005e-13
unrelated O 0 6.222392935108234e-13
C6Q0 O 0 2.552006890255143e-07
individuals O 0 3.0727575432015763e-12
we O 0 1.9727126876478707e-10
have O 0 1.0874864919165061e-13
studied O 0 1.158082690074641e-13
from O 0 3.359114769584874e-15
the O 0 3.666371270168514e-14
Cape O 0 1.054341267070491e-10
. O 0 9.52131927987876e-13

We O 0 2.717263747342713e-09
have O 0 1.938798378569792e-13
also O 0 1.5485999501580546e-15
observed O 0 1.2996667078389091e-15
the O 0 3.4329006566531433e-16
879delG O 0 1.4881831766899722e-08
defect O 0 1.8975574889168456e-08
in O 0 6.292265140325033e-15
two O 0 1.5284265519888152e-10
Dutch O 1 0.9997833371162415
C6 B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
deficient I-Disease 1 1.0
kindreds O 0 2.3154627797339344e-06
, O 0 1.862830221227205e-15
but O 0 1.8857072642610086e-17
the O 0 1.7291553924014676e-17
879delG O 0 5.155100790688039e-10
defect O 0 6.18077811154194e-10
in O 0 1.2850440074935437e-16
the O 0 1.339148713455445e-15
Cape O 0 1.6535106617254769e-12
probably O 0 1.6180191951889467e-12
did O 0 9.51096840173804e-14
not O 0 1.0836321193120023e-15
come O 0 4.871549906906077e-15
from O 0 1.203012969367803e-16
The O 0 2.7758843045222947e-15
Netherlands O 0 3.6400679692683013e-10
. O 0 1.3916347288672314e-14
. O 0 2.198518331362337e-13

Complement B-Disease 1 0.9993878602981567
C7 I-Disease 1 0.9999997615814209
deficiency I-Disease 1 1.0
: O 0 4.224900811145016e-12
seven O 0 2.1121623059502243e-13
further O 0 2.27247149049703e-14
molecular O 0 1.205746880117431e-08
defects O 1 0.9999969005584717
and O 0 3.599263942444253e-11
their O 0 2.648480766024707e-14
associated O 0 2.013134125546101e-13
marker O 0 1.4710843743159785e-07
haplotypes O 0 5.907371587454691e-07
. O 0 2.544547905714012e-10

Seven O 0 2.1600054644216327e-12
further O 0 9.550629364240507e-15
molecular O 0 2.134178077317639e-11
bases O 0 5.89943283557659e-07
of O 0 1.1674601729794176e-08
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 3.5933905590673776e-12
described O 0 9.772916850780966e-12
. O 0 8.119696321556846e-13

All O 0 4.159839790338071e-14
these O 0 8.694146017454131e-17
new O 0 8.654712451534267e-15
molecular O 0 1.1923427739937709e-12
defects O 0 6.325371941784397e-07
involve O 0 1.8192416092999673e-14
single O 0 2.8408063661861105e-12
- O 0 1.7658047246627007e-09
nucleotide O 0 3.864171135847805e-12
events O 0 3.178370855893252e-14
, O 0 4.3621651506136673e-16
deletions O 0 7.080723594260485e-12
and O 0 1.2321737597256743e-12
substitutions O 0 3.275376931483054e-13
, O 0 4.9278977281658754e-17
some O 0 2.9688175996969737e-18
of O 0 2.332182466661813e-17
which O 0 1.172460430609243e-13
alter O 0 4.909880488290774e-11
splice O 0 3.213356691844638e-08
sites O 0 2.5463711139650513e-08
, O 0 1.047173415688607e-12
and O 0 1.2600611201153689e-13
others O 0 1.2424982646485477e-13
codons O 0 2.73949363194248e-10
. O 0 3.024378707541797e-13

They O 0 6.134649645911372e-12
are O 0 1.0697615180493497e-16
distributed O 0 4.65927214772826e-17
along O 0 3.270006945885369e-14
the O 0 1.3036837615912626e-15
C7 O 0 1.749372557924289e-08
gene O 0 1.0932879601632806e-11
, O 0 8.997823475610355e-16
but O 0 3.7186940067448276e-17
predominantly O 0 2.8306215852771173e-16
towards O 0 8.71258174249068e-15
the O 0 8.587917127379687e-15
3 O 0 4.594910064416313e-13
end O 0 4.7191656832312745e-11
. O 0 7.532529287812562e-13

All O 0 2.2799980219784244e-12
were O 0 3.5837360910871e-14
found O 0 7.264932131898459e-15
in O 0 2.0763285548820162e-17
compound O 0 1.6904815898889994e-14
heterozygous O 0 2.45151510203101e-10
individuals O 0 1.1679924605614844e-12
. O 0 9.967262475443772e-13

The O 0 6.476831293511509e-10
C6 O 0 0.0027491275686770678
/ O 0 0.0004474269226193428
C7 O 0 0.00027590105310082436
marker O 0 1.6785526213425328e-06
haplotypes O 0 1.761443542136476e-07
associated O 0 6.509946054444882e-11
with O 0 4.829478830736811e-13
most O 0 3.635651241867821e-12
C7 B-Disease 1 0.9997808337211609
defects I-Disease 1 0.9999942779541016
are O 0 7.684268499286162e-11
tabulated O 0 1.3112906344758812e-05
. O 0 2.1934282393317427e-14
. O 0 6.357050844930934e-13

A O 0 1.076477123586328e-12
genome O 0 5.4360248941121014e-12
- O 0 7.876194141331894e-11
wide O 0 6.200177497068735e-14
search O 0 1.5635345174466872e-15
for O 0 8.212289487840351e-17
chromosomal O 0 2.233821794206392e-09
loci O 0 6.04868585774021e-11
linked O 0 1.1252829068553183e-07
to O 0 7.150185998838765e-11
mental O 0 4.583880945574492e-05
health O 0 1.2249623537741172e-10
wellness O 0 1.8785467972848302e-12
in O 0 1.538758267726462e-17
relatives O 0 8.092286492084792e-16
at O 0 2.862057921389216e-14
high O 0 1.76279865704565e-10
risk O 0 2.432095191906569e-09
for O 0 2.2674212767775925e-12
bipolar B-Disease 0 0.012991989962756634
affective I-Disease 0 1.3345199477043934e-05
disorder I-Disease 0 1.5759917459945427e-06
among O 0 4.8109942509574465e-15
the O 0 1.74162357577173e-14
Old O 0 1.9508295281411847e-06
Order O 0 8.006510385238919e-12
Amish O 0 4.072381898367894e-07
. O 0 6.5795732577533794e-12

Bipolar B-Disease 1 0.9985740184783936
affective I-Disease 1 0.994541585445404
disorder I-Disease 1 0.9997780919075012
( O 0 8.844095589211065e-08
BPAD B-Disease 1 1.0
; O 0 1.4958111933083273e-05
manic B-Disease 1 0.999998927116394
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 0.9999500513076782
) O 0 5.333310290796256e-13
is O 0 1.5234863761840302e-15
characterized O 0 1.1240943538067482e-15
by O 0 1.471910659139724e-17
episodes O 0 1.2262854620637142e-10
of O 0 5.544356139019872e-14
mania B-Disease 0 4.246002572472207e-05
and O 0 2.464656811973498e-10
/ O 0 1.6491044974031865e-08
or O 0 5.012564148476617e-12
hypomania B-Disease 0 5.718281499866862e-06
interspersed O 0 1.9373238568931583e-09
with O 0 4.147108885140839e-14
periods O 0 2.314816090545624e-12
of O 0 6.627228605303459e-13
depression B-Disease 0 3.6977971262786014e-07
. O 0 7.476420199083178e-13

Compelling O 0 5.090820993924883e-12
evidence O 0 7.281183577075023e-13
supports O 0 1.3884645386555428e-13
a O 0 8.91469619156241e-17
significant O 0 1.1923175902219413e-16
genetic O 0 1.3111561803728217e-13
component O 0 6.243189125398896e-12
in O 0 3.661962982485736e-17
the O 0 1.7737783122901308e-16
susceptibility O 0 7.980862064965732e-13
to O 0 1.1938144700227027e-13
develop O 0 3.237929746546797e-08
BPAD B-Disease 1 0.9999997615814209
. O 0 2.944999799581183e-11

To O 0 4.422100164346021e-14
date O 0 3.907513635575954e-12
, O 0 9.523193543562467e-16
however O 0 5.1231864681112747e-17
, O 0 9.90533976999286e-18
linkage O 0 2.9261682053111082e-12
studies O 0 1.4094073943950874e-13
have O 0 3.249067952616064e-14
attempted O 0 8.149186756173724e-14
only O 0 1.7893618656350378e-16
to O 0 1.5005636992501934e-17
identify O 0 3.584419477268945e-14
chromosomal O 0 4.685000831727848e-09
loci O 0 4.263546980742827e-12
that O 0 6.482305875887481e-14
cause O 0 1.145042007987939e-14
or O 0 3.958089756016074e-14
increase O 0 7.614632394677828e-14
the O 0 2.9607148980745346e-14
risk O 0 3.82070242110899e-09
of O 0 6.50203157916314e-14
developing O 0 4.1214866541849915e-07
BPAD B-Disease 1 0.9999998807907104
. O 0 3.107556920123322e-11

To O 0 7.376804855440018e-15
determine O 0 1.538226739993681e-14
whether O 0 3.120577797902091e-14
there O 0 5.629173020863529e-15
could O 0 1.4241917107443713e-13
be O 0 2.3739875421925107e-14
protective O 0 3.797721143637689e-13
alleles O 0 4.504241692625775e-16
that O 0 4.315274862491547e-17
prevent O 0 6.418498460454341e-15
or O 0 4.000797072513341e-15
reduce O 0 6.149463262824367e-14
the O 0 1.9887753383962103e-15
risk O 0 5.856217594191193e-11
of O 0 1.360335866202472e-15
developing O 0 3.277734705875446e-08
BPAD B-Disease 1 1.0
, O 0 3.4256664658879996e-16
similar O 0 1.0335854398397361e-18
to O 0 5.632726706234704e-19
what O 0 5.2166846779816135e-17
is O 0 2.150468025266205e-16
observed O 0 1.3267420101187744e-15
in O 0 2.0797700232769308e-16
other O 0 1.72615550325661e-11
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 3.3919631307958694e-15
we O 0 9.54819882013902e-13
used O 0 9.386989796578149e-11
mental O 0 2.7503394903760636e-06
health O 0 4.6969223649329095e-11
wellness O 0 1.699665256628402e-12
( O 0 1.4886946037546782e-15
absence O 0 3.943944644610106e-14
of O 0 7.687126387094945e-15
any O 0 1.121903281386949e-07
psychiatric B-Disease 0 0.001917384099215269
disorder I-Disease 0 5.888528775699342e-08
) O 0 8.500882877392752e-17
as O 0 1.2135547973221952e-15
the O 0 8.817868149592627e-16
phenotype O 0 1.580465576120349e-12
in O 0 3.487823927314337e-17
our O 0 1.035383089757324e-14
genome O 0 2.5903346308198127e-13
- O 0 3.089479783113802e-10
wide O 0 1.4542231134562211e-11
linkage O 0 3.6556183080627136e-10
scan O 0 1.3904708495715568e-09
of O 0 2.083233064542221e-15
several O 0 2.132781739099519e-15
large O 0 5.632250308501563e-13
multigeneration O 0 0.00011629721120698377
Old O 0 2.71067074208986e-06
Order O 0 6.600158245460841e-13
Amish O 0 3.5240144136139406e-09
pedigrees O 0 3.8564362814241804e-10
exhibiting O 0 7.245102434660922e-11
an O 0 2.4942356851648728e-15
extremely O 0 5.846917134483265e-12
high O 0 7.562112713799252e-09
incidence O 0 2.8507841420832847e-07
of O 0 1.278557482109477e-09
BPAD B-Disease 1 1.0
. O 0 7.005582780550412e-10

We O 0 4.0831885095293785e-10
have O 0 5.917511082921892e-15
found O 0 2.124645352366431e-15
strong O 0 6.118589478350232e-17
evidence O 0 1.2925906740068855e-16
for O 0 9.323112979415772e-18
a O 0 1.4953016725014986e-16
locus O 0 8.396615347461278e-11
on O 0 3.5820231225613952e-09
chromosome O 0 1.2032344329782063e-06
4p O 0 5.35505648713297e-07
at O 0 3.5088245243369842e-12
D4S2949 O 0 1.0755356674718719e-11
( O 0 3.5894514035470513e-16
maximum O 0 5.421292924398958e-15
GENEHUNTER O 0 1.1515459696909147e-08
- O 0 2.8098343096694123e-10
PLUS O 0 8.578533716718795e-12
nonparametric O 0 5.126566948732147e-10
linkage O 0 9.780386500679583e-10
score O 0 3.524214253758373e-10
= O 0 1.1190950076345185e-11
4 O 0 5.3377858096016403e-14
. O 0 4.310883658404524e-16
05 O 0 5.266158620287342e-10
, O 0 1.991532176529639e-14
P O 0 3.869237730214081e-08
= O 0 5.546622189323003e-13
5 O 0 2.8941809259358303e-15
. O 0 2.1333982268838872e-17
22 O 0 5.215834071614113e-15
x O 0 1.4313443659486058e-11
10 O 0 4.068611292600173e-14
( O 0 4.3067747545169524e-16
- O 0 6.033196945504082e-12
4 O 0 1.5951126256983326e-14
) O 0 2.6301775910564915e-17
; O 0 5.965825101079448e-18
SIBPAL O 0 4.2814939094082405e-11
Pempirical O 0 3.683927728842518e-12
value O 0 5.077682574400463e-15
< O 0 3.393129283406002e-14
3 O 0 1.42429892393967e-15
x O 0 1.5222288707317233e-11
10 O 0 6.166094246523937e-14
( O 0 2.1590493954641772e-16
- O 0 2.4195203132681975e-12
5 O 0 4.489714230547417e-15
) O 0 1.046148555585615e-17
) O 0 1.1266468776671317e-18
and O 0 1.2713857831988029e-17
suggestive O 0 4.016503858564162e-14
evidence O 0 3.7100808066368844e-16
for O 0 5.1489871413154774e-18
a O 0 9.427512437142825e-17
locus O 0 1.5222580140861197e-11
on O 0 1.943289529293679e-09
chromosome O 0 9.417384717380628e-06
4q O 0 0.0008478043600916862
at O 0 4.486230831268756e-11
D4S397 O 0 3.137107240647197e-11
( O 0 2.7562147701189514e-16
maximum O 0 5.8689079088919665e-15
GENEHUNTER O 0 4.614330961771884e-08
- O 0 3.6663999614106046e-10
PLUS O 0 1.2162869669762877e-11
nonparametric O 0 1.0237212189068146e-09
linkage O 0 8.980106658285081e-10
score O 0 2.429182688334919e-10
= O 0 3.880175260956298e-12
3 O 0 1.21113200780734e-14
. O 0 1.5226780420545536e-16
29 O 0 1.0424305732850692e-12
, O 0 3.083685066126193e-15
P O 0 5.864519891929376e-08
= O 0 1.4007429927336695e-13
2 O 0 6.082242897536855e-16
. O 0 1.951378622016696e-17
57 O 0 3.65420245603508e-14
x O 0 4.4939215543271516e-11
10 O 0 2.694364371370883e-13
( O 0 7.810112288783599e-16
- O 0 1.0957054707994018e-11
3 O 0 9.484659050176553e-15
) O 0 3.110856546350241e-17
; O 0 3.434036590701138e-18
SIBPAL O 0 3.229961437201112e-11
Pempirical O 0 1.5782604173217307e-12
value O 0 3.682502843242383e-15
< O 0 2.3098830723047685e-14
1 O 0 7.385614315728818e-16
x O 0 7.509241145564616e-11
10 O 0 4.1221827383822185e-13
( O 0 2.4883625704668483e-15
- O 0 3.536171008788891e-11
3 O 0 6.885124675931999e-15
) O 0 6.388784468564044e-18
) O 0 1.6434996974283805e-19
that O 0 6.643839199795023e-19
are O 0 9.579846680495081e-17
linked O 0 1.4838734407884857e-10
to O 0 5.7677567583125366e-11
mental O 0 1.6655136278131977e-05
health O 0 9.692066038624603e-10
wellness O 0 1.6272383440707472e-09
. O 0 4.3873712714075086e-13

These O 0 8.556986364057981e-14
findings O 0 1.1210262752803235e-11
are O 0 7.6976938007383e-14
consistent O 0 2.2104334421874094e-14
with O 0 4.133338471993979e-17
the O 0 1.5174925088330046e-18
hypothesis O 0 3.5816684942507643e-16
that O 0 1.5172211315535413e-17
certain O 0 2.9376472421873524e-17
alleles O 0 3.311393653314572e-14
could O 0 3.905916931036535e-13
prevent O 0 1.2160723274722007e-13
or O 0 3.972934770746358e-15
modify O 0 1.7567452484032464e-12
the O 0 1.954133977842467e-14
clinical O 0 4.3900376389682805e-11
manifestations O 0 5.162741328196274e-12
of O 0 1.5976922475985367e-13
BPAD B-Disease 1 1.0
and O 0 1.2755182110177343e-12
perhaps O 0 1.4361379034434434e-15
other O 0 2.2534316297987637e-15
related O 0 7.493505815858725e-10
affective B-Disease 0 0.000827947398647666
disorders I-Disease 0 3.178854240104556e-05
. O 0 2.0013663035861606e-12

Segregation O 0 5.667317850566178e-07
distortion O 0 3.015857828359003e-06
in O 0 5.654162138490904e-10
myotonic B-Disease 1 0.9999850988388062
dystrophy I-Disease 1 0.9999915361404419
. O 0 1.2543303062884092e-09

Myotonic B-Disease 1 0.9999408721923828
dystrophy I-Disease 1 0.9999923706054688
( O 0 9.003436503007833e-07
DM B-Disease 1 1.0
) O 0 2.51564657993697e-10
is O 0 5.02752050060562e-12
an O 0 3.2586286100033668e-12
autosomal B-Disease 1 0.9999960660934448
dominant I-Disease 1 0.9999947547912598
disease I-Disease 1 0.9999997615814209
which O 0 2.416105648883615e-10
, O 0 1.0138282188320701e-14
in O 0 4.2308088031657975e-17
the O 0 1.3720881307082702e-15
typical O 0 1.3674370880414899e-12
pedigree O 0 3.833944273168299e-09
, O 0 7.187880297543814e-16
shows O 0 9.289371707835517e-14
a O 0 6.875226143031267e-16
three O 0 9.272478990955246e-15
generation O 0 3.6360326641921015e-12
anticipation O 0 3.914854551645419e-12
cascade O 0 1.4592479447017581e-09
. O 0 1.0108247789145097e-12

This O 0 1.6340962328935393e-13
results O 0 5.8996913257503e-12
in O 0 3.268563371350286e-12
infertility B-Disease 1 0.9888924956321716
and O 0 3.354726686666254e-06
congenital B-Disease 1 0.9999988079071045
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 3.2542407657487615e-10
CDM B-Disease 0 3.7849750356144796e-07
) O 0 4.903338206383584e-15
with O 0 4.0989515813134145e-17
the O 0 2.1313807333698704e-17
disappearance O 0 6.068261171332523e-11
of O 0 1.0312811368762276e-11
DM B-Disease 1 1.0
in O 0 3.353222647467513e-13
that O 0 1.8395780233305958e-13
pedigree O 0 7.237682808636237e-08
. O 0 1.9200606816288657e-12

The O 0 1.9000640955226097e-15
concept O 0 1.936683405063134e-14
of O 0 2.786842952096075e-16
segregation O 0 1.3271843476644896e-12
distortion O 0 3.2007022032765065e-11
, O 0 7.809542526777673e-17
where O 0 9.709382337240272e-18
there O 0 2.787297363765581e-18
is O 0 3.9623063072033297e-17
preferential O 0 1.3927055309784914e-13
transmission O 0 3.4381544378007944e-13
of O 0 6.132814255190122e-19
the O 0 3.3824349961385487e-18
larger O 0 2.4706267593425273e-16
allele O 0 5.113663263450405e-15
at O 0 1.66760404313529e-13
the O 0 5.950793243586494e-13
DM B-Disease 1 1.0
locus O 0 1.4199497133660088e-09
, O 0 2.7454525198394863e-13
has O 0 2.2747767211561687e-12
been O 0 8.567835026521142e-13
put O 0 2.061974341271977e-10
forward O 0 1.6724458484773663e-09
to O 0 3.988043297426533e-15
explain O 0 2.884869806148854e-13
partially O 0 2.1324568846847747e-11
the O 0 2.1456170411075e-16
maintenance O 0 1.1018711117138924e-11
of O 0 1.870257726086736e-14
DM B-Disease 1 1.0
in O 0 8.939359567524969e-15
the O 0 1.2811338387112218e-15
population O 0 1.7065492543269977e-15
. O 0 1.4459076026328982e-13

In O 0 3.3326070852587875e-14
a O 0 3.589959835073641e-15
survey O 0 1.309785353093007e-11
of O 0 3.230468125533896e-14
DM B-Disease 1 1.0
in O 0 8.095116937889557e-11
Northern O 0 7.911938465499091e-11
Ireland O 0 1.083851302041694e-07
, O 0 1.500551561532757e-14
59 O 0 4.836484945175412e-13
pedigrees O 0 3.2605328159629465e-11
were O 0 1.29345346282575e-13
ascertained O 0 7.162361675971951e-11
. O 0 8.179571928633445e-13

Sibships O 0 5.271229497338936e-07
where O 0 1.82691671036031e-13
the O 0 7.806802242844407e-17
status O 0 3.579785698827696e-15
of O 0 2.382275697377412e-17
all O 0 9.154108677675299e-15
the O 0 6.118733076904571e-16
members O 0 1.8731761728125448e-16
had O 0 1.1811828370868888e-13
been O 0 5.38729768057738e-15
identified O 0 3.968211122109405e-14
were O 0 1.1338272917662921e-15
examined O 0 2.8603126269420576e-13
to O 0 2.7217745262888773e-18
determine O 0 2.2677451631183813e-16
the O 0 3.592161842803816e-17
transmission O 0 7.96954863213628e-12
of O 0 6.079549200415689e-17
the O 0 1.0700686654309139e-14
DM B-Disease 1 0.9999998807907104
expansion O 0 5.655652812394663e-13
from O 0 4.0414923469477004e-15
affected O 0 6.797159948605802e-13
parents O 0 1.6051985858144685e-15
to O 0 3.5737921466324834e-17
their O 0 2.482578817744759e-15
offspring O 0 1.1732596231356363e-12
. O 0 2.8987679905100386e-14

Where O 0 2.1705820734546633e-12
the O 0 1.0609558614678785e-14
transmitting O 0 3.891345556894521e-07
parent O 0 6.966733678837045e-08
was O 0 1.5824587196178186e-09
male O 0 5.284489165702233e-11
, O 0 2.6507989257947527e-15
58 O 0 9.225210656146898e-13
. O 0 9.341805080149632e-14

3 O 0 1.0460984162241616e-10
% O 0 3.067063272734101e-14
of O 0 8.7941433853973e-18
the O 0 6.450179716143139e-17
offspring O 0 3.0511836546925908e-12
were O 0 4.4405642357636665e-12
affected O 0 2.152122013585056e-12
, O 0 2.0388513174329537e-16
and O 0 1.6222378182187912e-15
in O 0 2.8340099590164637e-19
the O 0 1.427609305714191e-18
case O 0 1.0686693670020498e-14
of O 0 1.9384097535008447e-17
a O 0 1.6061548860119186e-14
female O 0 6.1176980148403e-11
transmitting O 0 1.6912405920166407e-09
parent O 0 1.2667042414982177e-10
, O 0 1.2516384785977563e-14
68 O 0 2.0262182556796127e-11
. O 0 1.507233790901119e-12

7 O 0 3.5048568491902188e-09
% O 0 1.3714595865216284e-12
were O 0 2.865861031559752e-13
affected O 0 9.47827233366283e-12
. O 0 2.3277920931964735e-13

Studies O 0 1.6265972943574347e-11
on O 0 1.0694734214975604e-13
meiotic O 0 1.9634746606378428e-10
drive O 0 3.5703368039818884e-10
in O 0 1.2489942619649946e-13
DM B-Disease 1 1.0
have O 0 7.92031045783459e-13
shown O 0 6.386284526920839e-15
increased O 0 4.498747095776055e-16
transmission O 0 1.484741041050952e-12
of O 0 4.757531774640576e-18
the O 0 7.156137175362643e-18
larger O 0 4.072613290341889e-16
allele O 0 3.015466430158695e-14
at O 0 3.0147030163039934e-13
the O 0 2.0453121618232983e-13
DM B-Disease 1 0.9999996423721313
locus O 0 8.958755959298514e-10
in O 0 9.942161026746388e-13
non O 0 4.74688749818597e-06
- O 0 0.0003421054861973971
DM O 1 0.9999985694885254
heterozygotes O 0 2.228031803497288e-08
for O 0 3.3035913956681873e-13
CTGn O 0 5.01806525221582e-08
. O 0 7.25859530901346e-13

This O 0 1.18359926538431e-15
study O 0 3.039409648121586e-16
provides O 0 8.240564506410884e-17
further O 0 4.195304970504103e-18
evidence O 0 5.856426031381227e-16
that O 0 1.4272794211228211e-15
the O 0 2.3070529319400845e-13
DM B-Disease 1 1.0
expansion O 0 2.031806667357472e-11
tends O 0 3.177511693434193e-13
to O 0 1.7052275388221462e-16
be O 0 4.141486280436965e-15
transmitted O 0 2.586940210658195e-11
preferentially O 0 3.730811493074526e-11
. O 0 5.406181687213352e-13

Diagnosis O 0 8.871369936969131e-05
of O 0 3.2942024108528756e-10
hemochromatosis B-Disease 1 0.9999990463256836
. O 0 8.181959998410093e-09

If O 0 1.7437452592972136e-09
untreated O 0 8.16800820757635e-05
, O 0 1.1170435236518284e-11
hemochromatosis B-Disease 1 1.0
can O 0 1.468524533265736e-05
cause O 0 9.665085798360451e-08
serious O 0 0.0012674846220761538
illness O 0 1.746156340232119e-05
and O 0 2.2896287730361786e-12
early B-Disease 0 5.655822625559928e-14
death I-Disease 0 7.958338849034519e-12
, O 0 4.557949680118918e-14
but O 0 1.9671291573192425e-14
the O 0 1.7706061633147516e-14
disease O 0 2.9176474569680977e-08
is O 0 2.1271289037897573e-13
still O 0 5.073992007803563e-12
substantially O 0 2.357242526174197e-11
under O 0 1.278654959691039e-09
- O 1 0.9981182813644409
diagnosed O 0 0.3446210026741028
. O 0 7.92425760426374e-12

The O 0 8.809438774163084e-14
cornerstone O 0 3.9578163663067656e-11
of O 0 4.29098023702862e-17
screening O 0 2.0513443916604646e-13
and O 0 4.129160300001912e-18
case O 0 1.0113461720833651e-18
detection O 0 3.902751619205227e-17
is O 0 2.2512039662347094e-17
the O 0 7.785263142117531e-19
measurement O 0 1.1461963106071393e-13
of O 0 2.968118590720336e-16
serum O 0 3.052838537520586e-11
transferrin O 0 3.153798056043655e-11
saturation O 0 2.0501955168283903e-12
and O 0 1.7438390141621962e-12
the O 0 6.813226062973507e-14
serum O 0 3.973358531084159e-08
ferritin O 0 6.928607945155818e-07
level O 0 1.1035253821845004e-09
. O 0 2.9602321028471268e-12

Once O 0 1.4619364607781904e-09
the O 0 4.938214364470306e-15
diagnosis O 0 3.0175827114842235e-11
is O 0 9.928085880261863e-16
suspected O 0 9.636949016567087e-10
, O 0 8.339077482201213e-15
physicians O 0 6.523908068498466e-14
must O 0 2.2514534182317691e-13
use O 0 7.15298859640251e-13
serum O 0 8.886009936759365e-07
ferritin O 0 0.0001990824966924265
levels O 0 2.4982782633742318e-06
and O 0 2.526370446176429e-09
hepatic O 0 0.00010633016790961847
iron O 0 0.11928680539131165
stores O 0 3.236201280287787e-07
on O 0 1.8127205292373105e-09
liver O 0 3.6884170717677023e-10
biopsy O 0 1.6271887171015464e-09
specimens O 0 7.334246599800809e-13
to O 0 1.8746844208542495e-16
assess O 0 3.1926585940950103e-12
patients O 0 4.223975854554746e-15
for O 0 3.2958229821496525e-18
the O 0 6.381094650173894e-16
presence O 0 3.1826388312977683e-12
of O 0 1.48497479503934e-14
iron B-Disease 0 2.0486400899244472e-05
overload I-Disease 0 5.456806206893816e-07
. O 0 5.479872632052629e-12

Liver O 0 0.10175367444753647
biopsy O 0 0.018001338467001915
is O 0 4.820078711165188e-11
also O 0 1.6679466171404776e-14
used O 0 2.88900597814458e-16
to O 0 5.60441930354319e-17
establish O 0 4.6720761889265314e-14
the O 0 2.471299803252086e-13
presence O 0 1.6679183034717937e-10
or O 0 2.2561627913142424e-11
absence O 0 3.2946231853792085e-10
of O 0 2.9562398536076007e-14
cirrhosis B-Disease 0 8.645944404861439e-09
, O 0 8.724584411111511e-16
which O 0 1.27139677146606e-15
can O 0 2.8973889260042185e-12
affect O 0 4.661259919713778e-11
prognosis O 0 9.253663807440304e-11
and O 0 2.856898474300901e-14
management O 0 5.038512142230278e-12
. O 0 1.4086977840731957e-13

A O 0 5.791448863447929e-14
DNA O 0 1.4926070796006385e-11
- O 0 1.4670921422155203e-10
based O 0 3.8930179745025675e-14
test O 0 1.0650185594540673e-11
for O 0 1.5518322915776841e-18
the O 0 2.7832598951957095e-18
HFE O 0 2.1464167249130028e-11
gene O 0 1.3729789129072502e-14
is O 0 4.5228668387138765e-18
commercially O 0 7.601796711505021e-16
available O 0 9.69557753852622e-14
, O 0 1.5025125698605929e-15
but O 0 4.96988789098346e-15
its O 0 3.643154615891954e-16
place O 0 4.818968303826193e-14
in O 0 2.8035411478600093e-16
the O 0 1.4226922930211418e-14
diagnosis O 0 4.8699480004188445e-09
of O 0 2.0731827983944823e-13
hemochromatosis B-Disease 1 1.0
is O 0 2.3405966054212968e-09
still O 0 4.3373696995141486e-11
being O 0 7.39544016303828e-12
evaluated O 0 2.6315419288103215e-10
. O 0 4.343276226951437e-13

Currently O 0 1.2346350786174298e-07
, O 0 1.3897076336210213e-16
the O 0 1.839340911304904e-19
most O 0 1.1953351802517108e-19
useful O 0 4.749104623996009e-16
role O 0 1.383824424407848e-13
for O 0 2.835342536643529e-17
this O 0 2.5807030914390824e-17
test O 0 3.162484163432566e-11
is O 0 1.0690225810645438e-17
in O 0 6.938310198738102e-21
the O 0 1.1626982521955483e-19
detection O 0 1.3026851732739209e-14
of O 0 3.985351850236633e-15
hemochromatosis B-Disease 1 1.0
in O 0 1.0992754287137557e-13
the O 0 2.3004112534270394e-15
family O 0 5.127987335977469e-13
members O 0 1.3371585671942236e-14
of O 0 3.0074292309837302e-15
patients O 0 6.574895894384796e-15
with O 0 1.2703912225892997e-18
a O 0 3.682133947158964e-17
proven O 0 6.588636971074924e-13
case O 0 3.636273682335045e-13
of O 0 7.461739390160049e-15
the O 0 1.741317159908995e-11
disease O 0 2.6628889827406965e-05
. O 0 1.1210262752803235e-11

It O 0 4.6531690582911e-14
is O 0 3.732141515050327e-15
crucial O 0 4.581372173989573e-13
to O 0 1.4730932944816144e-13
diagnose O 0 0.0002604030887596309
hemochromatosis B-Disease 1 1.0
before O 0 0.009616187773644924
hepatic B-Disease 1 0.9998782873153687
cirrhosis I-Disease 1 0.6726393699645996
develops O 0 1.2747639175358927e-06
because O 0 2.517391243378464e-12
phlebotomy O 0 4.52002814199659e-06
therapy O 0 3.772460566153768e-09
can O 0 3.666155157233675e-10
avert O 0 0.00020166915783192962
serious O 1 0.5910113453865051
chronic O 1 0.9997939467430115
disease O 0 0.0010534529574215412
and O 0 9.612689116922368e-12
can O 0 1.1168284179408072e-11
even O 0 9.559081824705995e-12
lead O 0 2.3994944919891736e-10
to O 0 2.0189009969015514e-14
normal O 0 2.054407425428062e-12
life O 0 1.792699669267428e-12
expectancy O 0 3.609191071007878e-11
. O 0 1.7889318640654082e-16
. O 0 3.5104809548635804e-14

Prevalence O 0 1.0516055226617027e-05
of O 0 1.9169922607317237e-14
the O 0 4.625187833098322e-15
I1307K O 0 7.141735813842587e-11
APC B-Disease 0 6.560975721048301e-12
gene O 0 1.1066474342805166e-12
variant O 0 5.843541622807535e-11
in O 0 2.619686558609155e-15
Israeli O 0 2.6079062520611984e-11
Jews O 0 7.2695295090988e-16
of O 0 4.3357163979431415e-18
differing O 0 9.16934235347343e-16
ethnic O 0 1.3816262510899457e-15
origin O 0 1.9980279366768605e-13
and O 0 9.98534935292561e-11
risk O 0 2.7716563266722005e-08
for O 0 3.4920983882358314e-09
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.580879676639114e-10

BACKGROUND O 0 3.759856497254077e-07
& O 0 2.134873255954517e-08
AIMS O 0 1.2759690548591607e-07
Israeli O 0 6.565669963265464e-08
Jews O 0 8.162058702521069e-12
of O 0 9.05306732357225e-12
European O 0 2.7833807507704478e-06
birth O 0 1.3647873942090882e-08
, O 0 5.4854227713938e-13
i O 0 5.987074169766515e-10
. O 0 9.509316298385134e-18
e O 0 1.1731403608966628e-13
. O 0 2.6150011429218586e-17
, O 0 4.0418582519460245e-17
Ashkenazim O 0 8.327196896439071e-13
, O 0 2.4267149831700883e-17
have O 0 5.5927218050113876e-15
the O 0 5.128192792289155e-13
highest O 1 0.9972111582756042
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 1.8716058036716277e-07
of O 0 2.4386991652968447e-14
any O 0 1.106169461584372e-10
Israeli O 0 6.802857228649373e-07
ethnic O 0 3.011566690469536e-12
group O 0 9.124737770926927e-11
. O 0 3.424732719636836e-12

The O 0 8.813510359896581e-13
I1307K O 0 1.1982744796412703e-09
APC B-Disease 0 4.3064757315747215e-10
gene O 0 2.4878835103159247e-11
variant O 0 1.7062355972541354e-09
was O 0 9.372566091292445e-12
found O 0 5.8746956951849505e-12
in O 0 9.421415335169811e-14
6 O 0 5.672363134756608e-10
. O 0 1.0227128388953788e-12

1 O 0 2.0086869667590435e-11
% O 0 2.2066800697915362e-14
of O 0 2.0922075109672782e-16
American O 0 4.191254981966708e-12
Jews O 0 1.3777427956091978e-14
, O 0 9.04152084656802e-16
28 O 0 1.226610433775581e-14
% O 0 6.102596106642641e-18
of O 0 6.899450226531556e-16
their O 0 1.6330222507576764e-08
familial O 1 0.999994158744812
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 1.2252580283700354e-08
, O 0 2.958184005979786e-15
but O 0 1.9292791089063578e-15
not O 0 2.7637665241239326e-14
in O 0 7.75475010947194e-15
non O 0 1.3328890702268836e-07
- O 0 1.4979740114995366e-08
Jews O 0 2.6962590146673016e-11
. O 0 3.0768157119331896e-12

We O 0 8.194347977941163e-12
assessed O 0 2.4117981917148867e-12
the O 0 1.0584570295701836e-15
I1307K O 0 1.1545445849359126e-10
prevalence O 0 3.970189954571879e-09
in O 0 2.6938684335802657e-15
Israeli O 0 8.154262855220029e-12
Jews O 0 1.7962418907491108e-16
of O 0 1.2913375036506738e-18
differing O 0 1.0834538056417155e-16
ethnic O 0 2.6395066001793136e-16
origin O 0 3.832669926329309e-14
and O 0 9.62389890002413e-12
risk O 0 5.231103550329408e-09
for O 0 1.1399370336562242e-09
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 1.1722318948859112e-10

METHODS O 0 5.925231008965803e-13
DNA O 0 9.803717082937369e-13
samples O 0 2.659957384833645e-14
from O 0 6.2894954980974665e-18
500 O 0 2.868414541022379e-17
unrelated O 0 2.304170173888717e-15
Jews O 0 9.721330220034772e-15
of O 0 4.960041980004576e-14
European O 0 3.8077111241818784e-08
or O 0 1.4920584212596566e-10
non O 0 1.355789095214277e-06
- O 0 2.4342221877304837e-05
European O 0 9.765795283556145e-09
origin O 0 1.3799203479099992e-14
, O 0 1.7286690962280702e-15
with O 0 1.2482851598628712e-16
or O 0 2.5239994488434996e-14
without O 0 4.603605010085809e-16
a O 0 3.546562022611728e-17
personal O 0 1.474890522212835e-12
and O 0 9.048756188789753e-11
/ O 0 6.789914186455803e-10
or O 0 2.9123136736398936e-13
family O 0 3.555713395161225e-13
history O 0 3.45278954082609e-13
of O 0 2.665573086218999e-15
neoplasia B-Disease 0 2.937528831292724e-10
, O 0 1.4402629274267923e-16
were O 0 6.681133307728272e-16
examined O 0 1.2986032605147302e-12
for O 0 7.396892030025917e-16
the O 0 2.6952457091525012e-15
I1307K O 0 4.345888666296149e-12
variant O 0 3.672040292277898e-14
by O 0 5.4749248403925034e-18
the O 0 5.840916196372511e-17
allele O 0 8.741082537693304e-14
- O 0 2.288267839101188e-11
specific O 0 1.3183457960291162e-13
oligonucleotide O 0 1.0161461672097971e-09
( O 0 2.069177945304701e-12
ASO O 0 3.5187817957194056e-06
) O 0 4.828624077084242e-16
method O 0 3.154238209599619e-14
. O 0 1.269818560196978e-12

RESULTS O 0 2.2229156293462893e-09
In O 0 1.4744634973287403e-15
persons O 0 2.0173370776193885e-15
at O 0 2.4239336869603077e-14
average O 0 3.6140973547205135e-10
risk O 0 8.290923005915829e-07
for O 0 1.5064326817082474e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.120903279390074e-12
I1307K O 0 4.9425945107539615e-12
was O 0 1.918302349650583e-13
found O 0 3.481078543910582e-13
in O 0 1.9148787017700874e-15
5 O 0 1.2461133470573205e-12
. O 0 3.1541433419095266e-13

0 O 0 2.7856278048132843e-11
% O 0 3.075498704449217e-14
of O 0 3.0868847860240055e-16
120 O 0 1.4744038238576063e-12
European O 0 1.3099397122573464e-08
and O 0 1.0177200228389527e-11
1 O 0 4.732312089937574e-13
. O 0 1.0396084627927252e-13

6 O 0 1.2577968666604988e-09
% O 0 1.2094660125847034e-13
of O 0 4.589577085688094e-16
188 O 0 1.1845817729505548e-11
non O 0 3.164033302027747e-08
- O 0 7.561209258710733e-06
European O 0 6.601622004609453e-08
Jews O 0 2.900120248117144e-12
( O 0 2.131686076571257e-13
P O 0 5.825089033351105e-07
= O 0 3.2433376730839347e-12
0 O 0 9.695035776253157e-15
. O 0 1.1056450762430431e-16
08 O 0 2.766533096359991e-12
) O 0 3.417797212170652e-15
. O 0 2.0368321761751566e-14

It O 0 4.316501583251364e-13
occurred O 0 1.32234305970369e-12
in O 0 5.607397921371989e-15
15 O 0 6.947687325627172e-13
. O 0 8.252955746102311e-14

4 O 0 1.0800691591095202e-10
% O 0 1.9072117745776856e-13
of O 0 4.007043940499342e-15
52 O 0 9.689995472683677e-10
Ashkenazi O 0 1.8690050751501985e-07
Israelis O 0 3.058051811777318e-09
with O 0 2.691377849750598e-11
familial O 0 0.000939658610150218
cancer B-Disease 0 0.010898496955633163
( O 0 4.1359796143503047e-10
P O 0 0.15411338210105896
= O 0 2.938658205664524e-08
0 O 0 6.408257605117207e-12
. O 0 3.144399074884313e-14
02 O 0 2.1111908055093664e-10
) O 0 1.5051400660629757e-15
and O 0 4.187812206388197e-15
was O 0 4.954872232995622e-13
not O 0 1.0654938616586171e-15
detected O 0 7.637943229277244e-12
in O 0 1.1604535342352146e-16
51 O 0 9.855618057774684e-12
non O 0 4.82183049044238e-09
- O 0 1.0673405270722469e-08
European O 0 1.5824518084794903e-10
Jews O 0 1.2217631183283287e-14
at O 0 5.738310217620612e-13
increased O 0 5.425283486348853e-12
cancer B-Disease 0 4.724238222841848e-10
risk O 0 1.4268312920062698e-10
. O 0 3.862341219421084e-13

Colorectal B-Disease 0 0.38786134123802185
neoplasia I-Disease 0 0.0005702401394955814
occurred O 0 2.563699252888796e-09
personally O 0 1.7375134664376901e-09
or O 0 8.483342067017174e-13
in O 0 2.90301431490539e-16
the O 0 2.3463363210359835e-16
families O 0 5.259126454943872e-16
of O 0 2.0483296491999538e-17
13 O 0 1.6386092244365102e-13
of O 0 2.704998393567628e-16
20 O 0 3.410428948795452e-13
Ashkenazi O 0 1.4856277015876107e-12
I1307K O 0 6.14339362801225e-13
carriers O 0 2.356474797194849e-14
, O 0 1.2602934152615587e-18
8 O 0 2.4217868396038443e-16
of O 0 2.4765890110233605e-17
whom O 0 1.0340159839472562e-09
also O 0 7.786253419794775e-09
had O 0 2.2003643351808932e-09
a O 0 2.0254192542438522e-14
personal O 0 7.940799406913612e-11
or O 0 6.005312913615057e-11
family O 0 6.629453930262486e-13
history O 0 1.8963450601483522e-12
of O 0 1.0272169399805353e-12
noncolonic O 0 8.56692531669978e-06
neoplasia B-Disease 0 1.0874227882595733e-06
. O 0 1.3445670792033848e-11

CONCLUSIONS O 0 4.279767207293617e-09
The O 0 2.618979794317966e-13
I1307K O 0 8.193918321630633e-10
APC O 0 4.568926070813717e-10
variant O 0 4.696728006514661e-10
may O 0 6.639700860519918e-14
represent O 0 1.0075998710891125e-17
a O 0 7.653994852181771e-17
susceptibility O 0 3.833327901522736e-14
gene O 0 9.145571452928714e-12
for O 0 1.956926981572238e-11
colorectal B-Disease 1 1.0
, I-Disease 0 3.7127199643653686e-13
or I-Disease 0 9.959313782741466e-14
other I-Disease 0 5.124741234673047e-13
, I-Disease 0 4.061791701592821e-12
cancers I-Disease 0 3.1807689993001986e-06
in O 0 7.402792788491208e-12
Ashkenazi O 0 3.713307137331867e-07
Jews O 0 8.396167094915086e-11
, O 0 1.654795571404133e-11
and O 0 1.70931532816887e-11
partially O 0 1.2300347407290246e-08
explains O 0 5.326942012495728e-11
the O 0 1.755611308456098e-14
higher O 0 8.269181867026631e-11
incidence O 0 4.508236816036515e-05
of O 0 2.1590150936390273e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.9774486482180293e-10
European O 0 1.3280764221690333e-07
Israelis O 0 2.2686099665492065e-09
. O 0 1.5310568568169258e-12

Systematic O 0 7.034967226815514e-12
analysis O 0 2.2276564002731564e-13
of O 0 6.8726339045753135e-15
coproporphyrinogen O 0 6.984615197325184e-08
oxidase O 0 3.771251755324556e-09
gene O 0 9.618702279112767e-07
defects O 1 0.9994138479232788
in O 0 1.9325378970702634e-12
hereditary B-Disease 0 0.04592166468501091
coproporphyria I-Disease 1 0.9906202554702759
and O 0 3.0945812579119547e-10
mutation O 0 4.675366760409361e-10
update O 0 2.2912235664307445e-08
. O 0 5.554692990294985e-12

Hereditary B-Disease 1 0.9941715598106384
coproporphyria I-Disease 1 0.5806461572647095
( O 0 9.50937328880741e-10
HC B-Disease 0 0.0003443873138166964
) O 0 2.001786106667347e-12
is O 0 1.5508901671582032e-12
an O 0 7.641692140181178e-11
acute O 1 0.9987092018127441
hepatic B-Disease 1 0.9999977350234985
porphyria I-Disease 1 0.9999996423721313
with O 0 0.08368854224681854
autosomal O 1 0.9999978542327881
dominant O 0 0.06267145276069641
inheritance O 0 1.05383560367045e-06
caused O 0 6.141086306143961e-09
by O 0 9.393919798668989e-15
deficient B-Disease 0 3.203345499969146e-08
activity I-Disease 0 6.2688669359711735e-12
of I-Disease 0 4.776396766710371e-15
coproporphyrinogen I-Disease 0 1.4531960914609954e-06
III I-Disease 0 1.4886181531892362e-07
oxidase I-Disease 0 3.845890272913266e-09
( O 0 2.9130858966372464e-13
CPO O 0 2.6259490581992395e-08
) O 0 6.6282335590733994e-15
. O 0 1.2996425462240887e-14

Clinical O 0 7.4405138548172545e-06
manifestations O 0 1.216432732320527e-08
of O 0 1.1266626466412827e-13
the O 0 1.853688860395386e-12
disease O 0 3.1207029678625986e-05
are O 0 1.3168221531635951e-14
characterized O 0 1.962564496766489e-14
by O 0 2.44435226318682e-14
acute O 0 2.1876529388009658e-07
attacks O 0 2.536811471998135e-08
of O 0 3.1975082581681136e-09
neurological B-Disease 1 0.9992582201957703
dysfunction I-Disease 0 1.5325111917263712e-06
often O 0 5.476711410225786e-14
precipitated O 0 2.2844107248204404e-13
by O 0 3.702444539919591e-17
drugs O 0 4.5712314142298816e-12
, O 0 4.8309061691326026e-17
fasting O 0 1.2386624928875656e-13
, O 0 9.940206921737072e-17
cyclical O 0 2.2417875555902356e-08
hormonal O 0 5.0835611276056625e-09
changes O 0 2.8490324249091925e-12
, O 0 1.6399655613542896e-14
or O 0 1.0678810613562462e-10
infectious B-Disease 0 3.3815410915849498e-06
diseases I-Disease 0 3.697112731515517e-07
. O 0 3.9883539179608185e-12

Skin O 1 0.9999274015426636
photosensitivity O 1 0.9980533123016357
may O 0 1.110364610212855e-05
also O 0 3.0350843366333535e-11
be O 0 2.336024982393242e-13
present O 0 9.529035953316153e-14
. O 0 2.8651629679909973e-12

The O 0 2.6881635480958954e-13
seven O 0 6.592106418026877e-13
exons O 0 6.96097207653068e-11
, O 0 6.594080025969804e-17
the O 0 1.210298908552068e-17
exon O 0 2.020858341778009e-10
/ O 0 1.4147239824069402e-07
intron O 0 6.914429917515008e-08
boundaries O 0 1.1830842971960465e-08
and O 0 4.001060821632457e-13
part O 0 7.146350801535528e-16
of O 0 1.017724727222884e-17
3 O 0 3.180126437555555e-16
noncoding O 0 1.0917698358868175e-13
sequence O 0 4.69372243353097e-16
of O 0 9.096241325630241e-18
the O 0 8.108752944928314e-17
CPO O 0 6.168944466367066e-09
gene O 0 3.737286562578539e-14
were O 0 5.645079531989356e-17
systematically O 0 1.620927310018623e-14
analyzed O 0 1.0420631303925502e-15
by O 0 2.910916300986757e-19
an O 0 4.060615668349976e-19
exon O 0 4.822897181448738e-13
- O 0 9.352363718531653e-13
by O 0 1.6545112558168378e-15
- O 0 1.1091674106955551e-10
exon O 0 8.999809231191591e-10
denaturing O 0 7.17818124940095e-08
gradient O 0 1.0043765819034434e-09
gel O 0 2.0092189245701775e-08
electrophoresis O 0 1.8426922487879693e-10
( O 0 5.0273235010708794e-14
DGGE O 0 2.4137347676145282e-09
) O 0 1.8085835578373e-16
strategy O 0 2.809043420945814e-16
followed O 0 2.2294031248825068e-17
by O 0 2.4209138608442076e-20
direct O 0 5.020679744382351e-19
sequencing O 0 2.952650127977137e-14
in O 0 7.333308840095783e-17
seven O 0 3.5914116495452345e-15
unrelated O 0 8.473347891391203e-13
heterozygous O 0 2.2987469705526564e-09
HC B-Disease 0 2.0076857254025526e-05
patients O 0 1.6823983872704673e-10
from O 0 2.068538916544238e-12
France O 0 5.558508178182819e-07
, O 0 1.3263999273926963e-12
Holland O 0 7.278298994606303e-07
, O 0 6.393070534765899e-12
and O 0 3.071764509421371e-10
Czech O 0 1.7083624697988853e-05
Republic O 0 3.400844883483245e-11
. O 0 1.391954802289208e-12

Seven O 0 6.526978957310803e-11
novel O 0 1.5171159467586293e-11
mutations O 0 1.2468903687334887e-09
and O 0 5.784736974373886e-14
two O 0 9.482768102061367e-17
new O 0 1.3584671209384159e-14
polymorphisms O 0 1.054658999022351e-10
were O 0 3.342947663478868e-13
detected O 0 1.2531131687865127e-09
. O 0 2.443693034384631e-12

Among O 0 3.391774057795449e-12
these O 0 7.185303729197385e-16
mutations O 0 6.322398767716342e-12
two O 0 2.8145380177955343e-14
are O 0 1.5468950718879743e-13
missense O 0 1.9865258327200763e-09
( O 0 3.439366101491183e-14
G197W O 0 2.8500667104136568e-11
, O 0 6.966732171114333e-16
W427R O 0 8.361734156643597e-13
) O 0 1.7215938035498754e-16
, O 0 1.2153186540993461e-17
two O 0 1.920841390202284e-15
are O 0 3.4472112664385435e-12
nonsense O 0 1.4386762892115712e-08
( O 0 9.79375916032154e-16
Q306X O 0 4.2267361485825994e-13
, O 0 1.0559198747255814e-16
Q385X O 0 9.458559423972807e-14
) O 0 6.57188048356235e-17
, O 0 2.7193769432833923e-18
two O 0 6.55050613653398e-17
are O 0 8.418627640233785e-16
small O 0 9.23343627780098e-16
deletions O 0 4.788120455678779e-10
( O 0 2.8078957887110734e-13
662de14bp O 0 2.307068598661477e-11
; O 0 5.380106582613428e-16
1168del3bp O 0 5.6065322523446426e-11
removing O 0 3.4460279681874928e-12
a O 0 4.480372727688623e-15
glycine O 0 1.8949432301074154e-11
at O 0 3.0333869097121102e-12
position O 0 7.04375739592894e-13
390 O 0 3.858422099618092e-14
) O 0 1.3834616656075273e-15
, O 0 5.555211056821349e-16
and O 0 2.796926169943044e-14
one O 0 2.5757488420527063e-15
is O 0 4.198625428992846e-15
a O 0 1.9875229737139152e-16
splicing O 0 4.015544841085017e-11
mutation O 0 5.314743090067964e-11
( O 0 2.6928629207685802e-14
IVS1 O 0 3.4482575017591444e-08
- O 0 3.747944732346298e-10
15c O 0 1.326016657587914e-10
- O 0 2.1196154553759783e-10
- O 0 4.904108230618931e-10
> O 0 6.058516860939223e-13
g O 0 1.3601628157111634e-10
) O 0 3.911174369248936e-16
which O 0 1.3734693006468296e-17
creates O 0 5.594447211124945e-16
a O 0 1.0208435786352907e-16
new O 0 1.1982143318452383e-14
acceptor O 0 4.918496030381289e-14
splice O 0 3.400094095162842e-10
site O 0 1.1772126329301358e-10
. O 0 3.4050425239823268e-12

The O 0 7.579002123158166e-14
pathological O 0 4.2846389630701864e-11
significance O 0 3.9100894153347096e-14
of O 0 9.753228369097626e-17
the O 0 1.6579854673291197e-16
point O 0 3.757437340868447e-13
mutations O 0 4.858471481031246e-13
G197W O 0 2.2276405980264924e-12
, O 0 2.3722188354899922e-17
W427R O 0 5.2607071666542146e-14
, O 0 9.781353667977286e-18
and O 0 1.516700338639878e-17
the O 0 1.5829533698023126e-17
in O 0 2.646151679529642e-15
- O 0 2.8808685215153673e-08
frame O 0 1.3151217892470868e-08
deletion O 0 4.5450261332291575e-09
390delGly O 0 7.060177997786354e-10
were O 0 3.3403184732105906e-15
assessed O 0 3.9430400134224386e-15
by O 0 6.450721023135993e-17
their O 0 3.524475972031295e-14
respective O 0 5.721602878983045e-12
expression O 0 4.912456092544303e-15
in O 0 3.2561832464251926e-18
a O 0 2.043085820424735e-17
prokaryotic O 0 4.079503373972211e-15
system O 0 1.5860602601830618e-17
using O 0 2.9872224924033705e-17
site O 0 3.0953440765396634e-13
- O 0 8.179860955248586e-11
directed O 0 1.4700157757729926e-11
mutagenesis O 0 5.911152123339036e-10
. O 0 9.199877838705905e-12

These O 0 5.545180810297319e-14
mutations O 0 6.298113419678231e-11
resulted O 0 4.961937436452624e-13
in O 0 1.83536348384659e-15
the O 0 1.0664662343062414e-14
absence O 0 8.164950920236391e-13
or O 0 8.43508654919012e-16
a O 0 4.681169934648254e-16
dramatic O 0 1.0011498466182267e-13
decrease O 0 5.137603883986763e-12
of O 0 2.7781937398529835e-15
CPO O 0 2.783009949780535e-05
activity O 0 4.80149087156434e-10
. O 0 6.767510271794841e-13

The O 0 2.356978273578697e-14
two O 0 1.757882203787687e-15
polymorphisms O 0 1.6760431584272872e-11
were O 0 3.2563993192360812e-15
localized O 0 1.871479045952723e-13
in O 0 2.3769495740574116e-15
noncoding O 0 3.00976821243637e-09
part O 0 1.784589457546476e-13
of O 0 1.184217440617128e-16
the O 0 3.1272999043110603e-17
gene O 0 2.3028311842056975e-14
1 O 0 5.487535705139242e-17
) O 0 1.3695184792461232e-18
a O 0 9.476909678091022e-17
C O 0 9.289527480582649e-11
/ O 0 1.3957579536594267e-10
G O 0 6.847172828727821e-11
polymorphism O 0 6.410577364085457e-13
in O 0 1.6559825520462185e-15
the O 0 2.5505774792558555e-14
promotor O 0 1.679085315231532e-08
region O 0 2.517956546391198e-13
, O 0 6.449392240199988e-17
142 O 0 1.0144626465095636e-14
bp O 0 9.407305663622356e-13
upstream O 0 1.2563318712178334e-13
from O 0 1.2109922844287345e-16
the O 0 3.1682806238855606e-18
transcriptional O 0 6.673059495554163e-16
initiation O 0 1.8417378832307114e-16
site O 0 3.604425040230376e-14
( O 0 4.408623531342026e-15
- O 0 4.391023569055852e-12
142C O 0 1.030872175816766e-11
/ O 0 7.094363291271222e-12
G O 0 8.846828651598582e-12
) O 0 4.509483304556952e-17
, O 0 6.117979598084596e-18
and O 0 7.516440010270123e-17
2 O 0 1.2446096986162776e-16
) O 0 2.5108426429072426e-18
a O 0 2.5549996119568546e-17
6 O 0 1.8302606609107985e-14
bp O 0 9.842275648999643e-13
deletion O 0 2.482818367132572e-13
polymorphism O 0 1.3538512758787258e-12
in O 0 1.4717324513485557e-15
the O 0 1.350815057056656e-16
3 O 0 1.1802814585057386e-14
noncoding O 0 6.865910184145063e-12
part O 0 3.687478738291028e-15
of O 0 5.570083367188359e-17
the O 0 3.619895091160351e-16
CPO O 0 9.154010327527828e-10
gene O 0 1.1200627522635256e-14
, O 0 4.9411092087553886e-18
574 O 0 3.3833435117663728e-15
bp O 0 8.757086039385548e-14
downstream O 0 1.2276362923186596e-13
of O 0 3.410773707616248e-17
the O 0 2.36787107492874e-16
last O 0 4.2446393080063094e-13
base O 0 2.5557556288316463e-13
of O 0 7.756571865583247e-18
the O 0 4.468508019559077e-16
normal O 0 8.372327082919323e-14
termination O 0 9.160284293249776e-13
codon O 0 2.5315100710132654e-11
( O 0 1.2180867412273609e-14
+ O 0 6.093539301615936e-13
574 O 0 7.829357995259301e-11
delATTCTT O 0 8.352469826888864e-10
) O 0 4.199430787919095e-13
. O 0 3.161792930337498e-13

Five O 0 1.9815558915947662e-10
intragenic O 0 2.0036740977502632e-07
dimorphisms O 0 4.80224684906716e-07
are O 0 6.360179852400727e-13
now O 0 7.624141118781069e-13
well O 0 6.8621815180061954e-15
characterized O 0 4.289743134821243e-14
and O 0 2.0201876399484307e-14
the O 0 4.3062487999962666e-16
high O 0 2.918450203726053e-11
degree O 0 8.5445824982816835e-16
of O 0 2.2751450547038316e-16
allelic O 0 1.3111325393444506e-11
heterogeneity O 0 9.410290255362774e-12
in O 0 1.1474688420851174e-14
HC B-Disease 0 2.2650265236734413e-05
is O 0 8.127757147868842e-12
demonstrated O 0 3.536448613334145e-14
with O 0 5.62517425772888e-17
seven O 0 2.8578233072243603e-15
new O 0 5.768930174907818e-16
different O 0 1.476425576359161e-18
mutations O 0 8.815917326835982e-16
making O 0 1.3621585752258449e-15
a O 0 1.402463155713283e-15
total O 0 8.259994928707173e-14
of O 0 3.424466114322622e-15
nineteen O 0 2.7519920564600397e-08
CPO O 0 0.11869748681783676
gene B-Disease 0 1.445292809876264e-07
defects I-Disease 0 0.000999361160211265
reported O 0 1.2092220670958942e-12
so O 0 3.626794333334415e-15
far O 0 2.1868989705611276e-14
. O 0 6.929523178411754e-15
. O 0 2.7149994492187135e-13

Coincidence O 0 1.2294980138161105e-11
of O 0 3.1344930669178215e-15
two O 0 5.10051053584544e-16
novel O 0 1.5680456878688215e-13
arylsulfatase O 0 5.006736003565493e-08
A O 0 1.6203160232812486e-13
alleles O 0 5.404204861392259e-12
and O 0 5.602036846560909e-13
mutation O 0 1.6898942314935717e-11
459 O 0 1.6546984615839477e-10
+ O 0 1.747012604025322e-11
1G O 0 9.867994776868727e-08
> O 0 1.0676361704431425e-11
A O 0 3.758966228561977e-12
within O 0 2.248391360246127e-15
a O 0 9.37691832275829e-14
family O 0 1.071022298626545e-10
with O 0 8.580151984460826e-07
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999997615814209
: O 0 7.542384550035183e-15
molecular O 0 2.9983566610856894e-15
basis O 0 1.0015389566135364e-14
of O 0 1.865027424692383e-15
phenotypic O 0 5.324051866040236e-09
heterogeneity O 0 3.903476653022153e-08
. O 0 1.2070663912844282e-10

In O 0 1.672113917597015e-13
a O 0 7.65303924019859e-15
family O 0 5.444206012655134e-14
with O 0 5.189995839777889e-14
three O 0 4.3464771712353745e-12
siblings O 0 1.222484113938549e-09
, O 0 5.828763258812882e-17
one O 0 4.344112033006371e-17
developed O 0 2.6237245340753057e-13
classical O 0 1.5285366722350702e-11
late O 0 1.6907769406770967e-08
infantile O 1 0.9999781847000122
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999995231628418
( O 0 1.234743063349697e-08
MLD B-Disease 1 0.9999955892562866
) O 0 4.80674311117979e-13
, O 0 1.9486198092377092e-16
fatal O 0 5.822206605721192e-10
at O 0 1.8544978885870478e-09
age O 0 1.2547832106690748e-08
5 O 0 1.9832477674008864e-12
years O 0 4.211559215521604e-13
, O 0 5.044973761867528e-16
with O 0 1.4582038105215994e-14
deficient O 0 4.0520173882896415e-09
arylsulfatase O 0 2.25421112332036e-10
A O 0 6.401388750673642e-13
( O 0 3.617925051343715e-14
ARSA O 0 1.667875437760813e-08
) O 0 1.0816414860068363e-15
activity O 0 1.8901690651031144e-13
and O 0 6.65938522858775e-14
increased O 0 1.7710402372070333e-12
galactosylsulfatide O 0 9.728390750751714e-07
( O 0 1.2576558718058184e-12
GS O 1 0.9999994039535522
) O 0 3.321484526221802e-13
excretion O 0 1.4246338830847805e-10
. O 0 9.262006309476711e-13

The O 0 4.0669585619134904e-14
two O 0 1.4088609226188369e-14
other O 0 8.104339241528629e-15
siblings O 0 3.144862814608018e-09
, O 0 8.551370196804506e-15
apparently O 0 1.4308958748779355e-12
healthy O 0 6.583854121611221e-12
at O 0 5.711353265325236e-12
12 O 0 3.047878247529334e-13
( O 0 9.293610424816211e-17
1 O 0 6.524946255606092e-16
/ O 0 2.3535307817207363e-12
2 O 0 3.728982082157068e-15
) O 0 9.213762349414222e-17
and O 0 3.295916159082573e-15
15 O 0 4.405059640216454e-15
years O 0 1.8063987686987555e-15
, O 0 2.994673073616758e-17
respectively O 0 8.039829212265742e-15
, O 0 7.145614412267009e-16
and O 0 6.492690499820819e-13
their O 0 2.7800078726677654e-14
father O 0 5.291522220396416e-10
, O 0 1.0730321796034725e-14
apparently O 0 8.303090203234942e-13
healthy O 0 4.5683593762274946e-14
as O 0 2.9753511932987034e-16
well O 0 5.481787170458913e-15
, O 0 5.950398513527579e-16
presented O 0 2.111841083951571e-12
ARSA O 0 0.0003324473218526691
and O 0 5.537440017633344e-08
GS O 1 1.0
values O 0 1.384787076674776e-11
within O 0 1.2075923735877946e-16
the O 0 4.055637161892137e-16
range O 0 5.144487266739439e-12
of O 0 1.2911150013700246e-12
MLD B-Disease 1 0.9999984502792358
patients O 0 2.077327421190489e-09
. O 0 4.637887296432552e-13

Mutation O 0 2.0825481339414864e-09
screening O 0 8.579437854594474e-11
and O 0 4.72391756991381e-16
sequence O 0 7.464265427697218e-17
analysis O 0 3.347945369625905e-16
disclosed O 0 4.579475904389896e-13
the O 0 4.792269555336986e-17
involvement O 0 4.58083874652071e-13
of O 0 3.2324246339991995e-16
three O 0 3.779307189465467e-14
different O 0 7.354467749587975e-15
ARSA O 0 2.9475861538230674e-06
mutations O 0 2.5109090154296076e-11
being O 0 1.373333142085792e-13
the O 0 6.228679835294072e-19
molecular O 0 2.1310252045251502e-15
basis O 0 9.159418727221636e-15
of O 0 2.982432018160835e-15
intrafamilial O 0 5.587634177572909e-08
phenotypic O 0 4.250351182122358e-09
heterogeneity O 0 3.7197182223280834e-08
. O 0 1.8757773112554332e-10

The O 0 5.704276894585858e-12
late O 0 6.709001409976878e-11
infantile O 0 0.002340627834200859
patient O 0 2.538574335630983e-06
inherited O 0 2.5799429295148e-06
from O 0 1.840308938225177e-12
his O 0 2.3817559036132252e-11
mother O 0 1.3401142417990286e-08
the O 0 8.091051941564169e-16
frequent O 0 3.019757404201795e-12
0 O 0 4.318988743035046e-13
- O 0 2.477817950818917e-09
type O 0 8.81408279695961e-09
mutation O 0 8.304904680622727e-11
459 O 0 3.6168675693337704e-11
+ O 0 3.478357196457643e-13
1G O 0 5.94023025213275e-11
> O 0 9.006006660913779e-14
A O 0 1.7848718922124085e-13
, O 0 7.817863169646568e-16
and O 0 3.1074676337027258e-15
from O 0 2.5444977732219957e-15
his O 0 1.576464219582574e-12
father O 0 1.2775208668713844e-10
a O 0 5.17848044803579e-16
novel O 0 4.65095084840883e-14
, O 0 2.253705327319845e-16
single O 0 5.1659370547572567e-14
basepair O 0 6.460988410950108e-10
microdeletion O 0 2.0510412812591028e-11
of O 0 2.5708085223878456e-17
guanine O 0 1.134547208785086e-12
at O 0 9.08332128724031e-15
nucleotide O 0 2.9064869001144134e-13
7 O 0 2.522273026290406e-13
in O 0 3.0492108781125023e-16
exon O 0 3.8316304989960415e-11
1 O 0 3.4124873066199157e-12
( O 0 2.2513019348594822e-14
7delG O 0 8.493036829371192e-10
) O 0 5.554178333076233e-14
. O 0 1.0050299351430092e-13

The O 0 8.523337743059078e-13
two O 0 2.4117335732654066e-12
clinically O 0 1.246007172994723e-07
unaffected O 0 1.047401276821347e-08
siblings O 0 5.756541021639805e-09
carried O 0 6.893600967838864e-11
the O 0 1.3645730595826522e-13
maternal O 0 2.043787583616563e-09
mutation O 0 2.3032653909127454e-11
459 O 0 3.7403018182669e-11
+ O 0 1.567050851060403e-12
1G O 0 8.822504948824417e-10
> O 0 5.822575494668358e-13
A O 0 6.952141770252829e-13
and O 0 1.5010762815029222e-13
, O 0 2.8717116829440155e-16
on O 0 6.844306480076334e-13
their O 0 2.5075755816401923e-13
paternal O 0 1.8719093983210477e-11
allele O 0 8.316426974158686e-15
, O 0 1.9038703307153255e-18
a O 0 4.562878702316409e-19
novel O 0 1.6076498991638224e-15
cytosine O 0 1.1305293723742893e-12
to O 0 1.73570550480003e-16
thymidine O 0 9.659686245333532e-12
transition O 0 1.3960059779168088e-13
at O 0 1.1184579467009986e-13
nucleotide O 0 2.5703640604834987e-12
2435 O 0 3.2428195545497474e-11
in O 0 2.0543250211925136e-16
exon O 0 3.468792093841433e-12
8 O 0 1.254742295307698e-12
, O 0 9.430959960499824e-18
resulting O 0 2.4963844356984895e-17
in O 0 1.3008055163395323e-18
substitution O 0 7.368167025202156e-16
of O 0 7.522266670504946e-16
alanine O 0 1.048552022986371e-09
464 O 0 1.50619985234135e-11
by O 0 3.673903764761857e-14
valine O 0 6.117905968494597e-07
( O 0 2.9533612968396517e-13
A464V O 0 1.6448117867717826e-10
) O 0 2.7107032981102397e-14
. O 0 6.180011336660504e-14

The O 0 3.374558011498552e-12
fathers O 0 4.5757805877677526e-10
genotype O 0 3.579562479760767e-10
thus O 0 1.3983840127518299e-12
was O 0 2.0184506843712313e-10
7delG O 0 3.968905275542056e-07
/ O 0 1.184442908197525e-07
A464V O 0 1.51481067689474e-08
. O 0 2.846892209820706e-12

Mutation O 0 3.684061411490802e-08
A464V O 0 6.060575152844194e-09
was O 0 8.01751373624704e-12
not O 0 2.9335483968160296e-17
found O 0 2.1975310551700057e-15
in O 0 1.5597034403658152e-16
18 O 0 5.198002401771151e-13
unrelated O 0 1.6922528656149183e-10
MLD B-Disease 1 0.9999998807907104
patients O 0 4.143567156056349e-10
and O 0 1.838593855749181e-15
50 O 0 3.689392609235349e-15
controls O 0 2.7403415092663863e-09
. O 0 1.0609312039999708e-11

A464V O 0 1.9165263154263812e-08
, O 0 1.9869373616039632e-14
although O 0 5.0556105898609104e-15
clearly O 0 1.8159800919959057e-13
modifying O 0 2.384379915731927e-10
ARSA O 0 0.001624253229238093
and O 0 1.9809155205052775e-08
GS O 1 1.0
levels O 0 5.735272168294614e-08
, O 0 1.1061603369727697e-15
apparently O 0 1.3716341972815072e-13
bears O 0 4.3754899876902176e-12
little O 0 3.042173378985623e-14
significance O 0 5.6785406421283515e-15
for O 0 2.3523779952905116e-15
clinical O 0 1.6626186104956586e-12
manifestation O 0 1.2205602197348786e-12
of O 0 1.1720131972130926e-13
MLD B-Disease 1 0.9999996423721313
, O 0 1.058356656165934e-14
mimicking O 0 1.2243123181931992e-11
the O 0 8.931490800851566e-14
frequent O 0 1.5172273437613626e-09
ARSA O 0 0.0006145930965431035
pseudodeficiency O 0 1.295408310397761e-05
allele O 0 3.8117800471582086e-08
. O 0 1.5874572489860128e-11

Our O 0 4.601615269383963e-11
results O 0 3.93703014525508e-14
demonstrate O 0 1.2441261222127342e-15
that O 0 3.908634775875888e-18
in O 0 9.315287230435561e-19
certain O 0 1.9391875679744406e-16
genetic O 0 1.4330660269568085e-10
conditions O 0 2.5185656338244655e-10
MLD B-Disease 1 0.999996542930603
- O 0 1.116870862460928e-07
like O 0 1.1813744427158213e-09
ARSA O 0 0.0021094949916005135
and O 0 5.609422926156071e-10
GS O 1 1.0
values O 0 1.909193463045522e-11
need O 0 1.6198456489449793e-14
not O 0 4.85430859758683e-18
be O 0 7.103047896468377e-18
paralleled O 0 2.1124673055738716e-14
by O 0 2.866307993905359e-14
clinical O 0 1.3514700469841046e-08
disease O 0 9.084703833650565e-08
, O 0 1.2196983272886306e-17
a O 0 2.0758850206375653e-17
finding O 0 3.0911654258416327e-14
with O 0 4.653686832591097e-13
serious O 0 2.9580224381042797e-10
diagnostic O 0 4.542475839919291e-10
and O 0 2.2340217512278188e-13
prognostic O 0 2.3101675239445285e-08
implications O 0 2.3121280445792536e-09
. O 0 6.8055179547332756e-12

Moreover O 0 7.996019957268174e-10
, O 0 1.2455757725151478e-13
further O 0 3.029632751269662e-13
ARSA O 0 2.2508857000502758e-05
alleles O 0 5.829670773893625e-11
functionally O 0 7.594856167580932e-12
similar O 0 1.5902419956692073e-15
to O 0 7.552975320612059e-16
A464V O 0 6.889985804114929e-11
might O 0 4.398263437482841e-13
exist O 0 6.5184813825152916e-15
which O 0 1.0168337458388126e-14
, O 0 3.1087583530956637e-16
together O 0 9.001953777667757e-14
with O 0 6.434660746942877e-13
0 O 0 1.4526697986877446e-12
- O 0 1.448118638336382e-07
type O 0 1.0916584614051317e-07
mutations O 0 5.221182375336753e-10
, O 0 7.118334106838084e-14
may O 0 1.2274309173221365e-12
cause O 0 3.5313864056281744e-14
pathological O 0 7.773373056352284e-09
ARSA O 1 0.7545889616012573
and O 0 4.21704589825822e-06
GS O 1 1.0
levels O 0 6.144985604805697e-07
, O 0 5.084059461943867e-15
but O 0 1.550917326422624e-15
not O 0 4.201878035510302e-15
clinical O 0 1.0866203770110161e-12
outbreak O 0 1.2202279117690118e-11
of O 0 1.4403343958317168e-16
the O 0 2.9258041302215876e-13
disease O 0 2.1563424468240555e-07
. O 0 8.735778586784187e-15
. O 0 4.59863592518206e-13

Human O 0 1.3479170775099192e-06
MLH1 O 1 0.9633637070655823
deficiency O 1 0.9932471513748169
predisposes O 0 3.225655746064149e-06
to O 0 2.3487795042242965e-10
hematological B-Disease 1 0.997718095779419
malignancy I-Disease 1 0.999247670173645
and O 0 5.343248954403634e-09
neurofibromatosis B-Disease 0 0.16443133354187012
type I-Disease 0 3.226818807888776e-05
1 I-Disease 0 5.449089512943317e-10
. O 0 1.1971608600280792e-11

Heterozygous O 0 6.1609789554495364e-06
germ O 0 0.0009199516498483717
- O 0 0.0003295684000477195
line O 0 9.512733711858345e-09
mutations O 0 8.448371342784089e-12
in O 0 3.478295302966094e-18
the O 0 2.7311766747214612e-18
DNA O 0 5.514160308917049e-11
mismatch O 0 1.8610007757047242e-08
repair O 0 1.8961598957645265e-09
genes O 0 3.0235125514366246e-10
lead O 0 3.080802057908727e-09
to O 0 4.062785871616903e-11
hereditary B-Disease 1 0.9999939203262329
nonpolyposis I-Disease 1 0.9999996423721313
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.302018101285057e-09

The O 0 3.531691540777093e-13
disease O 0 6.681842301681229e-10
susceptibility O 0 1.3860786433547712e-12
of O 0 1.5893930568978217e-15
individuals O 0 2.5370688189196855e-11
who O 0 4.3491192514011345e-07
constitutionally O 0 3.9155365811893716e-05
lack O 0 1.5725271562336274e-12
both O 0 3.815024959488581e-15
wild O 0 3.5805884923689746e-09
- O 0 1.7643095588937285e-06
type O 0 2.2413930711451258e-09
alleles O 0 1.498033684946276e-12
is O 0 5.49389025483564e-14
unknown O 0 4.2452787162375327e-13
. O 0 8.883720039980225e-13

We O 0 4.653977758728445e-10
have O 0 1.0814604962418317e-14
identified O 0 2.7831701854730446e-14
three O 0 3.323386972809247e-16
offspring O 0 1.4302948202985638e-13
in O 0 1.361529229746035e-16
a O 0 1.9041595557267588e-12
hereditary B-Disease 1 0.9999744892120361
nonpolyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.352133267573663e-07
who O 0 4.779438711466355e-08
developed O 0 1.549502748332543e-09
hematological B-Disease 0 1.7825985196395777e-05
malignancy I-Disease 0 3.030669404324726e-07
at O 0 5.467769249520305e-13
a O 0 4.60376509931284e-15
very O 0 2.583573308902968e-14
early O 0 5.900498189007064e-13
age O 0 7.433918813859464e-09
, O 0 7.894290147796024e-14
and O 0 2.3786380918861157e-14
at O 0 1.9894440709080675e-14
least O 0 1.4480906699122796e-17
two O 0 1.1296863859151823e-16
of O 0 6.394810231172309e-17
them O 0 2.5275981530232042e-14
displayed O 0 1.2933408122250967e-08
signs O 0 1.752878802108171e-07
of O 0 3.7124207245657626e-14
neurofibromatosis B-Disease 0 4.8505989980185404e-06
type I-Disease 0 4.0205102891377464e-07
1 I-Disease 0 5.3912454361926265e-11
( O 0 7.404300154771615e-13
NF1 B-Disease 0 4.5146677507545974e-07
) O 0 1.6675348168265769e-12
. O 0 2.1293778101460353e-13

DNA O 0 3.2177355398232965e-12
sequence O 0 1.2450317740751032e-13
analysis O 0 4.661555023282096e-14
and O 0 1.0983061180902358e-15
allele O 0 8.93976953147144e-15
- O 0 4.174944352904053e-13
specific O 0 1.0507249951902911e-15
amplification O 0 9.00357653016437e-12
in O 0 3.408822553987358e-17
two O 0 9.399763478972097e-15
siblings O 0 1.2864808107693193e-09
revealed O 0 1.4824137750668598e-10
a O 0 2.755945699515344e-13
homozygous O 0 1.432896056030586e-06
MLH1 O 0 0.00017275002028327435
mutation O 0 4.480130044726138e-09
( O 0 1.0217417190094835e-12
C676T O 0 4.446842449823407e-09
- O 0 2.7160167519468814e-06
- O 0 2.3644206521566957e-06
> O 0 4.383162444110411e-10
Arg226Stop O 0 2.3148886612034403e-06
) O 0 7.533133188422636e-13
. O 0 1.3678304094846133e-13

Thus O 0 9.179405499604165e-12
, O 0 2.0878155127868666e-15
a O 0 1.9082430456612972e-15
homozygous O 0 9.92097959340299e-10
germ O 0 5.585577673627995e-05
- O 0 3.892375752911903e-05
line O 0 4.5884320343247964e-07
MLH1 O 0 0.00045188789954409003
mutation O 0 1.805605975846447e-08
and O 0 8.120842323253163e-13
consequent O 0 8.181210375823866e-09
mismatch O 0 0.0017528097378090024
repair O 0 0.010230865329504013
deficiency O 0 0.45291653275489807
results O 0 9.561338266267372e-13
in O 0 1.1594096984766217e-15
a O 0 2.580919961255035e-13
mutator O 0 9.000414706861193e-07
phenotype O 0 1.8301211934801387e-10
characterized O 0 5.313744236290496e-13
by O 0 1.1348409869162482e-13
leukemia B-Disease 0 0.0006825090385973454
and O 0 3.114158042549775e-09
/ O 1 0.9783011078834534
or O 1 0.8845048546791077
lymphoma B-Disease 1 1.0
associated O 0 2.694418071769178e-06
with O 0 2.7750985953645113e-09
neurofibromatosis B-Disease 0 0.027603082358837128
type I-Disease 0 6.548194960487308e-06
1 I-Disease 0 5.793973373996453e-12
. O 0 1.9724115935914992e-14
. O 0 5.275973343106533e-13

Missense O 0 4.810594327864237e-05
mutations O 0 3.2237753089248145e-07
in O 0 8.756797709370302e-15
the O 0 6.971191998104974e-18
most O 0 4.072840363827744e-19
ancient O 0 2.219440147994612e-18
residues O 0 2.937230667021673e-11
of O 0 1.1662008910103515e-15
the O 0 1.3030977630225284e-14
PAX6 O 0 1.5442289225120476e-07
paired O 0 2.6867001678976266e-11
domain O 0 1.2123674460184919e-12
underlie O 0 1.4311313419057559e-11
a O 0 1.0220793997053348e-15
spectrum O 0 3.193856583285498e-13
of O 0 1.0651941432853959e-13
human O 0 1.4057589226013079e-07
congenital B-Disease 1 0.9998784065246582
eye I-Disease 1 0.99937903881073
malformations I-Disease 1 0.9991100430488586
. O 0 5.288787185975252e-10

Mutations O 0 2.7292310633697525e-09
of O 0 4.017528514320455e-15
the O 0 1.2117136653322196e-15
human O 0 2.149667569601929e-13
PAX6 O 0 1.4466693301073974e-06
gene O 0 8.39899655602494e-07
underlie O 0 0.16936349868774414
aniridia B-Disease 1 1.0
( O 0 7.411721725247844e-08
congenital B-Disease 1 0.9999532699584961
absence I-Disease 0 5.938239344693841e-10
of I-Disease 0 8.175816116782683e-16
the I-Disease 0 1.034332938309318e-14
iris I-Disease 0 1.9575054466258734e-07
) O 0 5.024083430641042e-14
, O 0 1.3847016689027484e-16
a O 0 4.4979939776068276e-15
rare O 0 3.8787679734753056e-09
dominant O 0 0.023117056116461754
malformation B-Disease 1 0.9999738931655884
of I-Disease 0 1.8290341029930657e-12
the I-Disease 0 2.8308028143797515e-10
eye I-Disease 1 0.864163875579834
. O 0 1.4315069130077518e-09

The O 0 5.8954979671721735e-15
spectrum O 0 3.1361707935467775e-13
of O 0 2.9986656163532004e-15
PAX6 O 0 9.868631423159968e-07
mutations O 0 1.842209051972077e-08
in O 0 3.474393949626231e-12
aniridia B-Disease 1 1.0
patients O 0 5.88951110103153e-10
is O 0 1.8628933251817756e-16
highly O 0 6.885829936739707e-16
biased O 0 4.8495603366394135e-11
, O 0 2.9954530321425017e-15
with O 0 4.4678112290808415e-15
92 O 0 1.2000773638720652e-12
% O 0 4.584133376989658e-17
of O 0 9.232439095028935e-18
all O 0 5.275369984597544e-13
reported O 0 4.860459604238976e-11
mutations O 0 1.1219182700916708e-11
leading O 0 6.262440566118244e-11
to O 0 5.76488548670556e-15
premature O 0 1.528629002892079e-12
truncation O 0 1.797932028951843e-12
of O 0 5.980824995784138e-16
the O 0 6.0803209797795355e-15
protein O 0 9.220501966111794e-12
( O 0 1.06873873900043e-14
nonsense O 0 2.417934602538807e-11
, O 0 4.866193528627992e-18
splicing O 0 1.8588773302206062e-14
, O 0 8.902665676733439e-17
insertions O 0 9.573692750022844e-13
and O 0 3.319076580959347e-14
deletions O 0 2.126198175855798e-11
) O 0 1.377811845735058e-13
and O 0 2.032820119917192e-13
just O 0 1.1591201956595576e-11
2 O 0 9.889993283964532e-14
% O 0 2.490221112954357e-17
leading O 0 3.588790844903135e-14
to O 0 4.904605314733117e-17
substitution O 0 5.0060595859630075e-15
of O 0 1.5173551017255504e-16
one O 0 6.638000695988189e-15
amino O 0 1.5783363123208377e-15
acid O 0 6.480197505002647e-16
by O 0 2.9083540056417976e-18
another O 0 3.788110064073102e-15
( O 0 8.911237226643179e-15
missense O 0 2.801154863618649e-10
) O 0 4.1337883094870465e-13
. O 0 6.642059948921974e-13

The O 0 2.3486941219479605e-14
extraordinary O 0 1.910272578954566e-14
conservation O 0 2.6975498505272697e-15
of O 0 1.2969859478225228e-17
the O 0 3.908085279794969e-17
PAX6 O 0 2.995118042470324e-10
protein O 0 1.1244557531191884e-13
at O 0 7.034325717942581e-15
the O 0 1.0630532818048917e-16
amino O 0 4.836300088705003e-13
acid O 0 7.7457745079057e-12
level O 0 5.085286575515213e-13
amongst O 0 2.9953386826946224e-15
vertebrates O 0 7.045450919722362e-13
predicts O 0 2.9907223919600767e-10
that O 0 1.7212286825864231e-13
pathological O 0 1.1458882198667197e-07
missense O 0 5.965347554592881e-06
mutations O 0 4.674471256294055e-06
should O 0 4.816462784162923e-09
in O 0 1.4698409208982184e-16
fact O 0 1.0332524630818005e-14
be O 0 2.5594142690626986e-13
common O 0 1.4601074323672587e-14
even O 0 1.000649690603532e-13
though O 0 2.9532135742936505e-14
they O 0 9.994556451984465e-14
are O 0 6.95725503710486e-15
hardly O 0 5.061064211491807e-14
ever O 0 7.495989939876324e-11
seen O 0 4.448547752389231e-09
in O 0 1.1836558642952522e-11
aniridia B-Disease 1 1.0
patients O 0 9.186985394649128e-09
. O 0 2.941533193238921e-13

This O 0 3.005194631013931e-14
indicates O 0 1.226349750915734e-12
that O 0 6.310190316252624e-17
there O 0 3.755044293327348e-17
is O 0 1.3643472024824316e-16
a O 0 1.8235971374180437e-15
heavy O 0 4.957318999743165e-10
ascertainment O 0 7.386503142470247e-08
bias O 0 2.690595302112797e-09
in O 0 1.191580936255626e-16
the O 0 4.392317058537695e-18
selection O 0 3.7948621872121394e-16
of O 0 1.6227869139442937e-17
patients O 0 3.358318611554014e-16
for O 0 2.784289941853491e-18
PAX6 O 0 1.2019936435070377e-10
mutation O 0 3.861337587022541e-14
analysis O 0 3.463961905400374e-14
and O 0 1.84242229220484e-13
that O 0 2.0690564858622624e-15
the O 0 3.9934347468391015e-14
missing O 0 5.714503004128346e-08
PAX6 O 0 0.0005012968322262168
missense O 0 1.4771458154427819e-05
mutations O 0 5.980688797535549e-07
frequently O 0 5.230434751979374e-09
may O 0 6.042989025845102e-11
underlie O 0 3.366372958168995e-09
phenotypes O 0 5.789957957524905e-10
distinct O 0 3.0320838613311085e-13
from O 0 1.7585220389235157e-12
textbook O 0 0.021564044058322906
aniridia B-Disease 1 0.9999997615814209
. O 0 6.443623967733458e-10

Here O 0 1.440064040236777e-10
we O 0 5.2025950821738e-13
present O 0 4.90047417623068e-16
four O 0 9.814777224116471e-16
novel O 0 1.6312040693883256e-12
PAX6 O 0 1.5950586202961858e-06
missense O 0 7.082925890244951e-08
mutations O 0 3.664241576828431e-09
, O 0 1.6960689580222676e-14
two O 0 7.475242789405177e-15
in O 0 4.504364512403127e-15
association O 0 3.336603183416026e-13
with O 0 3.1077671360825454e-13
atypical O 0 8.166699672074174e-08
phenotypes O 0 1.2255712000808217e-08
ectopia B-Disease 0 7.798665251357306e-07
pupillae I-Disease 0 1.4510025039271568e-06
( O 0 1.0466462765923445e-12
displaced B-Disease 0 1.0316417164979441e-10
pupils I-Disease 0 9.380734411479352e-09
) O 0 1.624254342136311e-10
and O 0 4.64906690922362e-08
congenital B-Disease 1 0.9999855756759644
nystagmus I-Disease 0 5.791875082650222e-06
( O 0 3.27654976718314e-14
searching B-Disease 0 5.614493939209986e-11
gaze I-Disease 0 4.018913023173809e-05
) O 0 1.3909454642767327e-13
, O 0 6.996187741855101e-16
and O 0 6.582642010687437e-14
two O 0 1.8766478442847762e-13
in O 0 1.4059028294571407e-14
association O 0 8.298774807537906e-15
with O 0 2.553636782266837e-16
more O 0 2.654715182626383e-15
recognizable O 0 9.839258297006381e-08
aniridia B-Disease 1 0.9999992847442627
phenotypes O 0 5.384029222454956e-08
. O 0 2.6614066853114515e-12

Strikingly O 0 9.21987763913279e-10
, O 0 3.578490246638165e-14
all O 0 1.1511817263061119e-15
four O 0 1.9306089929851944e-14
mutations O 0 2.7170095600465016e-13
are O 0 2.006438939961778e-15
located O 0 1.2097983205505702e-13
within O 0 2.12054105422051e-14
the O 0 2.2112483556453039e-13
PAX6 O 0 2.598420223876019e-06
paired O 0 1.123906856470569e-09
domain O 0 6.395391161095887e-11
and O 0 3.1642941739074004e-11
affect O 0 1.7393402798777935e-13
amino O 0 7.480491852579312e-15
acids O 0 5.080746885493745e-14
which O 0 1.304658114178401e-16
are O 0 4.205112933745205e-17
highly O 0 2.387198513900511e-16
conserved O 0 6.36937876573318e-14
in O 0 8.738015600797885e-14
all O 0 6.473984542898492e-12
known O 0 1.3070426685413139e-11
paired O 0 4.4618445049771083e-10
domain O 0 1.3192349990198693e-11
proteins O 0 3.5844112400429395e-11
. O 0 7.390983658428496e-12

Our O 0 1.653115005995076e-10
results O 0 3.031667527696874e-13
support O 0 4.3751975466005627e-16
the O 0 7.652935440612244e-19
hypothesis O 0 3.7805867703751483e-16
that O 0 2.9711867690484175e-17
the O 0 8.913569240695868e-18
under O 0 7.35351314345642e-15
- O 0 7.14751313690698e-11
representation O 0 2.997169163245286e-14
of O 0 6.644457310507753e-16
missense O 0 1.6467147645471414e-09
mutations O 0 3.816561303104926e-11
is O 0 5.690792973710385e-15
caused O 0 6.497478353555174e-15
by O 0 4.755250377423931e-16
ascertainment O 0 1.8475739125278778e-06
bias O 0 1.2594186955539044e-06
and O 0 5.690017142352677e-13
suggest O 0 5.208716453758335e-15
that O 0 6.8741963858866996e-18
a O 0 6.54550996563416e-17
substantial O 0 4.104843364088201e-13
burden O 0 6.49052722678789e-08
of O 0 3.3216937772410915e-13
PAX6 B-Disease 0 0.0516451895236969
- I-Disease 0 0.005153502803295851
related I-Disease 0 1.0367563845647965e-05
disease I-Disease 0 0.024105599150061607
remains O 0 3.0451037524859004e-11
to O 0 1.08421508973795e-15
be O 0 1.6584117705411433e-13
uncovered O 0 1.630335755287149e-09
. O 0 1.5045961438558964e-13
. O 0 1.1564718366968707e-12

The O 0 1.2072166996526107e-13
chromosomal O 0 2.1824970275474698e-08
order O 0 1.9781041632168164e-14
of O 0 2.8586273400146517e-17
genes O 0 1.972909276269988e-13
controlling O 0 8.21369694481433e-10
the O 0 3.16042709818038e-15
major O 0 5.003487316308786e-13
histocompatibility O 0 2.283104911723899e-12
complex O 0 2.9193293341398105e-15
, O 0 1.505524036685878e-16
properdin O 0 3.9423583841902143e-10
factor O 0 9.686719482093764e-11
B O 0 3.444889898673864e-06
, O 0 9.217331758959446e-13
and O 0 8.893374925378339e-11
deficiency B-Disease 0 1.923385752888862e-07
of I-Disease 0 2.9927771756527865e-17
the I-Disease 0 4.848262535966333e-16
second I-Disease 0 1.6269317707276465e-12
component I-Disease 0 8.952268722335621e-13
of I-Disease 0 8.01440975351864e-16
complement I-Disease 0 6.041142412704925e-12
. O 0 5.080051505325367e-13

The O 0 9.5924048597925e-14
relationship O 0 1.3383669172917223e-12
of O 0 1.0803407899885303e-18
the O 0 1.806450271445235e-19
genes O 0 3.8436230946587113e-17
coding O 0 4.272998521651799e-16
for O 0 4.851270569992076e-19
HLA O 0 2.394497089757558e-14
to O 0 3.916692704114285e-19
those O 0 1.6914134364768728e-18
coding O 0 1.685201059440874e-15
for O 0 2.9953014000100534e-17
properdin O 0 8.799124623370957e-11
Factor O 0 5.161764028357996e-13
B O 0 2.6008946107936026e-09
allotypes O 0 1.1619155415587556e-08
and O 0 1.4500392260616973e-13
for O 0 1.7433649061046955e-14
deficiency B-Disease 0 9.018091828849606e-10
of I-Disease 0 5.295414860144768e-19
the I-Disease 0 6.832475463741056e-17
second I-Disease 0 4.514225636093744e-13
component I-Disease 0 2.2218101924237343e-12
of I-Disease 0 1.620327610691967e-14
complement I-Disease 0 1.1629075480357187e-10
( O 0 3.1974835106030053e-13
C2 O 0 1.623317658072665e-08
) O 0 3.794909536353891e-14
was O 0 8.563917804071952e-12
studied O 0 1.4247146865042914e-11
in O 0 6.068940245100227e-16
families O 0 1.5666749979777509e-15
of O 0 5.40091924091865e-15
patients O 0 1.4215814940141125e-12
with O 0 4.676512215667783e-12
connective O 0 0.05270504951477051
tissue O 1 0.6539046764373779
disorders O 0 0.0125573193654418
. O 0 2.5899815278562777e-11

Patients O 0 1.924882653270288e-08
were O 0 1.1500768057077365e-13
selected O 0 4.5464736034110664e-13
because O 0 2.0800486441770183e-15
they O 0 3.8094116721471265e-15
were O 0 1.2683456105592843e-14
heterozygous O 0 7.40580166636029e-12
or O 0 1.6316979776880014e-13
homozygous O 0 4.4049951952729316e-07
for O 0 1.3271990439989167e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
. O 0 1.1416482342818668e-11

12 O 0 4.4784706498823823e-10
families O 0 1.0214898859498694e-13
with O 0 1.0336224470731611e-15
15 O 0 2.3893144339664878e-14
matings O 0 8.859468159094774e-10
informative O 0 8.943583793552534e-07
for O 0 0.0006681773229502141
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 8.023904349112321e-13
found O 0 2.2380735502716687e-13
. O 0 1.6919533265755127e-13

Of O 0 5.90488920780563e-13
57 O 0 8.197021186817643e-12
informative O 0 1.9688729813172046e-12
meioses O 0 2.6174282297120044e-08
, O 0 5.866282847909307e-17
two O 0 1.4535910487544815e-18
crossovers O 0 5.266444832313644e-12
were O 0 2.208633835987673e-14
noted O 0 8.485878286949161e-14
between O 0 3.852835205823274e-13
the O 0 1.3813518329186536e-08
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
gene O 0 6.976383988728518e-13
and O 0 9.21840316352289e-17
the O 0 1.7061180814696208e-17
HLA O 0 3.801483128285099e-09
- O 0 1.8158156933623104e-07
B O 0 6.12426598323168e-09
gene O 0 4.466554621822272e-13
, O 0 1.9434955907790657e-18
with O 0 7.341411305547817e-21
a O 0 1.0331980220450287e-20
recombinant O 0 1.0180668987550727e-16
fraction O 0 5.835619196427517e-16
of O 0 1.9418172717564422e-14
0 O 0 1.3018476921478062e-11
. O 0 4.705142525596173e-12

035 O 0 0.00316333188675344
. O 0 1.2999341159058986e-08

A O 0 1.1343622569048861e-10
lod O 0 2.2992180959136022e-07
score O 0 5.467795660685226e-11
of O 0 1.2636404113587136e-16
13 O 0 1.5965756845323013e-15
was O 0 2.4447217124886326e-17
calculated O 0 1.5785823489222354e-16
for O 0 2.3117769532715344e-15
linkage O 0 3.6795713640458416e-06
between O 0 3.282776333435322e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.647905444913944e-13
HLA O 0 1.2331231591389269e-09
- O 0 3.1418769808055913e-09
B O 0 2.885848227052179e-10
at O 0 3.0083571555774473e-16
a O 0 3.4100544016953294e-19
maximum O 0 4.995481237984571e-19
likelihood O 0 1.907607863595085e-17
value O 0 6.571153226367794e-17
of O 0 6.946709313129783e-20
the O 0 4.767810243383978e-20
recombinant O 0 1.7336276271012968e-16
fraction O 0 1.8687438082182407e-16
of O 0 1.2918322883515173e-15
0 O 0 3.0781657604783685e-12
. O 0 1.7200810003767386e-12

04 O 0 0.0005126670002937317
. O 0 1.7251632344894574e-09

18 O 0 1.2972096286034684e-08
families O 0 4.521116960627333e-14
with O 0 3.0250664686488145e-16
21 O 0 3.9347589428740477e-16
informative O 0 2.7777272364572832e-15
matings O 0 3.5460503890888395e-12
for O 0 8.453382460850813e-16
both O 0 1.1569627261711225e-14
properdin O 0 1.0749467094228748e-08
Factor O 0 2.8620933748002564e-12
B O 0 1.7353277703691106e-09
allotype O 0 1.394630300133315e-09
and O 0 1.9160352829079158e-13
HLA O 0 4.965393429756659e-09
- O 0 1.0694826357848797e-07
B O 0 3.8731493567922826e-09
were O 0 1.6147033119221985e-14
found O 0 7.31234124358264e-14
. O 0 7.591097076018599e-14

Of O 0 8.965528514905119e-13
72 O 0 2.7493120627331002e-11
informative O 0 1.3651394251135152e-11
meioses O 0 3.477103120985703e-07
, O 0 3.916267419542098e-15
three O 0 2.3774393708591614e-15
recombinants O 0 7.389053990891625e-08
were O 0 5.06979115806605e-13
found O 0 1.0860334577174682e-13
, O 0 2.115325612629553e-18
giving O 0 2.179435832415169e-19
a O 0 2.876266609855706e-20
recombinant O 0 1.8206699239012308e-16
fraction O 0 1.7376597686280233e-16
of O 0 2.6336744607001125e-15
0 O 0 1.864226438150207e-12
. O 0 1.4444034076438461e-12

042 O 0 6.303420377662405e-05
. O 0 1.4335205245075144e-09

A O 0 7.661949547044244e-11
lod O 0 2.0389606447679398e-08
score O 0 3.1536999574310887e-12
of O 0 1.664868271770051e-16
16 O 0 2.653318213538124e-15
between O 0 1.2238796260234127e-16
HLA O 0 1.6354331777712616e-10
- O 0 3.718724883583491e-08
B O 0 1.6119788170954052e-08
and O 0 3.058265649730739e-14
Factor O 0 9.645572779078473e-14
B O 0 1.050707645888771e-10
allotypes O 0 2.3580252334065577e-11
was O 0 5.9638547965650164e-15
calculated O 0 1.7370708160318856e-15
at O 0 2.014445518895699e-15
a O 0 4.1854582124922714e-18
maximum O 0 7.926199312257659e-18
likelihood O 0 5.67227789227459e-17
value O 0 7.229951629940547e-17
of O 0 6.051450443693934e-20
the O 0 1.1245724637872135e-19
recombinant O 0 6.262616446072291e-16
fraction O 0 6.089068394904949e-16
of O 0 1.9735996843549654e-15
0 O 0 1.0737866758953052e-12
. O 0 9.645909288327759e-13

04 O 0 0.00037975929444655776
. O 0 8.174827481610691e-10

A O 0 4.4768236426989683e-13
crossover O 0 3.2119530559565623e-12
was O 0 2.6665588140351026e-12
shown O 0 1.8630159332008907e-14
to O 0 1.9645537893773182e-17
have O 0 1.0324357539140579e-16
occurred O 0 8.15400402577415e-18
between O 0 8.848986261340784e-20
genes O 0 3.0044907148710275e-17
for O 0 2.788596244122442e-17
Factor O 0 8.283278339767889e-15
B O 0 4.542230827575544e-11
and O 0 3.111276698514881e-14
HLA O 0 2.252328740182108e-10
- O 0 9.031762893130235e-09
D O 0 1.6429909655002461e-09
, O 0 1.3053495709960464e-17
in O 0 1.1738043409912032e-18
which O 0 3.021906241662168e-16
HLA O 0 1.2114302616605954e-10
- O 0 2.1609438682901327e-09
D O 0 4.3642173208624513e-10
segregared O 0 1.0650449272509022e-11
with O 0 2.2032207078256108e-16
HLA O 0 1.51864458508566e-11
- O 0 1.8593836539904096e-11
A O 0 8.639579936881026e-13
and O 0 5.844040529279226e-12
B O 0 7.134618451587471e-10
. O 0 9.489604197929213e-14

These O 0 3.7790767965038136e-14
studies O 0 1.4416028117883624e-14
suggest O 0 2.1203701653234016e-15
that O 0 3.7423987697129434e-19
the O 0 9.788136755795374e-20
genes O 0 2.1760922277585257e-15
for O 0 4.531511410142859e-14
Factor O 0 6.401612040463078e-08
B O 1 0.9997301697731018
and O 1 0.9955678582191467
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 4.90300151078705e-15
located O 0 2.707414290351875e-16
outside O 0 5.494618554939513e-16
those O 0 2.5467284675758144e-17
for O 0 7.464659827413283e-18
HLA O 0 2.212535032573501e-13
, O 0 5.2511427061948575e-18
that O 0 2.2171298325437512e-18
the O 0 1.9121614928671895e-17
order O 0 1.147017500579173e-15
of O 0 4.807027119209422e-17
genese O 0 3.145195562326286e-11
is O 0 7.163081290430576e-16
HLA O 0 7.861687646368298e-13
- O 0 4.925013847266457e-13
A O 0 2.0691139231664157e-13
, O 0 7.311389347956516e-15
- O 0 3.0936606054687843e-10
B O 0 1.5984689960557574e-10
, O 0 5.906953134871722e-16
- O 0 3.187804187287924e-11
D O 0 3.505427892402935e-11
, O 0 4.8469101287520336e-17
Factor O 0 1.9344988393295293e-13
B O 0 1.1567062330186673e-07
allotype O 0 0.0007869393448345363
, O 0 4.3620252654363867e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 3.2157072311014416e-18
that O 0 1.5770503724291778e-20
the O 0 2.81170839422021e-19
genes O 0 3.3061932098316094e-14
coding O 0 4.274641751678132e-10
for O 0 9.216861940331e-08
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.5903472075650136e-11
Factor O 0 9.10020843403192e-12
B O 0 2.3776292934485355e-08
allotypes O 0 3.886440058664675e-09
are O 0 8.446355793157747e-16
approximately O 0 2.433001767583728e-15
3 O 0 3.1991228242878034e-14
- O 0 1.5170152634080836e-10
- O 0 5.1576846959999756e-11
5 O 0 1.8030527767988642e-15
centimorgans O 0 6.43957164068315e-13
from O 0 3.0781212458397308e-18
the O 0 8.140109149242061e-19
HLA O 0 4.01930855405911e-14
- O 0 2.4458063646473713e-15
A O 0 1.4870761884902713e-16
and O 0 2.862611637414748e-16
HLA O 0 2.0822085375349353e-11
- O 0 5.1100366993406254e-11
B O 0 1.1256344164059517e-12
loci O 0 3.35120538768165e-15
, O 0 4.306394582307423e-17
and O 0 1.3946299869229774e-17
that O 0 2.5050641659431003e-18
the O 0 3.274782898806815e-17
apparent O 0 9.98883864077732e-14
lack O 0 2.795415613736558e-15
of O 0 5.6531578605696106e-18
recombinants O 0 1.445881522149639e-11
between O 0 6.449958693483464e-17
the O 0 1.3624851858363502e-16
Factor O 0 8.752331541808656e-13
B O 0 1.797626936195229e-08
gene O 0 5.954282187303761e-07
and O 0 0.00020605216559488326
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.215790575853637e-11
suggests O 0 1.0584621964711619e-13
that O 0 5.58429499185651e-17
these O 0 2.2592736094185317e-17
two O 0 4.647031796368474e-14
genes O 0 2.8979098634640543e-11
lie O 0 8.235852000382238e-09
in O 0 2.6578767331020096e-15
close O 0 1.7614493847892265e-12
proximity O 0 2.0932084190961042e-13
to O 0 1.2003742997420547e-13
one O 0 1.1252072407499925e-12
another O 0 5.338004777782901e-12
. O 0 1.0982748564758449e-11

Distribution O 0 1.1345412456731374e-11
of O 0 4.0045938976994086e-14
emerin O 0 7.757348612358328e-07
and O 0 1.7701386146803944e-12
lamins O 0 1.1736339899925952e-07
in O 0 1.5327374582757049e-15
the O 0 3.810719914534161e-15
heart O 0 3.2084893769601663e-11
and O 0 1.3197112131400901e-14
implications O 0 1.8609854597010506e-13
for O 0 1.5630702163366497e-14
Emery B-Disease 0 0.0005086510791443288
- I-Disease 1 0.9999568462371826
Dreifuss I-Disease 1 0.9997528195381165
muscular I-Disease 0 0.04258713871240616
dystrophy I-Disease 0 0.00011627050116658211
. O 0 1.8661912293271854e-11

Emerin O 0 1.230960333487019e-05
is O 0 1.38716035186226e-12
a O 0 1.8004489975190045e-14
nuclear O 0 8.277723506644463e-10
membrane O 0 5.396082682789828e-14
protein O 0 9.028128179940087e-13
which O 0 6.1420281770199585e-15
is O 0 5.902833696011869e-15
missing O 0 3.746680971115218e-13
or O 0 1.63402074531728e-14
defective O 0 4.264125053055068e-08
in O 0 3.7439235739400445e-13
Emery B-Disease 1 0.9963485598564148
- I-Disease 1 0.9999992847442627
Dreifuss I-Disease 1 0.999991774559021
muscular I-Disease 1 0.999222993850708
dystrophy I-Disease 0 0.05747808516025543
( O 0 1.405801808296303e-09
EDMD B-Disease 1 0.9999995231628418
) O 0 1.3449082125749356e-11
. O 0 1.4153049392173767e-12

It O 0 1.2447807541671185e-12
is O 0 4.4473061707904146e-14
one O 0 4.355233774127167e-15
member O 0 2.009258543236598e-14
of O 0 1.3438400219774252e-17
a O 0 1.453050080905678e-15
family O 0 1.6372660334700723e-13
of O 0 6.721504592060307e-14
lamina O 0 2.329086612462561e-07
- O 0 1.9030339970527166e-08
associated O 0 1.4816086183443156e-13
proteins O 0 1.255253191700164e-14
which O 0 2.2949419616866184e-15
includes O 0 1.4618525574078278e-13
LAP1 O 0 5.148159516465967e-07
, O 0 2.5091336818060077e-14
LAP2 O 0 6.327163077912701e-07
and O 0 1.0913087274133648e-11
lamin O 0 0.0001421729539288208
B O 0 3.530409958329983e-05
receptor O 0 1.4730842934351784e-10
( O 0 2.626874412436919e-13
LBR O 0 1.424321180820698e-05
) O 0 5.922824080142886e-13
. O 0 2.925340904843393e-13

A O 0 1.3204938011102119e-11
panel O 0 5.0450154470693676e-11
of O 0 1.4540980724196684e-15
16 O 0 2.969940645410757e-13
monoclonal O 0 3.809345200389558e-12
antibodies O 0 1.1765700393129297e-11
( O 0 8.854542029230778e-16
mAbs O 0 2.11536430733128e-12
) O 0 3.702714796369324e-16
has O 0 1.8248914037614482e-15
been O 0 9.268796726975294e-16
mapped O 0 8.606600432337075e-10
to O 0 1.3204413555406233e-14
six O 0 2.1423355507665422e-14
specific O 0 7.504636473801236e-17
sites O 0 3.0170213115993105e-13
throughout O 0 4.980343030409656e-16
the O 0 1.2305219028858257e-17
emerin O 0 4.971448057909666e-13
molecule O 0 1.6835608661652997e-17
using O 0 4.441636958098618e-17
phage O 0 5.307909602299266e-13
- O 0 3.1564078607770885e-12
displayed O 0 8.599100842195465e-14
peptide O 0 1.2191977943442744e-14
libraries O 0 1.6924680727327238e-15
and O 0 1.6069578732459157e-14
has O 0 1.0247033595451628e-14
been O 0 4.70264751381707e-16
used O 0 9.155741254271793e-17
to O 0 2.7579501288696386e-16
localize O 0 6.611709513215658e-10
emerin O 0 2.641653509272146e-07
in O 0 7.679124466842234e-15
human O 0 6.611034202713695e-12
and O 0 1.3410065159008555e-12
rabbit O 0 5.077261812402867e-05
heart O 0 1.6405311953349155e-07
. O 0 8.487003634594092e-12

Several O 0 3.087136666093948e-13
mAbs O 0 5.78456060829069e-10
against O 0 6.59437917683095e-14
different O 0 8.713408870163674e-16
emerin O 0 4.920910789962818e-09
epitopes O 0 2.643837648808045e-10
did O 0 2.454800685641745e-13
not O 0 5.74503696365255e-16
recognize O 0 3.1673066997779794e-15
intercalated O 0 1.1141199074415908e-11
discs O 0 7.02378528671943e-08
in O 0 3.6275588652726065e-13
the O 0 1.0877380810306314e-12
heart O 0 1.2675361871217206e-09
, O 0 3.382322466488017e-16
though O 0 3.616748099063505e-16
they O 0 1.702505900201632e-14
recognized O 0 2.2336979813540603e-13
cardiomyocyte O 0 9.986002025286211e-10
nuclei O 0 8.010921570197893e-13
strongly O 0 3.452990671171108e-11
, O 0 1.4441587760583496e-15
both O 0 1.3181514019677213e-14
at O 0 1.5705924061304444e-10
the O 0 6.463422679015007e-12
rim O 0 4.638434256776236e-05
and O 0 3.668442494220159e-10
in O 0 5.887968267787556e-15
intranuclear O 0 2.1323746324242165e-08
spots O 0 7.126550044533886e-11
or O 0 1.0123973057454827e-12
channels O 0 1.4442017581828281e-09
. O 0 6.313978506700124e-11

A O 0 1.4823685334786063e-10
polyclonal O 0 1.1185508697053592e-07
rabbit O 0 1.5603708902744984e-07
antiserum O 0 8.079472024746792e-08
against O 0 4.453637458823323e-11
emerin O 0 3.1619098450619276e-08
did O 0 3.3120015519201573e-13
recognize O 0 2.7092818074181575e-14
both O 0 2.948529100930508e-15
nuclear O 0 1.4576345686023728e-09
membrane O 0 6.432890651371023e-14
and O 0 4.924294225015129e-15
intercalated O 0 5.561052920238785e-12
discs O 0 2.0612322959578933e-09
but O 0 2.2800041544969625e-14
, O 0 8.599242469082096e-19
after O 0 4.180096841352009e-18
affinity O 0 8.879869075359845e-18
purification O 0 8.747808201640652e-17
against O 0 1.6824630320563194e-17
a O 0 6.083908028653537e-18
pure O 0 8.876766373821718e-15
- O 0 4.198286163159537e-09
emerin O 0 4.89484008880936e-09
band O 0 3.04319042838605e-13
on O 0 8.832151454423939e-14
a O 0 1.240993646143022e-14
western O 0 2.910547779351458e-13
blot O 0 1.9867520677507855e-06
, O 0 2.25289130748171e-14
it O 0 8.42730782211901e-15
stained O 0 3.3557751066837227e-07
only O 0 2.466862163760103e-14
the O 0 5.551294694110601e-15
nuclear O 0 2.6004978170846016e-09
membrane O 0 8.500867653034316e-13
. O 0 6.827669397739544e-13

These O 0 2.4170333161148416e-13
results O 0 3.2927605954358175e-12
would O 0 2.904534929628125e-14
not O 0 1.5670387456890374e-16
be O 0 9.420147750364245e-16
expected O 0 5.919452482436999e-15
if O 0 7.193013105445938e-15
immunostaining O 0 6.455270346039654e-11
at O 0 6.50402189483095e-16
intercalated O 0 4.2357266240473923e-13
discs O 0 1.5383302409688326e-09
were O 0 1.2682701243382777e-11
due O 0 1.596216436683547e-15
to O 0 2.3009780293109546e-18
a O 0 2.0222737907767784e-17
product O 0 4.822097040245443e-13
of O 0 4.0645537718487644e-18
the O 0 1.2720898297053713e-16
emerin O 0 1.2196142706866198e-10
gene O 0 1.8466237653586015e-12
and O 0 1.1827074692868922e-12
, O 0 6.335253756464083e-16
therefore O 0 1.0878893466095718e-16
, O 0 9.298646300385434e-17
cast O 0 1.2866610554773672e-11
some O 0 1.961626794236187e-16
doubt O 0 6.38017606411842e-14
upon O 0 9.355070275201146e-18
the O 0 2.8333533327064614e-17
hypothesis O 0 4.2776996815640025e-14
that O 0 2.8627797289855483e-13
cardiac B-Disease 0 3.912128399008452e-09
defects I-Disease 0 0.017490651458501816
in O 0 3.719696859555421e-12
EDMD B-Disease 1 1.0
are O 0 1.978021496595872e-10
caused O 0 7.015332867572888e-13
by O 0 3.163539308986829e-15
absence O 0 2.314702596262208e-11
of O 0 4.547319247224287e-15
emerin O 0 7.583464167737475e-08
from O 0 4.6361599590838756e-14
intercalated O 0 6.698919197134501e-09
discs O 0 8.575030960855656e-07
. O 0 3.9825101549872954e-11

Although O 0 5.393711085405206e-12
emerin O 0 1.2272835192561615e-08
was O 0 3.8460876736028105e-13
abundant O 0 1.2343122926067275e-15
in O 0 1.1434913024197533e-16
the O 0 8.380881734521765e-16
membranes O 0 1.9594902089803412e-10
of O 0 2.587783909683769e-15
cardiomyocyte O 0 1.244329195237981e-09
nuclei O 0 1.5307202662524777e-13
, O 0 1.0268426894842193e-16
it O 0 1.316371256349948e-16
was O 0 3.646902658333007e-12
absent O 0 1.733636969874705e-13
from O 0 6.727316985083925e-17
many O 0 4.7025400465118875e-16
non O 0 2.2647361763716845e-09
- O 0 1.6496919386099762e-09
myocyte O 0 9.263204647780299e-10
cells O 0 1.6822426698176463e-12
in O 0 1.8670907704821147e-16
the O 0 1.647257329184023e-14
heart O 0 9.276482915154816e-10
. O 0 9.69624879519626e-13

This O 0 2.0766780883216566e-16
distribution O 0 9.670432221992498e-16
of O 0 4.3500488736987865e-17
emerin O 0 7.68031582776274e-10
was O 0 2.5140490139989244e-14
similar O 0 1.6423222316758054e-18
to O 0 8.51921998264795e-18
that O 0 9.426618023290084e-16
of O 0 1.5189999338299998e-16
lamin O 0 1.1294233326353265e-09
A O 0 1.0905959837471946e-13
, O 0 3.1368806410378945e-18
a O 0 8.033803515831925e-19
candidate O 0 5.818059144639752e-16
gene O 0 4.857597410792315e-14
for O 0 2.1165072715674483e-15
an O 0 6.799840909527816e-14
autosomal O 0 6.7418500293570105e-06
form O 0 6.25337790438607e-08
of O 0 5.980876949251979e-07
EDMD B-Disease 1 1.0
. O 0 1.1942981714696543e-08

In O 0 2.7689612755454895e-12
contrast O 0 8.135108905960031e-12
, O 0 3.5410536265365056e-13
lamin O 0 0.00016933822189457715
B1 O 0 0.2432342767715454
was O 0 2.644725272116233e-10
absent O 0 6.468825041600068e-12
from O 0 8.134006041110619e-16
cardiomyocyte O 0 4.205189668704534e-11
nuclei O 0 3.1245859578084983e-14
, O 0 9.754790747838616e-17
showing O 0 1.4550554337799948e-11
that O 0 5.384365371098598e-13
lamin O 0 0.00010294670209987089
B1 O 0 9.119183232542127e-05
is O 0 7.60641346458403e-15
not O 0 7.182391060824463e-18
essential O 0 4.847776765879805e-18
for O 0 6.214155060725524e-19
localization O 0 1.9619047004522253e-15
of O 0 2.796266193634279e-17
emerin O 0 3.5259087316497073e-10
to O 0 1.2284031790084447e-15
the O 0 4.0653065088531656e-14
nuclear O 0 5.181495055239793e-08
lamina O 0 5.409544368006891e-09
. O 0 1.3439537026663229e-12

Lamin O 1 0.9832631349563599
B1 O 1 0.9997355341911316
is O 0 1.4026500849695367e-08
also O 0 6.825980319175029e-12
almost O 0 1.2690044327856587e-13
completely O 0 1.658045034602651e-09
absent O 0 4.836042233336002e-09
from O 0 7.024705795354025e-13
skeletal O 0 6.025588390912162e-06
muscle O 0 2.0342283413299356e-09
nuclei O 0 7.19429030238139e-11
. O 0 2.5799911252538665e-12

In O 0 2.087936212813446e-10
EDMD B-Disease 1 0.9999990463256836
, O 0 1.7254277128971648e-15
the O 0 3.0882126425177246e-18
additional O 0 6.76729349912298e-16
absence O 0 1.0698441169965968e-14
of O 0 8.289753694891411e-16
lamin O 0 1.835537113947794e-05
B1 O 0 0.00032121536787599325
from O 0 8.545639239646019e-13
heart O 0 1.6579731365595762e-08
and O 0 7.475173258164602e-11
skeletal O 0 1.1521169653860852e-06
muscle O 0 2.852100500216892e-11
nuclei O 0 1.2735872198434833e-13
which O 0 1.0815682388327225e-13
already O 0 7.918469435708175e-09
lack O 0 8.238458743328736e-13
emerin O 0 2.2350077344412966e-08
may O 0 9.049471783907637e-13
offer O 0 7.45041114505369e-17
an O 0 1.3018323576724403e-19
alternative O 0 1.1431947085393162e-16
explanation O 0 2.1537846886502977e-16
of O 0 6.620089893150921e-17
why O 0 2.2505745097406438e-12
these O 0 3.1053822385865857e-15
tissues O 0 1.390599441153384e-11
are O 0 2.292901776954038e-16
particularly O 0 1.6930945594763368e-15
affected O 0 9.020378438336432e-14
. O 0 1.4850871963114406e-15
. O 0 5.493390031058309e-13

Genetic O 0 1.2423087003554656e-09
mapping O 0 4.364115319122064e-11
of O 0 2.1990487264532486e-15
the O 0 7.231751310255666e-15
copper B-Disease 0 8.987687749595352e-08
toxicosis I-Disease 0 4.0827259795150894e-07
locus O 0 9.49829770391375e-10
in O 0 1.9222435600728394e-13
Bedlington O 0 1.21281217957403e-07
terriers O 0 5.043748387834057e-07
to O 0 1.7309011212177094e-13
dog O 0 1.0613900940370513e-06
chromosome O 0 4.013943737390946e-07
10 O 0 2.384268130151135e-12
, O 0 5.4396412859279315e-17
in O 0 2.448332190426304e-18
a O 0 3.2581639006234488e-15
region O 0 5.596739434746145e-13
syntenic O 0 1.8619843444867e-08
to O 0 2.336566007747642e-15
human O 0 1.994544937197751e-12
chromosome O 0 1.9556724240032963e-08
region O 0 1.5684301080121088e-11
2p13 O 0 5.659397839252733e-09
- O 0 2.2164043933514677e-09
p16 O 0 7.237983101759937e-09
. O 0 7.847489151557863e-12

Abnormal O 0 0.0351870059967041
hepatic B-Disease 1 0.5061177611351013
copper I-Disease 0 9.979409696825314e-06
accumulation I-Disease 0 1.0066704136946214e-09
is O 0 1.4465759319570726e-12
recognized O 0 5.814698549044817e-12
as O 0 3.6309684425805955e-11
an O 0 4.4355445538712956e-08
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 4.9852025285623824e-11
man O 0 3.03934399425998e-07
, O 0 1.423218808701155e-14
mouse O 0 1.0715052178866813e-09
, O 0 5.278477240261252e-14
rat O 0 2.1683939621652826e-07
and O 0 1.2459001712261664e-11
dog O 0 1.3294845302880276e-05
. O 0 1.3190086176062543e-11

The O 0 5.170040285641664e-13
major O 0 9.407453982479552e-12
cause O 0 2.133777963347905e-12
of O 0 3.3160976677278076e-13
hepatic B-Disease 0 0.017476612702012062
copper I-Disease 0 0.0006114740390330553
accumulation I-Disease 0 4.536705233704197e-08
in O 0 1.0679262649974236e-13
man O 0 1.8402424473151768e-08
is O 0 1.3264446507323113e-13
a O 0 5.621104185007985e-15
dysfunctional O 0 6.731911139645774e-10
ATP7B O 0 1.1689776258094753e-08
gene O 0 2.056666816019348e-11
, O 0 4.789898895406078e-15
causing O 0 1.1127395012355823e-11
Wilson B-Disease 0 9.025151484820526e-06
disease I-Disease 0 0.007782001979649067
( O 0 1.439761920796201e-10
WD B-Disease 0 0.00941137969493866
) O 0 3.5902938608223245e-12
. O 0 4.958805718477399e-13

Mutations O 0 1.2247346248273061e-08
in O 0 1.4029187323839638e-14
the O 0 1.969155302480722e-15
ATP7B O 0 1.1816246114904061e-07
genes O 0 1.670703506095883e-11
have O 0 4.682320069865353e-13
also O 0 2.0507252105760217e-14
been O 0 2.5816780896241454e-13
demonstrated O 0 3.9062354154247025e-14
in O 0 5.96694278752313e-17
mouse O 0 2.27125660501315e-08
and O 0 7.263616791375327e-11
rat O 0 3.6274136618885677e-06
. O 0 1.4266889752923007e-11

The O 0 3.592278384478842e-13
ATP7B O 0 8.752336810857742e-08
gene O 0 1.565998553054726e-09
has O 0 1.574592886632864e-11
been O 0 1.436983263500627e-13
excluded O 0 2.6751528509755262e-12
in O 0 5.256393235133038e-18
the O 0 1.7051866140613402e-18
much O 0 1.3102742073164931e-16
rarer O 0 6.888362493254196e-13
human O 0 5.722374071988334e-13
copper B-Disease 0 3.316270920095121e-07
overload I-Disease 0 5.5546256589877885e-06
disease O 0 0.15242207050323486
non B-Disease 0 0.005971050821244717
- I-Disease 1 0.9731202721595764
Indian I-Disease 0 2.178310569433961e-05
childhood I-Disease 0 3.601350181270391e-05
cirrhosis I-Disease 0 9.115931607084349e-05
, O 0 2.462301060745728e-15
indicating O 0 6.550691250290647e-14
genetic O 0 1.012531031241437e-11
heterogeneity O 0 2.754437788965447e-09
. O 0 2.935701334805252e-11

By O 0 2.2649034205199023e-14
investigating O 0 1.1228993429535095e-10
the O 0 2.1398180536508216e-12
common O 0 1.5050326540588799e-09
autosomal O 0 0.009409553371369839
recessive O 0 0.07429677248001099
copper B-Disease 0 0.018577923998236656
toxicosis I-Disease 0 0.00022327879560180008
( O 0 1.1238388691880985e-12
CT B-Disease 0 1.9851761408062885e-06
) O 0 1.5102661146421809e-13
in O 0 2.819877925253262e-15
Bedlington O 0 6.886861569910252e-07
terriers O 0 0.00010153732728213072
, O 0 8.464339472380455e-12
we O 0 2.934798454604093e-12
have O 0 2.9747609172135856e-16
identified O 0 4.4852932347234516e-17
a O 0 1.5455227646602828e-18
new O 0 3.4066794282819064e-16
locus O 0 8.472766216925665e-13
involved O 0 1.7899261933740362e-11
in O 0 7.630808311620552e-12
progressive O 0 0.0017741098999977112
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.8305723603617707e-09

We O 0 2.8260310758199125e-12
examined O 0 7.894504819826176e-13
whether O 0 2.021212719221198e-14
the O 0 3.840666340867863e-15
WD B-Disease 0 8.415285992668942e-05
gene O 0 5.580737538757319e-10
ATP7B O 0 5.517068530025426e-06
was O 0 9.516930646324973e-12
also O 0 1.574247366647086e-15
causative O 0 5.979966413542648e-13
for O 0 1.4764818246408146e-18
CT B-Disease 0 7.723633538292418e-11
by O 0 7.683599977177289e-17
investigating O 0 2.4890308997910227e-12
the O 0 3.633579914274869e-15
chromosomal O 0 2.732874406774499e-07
co O 0 2.452888026027722e-08
- O 0 1.0311080982094989e-11
localization O 0 1.6387225777736436e-12
of O 0 5.8277467663366174e-15
ATP7B O 0 9.273736623072182e-07
and O 0 6.50452100899512e-15
C04107 O 0 1.3417776919654855e-14
, O 0 2.5482310127241834e-20
using O 0 1.362862518748427e-19
fluorescence O 0 7.106738114617098e-17
in O 0 1.542042402232966e-18
situ O 0 7.87613653767047e-14
hybridization O 0 4.341851314246248e-13
( O 0 2.831888132467323e-14
FISH O 0 1.673652216815924e-09
) O 0 7.535547164559675e-13
. O 0 5.418879320956416e-13

C04107 O 0 2.085078676827834e-06
is O 0 1.2908835242061989e-12
an O 0 3.306869565639992e-17
anonymous O 0 1.7636798054984637e-14
microsatellite O 0 3.3477032701512144e-08
marker O 0 4.899522565438019e-08
closely O 0 2.6320939872093163e-10
linked O 0 2.1587617027307715e-08
to O 0 1.0842374090561102e-12
CT B-Disease 0 0.004426654428243637
. O 0 5.329787305941025e-11

However O 0 5.684686055218435e-11
, O 0 4.006312696955977e-14
BAC O 0 8.3866920352893e-11
clones O 0 6.224987192382514e-11
containing O 0 7.049594848845819e-12
ATP7B O 0 3.5145028505212395e-06
and O 0 9.987081725038125e-15
C04107 O 0 6.275814828753112e-13
mapped O 0 1.4916620022509264e-11
to O 0 1.5671291135165976e-15
the O 0 2.3879101803948822e-15
canine O 0 4.54031919616682e-07
chromosome O 0 3.6542562042995996e-07
regions O 0 5.914388978567331e-10
CFA22q11 O 0 5.672530960509903e-07
and O 0 9.949679101450837e-12
CFA10q26 O 0 8.770197013063807e-09
, O 0 3.0579006420579434e-16
respectively O 0 7.220340082390257e-15
, O 0 3.075517074476261e-17
demonstrating O 0 2.4758324120781154e-14
that O 0 1.5430289424661625e-13
WD B-Disease 0 0.014980977401137352
cannot O 0 7.078211714667271e-12
be O 0 8.230075459197018e-16
homologous O 0 7.468520566529177e-14
to O 0 1.7174114777876448e-13
CT B-Disease 0 2.4421673515462317e-05
. O 0 2.8253533193578484e-11

The O 0 3.311951136519137e-13
copper O 0 4.276217602239285e-09
transport O 0 4.730184560014505e-12
genes O 0 3.2384171299443265e-12
CTR1 O 0 2.414976052023121e-06
and O 0 1.4195981629799848e-12
CTR2 O 0 2.3353248252533376e-05
were O 0 5.8906959171656226e-12
also O 0 1.0828108700476624e-13
excluded O 0 8.538144150027627e-13
as O 0 1.4470311177220481e-16
candidate O 0 3.821330113929264e-16
genes O 0 1.017535491459789e-15
for O 0 7.133708834797757e-17
CT B-Disease 0 2.559675067459466e-07
since O 0 7.00824858215765e-12
they O 0 1.0125532140178861e-13
both O 0 1.0263854822751151e-14
mapped O 0 7.108436506086946e-08
to O 0 2.2490123912505267e-12
canine O 0 9.367751772515476e-06
chromosome O 0 5.550093192141503e-06
region O 0 3.805472825746392e-09
CFA11q22 O 0 1.0285804819432087e-05
. O 0 4.362525618528679e-11

2 O 0 4.651158125312804e-09
- O 0 2.1347975689423038e-06
22 O 0 6.954274378578873e-10
. O 0 7.513918415420762e-13

5 O 0 8.515830707267469e-09
. O 0 7.548645736266124e-11

A O 0 1.3350931688319023e-12
transcribed O 0 1.3493450063892243e-12
sequence O 0 7.311839122451508e-14
identified O 0 3.3816179023649084e-13
from O 0 2.6664160428201947e-16
the O 0 2.7283574446705335e-16
C04107 O 0 3.1819786389108984e-11
- O 0 1.136458028377918e-11
containing O 0 8.006690471219768e-13
BAC O 0 1.8329474049672e-10
was O 0 2.2425601143866852e-13
found O 0 1.5476845193003095e-15
to O 0 9.766589321223827e-18
be O 0 6.169637110056594e-17
homologous O 0 2.7058758667614243e-16
to O 0 8.216390814753512e-18
a O 0 4.4566062802078675e-17
gene O 0 3.2243015223899774e-13
expressed O 0 5.453190173489305e-16
from O 0 1.0020953977028784e-17
human O 0 1.764292040912739e-14
chromosome O 0 2.9213476082645684e-10
2p13 O 0 1.899746471245578e-10
- O 0 1.3678115584614403e-10
p16 O 0 1.1203059313569241e-11
, O 0 2.1155791352154944e-15
a O 0 1.2242725169620407e-15
region O 0 7.5851488718498e-14
devoid O 0 2.8721431699976763e-13
of O 0 1.8040693354495776e-17
any O 0 3.0854382125687727e-15
positional O 0 3.155616323802235e-10
candidate O 0 2.55978658408873e-12
genes O 0 2.6769506750179417e-11
. O 0 1.91815725629485e-12

Molecular O 0 4.696418601235486e-12
analysis O 0 2.0414888583872998e-13
of O 0 5.630995624007784e-16
the O 0 4.635907670320536e-16
APC B-Disease 0 2.9597251732793595e-11
gene O 0 3.76754888137959e-13
in O 0 1.6981647398799234e-16
205 O 0 7.965498513605798e-14
families O 0 9.942070394221032e-16
: O 0 3.416061906359524e-16
extended O 0 8.545802412072978e-13
genotype O 0 9.928381450308166e-10
- O 0 5.9194285029207094e-08
phenotype O 0 7.822954090075385e-11
correlations O 0 2.1494635498581216e-12
in O 0 3.815256358301859e-16
FAP B-Disease 0 7.553016372063848e-13
and O 0 8.651860048232053e-18
evidence O 0 2.1959532643998424e-17
for O 0 3.709779729437527e-18
the O 0 8.458793611720339e-18
role O 0 8.252644986654623e-13
of O 0 9.588360023359476e-18
APC B-Disease 0 5.461294055333042e-14
amino O 0 2.183333300666366e-16
acid O 0 1.8159688433983662e-14
changes O 0 1.8175220985357232e-13
in O 0 1.809576100075816e-10
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.00012003914162050933
. O 0 6.143564129645895e-11

BACKGROUND O 0 5.528340452087832e-09
/ O 0 9.126278399662624e-09
AIMS O 0 3.2396852561733525e-11
The O 0 2.794891617979563e-16
development O 0 1.0687760084501091e-13
of O 0 3.9766903658922104e-10
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 7.440002932311562e-13
a O 0 4.7785237987898246e-17
variable O 0 2.2197196337947478e-14
range O 0 9.994447760716674e-13
of O 0 2.0709221013395784e-13
extracolonic O 0 0.009043569676578045
manifestations O 0 5.4296921007335186e-05
in O 0 2.7331796825791344e-09
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999771118164062
polyposis I-Disease 1 0.9999992847442627
( O 0 1.1400169003250582e-10
FAP B-Disease 0 5.746127462735728e-10
) O 0 4.73575612590111e-15
is O 0 1.1301998731696756e-15
the O 0 5.13606203065403e-17
result O 0 9.414762738402076e-15
of O 0 4.536680513406773e-15
the O 0 1.3785852884598548e-12
dominant O 0 8.588341415816103e-08
inheritance O 0 1.2212948377055e-06
of O 0 8.105670531222131e-06
adenomatous B-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999732971191406
coli I-Disease 1 0.9999998807907104
( O 0 5.97636939936308e-11
APC B-Disease 0 8.151301300607372e-10
) O 0 6.147161620196793e-15
gene O 0 8.418420474609611e-12
mutations O 0 1.5336955039302325e-09
. O 0 7.269683553051687e-12

In O 0 7.789500652572584e-14
this O 0 1.8966730322055016e-17
study O 0 6.33367959867117e-17
, O 0 4.501211870662698e-19
direct O 0 2.5856977320547695e-18
mutation O 0 1.7347135233396769e-15
analysis O 0 6.669852417057621e-16
of O 0 2.232918311613612e-17
the O 0 1.5792689750051034e-16
APC B-Disease 0 9.436076052471432e-13
gene O 0 4.4672253363912257e-14
was O 0 9.457206881762631e-14
performed O 0 2.734475193071637e-15
to O 0 2.7633616106114095e-17
determine O 0 1.2428223055728493e-14
genotype O 0 2.062323402329813e-11
- O 0 5.633655209003052e-10
phenotype O 0 8.176951411982547e-13
correlations O 0 6.803645103900524e-13
for O 0 4.704606065749359e-15
nine O 0 1.295517026989046e-10
extracolonic O 0 3.4294663464606856e-07
manifestations O 0 3.839736861799281e-11
and O 0 8.790999205714536e-16
to O 0 2.503602537800719e-18
investigate O 0 4.254203326420347e-13
the O 0 5.180478492879245e-15
incidence O 0 7.200223750558621e-10
of O 0 3.155584610820927e-15
APC B-Disease 0 3.242177915030453e-10
mutations O 0 5.127892034606507e-12
in O 0 2.157676672694033e-14
non O 0 5.056615191278979e-05
- O 1 0.9511284828186035
FAP O 1 0.9943813681602478
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 9.958897040363013e-10

METHODS O 0 5.937172281589298e-11
The O 0 6.749585004811208e-15
APC B-Disease 0 5.0011644131542354e-11
gene O 0 1.8434424993440945e-12
was O 0 6.796508343100138e-14
analysed O 0 6.011415323858849e-13
in O 0 3.7968731625429293e-17
190 O 0 1.815060527617378e-15
unrelated O 0 6.974105402337769e-14
FAP B-Disease 0 6.245097494694818e-11
and O 0 6.834727824932968e-14
15 O 0 4.608909824968532e-13
non O 0 3.7594691093545407e-07
- O 0 0.006781319156289101
FAP O 1 0.5505452752113342
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
patients O 0 3.8218206377393926e-11
using O 0 5.938318277864604e-14
denaturing O 0 1.0447858755924244e-07
gradient O 0 5.5204902871253125e-09
gel O 0 7.573431730634184e-07
electrophoresis O 0 4.57304111245449e-10
, O 0 1.7344290261485178e-15
the O 0 2.6627744215324606e-18
protein O 0 4.439399287634385e-14
truncation O 0 6.402122387783038e-09
test O 0 1.1615515177254565e-05
, O 0 4.4250824932379207e-16
and O 0 2.3150929152064676e-17
direct O 0 4.798949336568372e-16
sequencing O 0 1.6757499554653776e-10
. O 0 4.520345469466447e-12

RESULTS O 0 1.0195540767199418e-07
Chain O 0 4.3411483297006725e-09
terminating O 0 1.1943481759146835e-08
signals O 0 3.431346318194528e-10
were O 0 3.667994524108632e-14
only O 0 9.17052661141281e-17
identified O 0 1.6817261559026742e-12
in O 0 1.3767124012046866e-15
patients O 0 2.8762299684429067e-15
belonging O 0 5.121020379872019e-16
to O 0 4.28486492384724e-16
the O 0 4.572674500873987e-14
FAP B-Disease 0 2.319756609026058e-09
group O 0 5.0960619188064604e-14
( O 0 1.1099053872699362e-15
105 O 0 1.5518065077293336e-13
patients O 0 9.516558141563561e-14
) O 0 2.0131243592562192e-15
. O 0 6.181531930207415e-14

Amino O 0 1.1771945918059856e-10
acid O 0 3.6862349978017406e-11
changes O 0 5.655021501798415e-15
were O 0 4.0474151189522577e-16
identified O 0 4.6802283728240857e-14
in O 0 3.3495549969234843e-16
four O 0 5.38199866617628e-11
patients O 0 7.766062234482521e-14
, O 0 1.009019147584131e-17
three O 0 2.2100739190529474e-15
of O 0 4.08020387021959e-15
whom O 0 9.629117642129259e-11
belonged O 0 1.023985366985225e-12
to O 0 2.5262981268557583e-13
the O 0 4.4491688978853805e-12
non O 0 2.7389849037717795e-06
- O 0 3.0271912976331805e-08
FAP O 0 1.616383693558987e-09
group O 0 4.108824825516111e-12
of O 0 1.6765306920518697e-09
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
patients O 0 6.196421153958909e-09
. O 0 2.758433130349569e-13

Genotype O 0 5.2233037422411144e-05
- O 0 3.2675212423782796e-05
phenotype O 0 6.305752364710315e-09
correlations O 0 4.887999449643132e-10
identified O 0 2.4034441103992776e-09
significant O 0 2.951189206207294e-12
differences O 0 2.5914256851500284e-10
in O 0 8.292346674501194e-16
the O 0 2.5796020478693253e-16
nature O 0 1.8460172355582588e-13
of O 0 7.104057917083528e-16
certain O 0 1.1074704385971232e-13
extracolonic O 0 6.850591915963378e-08
manifestations O 0 3.640461543330531e-11
in O 0 1.6909063557362237e-15
FAP B-Disease 0 5.2218201984644e-10
patients O 0 5.632333046679851e-14
belonging O 0 2.6155526143100804e-15
to O 0 6.11684313464101e-16
three O 0 7.076588121913974e-13
mutation O 0 6.699287236067164e-10
subgroups O 0 2.4613038274168275e-09
. O 0 9.926288090100766e-12

CONCLUSIONS O 0 6.216747561182956e-09
Extended O 0 1.5866952196574857e-10
genotype O 0 1.0190404964305344e-08
- O 0 1.5618761608493514e-06
phenotype O 0 1.938506688503594e-09
correlations O 0 3.371164458698672e-10
made O 0 2.823832747494981e-12
in O 0 2.6582593802359318e-17
this O 0 1.991543410634974e-18
study O 0 1.6590365293375439e-15
may O 0 2.248384855033092e-13
have O 0 1.9055581100371787e-16
the O 0 5.396788946140438e-19
potential O 0 4.885877680967121e-16
to O 0 5.013904101189776e-19
determine O 0 2.275985966514553e-17
the O 0 2.6985233064506242e-18
most O 0 2.162278245354441e-18
appropriate O 0 1.1721583549697992e-17
surveillance O 0 2.244118736324796e-12
and O 0 2.973286021094179e-16
prophylactic O 0 2.026734086547216e-13
treatment O 0 4.2976826499215655e-16
regimens O 0 1.3258608046860543e-16
for O 0 1.1056102271238362e-18
those O 0 8.132764608447299e-16
patients O 0 8.09345963271674e-16
with O 0 9.037994575616707e-18
mutations O 0 2.128110919907486e-13
associated O 0 2.9834746733672576e-14
with O 0 1.7853019410041249e-12
life O 0 4.804115860679303e-08
threatening O 0 0.044385701417922974
conditions O 0 2.9425715197817226e-09
. O 0 1.5140739139871129e-12

This O 0 1.10041184199711e-14
study O 0 2.166039090169096e-14
also O 0 7.727901917901057e-16
provided O 0 1.8677868512393842e-18
evidence O 0 1.2967194302291582e-16
for O 0 9.278165970163111e-17
the O 0 2.267944215860986e-16
pathological O 0 7.816004093941231e-11
nature O 0 1.4124125317666741e-14
of O 0 3.5441413612671526e-17
amino O 0 3.703961575928123e-14
acid O 0 5.3808509975191224e-14
changes O 0 2.166260928097982e-15
in O 0 7.128703399475076e-17
APC O 0 1.8284210950847424e-11
associated O 0 5.412221625050338e-15
with O 0 7.560874432240797e-16
both O 0 1.9453577000693757e-14
FAP B-Disease 0 8.623426417386781e-10
and O 0 6.9632663350638335e-12
non O 0 0.00013815748388879
- O 1 0.998619556427002
FAP O 1 0.9994799494743347
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.8985566896390083e-08
. O 0 4.235690320215273e-15
. O 0 1.1594043325229009e-13

Inherited B-Disease 1 0.9999071359634399
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999910593032837
and O 0 2.411178911643219e-06
cancer B-Disease 0 7.541177183156833e-05
risk O 0 1.678804295579539e-07
of O 0 4.848912104357759e-15
the O 0 1.3265053660539705e-13
APC O 0 2.0303955849954036e-08
I1307K O 0 1.846907626834593e-10
polymorphism O 0 3.671998538568033e-10
. O 0 3.3467005208787093e-12

Germ O 0 0.00010253032814944163
- O 0 0.0006970000686123967
line O 0 6.222349213658163e-08
and O 0 5.622305277727191e-15
somatic O 0 1.5822329340817176e-12
truncating O 0 7.396092766009943e-11
mutations O 0 3.079330193611618e-11
of O 0 3.0876839086701807e-17
the O 0 7.146919240052474e-17
APC B-Disease 0 5.374743185238007e-12
gene O 0 1.4846382857900547e-13
are O 0 7.309652798065746e-17
thought O 0 3.860260754036697e-15
to O 0 6.777446247787007e-16
initiate O 0 5.926520163512805e-09
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.0013659271644428372
formation O 0 2.0440894843432034e-07
in O 0 8.880675039790731e-08
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999995231628418
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 5.924305046534073e-09
sporadic O 0 1.040052120515611e-05
colorectal O 1 1.0
carcinogenesis O 0 0.11556199938058853
, O 0 9.209995266434845e-11
respectively O 0 2.5686708315930673e-10
. O 0 6.985800826697641e-12

Recently O 0 7.279270448634634e-07
, O 0 1.8625434582229122e-14
an O 0 4.547680718534528e-16
isoleucine O 0 3.193480097252177e-06
- O 0 2.876356006709102e-07
- O 0 1.0668880223718702e-09
> O 0 2.713808453132238e-13
lysine O 0 3.844105866956937e-10
polymorphism O 0 6.936307778149242e-11
at O 0 2.558371049732333e-12
codon O 0 4.5503299045401846e-11
1307 O 0 2.5383710758331013e-11
( O 0 1.2764897688196633e-15
I1307K O 0 1.9436858264380852e-13
) O 0 1.1875870104731996e-17
of O 0 3.1706851345286757e-19
the O 0 6.081196282451404e-17
APC B-Disease 0 7.962802292538207e-12
gene O 0 1.0933290947937047e-12
has O 0 5.960221465678428e-13
been O 0 1.0313503658954462e-14
identified O 0 2.982469143614913e-13
in O 0 4.503451305006869e-16
6 O 0 9.704782984176763e-12
% O 0 7.230230886115345e-16
- O 0 7.372434884800327e-10
7 O 0 1.015002144832966e-11
% O 0 1.4967626719866143e-16
of O 0 8.398640044958748e-17
the O 0 2.4440180239858333e-13
Ashkenazi O 0 4.85927575955003e-10
Jewish O 0 1.1274665825521807e-13
population O 0 1.781951492016865e-15
. O 0 6.87897140508667e-14

To O 0 8.23517144234176e-14
assess O 0 8.159817439790107e-12
the O 0 2.2906911268408226e-15
risk O 0 2.258297281815258e-12
of O 0 5.147001080664738e-19
this O 0 2.429242102659499e-18
common O 0 2.765610853663284e-15
APC B-Disease 0 3.701338281009159e-12
allelic O 0 4.155244724690643e-12
variant O 0 2.2340518324170944e-09
in O 0 2.5358482674819882e-12
colorectal O 1 1.0
carcinogenesis O 0 2.5534302039886825e-05
, O 0 3.746290170442146e-12
we O 0 1.1540728442338555e-11
have O 0 1.795530277194299e-15
analyzed O 0 1.1365305804767953e-13
a O 0 4.06155156944634e-16
large O 0 2.27176506501902e-14
cohort O 0 2.5219401567078137e-10
of O 0 7.840912841965489e-14
unselected O 0 0.0012585410149767995
Ashkenazi O 0 6.866538342364947e-07
Jewish O 0 3.320797456463076e-11
subjects O 0 1.6832403249011918e-09
with O 0 1.0724528036465397e-11
adenomatous B-Disease 0 0.00043357317917980254
polyps I-Disease 0 0.02193276211619377
and O 0 6.645766575941181e-11
. O 0 5.980924848263125e-13
or O 0 0.0005219379090704024
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 3.1369231620918467e-14
for O 0 4.2458773869485534e-17
the O 0 3.548379199451164e-15
APC O 0 2.2836570412465562e-09
I1307K O 0 8.594423783758742e-11
polymorphism O 0 4.9621976666580636e-11
. O 0 7.825322854981831e-12

The O 0 1.3660763058948033e-12
APC O 0 3.5827063538107495e-09
I1307K O 0 2.027580187080602e-10
allele O 0 3.354228570243145e-12
was O 0 4.650634261374464e-13
identified O 0 5.197547036858707e-13
in O 0 2.6808576898730845e-16
48 O 0 2.167727369134509e-12
( O 0 7.295449776075966e-16
10 O 0 2.994401864254959e-15
. O 0 9.964842180176249e-18
1 O 0 6.952024502776446e-16
% O 0 3.516464725151741e-18
) O 0 1.4062700104642776e-18
of O 0 7.256393616273662e-17
476 O 0 4.500912836880033e-11
patients O 0 4.1513316222097085e-12
. O 0 8.370442604018272e-14

Compared O 0 2.879260198318523e-11
with O 0 5.648033691741804e-16
the O 0 7.196021342958112e-18
frequency O 0 1.1733316378768118e-15
in O 0 5.878018224695719e-18
two O 0 6.02076643736522e-17
separate O 0 8.142237189654681e-15
population O 0 1.6525361338025183e-16
control O 0 8.889477966667753e-14
groups O 0 2.067122630234342e-16
, O 0 1.8964199149380604e-17
the O 0 7.827676311038305e-17
APC O 0 2.395424691936654e-10
I1307K O 0 1.603695475027589e-12
allele O 0 1.1772871631558768e-13
is O 0 1.9256331826398437e-14
associated O 0 1.3744559054332012e-15
with O 0 1.944608975883562e-17
an O 0 1.9318105065738967e-17
estimated O 0 8.271129549493328e-13
relative O 0 3.7268854669036955e-11
risk O 0 1.132718523422227e-07
of O 0 2.781425534770926e-13
1 O 0 5.143017955955287e-11
. O 0 2.764359921525461e-12

5 O 0 7.507845012355574e-09
- O 0 7.493569569305691e-07
1 O 0 2.7429744239859666e-11
. O 0 6.366138627540707e-13

7 O 0 2.148290434433875e-09
for O 0 3.694512751284407e-11
colorectal B-Disease 1 0.9999996423721313
neoplasia I-Disease 0 0.01855267584323883
( O 0 1.0075304479606473e-10
both O 0 5.147250403680914e-10
P O 1 0.9818022847175598
= O 0 1.3151512234799156e-07
. O 0 4.2279940941532257e-13
01 O 0 3.890995969868527e-08
) O 0 2.7647274660619336e-13
. O 0 1.7799356552463536e-13

Furthermore O 0 1.4933616843126885e-11
, O 0 2.8937061639688942e-15
compared O 0 3.5220368559563814e-14
with O 0 2.7644925584146716e-15
noncarriers O 0 5.332083574671742e-08
, O 0 2.0962667840180964e-15
APC O 0 1.8432044085470167e-11
I1307K O 0 5.268595022062117e-12
carriers O 0 2.0445829003370303e-13
had O 0 3.1330825453024062e-15
increased O 0 6.198819380322975e-17
numbers O 0 1.2659281150003495e-15
of O 0 3.679201426451341e-16
adenomas B-Disease 0 0.00731958681717515
and O 0 4.814086764781678e-07
colorectal B-Disease 1 1.0
cancers I-Disease 0 0.00027633304125629365
per O 0 9.91941771777416e-12
patient O 0 6.702116905898947e-08
( O 0 6.592159977614198e-12
P O 0 0.12380797415971756
= O 0 5.276671544152123e-08
. O 0 9.080039779958693e-13
03 O 0 1.5509820983083955e-08
) O 0 2.1109448485544767e-14
, O 0 2.4247818951657763e-16
as O 0 7.599074771129019e-15
well O 0 1.0311891755255837e-14
as O 0 2.7735572085546556e-14
a O 0 1.9573757423381986e-14
younger O 0 6.004018809901979e-11
age O 0 4.707270163939459e-12
at O 0 1.7784162814268867e-12
diagnosis O 0 1.8048743055665284e-10
. O 0 2.2809537461934704e-13

We O 0 1.1943145257486965e-11
conclude O 0 1.8615463988000402e-13
that O 0 3.372631747826938e-17
the O 0 4.345388538127663e-17
APC O 0 7.299027701690441e-12
I1307K O 0 4.415460781292263e-13
variant O 0 7.423248214039058e-13
leads O 0 7.660611511459137e-13
to O 0 1.2131949904316958e-13
increased O 0 3.4384715519308884e-08
adenoma B-Disease 1 1.0
formation O 0 3.006107807124181e-09
and O 0 3.1504516335122135e-13
directly O 0 9.352907310395883e-15
contributes O 0 2.1959756062173152e-12
to O 0 7.205371316146379e-15
3 O 0 7.490664989326379e-13
% O 0 3.629989606309254e-16
- O 0 6.315628575670473e-11
4 O 0 2.913490100759676e-14
% O 0 4.615310889611578e-18
of O 0 2.575313844312177e-17
all O 0 7.920125666416311e-10
Ashkenazi O 0 2.429352434774046e-07
Jewish O 0 4.377068592020805e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
. O 0 1.0641763859009501e-10

The O 0 1.2048604064592797e-14
estimated O 0 2.0960240243754133e-14
relative O 0 8.867158309694423e-14
risk O 0 1.74461174673457e-11
for O 0 3.5289272995757057e-15
carriers O 0 5.4044543146281043e-11
may O 0 3.859406521309391e-15
justify O 0 2.751791934645304e-16
specific O 0 1.8854915355572548e-17
clinical O 0 2.6126208215213964e-15
screening O 0 7.6965410524245585e-16
for O 0 3.694032226827261e-19
the O 0 1.1861551556629915e-19
360 O 0 4.028837304138807e-16
, O 0 2.2897703523963205e-18
000 O 0 1.8899922252701558e-17
Americans O 0 1.0032395870133862e-16
expected O 0 2.238838575606552e-16
to O 0 4.4622029842324013e-17
harbor O 0 1.1894443763260654e-12
this O 0 9.064996232352275e-18
allele O 0 3.756480159756732e-15
, O 0 1.0694799457688366e-16
and O 0 6.79836518225733e-17
genetic O 0 1.7797233718491127e-15
testing O 0 1.6664855259640454e-12
in O 0 2.0396737417569845e-18
the O 0 3.736338430955074e-18
setting O 0 7.47012992912896e-14
of O 0 4.1692401619866995e-16
long O 0 4.373270409002705e-12
- O 0 1.6375378830701948e-09
term O 0 3.056734986656151e-12
- O 0 1.2619665512234035e-12
outcome O 0 2.979566293942037e-15
studies O 0 2.27896840260906e-15
may O 0 2.832858916928171e-15
impact O 0 1.7773158501031318e-14
significantly O 0 1.159248478460606e-11
on O 0 0.00019109265122096986
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 2.03384442620802e-09
in O 0 4.5619785023352826e-17
this O 0 6.116839825918559e-17
population O 0 1.1043390043779361e-15
. O 0 6.096070371587603e-14

Localization O 0 2.1373239289523838e-10
of O 0 5.174770761364172e-15
human O 0 4.3973909257845334e-13
BRCA1 O 0 1.4489640989268082e-06
and O 0 1.0624918913432202e-12
its O 0 5.716006497572185e-16
loss O 0 1.3831787278040242e-12
in O 0 4.583837908074854e-16
high O 0 6.01762479846002e-08
- O 0 1.9826804418698885e-05
grade O 0 0.004425612278282642
, O 0 1.2944073764231678e-11
non B-Disease 0 1.131633689510636e-05
- I-Disease 0 0.000825693306978792
inherited I-Disease 0 0.1240767240524292
breast I-Disease 1 0.9998507499694824
carcinomas I-Disease 1 0.9999998807907104
. O 0 6.496085447338373e-09

Although O 0 2.572981975049182e-13
the O 0 6.09703778379853e-17
link O 0 1.6128981830676459e-12
between O 0 1.4904312118789627e-14
the O 0 1.550096720903324e-13
BRCA1 O 0 0.0012637481559067965
tumour B-Disease 1 0.9999997615814209
- O 0 2.416341793320953e-09
suppressor O 0 7.790021960829563e-10
gene O 0 3.6913104395353e-07
and O 0 5.15764320141443e-08
hereditary B-Disease 1 0.9999982118606567
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 7.519138200962061e-09
established O 0 2.502979811261352e-12
, O 0 1.4270181114585932e-15
the O 0 3.745046326699542e-16
role O 0 1.1610508110493356e-09
, O 0 1.2549933961073293e-16
if O 0 2.233098339202128e-16
any O 0 4.280143773957481e-16
, O 0 9.078808825092931e-17
of O 0 1.7889318640654082e-16
BRCA1 O 0 1.0368544280936476e-06
in O 0 3.8807325408729554e-11
non B-Disease 1 0.9640578031539917
- I-Disease 1 0.9994547963142395
familial I-Disease 0 0.17396920919418335
cancers I-Disease 0 0.14052213728427887
is O 0 5.30383419475311e-12
unclear O 0 1.7269580947568142e-12
. O 0 3.414323077738368e-12

BRCA1 O 0 0.028826436027884483
mutations O 0 1.1401699566704337e-06
are O 0 1.1730643312193173e-13
rare O 0 2.2282684323995244e-13
in O 0 8.870508494407403e-14
sporadic B-Disease 0 7.648380346836348e-07
cancers I-Disease 1 0.6743815541267395
, O 0 5.337024767439191e-13
but O 0 6.529484933423188e-14
loss O 0 3.2117511775120455e-12
of O 0 2.8563954214335264e-15
BRCA1 O 0 2.738248440437019e-06
resulting O 0 1.354564138807135e-12
from O 0 5.944293451562443e-13
reduced O 0 5.010695747209581e-10
expression O 0 6.3115788637158055e-12
or O 0 4.4632357705520764e-12
incorrect O 0 7.476403385275887e-10
subcellular O 0 7.908860372163318e-11
localization O 0 3.6668595243538604e-11
is O 0 1.8455409658726767e-14
postulated O 0 1.8075783044294545e-14
to O 0 6.706591941749184e-16
be O 0 2.7656279637288186e-14
important O 0 6.632912569074032e-15
in O 0 9.623209076391886e-14
non B-Disease 0 0.0009764122660271823
- I-Disease 0 0.28013506531715393
familial I-Disease 1 0.9945011138916016
breast I-Disease 1 0.9999980926513672
and I-Disease 1 0.9999908208847046
ovarian I-Disease 1 1.0
cancers I-Disease 1 0.9999998807907104
. O 0 7.932549755951257e-11

Epigenetic O 0 1.8440130133967614e-07
loss O 0 2.4857065454853e-06
, O 0 6.86692456369764e-14
however O 0 1.2488143436966683e-15
, O 0 1.7060277202595055e-16
has O 0 2.5013452138560044e-14
not O 0 1.5725719884169761e-16
received O 0 1.8557943420508373e-15
general O 0 4.457937366014698e-15
acceptance O 0 6.917770172752127e-15
due O 0 1.8674041726725988e-16
to O 0 1.475164539515324e-18
controversy O 0 2.865346103290457e-14
regarding O 0 8.883440146413134e-15
the O 0 2.3414710431962936e-17
subcellular O 0 1.2746517708515925e-13
localization O 0 1.298169064649704e-13
of O 0 1.6078269555195782e-16
BRCA1 O 0 5.545697234765612e-11
proteins O 0 4.3856431039665435e-15
, O 0 4.753540628185008e-18
reports O 0 1.3210956884923773e-15
of O 0 2.7351085950451708e-17
which O 0 1.324338994588073e-13
have O 0 3.1692435676668185e-13
ranged O 0 8.805288990347895e-14
from O 0 2.3994585548058535e-17
exclusively O 0 3.167611843397228e-13
nuclear O 0 6.904925076156587e-09
, O 0 2.9720582865418033e-18
to O 0 8.43848456992336e-19
conditionally O 0 7.1504004973965696e-12
nuclear O 0 1.647159318662883e-11
, O 0 8.334925693134784e-19
to O 0 3.465051934563967e-18
the O 0 7.0121961351626155e-15
ER O 0 1.3472690341131965e-07
/ O 0 4.961911090339832e-12
golgi O 0 9.372561320802886e-13
, O 0 4.863690314658284e-17
to O 0 9.639962031512372e-18
cytoplasmic O 0 5.510351289844673e-12
invaginations O 0 1.9970300968452648e-09
into O 0 4.8892922825357395e-15
the O 0 3.1945601966141234e-15
nucleus O 0 1.8768992436635212e-12
. O 0 2.0106743418672746e-13

In O 0 2.8376789579145217e-14
an O 0 2.6027302494068795e-17
attempt O 0 5.923428031574937e-15
to O 0 1.7271002853306368e-15
resolve O 0 4.178531652632156e-12
this O 0 1.0019577548489495e-17
issue O 0 1.0571271505735447e-12
, O 0 1.455329261278282e-16
we O 0 1.4461579855721066e-14
have O 0 3.937418255751512e-15
comprehensively O 0 2.625366812836205e-09
characterized O 0 1.7849128208444198e-13
19 O 0 4.672738433166013e-13
anti O 0 1.6624952081656375e-08
- O 0 5.0338055501697454e-08
BRCA1 O 0 2.0831438973800687e-07
antibodies O 0 7.73830943767706e-10
. O 0 2.351294885790528e-13

These O 0 2.7931997331948934e-14
reagents O 0 7.151597565015211e-13
detect O 0 2.0268114714772772e-13
a O 0 1.2956464777130034e-16
220 O 0 3.3101541476512073e-15
- O 0 1.354063736136446e-11
kD O 0 3.141705992582011e-11
protein O 0 5.4771921861266476e-14
localized O 0 3.540403579571465e-14
in O 0 4.622094184224819e-18
discrete O 0 8.749785970632931e-15
nuclear O 0 2.5357664412695158e-08
foci O 0 1.4054276839536861e-11
in O 0 2.3755265587060244e-15
all O 0 5.6468542407143996e-14
epithelial O 0 6.23897461471401e-12
cell O 0 6.810498276443866e-10
lines O 0 8.71533012425374e-10
, O 0 1.354540678535595e-16
including O 0 4.360183159691541e-17
those O 0 1.3871019485170303e-16
derived O 0 9.365617886802381e-15
from O 0 1.4484588658700281e-12
breast B-Disease 0 0.0001655089290579781
malignancies I-Disease 0 1.9982423964393092e-06
. O 0 6.469223073901631e-11

Immunohistochemical O 0 3.815217041847063e-06
staining O 0 5.276440333545906e-07
of O 0 5.792589715183927e-13
human O 0 8.668193940408742e-11
breast O 0 6.84341648593545e-06
specimens O 0 9.257486794922443e-07
also O 0 1.141357786060837e-09
revealed O 0 3.339056604545476e-07
BRCA1 O 0 0.008273033425211906
nuclear O 0 9.920599040924571e-06
foci O 0 3.990726415992185e-09
in O 0 3.4507092279076335e-13
benign O 0 0.0005220510647632182
breast O 0 0.003758014179766178
, O 0 4.1000276090885635e-11
invasive B-Disease 0 0.0028612075839191675
lobular I-Disease 1 0.9993645548820496
cancers I-Disease 1 0.9999818801879883
and O 0 1.4580880360881565e-06
low B-Disease 0 0.0898793637752533
- I-Disease 1 0.9990472197532654
grade I-Disease 1 0.9994871616363525
ductal I-Disease 1 0.9996918439865112
carcinomas I-Disease 1 0.9999995231628418
. O 0 8.408723495278991e-09

Conversely O 0 4.143411391765994e-09
, O 0 6.485648064609439e-13
BRCA1 O 0 2.2074880234868033e-06
expression O 0 3.614357424464032e-11
was O 0 1.8750011265833422e-10
reduced O 0 1.3014349797488278e-12
or O 0 2.7519536671162526e-13
undetectable O 0 1.3285243127825197e-08
in O 0 5.615226252810073e-17
the O 0 9.335003866157345e-17
majority O 0 9.134086512868102e-15
of O 0 1.1801328042234955e-14
high O 0 1.9763760406021902e-07
- O 0 1.8061765558741172e-06
grade O 0 3.0220337521313922e-06
, O 0 1.0419687709222261e-13
ductal B-Disease 0 3.648057997907017e-07
carcinomas I-Disease 1 0.9999992847442627
, O 0 1.605879261490882e-14
suggesting O 0 2.7549680202063054e-13
that O 0 9.218939732425196e-15
absence O 0 1.6205633569018468e-13
of O 0 1.992610280064904e-15
BRCA1 O 0 4.436823928699596e-06
may O 0 5.0422735431432386e-11
contribute O 0 1.6737588089937709e-15
to O 0 3.263845255003149e-17
the O 0 3.384166285160622e-17
pathogenesis O 0 1.0972094645334256e-14
of O 0 1.9805039357280238e-19
a O 0 3.1358398410321497e-18
significant O 0 4.967174844453404e-16
percentage O 0 1.1200399496757996e-09
of O 0 1.5200868992357175e-12
sporadic B-Disease 0 0.0003953493433073163
breast I-Disease 1 0.8383793830871582
cancers I-Disease 0 0.0012999125756323338
. O 0 6.968178204586062e-13
. O 0 3.3158905309027542e-12

